%PDF-1.6%‚„œ”
1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R>>>>endobj2 0 obj<</Length 12375/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2024-08-06T06:09:02-04:00</xmp:CreateDate>
         <xmp:MetadataDate>2024-08-06T06:09:04-04:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-08-06T06:09:04-04:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 19.5 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:4b9a57ce-5f7e-a94d-bbc6-a26e0d0b4162</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:e39f43de-0c1a-4941-9dd9-0badbdf8b922</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:3e3683c0-b9fa-49de-b78c-930e9c60c92b</stRef:instanceID>
            <stRef:documentID>xmp.did:4bcd62d9-3e53-493a-a33d-d24571dfb7a9</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 19.5 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2024-08-06T06:09:02-04:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2913240868</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Geneva</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>TrueType</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2913240868</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Apple Computer</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Geneva</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>17.0</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2360395111</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>PostScript</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2360395111</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>29583</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeue-Medium</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>001.002</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2027153225</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2027153225</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4218679263</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4218679263</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.100</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4226815537</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4226815537</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3939600684</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3939600684</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>20675831</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>TrueType</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>20675831</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Apple Computer</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Helvetica</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>9.0</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1593802331</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Verdana</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1593802331</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Microsoft</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Verdana-Bold</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.02</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2888882455</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Symbol Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2888882455</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>SymbolStd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.045</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj3 0 obj<</Count 15/Kids[14 0 R 15 0 R]/Type/Pages>>endobj14 0 obj<</Count 5/Kids[5 0 R 6 0 R 7 0 R 8 0 R 9 0 R]/Parent 3 0 R/Type/Pages>>endobj15 0 obj<</Count 10/Kids[10 0 R 11 0 R 12 0 R 13 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R]/Parent 3 0 R/Type/Pages>>endobj10 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 22 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300033005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 3964>>/PageWidthList<</0 612.0>>>>>>>>endobj11 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 30 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R/T1_3 31 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300033005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 3983>>/PageWidthList<</0 612.0>>>>>>>>endobj12 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 32 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R>>/Font<</T1_0 31 0 R/T1_1 27 0 R/T1_2 28 0 R/T1_3 26 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300033005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 21922>>/PageWidthList<</0 612.0>>>>>>>>endobj13 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 33 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ColorSpace<</CS0 34 0 R>>/ExtGState<</GS0 23 0 R/GS1 25 0 R>>/Font<</T1_0 27 0 R/T1_1 26 0 R/T1_2 35 0 R/T1_3 36 0 R/T1_4 37 0 R/T1_5 28 0 R/T1_6 31 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 38 0 R>>/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300033005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 22024>>/PageWidthList<</0 612.0>>>>>>>>endobj16 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 39 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R/GS2 24 0 R/GS3 40 0 R>>/Font<</T1_0 27 0 R/T1_1 28 0 R/T1_2 26 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300033005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 24437>>/PageWidthList<</0 612.0>>>>>>>>endobj17 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 41 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R/GS2 24 0 R>>/Font<</T1_0 27 0 R/T1_1 26 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 24562>>/PageWidthList<</0 612.0>>>>>>>>endobj18 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 42 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R/GS2 24 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300034005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 25033>>/PageWidthList<</0 612.0>>>>>>>>endobj19 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 43 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R>>/Font<</C2_0 44 0 R/C2_1 45 0 R/TT0 46 0 R/TT1 47 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 48 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300034005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[15575.0 0.0 3.0 -270.0 -360.0 270.0 -349.4 1.0 0.0 0.0 1.0 -195.0 -285.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 22778>>/PageWidthList<</0 612.0>>>>>>>>endobj20 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 49 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R>>/Font<</C2_0 44 0 R/C2_1 45 0 R/TT0 46 0 R/TT1 47 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 48 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300034005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[15575.0 0.0 3.0 -270.0 -360.0 270.0 -349.4 1.0 0.0 0.0 1.0 -195.0 -285.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 23742>>/PageWidthList<</0 612.0>>>>>>>>endobj21 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 50 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R>>/Font<</C2_0 44 0 R/TT0 47 0 R/TT1 46 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 51 0 R>>/XObject<</Fm0 48 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300034005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[15575.0 0.0 3.0 -270.0 -360.0 270.0 -349.4 1.0 0.0 0.0 1.0 -195.0 -285.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 25233>>/PageWidthList<</0 612.0>>>>>>>>endobj50 0 obj<</Length 26957>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 413.6983 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 315.2383 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 241.1383 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/C2_0 1 Tf
-0.013 Tc 0.013 Tw 10 0 0 10 46 715.6797 Tm
[<0037004B00480003>-14 <00500052005600570003>-14 <0046005200500050005200510003>-13.9 <0056004C004700480003>-13.9 <00480049>18 <004900480046005700560003>-14 <005200490003>-14 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <004C00510003>-13.9 <004400470058004F005700560003>-14 <0044005100470003>-14 <0046004B004C004F00470055004800510003>-13.9 <0055004800460048004C0059004C0051004A0003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <0044004F0052005100480003>-13.9 <004C00510046004F005800470048001D>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.614 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(diarrhea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.841 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(tiredness)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.259 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(headache)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.841 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(nausea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.259 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(skin rash)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.841 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(muscle pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.259 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B>]TJ
-1.8 -1.586 Td
[<0037004B00480003>-14 <00500052005600570003>-14 <0046005200500050005200510003>-13.9 <0056004C004700480003>-13.9 <00480049>18 <004900480046005700560003>-14 <005200490003>-14 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <004C00510003>-13.9 <0046004B004C004F00470055004800510003>-13.9 <0055004800460048004C0059004C0051004A0003>-13.9 <003600330035>17.6 <003C00260028002F>36.8 <0003>-14 <005A004C0057004B0003>-14 <0046004B0048005000520057004B0048005500440053005C0003>-14 <004C00510046004F005800470048001D>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.614 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0056005A0048004F004F004C0051004A000F0003>-13.9 <00530044004C00510003>-14 <0044005100470003>-13.9 <00550048004700510048005600560003>-14 <005200490003>-13.9 <0057004B00480003>-14 <004F004C0051004C0051004A0003>-13.9 <005200490003>-14 <005C005200580055>]TJ
/TT0 1 Tf
0 Tc 0 Tw 20.023 0 Td
( )Tj
/C2_0 1 Tf
-0.013 Tc 0.013 Tw -20.023 -1.175 Td
[<0050005200580057004B000F0003>-13.9 <0057004B0055005200440057000F0003>-14 <005600570052005000440046004B0003>-14 <0044005100470003>-13.9 <00450052005A0048004F0003>-14 <000B00500058004600520056004C0057004C0056000C>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<004F0052005A0003>-13.9 <005A004B004C005700480003>-13.9 <0045004F0052005200470003>-14 <00460048004F004F0003>-14 <0046005200580051005700560003>-13.9 <005A004C0057004B0003>-13.9 <00490048005900480055>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
<00490048005900480055>Tj
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(diarrhea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(nausea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(vomiting)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(muscle pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(stomach-area \(abdominal\) pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(cough)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(headache)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(rash)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.841 14.544 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(tiredness)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(constipation)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(abnormal heart rate)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(high blood pressure \(hypertension\))Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(swelling)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
<004C00510049004800460057004C005200510056>Tj
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(low blood pressure)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(decreased appetite)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(allergic reactions)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(nose bleed)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<005100580050004500510048005600560003>-14 <005200550003>-14 <0057004C0051004A004F004C0051004A0003>-13.9 <005200490003>-14 <005C0052005800550003>-13.9 <004B00440051004700560003>-13.9 <0044005100470003>-14 <0049004800480057>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<004900480048004F004C0051004A0003>-14 <004600520051004900580056004800470003>-13.9 <005200550003>-13.9 <0047004C005600520055004C00480051005700480047>]TJ
-27.85 -2 Td
[<003600330035>17.6 <003C00260028002F>36.8 <0003>-7 <00500044005C0003>-7 <004600440058005600480003>-7 <0049004800550057004C004F004C0057005C0003>-7 <0053005500520045004F0048005000560003>-7.1 <004C00510003>-7 <00500044004F004800560003>-7 <0044005100470003>-7 <0049004800500044004F0048005600110003>11.1 <0037>110.7 <0044004F004E0003>-7 <005700520003>-7 <005C0052005800550003>-7 <004B00480044004F0057004B00460044005500480003>-7 <0053005500520059004C0047004800550003>-7 <004C00490003>-7 <0057004B004C00560003>-6.9 <004C00560003>-7 <00440003>-7 <00460052005100460048005500510003>-7 <0049005200550003>-7 <005C005200580011>]TJ
-0.014 Tc 0.014 Tw 0 -1.734 Td
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
-0.013 Tc 0.013 Tw 0 -1.05 Td
[<0053005200560056004C0045004F00480003>-14 <0056004C004700480003>-14 <00480049>18.1 <004900480046005700560003>-13.9 <005200490003>-14 <003600330035>17.7 <003C00260028002F0011>]TJ
0 -1.41 Td
[<00260044004F004F0003>-14 <005C0052005800550003>-13.9 <0047005200460057005200550003>-13.9 <0049005200550003>-13.9 <005000480047004C00460044004F0003>-13.9 <004400470059004C004600480003>-13.9 <004400450052005800570003>-13.9 <0056004C004700480003>-13.9 <00480049>18 <0049004800460057005600110003>4.1 <003C>91.6 <005200580003>-14 <00500044005C0003>-13.9 <0055004800530052005500570003>-13.9 <0056004C004700480003>-13.9 <00480049>18 <004900480046005700560003>-14 <005700520003>-13.9 <002900270024>55 <0003>-14 <004400570003>-13.9 <00140010001B001300130010002900270024001000140013001B001B0011>]TJ
/TT1 1 Tf
0.014 Tw 0 -2.4 Td
[(How should I store SPR)36.7 (YCEL?)]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.662 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<003600570052005500480003>-13.9 <003600330035>17.7 <003C00260028002F>36.8 <0003>-14 <004400570003>-14 <00550052005200500003>-13.9 <005700480050005300480055004400570058005500480003>-13.9 <004500480057005A0048004800510003>-14 <0019001B008300290003>-13.9 <005700520003>-13.9 <001A001A008300290003>-13.9 <000B00150013008300260003>-13.9 <005700520003>-13.9 <0015001800830026000C0011>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.374 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<00240056004E0003>-13.9 <005C0052005800550003>-14 <004B00480044004F0057004B00460044005500480003>-13.9 <0053005500520059004C0047004800550003>-13.9 <005200550003>-13.9 <0053004B00440055005000440046004C005600570003>-13.9 <004400450052005800570003>-14 <0057004B00480003>-14 <0055004C004A004B00570003>-13.9 <005A0044005C0003>-14 <005700520003>-13.9 <0057004B00550052005A0003>-14 <0044005A0044005C0003>-13.9 <0048005B0053004C0055004800470003>-14 <005200550003>-13.9 <0058005100580056004800470003>-14 <003600330035>17.7 <003C00260028002F0011>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.374 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<003A>18 <0048004400550003>-13.9 <004F004400570048005B0003>-14 <005200550003>-13.9 <0051004C00570055004C004F00480003>-14 <004A004F00520059004800560003>-14 <005A004B004800510003>-14 <004B004400510047004F004C0051004A0003>-13.9 <005700440045004F0048005700560003>-13.9 <0057004B004400570003>-13.9 <004B0044005900480003>-13.9 <004400460046004C00470048005100570044004F004F005C0003>-13.9 <00450048004800510003>-14 <0046005500580056004B004800470003>-14 <005200550003>-13.9 <004500550052004E004800510011>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.374 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0029004800500044004F004800560003>-14 <005A004B00520003>-14 <0044005500480003>-14 <005300550048004A00510044005100570003>-14 <0056004B00520058004F00470003>-13.9 <0051005200570003>-14 <004B004400510047004F00480003>-14 <0046005500580056004B004800470003>-14 <005200550003>-14 <004500550052004E004800510003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <005700440045004F0048005700560011>]TJ
/TT1 1 Tf
0.014 Tw -1.8 -1.662 Td
[(Keep SPR)36.7 (YCEL)18 ( and all medicines out of the reach of children.)]TJ
0 -2.4 Td
[(General information about the safe and effective use of SPR)36.7 (YCEL.)]TJ
/C2_0 1 Tf
-0.002 Tc 0.002 Tw 0 -1.86 Td
[<003000480047004C0046004C0051004800560003>-65.8 <0044005500480003>-65.7 <00560052005000480057>0.5 <004C0050004800560003>-65.7 <005300550048005600460055004C0045004800470003>-65.7 <0049>0.5 <005200550003>-65.7 <005300580055005300520056004800560003>-65.7 <00520057>0.5 <004B004800550003>-65.7 <0057004B004400510003>-65.7 <0057>0.5 <004B0052005600480003>-65.7 <004F004C00560057>0.5 <004800470003>-65.7 <004C00510003>-65.8 <00440003>-65.8 <003300440057>0.5 <004C004800510057>0.5 <0003>-65.7 <002C00510049>0.5 <00520055005000440057>0.5 <004C005200510003>-65.7 <004F0048004400C000480057>0.5 <0011>0.5 <0003>-65.8 <002700520003>-65.7 <005100520057>0.5 <0003>-65.7 <005800560048>-2.2 <0003>]TJ
0 -1.05 Td
[<003600330035>17.9 <003C00260028002F>37 <0003>-67.5 <0049005200550003>-67.4 <00440003>-67.5 <0046005200510047004C0057004C005200510003>-67.4 <0049005200550003>-67.4 <005A004B004C0046004B0003>-67.5 <004C00570003>-67.5 <004C00560003>-67.5 <0051005200570003>-67.5 <005300550048005600460055004C00450048004700110003>-67.4 <002700520003>-67.5 <0051005200570003>-67.5 <004A004C005900480003>-67.5 <003600330035>17.9 <003C00260028002F>37 <0003>-67.5 <005700520003>-67.4 <00520057004B004800550003>-67.5 <0053004800520053004F00480003>-67.5 <00480059004800510003>-67.5 <004C00490003>-67.5 <0057004B0048005C0003>-67.5 <004B0044005900480003>-67.5 <0057004B0048>-2.2 <0003>]TJ
-0.011 Tc 0.011 Tw 0 -1.05 Td
[<00560044005000480003>-27.5 <0056005C0050005300570052005000560003>-27.6 <005C005200580003>-27.6 <004B00440059004800110003>-27.6 <002C00570003>-27.5 <00500044005C0003>-27.6 <004B0044005500500003>-27.5 <0057004B0048005000110003>-9.6 <003C>91.9 <005200580003>-27.6 <0046004400510003>-27.6 <00440056004E0003>-27.5 <005C0052005800550003>-27.6 <004B00480044004F0057004B00460044005500480003>-27.5 <0053005500520059004C0047004800550003>-27.6 <005200550003>-27.6 <0053004B00440055005000440046004C005600570003>-27.5 <0049005200550003>-27.6 <004C0051004900520055005000440057004C005200510003>-27.6 <00440045005200580057>-10.9 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.05 Td
[<003600330035>17.6 <003C00260028002F>36.8 <0003>-14 <0057004B004400570003>-14 <004C00560003>-14 <005A0055004C00570057004800510003>-13.9 <0049005200550003>-14 <004B00480044004F0057004B0003>-14 <0053005500520049004800560056004C005200510044004F00560011>]TJ
/TT1 1 Tf
0.014 Tw 0 -2.4 Td
[(What are the ingredients in SPR)36.7 (YCEL?)]TJ
0 -1.734 Td
(Active ingredient:)Tj
/C2_0 1 Tf
0.013 Tw [<0BD8>-0.7 <0003>-13.9 <00470044005600440057004C0051004C0045>]TJ
/TT1 1 Tf
-0.01 Tc 0.027 Tw 0 -1.734 Td
[(I)0.7 (n)0.7 (act)0.5 (i)0.7 (ve i)0.7 (n)0.7 (g)0.7 (red)0.6 (i)0.8 (en)0.7 (t)0.6 (s:)]TJ
/C2_0 1 Tf
0.01 Tw 9.531 0 Td
[<0BD80003>-27.1 <004F00440046>0.6 <0057>0.7 <00520056>0.5 <00480003>-27.1 <0050>0.5 <005200510052004B005C>0.5 <00470055>0.5 <00440057>0.7 <0048000F>0.7 <0003>-27.1 <0050>0.5 <004C0046>0.5 <0055>0.6 <00520046>0.5 <0055>0.5 <005C>0.6 <0056>0.5 <0057>0.7 <0044004F004F004C005100480003>-27.1 <0046>0.5 <0048004F004F0058004F00520056>0.5 <0048000F>0.7 <0003>-27.1 <0046>0.6 <0055>0.5 <00520056>0.5 <0046>0.6 <00440055>0.6 <0050>0.5 <0048004F004F00520056>0.6 <00480003>-27 <0056>0.5 <00520047004C00580050>0.6 <000F>0.7 <0003>-27.1 <004B005C>0.5 <00470055>0.5 <0052005B>0.5 <005C>0.6 <00530055>0.5 <00520053005C>0.5 <004F0003>-27.1 <0046>0.5 <0048004F004F0058004F00520056>0.5 <0048000F>-9.8 <0003>]TJ
-0.013 Tc 0.013 Tw -9.531 -1.05 Td
[<0044005100470003>-14 <00500044004A005100480056004C005800500003>-14 <0056005700480044005500440057004800110003>4.1 <0037004B00480003>-13.9 <005700440045004F004800570003>-14 <0046005200440057004C0051004A0003>-14 <0046005200510056004C0056005700560003>-13.9 <005200490003>-14 <004B005C00530055005200500048004F004F005200560048000F0003>-13.9 <0057004C005700440051004C005800500003>-13.9 <0047004C0052005B004C00470048000F0003>-13.9 <0044005100470003>-14 <00530052004F005C00480057004B005C004F0048005100480003>-13.9 <004A004F005C00460052004F0011>]TJ
9 0 0 9 46 164.3584 Tm
[<0027004C005600570055004C004500580057004800470003>-14 <0045005C001D0003>-14 <00250055004C005600570052004F00100030005C0048005500560003>-14 <003600540058004C004500450003>-13.9 <002600520050005300440051005C>74 <000F0003>-14 <00330055004C005100460048005700520051000F0003>-14 <0031002D0003>-13.9 <0013001B0018001700160003>-14 <003800360024>]TJ
0 -1.26 Td
[<0029005200550003>-13.9 <00500052005500480003>-14 <004C0051004900520055005000440057004C00520051000F0003>-14 <004A00520003>-14 <005700520003>-13.9 <005A005A005A>54.7 <0011005600530055005C00460048004F00110046005200500003>-14 <005200550003>-13.9 <00460044004F004F0003>-13.9 <00140010001B001300130010001600160015001000150013001800190011>]TJ
ET
4 M 
36.5 143.519 539 588.941 re
S
10 M 
q 1 0 0 1 36 98.5863 cm
0 0 m
540 0 l
S
Q
BT
9 0 0 9 36 127.4663 Tm
[<0037>-11.1 <004B>-4.6 <004C>-8.2 <00560003>-13.9 <0033>4.5 <00440057>-10.5 <004C>-9.7 <0048>-7.4 <0051>1.6 <00570003>-14 <002C>-6.3 <0051>-1.3 <0049>-5.4 <0052>-10.1 <0055>-21.2 <0050>-7.1 <00440057>-10.5 <004C>-11.2 <0052>-9.8 <00510003>-13.9 <004B>-5.8 <0044>-4.5 <00560003>-13.9 <0045>-9.3 <0048>-8.9 <0048>-7.4 <00510003>-14 <0044>-5.3 <0053>-8.3 <0053>-8.8 <0055>-8.8 <0052>7.3 <0059>7.9 <0048>-9.8 <00470003>-13.9 <0045>11.1 <005C0003>-13.9 <0057>-11.1 <004B>-7.3 <00480003>-13.9 <0038>13.9 <0011>-4.4 <0036>-5.5 <00110003>-14 <0029>11.8 <0052>-12.7 <0052>-12.2 <00470003>-13.9 <0044>-5.4 <0051>-7.7 <00470003>-14 <0027>-14.2 <0055>-22 <0058>-7.3 <004A0003>-14 <0024>-4 <0047>-3.4 <0050>-6 <004C>-5.5 <0051>-4.2 <004C>-8.2 <0056>-2.6 <0057>-11.4 <0055>-9.7 <00440057>-10.6 <004C>-11.2 <0052>-9.7 <0051>1.1 <0011>]TJ
-0.005 Tc 0.005 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -2.704 Td
<0003>Tj
EMC 
49.464 0 Td
[<0035>12 <0048>17.6 <0059>-0.7 <004C0056>0.7 <0048>-1.8 <0047>23 <001D>8 <0003>-6 <0029>21.7 <0048>0.6 <00450055>-14 <0058>2.6 <0044>2.1 <0055>-34.9 <005C>7.7 <0003>-5.9 <0015>-1 <00130015>]TJ
0 Tc 0 Tw 9.98 0 Td
<0016>Tj
/TT0 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
-59.444 -1.76 Td
( )Tj
EMC 
/C2_0 1 Tf
0.001 Tc -0.001 Tw 49.37 0 Td
[<001A>14.6 <0015>0.9 <001C>-34.8 <0010>-22.2 <0038>7.8 <0036>-26.3 <0010>15.7 <0015>20.8 <00170013>-15.6 <0013>-15.7 <0013>3.4 <0016>-7.3 <0019>13.6 <000300030013>24.5 <001A>61.7 <0012>1.4 <0015>20.9 <0017>]TJ
ET
0 0 0 0 k
/GS0 gs
225.859 66.272 160.283 23.728 re
f
/PlacedPDF /MC0 BDC 
q
225.859 66.272 160.283 23.728 re
W n
0 0 0 1 k
q 1 0 0 1 241.8553 69.0858 cm
0 0 m
-0.143 -0.295 -0.448 -0.486 -0.776 -0.486 c
-0.907 -0.486 -1.033 -0.457 -1.152 -0.4 c
-3.856 0.912 -5.286 3.223 -5.286 6.283 c
-5.286 9.74 l
-5.286 10.216 -4.899 10.603 -4.424 10.603 c
-3.948 10.603 -3.562 10.216 -3.562 9.74 c
-3.562 6.283 l
-3.562 3.896 -2.497 2.17 -0.399 1.152 c
0.028 0.944 0.208 0.428 0 0 c
-2.55 8.013 m
-2.55 7.523 -2.155 7.128 -1.666 7.128 c
-1.178 7.128 -0.781 7.523 -0.781 8.013 c
-0.781 15.067 l
-0.781 15.556 -1.178 15.952 -1.666 15.952 c
-2.155 15.952 -2.55 15.556 -2.55 15.067 c
h
0.186 8.217 m
0.186 7.729 0.582 7.333 1.071 7.333 c
1.56 7.333 1.956 7.729 1.956 8.217 c
1.956 17.702 l
1.956 18.191 1.56 18.587 1.071 18.587 c
0.582 18.587 0.186 18.191 0.186 17.702 c
h
2.923 7.565 m
2.923 7.076 3.319 6.681 3.808 6.681 c
4.296 6.681 4.692 7.076 4.692 7.565 c
4.692 16.08 l
4.692 16.569 4.296 16.964 3.808 16.964 c
3.319 16.964 2.923 16.569 2.923 16.08 c
h
5.66 6.438 m
5.66 5.964 6.045 5.58 6.518 5.58 c
6.992 5.58 7.376 5.964 7.376 6.438 c
7.376 12.192 l
7.376 12.666 6.992 13.051 6.518 13.051 c
6.045 13.051 5.66 12.666 5.66 12.192 c
h
f
Q
q 1 0 0 1 258.3921 77.149 cm
0 0 m
0.002 0.053 l
1.115 0.436 1.805 1.105 1.805 2.301 c
1.805 2.484 l
1.805 3.857 0.689 4.986 -1.586 4.986 c
-4.734 4.986 l
-4.734 -5.725 l
-1.358 -5.725 l
0.854 -5.725 2.372 -4.614 2.372 -2.834 c
2.372 -2.726 l
2.372 -1.338 1.554 -0.321 0 0 c
-3.357 3.777 m
-1.783 3.777 l
-0.283 3.777 0.483 3.209 0.483 2.191 c
0.483 2.084 l
0.483 0.855 -0.579 0.462 -1.974 0.462 c
-3.357 0.462 l
h
0.961 -2.71 m
0.961 -4.036 -0.083 -4.532 -1.606 -4.532 c
-3.357 -4.532 l
-3.357 -0.67 l
-1.582 -0.67 l
-0.082 -0.67 0.961 -1.169 0.961 -2.542 c
h
6.873 2.384 m
7.27 2.384 l
7.27 1.13 l
6.95 1.13 l
5.664 1.13 4.822 0.487 4.822 -1.212 c
4.822 -5.725 l
3.537 -5.725 l
3.537 2.384 l
4.822 2.384 l
4.822 0.931 l
4.884 0.931 l
5.113 1.665 5.71 2.384 6.873 2.384 c
8.414 2.384 1.286 -8.109 re
9.841 4.204 m
9.841 3.577 9.556 3.284 9.057 3.284 c
8.558 3.284 8.273 3.577 8.273 4.204 c
8.273 4.83 8.558 5.141 9.057 5.141 c
9.556 5.141 9.841 4.83 9.841 4.204 c
16.829 -3.491 m
16.829 -5.052 15.666 -5.878 13.968 -5.878 c
12.254 -5.878 11.122 -5.144 11.03 -3.491 c
12.315 -3.491 l
12.361 -4.486 13.096 -4.807 13.968 -4.807 c
14.84 -4.807 15.544 -4.425 15.544 -3.583 c
15.544 -1.61 11.122 -2.971 11.122 0.227 c
11.122 1.558 12.101 2.537 13.891 2.537 c
15.529 2.537 16.615 1.726 16.737 0.15 c
15.452 0.15 l
15.376 1.099 14.718 1.466 13.891 1.466 c
12.958 1.466 12.377 1.038 12.377 0.227 c
12.377 -1.686 16.829 -0.508 16.829 -3.491 c
19.795 2.384 m
21.539 2.384 l
21.539 1.252 l
19.795 1.252 l
19.795 -3.231 l
19.795 -4.409 20.101 -4.654 20.881 -4.654 c
21.095 -4.654 21.34 -4.623 21.539 -4.608 c
21.539 -5.71 l
21.294 -5.756 20.973 -5.787 20.744 -5.787 c
19.152 -5.787 18.51 -5.159 18.51 -3.43 c
18.51 1.252 l
17.147 1.252 l
17.147 2.384 l
18.51 2.384 l
18.51 4.986 l
19.795 4.986 l
h
25.336 2.537 m
23.331 2.537 22.261 1.16 22.261 -1.074 c
22.261 -2.268 l
22.261 -4.501 23.331 -5.878 25.336 -5.878 c
27.34 -5.878 28.411 -4.501 28.411 -2.268 c
28.411 -1.074 l
28.411 1.16 27.34 2.537 25.336 2.537 c
27.111 -2.191 m
27.111 -4.118 26.437 -4.746 25.336 -4.746 c
24.234 -4.746 23.561 -4.118 23.561 -2.191 c
23.561 -1.15 l
23.561 0.778 24.234 1.405 25.336 1.405 c
26.437 1.405 27.111 0.778 27.111 -1.15 c
h
29.77 4.986 1.286 -10.71 re
43.453 4.986 m
45.634 4.986 l
45.634 -5.725 l
44.273 -5.725 l
44.273 3.501 l
44.196 3.501 l
41.457 -3.952 l
39.789 -3.952 l
37.081 3.501 l
37.004 3.501 l
37.004 -5.725 l
35.658 -5.725 l
35.658 4.986 l
37.946 4.986 l
40.646 -2.454 l
40.723 -2.454 l
h
51.885 2.384 m
53.185 2.384 l
49.59 -8.326 l
48.259 -8.326 l
49.162 -5.787 l
46.529 2.384 l
47.891 2.384 l
49.835 -3.935 l
49.896 -3.935 l
h
56.639 2.537 m
54.634 2.537 53.563 1.099 53.563 -1.074 c
53.563 -2.268 l
53.563 -4.501 54.634 -5.878 56.639 -5.878 c
58.245 -5.878 59.194 -4.991 59.515 -3.476 c
58.199 -3.476 l
57.97 -4.409 57.45 -4.746 56.639 -4.746 c
55.537 -4.746 54.864 -4.118 54.864 -2.191 c
54.864 -2.084 l
59.561 -2.084 l
59.561 -1.074 l
59.561 1.099 58.643 2.537 56.639 2.537 c
56.639 1.405 m
57.68 1.405 58.244 0.792 58.259 -1.074 c
54.865 -1.074 l
54.883 0.792 55.552 1.405 56.639 1.405 c
64.326 2.384 m
64.724 2.384 l
64.724 1.13 l
64.403 1.13 l
63.118 1.13 62.276 0.487 62.276 -1.212 c
62.276 -5.725 l
60.991 -5.725 l
60.991 2.384 l
62.276 2.384 l
62.276 0.931 l
62.338 0.931 l
62.567 1.665 63.164 2.384 64.326 2.384 c
71.211 -3.491 m
71.211 -5.052 70.049 -5.878 68.35 -5.878 c
66.637 -5.878 65.505 -5.144 65.412 -3.491 c
66.698 -3.491 l
66.744 -4.486 67.479 -4.807 68.35 -4.807 c
69.222 -4.807 69.926 -4.425 69.926 -3.583 c
69.926 -1.61 65.505 -2.971 65.505 0.227 c
65.505 1.558 66.484 2.537 68.274 2.537 c
69.911 2.537 70.998 1.726 71.12 0.15 c
69.834 0.15 l
69.758 1.099 69.1 1.466 68.274 1.466 c
67.341 1.466 66.759 1.038 66.759 0.227 c
66.759 -1.686 71.211 -0.508 71.211 -3.491 c
81.427 -2.894 m
81.427 -4.807 80.111 -5.878 78.092 -5.878 c
76.194 -5.878 74.633 -4.96 74.434 -2.91 c
75.857 -2.91 l
76.026 -4.118 76.883 -4.685 78.076 -4.685 c
79.438 -4.685 80.05 -3.874 80.05 -2.971 c
80.05 0.074 74.602 -1.686 74.602 2.308 c
74.602 4.021 75.964 5.138 77.862 5.138 c
79.698 5.138 81.228 4.236 81.32 2.124 c
79.897 2.124 l
79.774 3.425 78.948 3.945 77.847 3.945 c
76.546 3.945 75.98 3.18 75.98 2.369 c
75.98 -0.324 81.427 1.267 81.427 -2.894 c
87.234 1.405 m
87.172 1.405 l
86.824 2.121 86.164 2.537 85.322 2.537 c
83.317 2.537 82.399 1.16 82.399 -1.074 c
82.399 -2.268 l
82.399 -4.501 83.317 -5.878 85.322 -5.878 c
86.164 -5.878 86.825 -5.462 87.172 -4.746 c
87.234 -4.746 l
87.234 -5.725 l
87.234 -8.326 l
88.52 -8.326 l
88.52 2.384 l
87.234 2.384 l
h
85.475 -4.746 m
84.373 -4.746 83.7 -4.118 83.7 -2.191 c
83.7 -1.15 l
83.7 0.778 84.373 1.405 85.475 1.405 c
86.576 1.405 87.25 0.778 87.25 -1.15 c
87.25 -2.191 l
87.25 -4.118 86.576 -4.746 85.475 -4.746 c
94.423 2.384 m
95.708 2.384 l
95.708 -5.725 l
94.423 -5.725 l
94.423 -4.685 l
94.362 -4.685 l
94.056 -5.342 93.398 -5.878 92.372 -5.878 c
90.858 -5.878 89.924 -5.021 89.924 -3.108 c
89.924 2.384 l
91.225 2.384 l
91.225 -2.925 l
91.225 -4.226 91.761 -4.792 92.725 -4.792 c
93.658 -4.792 94.423 -4.164 94.423 -2.588 c
h
97.359 2.384 1.285 -8.109 re
103.565 2.537 m
102.71 2.537 102.059 2.121 101.714 1.405 c
101.653 1.405 l
101.653 2.384 l
101.653 4.986 l
100.368 4.986 l
100.368 -5.725 l
101.653 -5.725 l
101.653 -4.746 l
101.714 -4.746 l
102.059 -5.462 102.71 -5.878 103.565 -5.878 c
105.57 -5.878 106.488 -4.501 106.488 -2.268 c
106.488 -1.074 l
106.488 1.16 105.57 2.537 103.565 2.537 c
105.188 -2.191 m
105.188 -4.118 104.514 -4.746 103.413 -4.746 c
102.311 -4.746 101.638 -4.118 101.638 -2.191 c
101.638 -1.15 l
101.638 0.778 102.311 1.405 103.413 1.405 c
104.514 1.405 105.188 0.778 105.188 -1.15 c
h
110.947 2.537 m
110.092 2.537 109.44 2.121 109.096 1.405 c
109.034 1.405 l
109.034 2.384 l
109.034 4.986 l
107.749 4.986 l
107.749 -5.725 l
109.034 -5.725 l
109.034 -4.746 l
109.096 -4.746 l
109.44 -5.462 110.092 -5.878 110.947 -5.878 c
112.951 -5.878 113.869 -4.501 113.869 -2.268 c
113.869 -1.074 l
113.869 1.16 112.951 2.537 110.947 2.537 c
112.569 -2.191 m
112.569 -4.118 111.896 -4.746 110.794 -4.746 c
109.693 -4.746 109.019 -4.118 109.019 -2.191 c
109.019 -1.15 l
109.019 0.778 109.693 1.405 110.794 1.405 c
111.896 1.405 112.569 0.778 112.569 -1.15 c
h
98.785 4.204 m
98.785 3.577 98.5 3.284 98.001 3.284 c
97.502 3.284 97.217 3.577 97.217 4.204 c
97.217 4.83 97.502 5.141 98.001 5.141 c
98.5 5.141 98.785 4.83 98.785 4.204 c
f
Q
q 1 0 0 1 373.6002 82.1669 cm
0 0 m
-0.728 0 -1.32 -0.592 -1.32 -1.32 c
-1.32 -2.048 -0.728 -2.64 0 -2.64 c
0.728 -2.64 1.32 -2.048 1.32 -1.32 c
1.32 -0.592 0.728 0 0 0 c
0 -2.825 m
-0.83 -2.825 -1.505 -2.15 -1.505 -1.32 c
-1.505 -0.49 -0.83 0.186 0 0.186 c
0.83 0.186 1.505 -0.49 1.505 -1.32 c
1.505 -2.15 0.83 -2.825 0 -2.825 c
f
Q
q 1 0 0 1 373.3364 80.8863 cm
0 0 m
0.283 0 l
0.376 0 0.449 0.024 0.501 0.07 c
0.553 0.117 0.579 0.181 0.579 0.262 c
0.579 0.348 0.555 0.413 0.507 0.46 c
0.459 0.506 0.387 0.53 0.291 0.531 c
0 0.531 l
h
0.307 -0.222 m
0 -0.222 l
0 -0.832 l
-0.275 -0.832 l
-0.275 0.754 l
0.282 0.754 l
0.465 0.754 0.606 0.712 0.706 0.631 c
0.805 0.548 0.855 0.43 0.855 0.274 c
0.855 0.168 0.829 0.079 0.778 0.008 c
0.727 -0.064 0.656 -0.119 0.564 -0.158 c
0.92 -0.818 l
0.92 -0.832 l
0.625 -0.832 l
h
f
Q
EMC 
Q
endstreamendobj48 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 281/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 25 0 R>>/Font<</TT0 52 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 743.6487 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.025 Tc 0.025 Tw 0 Ts 100 Tz 0 Tr 12 0 0 12 36 747.2637 Tm
[(SPR)37 (YCEL)]TJ
0 Tc 0 Tw 9 0 0 9 90.1324 750.4637 Tm
(\256)Tj
-0.025 Tc 12 0 0 12 96.5388 747.2637 Tm
( \(dasatinib\))Tj
ET
endstreamendobj52 0 obj<</BaseFont/NXSWOC+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 53 0 R/LastChar 174/Subtype/TrueType/ToUnicode 54 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 667 0 0 0 0 0 0 611 0 0 0 667 0 722 667 0 0 0 0 0 667 0 0 0 0 0 0 0 556 611 0 611 0 0 0 0 278 0 0 0 0 611 0 0 0 0 556 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj53 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 55 0 R/FontName/NXSWOC+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj54 0 obj<</Filter/FlateDecode/Length 312>>stream
Hâ\ëÀj√0E˜˙äY6ã‡G#;cn
^ÙA›~Ä#çSA-ŸY¯Ô;“Ñ*∞Á›{ëfí¶}j≠Y y˜ìÍpÅ¡XÌqûÆ^!úÒb¨»r–F-∑]¸´±w"!s∑Œé≠&QUê|–·º¯éz:„F$o^£7ˆ_M∑Å§ª:˜É#⁄R®k–8P–KÔ^˚!â∂m´È‹,Îñ<äœ’!‰qüÒe‘§qvΩBﬂ€ä*•UCıL´hıøÛlœ∂Û†æ{/™<à”î
Òûy¯¿| ﬁ=F¶B,ôe‡Üπ!ñú#CéÃôÛ¿Ïï¡+9SÜÃ"ãLÖòıE–;Ê]`÷Qb>óúYÜÃíıe–YC%<¸ˆ¬–ö‹˚´ÆﬁSk„8cOC7ç≈˚ƒ›‰Ä\·ø ][ó>endstreamendobj55 0 obj<</Filter/FlateDecode/Length 19495/Length1 46354>>stream
Hâåï	XWÄ´¶ª´a‰ØôÓËI$¨qïe£K∆c›√H¢ªâGD9œD%t	®¡≈ìCºEDçàääﬁ3xF£âÎg÷`ˆ±Ÿoø|Ÿ7_UWΩWıΩ~ˇº™Nù>3\!89ÍÌ~–>ÃL"£ì¢R≤¯äg ‡ÒIÙ¨Tπ}ŸsÄ866erRªﬂù≈	ìÁ∆Jjí§1 >„b¢&›|= h%
écÌÒAÁôÚèKJù”·«‰Jbrtzñòrä˘7í¢Ê§¥Øo eJûï≥Ô‹µrÊ‡'ß$œHµ¿uÄB«{…)”c:‚√ÿ˚÷«]QïÉ N¬:°?;Eœˆ'W±*O'A•yïcM`?	s≥TgG˛ËÉe`?{≥––˙!ˆCq†›ng˚Ö2«n¿3≠l€–õÒcˆ`B–1…û*ï#Êø[‰xÅD'gµ∆≈µãõªáßó∑OWﬂn›{ÙÏ•’I≤ﬁ‡ÁØﬂx≥w¿[ÅøÍÛvﬂ_˜ÎÙõ‡ﬂæ3`‡ÔBﬁ}/l–˚Éáˆ˚·¯„ü˛<‚Éë·~4jÙ_˛˙Ò'c∆éˇiƒÑ»(ò=)&vr‹î¯Ñƒ§©…)”¶œHù9kˆúπÛ>˚|˛ÇÖi_¸ÌÀÙEãˇûÒUf÷í•ÀæŒ^æbÂ™’9k÷ÊÆÉ7mŒÀ/(‹≤u[QÒˆ;π]%ª˜Ï›∑ˇ¿¡CáKè-;V~º‚ƒ…Sp∫ÚL’ŸsÁ´/\ºTsπÍÍÆ\Ωvnﬁ2ôo[ÅwebG!†]%´∆®J8?n$óÃÕ‰pô‹.ü´·^ÒÆ¸H~±‡%úû/â#ÍI§≤ãI⁄xmÇˆ¥∂Zk◊-‘≠◊˝†{-˘HZi®4B˙X#çì>ïÊK•J©A2Iœ•óR´Ï&d£‹GÓ+…Â9T"G»…ÚByï|H/ËΩÙæzÉﬁ®Ô£ˇ@?Z°O◊Ø÷T2∏<>Ü…–€ña∏! „ßÚs˜”+†®≈]ÒV∫)Ω%P	RBîD%MIW2î% J%_Ÿ•ÏW îr•Rπ®\Vn*ç!∆0„˚∆Hc¥1÷ò`LLú›«∑®Gëﬁ¶≤€Bl°∂A∂!∂}∂«6{Ûƒñ˜Z^¥4∑˙µ6€õ˜å›∞<®Ù™±™›ú?Œ•rÛ∏tFmW»’r?Ú]¯p>CX.‘
ﬂêÜQ”ëû¬(R◊£ñ®≠‘∂Í@ó¶À”Ωê@Í&…“p)ºÉ⁄)M:,UI◊§€“ÈªÏûåZ £÷O–I-ûQÀñÛ⁄®uÌ†6B?J?éQÀÓ§Ê¡®u7Ë:®E&µQìÜZx'µl%OŸ—I≠öQª¡®Ï§cåg‘"S5ﬂ"ŸÜ6≠ÌF-Ã6ÿ6Ã÷`knéh	m£&∑¶9®ŸÔ±˙|Œ§ûı£wôÙv\ÎáÊkô–^ÇÕµÕÑ|ˆ¨ˇOY>xŒ?`]êU∑’«Íeı∞∫Y]≠.VçUmu∂äV≤
VŒ™≤¬«Mãò¨fíﬁÙ˙Nq”ÏßÒÃ.}:ÄÈÃ¶˘ çÒçsõ ¨óÓ6-≥Æm,nÃ±‰X
,Y ñmé¸F_À4ÀÊıµÑY˙[¸Õ√ÃCÕ!ÊÊ`ss_so≥¡‹”ÏmF”3ì’Ù»Ù¿t◊ëe™2ù0UòJôu∆¥’¥«4‘Ùæiê…ﬂd0ÈM∫˚πM«õ[é≈˙∆z
¨7àÎ≈ubn˚9È1Ö∫ﬁr≠sy" ›÷µX◊ÁXÁ«3bCò§	LØé∞h&¡T iœv“1ÈÎ‘œiíSû≥@›’1´ˆÏêaC§˛ài÷ß’≥~2€÷∑€g‘~6w±C‘^˙/ÌıìÃÒÍàN{Ïˇ“i≈jB4qˇ¿A!§√".r‡!,Üeêa;lw»dHøÑï=¸ Kad ≤ÔÈsÿ;‡^BÏÇsP%0¢!&A5ƒ¿Y85p.¬%¯b°.C-ÏÜ…ñ√®áàÉ«`ÖØ ¶@$A"LÖ<HÜiê”aÃÑTò≥·ÃÅy0>É˘9îB>,ÑÏ+ˇ<Åßpsp™êC∞A3Æ≈\\áÎ°ZëPD'∞„‹àõp3Êa>:£5ËÇXØ‡G‹Ç[qa1n«∏wa	Ó∆=∏˜·~< ˇÑ´òâYx·a,≈#Ëä](ñ°∫£zB‹A/Ù∆cXé>ÿó‡q¨¿xO·7Ëã›`Ï≈ÓÿOc%ˆƒ^®Eû¡*xˇÇªp%îQè<ãÁ<V„ºàó∞˝–4‚e¨≈:¨«ºe¯æâΩ1 Ó√ºJôîEKh)-£Ø)õñ”
ZI´h5Â–Z+¯S.≠Ém¥û6–F⁄Dõ)èÚ©Ä
im•mTƒ«Û	TL€iÌ§]TBªiÌ•}¥ü–A>ëO¢CtòJÈ•2:FÂtú*Ëù§SÙù¶J:CUtñŒ—y™¶të.Q]¶Zæôo·[yª 
*ÅxAH'¡YP™£zj†´tçÆ”∫I∑»Df∫Mj§&∫CwÈ›ßÙêæ•G¨÷üêïû“wÙØ·uºÅ7Òö4û¢ªË!zä^¢∑Ë#v}≈nbw±ßÿK‘ä:QeQ/4^oçè∆Ìﬂ4◊wpóEwü˝=ªœÛ>˚É$‘@HO E"Ωäàää¢gùQ,ETZBïÊ›âÄÄääs¢ûzäïét)°C°&!rÎ›‹˚◊ŒŒŒ<Ûô›ÔW !)ë√rDé 19.'‰§ªÏ*\•´rW\µ´qW›5w›’FÉ®äÇme[€dõbSmöM∑6ì•°4≤Ø⁄ÒvÇùh'Ÿ◊ÏÎv≤}√N±o⁄∑Ï€v™ùfß€v¶-≤≈vñùÏ⁄9¡n;◊Œ≥Û˝Îµ¿øbãÏbªƒækˇfˇnˇaﬂˆ{É}¡ü ˜€•ˆ}ªÃ.∑+Ïv•]eW€ÌGˆcª∆~b?µüŸµ“X‚•â4ïi&â“\ZHKIíV“Zí%ER%-R)¶NëËNÍLwQÍC›®;ı†û‘ãzSÍK˝®?†ÅTHÉh0°°t7£{h8›K˜—˝4"2[“%C2%K≤•ç¥ï9%ß•T ‰å‰Jû‰”TöF”iÕ§"*¶Y4õÊ–\öGÛÈZ@iITG#QUπ:ßŒ´?‘uQ]R™RU©+™Ze™uU]S◊UñœV¯†	"Ä`¿C®≤A¿AÍ@]àÅXàÉzP_µÅ–PµU9–C<4Å¶ê Õ ö˚åˆ∂œI*WÂA+ï≠!R “ 2 S
§ùÏì?døúïr9'ÁÈ'»Çlhm!r!Ú° ⁄¡p#˝Lø¿"åÉó‡ex^ÖÒ0&¬$xç~Ö◊a2˝Fh#m¢Õ¥Ö∂“6⁄Nø”⁄Iªh7Ì°Ω¥è˛†˝tÄ“!*°√tÑé“1:N'Ë$ù¶R*£3tñ Èùßtë.—e™†J™¢+To¿å¡X™°´áıË]«˙ÿ b#™ÂÄ6∆x÷ad√ñâôCvÿõb6√DlŒQÆ√u9[`KL¬VÀq\èÎsn»ç∏1«sn 	‹åπ9∑‡ñúƒ≠¢Üì9ÖS9ç”9É39[c2gsnÀ9úÀyúœ‹éo‡π=ﬂƒ7c
¶Ú-‹Å;Ú≠|ﬂŒwp'æì;Û]‹E.»EÓ ›¢6JQéÜQâ:ÓŒ=∏'˜‚ﬁ‹á˚r?Óœx Ú ÃCxh4≠≠ç·ªyﬂ√√˘^æèÔÁ¸ ?»ÒH~ò·ø(~T.Òh~åÁøÚ¸$?≈OÛ3¸,è·±¸LÖi0f¿L(Çbò≥aé\Üπ0Ê√;∞ ¬"XK¯y©êJ©í+P&ÔÀRY&ÀeÖ| +eÊK5úÖr=^O‘ØÈ…zäû™ßÎb=[œ◊ã|X™WËïzµ˛HØ—kı˙k˝ù^Ø—·úﬁ™wË=zø.—«Ù)}FóÎÛp.¿E∏ó°*°
€„Mx≥¨ñÂ#©ë´rMÆK≠‡
TC\Ökpju†ï≠u 4bf·-ÿo≈€˝ÈNÿª`7ÏÅ}p ∆a∫9ﬁá‚#8ü¿g9ùä/‡À>M¿I¯:æÅo‚€8g¯å4Á‡<ﬂ+ÍL\åÔ‚{∏W·«¯~éÎK¸ø˜ÕÊ7‹å[u6n«]∏‚ùã'∞ÀÒ"Vb÷˙ﬁc}ÜØkbM=”Hóöx”Ã∑†>—'ô÷&≈§ôìe⁄ò›Œ‰ô”ﬁ7§[}⁄Ôd:k2wô.¶´Èf∫õ¶ßÈezõ>¶ØÈg˙õf†)4ÉÃ`3ƒ5wõa~ÁY#ü˛>:‘¢›ˇÊcÜõf§eïµúq°´„‚\C◊ƒ%∫$ó‚“\ÜÀr9Æ¿µw‹ÌÆ≥ÎÊzπ~Æ–u√›7“çr£›„r ⁄8Øˆ´Í†:§J‘aÆÉPÖÍ0bhBR»aJË¬hX'¨∆Ñ±a\X/¨Øé®£ëäHe§*r%R©ëM≤Y∂»VŸ&€ÂwŸ!;eóÏñ=pN¡i(ïı¡ö‡x”¨W¡⁄‡Û‡{u,¯4¯,¯A~&ﬂìuﬂ;¯’_MU”‰'=H÷CÙP=PÜ◊√Z	ÇÀÍÑ(u£hâ¿∑ëóÉØƒ∑b%Fb›&∑Ÿmq[·-ŸÃŒˇñEÍ∂`∫∫C=ßf™"U¨û˛©∆	õ1f¨y~î/dù|)_…◊Ú/˘FæïÔ‡'¯~Å_·7ÿ alÜ-∞∂¡v8 ·î¿a8G·á^gGØq ‚ ›\∑–-uí7˘éƒáΩ”æÿ˚{•˜„|¿ÀÌâΩ∞∑∑ˆÆ«Ω∑∏7yªœ‚Î?âO·”:UßÈtù·5øà„%/yä˜<Ÿ{~À˚~EgÍ,Øz¶Œ÷mt[ù£suûŒ◊^È%ºå^lû¡≥ﬁiåó˜Áùﬁi¢Ì≠>f◊•˙¥_eﬁÂ^Êù^˙!,¡√^o∫7úÍgbìcrΩÈdÔ9€+æ≈t01”u;}Éæ®/·∫ ·økYêI	˛√w’ Eu]·sÓªª ¢¨?àÄ⁄∑<!ñç6*"Í
ª®•*àö]‘t°∆FRç©6	˛Œì6ö'©∆¶∂∆ø¸\‘F‘h0;ôDk≠∆k«håFfh¨’›◊Ô-H§3ÒΩ˝9˜û{Ô˘?˜"Î‚Ωo§⁄∫h„ÏqΩKﬂ÷o€≥ïı?PÈÈ¥õoS›B9ò&ê§õ®ŸﬂF}˚ı§©¥hÍE”hj‡dˆP=o∞ZWhΩ@õ≠ΩºÃ⁄¸Û®“oÅÉœ$”pöÑı”P©_—.Q–˙-≈Ru¶ë4Ö{QÀi∫^§utàü±nÅjO¯ﬂîGci¨uÿ∫CôT/◊8Œt˙*˙Ï¥f[’‘è“»Î¥ı9ePù≈‡…√Mr<πQÂØ§ó9Y˚†ó–_D8^Ã“
ÔÅ“öé˙ˇi2—Y|»›πÿq∆—b˝ ∫LNÍA¿S5]·°<QlëÒ÷hÎ,Õ†}Ù‰µﬂ&9CnuÃàå±^µﬁßD⁄ãˇ]>Ï‚¯Õ›•÷Ô≠∑(¸ÜF&ÅN9zö√ËP˛EﬂàZ´ñ∆S)(AUÆ£÷¿ßQK<'û”N“@H;‹>Eø#ãÏßt∫˘'j˛K®¯S˘«\éò˘’IÖ8Æm–ˆhß$ÀÌ–∑AÈ–—D◊;—>Ë8;p˛√\ÃsxzñW˘ºP‚ö∏)cÂr˘≠ºÎ»àúè|kM≤nPoJ°ü†Î©Önˇçˇø“«Ë∑Æ”–s‰p˙Ölt’Qöò,jƒz±Eºâ‹∞V;,á |˘∏<&œ"V«Ñc"w^èºy3r¬⁄kùÄÔt≈˘Tç.ÖWl°˜–ç}å
ÙS∫`˚Œ…e¸®ÃÁUº˝–tW!%Eﬂ41R¯@uû¯Ù¥,zõnA∞s¿YÒ©¯Z‹–Z"‡I‹âJk‘˛¶})]2CîÉÂdYÜû`ﬁq»€;Ô;Z7ŒÁW®©WƒΩõy˜≥E™"*≤æOZMlB∑˘6tq =ÊQh‰X·ﬂ∞B
zßá¿˜.‰"û»èÚLÆ‰e\á\ˆ2o@ß˜$Ä®'”ÑGå•",*Qø’°*ÿÉw?rŸiqF4ÉÛ$Õ@Ó¨M– ¥⁄êaÅˆú∂ö]´Ì–ék'µÀ⁄WZ3¨ñ$˚…ß‰b˘ä‹*˜»» ?«ª˜dì„Ñ„é„éS8Sú}úÉêS∂9/ƒ8cÜ≈£O8s=∂]`&8◊ÈæG$#˚â¢ß¨ÂfLÙeI	ê‹;î"*Æ”-ªtµÒ‡-Q$ÀˆNßW*Ï_¿h(°Zß–òHûß]|Núó£–≈Ü8Yn’ûp|(‹¥ŸhçxW‡|⁄#Úƒt±Q#æƒ€Ë¸˝ó¥éÁ˘¥ìõ9óüÂ·\KßD/≠îWPûµYHÓƒ∏Ö¿-ïÙ=·téÆD6….Ú‰ßFZãæAüÛv∫ÕÎ≤õÜlFñ©áøØ$;ÎÕBú’"ìëAÊ:è”v≈wéñã©Ö˛KW˚·Q˘»§ó#’rì¸¬ne#¬e¥qWE„1ó‡%1∂G3Èq»%C’≈TFÙ,≤ﬁZKY≠Â÷"k}ÑΩ∑—á‹Ê◊çÿëG‡}û>·’à√qñÛ˚ûH5—UÓÕÈ<Ò–ÏXàõiÍ™CécŒ¡–ˆ
⁄ èæ oéÉ≥È]•õ€$S=~s¿{ÄÊä†vê
8Öj≥ê«Û€$ôèSñA{œ-»3Èùa¡Iêh6Ë«‚ú"Ë˘ßX˝:,∏úwc¶Y;ìæÜ‹]9G, =/NZè¨’ûŒ—ó–∂Â+y¡«”q÷Mzî*@as,ç@fıiG°Ô˛Ï¢|N„?b_⁄ï˙“«,(+2… ’⁄A‹1Ê_√ÌïJ£¯Ipë 9ÓR"O¶°ë)‡·$kRÒﬂ£\º"*≠:ÌÈ»\˙à∂√&^π0∆Á;’;fÙ®ºëπ#rÜ}‰GC?<h`vñ'Ûá HÔo§πıÙÎ€'5%πwRØƒû=∫ws%tÌﬂ9ÆSlå”!5¡îÂ7
C∫ )ôaåümèç0&¬˜MÑîé©¬ékîä.”;ÆÙbÂœ˛o•∑u•∑}%ªÙ< ÀŒ“˝ÜÆé˘ΩëÀJÄÌ3Ç∫jé¬£ö(‹∞€ç∫øwïOW“˝™païÈ˘p\CÁ∏£†2.;ã‚:ÏH%5ú4ö£ÄHÚÁ6äÌ¶Tä·Û´d√gs†¥t∏Bó¸æT∑;òù•∏`∂QÆ»»W	ûË*àíQŒ%£W€“–jΩ!´…¨otQy»_aTÑgî⁄4∫y@◊ßí_Ï˝›áw/‘›èM’LÔj›öfùÆöJ˜c›ˆo0à3∞W§ÜÃBêÆáãJuP+É≈+AR∑%±•jïØ“€3°9∫Íd‰UÊúLìb*ö≤»Ω+%≈ªœ:O)~›ú0‹jL™˚˙4Ù$s ¢›…^=π#&;´¡’≠U±]⁄Ä¯.˜ïÌ∏(]nCES⁄5À6G∆8Ñ“gÎ‡$`@¶˚ß2áÃŸ9XÜ'»ÿ•*`ëj’© d∫rÌy{ør§ª›ºA £˘Z«ôp€å3›uÉl–ˆìvW˛¨<ïôiªHLl
GG«C≥≥6äaFçK«‘G≈–m8ò;ÍwªmØnÙR9jII†u¨SyÍ.ÚÚïŸò¶{òƒi6f…=L˚ˆêOﬁC∏ú(Q≈f¥\Ωz¯´r˜z ∫≤_Tjïîtøj”m—‘£V|N;ÆR=
Z™hÉD™≈¬)g∂/∂Åx%”ÒqFù∫Bip ËÎÖ ﬂ˙åsªøwOcLÏ}õ≠{WÙÔªmm\™\O«Ò»„‹≈õ¯ï¢hjôi∆u¿"ôf°°ö!3‹h-)7tóaÓ[≈V≥∆∫g–FkˇÍTUXÑUúgîﬂ`™í/Ø*˝’’µqÜwWZÈ$üt“ΩV|'˘ÏÉ≥Õü]éû±ä©Éqm0O;ÃQ7‘6òi·òòGf†!√ÿ–d&I†MÒ4ÂôñáMRõ@0i^§”)i$C2!≠[çqÜ∏@ãOÓÍÏ)Ù§›_⁄π—~˚˝ˇˇÌøè5H w,nÍEU∑Ãnn.»Ù&Ÿ¶Y0˚Ç√ˆ£*›0mPÄgiüÖ¡¢Œ¿¿ëÍ‘ºQÈN2ìlêFìıô$®"œ“ÈJc!9$áI…é?§«tÓÉ =Hj∞∆hD´á@5∫±¢êÖÉÄìÄ›r™ÄêÙ Ω®Û‹7÷}A:F#∫ÌÓì¨1gLgFá•aPU%%%2LA≠ ïKéäoï!‰r⁄=n‘z~oœ •€w∂WñkF„ux˚©!—µ≥∆∆≤[ø1Ôk3ëT$zI≠Ó-DÖ|;jÁ˜Fã,gë πÌíâ	êg1ù≤|É˜YM4ˆéjÕpfËˇ¡8fQÂqDïπÌ.'ã®Ô.ö33∑mÁπ=áf◊˝÷hÏ}„ﬁÁù∑‡8ÌäÒ»ΩFåQ„æâ‰„◊Ò
Çƒ.Î]‹NÁN˜~Ê]Óu)Á_Ê"÷à0≈9≈›â;π.la¨«„x¶†©T≥ºÔ·.PoÁ‡*8ü‘% ØëÅ˛Ò¡>ŸœZ^ >¶{º≈¥E‘E{\¨˚æŒ∑AõÓÚ∆m˝0¢´ˆbû≤çàK¡»~ ÀÖπÆ¬⁄ÿ<6∆R$4ûÌl]‰ç◊ß“ı√RÍN™~xîêç¶“CQ”ö©“H¡T*1CkA K Ù∏=∏†@SYróMØ†´`ﬁl„O_ü;‡ì0Ö√?ún\ıÿÚﬂÎŸpñ}>Gé,?ÜªˆØ8Q≥~˚M„?∆ÕØvõÃÌ"e◊¯4)¨ü◊+-òf-a∆ûáa«cé¢√$–y.úHaPG°π<»Å9˛†tÅh.Hä¬òIz¶œZ:π*3¢≥ÀJ÷è&G'Ç€lrbZ*MÙ` ‡Ò¡^%ÅI&ˆ˙≥Ê§#çFõ…ü(,%I0î…!Wh≤Ì¢´∆n†kô UÜOﬂ3^øk§ÔÙ/Ù1ízï∫KÿF4Ò'∞–ÿO¢ÁahLÈ¿√–SΩ	 å:2ô‰%A◊±˚µwI¨fôπGò±ë"l£fÄs¿K=äa;æåë]¢íIèX‹Ö«Y»öA¬ÂƒMÎÓ<%¶¥(Îîß¨H∂á±‰>LSΩîæ%Q@òŸ”≤ RÈ,.‚nRü1ÀhöWî«
¥]*n=˙¯ûÜéÁ}|CıäπÂ=¯¥;ÙŸÒÓ˛’≤+sÖ~”h)y¸;V	<ôò∏ü!ÎqÅ∏ß?ù∞’⁄ñ±9÷£‹!±G{M¸ò„√{,næB¨kl¨E‚dßË¥9•
±¬ˆ®≠S‹,}»Ál‚6˘6(;∏æ.Ö·‹NŒjâù‚vÒEÒeãA¡Í´ÕÍ<Ó∞Cr¬gè9ù 2È"ƒπÄEÏágÙB H.
{òÃ së°ôÓuj1i!◊√¨©•+∞&•“D FS&mD:&ôK•âÖ≤=ëË.â¶ƒ-“[PN ÚûÕ£t $tzñO÷Ìˆ8BT	“4Y~¿™∂≠˝ÁGOΩyæeKGüÒ´ÀÎØhK^˝®#9n˛©Î¯Ù¸˜ü>p%wF◊+∆_a’+Õ°Ã/©Ü¸¶ŸÛñ[±ôMÛ∆ˇAﬂ&:T/ÍïrøÚZ‰ù"öàçãàçÀm≈≠ë'òM¬ëO¨ó5k3øD\¢6k´¨mˆˆ–ÍH{—F•KŸ≤⁄µ˛Òk}è‰≈M´∑˙¸ÒFµQ;Øû◊Ë¥ö÷∂©€¥/‘/4& OÚ’|-!ƒµ:æNò£VkB´∂YxR›)¸T=»´éÁFe4Ô‹*´jº@CœRØÓ∆◊z·ZÔ~/ÚûF≠ 0>®[˝âº ;)0íÄ÷k˝¡xÍp©òûá=dÔ$gØ[¥ÓOH4§ãßrﬁëqÙËO‹S«¯KÚ
{§íÍ‡à<·@_Ò_&cænQ”I†œhÆ7Ω◊ ›!6∫ﬁîætt4ö∞Î£CvO"ïJØèF≥r°> ,¬«≈I˚∑^GB%ÙCﬁ.Ù⁄Õ∑ã∫ÕûÇˆüm6sÏK]¥í1!¡{ÕñïôøÊì™^‹§ªfÚ3ÖrµúX+T´5⁄A˛à ÉTÛd*:¬nSm≥ab^ÂÒää≤ =!≈,„rz‹t6≤LùûÉ˛˝›œΩP˘Ω¯¿≠ñÓüåÅNËaçè[∂l´ùV4û¯sÁ≥„‡úq”∏?À}a«Ê∆xm¿^ÚÌ•õè≠˚C€Ì˜ÖÙ r5Ok˚—Ÿg∂~∫íégH7ë∂Ä∑ =˛Ü>+ß|êá4Ecä•…±O<t"≥#AÜ5Â“,≈XXRà‚hÄy\Jt™]œaå)
ëˇ:Úêo3»Û*ÀZÇ ı#œÔ·ˇR∞≠è[±2[C$}“êW Lò!≤}'Õ˝[∫3dÊû=aÊú'!v„í®Ö§!±ﬁÏ—îd∑EzÀT]…§Æ ∑å‹ôÎp9lÜ·íÃﬂ—j™1sÕ˚]f/ôπv¸K∫Ñû40¶ıU¨ﬂíã∑^`nnm¯™ÙπÃU¯j|À
⁄|Ì]?Û˝‹–?x◊ˇ^¿ 0ÇÀÕ¯‹ÖÃW≥o#ÍBôWôwÎπ¯'RÚßó EBæ-âÁÎjÑt>%æ6,Â◊(fÏ«D[ºRÅ@ëî øZQä`–…®‰hKBzÆ\“È˛Kuπ7q]qxÔÓj•ïVØ’J+≠Â«Æd=,ß~hmY@ÒÇ-7ÿPõ<»åb”∆…4ÿIö}ƒ!L^êƒnÄBm¶0-åyŸm:„2•Ö°í?R¶)Láîî©œî∫ÁÆú>÷ñÓﬁª˜ÓËú{Ó˘}«/©Ú˘‚⁄ÃŸ≠ÂX‡ô—¬c£ÖÂ0C”[QUƒgcˆl17Ãë≈ö„ß9|*'µ™HÌÇlÚv%B(ó;EtCD≠bß∏Y§ƒ@≤g…<:<gßo:áÖ6ëÔ›¬ 9ab2>QF^L‰√|º¢ıeßÛùI"<7uÆ†P]^&sâlV¿R–_¨ã}9˙Qtú4)¡' 8ˆ&§Òü™M¡y AXüº™≠AÊ◊Æ|4—BîÍwl.3ı‰ë‹ë_µˇ¯›À€6∑¨BO◊ﬁ	ß÷4.œ$]6Ú/_90ò›}NüxÛµÂ¡T¿“‘4>–ÒVK∞¥$∏2≥Pø∆W˚£ã∂WGR·‡Ú]ÉÜ.âCì?˜P´≤•S_+ ˘v¶›⁄Ók˜gÉÃLΩ–æ–SSê°[Ï-ûL¡†y?kÂ 	Ñõ0n2x/<6õì∞ä≤EÍ-BEÆ8IE ‰‚ázâ~úπ
ÎÛ˛Ó[¥bzv—_øzùWÎi¯√J›à÷∞F≥md6Z7˙6˙{Ç¶\ñ»%0UÄÎx†6pX‘ÎÅëO!‡≤](∞}¸ºÆœNÆ=©ÒÍ≤≠πWwtoÿi˙≈ÏÃ†~[ˇó>£__õ=HñmÌ˛˘Ÿ√á0ì¨€◊Õ€æW{Çœ2Ykñœ[ºÃ{»≤ΩE˝E‰JÂx’@3’»5{˚YV0L∂aÀ5áÕÏpBÄY≈∏√AÿZßìêˆ`˚eK†pÕ"√`L¶}˜ÛVtÇ-ûWR∞◊ﬁ√ÙX{¯º≈L.+À582 R˘dµ’ÀˇöKØ”-9ŸqN§üﬂé≥|E„∂u;∫◊Ô:∏6ã¢†($]è{∂¸π£GŒ{ﬂÉ§wÏ≈u’w'	NdΩ€ZØ±m,Ÿœé±SÏUˆ.k*fªÿóŸ0Qåä.
¨”à´ƒMXôÉ˝fLåô∂íÊ¢Ò©fÂ∞J,ıy3ÛÂó¡_@~∫Ê¿Û	Ï"Çœ{(†ﬂF˙,¢ı«èöÈ»£Î‡¬wÄ≥êõ|ƒ∞Ê7{DOáeìÖû†ëjQ]çñFÁﬂ\&˚º–mvÿŒf∑ì(‚#¥í∞zr:ºDÚ„_ÂS¬Í^ˇàüÏıœ¯…ª~‰∑⁄"`R|h
œp¬íÕ@¶àÛør⁄e6tÓÜA˝g«dŸ≠e„5h"≥àÙ“Y˝vxezŸã	0ŒÙ∆«π≠≈d—Òum;∆ıb:rt√¶ﬂ√lS	±ÁKÀ»Û⁄„fBñ®ËC˚¯}¬˚—°2÷,4	$ˇK˚§„wÚÁ°áˆ˚
∑Ø∂o∞ŸﬁÁGïIŒº$§Ö#› ˙».~ó∞Sy5Ã¶"¶…÷lou6…KÅL¬—Hä´ë±◊ÑÕå’‰feø= )ä2á≠¸nã∞’˚R¸;eﬁeºCeßï”!{?⁄#æÈﬂ_v¨l¨úeü&áTü,Vã}ËÜ˘íπ≠tO)Y™˘’R	'cMÑHj+GïÂ®¢ï…ï.‰J"Ÿ®Ùúl}æÚ≥≠∆≤P˙[&∞œCö42Ôº«1Ω„}HLÛ0Q√ ƒ ä(µrìº
e≈ı®Gºè¨H$iIV»ò«Œë1©¯©)fkìê‘‰1◊œÊ‡ÀÊóü\_FüÀßbe -˘V1–0å˚7OáÛ˝ÄdÙµ∏y÷éjï&eü}P˘çÚâ¬»
gßi	€q&P†ILußƒ'Í°;≈Z}•T5hØP
™ Û›Ö˙—¢‰2Ëè6fz|0!mA£NzÜ&±	>^ÌKäºW‘‡•¢VìRE¨¨¢Vá/xØS,6DåWKDªSBm“úDŒo †q›J‡ÓΩÑ¡∏õw∆<±Âï©Æ\ŒÄ√‹%çµÒıŒ|Å˛~÷ûÊ.ço«9ÃÄwN⁄“^å`=$Ï<ÕÅT©†gaÉÊ@„˛ÊDsê∑+ëƒ?˜≠oßJÔ2˝¯⁄^ˇ¸˙'1˝ÅªsÕÊ í`˝:ªÊﬁ›?Œ¢äƒS´c¡äØ‡nY‹æˇıèﬁ~£jÒ“b_®»‹ÿ‹≤Û›kcpääÁæ ﬂ1"ƒ¥x	QÇB÷∏sÅ£Ÿëuö^¬O˘ºÑ»{ÄyR@~ä5[Õúª€Ià#‚òHuA30ÅËq/¬i˝·eÃF^ÁllÖµÇ *P'»Ã–b~*"Ú´Ωı¬∞pB†∫Ñ~aØpUòLÑ‡JÑJÅ“ñë/â¢e,ıçñ±Ö+;¿≠¬‹T]v—ä«PSA—Â∫∏E¯±‰AıSo)∏ìN∏0À!o»->±”0 ªC5…öR7πm Fõ˝ﬂ¸˛Úmi˚ +H¢#7ıU€¡ÇÎe…ïô™!tÂÊ«GÙ›Ä¥Ê˛d˙áÈS„U— U≈÷t—(:f>∆é:Miæ÷W+Q≠…VïÙñΩ•FMÿ>∞üH|ñ∞ºŸö¸ÅJm*‹≠LR›ûnÔ&â™ıu®›"UÀß•tW”d≠É™TT’Çt¶6ï™[⁄êQze$Ë PUuu›ÀPs~Ë∞ÿcØ€ácËDÏJÏFåäµT„k}UoU’ﬁ*∫jÇåh÷‡@?úb)”POœ {JÜK»xrF‡çOO¢f"Ø¶≥¿Õ8Kﬂœ·[®~˙p’É8OÁ∫”∏ÄuâIiÀò∂¬ilEdÓf]ÂÚWëÀ°jö˜
$R¬dç áEÖ&ΩO'´√|çJÜµ"‰˜|•Î≈Pb˚øµ.‹ìˇºÄûπrY∫xQ∫|=Û€üË˝)
èF°#£˙g∫˘Ë¡ß÷~ıÖM•±õÏ˙}c¶#ìhÿìâEü|´¡ÙÈ}Ô%ºÙ2zˆ‚%‘{·GˇÊæ¸Éº™™ ~ﬁÔ/à≤Z¨∞Ö"≤∏∏Î
Ç∞à®e"ª¸–‘iÄ»q0G6óü" 	¢!ãHÂM∫jÈöô„ÑÅ+ï#§Ó.˚˙ú˚}oÁ˘X¡¸ß7ÛôsﬂsÔ=˜ûÛV5Ωπfu”€k◊ZﬂXΩ∆Íπ™°…ÈmóN*;≥˝Y\‹nÃ⁄÷¥Ÿz9∑_∑Æ}œUØ¬ç˝He·®’∑∂x4”)#˙≠Ÿ?∞≥ ]Ó¥Öııç«r$”Å∂m@{@0®i∏Õë˙˙˙{s≤„$æ3˚˙Që›?bΩlu^îinπúWùeú∑[∆[ˇêõ©õCùŒÚuwÉî“˛nÚÂ»EvˇÌÀ`\
◊C∏	∆D‹CË≥÷3∆≠:éë˚erP#W0ó¿R¯,ˆ d	uè˙˝Âv-gÆ˘å—çÙcî?ÓØó§óQ?N€©˝À‰€‘ê^‰ïÖaP!eB˙ÂπÃøPuFˆ`˛r∑<<L∫cã˙9»R‰ËHﬂé&Ω_˚òµÍ÷4˚3ãÚ0
Ê¡MÏèˆ/¢ﬂ˘‰+HüÅ^mêÌ‡,W§+m⁄W»FdoÊ≠[Ã∫YGÛö–ﬂËt|JUø$Ë§Î:5jB∑4ü°\Ær.5Áßk>ÿ5r%˚“§ÎÚÑ+ÿ›õ¨k;xÓπ$#·zÙÏmëe‰ãa†°\,w•Luép[‰^©¨¶\ÏK‡?“›˛@Ú¸Ó“è˝À¯c‡∆‹eÏaÇÍ~Ä<ﬂ= yåuLfÓ=Ò>ÈﬁêøñsK€FΩÏÎ0â=Xw©~Ã_®{Œπlï5=C€wôÁ:Ö9œ7∞ˆÏπ ›ÙˇcYfûÏ9d%P?ô=˝9<;Uácgf¨ı‚ÿÎ√èê_Å<®ÅjopÙ◊6ÃﬂñˆmçΩb3jõjjﬁnc´7™ÓŸ5òª0/∫3w“ˇ&Ë=˝rsDO⁄Í˛‹Æ6´˜%[mKm&ñ∆¶ßªA◊©6ïêãΩjπAu0Ûb[±‘{«∏3T:åNÀùZ©TõU{ã•Óã⁄öﬁGΩëôXkAtG
Ëû±ul1ñÒ^4ÀWd9cñ˘∞”:Óæ%√ùód∏7πêı˝ö2÷„÷ÚÜ]$#2’íœYé†Ôc)πL	j≠…Ãıà[≈^‘ „f_kÌÆn≠ÂyU·!O¨=^ï=À§[»4Vu∂N•í¨;’Ú”¡~√´íâ§ﬂ˜j√êı,‘;‘YE–%ñîoÜ˚†WÊ"kYfäµ5(ï_‰LuK‰rØD˙π’2ÿÌ %ÏSw K˝kÃª[…¯ª≠:©‡º
:H7Áo#sŸo‡@«G^ü∞£œÿ\⁄ñb€kZ™ÕËªãÙêù∏w€`;ºÒ7ÿá=^◊®o–˜Ÿ¯ﬁh®»⁄kx∏Ÿ>˜»J‰Ob˚LŸiØî}iªLKı-˙æﬂ¬=Eèäx˝˙>Íßo§æsÍ˚‚ˆiôËøÑ∑„œÊÆëÒ—ΩŒá"(då—;≤›Ÿ·éÙ_∑É√ÌŒﬁpªˇX¯t0%|¡ﬂÆd›˘Õ>µ:˚ñÈ}ä}©Óì˙≈ÿèz=dbÙû-7môﬂ¯—2Ûà?É˚7Yng‹ó‘ØÍ=tVrÔÿO∆ªﬂ]'?t˜I%∫∑w~ë-woî·˙&∫”ISŒõÆıg8ï¶~î˚ëLwÛIØCÆê≥˝@¶˚ø”>aç)€ü≠”2oº<ä›∫ÀZoìå’≥“uÿ}√Ωzˆ‹˘ºÃ}Úx ÿ>YÓ÷≥Êj÷∏€»∆û¥ÔsaΩÆ/ ÁzÎ”6†}¯ÎËÌ«R≥’fèñf/tLˇuo¯rÔß23”Vñg.‰}:*yoâôkìå…îò}wçø˛ê˚Qáçï \Ô´·ß∆˛7Ñ°Sœ™„~)u§ìW'+∏KsÕ˛dÂ<Ω?NùtPa}£M<Qáç?%w˘U2ﬂØ∆ÓjÒµú[kô"ﬂ$Ω¿≠
h;å1DÁ¶¸ü®ü*	_’˚TK«†Ñ˘i£:ò¯èyùËªHÊÚñ…‘…ì~)¬=j–x\í≈‰g√,òü≈îÂd•ucÃ‘r˚y-lë–“ª‡>√›[!CúüI[w"Ò√˚rø](sú·ÿ›a|Ü#35ÔHOÁ∞\Á|b¸œØ≠Ù3ÌrÒ„e§;é˛’2¡›,úêtGXÇ=“œ€*„ΩÔg›¬8ˆeÙi##˝y§√⁄ŒÃÒIò´∏3§ÿÙK`tçQù◊$t^¬™~å=®æ§ì˙™ÆÕzF:O?≥Nó~¶Õ_e˚Ù6tœ ¶Ï
©Ç'Ï∑à√´eñµ4‹∆æ^ù‚⁄dﬁùeÕÖë‡∫≥d≤7Ú}®Öï∞˛Èˆï{'Ú9˝/PÏﬂÚv!©
~ÔƒuItû„ï'qﬂ∑%Û^±ÙWÏﬁÙÇœ÷ôˆ´§è{ÔpQ∏Mq¶K[≈?KÚÉå‰€˚(/£_*ÔıîG›©¥%Nk:ùæ¢ƒ>ñ$◊ü2˜svBvQ…˝Í≠˛˘ãËw:pæ≥·fˇüêãç$&¬]÷π≈z7¨Á=˜ïl^ÚÃ~Æí≥„s¢|Æ)Où∂rôÓy∫úÙ@%Œßœµµ<„NJ€ALP,%ä˚Ì!ù«î(æ⁄XAÀ|Ûº'b¥ÙaüÆvG£Àæñy?G
{˘e‘ø'*Õ˘—íØh[ÖΩÌ¶∞◊€{ü\†8£®e⁄R˚:V˜’©÷æ¶ø9üÿŒ”ÁC_qœ{ÙwbÊ—íóñ…;õæ∑È≤¯-9^õ‘›(:—òˇOpwˆ¬n¯√ó:vn	∂
9BL˜Ò∆Fb’'˘«|Q*DéÕiÿ)“x+Ô>∏ÒY JI˜@~)õÑƒ5ºKzuØC<·~MÓâ‚ N‰áe˚{:Ø{∂øˆ´'⁄i∏,€øa¨ ˝2`eªêãëGiøë~„êƒ ç˜#˚ê	ÿC„…¸~„Âp–≥ë0¶±ê˛´`∫∆#«˘˝ﬂ ¸|^âéì·ª&ÊDﬂÙ?ƒÁñÒy∂"”ˇÒ˘∑&„â2⁄bæΩJ‚ﬂÁ§ˇ8±‰<?ç8ˇrèS&é&ñ51∑∆èë4Òv≠â'-SFí˝T=⁄iÏ¨Ò+r•˘œ{} Â;ËUfÙä˝H‚mµ‰»ç‡›ì°¥˘˙¸õ∑ß=˛ı(±e•"ŸÔñ,·ã¯Æˆºπœ[;¬£»ÚùÒembüø≠-ﬁÿñ>ÌKÕü™è<ü:"bRä∏|bD∫æ0¢´íˆ≈ßJkæ˚¥}˘	|t“O—|ÏÁc⁄íb%(AÔíñqi:h-ﬂZú{™˘t‹ë»oRNRoÚÈ∏$ŒßiQﬂ“ˆ≤ÒL˜-&uÔNÓÈïÓ‘/Ò}çuHﬂ„Ê˚Â˝Ÿrã•µNzÚé‰√¸Ëø´i|`xØ˙∑L£gûïbÚøÑ_eﬂúp\÷˜ÖÛ≠-ƒ“Îì”Ù ˘¿≠1m«FåkÕû”v´ÒπâŸ3£{%gqD
a úõ‡Œˇ≤^6¿UW?y˜æ{ìÄ|(h %êÇéX@'E, ∂êJÂc`Iê‚@µ-úé¥h≠µD˘— C√Gh•)	
„iËZ@+VG™•@Ö‘X≠ö‡‘y€ﬂŸª7y>xaúÚf˛sv˜ÌÓ9{ÓŸs˛€ˆ≠yC¢{üGÂ’wÆ˜OÛ	{}íçfìºÛÊÈ{è~W˙]…≈Ö¡v)JÓñu¥#Ûë˘‰˜*p+9ª"π◊¥œ⁄9∑_πH&ëÁg'=πÀo4ı‰Ù€í<5Ê…J≠ù dÌ÷.•]àÏ~(´Ÿg+ÎWh®É-Råñ"∆÷:æ√‹o„€o&éIyæ/ˇ898òÉÍU0–÷ò.å]ÍÁjî`∫?LÆ√˘ÔÀ`ÜwäΩ7⁄µ'F…6Ô¥lÛ∑J%˚ÌÃﬂ"´Úˆ ™\ŒìW)µ·§÷ü'èÁèêﬁo5Ù´µ^≈uﬂß‚6‹mKÿGn÷s≥˜ 'À„3grkﬂ0ÚÍp≥1]oº.∑ﬂîq˛ΩRCø˙|‹Ü}ÆÉ¡I–î©Ok≥◊«ºI˘©´Ò∑∑’¸Jœ>◊–d}ªAÜ¯≠æ’∂VS≥ìùŸß≥µ›˙8”ñX~iÕ∆Öbnn¥q”(5∆Ë=‹XπÂ£e"ﬂk2(H.ñôî%∂ò=ms‡LG˛≥À‘NÖ∆óãπ«õπ£ì⁄ˆﬂê«˘F:‹OúnRﬂ˙'dπµ±º@)√WMÌ‡nµ¡4˘uËR‡/µ«aù?≈∆g/õÖ˛ß2ŒﬂlcÊbŒügm≠ÍªπƒË0á˘‰3ÓT,≠ØN‡˜e2ŸûNÂ’∑¯«€ øjîÒ‹‹ØJy∏îx}ÜÿYàﬁ±“7®'• ∏~∏åsﬂ»⁄Ö≤$Ò±î(rVò„	ü6Ü(<ëfNÓëúwÂÔeôãøj¿¿*Œ”¢–yvnΩÃr∏JëÿíSÃˇª@‹æ$j€±óZ6•ÅyÊ8ù¯ ›≈Ïü¿ÆG6y›à’∞Ê6Ù¡¸*æ˙,J3¡ZïWgÇqïóg¬ç˜Œ„*«dÇÒ1Á∞#€ºlvdø"å_qÏ»∂oˇL0ﬁø˚&dÇÒ	ü√él~ê	∆t`«§L0>)”Ú”3‡èºQ£ıìZ}r;rÚ.4mﬁΩf∂ÎÔsÛÓhá˛L_áØÉYÃ°õ˜¡z0•™ÀÙå÷ƒzÃù¥õëﬂàtÈ⁄‘ÆH∑Ö”ô⁄‰l}¸6≠Ø∂£;u<“gucG™!‚1f≠õ?“È}*≤;uÚ˚—|˝_œh◊=’√ı3‰ÒV=€‘v®Ì©m¥üà8SjßÛÂ∆Ho+ÔD”vˇ/iœ≤èw‚c‰√Z´s"*5◊⁄ú[%=“jïÂ¥¶˘.¿ˇzÈ¿·ÿ#_yÉÊp˚û$Ô€˜‰õ∏Ç≈ Í»Ùè±«/à√.‰ÕEr•Í?ÜØ∞∑÷]Âﬁ2Eaπ∆n[´Gk=»%”ÉÿtRz≥ax@ñ3…ß—[∂Sx˝€·?î  îπdy¯ˇ{2ñzUè«o€‡AcíÉ§S,;çêÈyøg|\™∑LP}·µRÅœÆãu∑˘°^ﬂπˆª´ˇ∑Ä≠"gæ&Zõ±ŸYhk±r'ı…~YÇ=É¥~‚∑Ó~é\\∆Ω:#WÜyã≤$/!k¬YÃS]?W^◊Ê˚¡ﬁ	Èº.ÉíHOÎÎ'e^pø~.Ì$ıay8R.K÷sÆZYÎÔcØZÈóÏ)Ω,w8h˜édº«¯Ã	YGLÙŒ‰51èj„7ØpÅ6Ó<*µv¶ùﬂ 4æa˝û‹.”¸;Â+˛)«3dlSxPjÉÉ6fZ˛uÉÃÔ•∂nï±¡)Mñ¬”«KinoÈ>)ΩîüÖ≥âMÂk‘Ë†üNÆÓ∏)Â˚ÏGﬁ∂π˚]ÈÓ‹õ†ﬁÂé≤h‹ﬁM∆Z◊∫Ò9‡>P˝ØˇôüDÌ÷£˝Ì˜EÛ[5Wq◊r∏Q©Z¡›ù˝T€i~^m9˝Ÿ“ÒzYÂxk«2Éfìzá˘Œi|8‚ìgÀI»ëqü˚˘zÂrÊ@Ã£3%sk-∑≥“úpÚàì/k¨)◊Àîiº˙ú2mÁ±Óû≈2‚’ã≥»È1ø>ül„ﬂYd_?ü¨4FÛT,√G$TKó«:∑K«À€ﬂOôr%<Ì®„± ﬂ«·˜G∏sì:Ç∆ù"h1ÕAK∫$GÔœ‘Ës (b^ëH¯¥iünó˙VÏ¡£¨{î˙“◊4ÁˆMó“CÅÕèE0;¿pºûªΩ”ÏÂ†ß⁄4√’”$µ£⁄æO ŒÖ†ΩµË©@Y<‹èΩd≠wŒ.aäu∑Ÿ3∂h-Ï–[»}=±ÊzNYŸ¢à˝˚1ˆg{◊~ØÿÊXø€˜ˇ˝éÏπº#dˇ.¶Eq°Œ›ëÌ…ΩÊ5pD€‹•√Ó]Ç4-äõWXªõ8#ßE–˚Ã‹fá¸˙¯ªÊ(á¿./ç-èP†«=ôq–‚‡˙zAìy+oéË=vöì
ÂRÁÚO¯]Û1x$\ç<¿ö9ˆç§‹Î0w5_Ûª¬Âæ‚ºW®_‰⁄˝¥÷Án#∂Ö¸ÛºÃ˛,Á3S]ﬁ»>Bæ∏8xV ΩîLÍx€v&'˝’4)–µ»aøCuƒ˝Ãã‡OëüÌ¯Ø”·ë"ÌËCã©u|[yÏº©w£Òvª‚‹Î√ÑyÎ
gªïÔ›’Úó5ÿ∂F
·<Àï/ÿ—U∆˘dú≤ãÚÂˆ.Ãó°¬2áb¸RÓØÑ76 Tã˜òWgN+îŸÔ‘(SÇ2≈ê_m^$Ozˇ Õ¨}ŒY!K¯ÔbÂ>∫áÚAÂE^#~$ßxy„¬úΩ_"+"¯Ú>)…ôG=J{(b¸ã»ª¡=¥Ø@ﬁfÄz7˛#)Iˆ`Ø$mE1ÛvD“"!ÒjØ:OºƒºE24—ÃÿM ås–9øÉ„ÈcÏºíƒ{Ëò(˘^°kóÚﬂ!ê—˝|–Ï˛ãÁåiüì¸@∆Ê◊¿©.KMCr¥i»yOä¸rÈ∆7Ω%S˙zŒÒ(n´ô6–ˇ(Ò©Rx∞A±€4xÎÅì…}2<πRJÇKea≤óL‡-0:ËJæYÆ$ˇÜKWDo¢îæÌÓÁõ3|∑EﬁAÏx€bªì¡_dHﬁ"ﬁΩ∞,LóX&Í 2ß¬÷N!∂$GŸ[]ƒ»íÔòˇË]ãyn¯-y$|.˘ÑÃpπHπñ÷íÓZ◊i◊ÿIî1ÏDı1c"éoÙ>L%7Ë˝≠rw∏ _*ø“ÿr\PÁ◊{ó èë◊%j√()rko„¿˝Œá„ŸwC≤Åƒ j †}ΩÇvÉ"Ìˇ“˜7pøÓ!∑\C˚ö≥˚|œ…ü˘∂aâ|M·eû¢\Üzª··Â¨9~˛~–MÆV$Ê“Ø9Gøãse†][y˛~‚∏+º2|\vv˝7(⁄Œ}ûæ∑^˙+‚xkãÈlÁo4œ+á÷<ˆ—∂9^Ùh+àe√áà•bÊ=ê¯à;{ò˙pZ˙F9ú|ÿH‹mü⁄¯[Ì?øúúüfŒ\≠ Å5∑¬]g+/ıÃÕs -ÑˇÈZx>9v≤}ó› ˇcølc£8Œ8˛Ïå}áÏ;6Æ‹&óò_GIÖwCJ’F‡+òÜ|H|.æ`ÁÓt>C	vZE£ÄC_‘•> –§§¯ÿÎ∆P_Z•≠RNm™êJUÓU´™-iUıR‚˛ÁŸ¢Å4°ä"µ[ø}û›ùﬂÏÏÃ‹ÏÓgx≠≈öä∂úUÔ¢Í;ç◊†J∆ß÷µoP% µŒàøa?É˝›uIÂb~˚êGq˛SÓ:•÷ Ÿß«.πkØôjmSøC¨W“`ˇOXÉƒD Ï∂C¸ë"¯-pQœú∑∆’≥â◊N·÷+˛äÎ Wﬂ.¸ª˝,-RøAî≥ﬂÎ}…{ø|˚ÛÏ;˜ﬂÎΩe~v%Ô<//`∫®œõ0ﬁiﬁDªÍ‘ª¸ÂÔÆA∫Y=≥}+¯{Ö◊åe„Â˜|ıÃSœI5Njºˆ–¨)çW}HJ™±-äLıÏB?˝ºrEÏv·Á¥Í«?Zi–˝|¨qﬁºÛÒ{ç˙æSﬂﬂùy˘äoø∑øÂÍºπµ˜ˆ5<wóO“:ÔyuøÂÒ¥Bµ€]qi‡:¯'f…»áÉ8ÂÇßˆªÛ øSˆ¥ã›8´Ô⁄T<üπ˜9ªœ•j”5∏t5’Æ¶¶ôhÓßˇ®ΩC£—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£˘@0à™V“ﬂÈ„¥ü|$(H≠¥ë»wIº@Âÿ'™¶„ÿJRüÁ≠ ˝t
{π+ç≈^.iÆqüóó!rÚa/˜”˝∆î4 *Tù∆E/7®I‹ÁÂÇ™≈∞óK¬ÀÀêÁΩ‹á¸5/G{ƒ=K&E(åˇ€êuQ≈◊Rí CSäè¨∆^π⁄ˆ‡x?óXé36‡ﬂ§ı8∂~Üy/éGÈmÿˆ¢§çºÆ*€œez@ÜÎÎEôá”¥«íÙ‡—UkÇktΩçÿÎ«û∫∫Iêıû{Âé∂r&◊›«m5i3ˆÜp6√≠U•ó?kF¬·€ÃÆæ∏π6ôHfN≈Õ’…t*ôÓ…Ù'ÀM{`¿\ﬂø•/3hÆè∆”€‚ΩÀ◊m⁄poÁÍev∫øg†ÂÆ‰@Ô⁄Æ˜wàs≥–Ï13Èûﬁ¯C=È≠fÚ¡wΩºŸü038∑1—üâ˜ö2=ô8‰Dok2m&q&mnN%2È˛¯‡Úq∏◊—&t˙Ω‘â∫ñ]1¯-tÍ@ôµ∏æÚ∂†√xﬂüÛAñ˙üùîﬁÚB3•WÈ'∫FÏ*˘M ¨Qÿö $YÚπºø*bùD¨ô«—©[ôú) πco˘Jd‰¥<F›¥áè9’·cyÎÓ«w∫±ıVéŒ,˜¥^$d7@kÇ^÷	ˆÉq0|h–1zÃ )üëáú5!‘pÏyÚV6€s`H¥˛ÓÂ]Ùéî°UáÛ≥’Â≥’(√
`#`úÂîƒvÃ âÏŒ"!…ÉN0¥+Â∑i˘M
ÖP˚◊ÛAÓõo‰s#ñî_•(îìk© ™}⁄ì$P¸ßÂVÓ¬{Úï’ë  ÔE£˜¢!{q…,∂Ô[@ïﬂõü[ß™ˇíò√ﬁN'‹Ê&˘`}$ä^¯2.t3Ö‰.ƒEàõ"~NˆR∑” Çë\Ø≈;d-›Ç”∂¨√Ô<$Ôñ‘»≈Üúj˜:CŒ“ÊÓxµ¨Á"YEmà≥§ﬂâÑÃ)iqÁÔŒW‹†⁄∑€	÷FŒ»«•üÊ°‘JÕŒ»Jål%ﬂIWæ¢*2fœñ]∏Õ.tKm4–À	Æ(·†"{é¸Ñ\@u8∑U.§Zƒ5r«Ô»É¥Ò©|”ÇPaJ~ô≠™R\~ï;µVÂ´™#ªBÆ¬Ÿú‹áÿ«À7›!ªI.•0Ë„ad√<ÈGëçb‘F1R£©Q4j≥è‰úŸÉ2≠r•‰v„»’¥™u–°ìú,^ôîëıËò‡∫“¿—Ü|EµjYΩS3óã’ÁgWG:Œ»AÃÛA‘i…L~~}$9%õ˘V>ñØoTB ¡t=#ÁªC±N…π °:f°\‰‘Ürv˚j"á»?E’I‚◊‚7j∏≈9Ï´¯/æÏ≈_∫q¶ äÓèB¸J≈íΩ@¸ïuãﬂ—82!¶ƒãX¸C‚∑‚§jÖxMLR‚yÏ˜"N"Æ@<Â‹¯RË§8ôG@€øÂT’©õ/:ÀZΩ$¥ƒKÊ7zIM]ƒ^"^œ”TÒ*‚bƒÁEÅnBúF¨G,àΩÑ¯±íÓD¸æœä”jäãâ“ÌàyßZ5!Á¯Uòp|*w»›ã∂ÜNã„‚5†Ë˜ú¶}&ﬂ¥8òB}Ü8"2Œ¬Pç])õå†PñŒ´H5‚ê”Æ*sNõ°I1&∆¨˙vkâ’bï·%·ñQi.1[ÃvÛ®i≈>, „ø_±€v2f∞¿òÿ„îµÁÏ7qOÍæç`õÂ,Ümä3¬6x˘Ïúuà«©‘±É^ÿ∆ƒ∞<Â#0∂c5I¡H¡H¡H±ëÇëÇëÇëb#≈W à¡à¡à¡à±ÉÉÉcCµ7#∆FFFFîç(å(å(å(QQQ6,Ü≈Ü√Ça¡∞ÿ∞`X0,6¬0¬0¬0¬lÑaÑaÑaÑŸ√√≥a¬0aò0L6L&Ü…Ü	√Ña≤ÑÑÑd####»Fê«g(££££ƒF	F	F	Fâçååíÿ~BÌü@)B)B)≤RÑRÑRÑRd•••Ë›zÜ;C`⁄Ï√`(∑ ∑ ∑ ∑¿nÅß◊PnFFFéçååå9996≤0≤0≤0≤ldadadadŸ»Úƒ ∏˛Iy›C#36Õ¬≥Vå∑p¶?s‹EÁ9>J'8>BG9Ó§/r‹AÌ∑SG‘«1C°YÜjÿuX:A7HÇq0¶Åü≥s‡u0#VZ7ï¸ù˛qˇÑ⁄_>·/˘E¿◊È˜M¯¶}ÂæíOòv£®‚uKÌÁÌ0∂"ÿvp÷!⁄p›6¨≥+Òﬂ&⁄¨91/6ÁöçÈfc¢Ÿÿﬂlÿ‚ìFØtˇ"Ωjb⁄8¢Ã⁄aÉ	D›P:k∂Îl*q^;v™fòDª˘ëÄ)9…v¢^h	©®!U™TU™Ë°¶U«kÖÆWäÑz¨z•∑∏5U{Íïæ7kU}Î¬õoˆΩoﬁ7~3ˆÓ®$%¡ƒ©cu&¶Ÿ>X*aL√/”∆Ó´◊òó∏»|Z`ÿ2_ÅU¿∂¡ûÄ•¿∆¡í`:æ‡;÷P#eÃ ãÉ©(A˙˚·±∑G±jRînWäív‘1Œ¡∏ûq¿˜å˜~åEñißªƒ¿∑"˙VÓ)‡˜;Äw|Î± ;{‡Ægú∏Ì?≥Lîﬁ ,åCÁXÄœç8Î±õ@õÒÿ0ÄÈ	dèÄê—aÍê@Ω1Í≠@IÛÿ¿ê«&ë≠û∂ë§òﬁ)0ƒP&Ùgç:aju∞?ÿgÏˇ
€„W’¸¢˚Ù¶aı‰W@Œ0/A><*‰àœÿ∂æ∆æÑ\Tﬂe_∞Ûl#È+‡^áyØ		è=Q}È©uÜ=fX)y¿äÏ[`≥ÏÆ~è›auú&q©#=›e◊!·{)tèΩ´˚bäWŸáÃbõTÎX_r)»õJ÷±d<PÍ;¢˚∏«o§|⁄cç»…õÚm9+O…ö<$ø) }JØ“≠t)ùJDQî6%¨H
Q˙¸√ﬂ,ì¿∂ÌkÎFhc˝n	[h†%U$rç3![≤YjÛó˜àΩ®ÚøöO#3∑¯)-KyØMÏπ,ød⁄æ|8ÀS¶ÕÂÎ∑ù
•.xπÙâO…ú„”Ct≠ﬁ+$´Î5BÈÎ´ÎÆKb˝”±tÔtœ‰’\ãfæ—ö«WÏdwên˛Õ†À«±s8Ë⁄¸„Çz«©Iß•h>Wì∫\ß^ñNÁg—^Œπ@;4ÿÕ]@#–î,Qëø'Y§¡º^xë(I^"º0E^e_ÕÁ*™*8:!˚Ç≥Øìÿ106WI$KS©É,Íh™òÿ∞HƒPíLP(º◊âDå
1>zL—îâ# Ñ–
—c8}Áöúæs¿1ˇÁµî5iu¨º≤ó_“ÚÛZ~	lû˙~å?^T’ J*%ÊÔ›G\X‚em)«W¥úZ€kﬁ√òñ´êΩ¸úSŸ≥ñrﬁò5ñ◊rn5}Ÿ…¸KkÌHÀπ‹"ŸeLÊ†V:”"ú¡pµ2®ïA≠¥ïZ˘∏ÔØ;Öd›+w¨Jÿ√Ûq7€ﬂΩ<ç∫6è≠<∫C:LówjY√P2ìÃ`ægÍ˜ÈF(∂2xNw°np˜hY“,-AíÕ'fl/‹rp´pk°ıöÒ·…?»¡?‹óÑ¡ﬂI&)∂ºJ≠Ærπ\ƒ¶l	±˘H¡Êg`&≤RÛ9|ÁõæPH¯*ÌÌyˇ%Mò-°ˆLjB≠ú∫di´mKñ®P™ûˇ‡GxÇÁ8Èë7:&Nè™C:û_J’—â ·∏äËùçèÉB5Cı ≠û$t6ıÕ‰fjKﬂJn•⁄¿ªªN∂çèRot;DJf±YËñ\(6Lıæˆﬁ¬[ÿ1M◊,RQØˇõ6ã~Tÿb#kQ§/5$I`%ırsXπ1HÀbPê$∏;jé/∏˚GÄ h!ßªendstreamendobj25 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj51 0 obj<</Metadata 56 0 R>>endobj56 0 obj<</Length 5767/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:illustrator="http://ns.adobe.com/illustrator/1.0/"
            xmlns:xmpTPg="http://ns.adobe.com/xap/1.0/t/pg/"
            xmlns:stDim="http://ns.adobe.com/xap/1.0/sType/Dimensions#"
            xmlns:xmpG="http://ns.adobe.com/xap/1.0/g/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">bms_logo_cmyk_blk</rdf:li>
            </rdf:Alt>
         </dc:title>
         <xmp:CreatorTool>Adobe Illustrator 27.9 (Macintosh)</xmp:CreatorTool>
         <xmp:CreateDate>2023-09-25T13:28:08-04:00</xmp:CreateDate>
         <xmp:ModifyDate>2023-09-25T13:28:08-04:00</xmp:ModifyDate>
         <xmp:MetadataDate>2023-09-25T13:28:08-04:00</xmp:MetadataDate>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:OriginalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.did:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:e9ccb478-a5e7-984e-a54c-e534a8c2b689</xmpMM:InstanceID>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:db5659f3-6411-f742-bf8f-b16bfaa386c3</stRef:instanceID>
            <stRef:documentID>xmp.did:4edd90c1-b301-4d0d-b22f-f129dd224159</stRef:documentID>
            <stRef:originalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</stRef:originalDocumentID>
            <stRef:renditionClass>proof:pdf</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:b521286a-9a99-48db-800b-c0dd2945b62d</stEvt:instanceID>
                  <stEvt:when>2020-01-02T15:36:11-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</stEvt:instanceID>
                  <stEvt:when>2020-01-30T11:01:24-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <illustrator:StartupProfile>Web</illustrator:StartupProfile>
         <illustrator:Type>Document</illustrator:Type>
         <illustrator:CreatorSubTool>AIRobin</illustrator:CreatorSubTool>
         <xmpTPg:NPages>1</xmpTPg:NPages>
         <xmpTPg:HasVisibleTransparency>False</xmpTPg:HasVisibleTransparency>
         <xmpTPg:HasVisibleOverprint>False</xmpTPg:HasVisibleOverprint>
         <xmpTPg:MaxPageSize rdf:parseType="Resource">
            <stDim:w>415.562183</stDim:w>
            <stDim:h>104.989900</stDim:h>
            <stDim:unit>Points</stDim:unit>
         </xmpTPg:MaxPageSize>
         <xmpTPg:PlateNames>
            <rdf:Seq>
               <rdf:li>Black</rdf:li>
            </rdf:Seq>
         </xmpTPg:PlateNames>
         <xmpTPg:SwatchGroups>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Default Swatch Group</xmpG:groupName>
                  <xmpG:groupType>0</xmpG:groupType>
                  <xmpG:Colorants>
                     <rdf:Seq>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Black</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>100.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Dark Gray (CMYK)</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>11.000000</xmpG:magenta>
                           <xmpG:yellow>7.000000</xmpG:yellow>
                           <xmpG:black>77.999997</xmpG:black>
                        </rdf:li>
                     </rdf:Seq>
                  </xmpG:Colorants>
               </rdf:li>
            </rdf:Seq>
         </xmpTPg:SwatchGroups>
         <pdf:Producer>Adobe PDF library 17.00</pdf:Producer>
         <pdfx:CreatorVersion>21.0.2</pdfx:CreatorVersion>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj44 0 obj<</BaseFont/NXSWOC+ArialMT/DescendantFonts 57 0 R/Encoding/Identity-H/Subtype/Type0/ToUnicode 58 0 R/Type/Font>>endobj47 0 obj<</BaseFont/NXSWOC+ArialMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 59 0 R/LastChar 148/Subtype/TrueType/ToUnicode 60 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 584 0 333 278 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 667 0 722 0 667 0 0 722 0 0 0 556 833 0 0 667 0 722 667 0 0 0 0 0 667 0 0 0 0 0 0 0 556 556 500 556 556 0 556 556 222 0 500 222 833 556 556 556 0 333 500 278 556 500 722 0 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 222 333 333]>>endobj46 0 obj<</BaseFont/NXSWOC+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 61 0 R/LastChar 174/Subtype/TrueType/ToUnicode 62 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 333 278 0 0 0 556 0 0 0 0 0 0 0 333 0 0 0 0 611 0 722 722 722 0 667 611 778 722 278 0 722 611 833 722 778 667 0 722 667 611 0 0 944 0 667 0 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 556 278 889 611 611 611 0 389 556 333 611 556 778 0 556 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj61 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 63 0 R/FontName/NXSWOC+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj62 0 obj<</Filter/FlateDecode/Length 458>>stream
Hâ\ì›j„0ÖÔ˝∫l/äÛ#Õ¥`i“B.ˆáÕÓ8∂íŸ(ŒEﬁ~Á¯Ñ.¨!—g$çæcFÂf∑›•ntÂœ‹7˚8∫có⁄/˝57—‚©K≈|·⁄ÆÔo”sÆá¢¥Õ˚€eåÁ]:ˆEUπÚóM^∆|sÎ∂?ƒ«¢¸ë€òªtr6˚GWÓØ√œ1çnÊV+◊∆£˙VﬂÎstÂ¥Ìi◊⁄|7ﬁûlœøøoCtãÈ}Nô¶o„e®õòÎtäE5≥gÂ™w{VELÌÛ·æÌpl>Í\T,ûÕl0~&?É_»/‡yﬁí∑‡7ÚõÒr1±∆kÚ¸N6ô œ'∂¡òÎ=÷˚%y	‰ ≤Äï¨`zzxzzzx˙WÚ+òŒŒûŒŒûŒŒûnnÅﬂ!‡;∫∏∫∏Oˆ`˙¯:83
2
ÎÍÎÍÎÍÛ
Ú
Û
Ú
ÎÍÛ
Ú
œíÈ,Ê‰Ê‰Ê‰Ê‰Ê‰UÊU‰Uz*<ïû
O•ß¬SÈ©Tz*<ïû
O•õ¬mÕsm@ﬁªÌh∑∆}ızsÕŸ⁄|∫ZS£≥ªønﬂ–Œv·W¸` …;ÂQendstreamendobj63 0 obj<</Filter/FlateDecode/Length 27104/Length1 56440>>stream
Hâåï	XWÄ´¶ª´a Âg∫g†«HXuïe£Kû1ªk$—›ƒ#"àÇäg¢í∫–‡Ö*†ﬁ∑("jDT‡ûq¿3Í∏ö∏~f›&oÄèÕ~˚ÂÀæ˘™^ΩzUﬂÎ˜OWu åY—‡©¿Aÿ®—}˙A€01âàJåLŒ‰Àü`0Ä€ßQ≥S‰∂m˜U ‚∏ò‰)âmÎn,Fàüí0/∆Tùµ@ú9˘¶˚õQ „ﬂ∞††XÊhãü–á)øÿƒîπÌÎ— ÅWí¢"9∑‹ÄÂ=Ÿ˙fb‰‹‰∂˝≥6¶‰iëâ—˚œ_/®î ¯)…I3Sl˛p†jâ}?yFt{|U!{ﬁ:‡∏´™2¿AX/Ùg∑iõπZàQπ;*'ëWŸﬂ˛∂S0wKu¥Áè9Dˆ≥5	ı-a1Ñ⁄lÏ9xÉPj?x¶UÄ≠z2~Ã¬ÓL⁄ùlV©Ï1ˇ=ÿ&«$:8™ùú]:uvus˜ÙÍ‚›µ[wü≠$ÎÙæ~ä°Á[Ω¸ﬂ¯MÔ>}€Ø‡ÔÇ~ˇŒÄÅ~7‰Ω–AÉá6¸˝¸ÒO˘·®∞è>=Ê/˝‰”±„∆O¯,|bD$Läö3%vj\|B‚¥§‰È3f¶Ãö=gÓº˘ü±`·¢‘/ˇˆU⁄‚%Oˇ:#3kÈ≤o≤óØXπjuŒöµÎ÷CÓ∆MõÛÚ∂l›VXTº}«Nn◊Ó={˜Ì?p–·#%Gèï/;Q~Ú‘i8Sq∂Ú‹˘U’/]æRµuıWØ]ø∑nMwÃ¿ªÜ∞ã≤´ä—¶íUcUª9_nóƒÕ‚r\óœ]Ê^Û.¸(~â‡!úû
Øà#/Ú!âR8ŸƒDMú&^sFS•±ii7h–æëº$ç4L)}"çï∆KüI§CRÖT/•“+©EÓ,ÎeÉ‹[Ó+ Â`9D*áÀIÚ"yï|X'Ë<tﬁ:ΩŒ†Î≠˚P7FÆK”≠÷ÎUz“w÷ªÎΩÙ›ıíæó˛m˝}§>⁄WÂÎÍ´S@Q)Œä´‚©tUz(~JÄ®+	J™í¶§+Y J%_Ÿ•PJï2•Bπ®\Qn)è¡ÜP√`CÑ! cà7$$ÃÈÌ]‘ΩHgUYÉ¨¡÷Î ÎPÎ~Î´≠iRÛ{Õ/õõZ|[ölM∂÷˜ÚT†“©∆©ˆp~\ó¬ÕÁ“µe‹ÆÜ˚ëÔƒáÒÈ¬r°F¯ûÄú5-È(î"ƒ00j	ö
Mã¥©⁄<ÌK	§Æí,çê¬⁄©MîR•#R•t]∫#Ωî^≥ó›ùQÛg‘˙…:®≈1jŸr^+µ.Ì‘FÍFÎ∆3jŸ‘‹µnzm;µ˝‰VjÚ/PÎ†ñ≠‰);:®U1j7µÅ‘¢qåZD@
£Ê]$[—™±æ√®ÖZáXá[Î≠MM·Õ!≠‘‰ñT;5€}Vü/ò‘±~Ù.ì^ˆÇkôj◊|≥¸€J∞©¶©Z»gs› Úy¿˛≈H À"ÄG¨∫-^ãõ•≥≈≈‚lq≤®-é—B¡¬YTxjˇè†q1ì’L“ﬂ‹-núÛ,éŸ%œ0ù—∏ †!Æa^c©Â“˝Ä∆eñµ≈9ÊsÅ9¿\hœo6O7Od´æÊPs≥üi∏iò)ÿ4¿dÍoÍkÍe“õ|Lû&4>7Zåèçç˜ÏY∆J„Icπ±ÑYgç€å{ç√åÉçÉå~FΩQg‘>X◊x¢Òà˘xåwåªPŒJ0W‹ Æ◊µ›ìûPàÀmóZÁßpQ≠]ãu}éup~#6îI™êŒÙ
·(ãvfD‚—∂l-ìæ˝&;‰9ö‘]Ï^µ{ªá_Í@ı«L≥>≠û˝3okﬂnÛ®s1wâ]‘ÈÌ´¥_;Îgô‘·ˆ∏ˇ#>∏√äq
vä˝ü ∂@,Ê¬!¡Xô∞∂√VpÖÜÙ+X	ﬂ√∞÷@:"˚ûæÄM∞˛	/·¿.8ï∞&Ad√d®Çh8‡2T√E∏ﬂA‘¬®Å=0û√r∏
uP±,5ƒ¡TàáDHÄiêI0íaÃÑYê≥a<Üπ0Ê¡Á∞ æÄ»áE∞ê}ÂøÑßéaÆAr»£ Vh¬µ∏◊„hÜ$—lòãqn∆<ÃGGT£:cnÅ◊#n≈mXàEXå€qÓƒ]∏˜‡^‹á˚Ò Ñ¡5Ã¿L<ÑáÒñ‡Qt¡NxK±3∫¢∫C#‹EÙƒ„XÜ^ÿ≥ñ„I<ÖßÒ[Ù∆Æ∞ˆa7Ïég∞}∞jPãg±ﬁ¿ø·‹G	e‘°œ·yºÄUXçÒ^F_ÙCxk∞Î∞ØB)ˆƒ∑∞˙√xà◊(É2)ãñ“2˙Ü≤i9≠†ï¥äVS≠°µÇ≠£ıPH(ó6“&⁄LyîO¥Ö∂“6*§">éèßb⁄N;h'Ì¢›¥áˆ“>⁄OË ‚¯D:LG®Ñé“1*•„TF'®úN“):Mﬂ“™†≥TIÁË<]†*™¶ãtâ.”™·õ¯fæÖ∑	 ††8ÅÅQpµ‡DµTGıtçÆ”∫I∑Ë6…Dw»L‘HwÈ›ßÙê—wÙò’˙S≤–3˙=«Îxo‚-ºçF'w—Ut›E—SÙªàﬁbW±õË#ˆ5¢VîDY‘âz'ßühÆÔ -ã$‡ÔÙ|=”˝ˆ|ÏíÛõõ** "9.=EŒàPe&(†í≥†xw"  "`ù®ßú¢"DreÅ6±,ÏﬁxW˜«¸555U]øöyûZR[b‰ÑúîSrZŒ»Y9'ø…y˘›ï∏RWÊÆªrw√U∏õÓñ´tU— ™¢`õ€6¡&⁄$õlSl™M√©#uÌ´v¢ùd'€)ˆ5˚∫ùjßŸÈˆ˚¶}ÀŒ∞3Ì,;€Œ±sÌ<;ﬂ.'Ï¬‡ª».∂K¸Îµ‘øbÔÿwÌr˚û˝õ˝ª˝á}?8¸	é˚xÃÆ∞ÿïvï]m?¥kÏZªŒ~d◊€èÌ˚â›h7ŸÕROÍKi(ç§±ƒIi*Õ$^öKIêDIí‰»‹»<ÍyûÓ°Nt/u¶˚"„®u•n‘ùzPOÍEΩ©ı•~‘üÚi §A4òÜ–PF√È~A#iTdÅ§H™§I∫dH¶¥î,˘C.HÅ\îKí-9íK3h&Õ¢Ÿ4áÊ“<öOh!-¢≈¥Ñﬁ¶•¥åñGu4≈ N™+Í™:™Æ©"U¨JUô∫Æ ’ï¶*‘MuKU™tü≠A4D ¡ÄÜPeÄÄÉ(TÉàÖÍPjB-ï	µ°éj©≤†.‘É˙– B#hq–ƒg¥∑|ﬁàWŸ*ö´\h	êIê)ê
ií'≠‰àïcrY
Âä\•Ô!2 ZBdC‰B¥Ç÷–Ü~†Ì<º /¬K2ºØ¬Dòìa
ºF?¬Î0ïv–N⁄EªiÌ•}¥ü–OÙ3§CÙ¶_È•ctúN–I:EßÈù•sÙùßﬂÈ–E∫Dó©êÆ–U∫FETL%TJetù ÈLÉÈã’©Çnb¨I∑®kam¨Éu©äVXÎ≥Ê#∂LÃ≤∞√ÿacå√&Âj√±ÿõa<6ÁÍ\Ékr-ÆÕu∏.◊„˙‹Är#nÃq‹Ñõr3éÁÊQ√	ú»IúÃ)ú iúé-0Å38ì[rgsÁr∑‚÷‹Ü€Úm|;&bﬂ¡Ì¯NæãÔÊˆ‹Å;Ú=‹âÔÂŒrMä¯>ÓµQär4åJ‘qWÓ∆›π˜‰^‹õ˚p_Ó«˝9ü@ƒÉ£—hµhL4ñáP∆√˘~¡#y?¿ÚC<öÊG¯/¸(?&≈<ÜÁ±¸W~Çü‰ß¯i~ÜüÂq¸èá0f¡lòsaÃá∞PJ`,Ü%6,ÖeºÀyÇîJô\ór∏(»
Y)´dµ|(kd-Ê ∏Öz¢û¨_”Sıt=Cœ“ÛÙΩDø„;¿
ΩZØ—ÎÙzΩAo÷üÈ/ıVΩMo◊ª‡äﬁß÷áı1}Jü”ËK∫P_Ö´pä†J† ‡:∂≈€vY'…z©êõrK*• P7†n¬-®Ñ*h•AkÅã1”Òláwa{∫#v¬Œÿªa/Ïáq®nÇ#A|«‡¯é◊I¯<æÏs—$úÇØ„4|ﬂ¬ô8€g§˘∏˚^πLß·ª¯æè´p-~åõS‹Çü„W¯ço6;pÓ”x ·<Ågt6û«,ƒ",√
¨ÚΩ«˙c™õö¶Æ.0ıMcﬂÇö˙DoZòDìlRM∫…4Y∫ï…1y¶≠oHw˘¥ﬂ—t“dÓ5ùÕ}¶ãÈj∫ôÓ¶áÈizôﬁ¶èÈk˙ô˛&ﬂ0Õ 3ÿ1C˝Œ0Ÿ ˇ?j—ÓÛ1√Õ(3⁄<jìÕúq°´Êj∏:ÆÅãsÒ.—%ªTóÓ≤\ûkÎ⁄πˆÆìÎ‚z∏>.ﬂv√›(7⁄=Í∆∏±r<Z/Z_S«’	uRùRßπ*BB®√Hà°	mH!áa(°£aµ0&å´á5¬öa-uFùçîF "◊#Âëë
Ÿ-{dØÏì˝r@~íüÂ†í_‰0¸¿(êm¡Ü‡x√lSy¡Ê‡”‡u.ÿl
æïÔÇI¡÷`™ÓÂ{g?ﬂ°˙™j¶|ØËÅzê¨˚Î¸∞2¨í (QÁE	®6¢%_G^æˇ›äïX©Óvª=nØ€o Ø¡í‡RÔ`E0W›ÃR‘x5GÕUÛ‘Ñ‡üÍEa3Œ<g&¿wÚôlëœÂ˘R˛%_…◊≤æá`;¸;`'ÏÇ›∞ˆ¬>ÿ‡8úÄìp
N√8Á‡78ÔuﬁÈ5ˆ«|†õË¶∫ôé˜&¬—¯∞w⁄˚`_Øt$é¬º‹Óÿ{zkﬂ‚6¸Œ{€âªp∑∑˚,é√Áº‚'Ò)|Z'Èdù¢SΩÊE|…KûÓ=OıûﬂÙæ_—i:›´û£3t¶n©≥t∂Œ—π:œ+-∆,ıb/‚%ºÏù∆z©5˛º”;ç3cº’«ÕX]†/¯u—ªÏ‡eﬁ„•üƒSx⁄ÎMÒÜìº·4Ïl≤L∂7ù‡=gx≈wòvÊNL¡›J∑÷E∫∑ç˛ªVˇ·ªZÄ£™Œˇü{vBÄÂô–ªπ$“lÜ!¿íÏ“Owÿ›êt§b°JxNúKZAë—Ç‘“"/'@%Ä`∞C«Q(• Eä  à ô°R
Eÿ€ÔnBL:#˜Ó„?Á?Á¸Ôˇ¸_ôN}â¨ã˜øëjÎ¢ç≥ˇ≈UÙ.˝Zæ≠œ.T÷ˇ@•ß”næC	td6ì§[®ŸﬂF}˚ı¢©¥Ë ÍC”®5p{®û7X≠+4í^†Õ÷^^nÌ ˛yTÈ∑¡¡gíiM¿˙i®‘Øhó(h˝ñb©é:”öÃ}(åäÂ4›/“::ƒœX∑Aµ¸Ô ß14∆:l›•™ókg:˝	˝vZ≥≠jÍO©d
èu⁄˙ú“)àŒ‚‰·&9é‹®ÚW—Àú§˝–KË/"/fiÖé˜@©ò¶£˛öLtr.uúq\∑~e]&'ı§Å‡©öÆpè[dº5 :K3h} yÌ∑IŒê[3"£≠W≠˜©7ÌEçˇ.vq¸Êﬁ2Î˜÷[~≤°ë	†SéûÊ0:î—7¢÷™•q4îè†*◊Qk‰”®%ñà%⁄IigÅ€ßËw§`ë˝tÄB7ˇDÕ	
ˇòÀ3ﬂ†:©«µ⁄Ìîdπ˙6(:ZÄËz'⁄gŒòKyœCœÚ*üJ\∑d¨\!øï˜ÈëÛëo≠	÷MJ§d˙	∫ûZËˆ—¯ˇ+}å~Î˝=G.W°èQ»F◊P•äâ¢F¨[ƒõ»kµ√2G»«Â1yÒ∞:&π˚z‰≈»õë÷^Î|ß+ŒOß"htºbΩánÏcT†ü“€p˛.„«@e>?«Î–A˜qRRÙM#ÑTÁâ_@OÀ£∑Èd ;úüäØ≈MÕ°•"ûƒù®¥FÌo⁄ó“%”Â ô-' 2ÙCéEFÿÊÿÈxﬂqqS·¨q~ÖözeÏ—{˜>ãP§*¢"ª·ª±§≈–ƒ&tõoC–cÖF>Å˛+$£wz|Á".·Ò¸(œ‰J^Œu»e/ÛtzoA»Äz2Uxƒ1EÑE%Í∑:T{ÓG.;-Œàfpû†»ŸZ±V¶Õ–ûÄ¥%⁄Jhv≠∂C;Æù‘.k_iÕ∞ZÇÏ/üíãÂ+r´‹#O É¸Ôf‹ìMééªéªN·LvˆuFNŸÊº„åSä>·TÃçÿtÅ‡\ßvèHBˆ;D/YÀÕòË«í∫ArÏ0QqÉFkÿ•´çoΩEíÏiÔtz•¬˛|Är¯’:Ö∆DÚ<Ì‚s‚º¸≥â.6ƒIr´ˆÑ„C·¶ù»Fkƒª‚ –ë/¶ãçÒ%ﬁFó‡Ôø§u¸8œßù‹Ãy¸,„Z:%˙hSx%Â[õÖ‰N\Ã◊	–2YAè—NÁËJdìÏ"üA~j§ı∞ËÙ9oß;Ï∞Æ!ªi»Fadôz¯˚*≤≥ﬁ,ƒY-‚1	dÆÛ8Ìa'QÃ0Á(πòÆ”Èäc?<™ ôÙr§Zní_X√¨,D¢å∂!Ó™h,"Êº‰ ∆ˆh&"=πd¢∫î ®ÇûE÷[k)k£µ¬ZdÕ£è∞˜˙ê;¸"¢;ÚÈºœ”'ºq8ˆ¡r~ﬂ©†&∫ âú∆CÕéÖ∏ôv†Æ:‰8ÊÃÜ∂W“xÙxs$òM'Ë*›‚Xÿ&â2Èõﬁ4WµÉT»…TÉòà<^–*…|ú≤⁄€àx>àÿ∏é<1ì—ú âfÉ~,Œ)Åûä’Ø√Ç+x7f*êµ3Ëk»›ïs≈–Û‚§ı»ZM‡È}	m[Qæ2ë|<g›¢G©ÜR)7¿Ô–pdVüv˙¿.*‡T˛#ˆÖ°]©w|¡Ç2#¨\Q≠ƒca˛5‹^)4íü› «=ÍÕ)'2<údM*˛{îãWD•Uß=ôK—vÿƒ+∆¯ºc¶zGèô?"oxÓ∞úG~4$˚·¡É≤2=?¯Pz⁄ #’≠ˇ†øæ)…Iâ	}z˜ÍŸ£ª´[◊.Òù„:≈∆8RLô~£(§´ÙêíÈ∆∏qYˆÿc"‹n"§tLu\£ÙPtôﬁq•+ˆ+Ω-+Ωm+Ÿ•ÁS~V¶Ó7tuÃgËç\6) ¯◊>#®´Ê(<>
Øâ¬] ª›ÿ†˚´|∫‚êÓWE´L»á„:«ÖïqYô‘◊`g@*¡®i‡ÑQDÇ?ØAPl0•íü_%>õ••˘√™tR¿ÔKqªÉYôägÂäå’Õ]BÖQ2 Y®b¢dÙj[Z≠7d6ôıç.*y‚+åäÃÄ“¬AõFwË˙T¬‚ãâﬂqxè¬@]{läf˙´u{höu∫jöhèu€ø¡ Œ¿^ëV2ã@∫J,ô¢ÉöX(^í∫-â-Uã|ïÜﬂû	Õ—U'£¿®2ÁÑ`ödS—‰EÓ]……ﬁ}÷yJˆÎÊ‘Ä·V£Så`ÿ◊∑°ôìÌNÚÍI1YôÆÓ-ämË⁄≠àÔ“®l√E°Ër*ô‹¶Y∂92ä·Jü≠ÉìÄôrÌü \2gÁbû có™ÄE™Uß¬êÈ ≥ÁÌ˝ ëÊ2tÛ&¡åÊkg¬≠3Œ4◊M≤A€O⁄\¯˚∞ÚxTFÜÌ"1Ö∞)xÁde.lCçóé?®èJ°€p0o0‘Ôv€^›Ë•r‘“IÅñ±NÂ)ª»;ÿT"dcöÓczO≥1KÔc⁄∂áxÚ¬ÂDΩUlz€ßõ´OOUû‚>@W∂‡K¶%ì ∫ﬂµÍ∂djáQ>∑◊
©ûÖ-E¥B"Eãb·î3€€É@ºíi¯8£N]°48etÇı"Â
çk˘∆π›ﬂªß1&∂›¶FÎ∫Ω+˙˜›∂V.Uûß„xDáqÓ‚M¸ tQ2µÃ4„:‡äêÄL≥»–ãÃên¥ññ∫À0˜â≠b´Y„›7h£µuä*™Bà*ŒÉ≥
*h0¯πIˇcªj`õ∫ÆΩ˜Ω˚~l'~∂c«øÒs'&«IúS∑~$¥0≤[~íıAÖPòVR5¥eÎ©àÑé©H©©6(ZHB´$öUå¶J†VS'M¬•*^ÑJ¸≤sVµ”lø{˝Ï˜ﬁ=˜;ﬂ˘Œ9Ó[÷±jDAHÌ{r’ ¡§ÂÈÊˆˆYà0PxCöQÛiÇA&iÕÅ(op»$ÚFI†·Œ‡
$CuÍFÓ®2ë •*ŸT[.Ö“]ôÑ°&≤Öla0d¸Iïõ‘(zÄT~j¥ŸXB6“œêÇû–
#÷w8"……
≤Kgq)íÜë75ì|œrPÂ„<·á…æ!€·ÕlE=ìÀfîJßïîkaóUêz≈—–XGà≥»^Ï"Îˇt†›äÌc;;≠/3ñ‹¿ﬂ‹Çí\;k\1V~ı„Ë¡Ãí∞DÀ[Ú#Õ]I*Mù§”¥=Z( íÇ‡cWòMvú∑È¥tè¥0kÏõZò5ô‹¯çq<∆’'WÁ≤;ãD¬=ælÓlˇÜùÓßπıÑ±d‹˝tÖˇà´ˇjî‹ør◊»ò%›∆>åYyò~_ñÃÇI∆%öO8ÑõÃ&”∏B,∑¢ RQıX:∑∫£ ªﬁ6ûÉµ€2Ÿ∂%ë-ô¨â;BŒ"A+ÀvaOUwG„Ú˘§{.n˚ÕıEˇ⁄ÂlΩ9∏ó<G˙¡ﬂµZ(é5®"¡˚
ßrqéÁÊR%øá<¸·ü≤µ∆ı6Â∫é™3:,ﬁùC"P{åÏi{`8÷s®\sí&d"ﬂ≥ñˇŒ⁄≥µ&^˜Ôa}›Ù›uP»ZË√imÕ˚Óº#æK¸«ÓÀÓÀûÀ^©≈◊‚o	¨‰˜∫èÒG¸í‡UQDhÙŒÁ[‹-ûØTÓ.˜î{9WøÇÔsÚÚ
ÛHvPj†&∞5∞=∞;E@
OçiÆ"g"@ã5¿6IòïòŸ]	4Lﬁ"ÿb∆+¥≤†•⁄B,¸n9‚†ÚUó*åºAÎUÂ%‚)˘Ï£¸÷⁄≤ôÖ DW*’∆∏êãvçC0DıÆîÕûƒ∂∫®
2ÇScÉ∂$≥a–öü¥B%…KJíJ6òm…h˛’> êñ'WifŸÁÒü≥ ΩùQ¨u…™≥»ŒG`ÍZSSS;Ó“u€Bˆ∆Ü∆Ü˙DEY© Ü Îj°8DÅDﬁ2Y©Ùﬂ9ùΩæ}’F…∏È¡“Öø›ü◊VgLÃsaj<xÀ_§W._Ω~”œ˝7/›~o›–⁄9Ÿ≈¿|t\ıOh*òBƒ4◊Ñ°â7…'9BÑ
¨“8%Ù§ÙÈÒ|å2)HM†t&ùôÊòfª»<é=\õ'ÔM˚ü†M‡ˇÙ"îäAÙöV%(ÖéU{b∂{∂G£Àùº«EAv9êÊ	&±Í(iÚ[á…ûAÂwç/j•Ï7˘qÅ8!E).’E\ﬁê5§(XÒ®á[Rê˘	F{≤:√"7óWr◊ı®ùE“£Qêì˙D√ˇ†»ÁQ8ÿπ;ÖóN∏√Ø=øy∑œ0Ãÿw˝\Ú‹âˆhHΩ≠—Úã˛OÇ5è,Ìﬁˆ™:ÙmÓ®~‰çÜ=ø]¬⁄h GEû3Çƒ©´ö‹òLD∆	9Rü4‡Ï™∂8T	ˇ¡0UÒU4b™∂4°Fö∂lBõ»zn›(uönr÷f2 ôdôe}éXÌî ÛºJÖ"J…§yèôÿfo a
éxyü—
ëPû«H≤{!û—ÃAxé„Ã·aRÆ…A«Âô»£§ÒpÖ¨RL=Ê’Î˛‹û	Ω+´wπs_?˜:§¿7ùjÀ o´!¢©^ãˆæzæ7Êfì®§RΩÁœOì˝¥úê( ¯›z º¨ıT	‰ ƒMÉoù2 ©…Åojz»ˆÈX	Ö8x„êÉ„Ëá∆πû‹Ø»#8YuÈn3ÜËË‰ÎDÕ]côm øêw@‘œDWµÙKUxc·ÀU◊˘	ûóCNYàÃÖ]ˆ†sëìƒù'ùƒÈ,*+€íZ∆à¯*∑=Z#ï'-ÿ¬C6'Äª@CcZlqÏÈÿñXOlw¨?&©±xåƒäJU§:‚‚&øöU≥l,ñ/€Ωk"⁄‚≠gÚπì∂dµﬁïÁTœ` Èdb·eSœÄÉÈC;\ÑQ&ﬂae¨L*‡¢#›™-!å≠.W>4T€ÿ¿¯\YQ~xRQ∂è,xÔxo«ÛkvÏ÷ﬂﬁ∫¿¯óQÄ#Ω[ı„ï≠f^9ÜÌ˝—Êe⁄+óËh‡©k:OD+œ¸ÍŸ≥]·/ÔRyÂºπÀeö1^ñ-˙¬Êß™òû?3uÉÆÜ¨ÍE_hw»;ãv∫ﬁBø>ñ?Á>7ˇõì√rƒ)òQ4√’MªÂTbq±£∏x©‚¬Tå–tø|ë˚≥ô¶Ò"»LKÑØA∑IÚms'Ú≥	¯≠ïVÏû≈KÖZ°=Qÿ∫∆äY±Us∫†ﬂ≠‘>ÀƒYÔÆ@wQ˛Qﬁ∏˚ùï˝"∂äA1.rPÊÏÚ˝Ú°_∫ò>ËL ≤L«≥ ·„Q6≥/:ìÃdñ
|ôäl

©≈ÆbZ¡d¬¶∏Íj¯46üﬁ1˛nÙ·m8Åé>[k|È=ºı˜˘§Î1‚˚…◊∑∏ˇÔ}kı©'^ÿ~€¯÷∏}gCn/(·◊¿P3⁄≠=*Q^î¬Ç=Hqúûq•2«á°h3…a3Ç&∑ï#ÛM»åÕ^µ ^†pº¨bñŒ (`õÂ˚lÀo+’ñMeSˇálXHR`êç˛ÄlÖ8ÕÁlgË·±óOOﬁ"◊r*WGGˇ√vµ¿Fqú·›ôŸù«ﬁÓ≠œgﬂ√>º∆1∂0sú!`£€‚@QÇÖ)è§n,Jµ⁄[úV1&bZA’÷aÂ°V$0ÑIh*R©†HEkâ¨™Æ¢*‹∫ˇÏù	T9˚fvW£ΩˇˇÁõÔˇæ€ﬁâ[^€-àæ¢ﬂ—s•›MCÙ∫VNV√N≥02çÌdà1%õá¯”˙b8KK0®Owå«/æ-˛fæ>$Éˇ∂¯zh¶≠Œº!c{Ávfó¨Ï*¿‰)¿§Áæ·—	ã&,£ÿÜ¿V∂%∞5≤•àÎΩ(	UÊUF+„ïÿ„≤î?m¥íüëüF_åµé⁄2?≤/Ÿ7lÎéƒ†[ü-GÅî‘¬‚jùá$CãÁ´˘É˘Éì´É4≠{WÑñ°«¡êÚƒöâhb¨¢O®AQ"jã•ù˚¬¢Lﬁ˛j¥Õg—,&í£yíS€™Í}a©÷ñÊ.'>ÇjS f8$áÃ;»úUã”®≥Ÿ€w‰oˇ{C«˛W5Où1≈˚¨‰›ÆÆèúl>1› <Ω˝å∫Ê‚uuı≥Ø<Î«/ﬂ¸èw◊ªª05yJùÏ„Û-∑úM`ƒE9	¿*∆äÆi∞ïî1@ß∆˝<U·tΩÓNtÕF≥≈ƒÎÃ.I®ˆôC&1ëë›Ï!©Ω|∏Æò€o6Á|ÖﬂH`ê{Ó„˚x≈Yrî”ˇ·u˜ˇ~£V¢˘j•w9sRÃúFè›i@õ3õ ß è?@NXy¡?˝…TJì¸RVÓœn:I)ö´5j]⁄∞¶ïh-⁄:ÌKçti¿'+·+‡ü*√
í,%ì∫ wDyûLﬂÃˆ\*iﬂ$¥µC¥2æj•6xß‚ÿµ˝P÷V›Â∆ôÆÜBBhaŒgB„å6†s´®¶T«≤µhÌBphÂsŒAß–…!0≈0e`úV÷0ò‹ıâ›Ø¸8M¸õ∫«$‰¢Y˙ª_ˆ‘zNd∂_h‚—*Ú≤}÷ø`ÚÇŸıÏ,ñc}∂õ·éa¶`_>>Ã*†´À∂ÆÃ[·∆&È|'È’˚»A2DË˝wdÑ‹‘@Öå˜œZí‚≤‡è¿Eπ>Wºà∑·›x7ﬂ#ˆ„A|ã3¯æ'\Òå⁄A®UmÕ+}<Ëc#˝!#≠åç∏˘A#MjÃB·4qåP"π–åeg+íùaÖ?√"Œ≠;lÂßï¨∏P≥r\mñ;˛˛iﬁn@“2ıôÀ®¡€Ï˝Ë:≥Ωû˘„ΩÕË‡Ω«a'˜æ£ΩØh \7ﬁH%JÙ5Ö-é¡⁄Î”è?HqûD»ìôH|¸ÏÖﬂ÷ﬁøªñ‰1 3=(	†®kxõdÄ]S!.óœI	gN] Øfnvﬂ.û
Oa–C◊¯øh!ÚQ1±yâ(CSà√ßÅÒ]Kû„≠b#Í oÛ˝‚7˘Q∏èÏ‰˚ƒG¸ú∏Ñ.ìO˘qçêÎ¸ü¬‹»;ƒ´hyïÔ;]a<áZ…æVl@/:-"Û˘"±ú-Á+çäiV
Õ!)^'“≈(@tŒEäìß9«SÖ\Pö‘≠@“7§à523e»¡œ“d1◊™HrÄGo∏∂º0V¸#&±õÆóàÕnd≥
jˇìQ˘†h`¨Œ≠Ü_q„<âIcÇ!í¡%Ç◊‡ A( áäSVb©÷ÄjˆÉä"É‡l%A<”ú%ÜH”“îñ§.›ƒTvjÏ¬)√1h =ÍÜÄ\X®∏∞HIñHπØ1%«Ÿ_µçVUŸıˇ∂Î„1;”ñi´èGm»¿˛ºÇ∑˝ìó=l(Êú:Œoƒ≥±·CÜ#•p≥ˇÒ•JÅ∞§fõ∑K=°
ï™'ΩQÔ™wÕ˚;‚(π”@^π€)øÄ©^`û2Ÿ∑’ø∏«:ã·#!‡5®Æ"œïdXô∂ú›…êNRƒ0CàbıÇZa"3&2cí‘œÉ;êÏsçF£≈¿Îå.ıC ˆz∆s/ıœº’‘î‚…á˙Åx†ÄyÄé0ﬁ‡ŒgR©ÉÅìfœ~m™L*î≈ëÏ√.T0'ãë°c\¢∆∑U>ÕÛWu5jYóQÎ'67>5≈ö`–p!NbìºdK;Ã>«˙Y|û}∆∞Éß±ÆcãŸ/Ò>÷á∞É¯43≤÷mFm
π3|Î6Ïö”í)‰»ÅÜk·IèÀKß¶–R¸’∏ÉÅ!J£GËTAÎ–˙rÈ˜—2 √®à>âß{ËªÙœË
A7Ë◊»®@ïÙª¥Év”˜ê.ªI{’¯Gá¬J≈GÇ‰5ØWu–
5ﬂªî9 ®∆Ô4‡ì˜Ê+@C+A› eTäî7›Ôıh=¨7–k¶Rãi¥"⁄¡7ÜË∆ºéÇmd;€ÿfmmwtG∫£€‚$ƒBÒp<Zß˘’&èUS\Xq@®ä∞Öì’5ÆSìp-âuâÆD_Bw_&P¬ÆËS‘†Rª.˜|GqÁá˜≈èÔè‰ÖíMèJBlnwìÔ"’MV~+jXä03 tVŒK˛~Õˆ~uæ∫’ÎÙNy«ΩNu˙á]ªzÏÿ0˙d∏w›·™9ﬁÛﬁoØ˜àµ_{ccc˜nﬂïuê⁄˚6úYáçnπÆè‚'4uçˆ©ÜByÂ¶e)E∂TØAÖAzR›d†ÙnaI¢&óüñ∞É≤|Ò√∂/Î˙æë±0J	◊Ê3>äúm++ã!H-Á⁄~≠˛MµñtÓ_’ÛTÎπ3oÿ0Ôj˚¥¡¬“´^¯Q^AÊ˘¿kô∫Í±∆µ¶ÄñZ¥éR†î*∑›Wfó”V£5∞üˇ÷Í+;j]ÊBg∫à∞B1”j∞ÇîŸ</lÖÉa{¶53¯DpΩıí}Qº#∂!—Õªc€:/Û@–j≤÷[[¨_YoYöÂòÅ∞iÇÅ3RXûoá’ñp_Ö√äS*ÀÖ+P–Ëˇ®.‡&Æ+ﬂªOÌjW÷[Z…iW~!c{mcp`[¿≈6∂qÆU*¬LbÉ…tl1t(ù°@⁄‚–$-$4ôß–6ê§¥∞Åÿ<pH2”	√$§y0©ÅÍê…xxLê‘sW\=ÓŸ{w%≠Œ9˜?ﬂ9a!Ÿ Úa∞h/wê;≈ù„ÆøO√a≠B£¥àg™◊‘©\bÊ¬ƒd‚ñ<l L HÿÄE∞£›G‚dÇ8¥“Ù'Ôı˙\∫å“4á„°Wµ©ﬁm=Ωj”⁄°Ù.¨[∂≤ª˛≥è÷÷∑-éæ∆k{ˇ©}Áœﬁv ˝û I–≠—ŒÔ6≠êXRçõ2Wôo`Ôî‚s∆##é·–—‚3•¥≥hg=˛X€Uºû˚©ºæ¯ÈÇ&≈≈Â∂Âj\[#u;WGzäWónmΩëú©ÿ”¶Îƒ]J@oW€µ”ÍiçI™Im´∫Uª¨^÷∏ò8Cé™Q≠N÷µf±Y^®.–÷ ]⁄F˘gÍv˘◊Í~Ò5˘u’∏(s*ß)¢"{U^’Dô¡æø°Ñı^?ÓıÔÒS˛cT
Ç
I–¬qp¶õFã1ë•∆@XØ¿^äW·x/>àOa˛ä1uv33g˛õˆ.üÓkÊã
e”ãˆ⁄⁄){3æÈ»Pôy>óÛÕèvB∆Ïxâ^´˝ÿÿ:#4/ìâÿX÷ÆãçAµÀJó	t*¯#öß0À⁄ˇ∫ÍTpòΩ7Ë$≥sFû≥N;ÎDÛùG÷æ4l¨…u¢üº]u±©èx5<sƒ9rµZ~lî®⁄~ÒUDâxn+∫
ºﬁ¨∞ôœjΩÊaK≈s∑œÀòô≈ha‘Ñ√Å=˝ø›˘»}‰´U˝õoæÅ›ÿ«ßˇÌ⁄¥ikcyÈl|Éü<õAoßØß/‡ã˘;üﬁÿÆ7ùes;6˛ΩÔ›ﬂº/'ØVÎÙÇÚÓü|ÊÁü?â1…ØR–§ÿ√<ZghÂBS¡.˙Ñ-¬ÅÁ0K04≈#ã‡ÛòÕ§ﬁ‚ôÜ»Òa\Å6ì]Sm[JıQ[®C)ñ‘_sQiÔ<DATÍ[`•ÍaX‘µp,ßIı&~B·®éx #.•[òÁ“≠ÃËù;ﬂŒÉª‚‚ü!ä3Ü3F«∏∞µ   [ç¿|ÀXzäT™° _3Ñ@H§˚3Df,…˙∏7§3ax¿BN
 èPÇ
~\º&›Óä∑%ˆ,˚ûxV˙}zA∫éÆ¬ÊœÏqütúbèãG§w°åQŸr1,Ìf^`wãøì,Ÿà∂`õÃ≈∂E≤ #¿@dÑ‹Ú¿Pñ/°Õ'»Ã —ÛÄîÇIî <â“ù‡·Q+√Üá3C Âp¶“¯ç§0¢)*åëÇ(r,[i›V´(p<∂nãE`¨íîCO¯ZBf$ö≠º`·,<œíî”ÑPêNào90Ê0Æ0ƒ0w“z“('ÃS)¡ÜCëWÊ‘2†¥§*PR	+ÑıÍ¢¥ÁûÊ›√Àaé»A@≥e*i˛ø…ì	ö…eê!ôà‡à(”!ÕÓJˇ	ó_ƒËæåg§“g“üß/p8Ëõ˜ÉÄ:;åp&µ©2»ÇﬁALÊ-cûµ˙îàöaiûaöÕá)Ï?ò+aé'e3<*DÖ¶Ä;+Zp‘ﬂ’ÜïW¿S»"ß|›Â;åF@‰æ7ÒÉ““=$gŸÅ%˚êw÷@ˆÁ<tkå8»YÁ0]„»q∏ejœµ≤˙ﬁ∑†ÿ˝Ó–AyS◊
«ﬂ«ÀSW®∫=uÇZxÔo©ó·ó3_2eÃ<§°Jú4÷K>ÚöÇãÛ>≥_r5JÉÚÉ¬neu·∂¬Áï˚#¡≥ÅwÉ«…/ßxã∏O\Ÿ@m£ˆsG∏3úÙ∂˛âù
E+g9JÂ®+”£ÜZÉ“{£˜¢T¥!DRΩ¬ñß?¬(d›1°P)ÆB¨˙¢–ÚàëÔò1Çv¸=2L≠?¬í,ñíÁLßMWî¬Ü·∂NõUh)äÂ¯tièDAüìÅV«∞yu)–¶c}Ë≈o* 9™J"è˘%nÛ=ÊÎı—>•™Á;9÷[5!9ëhµ'n≈≤≥±>4I1ÿvÄ˚f•0Î},ªôÀC8ü∏è˚Q ¸`H_}"J%bÒ|H€ÏY)K&à§ÅÄ†›^_Ñh:«i™©Îµ5µYÄƒÑª<n~X™©∆]ôÿ˘N7”¡ÇÙu´ùßøöxıd«ÓÁﬂY≤¥∑y^Ys=Z€πp…¢*ªï˙¢Ï˜ª‚€ﬂL?˚´%˘µä•°aÈ>◊ú_Œo_47}ﬁYÈ/™ü€QYXÌó˜C6Ï2y3Ω2Çúô;∆,k]m{A Ÿ¡uàﬁ<ˇ6œU3sÂπÆÍ‡"¶Ynv-
Ó‚_D…õ É,Ô&±pY≠yHÙE,ÅæixöΩÑ¢ÛÜqâ!·>¥ÖT‰–¸¨øìı-©˙´≠¿°Y
∫ûO4ô¿âùÜµõÎªΩ›˛û|6]D  ÆspÉ√ä<.®}òª+Oé¶”©ëáßﬁ∏1Òã_ÆÓ⁄∆K}Ω+}-}7˝u˙”Òj∆æ∂æ=é˛ÒR◊ñ√ü;AAóçˆŒº∏3Ó]ì◊„ÏÒnÚoT^¢^íŒÿœ¯?∂_ès„ñq◊∏ÁÁöÌöÌir6y¸q©G‚Á8kΩµ~zª!Øü›ñ∑]y›˘öwƒy‘+ÿÃÍƒq∫u[ïLVîi∫iÛ∫|3Hü9Vd¿•»ÄÎP’»”c ⁄ú
˚xLVqïÀ‰@é¥Ÿ∞-‰#n%–ôueöDÀDlr"D3ôÉåMM∆b`≥>5â!õU5µ,I:“∫@*2≥“7lè∑ıl⁄¸‰“nv«&ˇ5ûæÅΩ£W®ˇV>∫lÁ_N¨Ë-k˛èÓ™é¢<„˚Ó˜«Ìﬁﬁ«ÓÌ…%gí€\éxÑªPÅ€ê˘h!¶^$&8í~@ÇU©»"-H≠|Ñ(¡j—ñ4$R¶”ÃÙ©N«ñ‚¥¥¡iòï‹¶œªwÅ:NìŸ{w˜ˆˆ}ﬂÁ˘=øÁ˜C4‚P≈aÏSñAÏVpÛí]Ìœ≤Y1Îœ£e@„∂ ÙD˙"‰L*Ìô©•ÕTìgÅ÷dÓÑ†	£∆V$NÒB*ƒP\ëc#≈Î%¬ª0v¢ºY¸h˝›ˆéÂ„ˆ¿ºs’5`EÓfª≈n-l{6≠-l\YúÁˇBÖ^·‹i¯e€)ÁéÛÎ°ÁëôÛ'õû]±mÀÍoº8XY†2d˛òT«{~ˆ’5oæqÍ–AÿoÏ◊¨â"ÙìBÖ:iñÍˆ˝Úı-Ê∞xZ8-áy>àÊë±Õ‚‚»[ÚIˆd¯úxﬁÛë¯œmÓñ,yã4B≥_⁄´ù—ﬁ◊(ÕEC$„éJFÚá6Xã“©êä·«j¯§9%çR~?S\öv«˚‚˘1Qùç"w¥Ω@ß‡g	BÖew¯˝Ê„¥‰7p∏À%éà¢§ñQ2“Y9°#ﬁ(oÀﬁ4º¿Ü	Òv™õÿ¯Ç∂ÉÜ]Ãvƒ@¡ÊjWÀfrÆXˆ√"‡	?^<‰/P5á&ΩYh›Ó¯¬_á=¬√±„Ç8«Ωlàf‹ÊûΩÇ¥›ù^±!J
ûT¡”+6À Y∞ÆâHv)‹	{Å-Üx)fåqÇä∫2:êWÕ!ÚsdÃ¯Ù®Ûè∫Q√k»œÊlÍ˘s€,j}ÎÚ˙zÑNˆ:±˚`!·úsﬁ€∞c˙ˆ≥õüƒºa@¸¸ñN€”g–®ä.UK}Y∫œ`x˙åAj∫è˙uü™@ÑJﬁ+°iB"%úëE>Øé&t§„Àà
ÔΩØfAQHe¯≈|OÒïj“◊·#}√à∂e%#Éƒ†~V'uå	¡ì÷Õ–˙≤õ»Á(utÛx;iÛ
a@ô`k
G>Í¶{·Ø–á)◊ILq.+h)≠ËµÃ®€ˇ‘˙'cçsf◊~Å3:@«Z∂nYZ˛µn…¬K„ß®˘nÌ;KËNWA$—"˚âgä_,&˝πßf´‹WCó¢2≤åöÜRdä≤Q#ŸH=ÊÕ≥≠ÒVH’∑º∑}∑˛YrJüUôö
ÊQ_XŸ4ıÜ'wBœñ<≤TÂë-Ei’≤ÏçQé+‡Ñ[.–üí„í'?VVÂ†¨"?÷§ÛÖ hS‹∆ﬂ¡`¬)ÒZxPƒjpI„ì≠äK±∞ÅIG0ÕpxW™
∂E"Uıõ”Ó≤œÕˇ®◊‘‹ï…fïªπ./C'˚?·.Œù|í„¬a›F`°ã¨◊
-Æ◊Â-ow∞ªbu|U¢;…‚.bÙ–dﬂØ
+ 8Tı≤¨ÑB xèÀæá¯‚ ÷5_©»œ~¥·	ÑŒ¸∂qszNÔr˛ıóÒÕù´wnÎZππŸz@ãDıö≤«9±Î"íP¯Øå?Ù´wøY?≤S!7ø˝Í°◊ﬁ|Çı#zY‡uù≤^TÇÍp"’πhÆÔœË?H‡ù)'ıu˘Ñ»@–ÁPAyqPã)N≈†&Í!â1^∞KÀ”G4! ¬)—Ô+Oøddèq√ Ø» Ç1]siû‘–if(ì|Ô∫D˝◊rı¿Dp6V∏ { ◊ ¶!W^ÒÆSÑnÄBÑ‘  i∑›±¯˝|€{+;£•Kf7ØI9£ ˛vp^œ∂]π›dÕ·∂⁄¶Ì[sˇÑM∂_ÜB<ß¯ÀgFVñÒâ[h»>·òpV∏ \ò°Sÿ$¬Üb9út1õ∏@|ølMƒ2,Gã$=”≈b¥<Mõ|a_˜ˆëqÀìbTº£ºH\ó‡E√Ò22ùQd“'ÌåﬂY@«Ó|⁄ÍÄJƒøGj‚“qŸóqç‰≥:ÕQ*`-a{T<#û~'~,äK©Näî9ChføŒ?Õ2'ÖÀÙ5zú˛åeqã¯UÏ˙ÙzÄÈg˚π~^,°˝lÇN0UlW≈'ÂÖÙBFM*à/2¢@±¥ƒ–,Ïíê$û)QîËaÚ;vòIÚu%‚V §C}*ÅõûÃsâç˜m™cΩTˆ8D>ìè›v4|˝d5QÁáÑhöò4}Ωƒ:P‘XÊ]Á€éL4µ9Ø†úﬂ;ümã7Üûvæü{]⁄ÓÅ©ÔesÈ¡@å‚8óLCˆ1«ò≥ÃÊ:√î0ùÃ&fn0∞%
$Cƒd÷ì˛R÷
yJÂsƒº˚y3Ãµë ÿ}¿äö5Bƒ·◊Ì0t!è∆Íû4ïÊ”F∫¨â|ê–h*ÛîR…¯R°3ﬁ?É=Ã˝‘sÇ=·9øˇ$ÆÒdºæ8øg„v∏(ùÅÎ>˜KÜã“\∏∑ç!ëã∫›ÉÊTüœöRT≥DÄûWç˘}v[mß≠ ìÕ∂7<%V\˜÷°Œ"T˜ﬁ©à≈,¨∏Ü¬rEàê¡£=÷m¡£ñ› G=ÂV⁄≤gŒN'≠˜≠ÀÂµJ¨>ã"¨Rkö5a—ñY˘◊˙IïßƒDû+Î«†ﬂCKÎm«√dÈ™n˘fÆaãπ‚π.Å€J¢ˆG!◊%Öt∑î≠ª•|Ø™7"j«ŸU{¶5øæ¸©◊+°∂ã≠%≥∫ÓwF#ô]’Œ(€˝ˆ≤GY÷±ºi_.Kvºv˝º{íl>–6µyÀ˛‹8‰l7f;»ôN¥.
¥Ò]<=L#»ñ⁄ƒ7y?U÷•6ß»¨Gí@™í(¶.µh^Úˇ®Mîb«Wñ=wŒÉn@ó˚"√πë˙…ÂcRÂFø@inêÄËË¨3Zæ§n˛w@Ãé€˚óêë#+hŸ2‰î–±Åwª∂<áyÌa–Ø˝∞S‹Œ^{ﬁU4 ﬂ
‹“Ës‰UÜÙõå)êYµ5–™gçΩ‰>vø◊3,\$ˇ»¸I∏ËeFŸ´≤z¯ø|Wkl◊æwÊŒÃŒk≥≥;ª≥∆ﬁùµ◊kØçﬁµY„‚!5∆`õáú µExî“‹ä‚FUCRÑ	§°çj à´™™∆`∑ÿ}HnÇJSZ5jÇT¯—Zï”
ä©®jº€sgÌî¶jW3˜ŒŸyhŒπﬂ|Á˚\◊ô_Ûo∏~°p]œÛG\¨œA°l–ÈD–≥ÇŸ9a"Ó˙{R0y—æ‘˝ƒΩﬁ›†Ÿ˜Ü¶≠˜˙”§Ö:º“DŸC}nÀÒÖswq:˜Ê{/Â>8é£ßˆÔﬁøˇcΩÄ˘„πkÔﬂÕΩq$?˙Ì——ës££4ﬂπœì”êØ¸…Y{˘*õü—“lVÕ˙”ëvÉ∫¡ﬂy©«]Ú-Û¬Éàæüá˝lPñΩ˜íüıU∏›ûÑ◊Î˘„é∂„N,§wˆø<≠”õhøßûˆ!ü:VíÊºhj©U˘w÷'0_˜ÉœMa&˜·‘ˆìù∞ƒ¡wÔxÓË{é¡“vÌÃ˝!∑êõœ›lÌ^¯;5~ÒïÒWøs 9Ñ€‡‰>j'OsXt„≠‹nÓ «÷h€›üu–à$zîÖ9©‰¶YÈTeí9dW‡õex)âDØX+âh>£ù◊ò>ÌÌ5Ì-çh^î¿¨ì?√∆#ò¡a_Û.*à–Åá‡<ﬂÓ(»P®†;ª≤Pä‘>flmÀl~|˚%iÂ*®CÃ¡ÙGÇî˜·äËOÓkÈÔyl˝'Vo©!â”˚Z2ˇXæˆBÓ.‰XxˆBéïÃÎˆ4Ô„„Ær√gƒœhgÙ”Â√ï¢†∑Íåˆu }-ˆn¸æ:oÒj∑∫KñOkØZSä∞6nó∂$ˆX;C⁄ê~‘˙Z©ÿêX«∑ ’NOkÏK∞JÀJ&ñ±2ÒL©¿KúOåÖ‘r≈≤¨∏PjŸU_Tı/æTq∞ÚX‡HÂŸ¿pÂÑ5W„ì∆°ó+øW9V≈±†ãßÉvQI∫$àˇíøŒÎ*;Y∆îŸ°eÈ2≥ä≤É¨€UÖk´pMÆ*é’z±∑«–"3;3\RËK¢
})58IK˛!∞-(‘Å;ãí†Th•vÜ«ò«Aú∞Íc≠±m∏«ÿâ˜ÛX¬CÃò≈$˝™¬$Õ>ÇIkRÓ2±ŸÍ¿3¿FÂÎ“ﬁ;ôBV˛:U‹±…¬lMÊg∆ãKi<3^RZà√¶€8ÿß‚z´’:£~À∫jΩcÒ1KQ	1—¢¶GuT›è’Õx— :±Uñ¶≥Ωz¬µÿ∆]òÙ„√x≥{!Í«ƒπ“Ñ+1∂;¡}dé04Ö†è÷6<◊∞·°ÜùiHvj9e0¿s=Fâ—g<e£€¥ÅΩ=&Ó2Û&≥ò¸@Í^o°óÕ¶hx/µÿ›®'•≈(úÏ)8™¯ıˆ:∂∂4ˇ¶- Z≥'	‘·Ω©YEW≤Ù≤íÖ
›æ$gÎä·~‡CY–˝huÂ :f¥˚qª–¡A+‘¡$j±©Ì‚…Ü2=∞!˜˝Oı÷ª∑ﬁIÊ>ım™6Zî¿?ÔŸ~Ô˝õ∏&µ•;YTËæˆ5üz˘¯O_<±bÕ#%¡xq†h˜∆ˆ£/˝næ¢í¸_ôorØ@O¯ç]E`›§
O£{£ª«#Ñ(ƒ»–¸:64F«!V$A	—r{ê1bål?L”kÄEΩ¿î2«QÄ(u∫Y¨ëj∏ƒ>`	jbì!6ah›Åf˝º˛öŒˆÎáıoËoÈs:átØ’ku¢áÕ¡ë%1—>÷ <±xb
È˘ÈU=á{Ø∑…{œq∏@Ø¿∏pÈ,»_›¢√Ì≈`guß¶-ZJÍãgÍ2e>ÊÈiπº®|ch«W6=ùï≈gü≈&IÃ‰∂=ó*ä‹™¨€ºn≈0˛ÌÃ€ﬂÕ=ı˘:∞ÃVí }pŒ6ÛÌÒù‚XëÛMLìØùi˜˝ÖÁ„#rI]óDﬁØ'D	“tTBÁ·õˇ?*At}$\xŒÖ]ˇ€ ZÃ«‘Ao,√;if@8i◊◊”Cˆ—∆üÌ›waólin˚B%üÔﬁÒôßòë\hf◊ÍŒÉ≥x,‰)ÉzÚîqƒpI≥&-–ÅßÉã`0~?≥cf¢fc˙,¡<+ª\í"Écc4÷M…B’Ú5YÅo{Œ.ã¶%ƒ…:
Àe®RN£FyâJöê∞™8œíE#M01è$‘‹‹Àò¢≤0±5IDñDëa0«bV•wÑäíiY-QkU[%™aò^©YÍ2…‘⁄2a≤2i&ùÑ%?fjA†∂=J·(Pã√ U¿VòÇ+Í∏”ù™7¸Ë∫]-vbGüRq™e1ºÇÛiß†a—Ô~1Ûıı~0 Wr€p˘/ﬁÌ˝éÂ†z˙·∫`u5S\®©~`‘Ta ÌPY	Òå$pbôb‚„LAã%ü¢h)6≈«Â,õÂ€ÿ6˛{Ü›4”¡™ıPBôéà≤Dî2Iê”≈∞Pî8JírÆZLJÂ 
‘¿≠[—zf=◊&l°Arà•C :FÜ∏c‚1iHπâní‹Ò¶tCπçnìYnVº-Õ*–2œ›Ê≈“ºRÕMÊﬂ∂≈Hcö$`'Û∑úH¢ë≤t—àßn§òæ≥l√∞∏ƒ.äôûÁ¯” »6çdH\ ât—©'†åJ˘–Y˘â◊e¬E'Û„º$¬º…^…"%
w±
b0QXNí—≈ªÅ„°¯P$ 
íj‹Õn∆†p≠±E°ÊO"v±ÿ=≈aıÍ6Z≈w,ò°Ö3º*Ä ñøy—£xõúÇÕÁå»Áº%‡»€·pËà2ˇÑl´Y»¯˛e5	ﬂ⁄ómÖ˛3¥œ&àf.À4öYjN°∫à‚ÀO7cY‹ì√ækW∞Á“u»]Ã˝˝ `¨çô§˚?o1∫eÓ‹f≤PÊ«È	-…·q^ÌAQùW¸‹˜
Àcyç´hy-è5Vëƒ∆_É±÷®Åv¢2qÜÃà6+éA≈(¢F£E¡Ò›éJ⁄nöZ!JÕLKÍXì¶Zïÿ±ıY"{˚;ﬂÓ:Í?ÌŒ¸ˆ|˜{ûsÓÔúÛ›HÆª±C√ñËê0á¡:ˇi—Ëì˘5åDÙ‚≥T	’≠2EÍj§¨‚<\|#‡“qZ:ä–IµSÇ-√∂¿¶‹Eàã™ú‚`Èä6¬aÉìUß‚äçs¨V¯BòÍ"ã'Yí˘)BríkXÆ#Å2¯ñı[_VOõ6áé¿·ı¥¥Â+¶YÔˇﬂïÈ^◊#˙¬≈ó°pΩj-`ó{^9ıòEa<ä¬	’JgÕªàÚª«´îè_π(¡öy”^içå√_Dl!8}˜$Xû¿≥wØrØªçP%)15ïg^®îÊy,%y÷%ÕY=cfI‹§úÖÛ„‡˙P˘_O‰3ï'$Ü_©)G 4ôWµ{⁄e
£ëîOERå´÷9¢M:d“¶9#r£s„ïÈŸ”≤mÃ⁄î6•M;|0‰h⁄iñï)µŸ´ “·Î≠Ÿ í»%∂•ÒJntÖcIåí·åwéPF;úrn®í·HS2«;ãsÛÚÚ''.?éXÎI Ã  _ù %â≠∑ø¿U9dè]:jødˇã]±OÕ‚û†¬Ãeôk23’Ã”rä+hX˝‹Ú‚ããÚ1˙ãÁ6%ÏIê0ÚÛ®˙°qìÁüë^ˆ∆∆¥Åáï\yVrÛJ,“#wr|x√ùÈ¯ó¨1ŸHîSè„≠ÑâRùb~ïF{À©≤R R#lQ≤äÔ:9«1*&QïmQjv÷®àá<J
«Õﬂ≥Q∫ìîäªORx∏(e¸·õ$?8'U]∫‡iÓÍÚ4_∏$U˝n∑ÁÀ∂•QÏïíˆ∑yænõ5oBÕ“d{“êÏ'Wßm*∂ßNi(“.üÛ4vÛ“RuW∑¥Ï‹∂›ûÀ˚ˆzÆÓﬂ/ç⁄ªO≤Ô˛÷£åìçÏ7\sWÖÖ>˜Ω°sˆøª∂ÿsB˙}t^RbNÁt"MﬁsÎ◊ØÖ<∞ƒYà˚Æg˘â∫lsˇì+Yl"ˇKb`º‡)°"+ı˜˜ømıÓ…—}]≤”áv:≠\†ejE /√©\;O“◊Ù*∆™Å"e8SS)ÊøÖÁ»-≤”¿¸2`êLRÄy¿f±¶h«ØÒ>B^ß*£á&‡,∂? ∂je‘å±˜u'-‰~úµ{$°Ω˝ªÙvjB{;∆ÀyÆêºæå^∆¯X¥∑he¶i4êÅ>B{ ˝—83ÎôÇÛk‘Û⁄c∞˜˜1æ≤Úüæ±¢}ù◊[Ÿ∆ı‹ÜÍ–ﬂÃ6 Û‡^üÅu#Ò‹Äv0Ù9Uâ1ß@û@« «·¸"ü›$ÏÜOmÇ˛Bßg£îıtbªn=¿g∫F√wPCìïlÒ˛ÿÊ‡yπá&¡/∂Kªa>bÄwóaW'†©ã(”Bf;Ù,‘N—v<g5$©≠Ù¶rÔ‡Ω≠o£ΩË'9xH…Ú7Ø'S¸7˚œ^«ûü>,bÃo G™7pÛ®°@ŒÓˆ˚â}ÉÁ)xØs1˜	«¸˙.|∞X¡˙·¸tˆ9ﬁ˚#©Ãssø¬9S8s§ l˜æWzÎóc/Iú„}^	`º
>=¸¯òuCÃ±W;)rªy2àzÄ&Ê∞ pÚúÑ˘AÇØ‡sì˘¡‹–ŒÆŒf›Ω6àXÿ‡ãôc˝< ∞ÎáÈUÏòÀ˛Y»úÂxÒÔÕ‹bŒ¯•‡tµ‡}€…ú
ê[57Õdƒπ‡ñ_r‹aﬂZñäMË‘¢ÙR#sñ˘ÊóÏÊ«#«ÑOŒ∞u¨/F∆b˝¡up—/˝æx*/Qˆ,”õ¿”>*QØPârëJ¥Z»Õ∞Ô˙`è⁄ãñF”-nçw9kwí€FØTÖ≥6©E/Ì~Ìï’^I”:Ã[I›Zá\'⁄ˇ%Cr{«X2«˛◊˛ˇÚÁZ-F˚∂÷kö∞g3«Ñ—'e 	~â˛¿`å%M⁄n©ñN•d’âÓo™.Øπ(OuS°j#¸îå˛R˝%ëw±ˇy©èæ~jÿ(IπÖ‹à≥‰œQ ﬁrZ èæ√π¡\ÚK?_KÊÁ]H2qwËÆ¯W‡¯8xâkÁgQê£Å/_Õ;O˘ŸM≠êÔ˘˘9àßcÒ”ÃÀ¡íkÁwQ[ß–£¡o?ÁGŒqú#9œqÌÛœ,÷7#w¸I‰·™≈ıh H«˘ÚH'nÛ˜£7ı?òùF°Ÿ©|jvÍ;Ãü’fó~ lÖ›£ü÷T∑7óq<˘k)˚âÎ¢øéj)¥ÿóœZƒ\ú/Íhô»§◊"˛™h!ˆΩ»uï„PiE‹¡üÿÔı ˝HΩFç–=L9ÍÌWgS	ÁDu%⁄ËGNÁÒ`•QåœRÔ—Ju4⁄!wR∏n–J˝7º∆Ï}◊Ωc‹ßU–˚‡]∫∫ûˆk«i.ø+∂CŒ1?Âwèòè∑¨°]Å√◊®EÌáÕnÿx^»ùÇOºˆ§ŸœˆœSå¶¿>ûm%¯¸±M¯¬-|‘,8_û˙≈}Épo—ˆ–*KµXRëüPºÅ\"Œ:Ns,.·wU‘Î">˙¿±R™◊¢Ã˛6M•1‘á¯bH≥Qú÷G;Kı¬?^πÅ„GÈ#sˆΩ"Ó}‡¯Z°w–F›ﬁı¢Ù‚Ωı¡ñj GªIÌ0ø≈‹bÏA|6˙gä˚	◊)ó˘«ã·¶X√ÖÛ1áu˜?ú´‹Äæ[®πd¢•è>‘˘õä$æ4é 2Ωœ´Å:`£¢œÍï¯™‹B´∏_~ù∫†ÖLdJÍ!ƒﬁNö®¥Qê∫˜á€ÙéúNÎîÓjÜB´¯YKvÂMUã˙≥N¢<1/u¸&ÕPÀ±ﬁMã‘¥H1—éö¡G¨”NSÖˆC‹≥Êc‰\¨B3Ùhßõáyû8„±ÕPk)K¨Ä–’÷y_ÄŒÕ∞Í'‡Îãv†æ¨ÎS=}:>K?a'ÔãubŒüi"¸tHˆJœLπÅ:Ä‰+∏áª©N⁄fûÖ__Ñ)ÅœjùTÃ TµévCéÉºÙ≠¿G¿?‘ZãΩ?Ü<…ﬂ˘W»]ê? ¸¯“?>ÁY˝ÅPˇ˛ÓÀ=∆™‚é„ø{ÔπÁÏÆT–Ç.Ky¥`![ƒ
J—¡∫.´[-§∂¢ã1l©5¶6TÂ·™ Q\jiDÉ†K¨÷¢ç®§†å‚£b,⁄`K›ÖTŸ«ÙÛõ3s˜zvÔÆ¯¯ß7˘‰wfÓ<~gŒÃÔ˜≥)øú≠ê3ît91Ω¸”ˇŸˆ´elpqxåŸ§dÊIâ+#£"ôﬁK}˝ÂÏπ'òM€*…Ù‰Swì∑éìÚﬂ—Ï	üÅ∑ÚÏµúØQöüøàüæÔÕpµ]ˇ‰Tªá>@ìGÊÖ‘32=ıé9B<ï∏,ev=WÀq˛;Qø–÷'æ{eúÆy≤ûÁ3_N~◊û å[óèﬂû®B&)¡€¥ádô|0I	uèïw.ÁÊ-Dµåeù¶’¯≤∑s9Ï#£ïÙ +˘ø|K…ï´e§¢m÷vò¬ZoR“{e®í©‚ø*€~¢í∑ÆóÈ∫f6k_€ﬂ~øœìﬂáæl!ΩáfÆñ≤§Õ?≥…sõ¨Û±§´6â≥1¶–òˇOpv^Ç≠óØtˆyJÿ´–G–tCo4¢Uœsª‹!“∂P§Â9ë÷ƒ!rpÎÍ¶Ò|2ˆ#(•ÆK6jyáÁ9¸∑v¿¡ π¡È ˛î'«}€÷∫ÒNä˚kø#®ùñqqˇñ∞äÁù¿.kyª{òˆçÙ´≈¢ZÁc«R˛∞Z_°<»˚≠„·üÄü≠»ò÷—Ù_ÛTètq˝rmÅ˚«gµ¯8~d5'˛&ÔüŸ˙ÔŸÉMﬁ5¸˜Ô…˙ªD'Î÷Õ˜ííw˜Èˆé„-ﬂÛ«!8,2mh »Íh¥¨’‹™ùµz{∑’ì)´)ùe=’è^™ùUøbÔ∑˜ºóÒÁzπøj¨_>è‰≈÷tπ\'8à{RIõWÒÁ?ƒûﬁ‰◊√hÀ%äƒøÈ1f;π´71˜Ÿ‘3Ê0vÂÅ‰≤bü”|lÌc;Á¥Ø¥|¥9Ús‰‘ãu	|˝LGÚˇ—éo*…\|¥Ùîª?w./ê£ÛÛÙ-˚<Ô)û(J4	ø'u÷•I–Sπ'ù{¥Â§Ó»+oT∫˘ﬂñì∫ƒóìt˙øÛﬁãıLÁÕì8wGÁÙú`∂y√üWÔCÚÁŒõ+á7Àπ0Ÿ€‘√2Ç82Í›Ωkœ‰@s£Ê∑¢V©(⁄ îüÄ'„òcj„‹gÍS@KˇWCN˚≠î£`ám{ô£∂ß˝ú‹∑™œ≠>dÕ¨ÔK¯ád4LÄ„a#\ó˚÷‹!ô{[ÜÃ´˜‹Ã{Ê0c.§YÓysıæGπ7Âﬁƒ‚·Fî›,´x^Ä-¡ñﬂÎ‡«ƒÏiŸ≠¶-|‹∂πÇˇ™É7e*q~f6#≥É}f=1˝ l)Wçπr∑ÊNàË{/}Ò< €;:(+g˝Ô‘ïíõeZx∂¢ÓvÕ√S⁄˛Ñµ˝a˙]DúÃ•Œé
g1˘*isÃ±‘ùÔµO∆Cm0NNÅ3¯Ô;pyÊcØ±}oOü%çôi6H„=U≤NñoïÂEºOqç4DﬂêÜ`Æ,+/+πø≠§ºTÛïœ´¨}ªFª≠ã e˙ﬁå=‹ŸjˇŒIM`˝G\=√¨…ü◊˜+™dm™xˇ≠≤íÚ“û¥„ú£‡ÏOŒßπ93–Ïà≠¸⁄Â¯´s9øFŒgú1<ó€µ]-ß#Ì|+lÆ&gg{1N/Îª]„§/~.÷•≠êÚ⁄&€}≥OÊÎ£<˙∫∫j´Œñ˘^AivÅîã•*ΩŒl…µA3È>
v⁄=ªX˝Ttπ=∑,˝0gÙÈ´œ¡.Y∆7∫’Ò+ˆÈZ]€‡Ä‘[ÅÁŸ«F™X´˝p∂rò˝¡#Ã•∞^ÍècUp±›ü˝›ﬁ|,Á€=s<Ô_l}]
∫vsÿ£„◊œ8Sﬁ⁄µ:¿∫/ñãÏ;¢©2è∞oYüÃjÙ’>π‹∑-˙ûTGãÿØè±wÊ3ÔÆÑCRûÜ>\Ã{O¶Ô|Yò˛H*î‘ùfo:‡GîåHEÄ2'ˆHÍ}π"≥]Ê∞^+·Á∞ú˜iV¥ùmª^f8NQ“ÎRC˘ˇiœ_èüm›Kéf«⁄<hgﬁÖñÙøò{(„ßÒÎﬂ±Oô>Ï’Ùπ“ëÅÅ∏_\ Z}ö $ÙU;:	ıjOJ‚ÍÀíPØˆú$‘ü”ÖÖ⁄Ú£P˝…I®?˘K£–∏√íP?¨ˇ.HB˝G·G°uûÑ˙·›¯15	ıSì~üÉgπ£>°˘ì\}v#ˆ,ÏlxîgÓΩf¶+osÌÆÈ@f∞„\òAÚ±˘Óáã;–πLø∏èü«\Àsˆ˚Ò\⁄∑˝Èxnãõ≥}≠Ûıèßº≤˙Œ‹Ì{„˘Ï‹¯—æ)÷1Ê>◊~Çõ˜°ÿÔˆ±?ã€Îˇ˙é∂ﬂCéü!é∑Èª]“Å˙ﬁﬁ»ÛÔbÕ‘˛î[À5Òºm‹MÂ˛_ÿd˜ƒ%ƒ√yö´ã“"j5÷⁄ò['}Ûrï’<ﬂ£Ò.ƒõ‡L¢·£DuÉ∆p{ü$Ó€˚‰kË¥Çe8ydÂw„ˆ·±ƒÕ[dÑŒ|Ñ^alÕª™92ª‰b≈jçÕ6Wü≠˘†‰,©«„”!)c¸—N©ßO„ªÏ1—5îØFw¸Rj¬HÊ≠ñ˙Ëu˛œ»ÚU•Ø˜w€Vc≤Ârå∑«åó⁄‚?SZ™L.–˘¢”dkv∫ü;∑ÎıûkøªÆˇ:ÿ “˙m∏–˙åøÿ„∞l.VÌ§kÚ¢,ƒürÕü¨€qAJæû»πjïQ1˙‚IYXúñ{£¥”π~´∫.∑ˆ£2§_¯™îg#˝ÏZ?(s√7Y◊Î–“ŒíÍ£	rbv=Ô’ ˜€´AÜd˚I´v€±cÎ«Xáû9 ´ÿeI]„uTNﬂºÃû@‰ÊpÔ£Vsgﬁ˚[õß7Ï∫g7 •¡µÚ›‡à”á	Î}ävKC∏€ÓÅÈVMîÈ—ç‰÷2%‹"ïŸJt˙˘RYT&C¢•øÍ≥h&{Sı9:"£≤´Ñ3n*˘>/bçÓ|◊∏3˜¨w±£*Æ∑gì∫∂˚\˝,∏	Í‚ˇı?ss¸‹v0ﬂ˛wS‹æMcg-≈âj?ËhÉO‹ô˝XüÛ÷yÖ’Ùù≠”ı≤‹È÷ÓmB≤zÜ˘Œ•yz8÷ìùÌTÏ_Ê|æ£ZŒÏÙ::ii€`µùµÊÄ≥{ú›Æ{Mµ^“ÊÈÍ.m!˝⁄°c›9Û6÷’
ÿZØØ{≤9˝]¿ÊÙzO∂∆çSﬁFwH§‘[«zuXßÀ;ÓOI{7:ÌmßcUøü«∫ﬂ¡ôõ⁄∫Ôî∞Ÿ4ÖÕ˘ñ	ôøí£ª DªA"—£¶)z¥√Í]±;¬ªËw˘e∞i*úo•ØÇœKbÃì∞ﬁÜ·qÿúIô¶Läyñö&¥zû%w,µ˜ì™Æò∑Åy¶1Q<zâöÔ∫Õ.Q;˝Æ¥Ôÿ¨π∞[v2j°Ë6Êπç>GòÁàµÕä_wøé~]x∑˜Ì˜Ú>˚˘›∏_Ù;2f}w˛.¶Y˘≤ﬁª;ﬂ≥[Õ+∞Gü9Koπ{	÷4+	üÔ¥~ÔÁ!∫4Fœ3mõÕ¨Î?‡Ô£œ√”ÅÓ≠{@aÛ$˜A≥√ïı,*·~ÛztæŸ£Á Ûî9§®ñÍj}¢´Ã+Ï¡=—
ÏN˙Ã≤w$’^oqVK4æ+.ˆ-ﬁA˛"<Ds}Q#{[à?œ…ÃOk>sâã¡k˛«~˘GuUq¸º{˜â$ªÅÏK°i¯ë}ƒ∞(S§õBÌTådÅ-Ènf≥P⁄b…¥®Z
®p Ô¢`Kwg¥®—R«V+Lµå∂L°Vµ»Í¥5œÔπÔ““ñÍ0ŒtÊ&ÛyÁ‹{œ˝±˜«πÁ¢ÇøÏÀRTˆ“B_ﬁ∂·ì~cˇëA_Î\^pŸ‚ƒ~ˆÛ‡9gûU˛¡˛»**e†OAË≈ﬁ·∆€«¶zﬂtÚØå´œ˜z	„≠K¯mÕXÔÄä_∂cl€©1œ#/®;"@≥<´hb |é?8^Pg°ùj6∫îa^¢û≠àœ—≈ÿuŸÔ0©u:GÛ}£iæÁ,ÄU~~Ræ.°Ó_s6—zîÊÿá€‡xê„"yÛü"˜‚çã»YÓÉlrH»5d)ƒ®ØB?Jë‰Ω`5Ùr»˚¡ù‡êõˇ Yﬁ!hÀù)É›©‚§É4—Ú≈ã∞[Gµ‚Únπ`ñ€Cå«eı Œ–«mî+K\}: ŒÄà@∏=∏‰ñıŸ‘_±Ò˛ïfÊnCLU 6ÿ›ﬁà›m\†ROîÇX”<ÄïÏÂ˜–›8
ß’n ;ëæ(û•8#WaLè›-ü ÆÙ˛å&{∑íÂ+¢áº√h6ﬁ_ ˜"™Äˇ©D,›‰ºâz˘m∑‹”nøãu['OcgOª≤€wä™r÷·›ã(Cß>)∫ §—§ÓN¬ﬁ"É£∑.'"ÛæaˇìœZ_úÎˇ=ÍﬂÉXr›È˙"éµ¯.ƒ˜:Ù…ºwºc®-·ˆ±ÎùﬂÊÛ∞ æÅœo‹=√qœzí˜ñ≤˝!YD_Å¸¥ÿÜy¯ï∫uo≥¿ÉÓ~ÌÓÙZò# ∆„–ß2–ªô~Â◊%ÌŸâÛµæ•zÕ’i¨gÉÀ{÷÷oQòÒº
;&Jµ≤qxu^øv⁄§jF¥!ΩÌ“˘4∆?Ä∆®∫∑_;-^ß2F6béØN£ˇ:ÊÚÔæFZ>A£òæ˝vyOÿÔ?gˇòchˆ£˛ë¨€ß¡Û:ÉΩl£ÏˆRÏqfè˚·
9>˛ˆ›/µˇæÓ¥á¯¸F¯<ƒ”∞i„;Çc`ˆ≠à]ór\*ªÌÏÁ8VTÒ ‚?Æ´@ú€†ﬁeu4_˘Z¯TåÂ«¢¸NS>(W·c?√>»∏HπÄÿœàø#ùF∫ÃÒK¨ãU8õ†œC˘,«O±íãQg1Úﬁv|ñÚôÏ€¯¬_…0¯"“vÅÁ!Å|÷á¯Y8[¯ŒÈ›≈wìÚù¬iW¸˝@Á∑ã:∑∑S)üAÿEÆ/πÒe_åy‚˝Èk≈Ö∞y°?Ô/óÁ±Qé˚¶1Õø1Æ"éÂ/øª⁄iﬂŸæ	ÍΩ¢¸÷≤‰rúœwﬂìºNº^h|J…UÔII^[Ô2˘Ó¬<˝¸∫ü\Ï†Óiû«7ïØ4Ë.’|úªÔ|*Æ·˜øægø‘ÔÌ◊˜ñ+r˜V~€„∏◊{è–\˜æ?Ü∂{]ûdx‹é«•÷ˇÇ`ótÙ;P‘Å5Ô7ÓG≥Êjºw;¯Œ„¶∏ç(Ákπ3¿Y¢ÅÂ QkﬁCÿzó® ˘Ö∏V
_v:âhÿ„D√«_aD¬adÀG¬Zò∞+Cƒyn¶—ﬂ!∫‹Ñ>+¿ò—cÁÃÎ¯6¢ /U·~®ûÈP3ñhÚk7M\M4ÈDì-á)á?ôL›≠—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—\¢ºâtâ¶“c‰#AA™¶&"ﬂ€‚'‰Eö(üæèØ$˛ª[}Y˜S7R9ç—Æ.©¿∏√’=–[]›}≠´˚È.c+,O∑iºÂÍïã;\]PæXÎÍ˘è∫∫z÷’}–_quåGÿtêL≤®ˇì†Ei9≈ ÁPí M˜Qõ ôéT
:õëWU(âP+˛MjDﬁ2‘OSªJ≈ c∞^Öo,#–„®À∂qe”“™Ωÿ‹ô¢»K““ˇa,‹jBµË‘kB*é˜n“hÕ*ÂÙú@nµj¡Tm/Wc5i	R+QöV£eÎ™É¶US3…å.èôsíâd˙æ∂ò9=ôjK¶ö”Òd¢ å¥∂öçÒeÀ”Ìfc¨=ñZk©öªh¡¬ÜÈ„"©xske}≤µeNÙ„e)›å∑õÕf:’‹ªß9µ¬L.˝–ÓÕx¬L£¨)O«ZÃÈÊtï-’…îôDI \í\ôHß‚±ˆ™ˇ„rœ•EòÙÖ‘Ä∂∆ı[¸J™G[≠∞ôÉ˛πﬁ2Lx´Z¸èWÁzZ}b7•Î^»æâ~K˜t¥#í'—S >
_Ïí¬ÚP÷ügÖüÅ<D…L—8Îà›e ï_˘M´„òÏ¢≈4Ÿ]ô&ŒÓ ÜgXJN¯¨#´oV23¿)ˆ±Bë·®V\≠<vÅ‘EØHy@ÓÕÃ°Ö˝h("˜√≥ÖÒ=	l 1˙˝¯-˚È-7«ÉQÌÀÊ‰Ó˜©Z%rjÇ8	ºîƒw∞ÅÑ∂e{I»ΩrO&
FrÂNZÑ¸6ÉBh}[6®Êf{6P`Ö#A˘-öñs®4ª’∂êÄ˘ÏLÂÕj
ggsÛ≠ Ï7b–1êçËr7æÜJá€oÃqÛgÉTΩ25µéí[Û0´…ê1ô†QíBñB.Å	˘eŸByjú·l hu†øi0ü&iä#≤Á<$g»·T¢ÃVfÚù~Vf*∆Z¯≈”e±2	»<™Ö ˝+dïa5˘Î≥9ü‚Ò≠œ≠„Ú´“OC`’´°°¿qôãïÕUø$öÕ…≥6G (~f”¬ÃrB5î»†°» yãAE([!GR!‰LY™‰wÂö	π#[>"‘sT~C’⁄ ç¢˚:gk’eÛÚ≠ûHé¨CÈaπ	∞Iuæ9[˛ã"Â≤ÇjÄ¿ØÖ∂Vm˙NhùXµN¨T'V™ÉÍƒÓ#π%`S-Ôß6y/mª†Û∂*Ã`Bè(etÖuDì≈òò‡QL•Å‹·Ÿú|YqfpÅ2+ŒÃ∑¶óÌÿÁÌh3,”Ÿ°≈VÚ®´~ ¯lq	WhÀ`ªóCù•A≈"^í„r&Ç'f§,ÕÜGBHÛFë!^ßxíƒØƒi^nqiñ?wÂKÆ¸•#Ìq 9‚eñg##ƒhl±¯ÌÇ&ƒQÒúHúœ(ƒ+‚MÉ¸“-êˇ!Ω|b€8Œ(>3§π+Ÿí(EPT+Í¨D/ië•E©RhCÜπd»¢-'X∆J;êúBÄdÑÊè$0P#∞#†@Å"@Õ(aƒI4\÷
e´êR5@.Öy´z*æ’Åsr+‘7CJvQ]ÇÆÙÊgæﬂ|≥≥√]Ó:¸Á{Œ»7ºŒÍ5Ê˛±”5 Oñm;°ÒvÖõÌ ≥CÌJﬂ¿d‹da_ëÁ0ƒﬂ·«‡_±-2
ﬂÑ¬∑Xë|øÀ¶…¸Omˇ+€ê[ú}…÷»IxÕÈñSé&m’ÒH˚¬!≠Oôqæ¡æ`w»QÑ~Ó¯è¢ıvÕå˜‹«xî˝ëùaﬁÔdüPõ~è†2ŸëN˙ÿú®d≈Ÿ0¯:[a+÷`‘2≠∞UqEÃH8Rq¶6¢F≈à{ŸM‹@n1|Ÿá(£ƒ`ÿ=ê≠∞Îé;*‚ˇ∆9…ÛbdeY’r(Û™FPz˜{øSµªFf!Ü1°%h∫Çl+Ï]Ë=Ë}Ë’RÑJ–Ó&yyyyE‰A‰A‰A‰ëWŸKê$r r r rä»Å»Å»Å»)BŒ7"ßààààå"2 2 2 2ä»Ä»Ä»(¬aÅ∞@Xä∞@X ,ñ",KED@D@D@DQÑ¬ aÄ0aÄ0@ E Ü"º º º ºäÇÇÇ*¬´ÆO	íDDDDSMMMME4A4A4ŸB’’à§§§°êêêêÜB@@ÌS/™≈`ÿ6ã–¥IvÏÿ-∞[ä›R€´IVÄ °BÄ Ñ"B(¢¢¢¢¨à2à2à2à≤" j„ñ I¸¯M˘£/ªBmœZ∂L«î/ëG …éÚHU˘˚§¢¸=rU˘ª$™|Å¯ïc<ÂE¬uÍhO| ∑ÄYËó–€–-h⁄Ñ4U{ ˝⁄e”÷®ªGõ’ni´⁄¶vhUkj¨«3ÎπÂYılz≠zöfƒáXó∫è‚÷B>RÂ «"(c™cS»;Ö˚Ï4˛¶ÿî’˚≠Ò8HÈfêÆÈGAÔ`/Q∑∫”$ 0qj[G¸g¯ıŒ‡ŒtsÌ—≥‹Ò?œÎt£ecV˛™BË*Ö&°0dB\µo[£Ì!7† 42¿ƒæ^›Zg]¥R˚∫ãt»<Å„‡Ó;Å¨Ófa_:ÅÀ<ﬁA◊H@˛*¢wqÂÓ¿W˛›ü∑Ï3áﬂá›v¯Ïu'pv¡	¸ç«ªË+Ñª%zæÌs8oÈÁ˛*¬Œ:|r~D"Ωc‘&·fõ:÷ ‰s¯l‘·ßd¥NÚ¬S	´ÈÇ§ªjò–„ujª©uòÀ√ˇ€„F›{`÷È´V'ﬂˇ¡qÓƒ;e<û’∂Èwy≈ºŒ?∆X‘\„ø„'¯Õp]GÛÃ˚∫J·´Fù›±û·À<¬ã·áº¿_Êó¯9˛∫âvá_‰rö$Kmvgçg0‡/p¶√_2Îjä/Ú_qã¯)cCÆ/9Ÿ7ﬁê+@&[ŸÜıöuπ«_â÷iØ‘æ”V¥ZBõ—|⁄®ˆSmXÎ◊˚tØﬁ≠—;u]˜ËnùÈDÔØÔ6≠¡∂Ì˜x•y‹≤t´∫ó…J¬®Œ»ÀD<„J≥Ù\Ç¶≈÷$}Ÿ?Ã˘Í¥ÛÏk‚ê/AE_ö§œ'ƒ…P∫ÆÌû—PZhôvï“õY¥
ˆÎ:%ÁÌ:›ïM◊ÜDﬂË$◊n≠JrÌF6Kﬁâ∆˙ŒÙûz1y@ëkó°'«‡”’aÒ€Ùú->ŒäIYŸŒ¶≈ï9„¢ΩŒzXW*πŒ∫•eÌuwûı§Œ…vw>ôEÿCÜ›‹ç0êÜ0=AÜ˚IBÜ·µ‚¸¿7"qù]ƒØ‚¸ù]*ŒMe\u«H%´Ü°bLBvTÃéIûä¡éõ¨˙˝* gP[FQ€g®âç©Å8GHò´äﬂuj NU21˛$ƒláLÔáL´\.˙$Ü∑b˙èÔ≈ÙGLËˇ<Ê!Zõ(-nßÊ}©ú/5ÂƒáÔº9(ñ/Fu±$;·ÚÁ.øÒ¶ÙKÛ¢‰õOäE_“®Nl–Ω-ª'|…*ŸNù∑´€÷|“ô∞&RæK…l-v⁄éˇWÆÎ˚πÏ”vZfÀ\±¯›qŸìπ‚2W\ÊäY1ï+ıñ‹˜ª™ìDˆÖã-Ø±√ùÿ√π°ëlb¿õ?#7Ù˙Ã»‡‚–=7°∑…·PVÒ%D$ª¬Òp\v·{&ª∫—‹”Ó\ú∫Go∑ªºhÓı%»ﬁ“î”g”bdÓ5[na]:¯ö‰°∫IÍ≠$˛Òπ®Ñøß#I·¿£x–Q*ï
≤(Ö
Ñ§Ep.-û?ãôhRÂíY¥ùÿksπT[µ£#Uﬂ›Bgì†EôN÷B4Ñ¥:Ò÷•±≤ß¨1˘™P¨û|˚œxÇ/AxècŒ¯ÑzãX®çöÚ˝•Xün9^W•;GG&ë°*›lπ’Fe≈\	ØDÀf9\éz–∫VA#Ø»G©3^qëb®∞∑®≥XlLKÊ˚ƒynX%.ÀJ(î®ZØˇ]l∫∑Ë˚[hèZP√˜.H´Ω–W¢ïΩ¥áï⁄êÍ,)®5HÎ”~Ò‰¿ßˇ0 YÁendstreamendobj59 0 obj<</Ascent 1006/CapHeight 716/Descent -325/Flags 32/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 64 0 R/FontName/NXSWOC+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj60 0 obj<</Filter/FlateDecode/Length 425>>stream
Hâ\ì¡nÍ0E˜˛
/€EïíôFäêZh%Ø≠J˚!1ºH'2a¡ﬂ?_ﬂ™ï	|Çg∆'ì![o7[?Ã6{c∑s≥=æÓ<^BÁÏﬁoÖÌán˛∫Kﬂ›©ùLìw◊ÛÏN[M”ÿÏ=nûÁpµ7˝∏w∑&{ΩÉ?⁄õœıÓ÷fªÀ4˝s'Ágõ€’ ˆÓ˝ißóˆ‰lñ“Ó∂}‹ÊÎ]Ã˘â¯∏NŒÈ~AônÏ›yj;Zt¶…„µ≤ÕsºV∆˘˛◊~Y0mË˛∂¡4ÇÛ<.ëÔ…˜‡ö\É…è‡y~"?E^>$éãi E‚∏D^íó‡ä\ÅyVâ≥ 5yf˝ı+∫Up´
rfÕ
5+zVû+8W/à∆‚•$ó`˙|D…
¶õ¿MX_R}ˆA–°≥¿YË,pˆD–y&«—(üEÒ,J7Öõ“M·¶tS∏)›n*d”S·©tS∏)˚ØËç˙Eæ¿Ôıíœ∫$o“`|M F$N≤˝ûøÓBΩ4ÓiÊ0mÉwﬂˇàiúlÃ¬«¸` yÂ–endstreamendobj64 0 obj<</Filter/FlateDecode/Length 26082/Length1 55908>>stream
Hâåï	TTW@´˙ˇ_hPVA±˚ˇn¯ùHàaîa¢CÆ„åc$—I‚DA≈5.dÇ5∏·ÆÄ
∏Ô¢†®QQë≈Ω€◊®ÌH‚xÃ8Ùºì9sr2Ôú™Wı^UøÛnˇ™ó:mF,∏@p1|ƒ{Ω†mòòD≈$EßdÒe/ 0¿ÌÛòô©r€∂˚* ó21©Õ˜y ºòò8'n^£ÓÄˆ@ø—Ò±—n^xX ~*àÖƒ≥Ö∂¯®8¶¸„ìRg∑˚ô ¡◊ìc¢π°-˝VG2ˇVRÙÏî∂˝ ¶‰)—I±ÔN>î˘üA)…”SmêPµÿæü2-∂=æ™ @]óÅŸ ÄÉ∞^ËÕn·€6s5ßrwTj‚Uˆ¡7@ÄÌ4Ã¿RÌ˘#áê!d[ìP◊Ú1ˆ√`8†ÕfcÁÑR˚i¿3≠l=–ìÒcvcB–æ»fï ÛﬂÉmrº@¢É£ì⁄Ÿ•SgW7wOØ.ﬁ>]ª˘v◊h%Yß˜ÛWoΩ›#‡ù¿w{æÙõ^ΩÉÚª˜˚Ù˝}ËaÜ˜Î?`‡†¡Ú«?˝Û∞èÜG|¸…àë˘Ù≥œGç3ˆã»qQ—0>fBl‹ƒ¯I	ìì¶$ßLù6=u∆ÃY≥ÁÃ˝rﬁ¸”æ˙Î◊Èãˇ-„õÃ¨%Kó}õΩ|≈ U´s÷¨]∑6n⁄º%7/Î∂ÌÖE;vÓ‚vÔŸªoˇÅÉá9Z|ÏxIÈâìeßNüÅ≥ÂÁ*Œ_∏XyÈÚï™´’PS[wÌ˙çõp˚é—t◊\ºkªh0ª™¡∞ m*Y5JµáÛ„Üs…‹nó…-·Ú∏*Ó5Ô¬Á¬y·ôä8Ú"_í®/EíML“$h&kŒj*56ÌBÌÌè⁄7íó§ëI√§œ§Q“ÈiætX*óÍ$£‘(ΩíZ‰Œ≤^6»=Â 9XÓ+á aÚ@9RNñ ´‰#:AÁ°Û÷Èu]O›G∫ë∫H]∫nµÆHØ“ìæ≥ﬁ]Ô•Ô¶óÙ=ÙÔËáË£ı±~*?W?ùäJqV\O≈GÈÆ¯+ÅJ∞™$*iJ∫í°,QV*y nÂ†R¢úP ïÀ UÂ∂Úÿj7Ù7DbqÜ…Ü‰¿ƒ¿Y=ΩªÍ¨*kà5‘fÌgh=`}jµ5ço˛∞˘esSã_Kì≠…˛ù±/,W*ùj¥j/ÁœEp©‹\.ùQ[∆mÂ™πü¯N|ü!,™ÖHÕ®iIG·%FhÄQK‘îkZ¥†M”Êj_J ˘H≤4Dähß6NJìéJ“ÈÆÙRz-ÉÏŒ®0jΩ‰>‘µl9∑ïZóvj√t#tcµÏjnåZWΩ∂ùZî~B+5˘®EtPÀVrïù‘*µ[åZﬂj±ÜF-*0ïQÛ.î≠h’Xﬂg‘¬≠¨É≠u÷¶¶»Ê∞VjrKöùöÌ´œF&µ¨}¿§áΩ‡Z&Ÿ5_Õ¨Ä∂l™n∫$‰±πˆ?e˘ÇıòFæqÄe!¿cV›/ãá≈Õ“Ÿ‚bq∂®-NGãh!ã`·,*<≥ˇG–∞à…j&ÈoÓ5Ãzû¿Ï‚Á}òŒlòPüP?ß°ƒrÂA`√2À⁄˙¢˙sé9ﬂú`.∞Á◊{õßö«1/»nÓmˆ762Öö˙òBLΩMA¶&Ω…◊‰iB„£≈¯ƒ¯»xﬂûe¨0û2ñãôuŒ∏›∏œ8»ÿﬂÿœËo‘uFÌ√u'éöK„º„‹Ö2VÇ≈‚zq]€=È)Öπ‹q©q~& ”⁄µX◊ÁXóÁ«2bô§	LØé±hg&!î/kÀv–2	rËÂ0¡!◊—‡‘≈æÍ‰ﬁ.É·WÜS∞”'L≥>Ì4Ûg´≠}ªm≈i„/Ê.∂ãSFªó˛kg˝,s¨Sdá=˙ˇàÌ∞‚‘°Í¯ˇ	‡`+§√".íΩ>èa1,É,ÿ;`∏B&C˙5¨Ñ‡GX
k ëΩßç∞v¬?‡%ºÇ|ÿ†ˆ¿xàÅlò ïÁ·"T¡%∏W‡{àÉ∏
’∞&¬X◊†Í ûÇæÅòì!	a
‰B2LÖò”a§¬LòO`6ÃÖ9%ÃáyPy∞∞W˛+xœ·8Ê‡T!á<
`Ö&\ãÎp=nÄfhAB¿Üqn∆-òãyËàN®FgÃ«≠~¬m∏∞ãpÓƒ]∏˜‡^‹á˚Ò ƒCO∏éôòÖáÒ≈b<Ü.ÿ	èc	vFWtCwhÄ{ËÅûXä'–ª‡<âex
O„¸Ω—ˆ¡~Ïä›,ñ£/vGjÒV¿¯‹á(°å:‘„yºÄ±/·eºÇUËá˛®†Øb5÷`-÷·5(¡∑mÏÅ·u §,ZBKi}KŸ¥úV–JZE´)á÷–Z¡ü÷—z(†¥ë6—f⁄BπîG˘¥ï∂—v*†B>ÅüLE¥Év“.⁄M{h/Ì£˝tÄ“!:Ã'ÚItÑéR1£„TB•tÇNRù¢”tÜæ£≥TNÁ®ÇŒ”∫Hïtâ.”™¢´TÕ7ÒÕ|o@@A%p/	¢‡ 8
NÇöj®ñÍË:›†õtãn”2íâÓíôÍ©ÅÓ—}z@È=¶ÔÈ	´ıgd°ÁÙwzÅ7&ﬁ¬€xçjw—Ut›E—SÙªàﬁ¢èÿUÙªãQ+J¢,ÍDΩ⁄CÌ˘oöÎ;HÀ"	¯;=_œtø=ªdñ∞¿¬Ê]ÿÖ%(ADrŒY@Eë3™Q≤HŒ …ªÎD=Â… 9ÁúaX`oÆÆÓè˘kjj™∫~5Û<R\b‰§úí”rFŒ 99/‰¢\r˜]ÆÀs‹C˜»Âª«Óâ{Í
¢ATE¡V≤ïm¢M≤…6≈¶⁄4õéâRBJ⁄èÏH; é∂cÏX;Œé∑€	ˆ;—N≤ìÌ;’N≥”Ì;”Œ≤≥É¡I;'8dÁ⁄yvæΩ¯Wlë]lóÿœÏﬂÏﬂÌ?ÏÁ¡·‡Hp48é€•ˆ˚•]fó€ØÏ
ª“Æ≤_€’ˆª∆~k◊⁄uvΩîí8)-e§¨îìx)/§¢$H%©,âí$…íôôI#√ËjDç©	5ç¢f‘úZPKjE≠©µ•v‘û:PGÍDù©u•n‘ùzPOÍE/RoÍC}#≥%U“$]2$S™HU…íÀrEÆ 5π.ŸRM™”döBSiMß4ìf—löCsiÕßOi-§%QçD1àW7’-u[Sw‘]uOÂ™<ı@=TèT∫ Wè’ıTe¯lÄö†!,0Ñ*D°ƒ@,Ü"Pä©*PJ®™*JB)àÉ“P B9àáÚ>£MÚy#Ae´jPIUá êIê)ê
iê.9RCé 19.7‰¶‹í€¥2 ™@U»Çl®’!j@M®Eø”VÔ√p¯ F¿áåÑQ0∆¿X˙∆¡x⁄F€iÌ§]¥õˆ–^⁄G“~:@È¶#tîé—q:A'Èù¶3tñŒ—y∫@È]°´tçÆ”∫I∑Ë6›°ªtèÓS.Â—zHè‡còÄ±XòÚÈ1¡¢ÙÑûb1,é%∞$p¿äKaké0≤aÀƒÃ!;,çe∞,ñ√x,œQ.ƒ1ã∞"&`%.ÃE∏(„‚\ÇKr)é„“\ÜÀr9éÁÚ\Å+rWäN‰$NÊNÂ4NÁ¨åâú…U∏*gq6W„Íú√5∏&◊‚⁄¸?ãIòÃu∏.◊„˙¸7‡Áπ!ø¿ç∏17ë;róõr≥®çRî£aT¢éõsn…≠∏5∑·∂‹é€sÓ»ù∏3w·Æ‹-çä∆Dcπ;˜‡û‹ã_‰ﬁ‹á˚ÚK¸2ø¬˝¯U~çˇ¬˝˘uπ«¯»Â7˘-~õﬂ·w˘=ƒÉyLÜ)0¶¡tò3aÃÜ9rÊ¬<òü¬Xã`1,·°í+yÚ@¬5˘Bñ ó≤LñÀW≤BVbuy7‡¶©GÎ±zºû†'Î©z¶û≠ÁÎEæ,’Àı
ΩJØ÷kÙz˝Ω˛Io‘õÙVΩnÈ=zø>¨èÎ”˙ºæ¨ØÎõ˙6‹Ü;pÓ¡}»Ö<xÄµÒ|VV…◊≤ZÚÂ±<ëßR‡xè √x
:–JÉ÷:◊4b
f`¨ãı±Å?›alÜ-∞v¿.ÿCó«ﬁ¯2æÜM|áËdÜ#|.Öcp~åü‡$úÇ”|FöÖspûÔïu:.∆œs\Ü+Ò\áﬂ·¸∆_}≥ŸÜªpèŒƒ}xè‚I<´≥Ò"^≈õxÛ0|Ô±>√«ò¬¶®)©Øö8SŒ∑†
>—'ò &…§ò4ìa™ò,]√T39¶∂oHı}⁄ohi2çM”‘43ÕM”“¥2≠M”÷¥3ÌM”—t2ùM”’t3›Mø”S÷»⁄ˇœGáZ¥˚ﬂ|L/”◊Ù3˝ÕÎ≤ﬁÅ3.tÖ\W¬ïvÒ.¡%πóÊ2\ñÀqµ]]◊¿5rÕ\+◊Œur›\/◊◊ıs˝› 7PNDKE„‘quBùTß‘iuÜ¬ T!Ñ:åÑö–ÜrÜ∫0
c¬ÿ∞pX$,Sg’πHn$/Ú Ú0Ú(í/;eóÏñ=≤Wˆ…ü≤_»A9$á·\Ü+pU6kÇo·≥IÂÎÉÔÇ_’˘`m∞.¯M6£Çç¡x›∆˜ŒæCµWì’Ÿ¢;Î.∫´Ó¶;ÍN·”∞@Ç‡æ∫(J@’-¯%2"¯Q¸w+Vb•∞€Èvπ›nLî#¡¸‡zÔ`i0C=LUœ´!j∫ö°f™°¡?’pa3»6Ca≥|/‰˘Q~í…œÚãlÑ-;lÖ?`lá∞v¡nÿ{aúÄìp
N√8Á‡<\Äã^g=Ø±#v¬Œ∫ºÆ†+ÍoÚÏáØzßm±∂˜J˚`_|…Àmâ≠∞µ∑ˆn¬Õﬁ€v‹Å;Ω›˜pˆäﬂ¬∑Òù¨St™NÛöﬂ«·¯Åó<¡{Ô=OÙæ?‘È:√´ûÆ3u]UgÈl]MW◊9^È=ºèπ^Ï5ºé7º”X/µ»ÔÙN„Õ oı3P_’W¸∫Ê]>Ôeæ‡•ü¬”x∆ÎMıÜìΩ·tlb≤L∂7ùË=gz≈uL]SS1U◊–5ı]}7q~ï˛„UUq≈Ô|º›∞$a˘˘Xî∑<ìJ6+J	!Ü%õ]†!@æt7≤íí`+AEA¢Ç	è-©P™mQAiÈKh†“F™{4ÑÇm≈ˆ ¢Ùà§P[Å}˝ΩMàIˇËÈŒæ˜ÓÃΩ3sÁŒù;ø´Ï£tôEiDÊE<ó¨o¨—ºdÒ≠/ˇHº≥ˇ!⁄Oø`ç¿‘ø£„¨ó,¸x>6•R1Ì
ﬁA-d£j¥l¢rÌ;X∫ŸAìÄèûn»ﬁú|î∆≤4ÛS`Ê‚4zm†$ö@≥h!êˆV6œ\I5tNÆßi4¯ªâ≠5CÊ6sª˘"º‚àx€ºA√)»~	uõ_(Ôõ#/z<œ9«∂;D>Ã≤í?fﬂ-If.5øÇn ˜níTJ›¨ã{0z=]di¨Y¯1 ^”0ﬂÄ‘8ZÑ<`70ÌT6õªï≥‘Ï¶±òcF›EÌ8áaìcÙKTzÕÕ^Jßöãıt–	÷%b7÷≈f¬b
¨4ë¶É≥ú~ã¸„$∞ÛÎ|πí®‰".>jæGch2UA€}Ë˘wˆ%nr‹Â‚-4ã(v˘ÅemzX>òbªHa9^<@	òq2J2ïMÙF?‘rà§GÏï‰5€-±Ûf2v$ã~Ñ‹Èudi@Ù≤'ÅT?‚~æ˜À±Cæ"OŸ£XıΩ»w∂“d£X+cﬂa¨ôµ‡ÙÌÓ?….ÒYºíﬂáõ¶A¨«dJÖ|PÆááo∂]äÖboƒ˛˚“Ã57R¸a¥YY¸§XÚù£LAûìåbÂUl „à?ãg:òÂ$ª¿>ª ÆwñÀ¬L(Ä?Ç;rŒµu≤?Áˇ©bŒ‘TQ ¬b9¥jœ† Ÿîüã≤Syw∆Â∏“kK¥?ô@	Ô^ﬂ{#˚∆Ÿ≈Zc;cÌ±ÛCJ¡f¿
„© ⁄GQñaøw¬„~Ißëô•a≤Y!õÀ,fÀÿ
∂
ñ|
Y›Kq›"œÍFp:'ÒY:ﬂ¨Vƒ†‹ÀÎ˘
‹Û€yˇ3ˇJÿq'å)"[ÃãDΩxH¨;Ö!ﬁ≈]|A¸S\G1•CéódñÙ»Ÿr±\)üóÂE•—Áõ√ˆ}€F‰?ˇ∞À^h_h/≥/¬?l/!bEhƒÈ_”†;|áhü"”O¿üSù(ÂTæüµÚ«XøMYeõ¡g∞˘‘+≥`Î∑¯@3D)+a¥åOÓÕ6FæäOÅ¸=]ñØam'0Ú*["{ú_±%R;#>sæ)ÓîÒ} Œ1ª¸)˝U:êy^Ê˚ƒBx¡1Y®Ñ»-ˆ–A±Ç=FáxÄ»q-a¸x>{q°íÂ≤	ìü/ö&>¢ıt˜√#‘J?dur)m£)¨ô.“À8ï˚Sÿx£‘˘h÷A\æÇ’MG∆*î1Ù[$v€Æ3¥íz§ÉŒäüC˚~Pî ^•ú5‡<FiÖπéV+!yä-≈µ}7e ÛànÕ"W∫Ò}Q•1Ì0N˜QƒÅY¢-iúyã*Dà›(œ!NHxP#Œ¯=àb'®√V…;i©íÃuà‰;±r™6_¶]ÊR∫ﬂ‹N^ƒÉ≥#ÓßOËi⁄œ6ƒ÷P›äìsñÕSÇºG	ö^ÆÛ3ºÇÔ∫ø∞v&K£œP¢R®¸Üt˘™†ôÊÛOÓ€awQ-}õ>∆*ø¿sDMâÕÁmfP4aΩÁ®Ã‹gégj0øGË5z…ÆP‘Ó¡Ï÷ªÜÍyπ˘ê®è5¬O√
>Xk%‚œ&üø™rñof·]3ÚßÁMõ˙Õ)πìÔútá7«ì=Òˆodeﬁ¶Mp´„oΩeú+#=-ul ò—£F:G$'%wK∞€)8£úÄå®FVƒêY⁄ú9^´ÆE—‘1T4á j$.¶ïÙAÚªˇ%ÈÎìÙH2ßZ@ﬁ5†©Fw±¶v≤Í≤Ë≠≈ZX5.«È“8˝LúNÌv£ÉHk(VQF·=)∆pm√~Õ_ÔÊPõc8»·†åT≠©ç•≤8¡S˘múí†îë°åt≠ÿ“¿ôÅhù±∞,(vπ›aoé¡¸K¥ZÉ¥"cÑ'.B˛¯4ÜÕoÿ„”®ç÷jh≥⁄ñ”•oÈtRmƒìXß’EkBÜàÜ≠9Fz0o±ë˙Ë«i_W1¯(®e0◊%Ù@Z£jUuΩE5~RÃu[Ôpc†/œFÙ ¶ﬁ#ñT®òçoá∂S™÷J¨Uı≠Ø^X-ëe™1L+“ÙelMÜnP˘jw{FÜÔàyû2™^“‹∆LóéèkCz˘Í_•˚‘Ù°oNõsdüa€íGÙâIÉâ˙^úäã[TI˘Äeô•ë6a®KTh“∞¶<ÎUüG˙í<à·fËe‘aGça˛àÓÃ∑⁄≠˛ÜíÈ‘T˝*¡¥Àümâˆ∑ÿ2ùW…"-?p5o“Ü«cdg[.b˜cO°caº>’õÛp'◊¥&ßäÃGa€h8ÃÔv[ºπ”Gµ®kÀB}uïj]Ì‰õ‰	<bq∫nrR™,Œ⁄õúÅÓû‹AA#≈H»¯èpéh»7ÿÿˇ¡ÆÔ„óTh%e’!5†G˙m[R9§÷«œ‡ıS∆hH∏x?≈]"ŒÖS÷[ïP¢!3Ò∑≈ù∫Æ”û Øå∑05h8#s˙ﬁaá€˝vÍ4{≠^Òœ◊›˙’4Ú=CÎ3Ü‘á®ó®(å´≤§≤Z◊Cxpµæ	Áˆ‡ÒTr´~É™p23ÒÔ4ªÚ¨'Ï2|0ôﬂÄˇı5ıWá∫˙È0~ñwzsÇt∫‘‘†—£ùÊ⁄ZMuj˙~ú◊õëõé”i›Ï2Ç[¬∞UÀ«°‡T‘¶±÷≤6k≠®q©≠ï°vŒ∏?R∂…˝ï°¡ª?a/qá∑
/€â‹#›#3Òb∏ÚÆ´¢Î∫O°k§ .\K‘+„Â49È.ﬂØÿ&Œ;˛=ÓÂ{˘Û%!éCús!`hú<år›*÷63£lII‡
¢EÌà4±GU"mUJ’àá∆´ld+®<sB™e⁄VUY[ÈVmÉm)£“L;à≤îƒŒ˛ﬂ9∂I€Œæˇ˝ÔŒ˛æˇÎ˜®s¸1KVK„ÿYt»T‡Í‰CÊà2ò¬(=¯Œã¡(s≥c6ñAMâ¶D]-vq	‘/j\ìd¯1åØæˆãd˚¿ˆoÃYZ≈—‹cxõ7?»N\j€’s·≠\yŒ˛ó˝78z5©fƒß2å,ó@=D1\SË}¬ÑxH1FZÄO˘˝3í2è˘´„WU“‚7ÀMbû∞¶eå¬ÒorT¢@˝ú*¯ƒf@•c$ªG£KÁ|s˚@{Ú›‹c¯˛„@_œÆˆÀŸnÊnÂêr3TŸœÁa≤YÏî£˘T°¢,˘:TA˝TƒM–FR¢?ﬁå.g£nr4ëI∞ëD’å&≤â—∫⁄ŸÅHC$Dä"Çs]¯Â‡ós]ºßó_{s∞œÉ8Mû&õ¿oÛùíN“II'	¡ïàÑƒN¯Aâ–˘ﬂaƒe◊QM2SWã∫@©ÜH—Éd.Nü;«}⁄§f)äf;Aí@*I¨Ö!g+4À¬axX8≤◊≥èvÅ%b±¢˛··ah∆`@x'Ãù<r;∂ "Iˆ)!–ñX©5!¬=wDÒVuª`ï¶À‡Äè√∑Æ∂ §pˆ¡¢¥mxxÚ8,N`2DbÃØ22ÒSÁ±ÈoíÙ‘≠‘43ﬁî83Í¥È∫‘‚”9=Z√jŸS Fﬂ:ˆ<›Õﬁ*≤Oò¶àm0v≠`µSÏ∂~€∏m˙]0ìBÎ"
Çnòä$À:
Ã ÿ∆ÒÎ:iA∂¨¬+B)VƒüQ[–·_æ∞(*aâJi“È¯ê¢‰ ÓH?÷∆öcÈ6⁄ ”ï+`åπ*–›“;⁄
}Pæ™”›:÷˘=ÛÀÔ d´ºM&Ú´˛+ÔÁ≠U'|É`±P	ÀdP∞) 4ç$DL¶[| }é]Ï~ Ë]=£‚ÒnvÒ¢yÒb∑òøB(7ü“æ‘|*‡O	~™»˝0È¢©Ò≈p¥·Õ]^G£ï8Ü+iÑDh’I¶$ˆK≤Í˜od˘-˛€æe3cbˇùex ˜i«=}_{ÈAON˝E‹®,Cø:∑û<]FpzÍFJ”§∞ﬂg-Ál¥–XWÀ∂°eª—~Ò˙]£è¶åüó–HŸÌ≤Äiï  Ë<©:0o¶]˛y£µÒ¢÷íç‚3eœZ/X˚È>sˇÃ^|åÙﬁ3†±B ˛p¶:{:™„Ãè∞PZ÷iiX±*ˇ£® ∆á ã´l+:óF)	Ø_„a/Í&3À!∏ìôQﬁMô@1Ñ$Ä‹uªXo∆≈íPY1ã4‘[≥bÖbπ™™≤B"EÖ÷åÿ¬F!5¥4˜ì3π˜ºâ?7Ù;<…èbCØ~ˇœk6]ﬂ˘˙ü©˚x‚«∏„Úá∏ÂÙµwﬁs4˜Ò+rÌ‡ñ;
≥√àqΩÊIbXQdQ!·£˙¬RdÆU≥ÍÂ/”Gm’6à2üç9¶lû‡¿ƒc^ÇÛû‡ÄπìÚb6œxn¯ƒQ9\ê´/YùW‹;‹D2õÙâB⁄À&¯i≈k,0üÄÚÁQa÷‰Aù|èÓ˚OÊöN‰åì\ácÄ”
OáﬂÙ!ƒ’4ÏS´óT¢äÑhä"*∂,KÈ©õû¨¿‹r4.¨ƒ∏§pÕ	rœHò,π€l-Ø'∑Å
ã˛7ÖÕ”Xôé∫øﬂ’{‹ô1≠∑m`€Xa¨3:aI[0Ív±±hÙÆ≤	ÊÊoπÊ^àª5	nçÒLg%–cC‰Œ–PV˚≥ﬂ#Ìwñë≥Ÿ$»ÿûúV—&G«Ùëbs®ì„é_&ÙˇvŸÿ=—ß]&-Y√}¢^wÛæ‚‚>Í"óô∑O¬{í¸ 	##ß	/˙}HôÀ€G1çÄó<o¶8#„TsN∑¯k—ØS¬DÒi&R|D’$.Ø∆∏å»xûˇJc ‹ı‘¥&„w5ôÃkR2{Ú¸‡ ªti0`«£QUQTzZ‚B9Â≤Ì˘€£‘£ÇGEè*<B*9G<ƒRâ[Öò˜2ΩÍQ˘n!P∏¡ 9W%b›V≠zøGDù"lî¿WúØÊ1ﬁ"H+≤¿V≠éÅºçêt◊¸ﬁ≤s]Fk /^P$Ú ∏ymºy¥‘Ÿäà_)$•ä∞Eﬂ©ˇL©?¢?‚ßsÖŸ∆|s]-l1ænväFD%n4ö_$ÕÙ!ŸQí∆gMu/ŸG{‰•óó%ã¯M≥V$Ö¢H›0jEXE_È_â(-ä‚S5¿èi2Óßu÷6ãX˝§∏ÓåhC#VÁ®∫Oµ}´Üµ~P“ƒº!i(H>h‹l'√,MZhãÎƒm"”§˜lÄ£ÍŒ®õBúy5¯–?oF\®@`vﬂ'uâW¢ÓÁºBh4Óú∑ê>51xä˙Øﬁ4ü“·]5º„c¸¥©Úß–ËÛ€_üèƒÕ˘ë∏ëvQ‹\∏»cœ-Äß‚yì∑A≈B].v€⁄ ¸Òå‚∆E8ƒï8∞œ¬´kgî4‡µXºêk}3∑JÏü∏ı √+–…;ÀÑw&Ñk6t/≥Y@äÅÇËå3C‡ôB“ÃöW≥’ÖÇ¶á¡®8»ì1R¨*EÂÒ≠∞ÈËuJy†(!;Ñ·
ˇ·”9JüŒQˇôõKÓ∫áÙÂ¨ÀKKIﬁ5Mgf/'π»Õá°ëH$ |cC=t™ïëÉdÓû‰Wˆ¥›ÃΩù{?;p–˝B›é‹∑≈~”⁄p~”Ö\6{Ç‚∑Æ˘Vë¡{∏#êøOÇÇ®O:K3±’8≥Ω¸IeS9P[ï=:ÎåWkp◊›ª/iµO…zk%Y“j%Y?$c&ﬁÊvCB∞Ç	laLc&iÃ$òWSËãLC2Åí¶Ö¶ÉÇ„R:°&Mì00má&Lì°ƒ)¥Ö	ì:Ã–ƒVÔΩí3˝SÀª˚i˜J˜^}Á;Á|êç1U¡§å·@(|9∞çÆù≤y3z˚T8ñ±¢˜˛XF)]Â“>ˇ‡î_/>á„ï“=7Ê√ *-PT.Â€’çÍÓ	©_ﬁiŸ-?/ìG‰“uYÅ|PiïÌV´lïŒÊ#C^ßÖµYQ`‹Áty=“˙—]."∆˘tªeY2tÈEyïí&SÖ≈(åeâE;fsï⁄fm@£¥∞˚ˇÕ1˚ø:T qd˙/Ó”ﬂ¢ ó§«3ÍF≠*©RÆìYc∂RÄædó49…@óá“üºˇ1Pñèa1rVV¶Ym”PïÄ<Æ)©±·ıd≠aO÷…P≥Jÿè <•íJ¢J™s:v÷{WEÑöLB8E0¥∂"°#‰ﬁÛÔo˜Oã„mã
coµı,KÖ˛Ÿyp…ÛG'jò3-ÔÙøxŸ’ñÙ¡ñ•ˆŸÔNÂM„}T∫°nÁ Ú
ÌÖÎÙø†S¨!Fl5µöÓ•∂“t4VOe’Y‘|”"sp∂6'∂îZnj˜/ãÔ©ê"»Ú£ﬂ[+—r†óÉX9à‡TÉh9–À|«òÉ¢∏®k§F≈¢S‰Ldv¥π˙ë á"m—|∑∏^Zk_„ÓÁ∑ã€Âßî>≠7:HÌÂ˜à{ÂÁîù⁄3—àÂÉé@IÀR!›Ê”Ωúû :A$º6∫ÆV'÷¿‚S˝æ=>“uä©@,
¢åìA‹QÏU).pRÿw&°uœ¡£t…$4’∑ä/üëäjí»3!’ôM,Më,àjax⁄F_ k ÿÌá<tÀI§∞∆äÆÄJ–
:¿fp ∞`)4%öÆxß	ê)¸ÛuI"€hi"˙\¬[˜tX°7Ò#[‰∂Ø["€∑P-xjWØ(u±£E∞OYÇÏû°V∆s…QtC;Ç0F=
Ä·r®π¸=É\æ¢!@¶ãhãÈZL◊Î3S¶§!*KÆ€aw9i)=πﬁ˛Ü∏Úùß6_⁄⁄>}b√7ª÷}ÁÛΩ;»úëulËHv*¯·ÅÌÉ_æÙ˚âˇ¸EÈynŸÃﬁŸÕÎ"ÆU…Ü£k6˝ÓÒÆ˜wH˚æ∑cEK:Ω>>˝Ù∂æãΩ[ˇÅê BVúYQ ›√fnEOÁF
◊OŸ\»˝◊	¥û(t‚èπCË—∆t–qx≤Èt¬\e©ñËN–…vÚ≥4CSk6q,À±g πJo∑@ßE±Ö†ÈDw©JÿI∞œä$ ?BzŒb·(™ë4B∫N‡4,–bèÄ”Ü»Û∞œ§l!˜ì$âÓp ˆ2S<¶*°ƒS◊Jnìtã“[°»I…;E˜;ñÉ)+^˛éDj˝v=¿ñ›€M3d 7ú(⁄Ö⁄Lûπ†¶´®¡4ú@ü)åTa‡e`Ü‚8»@fx–∞m;ÈA‰≥¸kÑ¨∞ˇƒbûVr˙¯{7A®µyÊ£@Ω6˛πëZ<1Á…'{Ä_ùˇ!“ÆÖ¥J?@ƒâ2eL‚DÆ #z´bU4Xéﬂ¥™˘U91W’-vUu‘Ï/8yèâéxπEç°´√´û„Òaœo‚Á=„t|7œvÇ ™+*Võó,.‹z§m(
∫ÇÓ‰§™LñŒNöOœõÙêyyr≠π+πMÿ%¸A∏+ﬁMZ2†ïj-„™Ÿ›+õdB≠ñö§˝“ÀRAb^ñNHüIî$†I®QŒ$4±CQÿ6I@¬!±≤œíJπF»„√Ó€U’D†A^¨0Õ1KùJÒâU *Ç≈IéÜ4Tº%ÍºYl∑4ÂæÖõ«¡˛`WÉG”ix"˘yÙ≈⁄π¬êb°+z•^£ü–ô,r à •^∆A-∫gàÅH¶&{.KŒÇ¨≠ÌË]Qw∏Z{ìΩ»íA∂â%Y	À-Ü"Î∆:+†≈∞ÿ±÷\∑ÅµSÔπ°<$î§	±À≠≤~&«ìü~äàf4Ÿtk|‘äT≥4>_§”,¶RAÃ2yx!ÚQD ò^´>Ccä=@bæq:vß+¢S¨IÇÀ	Y	¢ˇu˜â≥s{Á’Øø≤§õw?›Ôr˜\⁄≥˚x´¬π¬gU◊cÁ7µ◊mÏÍ¸©Ó¶mŒ/w.Ÿ±ƒ.â^-jÈIÕXûwÁ˜-4V-ò¸ƒÌ/wŒò
>ä´J|qıºé-3æ=D›·∆!¿≤∆‘3Õ”
í¡`XM´3’Õ¡AvZE£≥—ª»π»õ3ÁƒáÂúÛQo∑yÉÿ)˜8{ºÁÇ
W\W<◊*n∫nz>Ò_ÇûJ¶ZÆ∂◊0M≤¡,í[ôµÃˇÙAqH4K>ï5ãCïx∑vâ
o¸ O‹båÚÓR;xßÏ˙nca˚á¿É´<ËéQçÚ…o÷4Å¡G–ÿ•©(IûPóÉ!p–A–Z µkÉ_~/Ä°Ùi`CP* 5iax®M‹h^`GS O`n√˝^£bK„beﬁÅítÔ&V*¯oEx)íU~ëE¨i+‘h≤"éQP~“ÿgC®Ä‘œ_ﬂrÚ±yc‚Ûﬂû]Of⁄æøÌµüım{ç93˛≈˛ñ˝ÔˆN|6q˘%pÕ∂}ﬁªÙˆ®*≠Ö‘-»W^»I[áåÙ¥dD+±ô†⁄¶Ú&∑JÛ@ròÃh˜&º{ìÄvoR–ÓM·˛¸vQ_œÁÍ–Q[„3Êr™≥*fπñV,uuTt∏ëá®ƒWîWºÇYÙX∫….™õÈ6ã‚´¬inÿrZú∞]˝Ñ§§Jyì¸¥L… Rå—_C†Eu¿e Wâ€G»2O‹[£
óÆIfÃOa‹ü∆'ÉPu  NêÅ≥3Áƒãs2_uhM hj2ë&	2Y– ¶◊ˇr]5∞QWxgwv˜fœÎ€=ÔÌ⁄æ≥Ô≥6pW¯l0:Ö%£∆¡Ê?òÊR# °–6ÿBHúBIIdUJïHU1
Eî&¡+ïkAT™®LZàZ~¢íVJb∞›˜Êlp#˚Êowgwﬁ˜æ˜æßNßNçî@ÄJé¸ôñ∫≈euºX$√Ÿç7Zn'n¥≥ŸÕöáåL/¸s5∏5π-ò© Já˚ ëì“áKnΩaËÎñÎØæ˜iÙP—∂ªÓ€±ÓÚ≤ÛªRB¥wâ¯“°Ω·ı?:˘˜èˇÙSÃ1µÄŸe`§	å\ÍÌ”D™ªzJˇÆ.WYUë«≈%⁄"kq‰iqµºÜ≠≤ö"ŸË9˘|¡≈¢´W≠[ŒóEW9ÛÏh4Qåt≠+FÓ™ì≈Ò˙d{¶X•◊âsıZÎ{ë«µe˙”˙UÂ_ˆ πùoêêîÔ7¿Høj
@I…_XI◊∏Üq÷$ÜÈôMfõ	‘Dü»‘"sLû¥ê™¶Çdr¬¬ÍWp+X‹ÃGã√¸&g©âäÓD«‹BÌQ/´√*EàTI-Â.«„¥ZösEOK*œ>jQij¡¶eöÁﬂK∫¥Åö¢1K„Ôœö3@≥*å≈åsÄÁàıÄg“å5ß∂ùﬂ¥Ó‹ˆ¶_<td0ˆÓ¶Õø>¸ñΩØ¸j˜›wˆÈµÖ≥≈¸ÅZ1xÊ/<}·Ã)ƒ¨¢h),ò-ˆú®	Å¶ »∂‘øFZ/?√÷¯}!ÃÇ¸ÿ0·®$ÇmEüÚÄ’_LßgMçÃŒ/ûY|¢hQde«≈+#[î-°~±ø–l–gÅ›do∞%;h7:—0h8¢©¬qÒ zÏh4À¿Ó∞„Õ`è„Èêuπ®÷|µé˘M™„˝¨bR™S'zqfG‹ÚˆﬁlL≥Qµ+çÒ™7~Rj©ÿ§"©¡"#õ„Hççâôƒ¸¡ﬁzTx?W‚Û1ÇVOÙrre“ÉÕiÇ9·"ûBIsÀ(≈°rö`Zj‹FºHºú'QÈ…„…õ«Æ›"÷ßÁI>πwMÎzy’Ó¡‚¬ºÀ^}·7dôÛN7âB∞œ#Ü.}cƒ_Kﬁ|eŒ⁄˝Äﬁ#C•/ ΩRay∆kÚ˚e+Èw≠«¸s-Öïï$˝ÂV≤¨∆_m=ÍØµñ©À˝k˝⁄C˘ìÀíó=\ÒXE{≤#©V«´'ŒJ÷˙k„s'.â/ô¯CuU|’ƒ¶d[ÚB≈µ¯Õ≤[¶c+°£‚·Ó	ëïG=#&L·1ØM»
gêXb´7MéD⁄‹që<ÕU∫ïö[Xx÷!Ü„9MNõCìûlû‰t8ù˚t8õ_tsƒªúÁ(Ë`{r6à+åãé?Ë	\h40+– Aô£(Ft„p∑@w
p8Eâ‰∆8R1Q?Üä∑oﬂb„`oÄÓE¨{±O#∫Õ@«vrbßsút™*M^qïå!ÊSá¸”Êll›UòO6w~“˜ìè^ˇpÎ˛5üt¸·ã∑˜∑æp‡Ω≠[,/^ËN[ΩbzÁœH˙‚[ÑÏ~´Ìﬁ∫;=[~+M˙({‚Ã…”'±÷⁄)“5à∞YyL∞¡”CPW°ƒÊR–•U“\È∏N˘“Lß(Â¯Ã<”íd""≤j˘µ<óyï’©aF≤åÿ<⁄¬¿&÷Bä`«∏a≈x„µíY	√`Ë«˜2^ˇ mÀÍm$üì™Nu⁄}∂∏¡Ó∞;Ìaõ⁄¢ÂÅ”æ°Œ#ƒ¿sÆ∫G
∞œ¡èë@>|µ@Òµ¸◊.Ç»ïº»ÂQ}hﬁÇëD8Ç(›4 ﬂ1jÜ/c”9ÈÇ⁄‘)sûÛÚï|’ÕWÚ¬D˜¬DHêD‚%»Nï9Ec€!≥Ã‰0*!sg˜ãŸÕÔ◊uoZø‡ı4»óØ~ûŸ˜À¡à{w>ø¯ç÷¡ﬂ'wPp	ä*¸’{íU„	X;Î`ù,À.≥>¶
, 6∞6∂gdÈ
fZîÅP©(A≈˚"Y°ö¢∫≤@˜–⁄I≥Ù
U≤¥èäç—≥0£4ßÎƒ•Ùæ›(∑’≠‘Bª—\•ƒC<vR$ëÜ6§ıæo[Ø¨á’Ï¨<ú·]æ•9QPUí¿*ª∫ªªÈó==wC¥¸ÓÙK8≥tŒÏWza%óÔîe 
&Ùˇ»˝äƒÚ+‘Ω¯y⁄ËÄç$,.|p©Ù¨&ïXA<Â¡|$Xëb(ú° |!Œº∞¢P*Se:õGeW˘é∂\{V⁄§]ê>W‘˝
)S U◊W£Ã`≥ÙΩë6*À’F÷Jüìﬂfßïø—èï^Â∫˙µÚç/‘4Yí®®(*c>ò0üœUKUâRW÷,Y÷4 Ü˙ò_VTx¶†—£$‡1ôÚäwúgÒWlº,Sã€!)˘]AtAødñ– 0xSπèº˛‰r]‡à	AÓÈ\‚	\.
Ey˙gÒyOçâTòÊÉN∏È®?ëÅ∞≈]€Ä?Ä-m:5;Â…	⁄júÇæ0ë’•}iâ∑áÆßı:F¢lá$≤B›LÅœ77ŒsûXÓi,YR√|%%i ÏRWItÁ∫bº;Ø·ü–j4âêH¿«e8€Ø≥]6vó∫å%◊ÒYÔ˚s'Åf¯†ºHâœ≤·mñïÊ<’ﬂUàˇ˚p8w;…4Ê*R5s^íJB à
ûH^ZGN\⁄ªM>~ÔC“9¥ypµ›:Ù}ÙÀÌ–LÁ\¸¸ôQF}0}Fä˜©™\?ejÆÁÚﬁs!¨‰®ºGæ,”h˙d)*oê€‰aôB‘“D)»p'–BïU©=…ÇÙ«Fµ;¢Z…ò®ñ√ö≥S!5ÖQj¬`ò':·>GÖz˙ˇEí&9öÚl‘í[FÀlÔñè‘é‰
•¥A˘Û1Aö·ˆæ£#`–?º˘~=Â“^⁄À>sÆ∆‰ÛrLt|±2Vé1I*+ç(!Lù*Q äãÌ¨K⁄›Wtß8ﬂm7âIπä.‰
≥Üü´hi"£<®)r-ù«µ¥Ç‹ƒx?™®Gî%…xyÖn{òÑ˘v·˚€Ö˘v0øÈô∏]ògÉˇËÆÿ¶Æ3|œıµÔ”ˆπæˆ}ÿqbl«vxÂAFH±ad°<BÅéï`b§]B“%@0ë	öueî¬Ì¥≠<"ÿË$B™°E Ò®ö©Î∂jB0-c”P&T!¥≠M≤Û€``ãúÎˇﬁ‹W˛Ô¸ﬂÉÜ° Ã°Ä7&˚_“‡~:√VG —0É ó±eÃüçŒ_ô˘S(&z^iæÃ√Ú Ì•íìÉ¬ï…h˘¥ÌÏ§¶bˇê'O‚q—ë—" é57∂Œø€MYCC°X:ƒd\ÅhÇ§xµòWQ»„Ù)o'	ææô‘¯√&'K4±‘—™Ì[ó}˜˙œNùçdÊt˝h•ã{Íπÿ°ÊµÎ_˙Ù˘±8˚”éµıá˙∆≥€∂Ω„w∆>+xãªdΩËhgZ≥€˚s|ˇ≈ˆ7ÌæÌ°Ê‡Är»Çy£wÒ∞y«ú0πê‡uyuÒ»°;%ßKqEMÍ'LÍ-dÍ*dÍ*‰GÆB¶C áÈ–aÍ*dÍ*»˛øsÄ ‘U»‡:( ‘∏»à|‰fÜŒ√ºo≤]Ê≥ﬂ29”∆V˚t:õU57yˇ€XHOµ»Xp˘IJ{û6*Õ~òÌ~å)ô¬‘l<qî¸å6øë}Ï6tá*JÇƒK6éëƒ@n…ì9—∂í,!ä2¯„	à{èΩvk›—∞4òÿ∏`ÛI.v¯tc◊í™ùcõŸ7^Ìú{‡ÊÿØ œÕ'y.NPt2⁄xﬁg¬¢ëI§CÊÜë‹ïEˇ‡·%Kir,V:V	Ø8⁄°◊{ÍıZ≥/Ú,“Õå=#.«YOV_nv⁄;≈∏””©o0øÉ|¢√Ó\m{—˛¢¥ZÈ∞µ⁄[•E2J8^%î·ç®«–e¿Éõßü7i⁄¬˘£˜iÏÇÇz( ZP¥hyÕt1<ÊC$ºÕ∏M8é?Òé‘Æ(£∏‹ ûtúäo	≈ó∆∫¸‘R˛atäpö‹ËÄef¯!ÊP#GB^ˆa6[Ñ%I ©QBµ›Dı@∂ƒˆ‚z˚zëmÇS4\G@c|‘¸3≈Ê~ﬂõW˛ÑÙÌ˜ﬁ∫=>zq†˜çÅ≥{zX≈˜mˇÛÿG˜æáJëÛÊçõøΩr„:y°ﬁÒ6nA–√î¢ıÈ}
ûÇü√ã0ó
ıáÿ≤–d%¨ÚUÁªB˚CBΩQXh,¨V+#h6*m∏”ÿ
}‚ΩeﬁÚR:‚)ΩöÈ.âìæZÆç[à[_Â{¡q,´.õ^R,Øó∏d∆eEá%Ñ•¥¥N⁄%q!
aà¬I|€›¥@Jf~ˇ?C˜Oä%uv °k-Õñ∂ ≠ö≠ˆî3ÃqAËÍG˜WÜRh)	∂†sîçecDŸ—Ç∏%ÇaÏË©4  nL(í‡ä¨≤¶:%õÒSDå«å<ésŸnÇ"ÅÊ∆ë…Çp2›ZÅTuüóÖ‡WmEËıˆ’¯÷˜á€_ªΩΩÂÌ©Íâ≠€>8πeÛôÒ6˚•,[∂w‚›„„_ºµ∏~Ï[ﬂGóo|z„˙ÄK˜êQºJ0TôkÈŸ”4Ñ9·j∏Ør+∏óπ-úCTQùö*:õÄd⁄|F+ˆHá4§±aıˇg•GÆ‚_iµà“t…?°]π∏‰(≤ìÕû¶Àœƒ•ú}∞iÑÙ∫C‚U§Yæ÷Î⁄yzµ	eÍc–ûP“ûcs⁄R´◊Ãô7oˆo);⁄Ω†˛dº)µn”ÿÔ†©âø€Œê.L∑ÈÌ\ÿÆäÛ£+√≠·‚>qwÙÑˆAÂolN—õ∆ÙEïø7ÏˆÎ,ã´êdfÑåòë2rF…8€Öv±]jó€ïvÁ`l0Óé«¢ÒË‰ô—iïº!∂°bKdKtWÙ†ÙÂ@≈· C”˚§_(«„}gcWbzE¡ÛÑE§PDEE.á‰œÅ"R(¢Ö"Hl⁄S:´Eàó+Á≈|ú<5Ëø¿ûJá≠Jh~ôï≤ñZk≠”÷«ñ√mïYﬂ∂n[\ôı∂≈Zó6>≤.N1à†ÍÖ”1J#£a)F,GÈ’kÖ›•÷ 45Ï≤¡œ¡k–PGf∞ÁÓ¶5 ò+ô*ó˘ë?j•5≥¶
.üCjôπ-Ãï•√±Bp•Ç´,Q,ùÍ¡vı MêKœïÃN†<ÆHÄx¿mhWê‚Á·¢Ñü>jR<Q≥Æj®äMUÌ™b´0B( ò9gEó\(◊eB"P¿@ë∂‡%BQ7u7}=wNsÉá‡ôn<–M•;|ª†¨¿Ÿd‡≥›KÚC?J~1˘⁄‘L≈u'óπØQ‚∫‡§‘h∑g÷¥úá&Ù@ø»b'≤ÊçúNß„SJ#voeL≈¨aõ#Ï±Ç ˚≤)ıí›IÆHÄ	Gúä0Y
†ä∏(9í\Ä)√APÙ$§±‹≤N2ëÏÈÈaä
e7ugµ:=G5ÒX|*[[3≥.GEd∆®Í{‚åR6'+±‘Ä˚ÕÌ;∂’ñº˙ﬁ“π_Iº≥bÁ•µ_Ÿ‹∂£]◊ßvˇ˙ ∂´;?˛=W≤qSÎ¸Á"fy’Û=ÕMØWî%l≈\ûY^)	jR¥zÓéLÀ˚ﬂ¯%Ãit‚s6aè1ò?^d$≤#±êùKä]bê‚îêç—±òtKD$l≤áô0rz 4¡çb„:æãﬂ≈ÔÁ9ÜhÙæü‚áy≤ \≈ÁdÅügÒ9Áü/ |>Á’rÍ*C*Gﬁ‰¸ˇ!€ŒòhÊôóüäCÑËGâ√#@™I	$ØVW„kêí…r˙´U#µ’ja≤àÍÖ÷≥ÿø∏a}GÂÓ›gœù”í•Gﬂ«sZè±ﬂ‹ã¯éÒÓ;∏§“Oì$·≤;\å<}ÈE∆Oz#íå»Ü4Ω∆o[ÌÒ÷$54]Aö.2WIõòjΩ‹4¿∏˙©+6®6<– ÉËÄAÈ€x‰ÑÍÑ†wÍÑmp¬NË«ÑÅÜd4˚iÚÏøÔgª¸G¸˝˛	?ÁW ≈G¬!"Fâ√‚ë¬!>ë>Yî‡©"‹üÍÖH]∞»“úÿl=>…pç>kwâÇ@ﬂS9Â†C‰Á∞ÀÈv≤^pvÅX^N	0NA0`xâ"¡‰⁄Iµö8ßZ%b&‘∂‘éO◊_äÂAY}uŸ≤}≥ˇKuµ∆Fq]·{ÔÏÃ‹πÛ~xΩÎ]⁄`{Õ Ï÷kÃ&N=ixX‘ªà‹%L
†RMã ü•U’ê™„'êññR)iÂÇZJZ$§8çE„&R*ÍÆ∑Áé◊ÑzvÓ‹«ÃxÓ9ﬂ˘Œw0∏rg[„ã‰D~‡;_X±Æ˝¯íùæﬁ	‡ÜÔˆ≤ºcCP*Rƒ®Ñ%ÜDÖäòà9¸ƒ:ˇˆòu{†¡≥ˇ‘ƒH£àQ•ùeúﬂu;´@Aì°º!¿tp≈≈+‹Ò◊@ô_ëAihBÖ£TVeP›
¶ódP
S´Ei•öeQ#[âV∞ıx=…— Vºïlß€ïó–^ºóÏ£/){Y/Ó%Ø	GÂ#ÙòÚCtR˘˚9˙1˚%ë˚Ÿ;ËwÏ˙˚}¿¶—[€a1eiTÕöX
ò"N4#T2˝R∏wˆ√∑é∏LÓFÜBÂ∂‡s°p‚V	gâ(j*∏≠Ó∂∂ÅsÃÛQ]KKË D–ƒdJ´Ê)
C! L<å·CHJ	¡íÃa±N√Z%Ç@9¨e'ÜÒ∞HDËJä∏RΩ˚'é¶…≤xæ3ﬂYõÔ‰RÉ´çñfNó-∫Ω‚ø˜Â´ΩKb¸í‚˚†Ω.ØPgÆ7∏—“•Mn∆øòÈ˙’xUyÃˇ¯¬ÃÛëÍ¸+€∫;ˆê# @áÑê8Ëp"Ûf—q9`Ñ∞ï•0QIE5{cP”√;®ºgß¥ŸÖ_V∏ ©ï˜Ï 3[¿H5Ñ%¨°k(Õ∆$¬"6„{éËl»:cc÷Õ1ÎÜ?∆—«Ã3N1-`H@zxQ§ñë’ˆ&˚ª∂`ßBˇçÓÑôÎÿúvîÚäåïúW√È˙”`§|a&"iä+%î∏#FPDR’†éÖ\¡ìì4°ŒÉZ©J^D}#ÉÂGË£∆¬
)ê◊–Vuππ¬^Ìl2ürv»œ“mŒ>iøºõ^ê.ö√Œg“¥íVÌ4JÎ5F⁄¨qÍºe®…ŸK_£'ÖÔkßÒrF˝ô6ÑÜ•ã∆€ëõ“ﬂîâ»Ñ˘ë3%˝GI™ˇb-l≠∞5¬÷[ß€3ÃàÉl*”*Ÿ¨2x¡`»Çéµ*}¥p3h‚,•˙ÖUÅé=Wb™]Õ|ª#Ú€lwŸ=ˆ1õŸ,X‰ÓòuÃÁ¶Óemù??>∂∆˘1õ˝·ó<AÅ∞dQaå™ö∆,€~oëöeU∞ïôFÍ∑∂LS≤Ì8æ({¢(‡Á*›t›†PÂ˙åz8D
"Xv"‘¥5C?œßTñyË8¶iày˜,o—_–ÎÇ>äO,’∆p7;ƒ%_î6w€álbÛëjâxã¯ó ¡uzﬂsÔm%Q|ÕTggt¸xêu∆˛˛ ≤¨‚[«≈®≥√∂wÕ√˜ˇ@eØa]ï´ôüºœœ÷sÂÌıîñ"oÓÄ¶ΩÉå¬ıATo¶¿(^V¸ÀµûÀ¥Cƒ—¬ı~πáÌ≠Á÷mgÔÙÀ©ŸYfÁá≥¢aêÇn`´ÎÁÂz˛∆Ûhπ8˚üº¸¡s•·sv·Œ KERà/ m‡Âõ√∑›v≤h1ú‡˝nvîõ+9ïp≠’`H(!ü∏•úT5nùπtÒlK§·ÏÖSçè˜Õ^:[˚.Ãõ„ˆÔ…Û˘ì#[ßoëû°ˇ^¶©òY'¸ò¶ˇªòáÊ1œT!7Iï‹¿1Sj†•ÃPôõÒ:øÏvYl¨,nÒKXÄÖîê0ìÿ‰	ig2õˆ÷õ}LÙ¿$f*]ü±x#kä’cNçZ£’ËKµ•z£ÒÜ≠¶ù¥ª2ösrnÆdª≥››^≤O⁄£Ô≥˜{˚K^’èŸØ;ØªGΩìÏå˙ñu…æË›eyüÈyÎæWHŒü≈®´&Û	ÛS0„>∂@täqâ¡45‚ ≤B‹s›*áy005 zï †ƒaÆ„hö*Ò†§ï$u…ÀIí%-C&ÿ"FIG†∂8ÅCæ·\và3ä6q%˙JÇÒ•–ZAJ´◊⁄4a≠V–àw‘ô`“2òHı Ë¡x˘]P
@2ÅÓdÃöè[„ùª&Àb÷dÿC1.
9Úyf°/ÇE ∑;877S@¥Häí.!≠0Å‘¬~G^·Ω·¶,´l êÜJ≤ve	«íü„ZA~π5\ø4Ò„ÛÙ4Áê˜Ë‚Êï•vµ®ŒÏºr€Ø,˜?úÈ˙Ú¬˙ûıôômg≠Ù¬ƒs^$ù„õﬂÍŸCvLø›˜xÆùg∞4ËõÄ+˜∫3Jﬁ°ƒ¡_tJ3Ë‡/Å"Å—ï`5tjIZ©≥≤8ÀV·'…ìtï“fm∆§ÉnT÷Z]¯Ú}N9Äw” ∑Ò´Ù®rOëDúV„ZÍ+Y˙S˙.ñ-»v#VIÜ@Ë@Çπ,Ä"â<¢0B´¬®ç`‡<â<-˙∞Eˆ¥ét./îê©}ÉëQl—â“%≤	!$√bî/ ï˙èåå¿ÿb6>5DÉ?∑ê/ª;àq¬m®êÄb|≈MkwEœ’òÔu
"∑yç5iÂyg‹∑¶∏sÛº¿k∂>˘ˇ°Õ˘º(#,„™>£<Lµ‡Õ°Z\M	û≥Â∂Ñ—ïnEn Fº+á;Cﬂ”¬{ÁMnÑ‚eb$ëUh4ÒOºÁK≥°§f—,Ò‡,ãfÁdJÆ°K*+J∞º¥°¢$M~Ú‚Üô6·Ÿ¸o∫˜=áˇqB†“âΩ˘ØPﬁÑ,Å⁄Öëç‚üë k±`Û©x_ú|"‚í˜Â˜]rMæÊíÀÚeóÙ…}.9%ür…q˘∏K ]2Mß=“Eª<≤ënÙàF5èx.ï°zPë`ﬁ7Ñ˚ƒ–	÷öu‘¨„Qº6®sªÂCÚq˘‹W{pUGˇvœû%	°7)ÜWyÑÑ®H[ #“$àÙm%≈RÏc∞"!bïÜB¡$Ç	3Ä•⁄2jÉµç©”ßÜVA•3"∂"hI√Ò˜Ì9Ár9`Qf¸«;Ûõo˜;˚Ì~Ô›kÿ"2&%öîò≈eî€•€®§e¬„D•†®a<+ÖLÎZ∂Kﬂ/%p<˛iµü¿_Ç®7¢	%¯«ı	‚¡a ﬁ}J…-¸ˇãññïïâ2ˇ'JDjﬂÏQ®è.ñe˜âãîCΩÕ2zî!ûFÍÔÔ¨äŒÃò‘en—Â<5Ÿ8%gò-⁄SGrghOùqŒ§H·àyÃ>ëÔŸÔEdì›ë˚Ï}Yo◊G‰{CDÆ≤WE‰{ID.t¶»|'ﬂ˜TßÑé•4Fÿ7	âpYú%úFõôî"©S4˛JOÏ2>!!ë›ï∏LJ#JpY:ıB,“ﬁJæP≈?S¯à]u"Yèë§Ï£ˆOz•≥b~*+ÉﬂDI$;+5≈∂ÏÙúú—Yq„¢CΩœíìm|‘?·†/Õ ò|À¸¸À#Óèßƒ8Ì´«r¸⁄>nÀ˝ˆÎ∂<ÎàÁú:Gñ;´Y‡,ƒCﬁ<‡‹S,:¬däYßÕKKÿˆd,|´⁄Ωÿ{ˆPvé{º	ÀØ•-Îà'∫|ˆÿ„?Oöﬂ)zﬁÈÓˇÍèßb˙∫ZÚùã{€J&'”XœÄ=˛“∫3ô.ÓΩ¯T≤∑O‹/1€ÚYrl˚‰áÙUUN©¿Tª=n“±Üäe-g=(WÌ°•X€Ä˘Ì†YÎÄ?Q†ËÊÛ¶˜˘<«⁄WY{,·}4-ßbß=j∫Ì8oìŸL€1ÆW«i∑5ñcærØ)¢—º2õ¨⁄˛ã¯˛ x€AÁ`^áÒ<»e˙„v•1,3∞œ:ﬂﬁt„Â®r˜cÿÚÏôT·åô†ìÄiXΩX#ö©Z4ªı¯Jï8ÛÅâ>ùÇ}V„˚»ı√º„n–√ÌÙ =Ñ^H?˚ã<ªÅfzòméŸ˝}ùÆÜß„¥x‡Ãü}ÂX˜$há8›¬®a™ëE†•@w`ñ|õ´/ìÄø^0Oí¡@ﬁ±ü˛ åShÊzÊõhœÅÈÂnªzëjçs4ﬂû≤6¡é˜‡ó•°VZÅ¸öà˝W€±Áüu>,†{p˛0–,uRÁP∞g˝-˚ÛïàÎlúı9◊‰ÛÅ…àKÎÉÛá≥œ9Ó¢“X¨=Å5Û‡w—ÄÌúì,√Úÿ´øüáıó)’cM¸zT©¨C ùg>ÌMÏìX@`p®JÅ€Äi¿@úM8◊–˘äú·‹‘˘Å‹0õ·CË¶s÷≥aªéßW3u˛^|Nkï˙Ë√{rΩpŒBó˝¡ﬁ\Sú3’˘]™Û˛S∂ìs*FQ{Í4Mft"∑ uùπ6…™›Ç<Æ‰úe˝ ~·\”>AM¯4gk¶ÆPÉ®ØüÎï|£”ÏyØu?zJ-MQè—„ªtø:CçffÇ{∞vü<M≥ù& B,Ô∆¸Ö›Ã∞[≈"≥	v6¬ü≠¥>-S≠ÚV’*L≥—=eíh1Â”z|C4yﬂò2‚ø˝∑¸Å<l6¢g6∫1[]ˆl‡ö∞OãL†w@¡ˇ!PrãÕN©x≈.†dãË® •€Ã\≠öüTÙy‘¯Ê«ÙöQCkU´˚[QA≤ï™ÏT∫OnBO√YÚ0U2x–%qytEŒÖs)†AæÜ)˜|?ßzÅZ®øw|úq8è<öÜúL„ªÅ˚≥æ–£Å*/_›ã±¸l°ù†ÎÇ¸Âii(?¬y¶˙nAÍz¨ÏÁ˛»=é{$˜9Ó3¡˙0çìF6 èπøM≈~]ﬂÍ#:˛…Ø}Ùaƒª»u≠IÓ.ÎÄª€∏Ÿ›mçƒ¯#¿tw¡Ó'bwÍ˜íüfw©«ßé¡=jf—bøüÌ–˝Ê,=ØÔ—B≠_k/≠0€wÙ@≠o≠_É'Ù.U˜¬Á[h=ÏH3÷†¡Ê±Ot,à∫ÚΩ¿w¢±~Êª®Ü*ç#x/∞lu÷˜≈*ÇÓ-öá;ï)ÛÃ"™∑N”HUÄ^€D8VlÎ√±wñQ¢ìä>—J#‘∞&ïn¬∫ZÌÉ\⁄•ÛÇeKÒ†Ç/Ï»FŒŒ¿ﬁØNÀ‰“Õæ?vh_hyºE8áŸÿ”J•Ÿ˙=qöægPj®ŒÆ†:¸#‘≈nÏ±r¨‰∫È˚z#ÕE}U£7U£ÁêŒˇb∑ÕhÑ=O†ØF|‘H]Õ
¯∞T€>Qy=v◊è—@8G¨çË√¸ûÿHœ®¡tóUJ5‡’òËì8wxﬂB˝f¢v◊Bæóﬂ∑	gØüe'[Üﬂ\/v.E¨
˝ ≠øSpæqäÍå<™FﬂÓlÑV”P§4?{#<Ë˘”>÷{–ºdèä>F2}ì˘2ã>¿	â\æC_U+Èk™êF#Pªùi®zµ˙m5:—|ımUØ–zû´4ˆ¡˛x[2ˇ]ö…|˘Êõ©XE!_M_WÛ©‹ÿè‹˚›§D¨!g~y“Úg±ØqúäçB‘V∆üπ{xù>„Ä[ƒPSh®ñãÉ÷5@Hg9VÂ!¶–ó«WË]cz:^C?m'Ô9^£∂R~:
Ù˜Ë•Y≤ÜÅZ˘;∫”òNOä›ÓA¯uRS‚Á*[,Ü©l˙1∞„!†?ˆzsº›≤È∞{}âˇ0‰î√ºÌ¿f‡W¡∑x9◊‚«√ÏÓºb˛2Ó@ús2¬Î·Áúó£∆π»≈<ÜµÇRÏoPäë~O»ÖÊfw‘”À‘œ ˜◊”ÈãÄ_fús„m‚zÀÄ£q¥7Sˇn∏a›nàÔ
†D˚˜SJıràíƒa˜(h°8L…∆2‰ Ä˘PÃ#Å?É8ÅˇúÊá‚á\!ˆyòûá„zΩπ|âÊ«#»ÉX>l†Ò5ÎÅ‹i°ÒÎ|{„Íπ⁄u” cÎÑLøzn›MÈŸ∫vc‘õøãZ-üHì\ªy ˇ◊Äÿ˜l∫ãÁ◊ˆ´±≈˚ƒ'àK8>–/WΩCSAÄéÕÕh|ÕÜÎ6Ãz…µ÷Ñj#ÛﬂÌ˘ˇ‘Œ[@3Êˇ˙,A»U ∞é‚2Ô»VºOÊR%Q;z…Á√ÅÔ£›˙!x∏Ω/e âwÔ!–mDmÁ1^
~´W™ÓTÎø+”¿˚ë/Î¯˚Â{Úmø$∫xÿÎ…∑5 ã0˛;Ä˚ºÌ˜ˇbΩ‹É´*Ó8˛À=Øƒ I:I
ÜéhS3c+’Vå°ò(ïK
Âa}åµ»U$<[Kë"TäZ:¯Dg®èä¯@˚áUßé:*8HFåπßüﬂû=77'$·Œ|Ê{wœÓŸ=˚˙}}
]C˘è®∑}:zﬁ<ÖÙM$ÈC§g¡˛ØDK–@Ù§˛jE˝Hõ{Ë)◊„ﬂ?æÆ‚Y¶“œ
t:/yá¯⁄œg'öºkƒÛﬂôzˆ.—V£q‡ŒÙæoGÓ›ß£;N¨Ãg&∑6l∆Sû¶>ZΩ¨˙g„≠ö˚õÒ±¥+R+˝)Pˇ™ﬁY˝+™Ôo=”üZ˙uïÈóçπgkﬁÁ≤∫√∑≠Œ§Ã±TˇpgO!Î˚w£˚“ßC]D¯
±´êX∑õs˜˙2ÈﬁËë8¶≈gkõ3∂ìòv™”'#øAL≠≤LI–^~ÃπñKîd,>Q:ã›ﬂ8ñ∑£s„Ù…¶„8SS©RÇ°·.%ÈK€¯ÄN“ù˘‹M'}«	ßæ$N'iÛ<πˆb?S.ÂY˚ÓD—ªÖ˚pã˜è˚ê‹«Ÿ˝f”å—≈πp∞1tÁ˛?Ïƒ®.ÚnÕˇJ™Ú∑KÈáÅ∏ô˘MÎ3Ù/y+DRG√f“∑ëÓÓæl N∞§;[œ…u´˛‹¯C∆ÃúÉ+µˇ2ŒÉûòœµﬁ!i˚ÕQWÔπÓ§àª∞S=GÆÉÌ§Ir˚=8∑á _˘øÌÇv·|ıúÂcº=a≥?◊î…≥˜F¡9?«}çwæ>Àô>€ÕHapö4;o'ÜV|5uì.AKÉ>r?Ôyå˙À4¯ü«4v–nù¨áôîΩ‹˝TÓv∫ 0ﬁ”◊}_ä≠ˆö‰jçW˛@ÍÛ»˚:¿Ë˚r∂;YÜ¡ºÔ|ç5ŒV÷»~ÍR≈Ú§3Zût∑…ıºoGóFY_∞G÷Áß•&æ¨ˆeµ≥Nn'o]{YÁWJÉæ#é´„ˇò©º†∑â˘≥Ió[≠éø9È	Lˇ&À(‚Ú¶‹v„z˘5ƒ“O˘~⁄÷ævÊmàÒK!Õw∏Ë—d{:F©∆•He∫çÒ7ec~ùL¶üËòö±ù,cù[π˜iL◊ˆ7£ˇë+›E`«8Ÿó∏-∆•π=/{˛èá:œë"]Wf-E‘zÕ|]¢sÊucÍ¸áèÎ¯n¶|J ‹√¿“~*¨Ø2X¢§÷≥GÁ∞WXÉÓ*<S£,¥P6‹lÍÕ2ıÜ˘„‡˙UO;ç·-»-Ñ∏µ≤‘¿xÈ¸•ä√«—ÎS/“÷)4„w}ZŒ<_Ö)gıªK›‰Î˙ºò¯-ÈæÊ€≠ö±JΩBÓu˙çx*g†œÚùÛ‘_1n∂l®‘CYØ]•∆€)}ùkÒ/ˇ‰¨Î≈‹çd^ÂvÁ=9√=W¶:=$≠‰’Ñ˚Ú°8u%ı˘o¢wínêI©◊ÂJ∆kÃÇ•|wì·º∞_~mô¶§Ûæ√Û∑a¢˝ﬂ;˙Oﬁyƒø£Q6Á@π=hJ›M€’íN=FËÌ8›Ÿ	®sçeÄmg∏;û=÷öãíPWuPÚUøõƒÊó'!_µ:	˘’«ÈG{Â⁄ÎG{˘˝íêﬂÔÙ£Ω˜ûôÑ¸3;Ëﬂ•I»øÙ˙—ﬁ8˜MB~ﬂ˙1:	˘£ì˝‡|‚õyéªÈ6ÙÔ¢£PV_ÊY˛søÎm˙[ÓO∞ÓÅœ°⁄¬ôN°L˙?ÿc[»ÏE{â˘≈ÌÑ´‡˚Pµ•u3ODmlõôùQ˝ÊÌ∂ø9ÈÃ∑‡@‘ûi[œﬁ]Ëô∞÷ñ_l€›ı=≥™•º>◊o4ıv¥:3ûW†„Z»<>É˛ﬁÇ=º˝Ü˝ÊGı]-ÁÇ|ÈÆïÂzj¨ELÃæEFô3˜ïV± x‚ÃsﬁÖú}ÁKïﬂrØT´o–3‹õf /Û“ƒ&¡ü‡å_xW<˜_RÊÌó)ÓÊ<Ç/ŒyKÓÂÁ˙n=∑’s8K‰2£1åsSc·•úπ]2˛•;eä›ÈÔ=≤õ;€boÇt’Û<Hz%ﬂ≤Qnˆnëπ˘≥e∑ˇ	}}MÍâW˛‚›&#‚ª≠?[
º”VªÊ…‘Ç^‰7w»∞Ç|›´2Ü1˚Q‹vv)&_Áßóa‰2Ã˝Wï0 Ùô˛‚√\∑?Üg2Ò˙åI⁄Ùg¥∆O˜Aqù"ﬁab˜%2 (¿{í≈•≤¡? w¯¥U©æ.;ˆÉùFÈ¸RŒˆ§üWÀU‚õ?`úØê.±r∂Ô¶J‡M
õn›È∆/ˆt∑J©ÒƒÆ¨∆Ôhî5ﬁYŒöòÙ5±è z
œÃqm‹Fˆ{PçüŸÔ∑ö„7Ã∏ì?“-ëJØÑµÉÔh£∂OAâl°Ï≤ÿœªed‡†õ•ﬁ_$„ºÀó"<#=É·R™˛,åØõ≠1⁄;Ü'˝X˚Ÿ˝˛–Ω4‹ÓÒ…∂E˚Q˜óÊõΩI^ÛZõˇ+ò3¢Á˙,ú˝o>Ωﬂ<õïofÜÀ∂î˙QÀ;Ê“'◊ß?yÎ÷öııf˝‘t™	ˇŸûÍfçe˝pÏ'€Í*tzú∆ÁΩ√Ωã∫}¿è}tR)ªèrk§∆™>`ı>]kÍıíöı’Ìh{˛5««F˚,÷»Wﬂë–+≠ˆã˝ugöıﬂ≠4m˙Ù¨_ÔLÎ§¿¯N´¡
ŒC<h¨6ø0G˝6˜ß\5s"éı±ÍﬂG™øv7‡E;@◊ù‚ﬂ∆hMù‚‹)◊üH¢≥Zc}~ª¯†‰W$	?SËÛÔ"¬?[Y6)Nûà‚ﬁô$¸Ã†w∑„‡ﬂKªêVD∞7¬¯ˇ`$`Á˜4Ík,Ï\Ü∂,ã	C%˜x„q·€›”≥}é€∑Ô=Ÿy<Ÿy9Uﬂ›QﬂsaOÓáX}Â∏˝f~üEË˘DŸ"ãœ∏>[·À*ÖΩRŒæ=‚Lc=Anù6Î`wS≈¶u/*>Œ.(çˆw§è"d‚Ò∆'ò≠ø†4N^ì\mΩ◊~æ£õûÔä=˚˙åëçÊ,®ì
=[àª∫œªOI}kœéc›îÈﬁ NzîÔ·›(5©√˚ºπú	üÑœ{ÛÒ@[-{-"Ô˛˝±Á!Ú8˙`.‹mœP¥Ì› Xø≠>ˆ˙àÃáQ~Kø‚≥◊˘ÇÔhí2ıÓP)3˛eÜ4@ôsàÁ¯æa±sµ\®1√˘!ﬁ
ˇ°~¡Ïë"˜m4¢„2∆Ÿí≥ø+e°[À8Åz"3Oœ¥¸s¶~π=h[ŒLŒÒˇJEÍÂxFΩ≈˙Ô!ô´æ»·F·]Œ∫KŸ±·øù5ËÀ0á˛÷…å‘B9À©ó™‘´¯ùÚØÉk˘_ä¬DX7…Ÿ&øâuÚ%Â¡qIøÑzíÜ™‘1ÀÚ}ûW-È‘#í∆ßy_TÓ5S'¬ótﬁ”¶≠¥SÕ˚(ó‚¶‰‡(ú˚ﬂÁ˘‘€ç·}yá¢wôgqôÇñ2ﬁ«R”•^j¸"XÓÚ.wÂîÛ›I“É9ÌÁ0◊˚Ï˝A}‘+¿hÖÎIøê⁄)SÁ†å4¨w9˝¡™∑]fx?ë≥ºf¸¡[¨Éwˇœ~π«Fq‹q¸7≥Á√ŸwvcË˘vmÃl‚3gû∆‡;ì§ÄJ°M+>‡¿Ò°ÛMˇãR©JÇbJ+öí6¶àV%&≠#rÿHGÂÜö¢@%BI´∂iï∫™PRƒı;≥k·a%j´Vö[}~èyÌ‹ÃÏof®>ÎÙRVMp/¬>∂èƒZöƒ›nï´3sÎÆôüÕú`?E_n¬ΩÇ
GæA_¬æ“º@≥er?"¨ib‚Ù÷cü»pÔ–úoMûsG<@œ‡;~ÿ±»>k›á∫9‚€É›$˜ÿSâ}éw®k≠å¯örPg±Û/∆z˙ëX[ŒYU3˚¯iqØÕLÁc3}|˘ù∫_±Ô•ôß¡w¡¥˚‹cÍÏrfá‡&øOÔˆ][hök*ò{ˆÌ>Ê3‰pÀ‹∫∑”Å´Â+©R€)Í⁄s=úÔn¢
/«;∆ﬁ¡ﬂå{›F‹E]ˇ>ç∆	‰z´∏›«zPp˝ÁÁbmÅ°ıv}MﬂÌˇwfƒ˘!Ï+i˜+ô≥_ﬂF|›#pQ&ÉºCŒyÌYmæÌ$Ó†Û©‹é·àçù‰G¸Úª∂bÌ·‹o∑G_@lj±q˛™ÿ#ú˝Ô[h˜ü‚\™çF¸±gEß}qOö'Íãs>‚ﬁ|˚≤¶–2kELï{Œ¢‚ûÜx”&b?Fµ¸™ÉÿY	âX§Â#v4¢èçRKõW:1•ëFÚZ¸óÔÿhûÃ1ìÚÏò•⁄KâxÜ˝◊éW%⁄X;~Ò3v‚QfàÀ‡œ¬∑pÿFÏ9◊ˆ ΩÈ;N Xà8-lqwqÓOÒ"^DÜ;/9gÀûOÈ˛!=‹π–©”„‘πΩ¸Jjvù¿:ŸÖπ{Úõ41kç∫~Ô"™„üıy_ôá|qπqŒ{ûÿ'Â<aéñ·LÙbüæ∏ŒR≥ò€¨0àΩ„túπI∑ÿ»}Zå„q.À¡æ˚e˘ƒ8¥_àuzŸÈß∏üå¡:}˛˙›oË.7t◊ öÂzôˆh´q™°yŒ~¯¶˚ÌÅXgvƒ• œ¿+XUãRhì◊}Fv‹úB$8!I‹snÄ›‡V∞◊Â||ÉQ◊lÚ÷Âﬂwg
˙ÓM·V¢b‘É}`Ïi"ﬂ6øIdîc˙G€å;@Tæè(p√æ√”F4iÇÕ˝’8û#ö¸	ñ“ãDS’6ı_'öÛ∏‚?A√sD·É6ëï
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(äˇQQÓT˙;’”iqÚRê!r≠qïP|¢<˙§F‚∑VJaè†>xåÏﬂTVÓÿÂ±G€{µcªaopÏÙ{%ôk§hì]rlF>æ¿±9ÂÒUé≠!=Èÿ.ÿ€€{üc£?¸ó¥ó
Qûi∞ñ“äB/§8uÄ$=EÎe \x	ÿB∂"=&KT#'BÌxZÇ¥’®ü§NÈE°£(Ω≤%#∞c®+ ∆dôVêîÌµ°Ãì–	Zá¥8≠˙}≠v»ÌzÀ‡≈‡â∑‘´Uzˆõ;êî-≤Ì5≤Ø=orì≤∑¢tı^#TS3ÕX∫&j,åwƒìO≠ès„âıÒDk2Ô®6"ÌÌ∆íÿÍ5…NcI¥3öÿm´~xEÛÚ¶πUëD¨µ}·“{yR±N£’H&Z€¢O∂&÷ÒUw}üÎ0í»[÷KF€åÊdk2ä m¡x¬à#'a<ﬂ–ëLƒ¢ù’ˇ≈˘}òV`îóS⁄™∫i∂‚≠¢Ùjåkªú„{ï¸ºyˇ∑´Àâî©†táﬂ!Z™MËå÷O÷&“%¿µâVUâ~H´–J¨Yz8•çÎ-(y"˜k"BPJ2ˆÉ4pQãÊG∫r30¡~êßÄÅ»/s›‡í»—J4üeËﬁHÖ6u« “x¥b†ëM†tÅn‡ñÂDJli7ô÷ä≠ÌµË{±ıºTΩk€C“mµ›Ø>&›ﬁÂè⁄z·b[?0ﬂ.Vgõ<≈NÆn¥u≈$[åôBÁ‰ÜéDä¥"¸…"t|=$„ø c§”.≠ê Æπùî∞V–[uß51çk©géhÃ ÕErxÜRÈ¸Ø¸C;áÿõóÍé,‡Ô”~êœ{¸=⁄Ã/â1ál › NÇA‡ÊóºãÁ"øH˛Ah› ¡˛§ó_˚Åî¬n ú_ÄÙÚ∑Ò∑ﬁÜÙÛ∞ŒÛÛË⁄o¨È3Cá§Qt}ºc—1
äB)~⁄∫2+*Äô∆äÍ◊ h’je÷¯…zJm’«Ùˇ]ØQ•Ôä‘3t `ßÉÙ,èÉı¿Î¨sdÇm`8 ∞  Ω¿‡«¡[‡’Ä0X≤˘)ØIÒìV†QèÒ¸M*∆àˇõï–oÒ£Rˇäø!ı1h?Ùq~‘ÚÎÖ|B/¥:à¸,˛ÛﬁÚ=…Áiåù†	¥Ä.‡Êi^fµÈh§üégJZÙÅ‘?°›Ÿ^´ás± !u≥aAt›Ï¯>\!/lá%D‡õ[a	¯∆XB⁄7¬"–∂ñÅï-∞Ñ4-Öë‚/ø^^°OoZ«åàáo¬(m¬(m¬(m"ﬂ$∫‚}{…™¨ƒàÌWM¨‘Õ>ffÊfÓffîôO3s3Îô˘5fV1”«L?3√ÃÏg30&øvã;3<öô«ô˘*3;ô`Êxfñ3”`”√)^jÕØïÍA©z#‚£Éû=—«√K1¢•XÛ•à	i»ì #Ω0
ev·1~°Àz+lø∫.èÃ„®8Äi†wÅ4Äe4ÄF–Ä≤¥Ä#`dÄ•À–Ò.)=êA– Z¿f0‹≤;ÉÄS‹È‚~Ÿ±†”È&·Ò<exJyi∏ƒÎÛVyÁi]>ÊÒ≥&∆œßSQ"rA~v~äÂ¸(˜„èridd$ÅwQ	&bõ£ª¨+%zäΩh˙ıH!˚˘]Xul&ÿxË‘)˝©‰Àz
Ne=–!À˜™y¨¿$ΩèÂâZı+æﬂÎ¯RÊü|˝˙oçîãY˙Y§Ù‘œ¯û’èSŸH9H1®>C=‰õ°øz\›Çåù÷ø/üﬂ¶a(é€ÌX“ç±nL£¢Yì)+Ã/°AÅ¢.t	E‰@YäKÖ∫UïÜ∏ •Â∆¥À$&$¸àì√§©Œ˚+ˆ'0\À{N⁄ÅVÌÁºÔ«~∂„$ÆæÜf[•ïÙÁöZ°‘á+k\_:S”ÔA∂∂¢[>Ùπ≠/hOı€!u€lÎW`,¨ûá¡û”dP3#;|îÎ“UÎÇÚAÒî uÂ™rAôUteFI+SÍ§öTO®«’UUá’!5¶u™€€∑Å[75úD3<ÑÂê¨'cX‚Å_zTçë˚Dúåª1∑R§Æ¯÷$Óä!~VÃ.yX«Ã"ì.q´EqÉπ]•∑$rÃJ˘âP˙éÉWƒ^w)©z]⁄C◊FZL.z;Ñ“âç∑i¥g7ﬁrNR”/RìÖâõwÌ#äFT≤√î˙£>#>∏O|û·‚*Vz3‹Ô+F›€°?Ëw«ﬁ°h∏∑/–Œ˙„õs∑KKéÙ 8ÿ1íS·√å1‘L»}π,¥npâ…J.õHHnà"¯séÃÕIÊîA|…¯ßåﬂôΩ,0Ÿ¨d¶◊…ûdˆ¶◊ëâh M"Ù4—$¢—”y|à\éêÕ≤)#≈È!£ÖÃÿ~ü€Ü˝oj£[yﬁ¨;-”iòNrCºyπöÎ+Ü49
Üàüi¨4W—.∑7[∂hö∂‰ÎG»uîÛ¶ê∫SıÇ∫’≤ø‰≠ºc.€|´Tûœ˝kskæ|DgeÏlcïrG»9îK+á±r´dïd,"˜xŸTR‰ãı–n≈FG`ø6“≥º8ù|Qêõ7?õZKÔ¬iÂe\7ãb2JÔ\ºÉ<S(ù ˜x$•÷Ú≥È]˙)íí‡û0ãÑµ;~á§úgv¯Û!Å´›¡KÊˇ+ÅÊkŸˆ€Ñ∏‚|≈k^†(‡m‡îƒ≠æot‘ÈˆæÖŒK‡ºÖŒx| ¢Ô6˙â¸˚˛w"ªàO¡zÏÎµ2˛ú∏»∏’º
™5òkΩÊÌ¬Y
?>á	˙îQøﬂG4l∆HxMpŒ˝‹ÓDµh-⁄ë[Bøø$ÉÑã≈+÷fÏó  ûçùÅendstreamendobj57 0 obj[65 0 R]endobj58 0 obj<</Filter/FlateDecode/Length 539>>stream
Hâ\îÕé⁄0E˜y
/g£$∂?$Ñ°H,˙£“>@HçTB¬Ç∑ØÒAåT§ÈL»‹s/ƒyµ€Ï˙nR˘èÒ“Ï√§é]ﬂé·zπçMPápÍ˙¨‘™ÌöÈIÈwsÆá,è7ÔÔ◊)úw˝Òí-*ˇ/^ßÒÆﬁVÌÂﬁ≥¸˚ÿÜ±ÎOÍÌwµW˘˛6√9Ùì*‘r©⁄påˇËk=|´œAÂÈ∂è]Øw”˝#ﬁÛ˘é_˜!(ù∏D¶π¥·:‘MÎ˛≤E_Kµÿ∆◊2}˚ﬂu7Á∂√±˘SèÈÌ&æΩ(t±L¥ÜfPÕ°-T%*hï–HC[àCBi°HC2êá,4ÉöCZA¢É°CICár≠i\,.ãã∆≈‚¢q±∏h\,.ãã∆≈‚¢I∑§k“Ì3ù=-{ˆ¥Ïiÿ”≤ßaAaAÉµ`m∞¨÷Çµ¡Z∞6X÷O¡”‡)xZ	ñGÇ%¡ë`Ip$X	ñ]ªXÚyñœ»ÒY“›3ùï+≈	≠!6sl&lÊÿLÿÃ±ôt|Ö=
˝<˝Ñ~û~B?O?°üßü–œ”OËÁÈ'ÙÛÙ˙y˙	˝|ÍW˙i©h4√lùÃ πÂ÷Îg[˜⁄¶*>ˇí6XoN∫(VÈq>◊è?ûOÍu™4∑qåJ:ƒ“IÚ8C∫>ºŒπ·2®x◊„'˚'¿ —É*˜endstreamendobj65 0 obj<</BaseFont/NXSWOC+ArialMT/CIDSystemInfo 66 0 R/CIDToGIDMap/Identity/DW 1000/FontDescriptor 67 0 R/Subtype/CIDFontType2/Type/Font/W[3[278]11 12 333 15[278 333]17 18 278 19 28 556 29[278]36 37 667 38 39 722 40[667 611 778]44[278 500]47[556 833 722]51[667 778 722 667 611 722]58[944]60[667]68 69 556 70[500]71 72 556 73[278]74 75 556 76 77 222 78[500 222 833]81 84 556 85[333 500 278 556 500 722]91 92 500 131[400]191 192 500 380[604]404[604]3032[83]]>>endobj66 0 obj<</Ordering(Identity)/Registry(Adobe)/Supplement 0>>endobj67 0 obj<</Ascent 1006/CIDSet 68 0 R/CapHeight 716/Descent -325/Flags 4/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 69 0 R/FontName/NXSWOC+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj68 0 obj<</Filter/FlateDecode/Length 41>>stream
Hâö ˘ˇˇ€˚+¯ˇˇˇ¡ `¿ÿ¿ÄpÄ—(†h 0 —	Nendstreamendobj69 0 obj<</Filter/FlateDecode/Length 28958/Length1 60728>>stream
Hâ\UxMW˛◊ﬁ˚‹y	Eí≠s…TERı DHnh	ÚPâÒ∏Wr%QëxµÒÆ*—[Ø˙‘ê™éQ5’&îV_∆|QL—ôzUáˆ+2Û}j¶∏g÷M‘0g}ÁÏµ◊^Ôµˆ:≥fÃˆ"/B¢Á»º…h}Î.z~ñﬁ∫•ŒÄ-reIyÎﬁ^	h◊K¶Œôö˜—V l‡=\Íıü>r˘`f7fz™î	≠¸3«Úß[i˘¨™{˚Ö¿ìß¶Vy¥ÿ˚Å⁄\ﬁü)˜TU∂ûœ}öß‹õ4s‰0ﬁ?®ûï3º˜Œ/ŒB>ÑîÀi4i5Z
{”∫ /1Y¥“DàMâ¿£. ﬁ:Ñ™mêœœŒ–ë›∫£ùÙÁPä=çvßÉ,Àb;q⁄ÎP⁄~DÛÎ–∂#Z≈!
∞Æ{5∞˙À¨´ÅÛ¿*~`˛Ü{/É˜®Ô·#|BÕ,ı>ˆ°GâLl¬|¨C5lÀîWêÀ†1}E[ıËÅ-\á-hdﬁ1Xà˝ËDQ÷˜XÑ•Ú$K-E∫bF°+i∏5„p^-A«4T“ãVÅµ ZkΩçmÿ'èXwπ≤14Z◊µ3÷ﬂëƒØc#Œ”⁄6{8c∏Ú˚‰õòÅ9^ëUb˝Ã8Ò˚†êçF:$XªW(äÊÀ÷≤’2≠œò´3∆£5ÿOΩiàpj„¨l´ùÿFk›à›ÿÀ–ÄÉ¯öBµfÎm´—Hƒ”O=é—!Èøªÿ?ê3¶qñ∫£üT‡C¸«…†èEÖ™%kÈ⁄\Î:†F≥∑€YÚtK,dX$´,k0¬9/Ø≤çœqë‘ÉF“≥¢ª®õÂ±≈^≈(„|o`ÌÁ(ÅˆäP—$∑™ùÍ∂ÌQˇ+ú+á7&>¶0éTßôÙ}Eﬂä1Qº!.…ujá:a˜p‘Péïÿâ[‘û˙R˝ÜJi>U”k¥ëÈ8]ÉDæxN‹ê•r∫<®3‰©ôjâ∂L{’v’_‡ˇÃˇ•ˇñïl-C˜√bˆ˛ulÊ»ˆ°	gŒ„iB·:9i4ÕcXH+È˜TK;®û≠ßKÙ=˝ãn“mõàN—ï¡3ƒbùÿ$öéã≈d§Ï*doô*e{U-◊0ÏëïC5)ãÛú¨≠◊ﬁ“jµù⁄'Z≥-‘˛RÇæ∏≥ın¸›s~¯ó˚◊˚w˚Î≠ãË»5tp∫ ïΩ˜0L·zØÁé{')îsÁ†xJ£·úôâ4Ö¶SgÚe™°m-æÔ¢ú•”tÉ}ù[|~BÙÉ≈HÜ	¬+¶ã5b≠®_âü•]Ü»∂≤£åóC‰xÈï≥‰π^öÚ˘çº$íw,¨∫®Æ*N%®!j¢ö≠6´+Íä6N;™}g∂ï€ñŸlˇ¥?eO≥è≤Áÿ«€W€˜⁄Oππ;?≈¸	<tA.ñ.π´Dää«ƒ1ÓÁâ(ñŸÇ;U‘“r±ÄÍE7≠ 6@†hVqúÎ√‚-Òì ≥iÂaäË’™Õ÷AΩÀK™˙◊‘éÌkÆ≤Ö“Bq√ä›—èm~.{™y_ÀÛdW[7LëtMló£∏™4≠ Nπ	ª‰tZÄ=¬ﬂZ¡}<ÇﬁÂπêO…ÙoiAä‹E}‰∑XÇÁƒ\„{ºø•bUÇUH°˘∏Çw¯Vt◊¶Ÿ‚mÈ/¢L˘ƒ#T°vpt˝®I≠^¶Ò≤∆vCú≈l4©`úì`Ôõƒ.ô≠öµ\*Â∞ À0›Zå9ZÅ:A%êÙ,by–Æ√|ô¨úº.‚©2ég⁄^æ›˚yíŸLâ‚ŒŒ}1ö'D√ûä;®åÔ¯ûb«PoÀ(—¬âßœ„£˛\åµﬁ¡F´”¨µH‚yPmÕgçµ¯´QKK˝ÛPâ«¯Êú£·Zñh“≤¨$·gEûXˇp}9€±ÖvÒ&çgΩOùFZ+¨ørw?Œv#&·\Ê(Ø≥Ö°ÚR¸#Dùï%+9ﬁÛ»±∂[](•÷Tå‰Â6ªè=Åkl“	éwº"◊ö%Ω˛2Œ√jŒB:gk6œüW“3FÁJòˆÎ‘˝˚ıÌ”˚…î‰^={<ëîòﬂ˝Ò_≈≈v3∫:ı.è=⁄9∆Ÿ©cáG⁄∑ãh‹&»n”îÑDóëÂ÷Õ8∑©‚å°Cì{√√œ∑©3)ÎaSw∑∞Ès¶3Á‰ˇ„LoÂLøœIz*Rìuó°õçôÜﬁ@cs
_ôiÍÊµ<ª_”Çá1Ót≤ÄÓä*Õ‘MrÎ.3Î˘RüÀù…ÍÍBÇ3åopR"ÍÇCaÃå4*Î(2çZÈÍ_'∆Nô#”eFôLÎÚõ£r
\ô1NgaR¢IE∆$∆`≥mB2ZÃò∂”ﬁbF/DÉWı∫ƒCæò‰N-6ä=„
LÈ)ÿhó¿v3Õ»πó£˛∑eÂÌ3
™<çë>WTôÿ˙|’∫˘ªúÇOùÅoa!Î`YõÂˆe±Èúƒay:[KLZ &ı@$Å®Z„ÛÆ ≈=E7€ÉçRﬂ7ó∆·3ë;«π€·Hﬂg]Ä√•˚Úß90∆(ÙdvÆÎ _Óú?FßÎ—ü$%÷E¥kMl]x€{HhÿÉà˜˛Y÷¬¿ÜÂﬁœ,<2ûÊÜ0ı"ù=)08¶æÅè∑/|E}ôçüBb)≥ò+Rf∂…p˚"˙ËySãç0tﬂMp◊~|ò‚πG±≈F‹D Ù…˝V„Û_p3!¡åè¥à˝øåWp«ﬁ›{Y“ù¥'…≤^ëœ®»0ÿ¯">ò&'ÏƒrQ0è§ßÆSà	è$ÿ¥°è»ê)ùñÇlÏ"?í∏î	3n⁄:√LÈ°†¶C=L¡Rˇ=Ÿ¶n;ùût{ª˚ÔÌˇÔˇ}ˇø∑UÄ)ÿ¯®—û3}⁄¶$	7R‡>¥|ª*:∑‹_P¿ ﬁù‘—jh$∂/´œ∂5¥⁄◊âÙ¢p4Aôd`Lí[«$€«$„Ø7Å…]C“»M‰Ñ∆ˇ6ÍrTØõõ¿Æˇ!~>+_º<∏xYCΩVoıÌ‚⁄	≠¨º|\6ZK8™Í9≠gHÅî+∆≥FΩú‡'√_4HΩ6)Â +ç¨-J–∆«≤e‘\PæîÃ‹aoèáØçöôòûÿû7°=¡<9ŒÅ¡∞U.Æmà«Õd@µ¨¬«G¿xT[_†U%PDÊd¯'3ÂÏé˙:∏¨ä ˛eªFõ˙FÎQ∏;ßO[â._‘≈„´íôÌ´É∆{»Yr6æ±∫qå8…LÔn_b—û(¯jûAA–¬é n_÷°„ˆÂı=NÌµıùì™∆ÖQÊHRU[ˇØË!ùé6>o8î 	°µ@ùÜ-ÔÅ∆<–ti¸ lK®5Ωå4
Cà¢˘∫π–ÜµK9î&qÒitÿöO]ï[üCÂ4é„N®ÔÌqáÈpld8EáS®2Rô5«pà®%e•e≈¢ø\äÒÔ¸∂¶°«Ê¬˘¡0ßóı„{ÿz˚Ú»˝ﬂE„˚˙>JÁßµ	˙ü◊Â)d
%&3≈»nbòsû]Ë0˜ú¯–E)©É Ω.õÕ®\ÎR£Ú•n3õIùÕöo%÷ˆQ√p˝õùé RK
C+v¡NG…»Oö_∏eGCÕgp.ªäˇ‹ﬂ≥/ﬁá˚#óoßˇñŒ+?H_¡Ø√ÈƒåûÏ6ÉS)&ÒR=Ñπ!ÿå#»L8h ±\ö˚|πmÄÔê# ¿À—`…›ÿ›k4°T…Jö¢#)¨⁄+fÕ,ûSúÎ•¬““≤_.}vvE)78ÿº;T„Yı–ª '…zÚ-¿qöÓŸH6r§◊Ä  "^a#øÁ?IØ≈ËTTìö55√"Á‰. Sq≤ªõag]‹÷sh≤Ó&ÃÿH÷ƒSà?Ú#ºaÂp,~JeçÍdÔ¬©ìT >ZﬁÉ∏ÃïNgIfÆËö≥b?á	wò;≈n¬Nƒ„êôªâ»M¿Ì8(ÁOoÅô#Ùnäf1hfÑc[È9ÜE8úãã1>æ7]Ôæ¸Ã@P]ÊØº* ¡uÑQ\7{º‡(Jû)ôπi`œ*∫áÅoRëÃzêKñ°îY*‡°Ñı∞˘:ƒˇúÈ.Ã$≤ôn ãå m›c±àlJ zïeV≤æÒ)ŒŸ%jÍZvÕÚ1lë.∏Ìp€2Wı’ºÿF⁄-Ì∂V¡$Y‹§⁄±$˜	OïØ÷±"wÖÁi_ì‘dY„x)∑…”Ë€Læ+n≤l±µâ§}ÙÇ˚2π$^≤¸…Ê7∑≈§Kfö02Q1ÌÕW[d›
Ω|Ë¥7p~wñÙ¿˜Xs85j&é5£*gÜ;uP{iÒlóÀ‰Éì
CÍ*û]™“Ppí$÷5Ÿ‘˘Ú¬ıCG?ﬂ¸Éû„≠≠«èø÷˙Dåaœ?±Út:s9ùNˇÊ‰Å3¯ΩÙ˛ØÓ¿9t˝Ìw1Æ| ﬁÏÃËîÆq∫¢ñ4Ò€»€‰`Ç«&$
Ñ3	X&¯¢Ÿ∞ﬁÃ÷Ñ0À…ÃU#∫°rKW@˝†VP≤Óapçab‡„ï]±ïcûò)`M–"x,Ω8ÇﬂDŸ–hÉ_¬Ÿëöƒ º
¨V0ˇ†X∏ ®ä¢4¢∞ò‹ÔZ0Tªˇ/E/ÛØ>⁄öˇ·◊/Ædkã ó%X[ üÂíI•ä€·ÎF%U5*∑u•P8Ö £h0i¿oI@fñí§Oóâ9/OÀß*!Z>dÉ¢œY9àäRÃ“JVûõÕ»K∆ v;1Í&õJ∆Ù\’-v©8Yõª¶f°b±ê∫<ñ/˛7måœL”f(”KÁ	Ûƒ>·±O:üs¡/=.GÂZkìº÷∫≈æ≈ÒñΩﬂ~›{›w«+b9„ >Íßè– ?Œ‹Aê?û&@À0”QºË˜:˝~oéﬂŸ"«ÎÁî MícßüR±öƒÓn∂d∏√Üâln…o3Æ„>≤ià‚r]Vª+…J≤Ål#<È%_C˘¯Ìé,Ÿ!ØáYzÅ‰2©LçƒÆ©vÜ,m÷a+§öl¶EcPéb8ˆÌhtrnA®/-ùS‘7í0ƒ§cÿ¿Dâóîëº…?}˜´_|uÁ!‹„∏˜˚°·«~~ˆ˝Åì'D÷ºvÓ˙M?:w|ˆ«['Î?Ë?÷æj0ÂôÃﬁL	„Ë(pè[g˛w˚fTÀ–¿SÉf≈&€fÛ‘‹ÄüLıSï†"ª=∞˝iîë_ìBE6<Tƒ≤œ`˚!{Ee%l")¿/ı)˝‘^AœÖg≥õ·7EP\Jµ≤K·´’g’M>Ói◊KtΩs≠Î; fÁ.%Ó|À˜3≈,hú¡ã¨Xy	É^Ã`—a}pTùä<ßKñsyw/9Ü<dù^V
`¶boY©m–àÊfL÷∂K-!#7Ö0
—ãÔûaí–ﬁÈÓ$.ÔÙ·^\…Änyò≠¶%Ò;∆ñÅ"ÀYw√±lﬁπ∆»	˚$√3'Ñ* —äõ£é2ÀYpRŸxuC¢ƒJúz¶+ˇù¶mßﬁﬂZºƒi∑¥$w≠qè≥´‡÷áØ\lzaÌŒΩÈõó~ù¡Øª∂%v∂u˛Ñº≤uÕŒ7ﬁ–∫œ≥sÌ C3} ˝˜`¥r z!ø)8§ó⁄ÎÂuÚªÚq˘Ç,,·ñ(?Ê9;p…"'	f'!Ç˝"«;9éÁDdÖó∏æ“]-¿M\WÙΩ›’Æ>+ÌÆd},€Îµ˛…€Ä®63J¿n$¢—8$S≈∆–¥
Û1¡LJ»gÄ)·”8aå16°ih”z“ÜÜ§Ìî°ÖV7Cl—{ü$c:≠F´}⁄∑ªÔsœ9˜\Ó}bãv¿¥AÄ[»Gv°ó[r⁄b±õ9πïˆ¥⁄ìââ5æ` ﬁKßòN…ÃUJÛ™§ÖC89úïÑS9É„9|üÅ∆ç|Ü;ÂÍ•ÌlßˇÍ«ÑpÂ•ZΩ©2T´á™µnr$“VÄ2ä¢¿vÉOÔ#N»˘ÓHŒe”Q·Û'Dx!'ß_Ö`¿=fÜl:"Ú∆⁄àlD‰¸l8Oà0µçÇÌ¨¢ZÖ7§ÒÂˆé¥roæz·Bw¢ä÷Ê{Üø}8qHΩg§Äáπ?œÚ6hÏÇ$s˙Öı9qA4€e◊Ωﬁl7JÖC=€È¢D
@æ`éÄ5ÀP”ê%à# —H?0âQÏf⁄´∞ﬂŸ¡ü‰lœŸÎ9‚˘µ|E˛<ÀjÛ\%AﬁVn)wú„Å™«Óu{<πîó'√•8Å"¶'b∫Ä—t)¶ó¶&uZË%§®öi‡Ù¥zu•∫A›•
*ê$¿H†$†∏@ö$Å√}ñVÖÓPMÌrù˙_d…}î,ÈCG	açipÄ,‹h≥ñÖ-E¬Ñèim∑ımÄ+û<o|!ﬁ	ú@¡¸_z_[æ©ª≥˝©ˆ¢cØpWGN◊¥Ó>O≠´w˛fÑnT∑ÔË?¥ø´f∫èª˚N‚Gœ$Ü>π∏ªÎ/Ë⁄Ê@‰º†y9§Ñ÷§T/W°π¥ûÚ4´H7ù‘ÈÑTïe…◊3úvùíÒ*&1Ê‡T›Øb˝LÛ¸Ã¡˘Svk‡ÚÄ˙a:í±∏⁄√HNhÃ§3$”;#sÜ±–=œh‰Kã≠À‹ãç’÷5Ÿ/[∑d_±^ˆiíÅ[\ò‰Ñ8?ƒ[y¨C¬éB#d‰aáÜ≥¨ur0œ,z©	¢gKœ¸ÏT”MNçoQY °FQÅ•∞ä;ß—ë®•våúN#¶o∫øﬁø“ø¡/¯}ÿÁ˜·p˛^n‹…p“§„£AL)S:Xc*bHTª(ï†ZAk&J(nnLP°|¢©SPÍh∆òêÚ_üîŒj\¯¸Á∏«œ6tèºá÷ø&nºπÌù◊F¶‘º2w’œΩ∏ˆ∏PÁZV>ß¸±/˛¸¸≥âˇq{¸ßt6]Gè}pÙW√◊b«£ΩoÌ{Ô=ÿÄE†w>À‚$M¶´ﬂI¯rV¡ZÜ,,Á®`ìù-<œ·ñ‘∞ÕsA≈⁄b˚'©Åÿ◊s¸t8≠§¿<f∫R(ûıPsıú¡¯\u›VòΩ#Z$ô™¨X¡àÑ•–d∑{ "˛T{">{≤“«o∫∑M∏ﬂŸæ'·N|›˚y'ΩM/æÅun 0Ë'!RŒë$ªeí•ó°FÇ„ÊóïπÛt—R§ªù∫MF∞a–√™à∞Çı%¬PI'l∞N%¿ßãO>}?
_~úW∆€ΩÏç^_Ô√j·—RW<≠HN≥âàÈâà…â‹`ïâí÷‘¯x√f>^ƒaÒI/ì3/[È√ı•É±Ëƒ‘“2hJïè˚f˘f‹îoï[lÂt=YO◊	´≠ÕéUÚÁZˇ≤ù∂[¨/9ZÂ-Œù˛ﬂk<Ó|`JW∂ƒìaLƒ”£ È£2—DÜi(£cv∫Âúç⁄zπS∑(¶‹Q(QTÖSzÈÓûIÅñ<Â°øk\ãw¥§Òö^Œ€Òç—íf∏?òîºxjm1∂8LZ)∆0ùã≠j&Õ—(-(®™LŸπ¥ p≈ì1Ü-c©Có5-øyÓ¸Ì∆m;CWØ&Üv?∑•qÈÀ€ñ4lù6´£Ó•£ùõ6·≥ä˜-;ŸıK~V\⁄øıÏBÈ˘]–yK[7◊?ﬂ÷:¸`NGÕ€7?öÆeì:®‚ª©x;r!å◊ ±Äb&`Í¿ß#–XH5VÈh≠4Ï(“WÆ´∆≈ª\§ñRf#ù*T3M>öh‹ï˛plëIlc ⁄?UÙ⁄á£ïƒòI<Ãùf	KûCÒˇı—±˛k®âc2+ßüÙô°Ô˘û
-·ó˚VBkÉÎıˆ‡}øÔXl∂Ô¶1dxæÂ{À◊È„ß/πBÃª! S œç"Ω∆UèI6á§ójìí‹çì»=C#ƒä¨=öV;JQßªQ¶µQ,i¶∆i·ãc›&B)>6w¶eóƒöi,ö îèqUïÖ®∂p& &∑¶rò()Éåóa©©”∑nQ›˙⁄…tÚ˚+zÜ©taW¸≈µwΩÛ˜ª√´‹ul›˙É¥N]˚√'7|⁄$4RÎß◊©∫?Ò∑ƒóâø'Næ{éØ|Ωßˇçvê\¿Lî?[ÑP4âLa!¢d„ƒjÅØ¶¢`Á™¡◊ŒÄΩ8h=∏V¨@˝ÑjÄ≈Å—¡SU·Â·Ë‡£√G˜`ÑK¸´D\¥°á∫ï≈/ªSçØ9T∂(%&0ˆ;Q-W¨Kmœ™[˘ı∑ñ‚yıéÍ∞Z¢tW´.uúPÔ…˜ú˜\6AúÇãwÿmAÄÍ¬*Jím´(Kî∆Tcƒê‰Ë‚xØyÒor<e”-´.Úb/◊d⁄àUæerî„ŒPŒa∫eÉ|_‚ø[+|,\¯Å
ΩîöéZ˘ºt]Ê;d*„Uë>ñ∏“Fâì^UÆ¸)π[ôp¿7 ;ÃTÅÈ’¡¯Ù’jæmñ≤pºS[YÄùŸ¶Ç;nS˚˚]˝˝mñ‰–2˚Ñ£nˆ	˝;üÓﬁ*ùÅ¬ó<¯
A•´–o·'D+hàœ„=y|A°(Ò\≈'‹”◊~1Ú˙¡´ÙÓk3Û≥+,gÓœ§g3∏Ötoﬂ;w`6€ô˜DJcé ”Gà…á8_fÜÑñÑZl≠6Ò¡5ñ&[ãc≥e≥C,ÙŸ¯@aâÓÀ±Ÿ<nΩ§§∏òdÁË∞oπ∫Æk†@î1ÖâPWòH{—çîE‹y—äoY¨≈ƒÅ8o|ÅúçO»vºOF\xÒ.9Xö£Ah`?IäY™Å˜B„~7r≤!b„éi«˜íX¯õœ$M~bê˘Á≤?s‚É…Ka 4\≈®YeJd‚HØ÷‡&Æ+|Ô›]ÈJ´ïvı≤,[Ú
€≤AP¸¬F±);uB∆âÀ§∆L q√´¥i0)⁄“ÚH°Ñ0¿–&ò	0«6t 73¥%Lô<h¶IS¶ít
…$°±ΩÓπw%„Ü?t*[wèV∂tœ9ﬂ˘Ó˜iIÊ-™(QÆ≈F˘<7…«±≤™JFÊÒ|0eUlvYºãƒ€/¨Zºd„÷«⁄Œm1_¿S÷OûQ7Ìπ}Ê{∏u^ºvŒèÓ‹bvH}MΩãÊΩR^t∫mIgK©0K.Æü˛‘ÿÅv◊‰e”f=]
Éâ(≠ëﬁÇÆºur!Y!ÿ<øèå˘,“Qô≤-G´#mhCd⁄#Ω*º¨Ù
] yÂ∫˘<¢πΩ-∆Ÿäµqπzﬁ7ïFˇcÅ∆Ï'§eëgº?ÛÓ^tÔ…m«ø!Ì⁄;nÚ£∞ÍW√"LÊ«ãìú¸''U¬bé/Ír¢¢Cç{f†∏,ŒÀäÎS€Õé.úÀ5W"Uœ¨i≈©ÒbBR+††	ºgŸƒ¸1P8oAyôòeè3ö#øóùÿ’?≈¸›µÊü_:äk˚ﬂ«„´œî˜øp¯s[Ø?ˇÎøR˙…¿9¸›7Ø·Ôt^π0·¿éÉÊ'€OôˇÙ4„µ}¿=s —®›5c¢ûák©ÖNMçzÖ-;pû¡µï√…ÂÒ;zúí¬yıæ°˜Ezw2–ã~zÈ8ur•%µOïBéù⁄®DE*⁄≤C·±…Nòß`˝A_P∞ÂY1Ïu√¢π1tj1UL$∆¡c=N1Ñf≥Ç ÿ	‡≥0VVi‘|l˛˜´s÷6≠^ı∑_‹hv‚‰ˆóK™ˇ’ìwòoH}Å»Ã«Õ?Ω~»4/(Î®,}Ë„WÆ1.
Yf¯Í(£ùF¿&E)µ€ë ≤B:QQ;CGDıVÿfËN]!Œ∞":˛èquU7[ J≠ûl™˛÷’ƒWÁ¥¥≤ƒ“œÉb¡‡>!1¯é∞AÍÎ0ß1ï6E éƒçêÉ˝‹H∂⁄ÒHê¬^ùË2!a˘>ˆm»|„ÆÙö˜lﬂY=w‘ˆGÌˇ™e;ÿÈˇ’Ω∑ºFé5∞}?–1¥ˆ–
≥ﬂ≥_à}F8«ü -ExıaØPPÄbﬁ,Rà¢ÑßŒˆÄ±-+Í@;0éËÇ yµÄG≤$~˙Ùeô@ﬁ~˙Ê∞ˇ'+€äpQ$Æ;±ìKAgv|aÛ»(◊´©€È|`ÛÃ:éå˛öÒ%<ô°@?(ÊÁ‰Üs≥sõ+Æ‚yqZ(∆ÛCJ$ÜÇ_˛ÿÔ”ÌjåT√π2 €Ø¡uƒb®@ÄqS
:ØF≠IdÎ(Ö'jˇ≈¡,˚◊–áÕB…+ÅTi¬L“∫’ºt‡]s◊	‹ﬁ~åwƒè∆Ô~jcˇ˜cì7a≤}Ìß_'Sè‡°++Wı‚yÔ^∆´∫ñÙ¸≤dy[˝∑7<≤yˇÎÊù∂UXÉ~ú(≠	Ëçì5DÇ“üò<•Ç_À+¨ÎÑÎZ<÷∫ÊZ◊H‘∫Ü¬¸
ÍW≠–•m“Q	∫2e+:Äé!q"2P˙˙I^nnCˇsô√/îÜÂø2∞ºôÅÂmCµ4áÂAÒr”(⁄©ù;˚xôT”äï5C©L!k èÑÂ⁄ô~&
 «™·Ö\6‘Edâm5˘ûm≥≤Y≥98“∫d¥6d1Íq8‚N'çÀL÷≥ùÒÄmH∂ÊÇ÷q≈ÓAÜ*9•˚∞Ó3|æüË√qvíe»‡üôiz?=MuﬁÓL&7‘‘
+#¶õ |7∞}î≤§30$‚g‚9^}‘æ|·Ù•≈˝MÁû;wµˇ®v’Z·≥¡Ïû?.˝Ä1”;„ O	µ.LD!*!™3YG;ÓõænﬂC˘∂{(ˇz ‚-´ÿ±¿Æ~Ú&¸Û¯ä›Ÿ<∞ï\µÃR/¢–MN2‘≠h|B°Õ n≈,ryŸ€í«%8&‘!ªußl„]P”-¯≤õ∑@ÖÕ]ÔJgr'ì…†ï	≥k˘`8{VΩtÈ¨¢'ë‡'uÂX6“»≥sdŸ¯*U‰´ƒW
ºb‰≥àpbÑ°gå‚æ´Íù|µgD?eÀcQ\¬.›È≠Er	ª·X°pæ∞ƒŸßÒÄ»)“àºP´FCI3∞-S~˛±≥\nMÚÖíO≠©±íIYŸÁîDé±ıì*Æq=Ô˙=î“5›5›#åïÒÓŸB≥∏F˘Å{ìBe"—§RÈ~Ñ‘	⁄ZØ|√Ì‹M^vŸw—v·ê›Ê%∑ªD"~I"‘•(%Öê∫fyfal•ßÏv´¨O-ﬁ6/Òˆëv§‡“„íN{p©·t9ú∫·Z'cπítcﬁ!=`> ¢gπä’“¯ö.µHmêi?°U√ldÉ«∏ï™	Œ∏øÄ8<Ú‚j
‹îAı¬\«¶gπÈÄL—]sÒ[‰ ^wô{ã∫c.xØﬁÎE ùN∑ì›Ra/ﬂÓé%›„cI•¬™§ª¨äá''¿›	I´‰M‡N–äÛπ Ã™¨¬1-_√˘X€çpsI0{ûè•Sf„Qs∂‘7Ÿˆo5º$~9Mº00Iº2¿Üq/(∫<vä„g;Ω2#Eß/PACÆ ¯8¶Üc,¢`Ôt;£Gâ]®C$ƒaß¢†€lRÜ9%WN©í5I ›å0ásJó±.7»-ÚrπMñd
ä ±/S‡ÀÓOàiipØtVè¢ÂDäú@j\)0E¿!ˆ3ˇ'ÚY„◊ãÑ·+Øπ¥
™√n*-a#Ù†ã”íê˛ŸÓiIjîYaY“>&;…‰{w6ÑeV»ÓÊÛ–êÛìv∑û>ˆ˙V∑¬àF ∞Ng ›ø5:–¬r4Ω€{^ }ÁMhÿzq4´m†-≠Ω≈!ËîÇBË∏1~ë∂ÃOÍ‘:≥⁄ÏeW¶eÖ,ÌÂçSÓˆ®öÊë¥°a=å·7R˛WIvØ¢ÃM…i∏"ey¿Q∆•8ì\HG¡ÜêXLÉxDCì±;Íü‹—t”¸Éπ?sz_jfÈÛ'Rü€ª®ªıî94tD¿[÷Õ˝q@aUò=¸È¶Ù6
†b¸Ñ±s~|údá™ˇaºj`õ8œ}w˜ùÔŒgﬂèÌÛ˘'é€Á$V‡b©∑-	
~
!bçB°îˇ- &™2~ªu+¥TBŸ¶và–(ù¥ñ1Q÷™ì∂“ñ∂k7ƒOYáTïiÖ8{ø≥/eö&Ì¢˚æ◊wÁ¯ªÔ}ﬁÁ}⁄e+â:ÚW˙ì\-ÆfÕf‹úaŒ¡sÇfw%{Ãx'≥d‚Á®ü2?£N2W©´˙MÍf¶é‚,Uãõ1[¿œGÃ´&õ÷kÕ=ov—∂ ∂‰ls1ﬂ£vñFóV,ÆÏéwW≠¡´kÕùÊ·ËaÛC„#3‰6P *ıl$[ıé’…≥Üﬂ®≈30K3z5„™6S\ÇÒÖ1M>P8ã…Õßb.!l˙í	ü£B|Ná‡sõ∑!µiôVöd≈7ã«kw◊“µ	*Õmÿ‚¿&qw®∆qé%ÎX∏ﬂY—∂¥dYcÛîöSÆ(W
eGIm&¸≤isd†ô·—Öƒ¡’FµÅwI©
ïõ:›Ã∞ˇÿúÒ¯‡Ô/ÛÎ”®Ì õ®˝‰˙±[/≠;ŸÁG◊ä◊Q‰£’ΩÀ˙é≤˘ùÀ^CΩ\C+G^/˛¸ÉÛ≈O’é°¸Y$˛∏¯^.æùiAŒO Gù‰Tzh%4∑iç—•ï´¯uï¨†ÿùœ]ˆò"íälôáÏ	$'p;Å6<~}H7¿¸˘PU¶A%ü+2JyñÀ3‹®¬,›áÁïÚLÓ[§Ω≥¢≥‚›Ω—u—Õ¬wº˝ÚÒÚQœÀÚ∞¸©˜∂¨@∑é´≤_UeUñ-B'¬∫»i™‚ë∞!z0ä	ÜH“ÇA*Qe◊∞8Ú1”{å# †‡úÚÑ‡ØVyé#oÃ‚©ç©›)&Ue¸øuÕ˝O>M6øÙ_V´lSB7@ç› ıùÖ{-˘z¿ x'eÒ.Â)˘Ï£UVÃñ»[r^Vf®⁄B{hì›Òº¿û·P^~’‡ÙZ—ºRÂá≥Œ	¬$}n™Æ¸úKÍA_íôDÖ$m:!|íLú†˜_zk«˛‹Y›5g|Ùb◊˙Ó∫ƒÏø°{éÃ=:XúåGÊΩ—Ï›ätjÓ∂‚&4Â˚õ‹Æ±mLnzˇÃ’{âÜÌøÕ~˛p2∞2+òÏf+À¶3”ò|ÙLákNE[ek™=≥êY‚Í≠ËÆﬁÁÛ&â˝#˚ùrÇ¥òNêqÇ§ùä“√• Ì¶dàÛh'Qµ«L—)&ìnîí≠È∂˙•Ò≈…ÆÙSÓ'=kΩ´¸}Fø{ágáºKŸñ⁄íﬁÀÏwÔÛÏó){RﬂK?Î9"	ƒ J≥.aj3,ò5`®ö∞∆NùbR}P\û∫˛»æIÎû∫X&ç“X«ÑXleâcuB,¶3∂)ÕGJñîLDd`˝›“_ƒ™Kßº7ND+bﬁ≈±Õ°t™
Æq8©[vœ@Ôπ´SuƒˆX∂JPPÕGÀ—FÙCƒÅ	:m˘Í»OíüÜœL™’„ı“]5diÚΩöTx'djD~ê[örç`Y∂´|©Ö–îÀl@:oÿéXæÕÜ£6ﬁU¿Ω› √(y#Ä±J‰ÑKà⁄ÙäÅ}”ctÆÑ∂åô òÊ¥Ü∆∆†òê¯É:¥AJ¯“Ï}≈ÛÕ7vm¯Â¬˘ΩÕ≈ß¨y‚ª_¸d_{Òà|ÍÂ”'ÚMËZœÓ{ø\º˜zOY®˚Î[Z€ûHøïù>ÿ∑·ıïkﬁz⁄{‡”ÀÊÂrk´õœoﬂˆ«-[Ô§N=0¨Ë¢ˆYL«`√)ÿwÃ
√Ùñ!€v!Ù
Gt=Éàœ#õà®s€Ù¿óπ·«v]wH‚°C
≈í ˇëø¬£∂‘’ç¬-B•v?erBMLK*Ì+V∞˚ãÏ9uÍÀ{dµ'∆o„*X≠ü∫fâ¶‹√ˆWxV'0–A6∞Õ|;;ãﬂ.ˇ*ª$äVáÈWœqÇﬂ§}IOËKZ!¶	Fm{TàÎ(Æœ◊ÈÂ˙F}∑ŒË3."—ë≥¢Má¢Cá¢ÉqÇE∂lâJt(N–°Xy˘fw;ïBaìΩù6ÄlÖì•
(ß˙i÷Óí Â¸∫@QŸÂWºÛvÒÀçgû⁄ıÓ<ÚÃ_ä#œfﬁ√≥ø=ˇÌã»Oˆ(DQÆÌ§œ°-≥Ü2’Õ4ÚT£ö◊çj¶⁄°Õ4z®nµGÎ6îÁ˘Áe∫\ﬁ9ÖCŸ@nêZq´4;∞/íñV‚ï“⁄¿VºU⁄êqÄ∏@çá¥”<È0èëÉ ûTr>±b^ãsÒ<aWèWñ%øO”z–0@÷¥a àìY“T2[K Â)L”†Á˝QÊ˘X¿Ü&	B,†A®©í,«’Ø(™&Hº¿≤™@éaIò1YûßaMÜ¶©*≈áÉ¡∞Ú5-†‚îc Nã¬h¡Öx!
£gJM™uéÅ5á∆åπm}≠∑&˙ìcÕHoÇ˜Sùl@Á£FÌ?'»ÍÄWπt	ÜñKNÙË ŒMÁ¶Çs;´â`©dÁ“p±÷∂s‘¯kMK ÊœWÜ$[–	⁄\H†úœ6k9üì/Üƒï°ã;/í
7â(¯˜?ÕKFÎn˝Æ∏˛’‚õW–_º∏yÏËsü•òè«¬≈‹;pé˘òÉ¬¡xﬂÃÉÄTR;†GBO^‡Ö€,èﬂ“Ç†ˇo[^ÿ¢kåπıæ’[Éf≤5|≠XÔeW£’‹j˜«ãYÜ·xó¿q«¢u$ƒE∑_›√	iU:π ƒi‰áríõC@E»=Lá,AÜbÚ”Ü%H¬„ñ∏[§≈atﬁÚ∏›RúbüG?C”4π" Ç¸ér±‹6=IeJ∫^&)⁄∏‡Ò^L,áÙgÔó<ﬁh(º4›"L‘qãZJ˚¿§lñEÇIzÌh¿âT`ò}:	äBÇŒÒí ±#„£‡GQ6Û#[±(N<ﬁô#K&:BBE9T &RÈÊS]Ì¡Mg¸ˆN“I:›ÈN:=N>˚,[∂dI‡óåm∆‡„aÛ∞Êa	"¬ÀÑáL†0eSÖÑ)n;‰hjR-î÷J∑ı0”$åôòâ&±[“bÃdÄŸ›oeKw´õÔÌ˛æﬂ„K}v˘k&/AÍ◊©Ù:¶a®v˚ˆMm®„ŸŸ‘œ°ô9|œ†&R!™ú£G-º%¨æpWÚ„\Â„√3¬q>nÊ◊ÑEÔ{
π˚NÆƒ@P© (8Iã«ïì°Û B]JwËoÆ;!ÛT7 áî@ƒb·ƒ»À@+õ`§y4o$éU*£3”£Ãã"+Õk"[l?∂˝’ˆîë c2àÖÅòßƒ/{_/ÿP@®ÖBµp@hÜcª–!å`Ä∞f¿LÄÖ]¢hjl†úÇ…n«WAe<ÈìÁΩeUe)ò‰#ÊR¥ñ®W∞T\Jô»y˛ h˝Hî∫ü÷˙Äp«ø{ÒÊ…‡9<∏>ÜGd°¿®k.“ØÈBPßÚ≈¸Ï¸¢¸é|c%têpƒ∫uûä·ôŒgÂ∆ä*;+È#ï®“Ô6	˛£'œõS∏bÍ6—ö©⁄DõøI)öº$w€‡e‡ä”∑@2∏ãõä+F-2O‚ÄqÄÄ¥—ˇ‹@™Rëæ>çﬁHu™WÇ=2?ôéWï$ZA	í‘ëƒ7*ôÅÇƒçrÚWB‡`Éií?‹.óÏˆ‰Ê3&V†ÒõûƒTΩÒIs«Âiõ¶ó≠ÌYÖJkˆÓÿñy⁄ª˛˙æΩ'Eã'Á≤ÍY÷µaq…∫5´ïüπ´©ˆ∑ªgÌú%º/êg]?f¬¢§7˘nùætÊÿ≠øﬂ=°›	©b®°pz‚µŸ~Ä+zÆhÎéHe¢V˝02⁄Ïcô±∆h¨÷Nk¥¶Â®•Ídu£÷¶ô∆;´‹UæzwΩ/néÛØÿ„Ó%æfÛõ¸j˚z˜z_ßˆ•≠«”£|ÌºÔπØ|ìyW÷îlc°ΩP.2V€ucΩΩ—∏“ÿì˘ÿ0(⁄Dó`0—TÜä•”ÍRŒ∏Œ!ë”π◊ 4–‚Hçr^2€Èí"Ì ‹%≈OÙB¿ì{I•)> @BP)ìG”ùÁ‘#Ë4zà™F≥É &A—‚¡3= ëRA$¶ î
"•Çg¸˜TôÍÜ•ë÷E2,Åî¨iÂˇ6†*Z™ƒ~Ç#Íãá$x‡èıí´dïÙÁ‚‰ÅÛhÌ©‹ú É„(.ËçrLhÃØœµúY÷ë‘áæ˚„Âµt¨Èß[N}∏yÀ)„•‘„≥|∫ih`Ë÷˚ËΩ+MÔ^˚Ï˙’kÿUáÔ1˝XØ|Ë’34…1aáŸ9§Sç‘Fä°ïcΩ™ÅCÇã5√ÓY≤{÷ªgEÿ=K*¸⁄ç´Èº›/ÅoqQÜ>ÕbCö:≈9≈3œ9œìp&<áÈ√Ã!˛òxÃg3Ûäµô^√47€6Ú≠¸q€«ñÛ÷èm6∑mèÌör^∑o∞Ô∞3vÑ%FﬂVD¡K%kµQG®ª‘C BŸÌı‚U¸Í¡LÙ)'Ô/¿E4Ï:8UË ù†3ù`‚#òÃP]Ånil5K≥Lb≠0â%Ú gƒ∫Fr1F%M˛xK›º‹:ídÅ˛ñGë˛≤wLv©≤På˜‚È.0nãê∏MI1¥œ;	@é©:ì9˚û°ˇ¥|ªÔw∑µe«´{O{ª˘'h∑ÁB7 D÷SàﬁŸÒA∆⁄7ˇÚ≈≠?ˇ<¶cˆf§ÑŸ§≥“>èèÒSycô\¶.§Á[Á Û‘UÙ∆ñÂrBÌ‘no:Ô(}Œ>y¿Ûo•è0œ≠i–µŒ‹e«“~¨{<]∆◊—5|≠<C]h]¿Ø‚˚Lˇt¢GÇà\å¿âvÃHéï(LIÜÛñ"*O≤Áâ‚u	âí.%§V	Sj"MP…ÃëàiU%TêD+ë¿'.	p‚¯˜¬R	‚˘d@GzÀ∏¬v≥_±√¨ öÕ2l)9¢”lV∫	lƒñX‚>¨ík|âiÒdCÍe“Uâê)zIºáÔû%„òfe†≈Xå”ÄaŒ!˘œòä];nnnæ±+Ò^·ŸTˆ©Õ[>¸Õ∑~∞Áó˚ø?⁄éòwÊL¢Ö¡Z⁄Ò˘ß∫⁄Ûy`VáU4ÛÃÖ1õß{4Ju·L7∆-M‹
f≠qÉegvÅím„Å>Fô*\Éé/çÉÚü°ÿ1^)V'9|ì‘9é≈ \u©cùo©∫’¥’ıÑ~‚)7≤ÛO£:%∆≠⁄€ƒ#"-äÜ’ RóËìP±£j÷âŸÄœ]ƒÏ8ËƒÏÒË<v]“:ÒÄ,ÕÉˇ√ëÚ0ﬂ«NÛà˜i¯◊Ÿº¸‹ıI`≥“‹•bÄ’·ÿ(RŸ/!•§“S	FnÇFÍeMåGRΩ≥ƒ$N…Á-X
;d/!Wº*ï¨"˝¿Ö‚ƒBQ≤eîb"UZBI2Î'›ÚÁeñ\ä>¯‰€°$ﬂæâÙÏûı£›À˜ßzË9∂ä˚∂ü@<Gœ!ãΩÖÜ˛>ÙTÃÓ∏¥‹3eıq¨"Na´Ò Éx=K∂ ªR®)∫≤Q9l˚Ç7˚¯ZÈT
úG»ß≈2Õ<c≥´V‰¢#≤”¿ò(kªå‰aßn‰(Ü˛ñ%8ƒ‚ä‹ıà™≈⁄(§Ë@EÁ1MF¬ràÂ âÀﬂ•˚ZJÜÛ§“ç˛A/êv‘´\Fó(?ıY©—L=JíÆq’/ˆ˜«”—:ÖÈÄ{®‚¢)€tYîL÷d∆	I¥82(…dœ@	Ô‹â"ò'-•RnYiY¨|¶	ñ5P5W©+W˙®Ω›È€µ•~qFE…‹©››Ã°˝…µ±⁄Öé˜≠µâe˚ü≠ƒåò<4á˘fDFÙ«Â(ó'◊s5≤…í©dFπ|9ö[…çìgrµÚˆn57h}Ï∆ÊFÉs'ÎÉm—#Qvú\Au¥ñ´ı◊Ã˜œ/X√.˜//HD[£=¡{˛πA…„6π.“gŒÖT'KúDÃ¶äàè¥˛èÌÍÅë¢∫√ÔÕº73ofˇÃ˛õôª=ºÃ—∏¥v·<∫È≠—+Z Å√)[‘ÄmQáä®=ã—rks%5H”ñ√jl¨«±!@MΩDkì∆hj”Jå‘j-Õ•5WDÓÆøﬂoñs•=éyoﬁŒºΩ˜æ˜}øÔcÏ€™UÀññ§›◊—≥Ω\1,⁄aÛπÎW¸[˝ÌæX[Æ›∏êdÕ'YÛÁdÕ'YÛ=˙–àdü2>í5M¡◊–˚˜&y»:ZÁøí<ö<ôúMä÷dor:bL≤±Mv‡l…ú)I⁄ñ$mK6ﬁ€éÚVËoê∑èœ∏)‹ÙÈ©2êÁ4ÚÁ4∂edÃ %ﬂ˜¸»@. ÷hëŒ˘Kä©,ô–LÉÿ›Òí≥¯ {á|Îÿâ…ªè?ıÚÉ˚6ú˝ıﬂwÔ˙ŒÛ/>∏Ì˘5Õ◊Üã◊ﬂ‹=ˆ$/ø˝Áﬂf˚˘çgèn˚Ö~ÈÒâWﬁxııWphò1˝®ZY~€aÊ¡¡œAV≈ÿBˆ:KÙ>˝H\––2ø©‰[©X*´KŒí-“Ã:v,Tï‚““¨‚ä{Tcº
¬†æ@◊,B†0X§p„y;’åœ) õ∏ë*ãê(,0~Ø≤ë.¯˘A‹[’Ô!˝“““ò7ÈiõΩQoÃõıÑßeC‚k≈Öøa÷√⁄‡‰úb©V´á⁄süXŸJøöâ:CœE~êiDKç,gn˘Í∫π®£È°åë¢¡!“0®`9≤Éòzâù	#aÜ	#ñÁqx…ÄòÖGêöäëKÙº\™3E0π‘pÌ·â≠ø\QªÔŒ’Oï¡˛kgıπüLØ”ˆ?t˝Ü¶ú|ÄÇè¿ıôÏ˜ïo®•∏ÇUjDç™15°N™Ie2’™6´ÌjO}ËîöUv´èe
MWÜ˛0gÜ4Ñmò°dbècbBú∆Ñòm‚‹	yeÌF1∑oÇˆMÿ¯≠ÇîM\P6Å&˜L âl‹C—o]º{[`˜P∆zœPâ¿ˇx‰∑2Kä9vÂÒZ≠&>:zÙ”úË˙Ù-êıŸggÆÂÀhÕiˆf•O»P~YÂ)}KJSM»„qG”≥1ëíéâ+t≥%ïE˜}`e<¥Ìá∑:ΩŒ*GwpE›∏"«•dBA¡°LÈ\B…$Üãr, $ƒmß)ì}±}y#´â≈ê ˝nﬂÜ´ﬁdΩ+1¿™“=sÎKã√ÆUéNÑÂ&ª,◊Œsï0Û,:ºäkÁ›DiÿÅ¨	ﬂQõ˘V«“÷Ó•µ‚ªÆ?˛…Cª◊Ïk?}mÂz‰+ú˝,Ïã£›V…ë∑2n2nVz2˛o9eË*ÜËò±pyˆÖé∫–*PqÒ≈ı˚m-m¥e⁄KÑ≥È%Ö!⁄¥§Åv®<#ÜR›j9@a|—^cﬂØﬂgø•øgò˚ﬁitô°’c\Æz„´‚b¿Xc®!ÒÄ‹≠^7˛ ˛dú6>4ˇc|bÂ“∂-u]hÜa*e¡ç≤¨–4≤¶iËBÑ“ŒJi€p`Ö≈·XJ√¥Ä±Ãáx≤¢§@ldáÖwÌmî\≤-Õ#`Äúêi!dE∆{Ÿ*`œ "‚>!ŒqF'ô•I(N0ä&¨)∑}˘çX‘Pá¡˙L™ ÁDy˛¡q.ß¸ûa˘•Çr_É6($†cÏVYßÎ~É≤[|Ö‚≠Í1]SA<U-ÄÛÂ⁄5[-ú◊£¨yÛ  ÿ;„Ûz†˘„x5˚€{ËO Á˛ó
∆afÃNå∑˜ à„6Ôåª=F‘–]åö˝NÙra æXIø-∏ïı‡€≤Ÿ2]‡≠©Ò _˛«˛|Ù8Øêu√ﬁ È/rﬁ…M`(·√ôç¸ïwfˆ~W9ˇ2õŸ:Ω^k}pÊ<óè¬•õ¯˙ﬁAI%—Fu_^¢∂¥$j/[µ!µï MR∂ =Ú§´‡2)ıVπYnó≥RÄö€ö	<ŒDBüg≥áÒ	àôZ£⁄ü˝LÌÁ5®}Ñu‰«¨∫ã$:≥d ÿúv±~ÒyÌBÒ*"˘¢*Ω%∆ùy¥&èú˚jΩÜ]‡ô:˘o≥8–ß∑’;¿†?WV:ÒR(Nã”Í]ˇØmÚM9’¶˘V[ß
ÚmJ◊;/i1rh)Lnt67πˆ±êèÑ£°Çé%¬ëO	Jl•5¨¶%∂,.2Öåˆq°)çr…ÿ¬$eñssÈ≠ûbxµ¬ë<œ”t˘πÈÚ4‹ˇ≥í¬ÈÚT%Û6NóG.QqŒ«pb∏?OÁq>èi≈Œêc¿ΩQ¶µ2‰üN¸õ˜?¸#≈e^Ωüø‡ë?Æd©GP$"JŒÒm.V`**êH‹Üë3≈π:›O⁄ºÖ°yÜ“C$∫ríÈHñcŸLW6ñ Ût<w°P◊£‡õ[J!/Qπ&›X∏˜.ﬁ∑qÎÆ÷á˜≥tÆ˝ Ê’÷¨ˇ˙#ÀD◊”˝În_s‰•É”¥üﬁµnŸ”œMÔ“∆∑m[˝„NˇÂÇÁzŒã«á*©Ìy˜ê˚û˛∑Ã§>ï1JnÃ.∆=ú
f—feY/ûã^‹é'bâ˘˘¨Ä<óCnÀ!∑ÂÃπ-áH‡t–∏√‰∂r[pˇI®CnÀA7FrËê°s8¸:˝íÆùW0hõÉ—`,òD†k≈úG‹ú™•RÛ˛ø·≤/2\©√%ÍLú®§/6p˝æ;U¸S`·«d¬>7
?g@ç—áAûsaûëR∂eõ∂n∏])#ëÁI;]˘“G–n√"î—è˘üÉx¯Ÿ˚ﬁæuÔj◊Æ]zÁ’˜¸\tÌz©oÛ ≈C”˜h;Óﬁt≈Œ7¶_á¬Æö˝@, „¨âﬂy0‡J2¿D"Y)yˆöËÉ¥i7≈ñW[7÷7ço[V…]ñ^Ê-	˙‹È^_∞VÆU◊π’t’ª.ÿ$7©ıÓ¶Ù&o}p?œ)C∆o—oê7ÿ∑ƒÓ“7»ˆ]1€of
$#;?OŸ'O«¿ƒîCŸ«p‘tÎ£ì5‹Íêg¿‚@*†Bf~X∫Ã‰ÃtÕ6S7ùç¿Òk.È,]˝ƒ|K`ÏMùcÑo·õ |#÷í˛0èÆ¿î([‘\ÍFq≠~Üú;X®NU´XB2Í=R9vÀñ∫^^Ønó∑+Åµ	…∏› ÀQ(bç°Ë™Áû¯Õ	Ó=Ù—ì'gŒﬁ1~‡{√„⁄…Æ⁄ÿ¶Æ3|ŒÒµÔ=«◊ÒıG|}Ìÿql«6vHh‚ê%|¯Ú—ÜBIDYY		C•∞%–ïÑîUXÈ†4—JùJQ≠e*)a•ìP—TîFd∫ñ	¡‘µtŸ™ä,…Œ{≥îJˆπÔµÔπ˜‹˜9ÔÛ>è'{7å˛}d‡õ_‚0v|zÒ”øúª¯	_–Œ—v©å#ËFa¸îŸ´jìµ⁄M EéGHidíUWáfá÷EˆFîΩ!8_ü\™,S[ı÷`á≤Fm◊û—◊œD.{Ø˚Ø.ááºC·õë±à/&e¥Lq≠‘†="Õ◊Z¥ÿø	çjvWë≈WR,Ô+)≤£"#>»∞∆L∂Çı0)" å8πnªe⁄HÊ?ø[tˇX
e2ÿk1H6Î∆ûR„.GËWA¯ >éø≈R)Œ·fl¡–Ác¡∆X∞1;´pK≈ÿâKÖ1¬*‹òS$«•çu~úi“ bm‰Œ–ˇmn['G1'4±‡Z‘çuz
§Í+ˆ0¥Ióez;è4Ï˚˘Æ¡éÁnliŸSÈ:∫a”ªowØÔm∑û~y—¢›cØΩ˜Î«FÓYéúΩxı‚'Ö*ú7⁄nπ…1‘P	ûjˆ⁄IÜ§˝”»≤YµÂäs∆co¯`ÿöıdÉπ\œ‹‡bœ‚‡Jœ ‡äpO¯äÌ™˚ñÌkı∂_õD¢j¶∏û‘™èíG‘“NæPˇÊˇ“˜µq+¯_‚ƒí√(±ÀE6oâƒÅ”ãjPπ¶:±Ê4ù+ú=N)l⁄y:√=ßò–	å+ä—iÉ¥;}‚?—H!ıN‰®BT†∏<'ÿ£€ˇHæ$ﬂê«d©îã‹f^åqQ…ò(GEm˚Ú¬W‘≥
wóe't…∂ŒÖ√#ô	8MÁ(Mˇ!0®ªD%π≤ é^À5ﬂT,ÈOú˝˜≥óü?◊yh§Ïÿ¶ıGﬂ€‹·—v¢Lk¬ïX>8˙¬—ﬁªs,ø¯Û«W>˚:‹ãöÛ∫`N´Ú`M¬1)+ÕëK´•n…F]
U®√„¢dQ∞]îb4µW¡J4‚¡uÂÖü©=ÿ&hΩˇòÆ	ç∆&àË{äBÏadõ Úõ‹çgøoOyg“⁄ÓtÒ‰@jÍ˘G9§]ÿY¥Ì,$™∑4Å.C^dﬁ(^<4≥=∑l˘ÃŸ≥ß-˜Ü•ƒ[ùÛﬁN6ÊVtç\Å,‰∆æ≤ÙÒ,L±ËÊ)Íç6–˘tn|ItUt+Ì•;‚G=ÔV¸…‚†z¿ØOYPÒôní'—™1Û∑*≠¥ïµ⁄[’VGá“A;XáΩCÌpÙ'˙ìŒd"ûåOöoaKÌO'ûNu«∫„=Ò˝Ïu_Í@≈o¶aøS'è§N$Œ%|©ÇçÇX!àÇTﬁé_A¨ƒAà˚
”ÆoQíÂ*ìëD±dØNëwÃ®Q…/5rF≥ÒS„=„ías•∆≥∆C*5ˆƒ8Õ±)Ê˚‚Ñ9™^∏\√&&‰Fkò`–˘^_ÿã\Yå+[CkC$TR,K∞òƒÉ[`L ,ïT⁄K87Lè?[”´†Ï~Ñj1|∞GåÃ4"0À∆—â.}ä,{_éß˘‘ì%ıÉiúÜß¿å4î'‹&]®S‹˛LJƒ£ íÈÏäÍ3’$W›SM™5åq˘ÛzWlπH>Àú⁄!Ä@`∞àH‹)ÿ)ñÁåå3ƒ]3"x£HÉ*H!z£`kçá†ìrÊE>N≈√¸´ÒCWìêHSgf·M<Ãµ0\îÓt◊WÂù'mq‡õù¯û◊ÛÍ…LN«¨ﬁäÑKskÕbã:"ADSr['Û!ÏÂßeE± ä∆™2âq*Iô-#Q©ùï—∏*À‡@3ÈÃˆÌ€—:¬m]ùmû:_ûjíâd%©ÕN≠À7^cBãyuÆÕÙ0…7˚DÓ}ÁK[∂n™-ﬂ˛ıÊY?Jø∫x€È◊qu}˚÷üØ*∏„£K⁄œoªÙûQ≤¶k’‹1yı£€õ7ßJ3Û∂¸ÃˇxÎ„u±íêá≈kfmmmyÛ'«†N„cﬂë¥ıu§£œ?DåÔ¡X"KŸY<Ë10¬™ÉaÚi4„dºu[ÏN-ä¢ÿ·.WÒò¨<L^!Øì{‰Ω≤Ñ∏r:(óœ»É≤MÜf\%ÁõµæÎŒíÛ~l<¨ûW–yMΩüG∂qiñWïÚIÚ„©}´0©º˝s}¨√ÁxÔ™©—.ÄmÕd u»_¢÷„¸^«ô,ÊÚBÍâxl˙Sk+vÏ8qÚ§'ì
øı¶6s’!≤r7ñ◊éæ≤{dˇ¬ä ‰ËŒe7•zÛá(¿sCãı,âx|Y'¨∂∆ÌÕf<8Æx|*ˆ¯ÏúÃ]<M®∆WÓ◊¡NÑW—ÖK—›ê ]ÿN»Ä.Ë[øÔOt·Ot†w·Ota8u'»«òéœËXo
 F≈`Mﬂ»∫¿¡¿Ò¿X@
®ÂÙ~„†—§7©DçÉﬁoT<ô2x*Ö˚ã~AÖ7°ûMõû˜≥Õãk¯á&Ñw»{nzæsà"
HZë√È 6Y±)VÖI"á‚
"∞!ÈÙvﬁ˘‹≤ZMíÉS„‚
b*ƒñ‹÷´À7kˆ~ªÎãıNÎ£ﬁ3ÕµÎ…æëØ<‘∏hÒû]§˛ﬁ5éá»ÚGá·€}ÑÃ˘Òì¶nUSlÿ∆êï*VL¨qÿ~÷™ÃıÌ˙ ﬂ–Ì`©¡j≠E]ı¯›·™ß‹ffg∫¸à«è¸äœM.À¢ÑÓ§—Ú,ÚÒÅü]3üOUfQÑNuJ—´GµljdK≤TyíÆ∆´Iª“N7°çx#Ÿ¨l¢ŸNºì¸ ÚíºKyô˛ΩF_e«–!v} ˜±ËªÜÆ≤¢/Ÿ=táU◊a~‰c)î`u¨ôåZM∑/kÂ[%€gÔN˘˚¿´#ê»¶`dHp(‰~r≤"~%V´jÁ∞U]œ‹Ô@f É™r9e–¨c≤¢îSÊ•î!!\òx1Êa\≤(
!ÿ&3jAÿZ•b5™ò¶I{(°ßp¨Wl◊}ofv˛3oÊÕ¨=˚ã◊.∆K±+€òWL˘,
	îfì¨ö -!|Br¯(¥NCı#%¶Qõ§jU~∂1&
®E%5–ñïñä™NBi\µíCïÔˆæ∑ká§R•JıÏºy3≥;û9sÓ9ÁˆÖë›!≥PK!Æ3nˇÜ±i$+å‚¡»pÅEñ6Ê¥3πú•€ôûÌ~Í|˜ÙÄmÚ@≤YËàÓmzQ!_ãõΩ™Ím^3∆?/Æ}∏æ&»æw∫¯∏4ylÔöç+∑	œ 9Ä2BëS¿*• Ï8ç(K¶\}dnTr•«∏⁄kZ‹boADÖôõ6À'Œı⁄?÷ fn»˜uWƒ»Ñ4ÑehX¶Ã
 t± Èí´≥w\Ë\pù°!Á⁄ês5;ƒÿ« féS±V	®@Oï¶Ë¬˜˜Wt”¸˝înr	î∆'.ì≠¶∂≈I¶ò\ˇ#<U3©EíMÕìZåF$$…Üfÿ*uê'˙JRM)Ë`Îï©j÷nA≠ ,u∂=_\$á Rµ√òGπKË#‰A∫N˘ö∫Ünów([’”Ú ÈßÔÀwµå·fP∆j∞3§Å6˙3Q˝Ü˙mµG|…<Ñáçüò}®_¥/J◊‰ﬂk∑§[‰]:*®%ô›±…Gáè6	iÖ∂	›&EÆ™®ı
©∑Yg+¢ÖÕzk†t-lc*e˚¶Ú^Õ¬æ'ÎÜ;Yœ∫+•ıG›ınó˚¨´ª∫\dØ£¸b>Ü∫¿cmcv>lﬂfKŸ˝·ì}1¡R"öÆ´–£ËéÎÇæwúå 
ôeq∏Z'v˙óÆ¢¶ó“lDÒ#≈Ü˜\oŸæeŸ*¥;Y]ı·Á(2Q)H¿
ïT‚ö∂≈oèÇé´™¢∞“°Ñÿ6“˝;éÖ≥û∞v[¢5ÄÖzzôé7ÍªtAæjÀ\º—›Â
.€3ú~,Úó≈u®ﬂÒÓ¨Êë(∂t¥P ◊¿áY!xg¢≤ú èé+UÁÚ±{ÈΩ˜…∞≤€vŒ+∂”ŒV6gk«±öıZi3-ºV∫	ôˆ&≤KWzQIS‡(ûY˘ÀwkYßñÆWö0?Pª¢„XÛÛ£7è+ÈÚQ
GÔ„G·B˝·⁄†VWN(MÏä'–La∞¸ü&.>Òªj˛;∑tÛ§ûñ“àù Ÿ¿ÛÂWª⁄Osh¨P‡«Ω<Qæbfõôî∞¨≠ Æ'^5ïœà"Ó(û<2Gj>r˙ï÷œ˜-ˆû92Â-òóá›7Ñ««zﬁVﬂΩ.tı}tîÜÄ˝î∆¡¨¯Pî`CñMdIx"'çYNJ∑ö˚°ò‘≈r2ÛüÂ±‹√‰EÈEuø˝Cr.rN>ßºI4VÂ‚¢ßE≠∏”äg{Ü⁄Hø,ÂïºÒê˝Ó—{åS¬Äy—x√˛ïs]¸ùˆkÎŒ€:/.√D‘%Å¡BfÍf≥ëë`!]†Fò@Üÿ&ÆñeQQ5À≤ëDà|¸‹¬ÑXé°B∞—ttôDw.†ö‡‘#ÕGHÎÇÖ≠zSÙMS‘5M:”D˙2äÈbkßYßìØ ⁄ŒPg8 ÀÂ›≤(ÛB;-ÓÍññã›.ﬁ®FÀf^·ºÌåéºS¯üôW*l-<ÂúGÏˆ	ÈV9KÀ#lu€’ˆ
)zÌ ï3ﬁF*g÷UÁDXŸ˛â⁄ú√4^èÊp]mNìπq«…6°,xßπöYOÃÄ&ò‡Ω≈˝>8=9≠˛‰[≈Ô·}7Æœ*˛U»‡‚ãöÊ6ﬂ-öcóí|± œU[|@¸;p$éˇU·HJ˜âhà…°≤!{!%i#4”Æƒ≥ÒÒ`(sÿÜgÑ€F‚$Ib¬bC2óÒWë£∫Z!ºêt¶©≈aÉbj¥ 
hÉ—`6X3ÃV´Ωﬂ524„›_ïßy/]K◊zk£€Âm÷vwáø#˙-ÎY˜9˙ú˜øG?lºÊúq˝€˙ª˛˚÷òÛÅ_Jﬁ7Œ®*œH&$2üÏ%"âM‹>ø?xÖ
è⁄1–JH1ﬂÛÍ©Ó√1AÎ›7›£‘4ô] %ù§–ò<õí¬ú>XÑ˛Ä∞24Ê–ê
_°g©@‹~ÇÎ–ÇÑŒNq¥¬¥Ÿd.3≈Âf…L¯∆…FÿszÈ.F ol¥ã@"òéŒËpÃ.lâŒü°Ä5„åRÅI∞≤vÖR›ú?†z6®M jsô•[»(›¬˜jç_˙S[NØkÀŸPe}—ú[ÕUÿJË„5∞å€∆ñè#X‰‡]˛ÏiÌ˜Wªì#Fq√/ndÎj≤È-Æˇ¬§¶ÆU-≈5GúÃ§ƒ:íí2c˚ü‹”µMXw˜‚—π˘‡0h∑xX¯i‰∑»Ä>nˆiDÑÁ˚êÜµß£¬Û'DLa”G¿ü6ai®¯≥‡G€yâçåF ¿√¯π&ØÖµ†–qB*oÛÀÌ)kFw‹ºı¿¡-õnË\∏†≥s¡¬NÈı-lŸr¿÷ÖùùaE"¸o$>	wE1î¬…≥U™a≈t5∂3@VR≈ûêìî∫Æ$âr<™CﬁO$‚a*à≈í…TπÒÉ`ïrXbJïsÑ®î…Z"ÿøN1†9y%u6UJâ©xÕwıc‡êJΩ3ÆÔGCë$∞‹ÔÇ8PÊ©&ÔÒ&≤Êì]Nd≠¶aLúí˘©Pgóc˜u-ÁVZÈmñ:£eﬂÑ≥¶√Ö/:w ›?æîüp⁄πÜ:„_6çT¡õ!€&≤b+NAÊI`»z{ˆ4≥f¥ï°]≠0Ä£Q÷ñ‚÷Ê®›œ©W_}Êù+ì≠”
Û/]¬´z{{≈ó˜≠˘Ò·Ím…7Ï˚ËÎ“ﬂ._æï&C»8Ó[ ∏„T8ï°.ÍjT#œá®W0g/!VUÖÙa,ÆìAÿ¢`ÚÄC0»ßq»É≥A)Éx‚»}Hˇ'‘„ˇuX>< g6P)€ πç˝Ô∞◊˛'‰+?xd√Ö¨“N†s_Ó¡]UGﬂ˚¸˝¢"à
D@ÅãÇ¢ÇIhDÉêQkT(Tj+°ëóí÷⁄Úì
M®`—å≠–éRÏ†SKb[È√3UZ€:ƒéâ…ÌgœÔﬁ„ç†˝ßwÊ;ﬂªÁû«û=ª{ˆÆt:-“M¯ïµÚN'Xd‡ aŒ±g˝¨(h€∑Õ€ø®Ω˝πùÌÌãˆœª·È9Mk◊6Œy⁄iY∞mñΩs·Ô\y„∂◊65≠Ö…#s«f∂ÀÔ<2◊—3Ë?N⁄3*%{ˆû∫†«¸“Ó„õìŸIÛ•ˆ›úa ørÁ?‘≤µÌñLIûÇòA⁄ß…•ô“≤µÂûÃÿº"›∆¯aì=Æ€Ï7ÂFw°dÅ)âæÚmØHfZÀ•ƒÆì{N_…w∑»˙÷!_7ËX˙ÇøÄÒ†Ù	€Æ7Å*”˜ÀÛu√•$ŸOÊyEAÎ≠Òˆ»Õ`ÔµÓª≤Ÿ'w od‹KÆ»˘⁄á1k¸:YG˚c|üK€x&rÔ≥óæg$™§∑2i <Ü˚ÕqvÀXwa6{˘:sÄe¨q|9òJüû%`πµGVX{ÇZæ√R…˙ÀµL
y2Û,Â˚D∆BÆ‰Ωz¯pw–±∑»8ªóºèdˇ≈©}É=r´ÓπcOËÍ‘)ß¶É5⁄„ÇÉpFönqT∆0≈-p9»◊⁄˚‰˜J±∞◊#ﬁAq¯ù⁄Èœ‡"∑L¶![Ë9√€.ÎUW,⁄‹«§⁄9,Ì˚(√ﬁ8≥˝±å¥ˇ.√˝sd1˛5â˘óÄÃ˘7„erÎèÄGªç-´XÎüëù‘6»K8◊È¨ı©∆„gÄ+8ó
pªÍ√˙#’ÊzÓVQ˚8˙æGüY
⁄œ0`ÔÍì:F«3◊9°÷a©•Ov˝+ÏÇ,’!ÇÒ≥|{ÖyzÙ#¿AP ¡Ö`*¬⁄¬∫éÒW|F}”¯æ·Ì¡ÜËf|6µáÊ<S1SŒ•ÎÙ˜∑Hyà˛:ß∆ã˙,∫<Õ≠1•>±ÒÔr„˜Í>’ß:òÿs…™ÉâA|+bç;t÷xXc 
x=~\©>´˙E¨vQ_36!&Bü∂◊\#∞#20Ùı à#[t≠≤ë9g˚s»)’2Ÿ˝ñLv~(s‹…$g®åric?Ù›fíÈ…]2ö≥º˘ëØS$≠€º]Ï≥{6 „ÿÙõn£=¿m¥<Ø>xﬂkØWoﬂgﬁ;q÷Æ‘7eE˙∑„m?ÿM^=9≥>¯¿kˆÛ∞∆D‚êïŒéòˆüÅ
0,yÆµ.Yn=ü(îL_‰0òÁÊÀÖ^æúÔÓ‚|≤»ÛƒÌÖﬁ€ÚíS≈]÷¸¡™ê
ªQñ%≤‰&{9çµÏ&©TË¸¸4?: Á‚æq‰Øq÷ú˙T?ÿ'˛^Ò^àèA3~4üÏ≠wÉÊgs?ê£¡≤îø-˛πWûÑå¸3ÊßÂ1ˇ<%Óóq6w˘=äSÙXÌ_Û£Ê8ÕëöÁ4œD˝„ú6˛ª?÷<ºOJ¬∏¢ ﬂ	cü<ÃyÅy∞…ﬂlvzõ˝<ﬁº`˚æª„Nù¥á˜È–Ë.MµÀ…—=Íçñ;¬|∂—‰õè‰«Ê-2˙e¯[e±◊ πìçæ’abOÙ.wgcÛı≤ä}Ùvñè¥ÉYjs"gÍΩ†w¢≥;Î]T%ïŒ[‘:v¥úfÓãâRåÓ{Mw™≤∂y≈RÎí<∑ê\ªK Ù¨t™èû}Ú.ÈñÃ"O4 (˜'Ù…íìËWmlê/õå_Ëÿr
*lëò+	|v}tæ3&_zÑˆÿhla∆Sã®´-ò”œíÈ¶û8$OxÖRL’$*§∆/$Ê≤d3s<…∏B’Öq}Ã}ΩZÆ'æVêõVêsƒ¯I–Í‘≥üª…Î¿©¿Fır¶WÅÀÕﬁ'π©ª\„«©ì¡Í#˛jÚ∞÷´Â˜\πÃ/ó*⁄™<Ú$Î>H€˝ƒo.±ªíÒ˝¬º-¨Ωív;Qk≠4^˘“”Ø0uÄ¥Na}Á}©q
d~|qr5vX*√qi-œJï¶¶<U˘æ´R0mô)∂˙;ôÚ]m∑GÀ¨p≤H†wËÓ˘Ü[$yŒ(b˜4Ó˛ñX˝Du∫K©˚™<Í>/´Tv{ g˚ﬂNm©ÌØÀ5⁄nøÅºNJ‹Òå_!w∫•≤–yﬂ€/'π7s÷åÛæèüb¸GÃ¬zWJú"bkÔü[¥üYc{P¨p'Àp3.F◊1ùÌ©Ï™Ä3E_}?J_tÌ–3“Ò˙ô}Íºå”>Ó£2; Á§∏˝ZªJÍAµ˝Gπ‘πJæcm∞ÎÂ1LNó›1÷Ω`Ñ;FvÇ%ºüˇlM…‘nc‰-∞îπw√œÍÅ¬æD∆*”∂¨øâæ•C◊9V{:ºÏ†·(yw∞äxÏ<ñı∆∫
|±@·/ñ^âE“À…°˝,∆≈d/õx⁄!É	˛”ïNüû‹4;ÊßÔ1:¯Ù/Äi|∂rx7ú∞n'
Œw1∏¡ÿ˜C…J˘êúj5‡"´I2ùªAÄ<πgdœËúhˇëièùæ"jÛx{\éükW≤˝¨î¶#ÚÉxX&(‹âÙq9πW&(¸ó˘ˆrgŸ›‘Jdò≥^u¬s:À˛’í£∞°kCÃÅ˘ur–æf|7πB°±´∞∑Ûø:æèëÀiv´vu÷ßæGÁùK¸|–/ﬂ}M¶¿É·q∏ ‚Ùòç«mº- %«Íãç‹œöÛˇ	ƒŒ´`xÂΩñ%¯*»˛Íêâ‘ëç‘'◊K•Hπ‰”ë‡)Ú–uõ¥q{∑›x?ç∂[‡«EZõy_@{c
ÅÌfKuXWˆ¶Ìπpl2úoFj|ÎØEZÉ≠©Ò≠u‡6ﬁˇ∏œ[ˇÔÜ◊—ˇ∆›ˇ2ıΩ≠yx˘ÚÌ`&Ô¡Yy†'Ë¡¯5
≠G:˝á~Â|Ïˇè/ ‘,s—≥‹ ﬂˇá¯¬ùgˇ◊àŒø+ˆ¬âŒú≤ˇLÔP˜mKˇ˜˘ºúà9œˆt∏ÖA5Â)ZGk-´ı≥©C6ˇo¶ée]ë^£OÜ÷ØZ;k˝
Î¸À}œËSà^≥ç^·Ωëû[≠√≤dÇÏêÀÈÛâùºFÓÈé7Ûo¥QÅ|*(J!xùª´;w›K‰›fxr_∏9∫”¢‹⁄)«vqß}’ÚÒﬁë'pßÊÖ(ç·≥⁄#\bä"~/∫∫ªO¯.ˇå;:˝û˛≤rtœG»ò yäD~–†à◊•ùÍÄ.‰ÆÍ‹„ï„u«qÀ±∫$í„ËÙ=Ó{Q=”G˙t w«˝∑pw©˝#‚q‹o°åç.Ky`Hxá÷í/®ˇÉæÄ;*xò∂˚íüJ^Úßíáºpo∂ˇ.”oVïà˝q–Ü¸=‰LwüÈ;3DYW˛˜[≠œM}àÕL|Hıóë‡k‡ø¨ólïÂ«üÛ]€"´–vim]ËÄŸà@Ç≈ÅÑvï¢»`hÈ`
N Œ°¥\Í6ƒ1D$‡Öa¡çEßÇ&lÛé›¶fFçäŸÇ¡K‘⁄ÛÌ˜ºﬂ˚ùûû∂4ãû‰óÁºÔ˜ﬁ/œÛ√üaQ≤◊˙Ü§Ô7¢ÆæsΩY—gﬁA»—Ä˝⁄1r-<L∫êt!æ∏8Ñﬂû ‡ˇÌÿl˛ΩZÂı˛ÛQg∞‹î©„[≠∑L&„Á{áhÛΩË|˙"/-Ö·I“JÏ\I≠‰˚FÍÆ&]Ç-OìhÁ	ÍØ”'Œ$ÊkÏ†ﬂ&Ÿ
WQv∫w\Ór»D⁄©ÚﬁìbkG˙2O„U0Ç:ƒ<Ú~ÄnÏ{2 õ-a<Ìç”X„Ó‚å¶.Ò«)ñß‹iÚî∑[ñ–ﬁûÇvŸöˇºlÕkñ⁄º≤1hóçÓYIﬁñ◊≤%®ñVm#â´ìˇà©Tx™â˘ãHó[[ìÃ9WòÒÕñ©ƒÂ˚≤˚MÍÂ’Kè3˙÷±ˆßmàÒk°ôyxÿœs˚”5r⁄£óc+låø.Ûõd6„Økj÷v∂4∏7ÒÓ”òÆ˝Ô¿˛KÊx∑É]„‹±$}±.ù}i°Dõ&L÷}6àÈπ2g)fÜƒÏ◊E∫g˛@Óp°Ó¥W◊«p=Â)ÛégH«©pæ `ç‚lÂé.ÊÆpΩh¶vYe°l¥√‘ª⁄‘õ4¬x∆’B?Ì—˚]»m]DÔ{3d≠Åı“˝sä£Ωÿ%ŒKÙ5V
Õ˙-eLmÏÛO—C"Â¨£Œª‘NæûœKÄ˝á_ëÆ2s∑÷¨’ÍÚÆ”9¢©‹"|ÀsœU}≈∫Ÿ≤·„RN‡ºêZˇ©rØAø¸_w
{W«æ J˜]©~(W∫É§YI’FSG±(u≈˘à¸7∞ÎI∑ ,Á5ô√z›W√ZÊ›a8ÄV ÓÀ/,Ûß=ı=æøóŸˇß∆ˇ…+èí6⁄eGîãﬁÖÁ.˙ÆëfÁ	˙ÿ∆XË«=ô˚óuÆ∞∑˝LÚfr«∫sA.‘U{f.‰´˝~.6ø<Ú’÷‰B~M/„Ë´\_„Ë+h.‰˝∆—WªCr!»	∆7%Úß¸„Ëkù´r!øÍ„òñ˘”r«Å‚õ~é∑ÈnÏÎ6ﬁ¡N≈r˙“œü˜E‘b”Ø€røáMp7|
5|^4ó2≠ÿˇ¿hË"˝"ˆ1ø§ühúMq_Z7˝d‹∑¡ˆô~$Æﬂ˘∞oV:˝]¯ ÓœÙ≠æwvl∂ÂW€~˜ƒcOoË*Øﬂué¶ﬁû."~Ã˜JlcÈøƒDOcˇo¬ÛÇ˝_a◊CÁ¸∏∂’Â‰+o≥¥©?‘X∂ãòò}ÉL5>˜ïn± h‚ÃN„Ô"|ﬂ8Dá‹+5™‘á˚ÛM˘u~3±I–'h£ﬁﬂ{V ¸√2◊[,›«–≈ì∑Ù·˝N.◊∂’o´Êp◊»≈PØ1ø©±p
>∑µ‡Q£_N¶L±˜!„Ω[ˆÛf[Ì_*‘üá#HˇñπlóÎ˝dyﬁ"Ÿ|ÃXIÒ™2ò+c˝[erÚ∂Iæ∫¿⁄)π2ˇÚ€âª»ƒ¸Vt›´RœöùùÙùYáPä…◊=CÈ•Yπ4{ˇu5L5cfºË0œ´Fè°ôLº˛	k“l∆3M„ß˜êxÓÕ"˛1b˜E2<ÃG{ù)´ÛKe[9ÛË´Zu]fÌG∫Ì24¸ôåÚ[e®?É=™F7øœ:_"â≈∑ÔØî–üu†›∂{å^ÏÌíR£à]õ¥—.õ¸õ•ç31"W◊$:*£)|≥«3í>2Û¡j¸ÃÃﬂ⁄,Ωa÷ù¸:ØD™˝Œ∫£áµc
Kd'e◊%z6‹/u°ã›!-¡Ì“Ë_Ã∫Ic¯¥'I©Í≥04∫në∆hˇK¥h£ÂÏ_`Ô˚/AÔ“${«óëˇÏéÔ£ﬁ/Õ7wìºŒÕ6ˇÁp#,åøÎ∑hE¸øÛX‹æ˘vc\æì{µ±léÍQÀ€1ÊrZ∂N5z4÷÷›mF◊õÛS€ØÕ—ü}YΩ√úë¢åNÙdOªª I£ÛﬁÊéﬁI›” HttÆ•ÏF4 M±5⁄PÌÉ÷ﬁØgMµ^ÆÕËÍ>l_˙5K«∆˜,±±Ææ-«Œ±vh¢Ø˚≥˝›ÕFëM'£◊˚≥Míotßµ·¯C4hbm~añzºü≤≠Ÿq≠éU˝^ß˙⁄€Ü=zÓî‡VŒ@wöwΩ\—ëD	ØÓé’˘}¸ÜzêWôKÙâ¬òoââÓ±µ‹ß∏)≈[üKÙâAﬂnΩ‹KøêwFL¯bå—ˇ'Ä5êêú7ÿÿ@c·	Ae(·1À∫Ñ(RíuO÷1YÊˆÛ^ês“øm˜õÓ„7›óokﬁ'{6‹…√êÿ@Èu‹Ïè·ìıOî-≤¨Îì∞X6(‹ïrÓÌgÓ|Œd◊ÈqÓ‡m™ÿ¥ﬁE%@ŸÖ•Ò=‡çÙQå\÷€˙ÑÛ„Ûã◊…ÔêyV{f’ø+÷˜UÂ◊Àv„ö§R}qWÔ˘HÔo““]ÛEçúõ2ΩƒIüÚÉ¸eRÎº›Ô/«'|Ω‡Ø@ }≠≤ºhŸkøËOÿsÃ:èïΩÿá≤·m[°h˙[
ZΩ≠:vIL˙√8øk\âÔuø`R¶∫¡õ eFø,îV(sèÚΩ¿VªÛ‰|çÓYh+ÙáÍsDäº∑∞1Yózwg÷˝ÆñUﬁ÷	Tô}zé†Âü3ıÀ≠_Æ}πW·«ˇ-ïŒQ Òçz´µˇQYÆ∫»ÂE·OÁ\4P∂!˙áª	;ŸÚ,fºM≤–Y%g∏-2⁄yΩSB˛µpˇK±ÖplÅÎdî…Ô‡ú|Eyp=“/c}iÜ—Œóñ∂˝û™ëfÁ1iF7”^\Óê©HsÍÔ¶Øf∑Üˆ(ÁRrQnâ˝˝6ÍÌGÅ–^Íh‹ñ˘ñî…Ô*„ˇWjZ§6(Ç5—>ˇ¸h_ÍàåÛf… ˆt åaØ⁄˜ÉÍ®WÄ’ä∂í>‡<"s˜à‘6G˚‹a`≠ˇ∞,Ùœì3¸NÙ¡õúÉwdúˇπ‹„èó·A=ql∑ËY:Ùm◊‚-çæÊ‹5:á¢É©ùå%ã‡R)…V&±á¬˝êƒ:ª õöa‚ëp¶%•ÍmW¨»xw∏ˆÆùNîï‹„Zà}Q¨µä©[†wèˇ”Må}PNçuúæ°“¨V§˜°ﬂP@ù{á8O€ılY-H’h∑ÛO}◊Fg;Â—>ß^*l›À„wit‹u¥ªÖwÃ9JÍ”h£íïﬁß|€iÔ9ÀÁÒˇºûiˆs¥•€ﬁw èo<ÂîYr∫ªYÎ∆{›_:ò.√ßä> {IØ‡]woC≠[—⁄yTÜ(ÊºÎôfN*ôy˜ó»ŸÇ‰ºeŒt_Û_©FÆ%ÆÏ⁄£C§áı¯◊O¢ào{≠^[„‡n/„zëT≈>ﬂ∏T*_^g›∑'E¯¶ıç¯˘Ø5Fÿ¯◊Jª™K›R¸ø˙2¥¢m_ﬂIìµæÍ|¸ﬁˇÿ/ÿ¶é;éˇÓûcõ¥âNﬁKHLßqpÄö;–.ê•°˘Å“@1§qîPß^’n⁄‘â†NÍ∂NkPUUb¨√s™Ã¸ë¬îç∆
ÍÄI¥•iWmk∑6UU≠cöñ}Ôﬁ£cùJµJ´Vı¸Ù˘˝~w˜ª{˜ÓŒøª[-b_÷bÍ±VƒTπg‡,*Óià7Ω"∂”T√ˇn≈ vQB"iyàçËc£‘“ÊvLi§YºﬂÚÕ3sZ∆§\+fiÑˆ2"ûaˇµ‚U°ˆy+~ÒV‚W‡sçw¡∆·ÑÖÿs˛qHÓM≥‚§åÖà”¬w˚˛‰ˇAƒãËGùóÏ≥Â·Ë„◊ÙGùÌ:áÌ:ˇÈøë⁄œaùƒ‹â=˘*œÍ¢õﬁøw’àÒœ˙ΩºØ4°\úA˛uŒ{ûÿ'Â<aé:q&˙±ﬁ©]ÃmVÑ|bÔ¬8ùÆ”›rü„¯úÀ≤±Ô~Qæ1Ìœ¡:}◊Óß∏üÃ√:}Ë˝ªﬂµª‹µª—mé«Ë	m;ŒB’‘dÔ˜'Æªﬂ>!ÎÃä∏TÒ_#¨™µ◊Ò,F& 6ÚcàËª¡€pí˙*—¨uDŸ„D7Âﬁ	ﬁ! ˚>~≥Û?ú9'â
∫àÊbÂÕªåøˆÆ˘D˛◊,
ÒŒ¢îÖé8]“KTökQ6õh°8é%â*«+œ›˙∂Euï≈¢7fÒìDK$™´#Zˆg'æπ„∂‚-¢˙≈74¢Ow,%∫ˇÉ¶-Dkn!j~É®∑ë÷UXèv|o'æg›”D]œm™'Íæá®'ÛˇÀñü-∂b}∆Jäœ{ˇ«å+
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P| 9•P(äOFî≥Ñﬁ°z˙!πàìóB¥é»—Á(§,§ârÈ'êâﬂ)ÖÌ¢cH1≤~KX©mkîÀ6ÿ∂ˆv€v¬ﬁe€.⁄ƒÄ'sÃm≤)€f‰ÁklõS.ﬂf€Úì∂ÌÄ}¿∂ù∞l€ËñëAa™∆≥VıQ∫Ö4 ít úïH¡≤˘qÈQÖí(ı„1®y€Q?I√2Éé¡{7d/<£∞„®+|„“ß$e{Ωπzàv"/A€>F_D´≤E´^'Rq§ƒ€já’#S÷õêí-≤Ì>ŸWÉ∂"µ•IŸ[·]u»WW/5:˙bFKb ëºo0f¨L&ÜzíÒƒ@ïÌÔ7⁄‚€˚í√F[l86¥;÷[uWW˚˙÷ï¡ËPºßø•„F)©å¯∞—c$ázzc˜ˆÌ4€>Ù}F|¿H¢¨s ûåıÌ…ûdïzCâ!#Åí!ckb◊@r(Æ˙Á˜.Í¬(ØßV¥ºn∂[V·Ω„⁄/Á¯Fû∑ÏSª∫éRávÀX`Æ~˛ÑVNSÄkÂÈ`°~T[®¶o”#m¡òoNÿΩU3èIi@&¿0‘≠!ﬂπò‡ò ÁÅÅ¶Hñ F¡î(—
5⁄–Ω—Ö⁄<‘ùáH‚—
hÃ çt»h›`åßÙ9	∞LÄ∑eID+H?\Éæ§íjlGX&{¨‰ó7…‰ÿ˙ñnπ€“´V[nÀ-∑Eã≠Ï™FK/¨¥¥Ø,l
ùù>Õ◊ÚÒë˘Ë¯ $„ø c§”Am• ◊úvNDÛçï¬£öÉò∆5Üâ“gNj,ùìéfÛ>M>“˘[¸M´Ñø9ñõçÆ·Ø“04˛*ûW¯+¥èOâ1ál £`ú”¿…ßºåÁ
øB˛Ö@Ë£`L	“À_Ò^Ja7 Œ_ÑÙÚY/@z¯eXó˘etÌ7È⁄e·£“ÜlC/≥çÇ˘∂·Àg¯ÛÈ´ÂXQÃ4V‘q≠ÑVPçVí.[§g¥πÈ˙∏û·ø3Ç˙¡h5ø@)Äù“∞‹Å÷%Xó»¿AêXeê^`3‡,∏D’ ÷7?ü∆k2¸\:–®GÛ˘s¸*¿àˇõë–g˘)©≈)ıiË"Ë3¸T∫HßËM('‘ÒB{°C(œ‚?+ıÈ3—<>Å±”!C†¥Çn0ú|Çó§{u9Ng‹œ4Ω.ıìÙ∏õ";ÙH`%†!D`˘Ì∞ Fç— è˘>íBˆ?Kà¿ÉﬂÜ%D‡+˜√"–øñÅﬁ∞ÑlÏÜ%D†µDÜ?ˆ≥“ÖzmÎNfD=|FiFiFi9¯Ò–UáË€“±G#¡Ú
›<∆ÃÃlcÊ„Ãå1s/3Ôgf=3733»L?3ãòaÊqVá°0Y‰ÈK.ãÃeÊf>≈ÃafòY∆ÃRf¨6í·≈È’5R›!’XT¸È†o_ÅË„·≈—b¨˘bƒÑ	»s`F¶"p2J,ÁyEBóåU4XÈ™Â·D¥âO¢‚$¶aí^L–$ñ—$ôD»–NÇi0ú.A«G§Ù@Ü@Ë˚¿4p ÓLN	ªãGd«Bvß[EäO‚)¡SÃã#Ö^ø7Ëm“F¸ÃSƒZãfäx-ÂÁ„xÂÀsÁeXŒ¯{9}/áfEgÒ˝|Ñ
1l=íæZ®gÿ˜“Å„zt˚.9∞Íÿ2
∞2Ë:ñÈ%‰wΩßÆ√–·¥™y“ÅJ˝Àµ∆ı´˛◊Ù◊˝Ûè˛„˙oçåÉ•ıã»9<Æ_K? ∏ës"êaP«Èz‘_ß?uF∫ﬁèÇG”˙^°∆ıØ˘ø†ÔÙÀÇòU∞y©àGol‘õ–ﬁ*ˇ=2å6«ıˇfΩﬁÚZ"ÍåÎ’ËB–2+–Ÿrø|ÈÇ"Ÿ`gmÜıE*]è∏∫\≠Æ•Æ∞´“UÏ“]ÖÆ˘ÆŸnü€ÎŒuﬂÏŒvª›N∑√Õ›‰ûùôôä	S7€È È“!m/RòE–cnNk(ı9≠ô7∑7≤Ê‘…≠‘º≈H˝•}AÜeﬂΩ1ïµ†ë•|Õ‘‹—ò™6g\3m©⁄`s µˆK]?elˇ‰¶¯73å:∫2lFd}}~ ∑ÚüåóOkA∆g‹B¥÷6ˆ`ñ¯áï’:§Ö"H≥EçŸ≠/∂Jÿë=hDHoÖ’Éó§‰TË°ü Ù4[/—^zˆS‰#‘|ÅÙ}gWm®ÖŒº„Û¸f^gúuW{J(ç_\&1Ó]\rN‘ƒYY-?-≈_ø574ù†eÎ¢ﬁÎß≈óz”ﬂ“\º¬Œ]ö◊≈Á¶ÊÿSzKYÊî.0p{™îË≠ıu•dr^ø¶«í#] 'f!π0‹òë#Z8„s_}.„ÅÀa .!y…Â#…=†»ynŒ2Ω\N2;q%„Óh2Û<0˘ºd#2óÃ<1BFî$íJíIIÑÓíîDRtW"«k‰eÄåW»XfRËöI˘LÏf…ƒnÄaˇ[˙U∆Ëƒ‡=«ÍÎVG∑˙P;‚”Ÿ©*F'öÊı8öPûuNzßª}¡ıæ)z∫©yÜ≥¡v–6t”#é’≤=ß“7ø√“ª&ü‘Ö‚Ω\„UÆBc√dú¨Äπj≈vÌÊ*bÆ"Ê™Uj2ëgºa{aRÂGé'°ËC8ØùdñW€KÚYı<9Éßï+e\<“´"≠˝√˝C¥‡öBÎ1»OK=7≤…Ω
¨mê„zï∞¡–’˙`˙/
HÉ!n∏ﬂ2˜_<KT∫¶; §.û7Î¢¸Æm{[[†vpI‚`©E£÷ı›O_|‚ää≤Q{ÉZ$Äˇ√ ·U0
˝ò–JÜ¬üÆàLΩÇüÇV÷Í¥Ì<K·Ì¡Â∞@ó2Í.Á>6cƒOpÕÀ:Ω`/AÙG¬wπ%´Çõ≈V;6`Ï∑  òÃendstreamendobj23 0 obj<</AIS false/BM/Normal/CA 1.0/OP false/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op false>>endobj49 0 obj<</Length 25103>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
-0.013 Tc 0.014 Tw 10 0 0 10 46 715.6797 Tm
[(What are the possible side effects of SPR)36.7 (YCEL?)]TJ
0 -1.757 Td
[(SPR)36.7 (YCEL)18 ( may cause serious side effects, including:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.469 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.006 Tc 0.047 Tw 1.8 0 Td
(Low blood cell counts.)Tj
/C2_0 1 Tf
0.006 Tw [<0BD80003>-46.9 <002F0052005A0003>-46.8 <0045004F0052005200470003>-46.9 <00460048004F004F0003>-46.9 <0046005200580051005700560003>-46.9 <0044005500480003>-46.9 <0046005200500050005200510003>-46.9 <005A004C0057004B0003>-46.9 <003600330035>18 <003C00260028002F>37.1 <0003>-46.9 <0044005100470003>-46.8 <0046004400510003>-46.8 <004500480003>-46.9 <005600480059004800550048000F0003>-46.9 <004C00510046004F00580047004C0051004A0003>-46.9 <004F0052005A0003>-46.9 <005500480047>-6.2 <0003>]TJ
0 -1.073 Td
[<0045004F0052005200470003>-48.1 <00460048004F004F0003>-48 <0046005200580051005700560003>-48.1 <000B0044005100480050004C0044000C000F0003>-48.1 <004F0052005A0003>-48.1 <005A004B004C005700480003>-48.1 <0045004F0052005200470003>-48.1 <00460048004F004F0003>-48.1 <0046005200580051005700560003>-48.1 <000B005100480058005700550052005300480051004C0044000C000F0003>-48.1 <0044005100470003>-48.1 <004F0052005A0003>-48.1 <0053004F004400570048004F004800570003>-48.1 <0046005200580051005700560003>-48.1 <000B0057004B005500520050004500520046005C00570052005300480051004C0044000C0011>-5.8 <0003>]TJ
/TT1 1 Tf
0 Tc 0.076 Tw 0 -1.073 Td
[(Y)92.1 (our healt)0.5 (hcare provider will do blood t)0.5 (est)0.5 (s t)0.5 (o check your blood cell counts regularly during your t)0.5 (reat)0.5 (ment with )]TJ
/C2_0 1 Tf
-0.012 Tc 0.012 Tw 0 -1.073 Td
[<003600330035>17.6 <003C00260028002F00110003>-27.9 <00260044004F004F0003>-27.9 <005C0052005800550003>-27.9 <004B00480044004F0057004B00460044005500480003>-27.9 <0053005500520059004C0047004800550003>-27.9 <0055004C004A004B00570003>-27.9 <0044005A0044005C0003>-27.9 <004C00490003>-27.9 <005C005200580003>-27.9 <004B0044005900480003>-27.9 <00440003>-27.9 <004900480059004800550003>-27.9 <005200550003>-27.9 <00440051005C0003>-27.9 <0056004C004A005100560003>-27.8 <005200490003>-27.9 <004400510003>-27.9 <004C00510049004800460057004C005200510003>-27.8 <004700580055004C0051004A0003>-27.9 <005700550048004400570050004800510057>-11.8 <0003>]TJ
/TT1 1 Tf
-0.013 Tc 0.014 Tw 0 -1.073 Td
[(with SPR)17.7 (YCEL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.397 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.009 Tc 0.031 Tw 1.8 0 Td
[(Bl)0.5 (eed)0.5 (i)0.6 (n)0.5 (g)0.5 ( )0.7 (p)0.5 (ro)0.5 (b)0.6 (l)0.5 (ems.)]TJ
/C2_0 1 Tf
0.009 Tw 9.141 0 Td
[<0BD80003>-30.4 <0025004F004800480047004C0051004A0003>-30.4 <0053005500520045004F0048005000560003>-30.4 <0044005500480003>-30.3 <0046005200500050005200510003>-30.3 <005A004C0057>0.5 <004B0003>-30.3 <003600330035>18.3 <003C00260028002F0011>0.5 <0003>-30.4 <00360052005000480057>0.6 <004C0050004800560003>-30.3 <0057>0.5 <004B0048005600480003>-30.3 <0045004F004800480047004C0051004A0003>-30.4 <0053005500520045004F0048005000560003>-30.4 <0046004400510003>-30.3 <00450048>-9.2 <0003>]TJ
-0.013 Tc 0.013 Tw -9.141 -1.073 Td
[<005600480055004C0052005800560003>-13.9 <0044005100470003>-13.9 <004F0048004400470003>-14 <005700520003>-13.9 <0047004800440057004B00110003>-14 <00260044004F004F0003>-14 <005C0052005800550003>-13.9 <004B00480044004F0057004B00460044005500480003>-13.9 <0053005500520059004C0047004800550003>-13.9 <0055004C004A004B00570003>-13.9 <0044005A0044005C0003>-13.9 <004C00490003>-14 <005C005200580003>-13.9 <004B004400590048001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.235 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<005800510058005600580044004F0003>-13.9 <0045004F004800480047004C0051004A0003>-13.9 <005200550003>-13.9 <004500550058004C0056004C0051004A0003>-13.9 <005200490003>-13.9 <005C0052005800550003>-14 <0056004E004C0051>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(bright red or dark tar-like stools)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0047004800460055004800440056004800470003>-14 <0044004F0048005500570051004800560056000F0003>-14 <004B00480044004700440046004B0048000F0003>-13.9 <005200550003>-14 <0046004B00440051004A00480003>-13.9 <004C00510003>-13.9 <00560053004800480046004B>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.009 -1.415 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/C2_1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
[<003C>74.4 <005200580055>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.378 0 Td
<004500520047005C>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.563 0 Td
<00500044005C>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.194 0 Td
<004B0052004F0047>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.284 0 Td
<005700520052>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.747 0 Td
<005000580046004B>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.841 0 Td
<00C00058004C0047>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.284 0 Td
<000B00C00058004C0047>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.599 0 Td
<005500480057004800510057004C00520051000C00110BD8>Tj
/C2_0 1 Tf
[<0BD80003>13.3 <0029004F0058004C00470003>13.2 <005500480057004800510057004C005200510003>13.3 <004C00560003>13.2 <0046005200500050005200510003>13.2 <005A004C0057004B0003>13.3 <003600330035>18 <003C00260028002F>37.1 <0003>13.3 <0044005100470003>13.3 <0046004400510003>13.3 <00560052005000480057004C005000480056>-18 <0003>]TJ
/TT1 1 Tf
0 Tc 0 Tw 31.31 0 Td
( )Tj
/C2_0 1 Tf
-0.013 Tc 0.013 Tw -50.2 -1.073 Td
[<004500480003>-17.1 <00560048005900480055004800110003>-17.2 <002C00510003>-17.2 <0056004800590048005500480003>-17.2 <00460044005600480056000F0003>-17.2 <00C00058004C00470003>-17.2 <00500044005C0003>-17.2 <00450058004C004F00470003>-17.2 <005800530003>-17.2 <004C00510003>-17.1 <0057004B00480003>-17.2 <004F004C0051004C0051004A0003>-17.2 <005200490003>-17.2 <005C0052005800550003>-17.2 <004F00580051004A0056000F0003>-17.1 <0057004B00480003>-17.2 <0056004400460003>-17.2 <0044005500520058005100470003>-17.2 <005C0052005800550003>-17.1 <004B0048004400550057000F0003>-17.2 <005200550003>-17.2 <005C0052005800550003>-17.1 <005600570052005000440046004B>-13.2 <0003>]TJ
0 -1.073 Td
[<004600440059004C0057005C>74 <00110003>-14 <00260044004F004F0003>-14 <005C0052005800550003>-13.9 <004B00480044004F0057004B00460044005500480003>-14 <0053005500520059004C0047004800550003>-13.9 <0055004C004A004B00570003>-14 <0044005A0044005C0003>-14 <004C00490003>-14 <005C005200580003>-14 <004A004800570003>-13.9 <00440051005C0003>-14 <005200490003>-13.9 <0057004B0048005600480003>-14 <0056005C0050005300570052005000560003>-14 <004700580055004C0051004A0003>-13.9 <0057005500480044005700500048005100570003>-14 <005A004C0057004B0003>-13.9 <003600330035>17.7 <003C00260028002F001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.235 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(swelling all over your body)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(weight gain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B000F0003>-13.9 <00480056005300480046004C0044004F004F005C0003>-13.9 <004C00490003>-13.9 <0057004B004C00560003>-13.9 <004B0044005300530048005100560003>-13.9 <005A004C0057004B0003>-14 <004F0052005A0003>-14 <004F004800590048004F00560003>-14 <005200490003>-14 <0053004B005C0056004C00460044004F0003>-13.9 <004400460057004C0059004C0057005C0003>-14 <005200550003>-13.9 <004400570003>-14 <0055004800560057>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(dry cough)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(chest pain when taking a deep breath)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.009 -1.415 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.012 Tw 1.8 0 Td
(Heart and blood vessel \(cardiovascular\) problems.)Tj
/C2_0 1 Tf
0.013 Tw [<0BD8>-0.7 <0003>-12.2 <003600330035>17.7 <003C00260028002F>36.8 <0003>-12.3 <00500044005C0003>-12.3 <004600440058005600480003>-12.3 <004B00480044005500570003>-12.2 <0053005500520045004F004800500056000F0003>-12.3 <004C00510046004F00580047004C0051004A0003>-12.3 <004400510003>-12.3 <0044004500510052005500500044004F>-13.2 <0003>]TJ
-0.001 Tc 0.001 Tw 0 -1.073 Td
[<004B00480044005500570003>-72.7 <0055004400570048000F0003>-72.7 <00440003>-72.7 <004B00480044005500570003>-72.8 <00440057005700440046004E000F0003>-72.7 <005200550003>-72.8 <005600500044004F004F0003>-72.8 <0056005700550052004E004800560003>-72.7 <0057004B004400570003>-72.7 <004F0044005600570003>-72.7 <00520051004F005C0003>-72.7 <00440003>-72.7 <00490048005A0003>-72.7 <0050004C005100580057004800560003>-72.7 <005200550003>-72.7 <00440003>-72.7 <00490048005A0003>-72.7 <004B0052005800550056000F0003>-72.7 <00460044004F004F004800470003>-72.7 <00570055004400510056004C0048005100570003>-72.7 <004C00560046004B00480050004C0046>-1 <0003>]TJ
-0.011 Tc 0.011 Tw 0 -1.073 Td
[<00440057005700440046004E00560003>-27.4 <000B0037002C00240056000C00110003>-9.4 <0037002C002400560003>-27.5 <0044005500480003>-27.5 <005200490057004800510003>-27.5 <00440003>-27.4 <005A004400550051004C0051004A0003>-27.5 <0056004C004A00510003>-27.5 <0057004B004400570003>-27.5 <005C005200580003>-27.5 <0044005500480003>-27.5 <004400570003>-27.4 <0055004C0056004E0003>-27.4 <0049005200550003>-27.5 <00440003>-27.5 <00500052005500480003>-27.4 <005600480055004C0052005800560003>-27.4 <0056005700550052004E004800110003>-9.4 <003C>91.9 <0052005800550003>-27.4 <004B00480044004F0057004B00460044005500480003>-27.5 <0053005500520059004C004700480055>-11 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<005A004C004F004F0003>-13.9 <005000520051004C0057005200550003>-14 <0057004B00480003>-13.9 <005300520057004400560056004C005800500003>-14 <0044005100470003>-14 <00500044004A005100480056004C005800500003>-13.9 <004F004800590048004F00560003>-14 <004C00510003>-14 <005C0052005800550003>-13.9 <0045004F0052005200470003>-14 <0044005100470003>-13.9 <005C0052005800550003>-14 <004B00480044005500570003>-13.9 <00490058005100460057004C005200510011>]TJ
-0.367 -1.451 Td
[<002A004800570003>-13.9 <005000480047004C00460044004F0003>-13.9 <004B0048004F00530003>-14 <0055004C004A004B00570003>-14 <0044005A0044005C0003>-14 <004C00490003>-14 <005C005200580003>-14 <0047004800590048004F005200530003>-13.9 <00440051005C0003>-13.9 <005200490003>-14 <0057004B00480003>-13.9 <00490052004F004F0052005A004C0051004A0003>-13.9 <0056005C0050005300570052005000560003>-14 <004700580055004C0051004A0003>-13.9 <0057005500480044005700500048005100570003>-13.9 <005A004C0057004B0003>-14 <003600330035>17.7 <003C00260028002F001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.958 -1.469 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(chest pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.433 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.433 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<004900480048004F004C0051004A0003>-14 <004F004C004E00480003>-13.9 <005C0052005800550003>-14 <004B00480044005500570003>-14 <004C00560003>-13.9 <0045004800440057004C0051004A0003>-13.9 <0057005200520003>-14 <00490044005600570003>-13.9 <005200550003>-14 <005C005200580003>-14 <004900480048004F0003>-13.9 <0044004500510052005500500044004F0003>-13.9 <004B00480044005500570003>-13.9 <00450048004400570056>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.433 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0059004C0056004C005200510003>-13.9 <0046004B00440051004A004800560003>-14 <0057004B004400570003>-14 <00500044005C0003>-14 <004F0044005600570003>-13.9 <0049005200550003>-13.9 <00440003>-14 <0056004B0052005500570003>-14 <0057004C00500048>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.433 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(slurred speech)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.009 -1.415 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.009 Tc 0.035 Tw 1.8 0 Td
[(Pulmonary )37.6 (Arterial )0.5 (Hypertension )0.5 (\(P)73.9 (AH\).)]TJ
/C2_0 1 Tf
0.009 Tw [<0BD8>-0.8 <0003>-34.6 <003600330035>17.6 <003C00260028002F>36.7 <0003>-34.6 <00500044005C0003>-34.6 <004600440058005600480003>-34.6 <004B004C004A004B0003>-34.6 <0045004F0052005200470003>-34.5 <005300550048005600560058005500480003>-34.6 <004C00510003>-34.5 <0057004B00480003>-34.6 <00590048005600560048004F00560003>-34.5 <005200490003>-34.5 <005C0052005800550003>-34.6 <004F00580051004A00560011>-8.9 <0003>]TJ
/TT1 1 Tf
-0.003 Tc 0.065 Tw 0 -1.073 Td
[(P)73.8 (AH)-0.6 ( may h)-0.6 (ap)-0.6 (p)-0.6 (en)-0.6 ( a)-0.6 (t a)-0.6 (ny time d)-0.6 (urin)-0.6 (g you)-0.6 (r trea)-0.6 (tme)-0.6 (nt w)-0.6 (ith SPR)17.5 (YC)-0.6 (EL)-0.6 (. )18.1 (Y)91.4 (o)-0.6 (ur he)-0.6 (a)-0.6 (lthca)-0.6 (re pro)-0.6 (vi)-0.6 (de)-0.6 (r sho)-0.6 (u)-0.6 (ld)-0.6 ( ch)-0.6 (eck you)-0.6 (r)-3 ( )]TJ
/C2_0 1 Tf
-0.005 Tc 0.005 Tw 0 -1.073 Td
[<004B00480044005500570003>-54.5 <0044005100470003>-54.5 <004F00580051004A00560003>-54.5 <0045004800490052005500480003>-54.5 <0044005100470003>-54.5 <004700580055004C0051004A0003>-54.5 <0057005500480044005700500048005100570003>-54.5 <005A004C0057004B0003>-54.5 <003600330035>17.6 <003C00260028002F00110003>-54.5 <00260044004F004F0003>-54.5 <005C0052005800550003>-54.5 <004B00480044004F0057004B00460044005500480003>-54.5 <0053005500520059004C0047004800550003>-54.5 <0055004C004A004B00570003>-54.5 <0044005A0044005C0003>-54.5 <004C00490003>-54.5 <005C005200580003>-54.5 <004B004400590048>-5.1 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B000F0003>-13.9 <0057004C0055004800470051004800560056000F0003>-14 <005200550003>-13.9 <0056005A0048004F004F004C0051004A0003>-14 <0044004F004F0003>-14 <00520059004800550003>-13.9 <005C0052005800550003>-14 <004500520047005C0003>-13.9 <000B00C00058004C00470003>-14 <005500480057004800510057004C00520051000C0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.397 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.011 Tc 0.028 Tw 1.8 0 Td
(Severe skin reactions.)Tj
/C2_0 1 Tf
0.011 Tw [<0BD80003>-27.6 <003600330035>17.9 <003C00260028002F>37 <0003>-27.7 <00500044005C0003>-27.6 <004600440058005600480003>-27.6 <0056004E004C00510003>-27.7 <00550048004400460057004C0052005100560003>-27.6 <0057004B004400570003>-27.7 <0046004400510003>-27.7 <00560052005000480057004C0050004800560003>-27.7 <004500480003>-27.7 <00560048005900480055004800110003>-27.6 <002A004800570003>-27.6 <005000480047004C00460044004F0003>-27.6 <004B0048004F00530003>-27.7 <0055004C004A004B0057>-10.9 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<0044005A0044005C0003>-13.9 <004C00490003>-14 <005C005200580003>-13.9 <004A004800570003>-14 <00440003>-14 <0056004E004C00510003>-13.9 <00550048004400460057004C005200510003>-14 <005A004C0057004B0003>-13.9 <00490048005900480055>55 <000F0003>-13.9 <00560052005500480003>-14 <0050005200580057004B0003>-13.9 <005200550003>-14 <0057004B0055005200440057000F0003>-13.9 <005200550003>-14 <0045004F004C0056005700480055004C0051004A0003>-14 <005200550003>-14 <005300480048004F004C0051004A0003>-13.9 <005200490003>-13.9 <005C0052005800550003>-14 <0056004E004C00510003>-13.9 <005200550003>-14 <004C00510003>-14 <0057004B00480003>-13.9 <0050005200580057004B0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.397 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.003 Tc 0.062 Tw 1.8 0 Td
[(T)74.5 (umor L)37.4 (ysis Syndrome \(TLS\).)]TJ
/C2_0 1 Tf
0.003 Tw [<0BD80003>-43.7 <0037002F00360003>-61.8 <004C00560003>-61.8 <0046004400580056004800470003>-61.8 <0045005C0003>-61.9 <00440003>-61.8 <00490044005600570003>-61.8 <0045005500480044004E00470052005A00510003>-61.8 <005200490003>-61.8 <0046004400510046004800550003>-61.9 <00460048004F004F005600110003>-43.8 <0037002F00360003>-61.8 <0046004400510003>-61.8 <004600440058005600480003>-61.8 <005C005200580003>-61.8 <005700520003>-61.8 <004B004400590048>-3.1 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<004E>0.5 <004C004700510048005C>0.5 <0003>0.7 <0049>0.7 <0044004C004F00580055>0.5 <00480003>0.7 <0044005100470003>0.7 <0057>0.7 <004B00480003>0.7 <00510048004800470003>0.7 <0049>0.6 <00520055>0.5 <0003>0.7 <0047004C0044004F005C>0.6 <0056>0.5 <004C0056>0.6 <0003>0.6 <0057>0.7 <0055>0.5 <004800440057>0.7 <0050>0.5 <004800510057>0.7 <000F>0.7 <0003>0.7 <0044005100470003>0.7 <004400510003>0.7 <00440045005100520055>0.5 <0050>0.5 <0044004F0003>0.7 <004B004800440055>0.5 <0057>0.7 <0045004800440057>0.7 <0011>0.7 <0003>18.7 <003C>92.4 <005200580055>0.5 <0003>0.7 <004B00480044004F0057>0.7 <004B0046>0.5 <00440055>0.5 <00480003>0.7 <00530055>0.5 <00520059>0.5 <004C004700480055>0.5 <0003>0.7 <0050>0.5 <0044005C>0.5 <0003>0.7 <004700520003>0.6 <0045004F005200520047>-13.2 <0003>]TJ
-0.007 Tc 0.007 Tw 0 -1.073 Td
[<005700480056005700560003>-44.2 <005700520003>-44.1 <0046004B00480046004E0003>-44.2 <005C005200580003>-44.1 <0049005200550003>-26.1 <0037002F003600110003>-44.2 <00260044004F004F0003>-44.1 <005C0052005800550003>-44.1 <004B00480044004F0057004B00460044005500480003>-44.1 <0053005500520059004C0047004800550003>-44.1 <005200550003>-44.2 <004A004800570003>-44.1 <0048005000480055004A004800510046005C0003>-44.1 <005000480047004C00460044004F0003>-44.2 <004B0048004F00530003>-44.2 <0055004C004A004B00570003>-44.2 <0044005A0044005C0003>-44.1 <004C00490003>-44.2 <005C005200580003>-44.1 <0047004800590048004F00520053>-7.1 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<00440051005C0003>-13.9 <005200490003>-14 <0057004B0048005600480003>-13.9 <0056005C0050005300570052005000560003>-13.9 <004700580055004C0051004A0003>-14 <0057005500480044005700500048005100570003>-13.9 <005A004C0057004B0003>-13.9 <003600330035>17.6 <003C00260028002F001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.565 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(nausea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 3.6 0 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.059 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(vomiting)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 3.6 0 Td
(muscle cramps)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.059 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(weakness)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(seizures)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.059 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(swelling)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-4.809 -1.321 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
0.018 Tc 0.167 Tw 1.8 0 Td
[(Slowing )0.6 (of )0.5 (growth )0.6 (and )0.5 (development )0.5 (in )0.5 (children.)]TJ
/C2_0 1 Tf
-0.018 Tw [<0BD80003>-166.5 <00280049>18.4 <004900480046005700560003>-166.4 <005200510003>-166.5 <00450052005100480003>-166.5 <004A00550052005A0057004B0003>-166.5 <0044005100470003>-166.4 <0047004800590048004F0052005300500048005100570003>-166.5 <004C00510003>-166.5 <0046004B004C004F0047005500480051>17.9 <0003>]TJ
/TT1 1 Tf
0 Tc 0 Tw 50.2 0 Td
( )Tj
-0.002 Tc 0.068 Tw -50.2 -1.073 Td
[(have )0.6 (happened )0.5 (with )0.6 (SPR)17.9 (YCEL)37 ( )0.5 (and )0.6 (can )0.6 (sometimes )0.6 (be )0.6 (severe. )18.5 (Y)91.9 (our )0.6 (healthcare )0.6 (provider )0.5 (will )0.5 (monitor )0.6 (your )0.5 (child\222)17.9 (s)-2 ( )]TJ
/C2_0 1 Tf
-0.008 Tc 0.008 Tw 0 -1.073 Td
[<00450052005100480003>-36.1 <004A00550052005A0057>0.5 <004B0003>-36 <0044005100470003>-36 <0047004800590048004F005200530050004800510057>0.5 <0003>-36 <004700580055004C0051004A0003>-36 <00570055004800440057>0.5 <0050004800510057>0.5 <0003>-36 <005A004C0057004B0003>-36 <003600330035>18.1 <003C00260028002F00110003>-36 <002A004800570003>-36 <005000480047004C00460044004F0003>-36.1 <004B0048004F00530003>-36 <0055004C004A004B00570003>-36 <0044005A0044005C0003>-36 <004C00490003>-36 <005C0052005800550003>-36 <0046004B004C004F00470003>-36 <0047004800590048004F005200530056>-8 <0003>]TJ
/TT1 1 Tf
-0.013 Tc 0.014 Tw 0 -1.073 Td
(bone pain.)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.397 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.006 Tc 0.047 Tw 1.8 0 Td
(Liver problems.)Tj
/C2_0 1 Tf
0.006 Tw [<0BD80003>-47 <003600330035>18 <003C00260028002F>37.1 <0003>-47 <0046004400510003>-47 <004600440058005600480003>-47 <004F004C0059004800550003>-47 <0053005500520045004F00480050005600110003>-47 <0033004800520053004F00480003>-46.9 <005A004B00520003>-46.9 <004B0044005900480003>-47 <004B004400470003>-47 <004F004C0059004800550003>-47 <0053005500520045004F0048005000560003>-47 <004C00510003>-46.9 <0057004B00480003>-47 <00530044005600570003>-46.9 <00500044005C0003>-46.9 <004500480003>-47 <00440057>-5.9 <0003>]TJ
-0.003 Tc 0.003 Tw 0 -1.073 Td
[<0055004C0056004E0003>-63.5 <0049005200550003>-63.4 <004A004800570057004C0051004A0003>-63.4 <004F004C0059004800550003>-63.4 <0053005500520045004F0048005000560003>-63.4 <005A004C0057004B0003>-63.4 <003600330035>17.7 <003C00260028002F00110003>-45.4 <003C>91.7 <0052005800550003>-63.5 <004B00480044004F0057004B00460044005500480003>-63.5 <0053005500520059004C0047004800550003>-63.4 <005A004C004F004F0003>-63.4 <005000520051004C0057005200550003>-63.4 <005C0052005800550003>-63.4 <004F004C0059004800550003>-63.5 <00490058005100460057004C005200510003>-63.5 <004400560003>-63.4 <005100480048004700480047>-3.2 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<004700580055004C0051004A0003>-26.1 <0057004B00480003>-26.1 <0057005500480044005700500048005100570003>-26.1 <005A004C0057004B0003>-26.1 <003600330035>17.6 <003C00260028002F00110003>-26.1 <00260044004F004F0003>-26 <005C0052005800550003>-26.1 <004B00480044004F0057004B00460044005500480003>-26.1 <0053005500520059004C0047004800550003>-26.1 <005200550003>-26.1 <004A004800570003>-26.1 <005000480047004C00460044004F0003>-26.1 <004B0048004F00530003>-26.1 <0055004C004A004B00570003>-26.1 <0044005A0044005C0003>-26 <004C00490003>-26.1 <005C005200580003>-26.1 <0047004800590048004F005200530003>-26.1 <00440051005C>-13 <0003>]TJ
0 -1.073 Td
[<0056005C0050005300570052005000560003>-14 <005200490003>-14 <004F004C0059004800550003>-13.9 <0053005500520045004F004800500056000F0003>-14 <004C00510046004F00580047004C0051004A001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.565 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 3.6 0 Td
(stomach-area \(abdominal\) pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(bleeding)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.059 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 3.6 0 Td
[<005C0048004F004F0052005A004C0051004A0003>-13.9 <005200490003>-13.9 <005C0052005800550003>-14 <0056004E004C00510003>-13.9 <005200550003>-13.9 <005A004B004C005700480003>-14 <00530044005500570003>-14 <005200490003>-13.9 <005C0052005800550003>-14 <0048005C00480056>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(bruising)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.059 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 3.6 0 Td
[<004F0052005600560003>-13.9 <005200490003>-13.9 <00440053005300480057004C00570048>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 3.6 0 Td
(dark \223tea-colored\224 urine)Tj
ET
0 0 0 1 K
4 M 
36.5 36.5 539 695.96 re
S
endstreamendobj45 0 obj<</BaseFont/NXSWOC+Arial-BoldMT/DescendantFonts 70 0 R/Encoding/Identity-H/Subtype/Type0/ToUnicode 71 0 R/Type/Font>>endobj70 0 obj[72 0 R]endobj71 0 obj<</Filter/FlateDecode/Length 427>>stream
Hâ\ì€j„0ÜÔ˝∫l/äO:¥â”@.ˆ¿¶˚ é≠dçlÁ"o_YüIa∂˘,ÕÃˇ£¥ﬁo˜ÆüD˙€Ì¡N‚‘ªŒ€ÎpÛ≠G{Ó]í¢Î€i°¯n/Õò§!¯pøNˆ≤wß!Y≠D˙'l^'OÎn8⁄Á$˝Â;Î{wOÎ√≥H∑q¸¥Î&ëâ™ù=ÖD?öÒgs±"ça/˚.Ï˜”˝%ƒ|ü¯∏èVësƒ¥CgØc”Zﬂ∏≥MVYXïXÌ¬™Î∫ˇˆeAÿÒ‘˛k|<^Ü„·ÛVE⁄D*^°ZˆvP)œ°wh©\G*t$YBí–+§†7HCTêT(3h°SeêÇ
àzäz%ııJ<(<3È"ã&ã$ã&ã$ã&ãDµFµDµFµ\C¢ÉöJ™Î•˙;¥Åp´q´p´q´ËÆ¶ª¡f§D'ùPx0xPx0xPx0xPx0xPx0xPx0xP®6®ﬁ,:ı√Gù}ˇâÍ7€9wëeÎ8tÀtÕ„nâxÃv{Û>åuºJqûÁIÓù}‹∂qEàöü‰KÄ ¯€·kendstreamendobj72 0 obj<</BaseFont/NXSWOC+Arial-BoldMT/CIDSystemInfo 73 0 R/CIDToGIDMap/Identity/DW 1000/FontDescriptor 74 0 R/Subtype/CIDFontType2/Type/Font/W[3[278]11 12 333 15[278]17[278]29[333]38 39 722 40[667 611]47[611 833]51[667]53[722 667 611]60[667]68[556 611 556 611 556 333]74 75 611 76[278]78[556 278 889]81 83 611 85[389 556 333 611 556 778]92[556]191 192 611 3032[83]]>>endobj73 0 obj<</Ordering(Identity)/Registry(Adobe)/Supplement 0>>endobj74 0 obj<</Ascent 1010/CIDSet 75 0 R/CapHeight 716/Descent -376/Flags 4/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 76 0 R/FontName/NXSWOC+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj75 0 obj<</Filter/FlateDecode/Length 33>>stream
Hâö È¿¬|p:ˇÔÔ/Ä±Åa–4  QT;endstreamendobj76 0 obj<</Filter/FlateDecode/Length 20571/Length1 48376>>stream
Hâ|UtMW˛˛Ω˜π7èàê'síKjÚ@‚M…Ω¡(BTì†sØ$$ûA§òV*òÃ\:•‘T©ñ÷õŒ	ôJ=£≥tTë5©—6£T©¨eCUÓôˇﬁòùµ¶{ØsŒ~¸èÔûíπÛàó —}tV∑d4è√¸8ÛJKÙÊ-E÷‹)≈Sg6Ô˝Jm˙‘ßú€qh˘7†kuaÅ+ø>¯˚—@ z&Í]»ÕÙ)µ¸ÍT8≥d¡„˝]†ÁÖ≥Û\"˜D0ÁœºØüÈZP‹|øÌ-~È≥\3*O^d,€éjjÒ‹Ç«˜ªcÅ6Á Âq¸¥7¥å2≤˘+Î0E˚i"–™Ñw®ƒô5XêŒ¨˛^˛q#”u4iÁ=c®áuÌKô¶…zbµÉ^ÌP¸çÚ=€•b¡>0Ø˛˚ÒôWΩwﬁØ∏…∫;4?è«>Ï¡_®ÈÿOäNIÖ˚ÏÈ?†	Ø!„∞éÇ—	ÌÒÜìböx¨§f©yÒ*∂ò®‹‹≈˜Ø‡#<`_*Båb˙gPÄÚrÃ7‡á
é· å•ˆp·"œ{åa÷‚(Ω`>`≠!(gy)Ç!ÊqÛ‚∞R≠“Í˝ˇà’8D3œ,BGƒ¿-‚ÕãÊWàEﬁ¡∆O5j¢1ÀÒ:ÖÀèxıﬁÖáZàI2]„»∞]„1œ√ç]8E¡î©’k∑Õ_ô◊aA[taLE∏AΩh§ÿ™ZòÉÃKòÄpíÌıŒ5Am◊&xõoö¢P ¶„Z≤ˆª¶%ÊfÛ=¥`<IÏëQ¨g2ñ‚8>∆ﬂqGîôeÜ,÷|Ç:êN±ÏÒã"\,ãÂytek'1⁄˘xG‰ ·˚ÊØh¿5
°H˙M¶’tG¥˘¢VnêUÚÇ"µì˝mCgˆQ	∂‚}ú∆‘í∆ÚªS&M£ŸÙ{zìÑ!nâ˚ O-U?®&-÷”‡˘¡eﬁC"4°å}˚ˆ£
gÒÓ‡.˛IA‘ó
i3‘@∑Ñøà£E±X'∂äΩrî\-è´^*MMWg‘%Ì◊⁄
´ÀÍy¥Õ≥∆≥◊Sg0Î8wZ±¸Xd∞GópVl≈1úgÈü„\ÒÊÀ@πÙkôGø°µ¥óNP›d+·õ1bÄ∞≥÷Ÿb.˚©\¨kY{-œO≈%ÒÖ¯N‹ìöåëΩÂπY≤Z~*øQA*VuUIj¥ U&G&Y™ei;¥›⁄á⁄mKä%ﬂRl˘÷Zn]Êw∫)ÆÈK<Ö√≥üs◊è3i{b∂pﬁWqN±Gœ2‚¸É£A—Ù„ÓG4ÇF“≥4ë
®ú*ËUzù6–zè-`Ñï±«ã!"K∏DÅX&*ƒÀ¢äÁAÒ±∏(ÍE##ï6/ì‰pô+'»YlCâ\,ó±gWÀ]≤Vûó◊Â∑≤ë£™:™˘jëZØ∂´*Uß=≠Õ‰πE;¶’hu⁄#ÌëEX",Qñnñiññ+Vãµ∑5”˙[ÎÎ]øbä¢8FÆ„â!¬π;ä]"DïQ#t Ö÷ly<«!ã´‚.K«•ï˜û±µ·™≠ó”í™Ê/°CËE'Pfí∏5`]ÍOb >#'Ö´ÌrñvJDc7w£U‚∞8Di®)bºÿ(A◊hÆqæ/¿ZöNÛ∞õ©?ΩH}®D{ôEÀêbnä¸i8›#¿ïèÁìÉ˙·2nx6©ñÍÓO’X«›ÉØh'ífﬁ‚Ó&ππ∏À¨‰|_o◊õƒuV∆ıŒdÜ•Ud·?HÀ µ∑Ò=nh9£“∏ì^˜©MÍk≥èô»∆UÜ\wÖ sç≥‰ÔΩªâ\È‹Kíπ™3ëã|º»]oµiòÕ•ÊBs6>aﬁáî@ÈmÆàjÊH¡IûØ‡sZ¡u8ÙßÌ¸√ìè‹§0ÍL…\çZ©∂J€•UiGµ3ñ$ˆˆ2l‡åæ¬Ÿ¿‰°7qü¸86·H@O∆€ó±gcÜ»ëGêN(ÊöÌ¬}<Ì±%ÛXJ9{o#◊ÛÆç€‹'&‚(ÍIP([î«˙˝XŒˆÛ/ôzGp)ÌÁì|Ó⁄q¯éÌnE}E	ÎKeIÎ∏k’0¶À¯ÜΩm˙p%p_∞”xñuœ"ü5ÙF&UrﬁG?Ó¨vyö˝›âÇêF1Ù.Û9πB[°˙i_ì@ÇgîŸW…#¸è1˘¸m˛{Eb Õa≠Ÿé&¥£—ËÂÀŒìTùÛ°X/
Ã
˘ºg>¡NéI™*µ⁄SáåK<h` Ä˛˝˙ˆÈ’≥GrR˜n]‚„~ﬁÂ©ÿŒùl1—˙œ:vàäåmﬂ.§mpõ†÷≠Z∂˜≥Z4%!¡aÀpÍF¨”P±∂a√Ω{õã\O8ùè2~LcËNô˛c T¶úÚ?î©Õî©ˇ°§ =)â	∫√¶gÏ6Ωör«dÛ˙eª-G7}Îëæı*ﬂ∫%Ø££ôAwÑ⁄uÉú∫√»(-t;úvWênK/HL@e@ /yeÑ⁄ä+)t˘"‘—øR¿Ø%É2"lván≥{≤≥√ïodé…vÿ#££sJœ≥M6`K3Z«˚HêÓScX“´Oç^‰µ+Ù Ñ˜ Í Lv∆∑»∑Âª&f“ï„’—&ûı⁄ç–EW√˛ªe·¡ÈŸOﬁFJ∑#¨H˜n›Ó
›®ì˝‰m¥˜ùì√2òWtŒp∫3XıJv‚à,ùµâÂ9Ÿ-gï∫◊ØUÕˆÿﬁÁ4›∑•Ÿ
›”úö∑Å±£˜ED§~`6 ¬°ª«e€¢ç¡ë∂ó=™2ÓÒ]-∞M]g¯úsüÁ^€π∂€y¥π∆µbBúƒ!æ"êÅ¨ !<:∑·»Ë4a¥–á∂¬*`òFUCPÅ4åU≈!∞ô¥¨YµnCS'UEÌ¶≠k¥2Q4¬CﬂÏ?N»©€µÔy˝˜úÛ˝ˇˇù«øÏ’˛BC/ú*©ú—ßŸ«€gÀ/X¨ì›≤\)˜9+≈ñMX3DæE@àîæN$>–©Å%›(πÆ>ÉßCØ‘z»wR¥π+©5±v÷?%¯5üûºèÄæÃ≠©-k∆[Døv±"„…’@˛¥ú
Så"R3¯0ŒÕ’Î*glMìYæÕöò-€ÆÈl™Û{ΩÃ¡{”Zï‘ˆ∂é±∫é÷üGFU∞3E∫òd©§`ìl*ôËﬁÂ&_@p8°Çîò¯Ái.ÁÇû¶v˝q˜ò<÷Óãµ≠Ó–$ª∆m[>•6&oòêçóRŒÊÆòåóH1óì)ø=Ò1´tXRº˛bé‘ÎSê2◊Äıñî÷µp,ÌTºﬁˇŸ'-…ì:•GÔ≤^πÏø›∆Q¶öÇSÎ≥ß‘ß†≥$9¿ÀHl˘ÍdRô"kÅ(ôlÒÈ-…Æ‰öÙËˆµ>]Û%/ë”‰trÛÇÆßMèÏ-NµÏÎ%zpêï†y}>ºª≠œ¿ª€Ww\“ rŸΩº„<¡§πk^gg%"Ã¸‡òñ–ºõ¢î&Q√âﬁ‰ê"Ò&FÖ≤(òÑ{Ö€©yÇ⁄ÉH6≤Xé¥f#(
emíÍê◊Óµ˚!¡p‚èË‹‡à!†'HÁ·ÆÄ^2€Hè)“Pãa+œ;ÕôbD5‰ê/„i}aH9`(ÙûÂ®Œáx¬ß…°~˚©óÿåÒLv8£eP4™E4ò«±/@Í4Á¨˙ZB
ÚnÈ˛ÌëÎVÓ‹≥qNùœlªéˇ}ÓêdË≤˘âπÍˆIÛÃ—I3 1rHû2R¶l$ï√`—36â ÇøCcò &√tAæ'µ04éMÕM&{m*Á\Æ.L∏Zó£ _"‹Çˆ˘M%ˆ|p¯Ùºÿ;f€˘ﬂ<˙≤˜6˛Æ˙‹|ˆ—'wÃaÛ	C“k^¬ß0ªF/RY)çü5ä≈c∏AUî-8 =óáJ!‚ÅE-∑zÇ`ˆxÎµ,Ã›öŒb{#≤76VáúﬁÇ|Qî fÕ™˜Ì√ÖΩ´ÎW,$ªq·ï◊~≤Yˇ~…⁄læ∑ yÊ„–sFi@
	Lüü?ÀFØ’Ç?ﬂbëòy¨ °¬ˇÑ&cÀL£òk¿¢ÿ¿+ÙGà¿∫àpN˛¯ó91ZD†h&
#9a$Ô6ƒäVñè‹£5£◊Ö¿#EË3cÒtO˛◊qÙ3ÒÙ*wUΩœQ?-∑î[ßÁOwı
ΩÙAñúí€Ìtªßì
Œ/HÂ¬·0Ω¬}§
QºÓFÀ4Ñá‡¶BPzt∞ﬂÓ	Ár≈
9^m∏=ïºl3lé∞-ˆb^íáÛåO8/çÀçiéJÖÀªc[âÓ†‹PE°\RPvB¬yR©í8X"˚˙ã_o≥U¢5≥Xã?àÉ7¿'Ÿ·`<q-»rVàWáP«„q,àºOGvyu∑À-æi¢]s’÷Ã‚£∏tû˘Ò-ÛÔÊn¸cÎôı5ÊﬂäNm˝˘ü˛xbÎYR¸¸›¯ß∫}<˛B™eÀŒõÊcÛÊ≠CÃ'`ØÄÀ•hõQ[.î+ﬂrwÛ›°¬›Ë^ËÍtı∏ÑF˜¨‚]≈GÑC™Pj˜cDúû&ñùì∞ƒC’0” pn˜b›ÚØ›°#]iDKìΩ˝zı∏∂l≈∑jÒƒÉ Ëù[˙—‹ GÒ¨oç€ï[ "˚˘ºÿ^[S?ó‘ÖÅ≤ÄÔ yÊ◊]?JwU÷oh›±ˆdˆS\˛≈Íæâ|∑}ÓEa†$°y˝œwúX´(Â?©≥9V~tˆÏØ68lå#!πö™hø1GxIˆãéRáÑs@;Årº∂6Ö˙UW¡G*H≈jënY+gÂ©é—Å†ëe≤F9FZá#√ë	ùÏçUÒú óê0:x˛ôFˆﬁÛEπ¨œŸ;·#N–"ë‹:)éø˘Ë»2î’πZa‡ë˘ﬁC3Ò–Ù;=E[å(†ø§À!˘˘KôØí˜ÀDñ—ò
G≈%e.„`è&E∫Râ:øÚM¯„>Ô`‡ø	ﬂa.ìùM÷gè1lßeﬂdñ}∞ùﬁÖÉ`éQ¥TŒVíy°ˆ≤…”ä’ó&Ok≤	[ô¡ÿ»∂o¡€∏ú	Ô>YÙêçàÖ†∑ÖxUÂr@Âxs`FÉñ4ÖΩivò¶Gá˙«s„d…LhÖD§≤ÚΩ•<U')·5Z™¯»^ßU∞e˜›tìÚ2yÖ?Iœ*ÈÄÚÄ>V\«˘˝Ù∏Ú{zE˘ú¸Öˇå˛UπNæÊˇEo*÷óÈ+ ≤èﬂA˜)˚â‘°vìM¸F⁄£l%ØÚ“|„Á”ò≤J^E;…£TŸ¬§â”ŸJ‘&qƒ¬ãî*§àwS©O$ÕÀ;åR0îBã$’à6K§kKekXeINKõjÀÜ≠,¨≤öé+®2Á$&íÇd∞"ÿ–Óp3b¡«UÌjÜ5ßGgï0ãŒÀî÷p|>«ÒNáé@ë¿0úÖ'ƒ¢(îJr©€“ÿ⁄œÇ°ÿ·Åº˝œ«√@€A√›æ<,‘HÜ¥M∆ÚÂm‡ÖÀ™ÆZHö4∏!2‡#TSj¡6åµ∫6Û·D&‘"∑µHQ°ñMdë"èñ°Aªñ ÏåF Ì.afp◊∑k¶áe¡N†E,ÂláU$èı©zCC'€·Ilaä¢`Ç—cvuÄ≥⁄˛&~ÇR	øofÃ/ÃØÃ#ÓÎ«-¸èüºŒ^ "€	ß˛Cv’ 7mûa}≤~,YímŸñ,€
∂Â¸·êÑDI0PG$íH„q¶YYíﬁ.	ÖÏ.Âgm[ªB« ÿË»∂ZÿVH$¥êµlÌ›Æ[°Îqti)∞î^/◊•∑⁄Ÿ+;ÉÓfüıJüd[zæÁ}ûÁ≥√2s´ëMë#ÓØeâ⁄…+$.:≥yA¿¸≥óÏòU˙?ïìf©≈jã⁄≠ÓPI’aˇ:øˇ+t˜tn¶©Ók‹4πî6]J”îºÑtÓ«Ë|¸ÿ#Vuæu·óØ<∂d˝Ú≤ArT
} ¿pá”ìºJå•Z
y†a#œ¬Éêìg·y<Xõ2v≈Ï5ˆáËN['wå9*jßÖ˜ñ≤R¨lïÿr°Z®∂”V„tnª€Q.î€óŸ∑Ωéø∞∂mÃ6Â1u7≥[ÈW)Fr3ú]X-lûˆøH!»snûÁÏúáó•ló√çZ‹Én‹Ì∆Ç!. ŒÉYÅ@gç\åw8ˇWÓ uÇ:O]¢j†[CA≠X√µêÁÎ®ÖÁn∏èöÈââ…Ñ	[ö˜Â9≈Xl†0ö˙o§£ãK;dO¬¥$ç'-I≤+d)ƒ5ÕÈºè™ˆﬁuÁ›cZ˙:_M˝¸ ¶5Î€*ØΩ€YYø<Úªõ‰h˝€ª^ºò◊<ı!Z|<J≤¨ä4£vGö:T;˝1Ò9$åt…X8‚VOÁ],  Fx Fxº—V≤5o3µçﬂú˜>wE„‚ÏZam8Æm‰⁄ƒˆPG^{¡Vµ_}.ƒâö©UY≥t≥≠äOo7j¬4¢'‹£ÌÔ‘nÑohTîùÕG¬-∆ÎZ[«WÖóhù|´÷À7ºáˇ~¯{î)ÏbXÜß¬î¶∞
/ÖÈ∞∆ÚíõºÜ‘ªº®À{ÿã{GÒVÃ˝À˘b≥¸»?«m¡ñ#≥°k|AΩ®÷Ñ{— §ÛÛ»ä>%_ÃA bŒl∆{wZF≤·íuπéŒÕÒŒ tú WØCwùô	TÊ\û·|›ÍÊìò1/æ“úΩUé/†F7ô°¶':ôàégÍ¶Ë8Ùy¶”ˆ<¸Í"¿„“L˝«ê+x†¿—[C¢yt…∞ã1>(∆ÿÙ«né}båÒ1÷k~\3Í7Ûäœà¨g>;ü/óé5¸ípµvÑ}9Ãbâ¯cG∂dÊ®4MÃwô^^^$2!ã¶<nY"“Ã2X-
˙<≥o·
}‰”ñÅÌw_Fn$”©˜\}};kä
Ê°Ôlyj{=u;u}ÿ∑ª∑QØÒãÖöz€˝á∂œﬂÊ{6îÖczvQ€wŒ˝‡Òø?äê…Ø–§Ëa¸]+bäâb≤ÅÈfv0{öB$ûMXp≥2≤Ï#∂ìàFsñ¢É®€nv:-BﬁçÔ¿˜‚ÆXìøûôï∆Êì8ÃJ⁄ﬂìï∞Y⁄Z5>£Iïi„Ò,3›]O≠$ûN≠"∆¶¶˛ΩC”IPñf∏++ˆÊFLøf,≤ïùga!HMêÑÖÃÏq‰∆qî	R¥)jà†-îï&ê∑0F≤V‘ÍŸnÿ(ä$¡xpÃ ˛ó·∑)\>E”÷ N"üA˜Ñ°ÌUf˝ÜÃZ@qåÉcd
‹{∆1_åõä ∆L%êcŒˇ∞Ç8@ı¶w@È*¨é7Ã«ƒ¢iè0móí7—:G¢µ…èKcÚ,^ı’oí·ük¶?!
âEòÜï†c#Ì≥HUÚ’˙ój≤Ø9Æ;ôr•Zy(ßMiœÈœyV˘ëÔàoƒˇGﬂü¸EÒâR§\*ﬂW∂‚˝¯Íuë‚^◊ﬂw‡j§dÆ≥Äè—B=bÑÛ`£®zW‰´©VÕé,Ï˙Ba™C=°~©™ZÄJ1FÕué≠Á‚ê·w¿∆Î”C√¯ÊSÕÒlÅÈPp.]·t∫¬pÖa∏mYss¨˘Lü≈ÊpÁi∞hCêtŒWØ#Ω8¯√bÑPi~Ëa]óQΩ¸∞‹%[d•¥„Åô• &ËËûâÑ£ô£Ò$$80˜(–	=›Áiµéföo®HE=ÒâÃ¡ô>∆ØÍk"ﬂé‡âh<ﬂÄ	¥é{fC¬¥‘îrã[íCfGRîNweEyt)¨|êÈö7¥-ïó°÷ÈËÂwŒ◊Y¸Ÿ©€6mY˛B‚ÖsM?{ˆÕ]uk–˙Ú€ëäÊ™KK6¸√¬üÓèÔ9ì~Í…Å
≈Z]=¥˚õO◊≤ÉÅ∆•Ró≈onÂÇ¶íúäH+@> lÿüNÏ˘Lúû2Ê⁄b˛e~\l¢öÿ&©…¸ã¶ à¸Wô)Q«◊πñ˙˜”ñ c>òÑ!ívõs·≤ŸÏ+á¨æÓ,îÂ»«-9∞pÃ78‘çÌ0ıT]ú¡ªßrÂD≤Ú„Uê"2bﬁf~ËÅ%·íf√÷Fµ±mRõ∑#@&‚X"jÊgÄNÑU" ñÎqÅreÑ @ Æ°±T*9≤Ó§!Í5ΩâÔ=—ﬁ⁄Oé&?€ü∫ô˙2ıYÍoÎ‚áŸ/÷w>~˙œõ™¥û}1tÇÇ›0õÌqñÉˆ±CÍÛˆ*‹E«EÔU«Ô-ÍñıñÎñgärÕsÕÛ‘äµRµ7ŒupÙ|±B™Z∂í[Ìdø}èÚíxTOKåêf®_7Î)—≠•º9¢dÈÈjwÍ¸("00ù6ÃÄK1Æ√J˜OGA7	8îidé¢Vƒõ;|®2¨œOá‹äØ9ÂJ”é+'¢ìQ£…ƒ8069çBÕ∏ `ö÷˚´ +Hìt 	T$Ê¶ÓÍ;˙∂?⁄–ÊAÓË‰üo•Ó ibÏ#¸ü%´◊Ï;vÓ–∫Æ¢◊∆P" {f≈`◊ vﬂö·Õ^céß‚l\Ã∞Â'@ç)ÜÈŒ⁄ëÖœ∑Ë‹|èÆ‘Z™∏ZOïrêa‹i∫ÿL÷@¸ß;L+Á|2ôb∑cægLÓÑ¨ä⁄\yÔ	{˛Cwµ GQﬁÒ˝ˆ˝∏Ω€›ª›€À„í3…m.·.‘î¿mHåPh⁄DbÇS È•Z #A,≠<Bî`µhK®”tÏåTßcKqZ⁄‡‘¥≈@%∑Èˇ€ªÄå”dˆ˛˚¯vøÔ˚?~øﬂ4õ1.∂„l…i#»πìÌ;µl∂∞≠ÕëHUnÉZrjÙÁSÖ^‚‹¨˝yÀqÁ¶ÛÀÅßQ(£%Íü\≤πg˘◊üÌ{∏Y†º(ÙCRÎ˙…˝+^Ì¯˛}∞ﬂZÿØπ 
–èÜÍ§A™ﬁ#Ù ;ï7ò‚I·§<ò«Û4õºèmÁáﬂêè±«ÚŒàg=àÙ‹‡ÆÀrÅØ@∑!t€´¶|˙)˝]ù“›lß]ÎÇ%øoÉ0’ΩÌ^“kjXÀÂßPR#ò¬‚îkÔäem|r÷öÆµ} ß˝‡RBÅe∑i∏˘-i&vw©ƒî–≥Iî∑ÖWÜ˜ÖÈ∞/¬€≤/œ°a{º'’5(Œê2v¿¥Ài”˚‡ ÿƒXÌ*ët∆ï:,Fhx10HÀA5∂Cf]ı‚æ@¿≠/z àÕ·#Ç8”Ω¨ç§°˘ÅÒó0Ç∂∫”{míOÍ≈”{mp·~èx(Ë$f¬UÄßx1»ú„qEê?´yÇ‰g»úˆÒ!Áüœt¢¿˚#Hc36ıÙíY-µ∂iqMBΩ˚èÓ∏ πwŒ8oØ€:}Î…uuèa‹0° ˛jŸ Ì©”hTA+≈j3›m2<} $uC%ö°z˝>BÒ˙°êÅ˜I®MóH	BdëÍ3–∏Å|V‡ªW·”¨? 
…4?üo‰)æ\I®m*©"⁄ñΩ˛(h#˙ç”i‡ú<)#\;DvŸò§éÅÍk∫DòP&∏±Ä#?’S}ó„!“’ÅSÉúã
zR/x-1˚™˜¨Y˚X¥nÊå™˜ﬁsÜ˚Ëh„¶ûE•øV™ÃΩ0vúö„÷æ≥ÄnwDÕ≥}¢ŸBRÛ»]ïõ‰ÓJ∫ADMAI2IŸ®é¨£ˆ5öÀöbM™o˙n®7¸⁄t9iL/ONÈoÃ-Øüt’ì	ä€Ä≥%è,UxdÀkı…≤ƒ©Yä+‡®[n¢{U7IéHû¨-Ø»@IY÷V¶≤Ö Ë˘.Ò∑1pä|6^q2v∏§sfà≠àI—<Éé
ÂÂmØDï AÉ∂H$K#Zh -Ùπñ√eD…\ö ´Ãµ’Y)>¡ˇÑª8wÚéõæÎ6‹…U„Îµ≈≠rqÀ◊Ë,[[ÔL∞òÂÇåú‡˝*Ä∞\´"––í%≈ ¸Å€Xˆ]TÀñ7≠¯Rô_^˙Éuè"tÍ7›àõŸurªÛÔøéml_æms«“ç÷=z8bTñ<≤˜‡—ÌÁëÑÚ~ˆ“ÿ}ø8Òçö°m^r„õ/ÔÂı˛ó¡Y/ÄRo\7à;ÓCE®RôÖf©AˇE«L)˘5µCe"˝UÛS˘∞S)N≈Ä.!âQ^∞ãKSá4. ‹!1Ó*M˝¿Ï7….Û™I^1ëI¢ÜÓ¬åÌ◊—UÈ°`:ÎxË¢j»‘ ¡ŸhÓ ≈–«Èi–ïWº´ÛÅ∞@ì:§r •;ü¢ün~{Iﬂ¸Bg∏x¡åÜIgd¡ﬂ˜ÕÓ⁄º=≥É¨<–RUøeSÊÿ4‰ˆãPà·îÇ^Ââ!BÄï•U1mçŸ-NÁÑ+S$¥Ñ~∏¡P,G@g ,fÁàè‡ÕV–D,√r¥Hr¿ôn.FJStàœÌÎˆ>“nyRåÇwîâ´„~ºh8^D!gÖËcàv∆n~Öéﬁ¸"¥"‘+îàˇ‘¯Ö#≤ö¶ÎBìS•P~÷ñ±áƒS‚Y·ÒCQ\DµS§ÃôB˚U˛qñ9&\§GË1˙Sñô«Õ„ó±ÎËÁÈΩt”ÀˆrΩºXDklúé3lW¡'‰πÙ\FM*à/2¢@±¥ƒ–,Ïíê$û)QîËAÚ€vì‡´ã8ƒ-ïI)ä∫	Ty“OÂ$6ﬁwH]eBE·á»F˛qwÉ;æf¢ö®Ò≥B$Eƒõqp[’WÉ¢∆*0€ÂpÍBsPãÛz∆˘ÉÛÈFÊƒÿ(z‹˘^Êtaãs¶æÕEC>ä·X2çŸÕfN3Áò+Sƒ¥3ò~∏¡¿ñ(êdTQ#BÙ¢ñãS2#Êƒg0◊zÇ`w*Zh˙É∑[a.`!èŒûï‚Sf™§ûºóø◊¨/ÒSâÿ"°=÷€{ç=¿˝ÿsî=Í9;˚(Ê%bâX#<8ªccv^A*◊›ÓCÜã–\^!¶çëã∏ÏAsä™Z˘QKÑ‘Û)QMµ[™⁄U¥iêl∞}y˘—¬∏∑≤ µ†∏˜VY4ja≈5@ñ+BÑ4∂ˆ4X∑C-ªé8J≠îeyF*aΩk]¥(üUdu[a[S¨qã∂BÂ´ôh¢≤êœbeÕ(=P“Ë™Vl&JWqÀ7=Ç˚[åç‡œ’qLK(ÓèË∏?
∫]R–pKŸ∫U ∑´z=¢∂û^∂sJ√´ã◊ºZµ]h-òﬁq∑3NO´ÌòÏ”—o>¯–C∂-Æﬂùi&€^πªfˆ÷ùI6Ïmô‘–≥'31€Å—bf˚lìÛ˝-|O“¢•‘ÛıæèÜu°MÂº2Îë$ê™$äÑmáè¸?h•®«ã˝+Àû[ÁAWÅÂÓD8◊S_ πlaL®‹»êÊ:	ÄénvÜKTœ˘NÄÇŸ˙~kÔ¸"2|pÈ=ç=NÌ{´Æ£Á)åkAøˆ¬NeËvvŸ≥/£a˛∫ˇ∫Nü!/3§bBŸ¨4˘õåfsπõ›ÕÔÚ
Á…?1Œ{Üôaˆ≤¨‡ﬂ!œ˛äˇ≠áY√oa{xJu≥P
bh.PÕÂµÁwÂì˘ﬁqG{ímÚ≤¢}Ç˝ÑNehˆNìFò˙P´?•¡∂= ^i¥Ïs<∑πLﬂøP ˘›'/8◊üC≈ˇ„ªZc„∏™Ω3wfv^˚òù›ŸùuÏ›Y{Ωˆ⁄Ò&ﬁµ≥é…Nä„8q\;”∏»ÿJÛ†Ñ¶5(ƒTà§•ä”¶4ÄpíFmcUH5	"NlàÕC2%RÄ
Q—F"˘ryDDuQ0â®w9w÷.Q¨fŒù3ØùsÓπﬂ˘æ”áçé:tö±^ƒ¸ÖÎÔP¯˘s≈Ò◊∆««^ßÒû,|ûúÅxΩ†OŒŸ´◊˘;¸åñasjŒüâ¥±[‘-˛∂»˝àH5ÓänYÓG\∞~‘≥AYˆz‹+z÷W„v{^Ø#T‰è+⁄Æ;≠0ëﬁ˘ˇ“¥No¢˝ûj⁄t
0òIÛ≤®•RÂ?Qüƒ|„˜?7Éô¬á3ªOu√_⁄øÁŸ„è8S€≥∑˚¬Ra±p≥ΩwÈØÏÃ‰≈W'ﬂx˝<‰Bl≥˚∏ù<√a—çwr˚π√€†Ìv÷˝îF$—£T(Ã)•®0y•[aîiÊà]#Pﬂ,√KI$z≈¥¯îHDÛ®v^c¥£⁄%Ìmçh^î¿¨?√√cò¡a_~óïHË–ÂºÿÓ*—P»Twnm)C®s¬ÿŸ9ë›˛ËÓÀ“⁄uêáòS”Rﬁá«hEÚ`€`ﬂ#õ?±~GIú9ÿñ˝«Íç
@åi®g/ƒXÀºiœÚ>>Ó™6|F¸¨vV?S=Z+
zªŒh?Vg‹◊cÔ≈Ô©ã_£ˆ™˚‘Q˘åˆÜ5£„ve[‚Äµ71¢çË«≠ØUäÕâM|ªºUÌˆ¥«≤´≤:—¨dcY+œV
ºƒ˘ƒXH≠V,Àäïñ]˜EeXˇr‡K5ákOû´=≠ù≤¶‚Í1| x1ÙrÌwk'Íx#¥cÒL–.´»TÒÄÚ7∫b=Uß™ò*;¥*Se÷Qt0 u{Íp∫7‘·∫ÚX⁄ãΩç8ÜñëŸ·ñR_UËK©·iöÚmÅ°›YFê‘ı áÔ†R+µ≥<∆<‚Ñ’kèÌ¬}∆^¸∏±à%l0ƒåYL“Ø*L“ ò¥'ÂõÌ~4lîæÆÏ˝Cëdﬂ¢å;6]≠È‚‹dy%ıÁ&+*K~ÿt|;U‹dµ[g’o[◊¨w->f)*!&ZÊÙ®ë≤˚I£>èó†„[U:⁄´†˜!ú∆6Ó¡d√òEÿﬁ &Œù˛ ‹â±›Ö Ñ°!mxu∞—∞·ΩÜ/5Ïls∆∞S´¡T’ÄÅ˜zå
c¿x“ FØiz{L‹cMf9¯°‘›˛R/õOQ˜njπªQMJìQ∫ÿWRTCÎÔwdmeÒó∂(kyO‰·o?TsäÆ‰Ë·%∫}YŒ9“√ÛÄá˛™†C˙≥–Í™°Ë@õ—Ó«ï‰j@≠P=êHcS;ÙÿÕUz`K·{ü˛Í≠˜nΩõ,¸”7∞˚…t¥,Å÷∑˚Ó˚7ópCjGo≤¨!–}ù>ıÚ?yÈ‰öU„ÂÅ≤˝[;èÎ∑∞ä*äaæ…Ω
=·◊vMÅtìj<-Ó≠Ó>è† CÛÎÿ–áXQê%D”ÌA∆ò1a∞É0Ã¨ıJ S»úD^†–ÈVd±Aj@† %®àMÜÿÑ°ıÚ˙y˝íŒÍ«ÙoËoÎ:átØ’”:—√Êÿ
ôËúhúX81ÉÙ‚Ï∫æí¬Ω€ﬂÍΩÎ(\ÄW@\∏uhÑØqY·ˆcê≥∫ìSÉ&-)ı≈≥çŸ*ÛÙ¨\]VΩ5¥Á+€ûŒ…‚3œ`ì$Ê
ªûMïEn’6nﬂ¥fˇfÓùÔûá¸|Pf'I ?x≈6ÒùÊXëÛ≠L´ØìÈÙ˝ôÂ„#rI]óDﬁØ'D“tXBaÕˇñ ∫>¢.º‡¬Æˇ-ÄJ-ÊcÏ†?ñÂù0≥@ú∞õöË!˚pÀO?xaWÏ»w|°áœ˜Ó˘ÃÖ”ÃX!4∑o}˜·y<í‚îÅ=
q 8b∏§Ÿê®·©qQ„wì0:b&j∂dŒÃ≥≤À%)2(6FcM—î,T/_óX€vpU4#!N÷QXÆBµrµ»#H,A“îÑU≈yó,Çëày$°|æ¶1Eia.bk2íà,â"√`é≈úJüï%3≤Z°¶U[%™aò^)/uÉôf“∂LòúLÚ§õ∞‰GL⁄1€£déÑ∞8¨\É⁄
”‚JÖ∫ÓÙCßÍ?ºi_€üﬂ·ßîúj9ü‡,Ì4,∫N·√1ø—‘‹‘Ïrµ∞Wˇ¢≈‡›ﬁ_·X≤∑Ù«l
÷◊3Â•úä†÷AN¶⁄^ôïœH'FPê)'>Œt±\Ú)äñbS|\Œ±9æÉÌ‡œ≤gy—M#Æ€)î	·à(KDâ ì9]KEâ£$©ÊÍ≈§T≠¨AÕ‹±mf6s¬Ò&G∏aqX:¢å†dÑ;!ûêFîõË&π¡›oJ7î€Ë6ôÁÊ≈€“ºr›'ã‹=aQº/-*ı‹tÒ[å¥dHå8]ºÂxıîïkàz<E‡p-èŸ´0 6òÂ)va`ÃÙ:à8Gü‡@∂©'Û ‚TêH'ùjä®ùôüzS&\t∫ÿ5…K"å€Ïµ,R¢´ ÖÂ$Y]ºK8éZäÖÇ§wﬁÕ∏°(\EÏFQ»˘HÜ›F,vOEqXΩ6ÉÕW1√]Kfhi…/ÖJEÄJ”ü_÷(ﬁVÁÉ`Û9˘úØÑ∫@%v0:¢»?%€j"æwEÕA¿˜ ˆe[°g ˆŸ“ ﬁ‹ôzs+M¿È"î—˙Ú”«X˜&∞Ô˙UÏπ¸.˛~u
j¨Éô¶˚øn1óz° ‹ÖÌdTôg¶¥$á˝¥ÔÜO∆T=Åû.Á:∞zAñUvÛ^˘y‚g¸_ˇ êéi|	ñûGmp'Q4êÿX‚NWNdËhkeÂô $ô‰X;Œe)!¸7È’’uÜˇ{Ôπ˜ÓBÑEX`•¢‚3òU÷ê£#‚j-±mFëë—Ãài&ç:J#mjõ6ßçèiÿvS3£¶aö1%ÕXõ§Xïÿ⁄FKÄ€Ô?w/≥Æ∂∆tgæ˝œ˚¸Á;ˇ„‹a∑*k™¢rm†RHÅ¥qc2©Ä_…	oÜ¢zÓå^˛Ÿ{%Îππ’´gxÆˇﬂï˘6ıæ8˘e(©7c<~¶‹&ºr˙´$Ö	H
GÑáZ≠kÚká5èÚ ~2Î÷•@ÃÄ∏¢xOºìã`”◊é¢¬ÚÍˆZ6›fåñ5dÿ0ú„cî‹æõJVﬂÊ‚°≈Û6îŒ*Ò=4vÈ"®èQˇ’£æ^πt‚ê∏Ûj*»¶ƒÕ˙ª»)îN◊Ûœª/ª‘hë*Ú3ã2´\UÓW≠˚Z¶{Ñò ¶·SS∏Ñ‚MåS&∆≈ƒ«í'&^!èöê2(=)-5%6I	$)Iïædîfƒ∫ï≈Ó∏-∑ÊÊ$s_,R√á±— ‚h%ø2î∏XdÓÏ·êc§ß¶∆'D˘“≥ìÛSãRg¶.I©„‹£]√=qú~ƒƒg´	ã)—ó±÷N0v>ÌÒ#õ&^ÈÔO-’˛ﬁj˘høQç?v—ï’~M˜pØ?îfÒ‡¡ÃhºV˙Ó^Ôh§ﬁ¡qY
˛MÖ{÷¨≠….û4qÏŸ≥}ü4i^≈áß=-}ÓŸ9ﬂx”S8k˙_z^”UûTD_œó”D6«OınœæÏR¢Eö»O+JÎÁ5ÌÆºÇ»{g1%)âYLãIEI3ìñ‡âxGSÔë≈Ø»€9ªçØû◊Ù÷Ó)¨pÿÔ~ªÆ´œ{?¨ç[Îø·Úπdœ¡˛A,OäU€ªª{z=‰Ú ,•»Ä9©ØÑä=‘››˝î'b]¢cçPìZB3◊~O´D¶òÉ®B?EîOË1Ù≠ äµAî&Q∆ØAΩráZhıb|9pÃ ≤ÅÖ¿ºÊ ì1Á–å5Û:R^†Âf;Mƒ^Ïæº†ó”NÙÌ6
i)∑cØ≠X#Â=hﬂo4S çËØ‡±RÚ¸röÜ˛<îwËÂñe÷ìâ6BπÌâÿ;Îôç˝kDçuÂX˚QÙoÑ,Éú“7Yñ/yV>„f.Éü:¥7 ≥Å-¿B√Û0/ızî£°óÚ> F¡ø:ë^Öâ˝ãCÁ&ynú£ˇL–_Ítgî±~·ÄN|ÆÀ@;Nònë®ø5Ù∞6Zﬁüy †⁄NÅó>>ó~—˙Çª{ÁjtQE˜ª»jÜûE˙1jD}‡ó®!E4—JÌ:Ó‡=eÏ¢£ùT≥˙9U?•c(çÛ±˛<‡q¨yR⁄CÎ`}
ô!.‚}TCKÄÂÿ˚å√sÉ˙T‹Î|åÌa ØœOÄÉF`5Îá˝Ûôs‹˚Jyﬂ+˚ˆôŒ¿û8ª}Ø¥Û´±ñ"˜±Ô¡ñ ˙óÉ”_ øﬁ`H;AÆ’Lö⁄l}§ Ì@€∞(‰1ÿ?
„£§Ω¬fÿ6Ÿ>ÿ6ÙS“VÁ∞Óˆ§/l	˘Ãìòø√çCÙX√1ñ˘Y 6À˛‚¨Õ∂≈6„Hi”+§›üÊs≤MÖ…Ù Õb‰æ∞-G≤ﬂa›u,5Ø‘iØ÷A€ÿfŸﬁ…º∞≠±?≤OÑdiÿYÛB>íá˘È“÷aãét∏Ëó†ΩX≥‹hÄùvQâ8G%⁄€T¢ØÉ‹éÛΩé6úGt ÜÂ“LWêrpó31wOÑldò rÏıºh¥_Ú⁄°äÆ∑XóuRŒË-jù,ﬂ&#°Ì>ñåæ{mˇ:Pﬂ”[h WÙÀ¬y∂≥Oò]JêÈH¥ûF∏rïF◊
Â∏YFÉË:∞RhÇ†Ò"HE¬K4Ìe∆#2Ón√˙ßî.™«}=gz)KªåÿàΩ‘˜ê ^rFò›bsë∂‰H«^#%€«]H“øk⁄Äs!¸ËÑ=N·‹¿ÒYÊƒh†ﬁ∂WÎjø}û°&»:ˆaß#"Ï”å¥ÀH…πÖ„ªÃ-SËQÔúü„#«8éëÁ8˜9„#eÿ¸ùàíq∏ùÑ¸:( Ú±∆âPi√7«u¯Ë%„]´Õ,≤⁄¥∑¨6cèı3sÖu⁄8f5·‹9˝95h«2ˆ''ó2Oúù<™g”≤P<€+«bôGÀe c¸o9-≈∫os^e?‘ö‡w‡Î=#^¶ÔâN⁄›cµ_⁄ÌbïpLµ(£1ù˚£µm≤∂¯åjE /CÓ£8√§Z„w<«jómÏ>n”–nÿ]æÿL?’”|æ+>á:÷zãÔ>ü‚zöˆõÓ§Ω¢g‚åß§‹'ÌâÁµ∫˘|ÊÉî§k8èxéæü2C|Ïí\%G;•É^”¯£|oê˛>∆ˇà÷ª¢hØk‚”J1K‰^áiû+ y2_ˇ˛—+£MzÇıoiˇá,KÎÜu¡ø
˙º‰”ªh|iì‰«ñ[ÿ¥.Ú≤ç‡|sÂ{¢6˛≠6Zh´Ñ›u t‡ﬁ∫pñÙ  ¢≈˙cøÖ5à˜F˚,˘>·<∞ﬁa1Éîl∞?∆∞Ú˝á}µã–wmB,ôÏÍ¢ü¸ÂG
?”Ìß©|ûr}Plµ!€<∂Tcçı‹Æ>Nß°ÖJd)Ï‚¯ﬁ>ö¨˝ú¢ƒ2ºÆ–3j>m‘J`wWë34ZœuëG√µ´4]ª)ÛœF=ä∆Àqâ»„ó®TT`~ê™ƒ™“,îìÅù∞GÃ”è”˝;xg-¬:!®„0«M•∆îÛ≠C<NÓq”Jdàu4JŒÉ‘’Î|0LÁù8’˜a¨/ ·˙≤Æ˝zÜtºì~Úúº.Ê…1¶…‡È<0‘ñ}≥‘zj^Tœ·§:eó’
^ßD`jx]‘)õÄR@à:: 9Ú
–4'Äøã±Ù¨˝‰Q˛.`®øAÏÇDˇK¿ØÅúæp>wjá¯ÿjØÎ£®ê°Ê!¶Á›⁄'«†1b-‚pÅ’ –j)äaƒPéÈ¢µÌÂòQ◊á”n±cgìv7ù˛+„1~FÁ> øŒá…LñØëúüˇ˝æpøÄÔJ˛_§oJ∫Ñ7πiùTN–"Â#´Ò‹`ÿuJë|†8Áû–æI∂G‹lesŸé≤ü·‘#Ôınu¨˚D8;p`é¢ C|ÄÒ@d˘ ¿0ÿ∆ÚnØ˜Ô˚ﬂ0ó∆Äß)b.tÈºΩnx(ü°ÆBΩ˝”0F}.Â0x,‹f1¿u+CÌ§¡m6˙fÀÒìaºŒg^µˇp_˛¡UW?Ô›˚ÓM"5JACR(2jAúT±BµJƒéË`Å$òja¥«—¡≠ujá™ e(?µ8"ÂáÜ±R[€ïêÇÖ˙£b’X¨É-5Å©í‰m?gÔﬁ‰yìóà?˛Èõ˘ÃŸ›ww˜‹ΩªÁ|wìˆµ˝Ì˜â˜yÚ˚–W¸Õƒ£w–ÃURö¥πg6ynìmq,ÈÍôƒŸ83ﬂòˇOpv^Ñ-ß/tˆyJÿ´pú†È˛Çﬁh@´>¬sªÃiõ#“ÚúHÎ‚9∏u=m’îá`?Ä⁄¶a…F-oRæôˇˆ¿xÿ/ì€úÆÏG}L‘∑mïÔî®øˆ;Ç⁄iıoôÀ)ÔvYÀÿEÿ√<ﬂ@øZ,†uˆ,ÍﬂˆCÎ.ÍÁyøu$º¯ŸäåiNˇ0SıH˜–œ◊Êπ|Rãè”·ªVs‚oÚÒâm¸={∞…ªF¸˝{≤Ò]¢ìuÎÄÊ{Q…π˚t{«â-ﬂÛ#«!8Ëﬂk⁄–î°’—hY´πU?:kıˆ^´'SVS:Àz™ΩT;´~≈>dÔy/·œ-r~’Xø‚<í[”CÂZ8¡A‹ìJûŸç?ˇ!ˆì_£-(˝&GòÌ‰ÆbbÓ≥©ﬂõ√ÿ‘˚ìÀ
„ú«÷N1∂sN˚BÎGõ#?ENΩ‹1-A‹>’ë¸∏„$%ôãèñûr˜ßŒÂyrtnû˛¨ı8œ«û/Jx~_–Yó&u@OıûtÓ—÷ì∫#ßæAÈÊ[OÍí∏û§”ˇù˜^§gJ9o1âsw¥pNG˚7ôW„Û˚ê<«ÌÁÕ’É;Â"€‘j9ï8r‘π{◊…î…ÅÊvÕo≠RQ∞^*®?£òcj£‹gÍRøFKˇWCNˆnÍ°ø√>{Ö£∂ß˝ú‹∑™œ≠>dÕ¨Ô¯ád8åÇﬁ∞nlˇ÷‹!ô{´GÊ’{Æ˜é9ÃXáÛi¡|ñ{ﬁΩÔQ/¶^L,.6Hyfì,ß<[Ñ-"æOÉ´âŸ’ô-¶-x“>sˇU˘Ø…8‚¸‘å'7˘çf1˝öL	WçÚÄÊNÈªîæ˜R.√áe1„¨ßˇ|Õa	y∞Y™É•ú∂˚4√˜yˆ{¨Ìw“oI9q~ ˇï8;,òŒ<‰´‡4õcé•Ì_xØF	µ˛9ŒÂøØ¡ïﬁ∆^i˚ﬁó>Oºi◊K„=]¥FnëEºOaç‘á_ëzÜ<X4Rñp[B}°Ê´8Ø≤ˆŸ∏åv[ˆó+ÙΩ{∞≥UÒ;'5Åıoqı\≥2wﬁ∏_A%k3Å˜ﬂ"K®/ÏI€0Œ90¡˛‰|öõΩ˛fGdÂß.«_◊ûÛkd,„úIy®]€rÜöùo±Õ’‰ÏL/∆Èe}∑kúÙ%ûãuiÀßÖbmcÏæiîY∫«®ü}\[ï’ e|ØÀ°$3[J¸π2!Ω∆lnÕ§˚»ﬂi˜Ï\ıS—˝Âˆ‹ÉÈ’ú—W•èñ˝=Ú ﬂËn«Oÿß´tm˝Rg}\œ≥èçL`≠ˆw¿Ÿj«Ï˜◊2ó¬z©?éÂ˛xª?˚πΩYÊ(ó¯´ÌûÈÕ˚Z_ÇÆ›ÕÏ—é[àgú©ÿ⁄µ:¿∫œïÀÌ;¢©ºµÏ[÷«[Åæjî+„gæ)U·ΩÏ◊'ÿ;≥ò˜b,ÅCRúç>úÀ{è°Ô,ôì˛@*î‘|Ûv⁄ßå#ä'R·£Ãâ=ízWÆÚ∂ÀÕ¨◊¯!,‚}ö}Œ>ªN¶8NW“kRÉ¯ˇàÀ_é ∂ÌEG≥cU<gﬁÇñÙøò{„ßÒÎﬂëOﬁqÏ’Ùπ∆·A‹üÊOb≠>Ne˙™ûÑvµß$qÌ•IhW;:	Ì£ª#ﬂs˘¸»◊>$	ÌC>?Úç{r⁄OÓ∆øKì–~ÈQ¯ëoù'°}p7~åKB˚∏§ƒß'‡YÓ®Oi˛$WﬂÜ›Ä={<Nô{ØôÍÍ[›s◊w†?3¿qL·Ú±yÇÒË\¶o‘'û«‹@π	˚≠h.Ìõ}&ö€‚ÊÃÆræ˛~õSWﬂô;˚v4üù?≤øãtåYÊûÂÊ},Ú;{"ˆ—Û˙øæ£Ì˜XÜ„gà„m˙n;Pﬂ≥îi¶Ï”n-WFÛ∂qO4˝`ò˚NG\ê≠‹gjÆ.Hã®’XkcÓ4Èìì´¨∆†¸sçwﬁ¯ﬂê˛é1äT7h∑˜I‚æΩOæå>A+XìGˆPã1fK‹ºKN’9¸–+å≠yW5á∑G∆+Vkl≤π˙BÕEÁIm0üI)„óÖ;•.òL<çÓ≤«Ñ◊Sø›Ò#©	BôY∞BÍ¬W¯ﬂìã…Wïq{|∑Ó6&3TéâÌ1#•∂¥ﬂÖñ*ïKuæl©fÕŒâÁn_áuzœµﬂ]◊¨i˝*\f}∆_ÏÒÿ2õãU;Èölì9¯3TÛ'Îvºüí/'rÆZÂ‘∞}±QÊ¶ei8ÖÁtÆ_®Æk_˚aﬁÈÏñ°ôüI_ª÷è å‡5÷ıF¥¥≥‰á∫pîúòY«{’À2+c’À¿L_Ègµ√^;vd„1÷†g»rˆDiR◊ƒ:™]ﬂºƒû@¥œ·ﬁG≠ÊŒú˜∑6GoÿuœlêI˛Úuˇà”á	˚Óï˙`Ø›ì≠˛:_&á∑ì[◊À≈¡f©ÃT¢”«JeA©ï~™œ¬©ÏM’k‰Ë`†À,Œ∏©‰˚l√ﬁ
Ó|◊∏3˜2¨s±cB‘nœ&mmÀ\˚t∏¶EˇÎÊŒ®‹v0ﬂ˛wGÙ|õ∆*ŒZäï=ËhÉè‹ô˝PÀ9Îºÿj˙Œ÷ÈzY‰tk˜6°?ÛY=√|Áí=È…ŒvvT\Á|ÓéP-gv∆::iy∂ﬁj;kÕg˜9ª]˜öjΩ§Õ—’]⁄|˙µC«∫s€HWœŒckc}›ìm◊ﬂylª^Ô…÷£q*∂·<	UÉ∆÷≈±^÷ÈÚé˚S“>ÄN{√ÈX’Ôó∞ÓÛ8s„∫C˜ù4õ¶†9◊#¡˚39∫Çrû+	7M·„VÔä›‹Oø˚…/LS¡Ä\+}|^a6¬fxﬁá'aìó2M^äyö&¥zé%w,¥˜ì	]‘3o=ÛT3Q<‹ÜøDÕw›Åfó0KøkÏ;6k.ÏñùÃÉZ(∏áyÓ°œÊ9bm≥Ø{ºéÒ∫nÔ⁄Ô˚œÔ∆˝¨ﬂë1Î∫#ˇw1Õ Áıﬁ›˘ûŸbv¡>-sñ^w˜¨iV>œ∑~ÔÁ!ú°ÁôgõÕ¨Î?‡o£œ√3O›[{@aÛ$˜A≥√’ı,*¡~ÛJ8÷Ï”s‡=m)™•∫ZüZ≥ã=∏/\å›IüÈˆé§⁄ÎuŒjë∆w≈≈æAÖ;»_ƒ 5◊4∞∑Ö¯ÛúL˝∏Ê3]^…8BºË<)U^V&kπ€ˆ"&˝’ÏWòÎ.«6«¬H˚ô?¬—:€ˆ_Â‚ù!Â
ÂëÃ«,¶ﬁÈm’±3"≤ÔFÌ~≈±◊G	s◊ﬁÌjæw±’/KÒm©î°yÍT/ÿQ,ó¯3e>öÚX’™ÏY∏EŒBNpb]™¸–çç2—Úœ≠5-äj"˚ùe|0X∆˚oÒ’∆E‚§˜wh¢Ô˚hŒjô√ΩU˚Ë™Uyç¨#1≈[…ÂÏ=Ç≠é=ÏRëöÅF}Érî”~ˆV∏çÚÏÌp%¨sÌ?ñäL∆ PVÒ‹∆»Z“ˇcølÄ£∫™8~ﬁΩŸ]Iv!∞Ñ|Ì£êL¯»G–¥∂Ü›Pô"BíñéSi$lIw3…Ç≠é%ck%aJS‘*%|K}´mæhE´FE[∆Ü“—vFãLGùjYˇÁæãò÷ÈttÊÓŒÔùsÔ=˜æ˚Ó«πÁäS“ƒ;ê/^Ä›C4G\Bﬁm ,taõAƒx\V´Ï,ÒﬁÒI íÆ>eg¡D ‹^∏‰ñ€‘æc„˘#-»⁄Üò*t§˚=ëtøÒg‘S sö0ìó˘>ÙåGa∑¶Î¿§/äg)∆»Ë3îÓó€Å+='È&œV≤ºA˙íg2-¬] ‚ı„^Ae?Âà•ú;—eæ€≠ÕhKˇÛˆê<É~úS<Â ~Ôi™»|˜^DYË:K— çuv÷Ωı8ôÁ’Ù_yØ«πæªÈﬂ.ƒíªË”Æ/‚Xãœíq|ÆCøâ◊ég:’¢%ú>ÈZ'∆OÛ~Xﬂ¿˚7ÊÓ·XFÌÂµÂ∆ÇlPÈãê’b∆·cTÏ÷Ω,∏c¯	¥ª√caåÄòÖ3@øÖÅﬁœå(ˇ@“;∞øÓÉo©Ç^uuÛYÁÚ/sÎ≥(Ãd¸vL=ÕëCà√ÎQÁ¸ËioÄ*—ÇÙ∂ìŒ°Èæ14]’Ω}Ù¥8OSπcºÏÍ4ﬁ_√\˘ÓQ“r;MeÜ◊€ï5}≠Ô%}åchˆ£æ"÷”g¿$tk9ç≤≥XKS`˜†∏à=˚kúßê„√·_¡∫; ˛¶÷ﬂWúˆüó¿Á!ûÜMü≥oEÏ∫ö„RŸü>¡~écE"˛„∫
ƒ˘±uÍ^VCüRæ>}9¡±(ﬂ”î RxŸœ∞2.R ˆ3‚œH'ëû‚¯%÷≈ÏÜ-–ó¢|°„ßÿ…ï®≥yo9>K˘Lˆmº·Ød|È◊]‡ÉƒH üu˙!˛@ˆ¬V>s.wÛŸ§|ßp⁄¬{†Û›EÌ€€©ò˜ Ï"£≈Kn|9cûxwz¥∏6?…ªÀÂÃA=Â„º©BLÛ6˙‰X˛ Ω´ç¶ÚôÌù≠Ó+ Ô`.Æƒ˘|ÊÒ9…ÛƒÛ’A„‡S
Æ∫HJ‹zû ìœ.å”¡/F»ïÍúÊq¸ΩÚï›•ﬁÁÆ;Øäk¯~«wáÔ§_q˜æÀ›µUÜo{Á‡&O-qœ˚A¥}Ÿe/√˝v<.5ø˛ÇU“>Çã¢‚}≤it‰qåƒAÃ =àPº◊ ëˇòßﬂ!Ûaá¨◊â≤·Ø≥œ]MŒ/ˇ3ÅD„`ó[H4a,Q0èh»{ìh2»‹° ˝+ƒ∑ù'*˛	Qclˆ:LŸN4˘•8ÍJ—ó≤¢{f]ß˘_°g{≈çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£qÈ’h4ÕáÑAî=ó.—-Ù(yIPÄ*©Å»˚ñ8N§ârËûí¯wèz≤Ó£~§r~sçiÆ.)◊∏”’3†7ª∫˙FW˜—]∆VXô‹¶ÒÜ´T*ÓtuA9b£´K‰?‚Í–SÆÓÖ˛≤´£?"MOíIU·¥zZKQ»≈î†8H“˝‘¢rÊ#’
ùüç»è)ã
îD®ìñ!oÍ'©M•¢êQXo¿≥	ñË1‘e€ò≤iI’^lÓÖl•u»K–Íˇ¢/‹j\µË‘k@*Üø›§Â–U ysπï™SµΩVı’§UH≠GiRıñ≠+û4≠™™Ã˙µQsq"ûHﬁﬂ5Á'Z[≠ç…X"^aFöõÕe±5kìmÊ≤h[¥uC¥©b…äÂw‘Õüiç56ó◊&öõ◊ø∑,•õ±6≥—L∂66EÔml]g&V_Ûıf,n&Q÷è%£MÊÚdc2ä Ò¶ D´ô@I´π*±>ûlçE€*>ƒÈ^B+0ËwP⁄ö9bÚÀ©m5√f1ﬁœı÷`¿õ’‰ø∑:§’ˇÌ¢|™æ=í-“a Ñß	vIay0ÂÀ∂¬Ωê„'(igZ}È!(ù≠ÚÀøfµ ZI≥ë›c7pvO*|´•‰ÏõYyΩíˆßÿ7¡
EÚQ≠ÚªZxtÉÁÄÍ°ﬂÅ4êÚÄ‹m/°Ö}h»ô ˜¡sÖÒ<“@¢˜˚-˚Ë7'Ω⁄ì ÀØﬂ£j»=®Â«3 ⁄¡ap
x(Åg7H	m7 vìêªÂ.;
D≤‰⁄Ñ¸&˘ÉBh}[*†∆Ê)Æé‰◊i)tD.¶! –Ïc®ˆ	ò/≤ÀØWC∏(ïïc`øùﬁåél∆+w‚i®t∞˝ÊTnêõ–ˆèSıæ`WÕqîT œZäQ∏èïqöJ!˘ d1‰*»"»œ & V˝ß¸´ÔõÛyr"MGqD±èCÚVôO lΩù„ºgΩ]6√¬œóy ƒ/≥i‰È≥≠ê9 √j7•2?¬˝€d&ZGÂó•è&¿™VìB˛£23õ•æ§>ïômuE∆ z|f=Ü%Ñ>Â∏j(n£°»8˘qYHAî≠ìE4rÅ,VÚ€r-Ä|"UZê_Uµ∂r£x}ç≥¥jRŸ9÷P$S÷†Ùà‹Ç	ÿ¢^ﬁï*Ω—¢H©,£* 0∆°mTãæZ'f≠3’âôÍDß:±˙Hv†§6ïÚÛ‘"?G]†:/´â6¥O)” ¨>9YÊa`Jπ˘©ÃÓYû=>WôÂ•∆ÊXÛé 6¨Û6¥ñ…‘§<+1 g®Oôï +‡
-6ñÎQ9…ôTÚîïÖò"YlOâÑêÊÖ"Cº NÛ âüã3<›‚“,Ï ]˘SG¶áƒigSàü±<)Ø¢±ï‚7‘MàÒ<ú{HúΩ‹Ò≤Ë£yê/!›Ÿ9≤ﬂûr2‘+zSË˚∑ÏÏ ¨xﬁûYÈ*°WôT‡*„ÉV§D«®M¸
r‰11D◊A>ô9$ítÚ˚b.›˘=WûÉºƒ≈3‚i∫2eÁpéÿ>ám/ãC69©•ï°AqHÙP>LøkóÊ#˜@™tZ»?Äˆ±O$Ì¢–¯Hñÿe¨0ﬁÑ—Nzâ%çªÌjn§À4C}¢KtÖÛ™√%·Ú~YURU^µ_ö%fπYmÓ7#±§[`ˇäÕxVì)∞z@tâ;£˙H‰m|ó†v<w*Ìn<[îFx˛Iz˘Ö∂q‰q|f≠h◊NÀÆÒπı˘fmu•X[%≤±´ÜÑh•J-≠¨ƒiY5)ß$“ß
$’ÙüÌé§ÜÉÉ„‡¢{1°π√£uÂ÷%”«=∫O’Cﬁöê<ı’˝ŒO≤ì£~)∑Œwæ£ôﬂg~£ô…Ævø˜)’⁄6icZÇñ°k¯A∂¢}}
}}N-e®-‡nRQQQ$¢¢¢¢HDë≤W E@@@à(Ä(Ä(Ä(°Ê[ Q """"GDDDDéàààÑ¬!¬·Äp@8D8 1111"b b b bDƒ@ƒ@ƒà0Aò L&&Ñ	¬$¬aÇ0âÄÄÄ    "@˚SÅ————"¢¢¢¢EDDDK[®u5ìﬂiii““““$§	§	§Ÿ˘ÍeZ«fZÇñ!≈nÅ›ªvãÿ-:^H±Ñ!AH"$	BÇêDHÑ$¢
¢
¢
¢JDDDDïà*‹
§àﬂ(˜÷h◊∏k‡Y´-Û	Ú%ˆà|ëÌêŒj‰ü±UÚOŸuÚOXú|ÅÖ»1yô	É{"ﬁó¬-`˙3Ù!tZÉÓC:’@?Aª⁄å3ÓÎ”gı;˙ö~_?¥¶∑t≠œ?Îø„_Ûﬂ˜ZÛ∑¸öô—zÈ>ä[˚Ç %îO <DP&®ñ–¶ëw˜Ÿ¸Mk”NˇcÛIÑ?à˚æ·_Dx≤[{ì˚ËNg≤∏Üâs◊9:#v†x(|w¶€Îè˛ º–´¢¡7€6·ÿGPZÖÆCqh
äB$®-Çx◊Ôπ	Ö°1»T)ÿ–^˙gCÎÂ´ıÔ{Y∑ >Ó[/É5º,Ïk/|Y$ª˘:´_E¸+Ï‹=¯ö'¢˚øm˚è'æÖ›ıƒ4Ï}/|v¡ˇ íΩ¸&|
=ﬂÒ9|oÂÁ<Ò.¬Œzbf{·êäé ëÖﬁ	Ó≤áp´CΩ‹ŒÙƒ)ÿ∏'N™hÉÖ’∆s?ã“ÙA ªÍò–ìÓ˙∏sX<èÄˇåÖ≈Ò¯—l¯`¨◊Èõ—!8)ºdèä«Û°÷q©¸+±j›ˇƒX‹Zˇ«≈Ìh√@Û-Ã˚&•ƒu≥°›s^À"& —á¢$ﬁóƒ9ÒæÖvO\õjö,œ]Ìﬁ∫»a¿∑-,Oºi5häoàèÖ#¬‚§π©÷óΩ÷7›T+¿¶⁄Ÿ_¡˙F¨Ü:„ÔƒºﬂâËOı˝Çû“OÈA}\ˇì>™F¿8j1z√>C3ò1ÿÿm96√±Ùî˘}™ÙQ=†©J¶qCco3˘BWVÀŒ•xVn]aŸÀ¶¸e.ÿ‡=gﬂìáÇ).≤,{>%_≥≥}˜úå€Y©Á.∏5ŒoÁ—*µø48;Ô6¯Æj∫1"^G'ªqkdÉq˛‚ç[˘<˙(1ú8”ÚçÙE°S⁄œÆ·Á´£ÚÔŸ9W~9öóS™≤;öœ ksÊEwCÎ”z3ÈÌ®≤ºª·+j}ôs™›WLÁˆê¬pöè"åÖï!ÃH1SÖ·~íRaÿ£v\8‚∆î!ÆßóÖ(.‘”Kq>Æ‚j;f&]3Mä±€°òã=É6]Ö(*hrWEq7h“ƒ&h !¬Òªéúí…œB¨N»Ã~»ÂÍ‚œbD;fÿ^Ã‡1ƒÿˇÁ5ü≤y}≤≤∏ùôf
¡Ã<Tê˝ËÍ∞\ælöµ≈äÍ0eW®p˘ UÂóÊe%8üñã¡¥Yõ‹>†{[uO”5∂ù9Ô÷∂ù˘¥7ÈLfÇó“˘z‚¥õ¸ü\7˜sπßÏ¥ÃUπ…∫ì™;°r%UÆ§ ïpî+ÛÅ:˜9∑f∞T˛ıãmØká{pÜ#c˘‘P†xFËçSc√ã#ﬂ¯øÀ€yy$òíΩêÍä&£I’Öˇg™Î(ö˚:]√ãß∆Fæ·w;]4˜Sloiô
  ô≥Y96˜û´éät.ºg%uQ˜0À|ê∆?|.ì˜|$+xï∫*ïJIªƒXVFÊ≤Ú’≥òâÆ#U!ùG€ÒΩ∂Æ.j´uwgª[Ë¥1	^VÈTÕÊ6V–È¡[óÆU˝U]SØ
Â˙K£S~á'¯Ñ˜8m¡;1IoıqKΩøîÎ'f⁄é◊UÂﬁKcS»PèUnµ›Èè¢≤b≠DW‚U´≠∆˝h]_E£XUèRÔƒj+€•ΩÖ@µú«bcZ*ﬂøΩ?éR‚™™ÿvﬁ.qZØﬂ.6ﬂ[Ù˝Ö-uF-—ÂΩi∑ó:É`'⁄Ÿ+{X•QgÖ†ˆ ÌO˚≈≥ü~` ∂endstreamendobj43 0 obj<</Length 21676>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 670.1523 cm
0 0 m
537.86 0 l
S
Q
q 1 0 0 1 37 524.7407 cm
0 0 m
537.86 0 l
S
Q
q 1 0 0 1 37 206.35 cm
0 0 m
537.86 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.013 Tc 0.014 Tw 10 0 0 10 250.0721 715.6797 Tm
[(P)74 (A)73.8 (TIENT INFORMA)73.9 (TION)]TJ
0.013 Tw 0.495 -1.501 Td
[(SPR)36.7 (YCEL)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 300.9913 703.1706 Tm
(\256)Tj
-0.013 Tc 0.014 Tw 10 0 0 10 306.4216 700.6706 Tm
( \(Spry-sell\))Tj
0 Tc 0 Tw 5.041 0 Td
( )Tj
-0.013 Tc 0.013 Tw -7.554 -1.051 Td
(\(dasatinib\))Tj
0 Tc 0 Tw 4.928 0 Td
( )Tj
-0.013 Tc 0.013 Tw -4.037 -1.051 Td
(tablets)Tj
0.014 Tw -24.42 -2.401 Td
[(What is SPR)36.7 (YCEL?)]TJ
/TT1 1 Tf
0 -1.519 Td
[(SPR)17.6 (YCEL)36.8 ( is a prescription medicine used to treat:)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.447 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.003 Tc 0.06 Tw 1.8 0 Td
[(adult)0.6 (s wit)0.6 (h newly)0.5 ( diagnosed Philadelphia c)0.5 (hromos)0.5 (om)0.5 (e-posit)0.6 (ive \(P)0.5 (h)]TJ
0 Tc 0 Tw 29.936 0.1 Td
(+)Tj
-0.003 Tc 0.06 Tw 0.581 -0.1 Td
[(\) c)0.5 (hr)0.5 (onic)0.5 ( myeloid leukemia \(CML\) in chronic)-3 ( )]TJ
-0.013 Tc 0.013 Tw -30.517 -1.051 Td
(phase.)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(adults with Ph)Tj
0 Tc 0 Tw 6.074 0.1 Td
(+)Tj
/C2_0 1 Tf
-0.013 Tc 0.013 Tw 0.571 -0.1 Td
[<0003>-13.9 <00260030002F>36.8 <0003>-14 <005A004B00520003>-14 <005100520003>-14 <004F00520051004A004800550003>-13.9 <004500480051004800BF00570003>-13.9 <0049005500520050000F0003>-13.9 <005200550003>-14 <0047004C00470003>-14 <0051005200570003>-13.9 <00570052004F00480055004400570048000F0003>-13.9 <00520057004B004800550003>-14 <005700550048004400570050004800510057000F0003>-13.9 <004C00510046004F00580047004C0051004A0003>-13.9 <004C005000440057004C0051004C00450011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-7.854 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
0.004 Tc 0.095 Tw 1.8 0 Td
[(adult)0.7 (s)0.5 ( )0.5 (wit)0.7 (h P)0.5 (h)]TJ
0 Tc 0 Tw 6.465 0.1 Td
(+)Tj
0.004 Tc 0.095 Tw 0.587 -0.1 Td
[( )0.5 (ac)0.5 (ut)0.6 (e )0.5 (ly)0.5 (m)0.5 (phoblas)0.6 (t)0.6 (ic)0.5 ( leuk)0.5 (em)0.5 (ia )0.5 (\()0.5 (P)0.5 (h)]TJ
0 Tc 0 Tw 15.67 0.1 Td
(+)Tj
/C2_0 1 Tf
0.004 Tc -0.004 Tw 0.587 -0.1 Td
[<0003>-39.4 <0024>0.5 <002F002F000C>0.5 <0003>-94.6 <005A004B00520003>-94.6 <005100520003>-94.5 <004F00520051004A00480055>0.6 <0003>-94.6 <004500480051004800BF>0.5 <0057>0.7 <0003>-94.5 <0049>0.6 <0055>0.5 <00520050>0.5 <000F>0.7 <0003>-94.6 <00520055>0.5 <0003>-94.6 <0047004C00470003>-94.6 <005100520057>0.7 <0003>-94.5 <0057>0.7 <0052004F00480055>0.5 <00440057>0.7 <0048000F>0.7 <0003>-94.6 <00520057>0.7 <004B00480055>4 <0003>]TJ
/TT1 1 Tf
-0.013 Tc 0.013 Tw -23.31 -1.051 Td
(treatment.)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0046004B004C004F00470055004800510003>-14 <00140003>-13.9 <005C0048004400550003>-14 <005200490003>-13.9 <0044004A00480003>-14 <0044005100470003>-14 <0052004F0047004800550003>-14 <005A004C0057004B0003>-13.9 <0033004B>]TJ
/TT1 1 Tf
0 Tc 0 Tw 17.222 0.1 Td
(+)Tj
-0.013 Tc 0.014 Tw 0.571 -0.1 Td
[( CML)36.7 ( in chronic phase.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-19.002 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0046004B004C004F00470055004800510003>-14 <00140003>-13.9 <005C0048004400550003>-14 <005200490003>-13.9 <0044004A00480003>-14 <0044005100470003>-14 <0052004F0047004800550003>-14 <005A004C0057004B0003>-13.9 <00510048005A004F005C0003>-13.9 <0047004C0044004A005100520056004800470003>-14 <0033004B>]TJ
/TT1 1 Tf
0 Tc 0 Tw 24.773 0.1 Td
(+)Tj
-0.013 Tc 0.014 Tw 0.571 -0.1 Td
[( )55.2 (ALL)36.7 ( in combination with chemotherapy)74 (.)]TJ
/C2_0 1 Tf
0.013 Tw -27.144 -1.573 Td
[<002C00570003>-14 <004C00560003>-13.9 <0051005200570003>-14 <004E00510052005A00510003>-14 <004C00490003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <004C00560003>-14 <00560044004900480003>-14 <0044005100470003>-13.9 <00480049>18 <0049004800460057004C005900480003>-13.9 <004C00510003>-13.9 <0046004B004C004F00470055004800510003>-13.9 <005800510047004800550003>-14 <00140003>-13.9 <005C0048004400550003>-14 <005200490003>-13.9 <0044004A00480011>]TJ
/TT0 1 Tf
0.014 Tw 0 -2.851 Td
[(Before taking SPR)36.7 (YCEL, tell your healthcare provider about all of your medical conditions\, including if you:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.447 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(have problems with your immune system)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<004B0044005900480003>-13.9 <004B00480044005500570003>-14 <0053005500520045004F004800500056000F0003>-13.9 <004C00510046004F00580047004C0051004A0003>-13.9 <00440003>-13.9 <0046005200510047004C0057004C005200510003>-13.9 <00460044004F004F004800470003>-13.9 <004600520051004A00480051004C00570044004F0003>-14 <004F00520051004A0003>-13.9 <00340037>18 <0003>-13.9 <0056005C005100470055005200500048>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(have low potassium or low magnesium levels in your blood)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(have liver problems)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(are lactose \(milk sugar\) intolerant)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
[(are pregnant or plan to become pregnant. SPR)17.7 (YCEL)36.7 ( can harm your unborn baby)74 (.)-12.8 ( )]TJ
/C2_1 1 Tf
0.013 Tw -1.8 -1.537 Td
[<0003>-1535 <0029004800500044004F00480056>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
5.992 0 Td
<005A004B0052>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.24 0 Td
<004600440051>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.964 0 Td
<004500480046005200500048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.982 0 Td
[<005300550048004A0051004400510057001D>-13 <0BD8>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-11.786 -1.465 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
[(Y)91.6 (ou should not become pregnant during treatment with SPR)17.6 (YCEL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.221 -1.411 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.579 0 Td
<017C>Tj
-0.009 Tc 0.009 Tw 1.8 0 Td
[<003C>92.1 <005200580003>-90.7 <0056004B00520058004F00470003>-90.7 <0058005600480003>-90.6 <00480049>18.6 <0049>0.5 <004800460057004C005900480003>-90.7 <0045004C00550057>0.5 <004B0003>-90.7 <0046005200510057>0.5 <00550052004F0003>-90.6 <000B0046005200510057>0.5 <005500440046004800530057>0.5 <004C00520051000C0003>-90.7 <004700580055004C0051004A0003>-90.7 <00570055004800440057>0.5 <0050004800510057>0.5 <0003>-90.7 <0044005100470003>-90.7 <0049>0.5 <005200550003>-90.7 <001600130003>-90.7 <00470044005C00560003>-90.7 <00440049>0.5 <0057>0.5 <004800550003>-90.7 <005C0052005800550003>-90.7 <004F0044005600570003>-90.7 <00470052005600480003>-90.7 <00520049>-8.8 <0003>]TJ
/TT1 1 Tf
-0.025 Tc 0.025 Tw 0 -1.051 Td
[(SPR)17.7 (YCEL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.411 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.016 Tc 0.016 Tw 1.8 0 Td
[<0037>111.5 <0044004F004E>0.5 <0003>5.5 <0057>0.7 <00520003>5.5 <005C>0.5 <005200580055>0.5 <0003>5.5 <004B00480044004F0057>0.7 <004B0046>0.5 <00440055>0.5 <00480003>5.4 <00530055>0.5 <00520059>0.5 <004C004700480055>0.5 <0003>5.5 <0055>0.5 <004C004A004B0057>0.7 <0003>5.4 <0044005A0044005C>0.5 <0003>5.5 <004C0049>0.7 <0003>5.5 <005C>0.5 <005200580003>5.5 <004500480046>0.5 <00520050>0.5 <00480003>5.5 <00530055>0.5 <0048004A0051004400510057>0.7 <0003>5.5 <00520055>0.5 <0003>5.5 <0057>0.7 <004B004C0051004E>0.5 <0003>5.4 <005C>0.5 <005200580003>5.4 <0050>0.5 <0044005C>0.5 <0003>5.5 <004500480003>5.5 <00530055>0.5 <0048004A0051004400510057>0.7 <0003>5.5 <004700580055>0.5 <004C0051004A0003>5.4 <0057>0.7 <0055>0.5 <004800440057>0.7 <0050>0.5 <004800510057>-15.8 <0003>]TJ
/TT1 1 Tf
-0.013 Tc 0.014 Tw 0 -1.051 Td
[(with SPR)17.7 (YCEL.)]TJ
/C2_1 1 Tf
0.013 Tw -3.6 -1.555 Td
[<0003>-1535 <00300044004F00480056>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
4.794 0 Td
<005A004C0057004B>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.227 0 Td
<0049004800500044004F0048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.371 0 Td
<00530044005500570051004800550056>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
4.178 0 Td
<005A004B0052>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.24 0 Td
<004600440051>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.964 0 Td
<004500480046005200500048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.982 0 Td
[<005300550048004A0051004400510057001D>-13 <0BD8>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-20.385 -1.465 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.571 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<003C>91.6 <005200580003>-113.7 <0056004B00520058004F00470003>-113.7 <0058005600480003>-113.8 <00480049>18 <0049004800460057004C005900480003>-113.7 <0045004C00550057004B0003>-113.8 <004600520051005700550052004F0003>-113.7 <000B0046005200510057005500440046004800530057004C00520051000C0003>-113.8 <004700580055004C0051004A0003>-113.7 <0057005500480044005700500048005100570003>-113.7 <0044005100470003>-113.7 <0049005200550003>-113.8 <001600130003>-113.7 <00470044005C00560003>-113.7 <004400490057004800550003>-113.8 <005C0052005800550003>-113.8 <004F0044005600570003>-113.8 <00470052005600480003>-113.8 <00520049>-12.9 <0003>]TJ
/TT1 1 Tf
-0.033 Tc 0.033 Tw 0 -1.051 Td
[(SPR)17.6 (YCEL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.411 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<003C>91.6 <0052005800550003>-2.1 <0049004800500044004F00480003>-2.1 <00530044005500570051004800550003>-2 <0056004B00520058004F00470003>-2.1 <00460044004F004F0003>-2.1 <004B004800550003>-2 <004B00480044004F0057004B00460044005500480003>-2.1 <0053005500520059004C0047004800550003>-2.1 <004C00490003>-2 <0056004B00480003>-2.1 <00450048004600520050004800560003>-2.1 <005300550048004A00510044005100570003>-2 <005200550003>-2.1 <0057004B004C0051004E00560003>-2.1 <0056004B00480003>-2.1 <004C00560003>-2.1 <005300550048004A00510044005100570003>-2.1 <004700580055004C0051004A>-13.2 <0003>]TJ
/TT1 1 Tf
0.014 Tw 0 -1.051 Td
[(your treatment with SPR)17.7 (YCEL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.009 -1.393 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.004 Tc 0.004 Tw 1.8 0 Td
[<00440055>0.5 <00480003>-54.5 <00450055>0.5 <004800440056>0.6 <0057>0.7 <0049>0.7 <004800480047004C0051004A0003>-54.5 <00520055>0.5 <0003>-54.5 <0053004F004400510003>-54.4 <0057>0.7 <00520003>-54.5 <00450055>0.5 <004800440056>0.5 <0057>0.7 <0049>0.7 <0048004800470011>0.7 <0003>-54.4 <002C>0.7 <0057>0.7 <0003>-54.5 <004C0056>0.6 <0003>-54.5 <005100520057>0.7 <0003>-54.5 <004E>0.5 <00510052005A00510003>-54.5 <004C0049>0.7 <0003>-54.5 <0036>0.5 <0033>0.6 <0035>18.4 <003C>0.5 <00260028>0.5 <002F>37.5 <0003>-54.5 <005300440056>0.5 <0056>0.6 <00480056>0.6 <0003>-54.5 <004C00510057>0.7 <00520003>-54.5 <005C>0.6 <005200580055>0.5 <0003>-54.4 <00450055>0.5 <004800440056>0.5 <0057>0.7 <0003>-54.5 <0050>0.6 <004C004F004E>0.5 <0011>0.7 <0003>-36.4 <003C>92.3 <005200580003>-54.5 <0056>0.5 <004B00520058004F00470003>-54.5 <005100520057>-3.8 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.051 Td
[<00450055004800440056005700490048004800470003>-14 <004700580055004C0051004A0003>-13.9 <0057005500480044005700500048005100570003>-14 <0044005100470003>-14 <0049005200550003>-14 <00150003>-14 <005A00480048004E00560003>-13.9 <004400490057004800550003>-13.9 <005C0052005800550003>-13.9 <004F0044005600570003>-14 <00470052005600480003>-14 <005200490003>-13.9 <003600330035>17.7 <003C00260028002F0011>]TJ
/C2_1 1 Tf
-0.016 Tc 0.016 Tw -1.8 -1.663 Td
[<0037>74.7 <0048004F>0.5 <004F>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
1.583 0 Td
<0003>Tj
EMC 
0.257 0 Td
[<005C0052>0.5 <0058>0.6 <0055>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.359 0 Td
[<004B>0.5 <00480044004F>0.5 <0057004B>0.5 <0046004400550048>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
5.096 0 Td
[<0053>0.5 <00550052>0.5 <0059004C>0.5 <0047>0.5 <00480055>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
4.127 0 Td
[<00440045>0.6 <0052>0.5 <0058>0.5 <0057>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.897 0 Td
[<0044004F>0.6 <004F>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
1.063 0 Td
<0003>Tj
EMC 
0.257 0 Td
[<0057004B>0.5 <0048>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.708 0 Td
[<005000480047>0.5 <004C>0.6 <0046004C>0.5 <0051>0.6 <00480056>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
5.001 0 Td
[<005C0052>0.5 <0058>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
1.729 0 Td
<0003>Tj
EMC 
0.257 0 Td
[<00570044004E0048000F>0.5 <0BD8>]TJ
/C2_0 1 Tf
[<0003>4.6 <004C00510046004F00580047004C0051004A0003>4.7 <005300550048005600460055004C00530057>0.5 <004C005200510003>4.6 <0044005100470003>4.6 <005200590048005500100057>0.5 <004B0048001000460052005800510057>0.6 <004800550003>4.6 <005000480047004C0046004C005100480056000F>-15.9 <0003>]TJ
-0.012 Tc 0.012 Tw -26.335 -1.051 Td
[<0059004C005700440050004C00510056000F0003>-28 <00440051005700440046004C0047>-0.6 <0056000F0003>-27.9 <0044005100470003>-28 <004B0048005500450044004F0003>-28 <0056005800530053004F0048005000480051005700560011>]TJ
/Span<</ActualText<FEFF00A0>>> BDC 
<0003>Tj
EMC 
/TT0 1 Tf
0.028 Tw 19.359 0 Td
[(If you take an anta)-0.6 (cid medic)-0.6 (ine, take it 2 hours before or 2 hours after)-12.1 ( )]TJ
-0.013 Tc 0.014 Tw -19.359 -1.051 Td
[(your dose of SPR)36.7 (YCEL.)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
11.028 0 Td
( )Tj
EMC 
-11.028 -2.401 Td
[(How should I take SPR)36.7 (YCEL?)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.447 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0037>110.8 <0044004E00480003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <0048005B004400460057004F005C0003>-13.9 <004400560003>-14 <005C0052005800550003>-13.9 <004B00480044004F0057004B00460044005500480003>-13.9 <0053005500520059004C0047004800550003>-13.9 <00570048004F004F00560003>-13.9 <005C005200580003>-13.9 <005700520003>-13.9 <00570044004E00480003>-14 <004C00570011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
0.009 Tc -0.009 Tw 1.8 0 Td
[<003C>91.8 <0052005800550003>-122.5 <004B00480044004F0057004B00460044005500480003>-122.5 <0053005500520059004C0047004800550003>-122.5 <00500044005C0003>-122.4 <0046004B00440051004A00480003>-122.4 <005C0052005800550003>-122.5 <00470052005600480003>-122.5 <005200490003>-122.5 <003600330035>17.9 <003C00260028002F>37 <0003>-122.5 <005200550003>-122.5 <00570048005000530052005500440055004C004F005C0003>-122.5 <00560057005200530003>-122.5 <0057005500480044005700500048005100570003>-122.5 <005A004C0057004B0003>-122.5 <003600330035>17.9 <003C00260028002F0011>]TJ
/Span<</ActualText<FEFF00A0>>> BDC 
50.186 0 Td
<0003>Tj
EMC 
T*
<0003>Tj
/C2_1 1 Tf
-0.013 Tc 0.013 Tw -50.186 -1.051 Td
<00270052>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.586 0 Td
<005100520057>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.795 0 Td
<0046004B00440051004A0048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.703 0 Td
<005C005200580055>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.395 0 Td
<0047005200560048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.562 0 Td
<00520055>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.253 0 Td
<0056005700520053>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.339 0 Td
<00570044004E004C0051004A>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.147 0 Td
[<003600330035>36.7 <003C00260028002F>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
4.579 0 Td
<0003>Tj
EMC 
0.279 0 Td
<005A004C0057004B005200580057>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.744 0 Td
<00BF005500560057>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.117 0 Td
<00570044004F004E004C0051004A>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.412 0 Td
<00570052>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.197 0 Td
<005C005200580055>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.395 0 Td
<004B00480044004F0057004B0046004400550048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
5.154 0 Td
[<0053005500520059004C004700480055>54.8 <0011>]TJ
/C2_0 1 Tf
0 Tc 0 Tw 4.121 0 Td
<0BD8>Tj
/TT1 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
-46.987 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0037>110.8 <0044004E00480003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <00140003>-13.9 <0057004C005000480003>-13.9 <00440003>-14 <00470044005C>74 <0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0037>110.8 <0044004E00480003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <005A004C0057004B0003>-14 <005200550003>-13.9 <005A004C0057004B0052005800570003>-14 <0049005200520047000F0003>-14 <0048004C0057004B004800550003>-13.9 <004C00510003>-13.9 <0057004B00480003>-14 <0050005200550051004C0051004A0003>-14 <005200550003>-13.9 <004C00510003>-13.9 <0057004B00480003>-14 <0048005900480051004C0051004A0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0036005A0044004F004F0052005A0003>-14 <003600330035>17.7 <003C00260028002F>36.8 <0003>-14 <005700440045004F0048005700560003>-13.9 <005A004B0052004F004800110003>-13.9 <002700520003>-14 <0051005200570003>-13.9 <0046005500580056004B000F0003>-13.9 <0046005800570003>-13.9 <005200550003>-14 <0046004B0048005A0003>-14 <0057004B00480003>-13.9 <005700440045004F0048005700560011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.393 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<002C00490003>-14 <005C0052005800550003>-13.9 <0046004B004C004F00470003>-13.9 <0046004400510051005200570003>-13.9 <0056005A0044004F004F0052005A0003>-14 <005700440045004F0048005700560003>-14 <005A004B0052004F0048000F0003>-14 <00570044004F004E0003>-14 <005A004C0057004B0003>-13.9 <005C0052005800550003>-14 <004B00480044004F0057004B00460044005500480003>-14 <0053005500520059004C004700480055>54.9 <0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.009 -1.393 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<003C>91.6 <005200580003>-13.9 <0056004B00520058004F00470003>-14 <0051005200570003>-13.9 <00470055004C0051004E0003>-14 <004A0055004400530048004900550058004C00570003>-13.9 <004D0058004C004600480003>-13.9 <004700580055004C0051004A0003>-13.9 <0057005500480044005700500048005100570003>-14 <005A004C0057004B0003>-13.9 <003600330035>17.6 <003C00260028002F0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.001 Tc 0.001 Tw 1.8 0 Td
[<002C00490003>-75.2 <005C0052>-0.6 <0058>-0.6 <0003>-75.2 <0050004C>-0.6 <005600560003>-75.1 <0044>-0.6 <0003>-75.2 <0047>-0.6 <0052>-0.6 <00560048>-0.6 <0003>-75.2 <0052>-0.6 <00490003>-75.2 <003600330035>17.4 <003C0026>-0.6 <0028002F>-0.6 <000F0003>-75.2 <00570044>-0.6 <004E0048>-0.6 <0003>-75.2 <005C0052>-0.6 <0058>-0.6 <00550003>-75.2 <0051>-0.6 <0048>-0.6 <005B00570003>-75.2 <00560046004B>-0.6 <0048>-0.6 <0047>-0.6 <0058>-0.6 <004F>-0.6 <00480047>-0.6 <0003>-75.2 <0047>-0.6 <0052>-0.6 <00560048>-0.6 <0003>-75.2 <004400570003>-75.2 <005C0052>-0.6 <0058>-0.6 <00550003>-75.2 <00550048>-0.6 <004A>-0.6 <0058>-0.6 <004F>-0.6 <0044>-0.6 <00550003>-75.2 <0057004C>-0.6 <00500048>-0.6 <00110003>-75.2 <0027>-0.6 <0052>-0.6 <0003>-75.2 <0051>-0.6 <005200570003>-75.2 <00570044>-0.6 <004E00480003>-75.2 <0057005A>-0.6 <0052>-0.6 <0003>-75.1 <0047>-0.6 <0052>-0.6 <0056004800560003>-75.1 <0044>-0.6 <0057>-0.9 <0003>]TJ
/TT1 1 Tf
-0.013 Tc 0.014 Tw 0 -1.051 Td
(the same time.)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.02 Tc 0.02 Tw 1.8 0 Td
[<002C>0.7 <0049>0.7 <0003>0.6 <005C>0.6 <005200580003>0.6 <0057>0.7 <0044004E>0.5 <00480003>0.6 <0057>0.7 <005200520003>0.6 <0050>0.5 <00580046>0.5 <004B0003>0.6 <0036>0.6 <0033>0.5 <0035>18.4 <003C>0.5 <00260028>0.5 <002F000F>0.7 <0003>0.7 <0046>0.5 <0044004F004F0003>0.7 <005C>0.6 <005200580055>0.5 <0003>0.7 <004B00480044004F0057>0.7 <004B0046>0.5 <00440055>0.5 <00480003>0.6 <00530055>0.5 <00520059>0.5 <004C004700480055>0.5 <0003>0.7 <00520055>0.5 <0003>0.7 <004A00520003>0.7 <0057>0.7 <00520003>0.7 <0057>0.7 <004B00480003>0.7 <0051004800440055>0.5 <00480056>0.5 <0057>0.7 <0003>0.7 <004B00520056>0.5 <0053004C0057>0.7 <0044004F0003>0.7 <00480050>0.6 <00480055>0.5 <004A004800510046>0.5 <005C>0.5 <0003>0.7 <0055>0.5 <005200520050>0.5 <0003>0.7 <0055>0.5 <004C004A004B0057>0.7 <0003>0.7 <0044005A0044005C>74.7 <0011>]TJ
ET
4 M 
36.5 36.5 538.86 695.96 re
S
endstreamendobj42 0 obj<</Length 20769>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 683.1981 cm
0 0 m
42.736 0 l
S
Q
q 1 0 0 1 36 423.7547 cm
0 0 m
24.176 0 l
S
Q
q 1 0 0 1 36 391.6547 cm
0 0 m
69.527 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 36 727.7881 Tm
(15)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(REFERENCES)Tj
/T1_1 1 Tf
0.857 Tw -2.375 -1.653 Td
(1.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
[(http://www)37 (.osha.gov/SL)94.1 (TC/hazardousdrugs/index.html)]TJ
/T1_0 1 Tf
0.01 Tw -1.663 -2.035 Td
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
-3.375 -1.72 Td
(How Supplied)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.355 Td
[(SPR)18 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 62.3997 675.4881 Tm
(\256)Tj
-0.01 Tc 8 0 0 8 67.1396 673.6881 Tm
[( \(dasa)-10 (tinib\) tablets are a)-10 (vailable as described in )37 (T)74 (able)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(21.)Tj
ET
0 0 0 0 k
/GS0 gs
36 663.608 252 -9.312 re
36 654.296 48.6 -19.472 re
84.6 654.296 33.84 -19.472 re
118.44 654.296 132.84 -19.472 re
251.28 654.296 36.72 -19.472 re
36 634.824 48.6 -28.912 re
84.6 634.824 33.84 -28.912 re
118.44 634.824 132.84 -28.912 re
251.28 634.824 36.72 -28.912 re
36 605.912 48.6 -28.912 re
84.6 605.912 33.84 -28.912 re
118.44 605.912 132.84 -28.912 re
251.28 605.912 36.72 -28.912 re
36 577 48.6 -28.912 re
84.6 577 33.84 -28.912 re
118.44 577 132.84 -28.912 re
251.28 577 36.72 -28.912 re
36 548.089 48.6 -36.912 re
84.6 548.089 33.84 -36.912 re
118.44 548.089 132.84 -36.912 re
251.28 548.089 36.72 -36.912 re
36 511.177 48.6 -30.6 re
84.6 511.177 33.84 -30.6 re
118.44 511.177 132.84 -30.6 re
251.28 511.177 36.72 -30.6 re
36 480.577 48.6 -36.912 re
84.6 480.577 33.84 -36.912 re
118.44 480.577 132.84 -36.912 re
251.28 480.577 36.72 -36.912 re
f
/GS2 gs
q 1 0 0 1 84.6 606.1624 cm
0 0 m
0 28.162 l
S
Q
q 1 0 0 1 118.44 606.1624 cm
0 0 m
0 28.162 l
S
Q
q 1 0 0 1 251.28 606.1624 cm
0 0 m
0 28.162 l
S
Q
q 1 0 0 1 36 605.9124 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 605.9124 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 84.6 577.2504 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 118.44 605.9124 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 118.44 577.2504 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 251.28 605.9124 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 251.28 577.2504 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 36 577.0004 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 577.0004 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 84.6 548.3385 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 118.44 577.0004 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 118.44 548.3385 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 251.28 577.0004 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 251.28 548.3385 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 36 548.0885 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 548.0885 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 84.6 511.4266 cm
0 0 m
0 36.412 l
S
Q
q 1 0 0 1 118.44 548.0885 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 118.44 511.4266 cm
0 0 m
0 36.412 l
S
Q
q 1 0 0 1 251.28 548.0885 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 251.28 511.4266 cm
0 0 m
0 36.412 l
S
Q
q 1 0 0 1 36 511.1766 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 511.1766 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 84.6 480.8266 cm
0 0 m
0 30.1 l
S
Q
q 1 0 0 1 118.44 511.1766 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 118.44 480.8266 cm
0 0 m
0 30.1 l
S
Q
q 1 0 0 1 251.28 511.1766 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 251.28 480.8266 cm
0 0 m
0 30.1 l
S
Q
q 1 0 0 1 36 480.5766 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 480.5766 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 84.6 444.1647 cm
0 0 m
0 36.162 l
S
Q
q 1 0 0 1 118.44 480.5766 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 118.44 444.1647 cm
0 0 m
0 36.162 l
S
Q
q 1 0 0 1 251.28 480.5766 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 251.28 444.1647 cm
0 0 m
0 36.162 l
S
Q
1 w 
q 1 0 0 1 36 443.6647 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 443.6647 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 118.44 443.6647 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 251.28 443.6647 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 36 654.2962 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 654.2962 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 118.44 654.2962 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 251.28 654.2962 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 36 634.8243 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 634.8243 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 118.44 634.8243 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 251.28 634.8243 cm
0 0 m
36.72 0 l
S
Q
0.5 w 
q 1 0 0 1 84.6 635.3243 cm
0 0 m
0 18.472 l
S
Q
q 1 0 0 1 118.44 635.3243 cm
0 0 m
0 18.472 l
S
Q
q 1 0 0 1 251.28 635.3243 cm
0 0 m
0 18.472 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0.024 Tw 8 0 0 8 36 657.8962 Tm
(Table 21:)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
(SPRYCEL Trade Presentations)Tj
-0.02 Tc 7.2 0 0 8 42.5461 641.7043 Tm
(NDC Number)Tj
0.02 Tw 6.557 0 Td
(Strength)Tj
11.042 0 Td
(Description)Tj
12.567 0.5 Td
(Tablets)Tj
0 Tc 0 Tw 7.2 0 0 8 279.7872 645.7043 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 256.4056 637.7043 Tm
(per Bottle)Tj
/T1_1 1 Tf
-0.005 Tc 0.005 Tw -29.979 -2.524 Td
(0003-0527-11)Tj
0.024 Tw 7.272 0 Td
(20)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 6.543 1 Td
[(white to off-white,)37 ( biconvex,)37 ( round,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 233.6063 625.5123 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 129.4105 617.5123 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS\224)37 ( debossed on)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 244.2262 617.5123 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 137.6507 609.5123 Tm
[(one side and )37 (\223527\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 17.872 1 Td
(60)Tj
-31.357 -3.614 Td
(0003-0528-11)Tj
0.024 Tw 7.272 0 Td
(50)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 6.854 1 Td
[(white to off-white,)37 ( biconvex,)37 ( oval,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 231.3707 596.6005 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 129.4105 588.6005 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS\224)37 ( debossed on)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 244.2262 588.6005 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 137.6507 580.6005 Tm
[(one side and )37 (\223528\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 17.872 1 Td
(60)Tj
-31.357 -3.614 Td
(0003-0524-11)Tj
0.024 Tw 7.272 0 Td
(70)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 6.543 1 Td
[(white to off-white,)37 ( biconvex,)37 ( round,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 233.6063 567.6885 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 129.4105 559.6885 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS\224)37 ( debossed on)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 244.2262 559.6885 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 137.6507 551.6885 Tm
[(one side and )37 (\223524\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 17.872 1 Td
(60)Tj
-31.357 -4.114 Td
(0003-0855-22)Tj
0.024 Tw 7.272 0 Td
(80)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 6.234 1.5 Td
[(white to off-white,)37 ( biconvex,)37 ( triangle,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 235.831 538.7766 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 141.1319 530.7766 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS\224)37 ( and)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 232.5048 530.7766 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 130.9655 522.7766 Tm
[(\22380\224)37 ( \(BMS over 80\) debossed on one side)-9.9 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 242.6711 522.7766 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 149.5556 514.7766 Tm
[(and )37 (\223855\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 16.218 1.5 Td
(30)Tj
-31.357 -4.219 Td
(0003-0852-22)Tj
0.024 Tw 7.035 0 Td
(100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 7.091 1 Td
[(white to off-white,)37 ( biconvex,)37 ( oval,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 231.3707 501.0206 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 123.4202 493.0206 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS 100\224)37 ( debossed on)-9.9 ( )]TJ
1.976 -1 Td
[(one side and )37 (\223852\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 17.872 1 Td
(30)Tj
-31.357 -4.219 Td
(0003-0857-22)Tj
0.024 Tw 7.035 0 Td
(140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 6.781 1.5 Td
[(white to off-white,)37 ( biconvex,)37 ( round,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 233.6063 471.2647 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 141.1318 463.2647 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS\224)37 ( and)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 232.5048 463.2647 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 127.5816 455.2647 Tm
[(\223140\224)37 ( \(BMS over 140\) debossed on one side)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 246.0551 455.2647 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 149.5556 447.2647 Tm
[(and )37 (\223857\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 16.218 1.5 Td
(30)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 35.9999 425.0847 Tm
(Storage)Tj
/T1_1 1 Tf
-0.001 Tw 0 -1.292 Td
[(SPR)18 (YCEL tablets should be stored a)-10 (t 20\260C to 25\260C \(68\260F to 77\260F\); excursions permitted)-10 ( )]TJ
0 Tw 0 -1 Td
(between 15\260C and 30\260C \(59\260F and 86\260F\) )Tj
0 Tc ([)Tj
15.302 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
[(ee USP Controlled Room )37 (T)74 (empera)-10 (ture])]TJ
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc -15.699 -1.72 Td
(Handling and Disposal)Tj
/T1_1 1 Tf
-0.036 Tw 0 -1.292 Td
[(SPR)18 (YCEL is an antineoplastic product.)37 ( F)20 (ollo)-9.9 (w special handling and disposal procedures.)]TJ
0 Tc 0 Tw 6 0 0 6 285.12 385.4447 Tm
(1)Tj
-0.01 Tc 8 0 0 8 35.9999 371.2247 Tm
[(P)18 (ersonnel who are pregnant should a)-10 (void exposure to crushed or broken tablets.)]TJ
0.199 Tw 0 -1.427 Td
[(SPR)18 (YCEL tablets consist of a core tablet,)37 ( surrounded by a \037lm coa)-10 (ting to prevent)-10 ( )]TJ
0.035 Tw 0 -1 Td
[(exposure of healthcare professionals to the active substance.)37 ( )36.9 (The use of la)-10 (tex or nitrile)-10 ( )]TJ
0.031 Tw 0 -1 Td
[(gloves for a)-9.9 (ppropria)-10 (te disposal when handling tablets tha)-10 (t are inadvertently crushed or)-10 ( )]TJ
0 Tw 0 -1 Td
[(broken is recommended,)37 ( to minimize the risk of dermal exposure.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -2.485 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(P)54 (A)55 (TIENT COUNSELING INFORMA)55 (TION)]TJ
/T1_1 1 Tf
-3.375 -1.653 Td
[(Advise the pa)-10 (tient to read the FDA-a)-10 (pproved pa)-10 (tient labeling \(P)18 (a)-10 (tient Informa)-10 (tion\).)]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.72 Td
(Myelosuppression)Tj
/T1_1 1 Tf
0.03 Tw 0 -1.292 Td
[(Inform pa)-10 (tients of the )0.5 (possibility of developing lo)-9.9 (w blood cell counts.)37 ( )37.4 (Advise pa)-10 (tients to)-9.9 ( )]TJ
-0.009 Tw 0 -1 Td
[(immedia)-10 (tely report fever particularly in associa)-10 (tion with an)-10 (y suggestion of infection )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
30.225 0 Td
(s)Tj
-0.01 Tc 0.01 Tw 0.397 0 Td
[(ee)-10 ( )]TJ
-30.622 -1 Td
[(W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 3.364 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -9.385 -1.495 Td
(Bleeding)Tj
/T1_1 1 Tf
0.161 Tw 0 -1.292 Td
[(Inform pa)-10 (tients of the possibility of serious bleeding and to report immedia)-10 (tely an)-10 (y)-10 ( )]TJ
0.047 Tw 0 -1 Td
[(signs or symptoms suggestive of hemorrha)-9.9 (ge \(unusual bleeding or easy bruising\) )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
30.225 0 Td
(s)Tj
-0.01 Tc 0.01 Tw 0.397 0 Td
[(ee)-10 ( )]TJ
-30.622 -1 Td
[(W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 3.364 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.2\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc -9.385 -1.653 Td
(Fluid Retention)Tj
/T1_1 1 Tf
0.138 Tw 0 -1.653 Td
[(P)18 (a)-10 (tients should be informed of the possibility of developing \035uid reten\tion \(s)-10 (welling,)27 ( )]TJ
-0.004 Tw 0 -1 Td
[(weight gain,)37.1 ( dr)-18 (y cough,)37 ( chest pain on respira)-10 (tion,)37 ( or shortness of brea)-10 (th\) and advised to)-10 ( )]TJ
-0.02 Tw 0 -1 Td
[(seek medical a)-10 (ttention promptly if those symptoms arise )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
20.707 0 Td
(s)Tj
-0.01 Tc -0.057 Tw 0.397 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.02 Tw 4.405 0 Td
( and Precaution)Tj
0 Tc 0 Tw (s)Tj
( )Tj
-0.01 Tc 0.01 Tw -25.509 -1 Td
(\(5.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.01 Tc 0 -1.495 Td
[(Cardio)-10 (v)16 (ascular T)74 (oxicity)]TJ
/T1_1 1 Tf
0.348 Tw 0 -1.292 Td
[(Inform pa)-10 (tients of the possibility of developing cardiovascular toxicity)55 (,)37.1 ( inc)20 (luding)-10 ( )]TJ
0.294 Tw 0 -1 Td
[(cardiac ischemic events,)37 ( cardiac-rela)-9.9 (ted \035uid retention,)37 ( conduction abnormalities,)27 ( )]TJ
0.043 Tw 0 -1 Td
[(and )37 (TIAs.)37 ( )36.9 (Advise pa)-10 (tients to seek immedia)-9.9 (te medical a)-10 (ttention if symptoms suggestive)-9.9 ( )]TJ
0.103 Tw 0 -1 Td
[(of cardiovascular toxicity occur)74 (,)37 ( such as chest pain,)37 ( shortness of brea)-9.9 (th,)37 ( palpita)-10 (tions,)27 ( )]TJ
0 Tw 0 -1 Td
[(transient vision problems,)37 ( or slurred speech )]TJ
/T1_2 1 Tf
0 Tc ([)Tj
16.212 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
[(ee W)18.1 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.425 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.4\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 8.946 76.028 Td
[(Pulmonar)-18 (y Arterial Hypertension)]TJ
/T1_1 1 Tf
-0.04 Tw 0 -1.292 Td
[(Inform pa)-9.9 (tients of the possibility of developing pulmonar)-18 (y arterial hypertension \(d)-10 (yspnea,)27 ( )]TJ
-0.021 Tw 0 -1 Td
[(fa)-10 (tigue,)37 ( hypoxia,)37 ( and \035uid retention\) and advise them to seek medical a)-9.9 (ttention promptly)-10 ( )]TJ
0 Tw 0 -1 Td
(if those symptoms arise )Tj
/T1_2 1 Tf
0 Tc ([)Tj
9.074 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
[(ee W)18.1 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.425 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.5\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc -19.917 -1.495 Td
[(T)74 (umor L)37.1 (ysis Syndrome)]TJ
/T1_1 1 Tf
0.134 Tw 0 -1.292 Td
[(Inform pa)-10 (tients to immedia)-10 (tely report and seek medical a)-10 (ttention for an)-10 (y symptoms)-10 ( )]TJ
0.032 Tw 0 -1 Td
[(such as nausea,)37 ( vomiting,)37 ( weakness,)37 ( edema,)37 ( shortness of brea)-9.9 (th,)37 ( musc)20 (le cramps,)37 ( and)-10 ( )]TJ
-0.045 Tw 0 -1 Td
[(seizures,)37 ( which may indica)-10 (te tumor lysis syndrome )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
18.522 0 Td
(s)Tj
-0.01 Tc -0.082 Tw 0.397 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.045 Tw 4.38 0 Td
( and Precaution)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.045 Tw 5.931 0 Td
( \(5.8\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.01 Tc -29.231 -1.495 Td
[(Growth and Development in P)24 (ediatric P)24 (atients)]TJ
/T1_1 1 Tf
-0.044 Tw 0 -1.293 Td
[(Inform pedia)-10 (tric pa)-10 (tients and their caregivers of the possibility of developing bone gro)-10 (wth)-10 ( )]TJ
0.072 Tw 0 -1 Td
[(abnormalities,)37 ( bone pain,)37 ( or g)-10 (ynecomastia and advise them to seek medical a)-10 (ttention)-10 ( )]TJ
0 Tw 0 -1 Td
(promptly if those symptoms arise )Tj
/T1_2 1 Tf
0 Tc ([)Tj
12.481 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
[(ee W)18.1 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.425 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.10\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc -23.323 -1.495 Td
[(Embr)-17.9 (yo-F)20 (etal T)74 (oxicity)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.225 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.069 Tw 1.625 0 Td
(Advise pregnant women of the potential risk to a fetus )Tj
/T1_2 1 Tf
[([see )37.2 (W)18 (arnings and Precautions)-10 ( )]TJ
0 Tw 0 -1 Td
[(\(5.9\) and Use in Speci\037c P)18 (opula)-9.9 (tions \(8.1\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.291 Tw 1.625 0 Td
[(Advise females )0.5 (of )0.5 (reproductive )0.5 (potential )0.5 (and males )0.5 (with )0.5 (female partners )0.5 (of)-10 ( )]TJ
-0.039 Tw 0 -1 Td
[(reproductive potential to use effective contraception during trea)-10 (tment with SPR)18 (YCEL)-10 ( )]TJ
-0.079 Tw 0 -1 Td
[(and for 30 days after the last dose.)37 ( )37.3 (Advise females to contact their healthcare provider)-9.9 ( )]TJ
0.042 Tw 0 -1 Td
[(if they become pregnant,)37 ( or if pregnanc)20 (y is suspected,)37 ( while taking SPR)18 (YCEL )]TJ
/T1_2 1 Tf
0.01 Tw [([see)-10 ( )]TJ
0 Tw 0 -1 Td
[(W)18 (arnings and Precautions \(5.9\) and Use in Speci\037c P)18 (opula)-10 (tions \(8.1,)37 ( 8.3\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -1.625 -1.495 Td
(Lactation)Tj
/T1_1 1 Tf
0 -1.225 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.24 Tw 1.625 0 Td
[(Advise women tha)-10 (t breastfeeding is not recommended during trea)-10 (tment with)-10 ( )]TJ
-0.028 Tw 0 -1 Td
[(SPR)18 (YCEL )0.5 (and )0.6 (for )0.6 (2 )0.5 (weeks )0.6 (after )0.6 (the )0.6 (\037nal )0.6 (dose )]TJ
/T1_2 1 Tf
16.269 0 Td
[([see )0.5 (Use )0.6 (in )0.6 (Speci\037c )0.6 (P)18 (opula)-10 (tions )0.5 (\(8.2\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.01 Tc -17.894 -1.495 Td
(Gastrointestinal Complaints)Tj
/T1_1 1 Tf
0.051 Tw 0 -1.292 Td
[(Inform pa)-10 (tients tha)-10 (t they may experience nausea,)37 ( vomiting,)37 ( or diarrhea with SPR)18 (YCEL.)27 ( )]TJ
0.275 Tw 0 -1 Td
[(Advise pa)-10 (tients to seek medical a)-10 (ttention if these symptoms are bothersome or)-9.9 ( )]TJ
0.01 Tw 0 -1 Td
(persistent.)Tj
0.022 Tw 0 -1.427 Td
[(Advise pa)-10 (tients using antacids to a)-9.9 (void taking SPR)18 (YCEL and antacids less than 2 hours)-10 ( )]TJ
0.01 Tw 0 -1 Td
[(a)-10 (part )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 2.096 0 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
(ee Drug Interaction)Tj
0 Tc (s)Tj
-0.01 Tc 7.259 0 Td
( \(7.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -10.001 -1.495 Td
[(P)24 (ain)]TJ
/T1_1 1 Tf
0.246 Tw 0 -1.292 Td
[(Inform pa)-9.9 (tients tha)-9.9 (t they may experience headache or musculoskeletal pain with)-9.9 ( )]TJ
0.026 Tw 0 -1 Td
[(SPR)18 (YCEL.)37 ( )36.6 (Advise pa)-10 (tients to seek medical a)-10 (ttention if these symptoms are bothersome)-9.9 ( )]TJ
0 Tw 0 -1 Td
(or persistent.)Tj
/T1_0 1 Tf
0.01 Tw 0 -1.495 Td
[(F)20 (atigue)]TJ
/T1_1 1 Tf
0.004 Tw 0 -1.292 Td
[(Inform )0.5 (pa)-9.9 (tients )0.6 (tha)-10 (t )0.6 (they )0.6 (may )0.6 (experience )0.5 (fa)-10 (tigue )0.5 (with )0.6 (SPR)18 (YCEL.)37 ( )37.6 (Advise )0.6 (pa)-10 (tients )0.5 (to )0.6 (seek)-9.9 ( )]TJ
0 Tw 0 -1 Td
[(medical a)-9.9 (ttention if this symptom is bothersome or persistent.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.495 Td
(Rash)Tj
/T1_1 1 Tf
0.097 Tw 0 -1.292 Td
[(Inform pa)-9.9 (tients tha)-10 (t they may experience skin rash with SPR)18 (YCEL.)37 ( )36.6 (Advise pa)-10 (tients to)-9.9 ( )]TJ
0 Tw 0 -1 Td
[(seek medical a)-10 (ttention if this symptom is bothersome or persistent.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.495 Td
(Lactose)Tj
/T1_1 1 Tf
0.399 Tw 0 -1.292 Td
[(Inform pa)-10 (tients tha)-9.9 (t SPR)18 (YCEL contains 135 mg of lactose monohydra)-10 (te in a)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -31.5 -1 Td
[(100-mg daily dose and 189 mg of lactose monohydra)-10 (te in a 140-mg daily dose.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.495 Td
(Hepatotoxicity)Tj
/T1_1 1 Tf
0.037 Tw 0 -1.292 Td
[(Advise pa)-9.9 (tients tha)-10 (t SPR)18 (YCEL can cause hepa)-10 (totoxicity and tha)-9.9 (t pa)-9.9 (tients with previous)-10 ( )]TJ
0.144 Tw 0 -1 Td
[(histor)-18 (y of liver diseases may be a)-9.9 (t risk.)37.1 ( )36.7 (Advise pa)-10 (tients to seek immedia)-9.9 (te medical)-10 ( )]TJ
0.056 Tw 0 -1 Td
[(a)-10 (ttention if an)-10 (y symptoms suggestive of hepa)-10 (totoxicity occur)74 (,)37 ( such as abdominal pain,)27 ( )]TJ
0.099 Tw 0 -1 Td
[(jaundice and sc)20 (leral icterus,)37 ( anorexia,)37 ( bleeding,)37 ( bruising,)37 ( and dark-colored urine )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
30.225 0 Td
(s)Tj
-0.01 Tc 0.01 Tw 0.397 0 Td
[(ee)-10 ( )]TJ
-30.622 -1 Td
[(W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 3.364 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.11\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc -9.385 -1.495 Td
[(Instructions for T)74 (aking SPR)18 (YCEL)]TJ
/T1_1 1 Tf
0.01 Tw 1.125 -1.225 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
(Missed Dose)Tj
0.17 Tw -1.625 -1.427 Td
[(Advise pa)-10 (tients tha)-10 (t if they miss a dose of SPR)18 (YCEL,)37 ( they should take the next)-10 ( )]TJ
0.127 Tw 0 -1 Td
[(scheduled )0.5 (dose )0.5 (a)-9.9 (t )0.5 (its )0.6 (regular )0.5 (time.)37 ( )37.5 (The )0.6 (pa)-10 (tient )0.5 (should )0.5 (not )0.5 (take )0.5 (two )0.5 (doses )0.5 (a)-10 (t )0.6 (the)-10 ( )]TJ
0 Tw 0 -1 Td
(same time.)Tj
0.01 Tw 0 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(Gra)-9.9 (pefruit Juice)]TJ
-0.046 Tw -1.625 -1.427 Td
[(Advise pa)-10 (tients not to drink gra)-10 (pefruit juice as it may increase the amount of SPR)18 (YCEL)-10 ( )]TJ
0 Tw 0 -1 Td
(in their blood and therefore increase their risk of adverse reactions.)Tj
-1.125 -2.823 Td
(Distributed by:)Tj
0 Tc 5.19 0 Td
( )Tj
-0.01 Tc -5.19 -1 Td
[(Bristol-Myers Squibb Compan)-9.9 (y)]TJ
0 Tc 11.179 0 Td
( )Tj
-0.01 Tc -11.179 -1 Td
[(Princeton,)37 ( NJ 08543 USA)]TJ
ET
endstreamendobj29 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 486/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 25 0 R>>/Font<</T1_0 77 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 747.0331 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 750.2881 Tm
[(SPR)37 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 72.6396 752.0881 Tm
(\256)Tj
-0.01 Tc 8 0 0 8 77.3795 750.2881 Tm
( \(dasatinib\))Tj
ET
q 1 0 0 1 324 747.0331 cm
0 0 m
252 0 l
S
Q
BT
0.01 Tw 8 0 0 8 493.5973 750.2881 Tm
[(SPR)37 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 530.2369 752.0881 Tm
(\256)Tj
-0.01 Tc 8 0 0 8 534.9768 750.2881 Tm
( \(dasatinib\))Tj
ET
endstreamendobj77 0 obj<</BaseFont/OKCCCA+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 78 0 R/LastChar 174/Subtype/Type1/ToUnicode 79 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 741 0 648 0 0 0 0 0 0 593 0 0 0 667 0 722 649 0 0 0 0 0 667 0 0 0 0 0 0 0 574 611 0 611 0 0 0 0 258 0 0 0 0 593 0 0 0 0 537 352 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj78 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/C/E/L/P/R/S/Y/a/b/d/i/n/s/t/registered)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 80 0 R/FontName/OKCCCA+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj79 0 obj<</Filter/FlateDecode/Length 312>>stream
Hâ\ëÀj√0E˜˙äY6ã‡G#;cn
^ÙA›~Ä#çSA-ŸY¯Ô;“Ñ*∞Á›{ëfí¶}j≠Y y˜ìÍpÅ¡XÌqûÆ^!úÒb¨»r–F-∑]¸´±w"!s∑Œé≠&QUê|–·º¯éz:„F$o^£7ˆ_M∑Å§ª:˜É#⁄R®k–8P–KÔ^˚!â∂m´È‹,Îñ<äœ’!‰qüÒe‘§qvΩBﬂ€ä*•UCıL´hıøÛlœ∂Û†æ{/™<à”î
Òûy¯¿| ﬁ=F¶B,ôe‡Üπ!ñú#CéÃôÛ¿Ïï¡+9SÜÃ"ãLÖòıE–;Ê]`÷Qb>óúYÜÃíıe–YC%<¸ˆ¬–ö‹˚´ÆﬁSk„8cOC7ç≈˚ƒ›‰Ä\·ø ][ó>endstreamendobj80 0 obj<</Filter/FlateDecode/Length 1660/Subtype/Type1C>>stream
HâÑTPT◊~è›ΩHû ÚÓÍ{œïhÿ]PäPƒÄ
jH≥∞Yªfw˘Gm⁄ƒ@ƒHêTå?%!∂Qà£IåD≈üX“ƒ—âIEå`lßRìíZŒ√≥”È]™È§”Nﬂùπ˜ú˚Œ˘Œ˘ŒΩ˜∞å:àaYvJv¶ÕfKùµD.≠ê}ŒB{ñ\./ÀÕÒ9b9¢b`ïµ29å«dt›ªpØP£<5^Ÿ2Ò„…ZW8ÄŸ¿˙lÓç’ÁÜbüdIö;◊DÁ$Ûÿoí¨f≥UJu∏d)ß⁄ÎìÀºRÜ´–ÌŸËˆÿ}≤#VJ--ï∆úΩíGˆ ûä¿ÊˇE\Êtπ}’eiqY¡íˇÚ#/…ÈïÏíœcw»evœ≥íªËﬂ˛6öJ,u⁄‡§…ydá‰tIæbYZõ+-ß)∫|í›ÂêrÙŒ.*r cõeˆjâ˚©w°ÏÒŸÈÍ¶0©§‹„Ù:úÖ>ß€Â} Ó≤ó…ˇ%∑GrR•ﬁÂïÂˇ óûìP$á\ƒ–èeBòP&öôŒƒ0&ûI`íôEåçIcñ2ŸL.≥ä9¿ËË1YÃ
¶Å9«F∞ÿ<v˚è w–>UÑ™Du^5®û°nPˇVìá—€∫ïoªY:Gw´∂©ï˙—Â˛zØ`è)∞SÉ%<ÀC@Ò7k˝$LÜ§:QŒ	Á‚pv≈ΩG*Ÿ3`T¡≤Q7è∫ıòç3ıhÓFÎú,@(IÖh'X¡™á∏√`˘
¶
¸Ü~j\ ˇ¬èC6Ã‘É9¨I0E¿PÚ>ÚZ—™«∏b¥§¢$pﬂ÷@îRQÏQ∞®FüP\<$Ua‘m¥9åƒ$,∆†+<6“˜àh"1[VeÃ2‡‘’„`‚Y∫LΩˆŸ™«_π€ ä⁄rCa/SÿÀë ªÂÁÈÊw¿·w£<DıCÑ{íö*}ï¨∂C˛UÈC·ﬁl´ÄäQ\‡/¥ÇâZP°íhóA¡úLÒ
r<p‰˜kÕÊ•µãD‰wçbtÄ÷›«ËãBÖ∞êæ∑K˛R‹π≤!}~0’›Ô5‘wm˝≤¸J ØÇ∑k˚:ﬁπ0†&˘è!¯˘˚íœèñ•€‰≤4Æ©8•∏v0aò‡ òtΩ∫¡vxû««‡—«¿jÄ’?‹Åáa&tÆiuΩ∏¯CgÛG˙ﬂı¥u_˘§|vì &I8Â"ŒDÖ4úé˙ëÇøªÖªÓëÕ)˙EâµπÇn01ı»ê® h~%Õî	4®¸ö¿>eômÑˆö√8k0ç¿ˇó∂i(˘kÄ°0B>u]J¨ÂK_äG’∫Ç÷≥gﬁ{˝xãp|gwc{[0f›Âœ7~„ú°˚ÿœ≥V$øí∞YåﬂÔ∆˝‘kO›πpiÔâ.AW’X≥£¶©6¢…Ê∂≠'NË·-L¿	oFc0é+ƒIø∏íM#±É00ôï·Áh‰Ái‰S∫∫së` ∫Só∂kW∫‡ªj¯T˝∞V†™?:3”ª∫XlÄV4eº-?ªh~bbQﬂ7∑éÙôüS‘ ü≠ˇBUÊQÿ—|4bk9˝lˆÅ,öRh!EQw
ß]E˙ .ı¥üÔ∂ìXÕœq'≈ƒ›¸˙f«ı¡€Á%
ú?≤≠BŸ]˘=Ñ∞=ÙıÙDÇQŸMÛ†1ÚxäFzQ©M‚ùô†c¥.PK «Ì‰nÁΩóﬁ≤œ∞ãÍ_h!Bæâ≥≤üpØÿ ‘]Ôóh–r“¶!zÏ˚‘"ì∆xÊÛ8ÂU…á0ÑBËqò¸ó‰És˜ã…˚Á5ü÷;Òj«Ècuπ;Z2–˝l⁄Q‘PÖƒâQÊÆ’‚p˘«uœËÛ÷‘‰¨yÎ”óÈ˚ÔzëﬁÙÀCÏÌ@ÿ<öH=n∂ÈÏ!—W+o˝ÊP„évT⁄˙∫M/◊ûﬁ≤Î§-ö¶Â¿\sˆ]Ñ†ã˝◊Ÿ=√0©Ã˝¿´ˆ¿=´ g¿z:2`TA%f¿t\OGΩ©ï¬p$Ìfig∞@Ëp<ÌdPá0-8&¿&°Ã˜√‚3dknTC¶Ê”¶ì{ıZﬁi–J˙óÚüì£'_»≤¯Öµb*·jˆéÊÔ≈í›ÿ6{[Ü[¸Ωªµ˜7w√ÅÊÔõ˝ﬁ2
∆q#ØÖÖÅÒı∞á‡TƒhˇO ±VâRendstreamendobj26 0 obj<</BaseFont/NXSWOC+HelveticaNeueLTStd-BdCn/Encoding 81 0 R/FirstChar 30/FontDescriptor 82 0 R/LastChar 174/Subtype/Type1/ToUnicode 83 0 R/Type/Font/Widths[487 537 240 0 0 0 0 778 0 0 296 296 390 600 240 370 240 332 480 480 480 480 480 480 480 480 480 480 240 0 0 600 0 0 0 556 556 537 574 481 463 556 556 258 0 0 463 740 574 556 519 556 556 519 480 538 519 760 537 520 0 0 0 0 0 0 0 481 500 463 500 463 296 500 500 240 240 500 240 758 500 480 500 500 333 444 296 500 444 704 462 444 426 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj27 0 obj<</BaseFont/NXSWOC+HelveticaNeueLTStd-Cn/Encoding 84 0 R/FirstChar 25/FontDescriptor 85 0 R/LastChar 239/Subtype/Type1/ToUnicode 86 0 R/Type/Font/Widths[600 240 463 497 463 497 463 240 0 0 0 0 759 0 0 241 241 352 600 240 352 240 278 480 480 480 480 480 480 480 480 480 480 240 240 600 600 600 0 0 500 519 519 556 463 444 537 537 204 426 500 444 704 556 556 481 556 519 500 463 519 462 722 0 462 0 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 204 444 204 722 463 444 463 463 296 407 259 463 406 648 406 406 389 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 240 240 407 407 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800 0 400 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 600 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 204]>>endobj28 0 obj<</BaseFont/NXSWOC+HelveticaNeueLTStd-CnO/Encoding 87 0 R/FirstChar 30/FontDescriptor 88 0 R/LastChar 150/Subtype/Type1/ToUnicode 89 0 R/Type/Font/Widths[618 463 240 0 0 0 0 759 0 0 241 241 0 0 240 352 240 278 480 480 480 480 480 480 480 480 480 480 240 0 600 0 0 0 0 500 519 519 556 463 444 537 537 204 0 0 444 704 556 556 481 556 519 500 463 519 0 722 0 462 0 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 0 0 204 722 463 444 463 0 296 407 259 463 406 648 406 406 389 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500]>>endobj87 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[30/greaterequal/fi]/Type/Encoding>>endobj88 0 obj<</Ascent 932/CapHeight 714/CharSet(/greaterequal/fi/space/percent/parenleft/parenright/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/less/A/B/C/D/E/F/G/H/I/L/M/N/O/P/Q/R/S/T/U/W/Y/bracketleft/bracketright/a/b/c/d/e/f/g/h/i/l/m/n/o/p/r/s/t/u/v/w/x/y/z/end\ash)/Descent -272/Flags 96/FontBBox[-171 -272 1068 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 90 0 R/FontName/NXSWOC+HelveticaNeueLTStd-CnO/FontStretch/Condensed/FontWeight 400/ItalicAngle -12/StemV 84/Type/FontDescriptor/XHeight 536>>endobj89 0 obj<</Filter/FlateDecode/Length 543>>stream
Hâ\‘Õä€0‡ΩüBÀô≈‡]]M¿2I≤ËM˚ é≠§Ü∆6égë∑ØéNòBéè∞‰˚qëúoª√–/&ˇ>èÌ1,Ê‹›n„«‹s
ó~»  t}ª<FÈøΩ6Sñ«≈«˚m	◊√p≥∫6˘è¯∂ÃwÛ¥È∆SxŒÚosÊ~∏òß_€„≥…è”Ù'\√∞ò¬¨◊¶Á¯¢/ÕÙµπìße/á.>Ôó˚K\Ûo∆œ˚Lï∆%1ÌÿÖ€‘¥anÜK»Í"˛÷¶~èøuÜÓøÁ∫‚≤”π˝›ÃY]Ó„‰™R∑é˘=Ê¢Pç◊*é´"ç„-f«åy’+Û+Úä9Õﬂ2oëwÃ;‰=Ûô5‚-´-ﬂoÒ~[2ó»sÖlô-≤02=´ÃäÏô=2ùNKßÖ”nò7»4[òÖÅAhÑÅAhÑÅAhÑÅAhÑÅAXWR]ˆJ–+aØΩˆJ–+«^9Ù —È‡tt:8ùNGßÉ”—È‡t¥9ÿ=˜∆¸ÜLèÉGYKQKYKQKYKQKYKQKY+Ì'’«~Bf]E]eO=Q“~SˆD—•AìÅ=QÙD{=ÒÏâGO<m6OõáÕ”ÊaÛ¥yÿ<m6OõáÕ”ÊaÛ¥yÿ<˜å«ûYamUî6∞«I¬Qã_Ûyé€èyéG8}6“Ÿ≈©Ìá˘eô∆…ƒU∏≤ø ˚ÖÎendstreamendobj90 0 obj<</Filter/FlateDecode/Length 4716/Subtype/Type1C>>stream
HâdTyTGÓfË¢9tzõ[∂;†"QnE0^£`XÖı@∆ôFaFgÜA.5ÍzÑËÆ‡Æ äDìàj^‚Å´‚7.£ÆTT$ Õì’∑Ô◊XìÕˆ¿ÏÎ◊U_u}øÆØ~ı´è$\]í$µ Mù∫0~bÇòc-z≠fÅò'&•®-∫êx√B'#@CJ~Æõº\$/œ¬_ºªˆ.ÜÇ.oâı˝ˆâäPê‰àøˇúe5—$Æœ”‰ƒ◊òÙYŸ!"66|í)ƒÈå´EA]`∂àπf!—†5ö÷Mrå.TàÀ…íùf!Y4ã&´Û„E	z≥†,&çNÃ’ò÷
∆LyNØsVã¶,—$Ã1Âi◊ÊjÃ⁄lΩA4qÛ&	‚mNûYos
ÑΩV4òEù`…6Û≤≤Ö$Ω¡h)X' `µIc*ÊÂÆNò$h:!WS »*MbñﬁÏ‹çN–≠h≤h‰~MûIo÷ÈµΩ—`õ´Nq˛d≤†3	ÇîÑ;IåP˛@!ÓDAL#àÈ1ì >§â_ªjö»%#AÓ àπÚ)âD1@FêπdyúºL6πDπd∏‘+bV≈c◊eÆ˚®âTıê@!®ı∏MtKw+us–QÙ«¥ûÆßˇ·æÿ}Ø˚œzõGøgòÁœ”ûMû?yÌÛ˙Áà≈#.*}ï© Vo¡{é˜
Ô€#›F¶èº3 }îa‘˘QÔT„TT_´˙ô ¶à)cÆ√‚“+“Î+$Lëv.rÏD∞ﬂfÒL(ß†a_c¡9pîπ9P˙ÜôX#©Åu"Ï)±Q	◊JÆCÌıïŒFÅv˚“Cπa‡ííUÔªŸrào9x‡ÊMÓÊul![P¨Vsqé1Ï_ë§Ã§>BLk O·¨∫¸ˇ©%2ïi¿}pñœ]o>Áﬂ‘îuaO{ÊÑY˘†ºma‡…1≠w îì]ojdJ˘0eÌ≈∫’IQbûj}ÁìOæhV@œ`:ãΩ±O4û¨«Qkp‰A}≥Ùü–*‹cÎ ˙Ñ›Ö)‡~Ùˇb!Â©¢'±‡>?¬‰SUëù,Ωù«Å{ÒÿlΩá%·)òƒŒXcÈ y∆+ö|.†ÌÊ-⁄ç˘b°ﬂ'+:é‘‹ØzÏW˝ä
CJv5ìP©Ä],ÏDõ)º«6Åõ€Öé8ô8±Ã:XòOnîV(6ñ∞6$ç,§ë≤¶ƒ&Ω≤ë?æÇ3ØI	Í†É˜OÚ·ŸZH∆j´S∞áØ·ÒÙ,N5'¬;¬OùÅ  8 Ã8`h:xmƒáâ£¡'yeMçU™Ω¥úÇ¯B	R-¶µT+Ç˜”®Ö»4usƒvZYS⁄,›∞ì“™NÖ¥ºô≈∑–·Kgæ≠?ûØ|ªÔﬂ∫u˙˚äœÄ¡17;è6ÚmËõÚØÄí{\ë∏`#_4cEF¬≤yÀ|CÊÖF±/-	C{Ñ:€o≠pƒ¶˙°6wh⁄ôß;x…2œ/¢∂⁄‘ò{ô÷ßr”ä5VÚQh◊*gõOÉd∆¥v {åg.Ó”^ùUEÔvk>t˘ÓÅá4ÛÙÈ¡M˝xáÉG¨ó’4¸Ò´ó›‹˝ä•ÛK¯9≈´ñÃÊV!g`ñ]ÛIõ¥L!K˜ÿ›h.~F·4ªå-úN¡>îÖg…)9≥®g® N}Ä˙$ëö:,˛µBõ…¶v¯¥]øÄVˆÒÍ‡û+Ê⁄˜«Œ(‰„ãµÿ5àŸ€}∂\üºiÊa:Z@æ«x>±§ı=nyZAvøk∑4Ï™ñ√<∑C≤M’“[;Wµ3íÙçtöe˙Oï ÀaM2∂‡ËlÂ¨«ã!çﬂé~ØÂ	¸j3:±77c…“ı˘¸.¥ˇ&≈Ùü-ø s¿Éªs4}—F◊‚G,#5UùÌË·z>çà+‚„ä2"¢8¶?j{GS’pô8öI $´fHû†®àAÛR±Kñ@˜°0ÆFﬁÚﬁ@”À+W´~uL—≈6ïΩ˝˜Ì0°M>⁄˛fHeC7Tc¢8àz tw5_”k¸n˙±'µÁÍ´”L/†£)6Ï a◊òDåÃ|—¨œW6h¶?‹ò∫»:……∏*©ŸøT/K(·K¥ø˘òõ_x≈V…ﬂ´¸˙r£¨ãéEÏãCıw[∏ñ√Ir≈¨LäÂbÛÔæ8ƒ…J∂√sõÍY{F'lmg^∑B∏ú“5€ä±?ƒr†πàÆ„a¸â/Â[ñ∆aﬂà Ïo‡ô◊ÿœx.ºπÊ◊æ¨Êw£Mj9•Y€“ÒGÿÉ[h©øΩüá„ ßÙıÏ¢Ã».‰≥ˆGU¸£™sÌm≤∞∂Ωë≥ã¯!ÄKNX°Ä(i,˚o'¿Ñcœ∞ﬁ´∞í=R£¢Ã¨¥U⁄>ê*È!UF∏àR~+◊nö˙ﬁñÊ´∂JÃì≠≤ßÙB–>úFu!Ì`:Ö=”]7^.ÎC∏è¬)Hyß‘56ÿlWIÛ{ñ˜2o¡ ›l?zrC∂ÚsKV&Örÿççga)Ç‡ﬁÔ`‹qæ∫Õt/¶Fæ`™Ø5V6“L7µ\êôFdègˇÜ^Àà+Ê±ãy ñLnººJâ]Íµìo;·aèl≤N∂f	VV¿hà=ÕÀÔ)πŒ˝sßÛ]˛≈xµFEu]a∆ÒâI&îÎÄxåWj|h¡ c¨! "ëäÄ¢ƒ!à<TE4H	
Xyµ*‡ãî®%È¯öÇà»´µKõ˜e¨›g Üïÿµ˙„ÆuœΩÁÏ˚ÌΩø˝Ì}'	igS(ò«|ô«Z	ØÊ¡[¡h•§zî™óØ†e=P¬ô~8«∞ilBÑƒ∆|¿ôu0B$∞¸∏ÅGïßˆÉ3ãBπ$™Td ⁄†®óÛïıÚØå≈ˆπ Y‰˘‰,DP¡Qi0–]√Œtì–ıø6Ù>ıê¨á*Ω9w˛ÅX+?îs‘ï«`>[5Ãª•´w3w¶Ü´Á.C2âöXAGZÂQ€D4Û∞&b≠]l(õ¬T/â[WÆÁ{âí ÄË†&—]Wˆøäç–â,b5K!çP#8f˜,HË&ˇÄG§êﬂ≥G∏P±Ã¬ÿ˛ <ªå.Åí≈	ùM5Ùõq[èé Ë„i¥ﬂåøÖîTò∆ƒÿ˛ëΩÊœSµ&œMjMƒ»n¡™§êFé<âˆ1;|¡¨W‹8õFƒJñ7–$§êπâØ1ü0⁄Ü„0Øó{ƒH#ê7‰<Ÿ7–"¿Î?¬¬É‚¿}<»Ú}Å<9»ØÔz‡VèRvÎWÁMÚ&ÄB@3¯‡Qï	æ,Ä∆#3TâlsE…t]Ñw/≠™ÉzÀ©˚¿üo‡"ˆ2Ø?i+‘ÌUgòSÍ" <ÈﬂU∂’ﬁ.naB˙Îü£[¢n®Û—5Í+û}gıÃ/ü?ìS|\
¸J≠›≤9y”KÄΩ ø≈1z÷øecΩ˝U¢Ω°á}X—o~õ˘P|¬_ÖºJjÍíì mc ‰u{ñek¨˙»÷úùásZÉjl÷ÂÕÁΩ3∞®ªüiœ3òbœJñ≈7ûªıiØ
v√™ûaóÍOùâÍ‰†_Wz°πW)◊À•j∞,º ∆S∂¿óY.Hê|Y.¸^	aA¶s„=‹(SÏlÀì87|>f”'`yñ;u	≤ÁÏµ”∞“ÙÊ°∫Õ¥„ê?◊G‰•vúIÚ•lﬂo¶cm˘ímsp'å>3„FÅÈ+N—Ÿ£| Î‘ÿˇjﬂÅI&ˆÙˆ˜Tﬁã¥ô8∞WòÍ7ù:G◊˛P4ÙTáR¡Ç)bÂè‚	œM¸¥&†i¡∆‚)√!÷H¬($·SuÉÃc	∑ëÉ≈Úm¡ö∞„"hÚ≥¡j9L	©PÆ^Ã eîCÖ¸W˜u¨Àe√K/êyÈ˙3täjô(´˘ÈNÍÑ)\˙3Ñ'¸ûπ€Ü€†ì∏Ó$an`.œ2p;ﬁ„Iï&AÁ” ﬂ∆¬ù˘Ö^òG¨ÖUÚhu⁄>° =øÛΩT†ïvÌŸÊπÖΩ∂~Ïºÿˇ¯˜Lm„ ?¶ÁÍè~YiTüvúH=Fã”ˇ∏_ i>›ùú¢•õˆÌìö†N∏î]¯/ÊBŸòÖ~LµIÇı,R-÷.MÙ
\Jóh´.dKŒÊ~ûw∫∏%£™‹T≈uPû©áô`€R–v#,_(T_t≤Øó“\ŸòH	-≠qöCõ˛FK¢ÜçgÖÍ6î=åA	˝¨*¥ûÇY+XÇ-éΩ#KÚÒWe2ı[±2'öÛêƒÁ∞ÿ“ƒÇRß–˜ÄÊÆR˛X~E›òì
£x7q˝ê9∞qÿº÷wK
„t0ÍnÅ‰B|∂oú;üN9
ØÁJ∞¸‰◊•uÙõÃ˝µ“p∑∫ ±±{ vSV’n†Ωª≠'≈pÏÎùÏÈúîv|,…fÚµYŒíê_Ï:∫Ç2[?¸´πYbs>*aà¥˛“â∆`cÓ⁄å©É’:p÷)+⁄%¿-u˙a·XF9òt”ÊÙ˜oóí#ÑÊÍå
F…ÖI|ƒ˛ÖOS¡ÍoŸËShRÑÀl˙V)ò·ØR«∑: zE‹Q∂Ytê«Úú0º$ßI®Ã,<xúVì\Ω‡MfÖ¨öµU⁄Ó%Ã·‘2 Ωt0Z/€‘˚ËÕ´;ÇªAS*∂¿M9J=Å—a3©ÀPtHC¡ˇ	+Í’≥âÿ¢q«PúJY{¬á≤ÒÓÏM69'Ôç, ÈWó j 07Al€ï0NÇ◊‘ÓGÿ∏Pßñ„ÔKg=8WpEê£x.ÚÙ^ÂEt¢U&Ç·–’ø‘–õâ´ì§wNË∑e3°)ß¯)õ@W,ˇâ!ºŸ…Âqˇ~®h ≠≤- ëÀÒM^ª∫É>¸q/·;xÁq·b¡?œC OÎÑw{≈ö¶!yWJ™Èµa^˛Ù.k∫‘wm‡zÈÚûç%ã®ˇ¢O˛∞1ä∑0≥âÍ≈g¶˜äïˇáó÷?Y∏6hÈ$øØS‹ËÇ‰ne'ÚïŸn<¿,¡ÅÇ˝ï°≤=∂,ôeˆÃﬂK0ôÖ´g`öë™~|óˆÓô L£$º÷L˝U1áXx[/œ‰‡¿æª≈€∆RUiE˜}c-èé‚]b≠+÷ÚææÔã$6árv`ØÃ™é¯íÇ§áwÒàNõA`"ıÒ›¬Ò?B>"~ÊÇ1ªÓ÷ëg~@< £†á{BO¡Õ™S¥,Î”Ωôíòìﬂ.àG”ì¥i€Ë‚’!À◊qóÛ⁄x≤¸#p°‚Qñ…o®õ≤Û¿Ñ9R{ßSc§h¶l⁄“””§—ÃÁj{$u›˝ıﬂsêvKµëåÇ'}|˜"∂A©®œªxqëw—¬Ïú&”ñCçeÙÚÅ0˜^U…zyöNÒûñ…ÂÍ°r·Èq”¸®ã˛µ8=ÌORÓ5aÔé)[iÆº”YøÓÛ¬≥'Â‡»¡E&*Œ‹Ä˘ñ–êã—∆úx˜èÉË‹Ï+'3%N2k¿L⁄=¨i]„ükç√b$÷)*»≤‘æ∑9µÕ¡L∂#ˇ´Ô˙bØŸæO¶m}Põ)¯è06˝pw)ªﬂ⁄ï˝z¨Ú˛3460‹˙ûˆü¡ÿ|ã˘.-ˆTÎyˇFWœ/`ÒΩh
∏÷sÚ;Ÿ˙Årlø}¿úI@∞÷6<î}üZŒ8ÒG7Û˜åÔ´E'˝^“≠Ò=„‰Ô ÀÙ˚ÍÔ·ﬂßÇ™@˘ﬂ¡¡ﬂÉAn	˚ÌrˆßT9c˜èIÃﬂ≠DcXÛ™KKR§À™{zÎÂÅ·Ÿ5sfÁÈÎœ^6V˛∏ “ÔˆNƒ;Æ¿ÆÄÃe∆e?BôøÀ˝H˝^Õˆ˚Œ%P•¯Tû˝nb˚~„á‹¨ã¨øØÉ3W÷ŸªØΩ/›˛ë/|Éƒíª¸ü,Qx°!¸©ÿÿÚΩÁ2„Å”ô|Ô˝—“ˇßÿ∆3˜3˛ò≥ü˘ª”è´¢˛Ïﬂﬂ˝vfÌ`ˇ¢¸Ÿ(}Oc=¿ﬁÛ˚´Ë˛?·Ï|µ3∆Õ¸2Ûª L∂ÔK'=öÙÁ–dˆ™9?„Ê¸ŒöŒy?ÈœÀÈúgπÓsü8q‚rû„ã˚˚yx$ã¸à0 -î™endstreamendobj84 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[25/minus/uni00A0/uni03BC/lessequal/fl/greaterequal/fi]/Type/Encoding>>endobj85 0 obj<</Ascent 932/CapHeight 714/CharSet(/minus/uni00A0/uni03BC/lessequal/fl/greaterequal/fi/space/percent/parenleft/parenright/asterisk/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal/greater/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V\/W/Y/bracketleft/bracketright/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z/quoteleft/quoteright/quotedblleft/quotedblright/bullet/endash/registered/degree/multiply/idieresis)/Descent -212/Flags 32/FontBBox[-164 -212 1000 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 91 0 R/FontName/NXSWOC+HelveticaNeueLTStd-Cn/FontStretch/Condensed/FontWeight 400/ItalicAngle 0/StemV 84/Type/FontDescriptor/XHeight 536>>endobj86 0 obj<</Filter/FlateDecode/Length 650>>stream
Hâ\‘Õj„0‡ΩüBÀvQlKWW5Ñ@˛
YÃìŒ§∂“1L„∏ãº˝ËËÑ&ê˙∏ír?]lïõ˝v?Ù≥)NóˆgsÍánä◊À«‘FÛﬂ˚°®≠È˙væﬂÂøÌ˘8eZ|∏]ÁxﬁßK±XòÚWºŒ”Õ<¨∫À[|, Sß~x7ø7áGS>∆Òo<«a6ïY.MOÈáæ«Ô«s4e^ˆ¥Ô“x?ﬂû“öØØ∑1õÔkb⁄KØ„±ç”qxè≈¢Jü•Yº§œ≤àC˜ﬂx#\ˆvjˇßbQ7i≤µµ]¶ºJπ™VÚŸ≠7»õ<GyõÁ®¶o€qÃ#ø|ç5ÈﬁV˘ﬁ‚˜¨g∆<˚Ã¸å‹0Á˘¨ü.)Øô◊»f‘≥¨ü.)Ôòw»¨ù.≈¬±ÆC]W3◊»ñ{uéŸ!3ˆÁËtp:eV‰¿êÈw;˙¸é~ø£ﬂ¡ÔËw;˙¸é~ø–)p
ùß–)p
ùß–)p
ùß–)p
ùß–)p
ùß–)p
ùß–)p
ùíùÏ≥†œû}ˆË≥ßﬂ√ÔÈ˜{˙=¸û~øßﬂ√ÔÈ˜{˙=¸ûf≥ß”√ÈiÛ∞)Î*Í*Î*Í*Î*Í*ÎÊÁWY7?Ø™˜Áôuuï}SÙMi»œ≥≤oäæ)=
è≤o˘}–˚˚ëmÏõ¢oz7–∑¿æÙ-–‡Ù¯˝˛@Ä?–‡Ù¯˝˛@Ä?–‡Ù¯‘µUç9çe∆ú∆1c/ç0c/çœŸ¬÷(ˇ€ä{\aèkÓkç}mÈŸ¬≥„ﬁw<êÓ'é¶tÇöœsØ˝ò¶t‰Âc6üu8Â˙!~ûƒ„e4iæ≈? Ë.L¥endstreamendobj91 0 obj<</Filter/FlateDecode/Length 5152/Subtype/Type1C>>stream
HâlkTWzÜd&0`∆AL53+≤
¢H¨
)ä‡R‘ƒj[1ê¬#¡$Äà¥¯™∏,ÙË™’„⁄Z=ÆÏ)mmQ\@ó¢´K|e©ZFz∞æ|É7˚ò`O˝±˛∏ﬂ„~è˚=/éâ}0«ß¶gÍ3ñ%ÕL·ä 8ª)«êŒïri+ıvcdíŸ´¿ŒOÛ¨?ç‚Q˛Àç/„	^¿«O∏8%xΩ#7ò¿Ç±P|Tj6©TZï©ﬂI*‚l6n]©°(œ ÏúuåN≤îTXMy˘v6F£QÕbcU™XVk¥ds¨æ¬fÁäml™9«b-±Xc´-*bu^´„lúµÃ{˘kƒ¨…∆Xª’`‰ä÷B÷í+»LFÆ(õ≥ÊqVvëµ4ß∞ÿ`À…7ô93´]2ãÂ÷Áï⁄Le\Q[d ·Ã6Œ»⁄Û≠ñ“º|6Õd∂ÿ+J8Å»∂¨Ïí‚ÏîY¨¡ldã¨•ïÀ3ŸºŸYìôÕ·¨vÉÄJ≠&õ—îc7YÃ∂®Ëd˝JØìŸ¨ëÀ≈Ñ·Fbòt6-õáaÛ1l!Üiò	√ä}0;Üïcÿóv«0¨√∑ã∞,omﬂ≈“±õ¬’x!~Ô¿o·OÒˇ¯LÚ…˜ŸÈsG¥ZÙâ®WºD¸ëÿC€àF‚*ÒÑ§»4ÚØI¢ƒ(Ÿ*y$íFHﬂì÷H?óﬁ8.k‹æq£æYæÁ}]~¥ü÷Ôè~ﬂ˘]Û˚Ÿ_Ó¿dºf¸ŒÒÉ≤Ò≤m≤3≤ﬁ *`q@f¿ÒÄÅ±Åº7Åô∞iBÀÑgÚ∑‰˘^yü¸ø‘B™öjßÆQO'Œúò=—C“I¥Ö.°O—˜Ç‰ü÷∂Ò√m∏ C€DµbæftπßÜÑz‘E£Ö'ÜHƒ¢≥4xœ.âá\3F√B$$ﬂA{)‰Âd28PuŒ}ËÚ”NuBàR∞òó—˙öŒ€∑Î;;;ÎıMç^œÏˆL°Øëpi4óXLRÉˇV˝ø’·âÄ&¸>s?~¸±˘!øè£√√?ã?Ü‡#–˝7Àd¸»º«-Í·GËô≥π<ÉÚ…‡·ùW˙w¢%2!Íπe/É ÒÔD∞bt=e¢ŸH≠@±(Ó¢ïgH-Ñ‰A(ƒ) ∫Ê‹Ç… ◊v@à:P˝Ç⁄a6®õqë@+ﬂ'{P»∑(≈)P¥Õôáºv°¸…r–	vaD∆ªiˆdÈ
 L	ëmπŒßŒÈmM	Ä¯∫¥ãÕ&¿oôDˆ¸Pî8p¯¬!Ç/ÇP"pH ©®ï§B	)´}ïb–õÖ˝¯9®ùÉ4‘Ù£ö◊Ó—§ôwïçn(«7AªhSÌ a„Ë"ïîUV9¯;¸∏÷ªD∞µä˝^0¬o·ùj–!=“W##R°˘{ëÙ"·%™ù00¿v¢iÇ(b
A¬∂AD(eïá ¯ÜÀ`ëÃ‘’À|3=$’4öπLB]›Æ©é˝D*´¨ÌÁˇÓƒ[\PËÒK˚iÙπßıÿ…Ê∆«wÇºrÍ¿◊%|u”ı*§P∫»ı@ ﬁ˜ó‘Ùπku´ï+VÛóhcP∞Çg«RÅØ€ ‡∞CﬁÏZË˙Çæt•∏®ﬁjHÅA˙È:ëè¸”◊e0Tkıº¬ﬁnFΩô,⁄ãÊÅ¶tﬂ˙Qf˚€îu™Î9¯Ì•ÎäM#hö§ãG„ÖÁ;v]9≤j©íÍ√¸>Q)∏Œ"ΩCÇìÁÑ~7÷ƒ_¶Î–MîB&Ï¢Á√nî0 	7ùoÛ‹\…Xå√àÍ«O∏¿Óu¡ ›∑ù¯ss«?Ó6h$U"qxd’PìRMÍé"Ê√å.A0D$¸Ê˝*ÚÕ u«¿@@]?∫˙*Á[N–9‰ﬂ∏¿ÏJrQ#œk˘oË∆*òä4»∞	ŸQ
ﬂèV@¶íÅ‡+#0&ø{,Xªj]≥£ìl⁄ã¿WIÒ◊,gÑÜ˜“=Ô=‘å—jm1jÜ‚’∂{=ÃX{=˝¯q~ÜË8Ô°·ô£7ÑdM3#üèXÈ#rLoÜ¿SÄ∑ºËlnó˛À3„Uﬁß∞—!or•∫ ] ‘≥&»†£Zê‘†nÈ–√úÛq«î‘ıÜØN˜)ÄLv 1'ß"2·´Øõï‘≥8KŒÚY
j≤x=˝œÜ’)©Ê˜~∑‘“Ê∏|Ïo›ıI<ÀÈü/›æ›ò_ê¶—\˙I9ˆ∫Œ	∑ºUJÚ÷I®“p;®ËÇ˝h*h¿∞ÏaU¬»{ãÑÇóLCS—‰ã*Ëˇ˛Ï—˝LùûÃ€ä#°H√À
Nw1¬éÙ“â±ëÇzd≈›ﬁﬁ#w]5Ï:õ»´≠ø|I°¥wˇ<ı‚±5|-x„"CÎ+µÁ˚ Væ^‘
6öØGïÑC‚IÑ^8^“{#{æP:~—ÎÙûzø"^˚ÿ"à†í∏ ÿ	(U¬'¢èpŸß¬‡f:·—ì⁄r˘~ucKêõ<ô¨'€Q&·&— —5Ú%©°Œ0∫éºèh%);\ÎÑC®v ª\`u'ªÖπ
É!zÑºqâãH.Lãbê?©N¢a	∑œ√tóÒ≤˙#lﬂ˝ysw∑òòñ(%≤êÆ$˙gr∞i≠˘Ã›úÀÑ	Œ´ú¸Cß¸åˆ∏Á∏©'‘.¸j≥k6Ü≥o!Y%(ÑéiH∆POÓMûW«∏I`∑ßˇèÓ™Åä‚∫¬Æª3CL›PÜÅ ⁄©T®¡ÆàDDX+""Ç†A©Î?øAÉÒ†Y6[¸	Z–âÆQDìÒ'$J]c≥b\Åéa§ÿD£5Íù=ŒÈùÖò‡9=ásÜ∑oÔ€Ôﬁ˜}ﬂΩ”M¸t$9]+öD◊íxHÿª0ı2∏Énè†m5ŸÂ´v’U	Ù©!»È≈aX»^8O<–…Ö ËTí¨âÆëºB»fÅƒ”⁄,ìˆ:`´C’Ç≤ıíÈ Á`/T:H%íÁÑ£ü¢µâX–ûüæ#Aœ˝3€Ïq-Plá˙°¸6∂ëmí∑…Â‹©í]AV>K`âÖD¡Bt*«⁄	fö-òlì≤)|∂1m‚G¥√À¡≥M=GÁœ)¥g»=Xs—^∑`◊&Vbk@ö˜¿HÓIÿ¨’9Œ¥‹!ºŒ¥`ZπÕÓúê´™·5‘(Å»ßIo%Ü-⁄⁄–¬_“/b¶ü^ˇ„}¿Ú
ã~:v”!Å‹£Ó”dªÎ‡"5â&&Ú=eÑÔÒ¯Dì√È>ÙuYÎ ü8›ÒSXÖßhzU≠í(©[ä∆L√¥%·√©°ÃÑG&“d|;eƒá‹N·oFMŒëo¿Xd1f[!±©Ñf◊…7Ã‰˜ﬂ†`¥í[—◊»ê"˘.Ehås—LÖ◊Pál8Ê\«=£é©ì…àG
DgA<I"4†˝ÒAG}œU^–b≈õQv•‚[˙\µh£ow¿XIÇM1ô?»˜ûSI·Å	È~Û˘O+∏¶K6™—æˇÈ#ü°Ï‚ôÚ√«¯∏À\QAvÒ¶Á1rÍÆôŸ	Ç°uY•=å»æ≤√{.±Ê)íz¨Ä˚
^§YŸ˙YÒ§2·}¢6Ø)[z∞pÃ:ß|{’Ó[≈†˝’Ó∂5c ‹P¥èˇUU€Ìj.:2OﬁT≤xLw7¶G>–î(Ñ–⁄“A’ìfıAæ—«^go 	Úáxcæ$cuƒ∞Åxˆ:9ΩIÛôùê…≥w∑ÎõN!ò&ÅM”!Ï!ånÑPûΩH/˘,˜˘˙”ÜûΩ)÷&¢≥f!M‹*à≈aÂ®”ùÉhG|8D∏K.ÁPò{Y(©/¿é¯€f·T2Óüw‡◊º\‹_¬¯oH¯m»⁄¶« í—Æ5=SÿÎaî3Ÿç0«44D£Á·∏B∆ı;¶çìù∏÷Bé	ºàÍG™Ìq.eì`≤◊Sö]ÛHæAôÈ˚Hµß4¯c8≤≠ú®˙ª0‹OÓ¢|i?◊ˇDÖd˚⁄A…∏≤àG,XàìÁ·_“C∆B5ÂπÉ,∞9Àl*áCÌ¿¢l~Œ≤á6ı≥ΩG5P¶$ p†Ãœ ∏)ØxsïN3Âv.˝›∞∑Í„
æëôæµ8j∂OH£M‹fãkÖˇ‰¿HõGù4GÑë˝<‰Q‹{Ã!”7}ü¥>9ÕT∞0è'‘ZämúóÛF‚üÄs±.\™;_À£%ÂÃ+m0◊U◊îæ˚æ– º≥{ó±H∑…T]#¿%Ês”}¢'ûâ	DÀ√d#«6.Yö∫dq^˝gç™k+¯˙√e«,n⁄,≈ÂvòëÎ—,¬râmB.Ws?T>ÈuTÖO¢Õ%ˇå‰Ÿ¬Y§öÎ§Ÿ&õô…ÿﬂò—¢˜ã‡†…«îóí÷/œå∞SØXôæÕµMu\Ç≈¢ZÊÂ∏øoΩ3t	B©,hûä¡>gÅπÕÎÈ∏7gG¯ï a ÈÚáó˛QΩ(ëÜá¨Â"¢{	—ÅgU∑£∑“w<—O	œÌOÍÂ≈úûÏ4“ÁÚíÍRt$ _ò4$¸<°ÄmilhÿØ8y°°”U~x›!6’)	ñ"<·&W≈ﬂ#§éCsc˘ıåd‡N0¿¬xÇáˆ;cæ@¿E˙∞	&pÔ∆∑é8öeŸÄ∂´:Eußó(gıŸÇ⁄ÈSïNÚßÌÈôkVŒÑå6©ÉokÚ‰ñ8;&ıöà’ao¡&y3Á hd˛Ù©˙Ì†Íq%)∞ﬂBlF≥∑¢åÃŸ¢‘Ü8ª
'§óÁÓ#…ÿa/‘Z+s$ùY:Éå¿±8}ı°¶›Çû&>Ä3Yt0¢£B\Úï7+ïT·=«àÍfDI”é∂è¨_ˇ9˙uæüew¶›Ùî)ã÷•gÛÉ◊®4)Ÿí˚ﬂÔT≠"ˆQ∂ËÈnç¯ùkã,∞ß‰8W‚ÆG´»ZaÇl·Ù˝Õt≤)#qGë˘›<õ¡∞÷íÚrcπÓﬂß>ïgôF ∫⁄5À4j®ÄÙê¶¥´EƒDÂp˝@ö˙öìH%v¥gÌrá3MØÿÇíìR«vÊ(ûcŸ¶vWbb€ë”◊~LåfÜ-ÛÙ]í≤:uﬂVêy$FóøaY∂`§ŸÆˆ0f∞V πÆR±÷ˇ[+_Wèq7ï8‰ï<◊¶™ì SR◊!QI@=ÒÜ òr⁄%ìÄ’‡çLö≤äxì ˚À:nz¡p∑ ∑{+¸âqÀ˜üÜóEÇr‡wvy∆‘eóKó†=(›UÑ9äπ°(Ã'?≥paáô^~»∫˛ºÑì*∂£‡†óöëQ§$vœ¶$ˆÛs’›xÓ¯|ﬂWÒ0
Yw˜`0«.Â\t¶Ü1ló¡»4“èM!	&~'âÁ≠uÁîIKR±hô‚∂‹£äì∞mX3Ë£Ô|Y∂vﬂ;%{x∂ºõa€Jwæe.–≈æ±"iã™Æ_Ã¶π™ÊÒWÒ˜"ÃÁäÆ˛E…/qÌ%≈0ÇL’M	OÒ'Í´yW≤ˆŒïl[aÑœÏòÌCÛˇvu∏ƒLt0ˇ¡ıf†ûœØ¡Üe®1|–Ós£µ¨∂≠23J—g±]ûhsâ9ä:ÏßÈ»Í?ˆ|\Sjﬁœ_˚ÂÂ“D∆qéÎÓ làvÆn*ô.5]∞
m%*îk$®dÑ9
°êK%2öÕ2ëÖ ˝B!àT∂eÎ¢R∂B&àÖN%≥ÁÔ=w*Yª˜«ΩÔÓ=ÓyæüÁ.5ûoÆ’mËr`˙ãº2Ò\ãÍsÍÙ≤ê4ÕøyﬁrDŸ^«Î·w*QÇÕ	ﬁÁ∑{T]>cCÅ19v®›Abn±S<$ë~çm…J.Ú(ô‰jdKsÜˆ‘k±÷^çX”«ÜkƒäX˚™X±Ä‹©bmõ˘Ìx+Öœ‘˙fÏ#‘LZ41mDb!˙æ¥7~É„?ËqµñHÇ>àá|¢ëoÖbı—&ö/á„N3xDv7àıG∏ìÁÎ™+Ù5ı-óœ
ÑK.Wsø~ÆGÈ6@yÉõ“µ≥',û=ì˙ç~z'Ÿ˚§BÑzû^Tπ˙i£ MD‚ﬁ“˜¯}óà¯qÚ2Ò”_òHM+≥≤R”÷œS¸—Å1»@è˝ß¿¬•R‘t*fzI©*ó‘˘Â˝ÖÍ˘eË≠–‚gúƒ¡BÀ*‚+Ã∏`∆ÑıCX4≤C°@  çŸŸF	ﬂ¯˚¬ÚÎbvêëG≈IM„+MÎR…∂!(b<ÍïıêÁ¢yÿÉ∂a≥Ÿf3KC±^∑€Îuóóññ´?∑W“¡ã≥>∏ÂÉæ)sGìHôM2WAe∞æ„!íZ9ôßQP»…Ìû{‚Ç•R%∫õóiâ&Ñáèõä¨áÖ™Tã‘Y4ÏhY†µ8 ¢v4úßv	Î°ó"µ`∫dÄ4µµ†m§öÉ¶∂Én™dÊπ¬>Ç*ë\ë±û—Õﬂ%EÃRƒíÍª¢{ÄÄfÂj¢ç£˝v;PÕ∞˚πeAƒ\tÌ®sÃ9ÛeâF1ﬂ-!qtŒ¬√é-Z´[VπﬂÉ˜”ä¡˚Û»òÄ)E> [É´€—´◊¢XM’(nπÓaûxXR2/˙:˘V5≥ê«˘%ë„$â>=äÒ‚bíËaΩdD,`ÜÊsXÚÃ–<ÆP 	påÛóÈ<.N¡≈g]·2-q¡f7€«€ïg◊Ñ∫ÆpY≠Ï\ç3≥Ì ◊Œ5rƒÿZ_[[€Ì»Hﬂç÷÷»u–¥û4âø ãI€endstreamendobj81 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[30/greaterequal/f_i]/Type/Encoding>>endobj82 0 obj<</Ascent 961/CapHeight 714/CharSet(/greaterequal/f_i/space/percent/parenleft/parenright/asterisk/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/equal/A/B/C/D/E/F/G/H/I/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z/re\gistered)/Descent -224/Flags 32/FontBBox[-164 -224 1066 961]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 92 0 R/FontName/NXSWOC+HelveticaNeueLTStd-BdCn/FontStretch/Condensed/FontWeight 700/ItalicAngle 0/StemV 140/Type/FontDescriptor/XHeight 538>>endobj83 0 obj<</Filter/FlateDecode/Length 561>>stream
Hâ\‘›é¢@‡{û¢/g.&(]]5ìGùƒã˝…∫˚ ≠K≤AºÌ∑«Ã&KÇB∑ı•Ë&ﬂÏ∑˚Æù\˛}ÏÎCú‹©Ìö1^˚€XGwåÁ∂ÀñÖk⁄zz‹Õøı•≤<M>‹ØSºÏªSüï•À§á◊iºªßu”„sñõ8∂›Ÿ=˝⁄û]~∏√üxâ›‰nµrM<•?˙R_´Kt˘<Ìeﬂ§ÁÌtIs˛ç¯y¢+Ê˚%1uﬂƒÎP’q¨∫sÃ E:VÆ¸H«*ã]ÛﬂsN;ûÍﬂ’òïÀ]\V)§ºX®¶Û-›ã˘>]RÃWº2ø"ø1œ„◊Ãk‰wÊw‰ÛyÀºEﬁ1ÔêY;]≤“≥ÆG]ød^"Ã≤gˆ»¬,»tz8Ω2+≤12˝~Oøáﬂ”Ô·˜tz8ÖÅAhÑÅAhÑÅAhÑÅAhÑÅAÿ+AØÑôÏï†W¬^	zÿ´Ä^:úÅŒ g†3¿Ëp:úÅŒ g†3¿Ëp:ú ZäZ ZäZ ZäZ ZäZ ZÛ:S}¨3d÷R‘R÷R‘R÷ö◊°ÚΩ(ﬁãr])÷ï≤Wä^){•Ëï≤Wä^ÈcM£W∆^zeÙ¸Fø¡oÙ¸Fø¡oÙ¸Fø¡oÙ¸Fø¡oÙ¸Fø¡ø¶-]∞9ª€4}M‹Á7†æçc⁄˛Û'gﬁ˜ÿÒm?øJC?∏4gˆWÄ xT‚endstreamendobj92 0 obj<</Filter/FlateDecode/Length 4685/Subtype/Type1C>>stream
HâtTPSgŒ%…DºÑ\.jê{ØäÎH61ÀtdPAD1≤bãÏ∆p¡(H¨Xîµv@S¿Í¨.VÒ¡8÷µ´¯Z’’b]|¨äµÿŸNù.X∫∫bz.ˆÒ'ˆπè…‰›Ûùˇ;ﬂŒ°™ EQ¬¬\Î“¨9∆4©∏RÚ8Ï∂ÖRÖî±ƒÍ)0Õ.òS0ë£)9B%Û°∆£Á≈π9jôìgÑﬂπTp§©–Q©∏"ódÛH.©º¬V\¯s«gŸó£h•G¸…ÙÈñãqKúò\‡\!â÷5nèT‚Áó⁄ùÆ2ßã¿
Ãbrq± ∏Eó‰ñ\ï˛√oπâ∑h=.[ÅTbs≠ùÖbÜ£‘ÈYS&âsà39‹~¢£TÙ¨îƒ≥’,."ﬁK=¢≠¥@\Ú-:´∞–aóá%∂5"·ÙC¥]ryldv7.qUÖÀ·.pÿ=g©˚Á•∂È∞p∫Dâ†ò∏/uK“wüÁï¨H3OIµ.Òo^§B—éR(hÖ"DØ‡äÒ¡
”H≈Ï1ä
™éR,kõ©X®xDES9‘fÍuóREyÉ>U.SÓP˛KÂQµ©ß®[‘Á’ü“]Kﬂ’Ë4âªÊäf0X<1ÿº-∏7dT»∆êÁ⁄UZØˆ≤ˆo#¶ç(—∫>Ù“Ha§g‰QfSŒºÕtÖÖEÜUÖù˚ßnπÓîn0‹æ'¸°^£œ—7ÈoÍáÿFˆLƒ®Foß<–Ië1¶SÈU…ıCãÜÎihƒ?r8∂©°èF/p‡ﬂo’”˘Å5ÃB≤ßÂÛúÖ˛√¿Ôjz†∫«ÊvUÈ€|ü˘@GˆT-€S+_Ñ˘‹Ì¶ˆˆˆ&˚‹Ñ:ª›^◊˛ÄW«!w t†;–pÂ]®C]y&r<¡'@ﬂˇ75˝∑CˆΩ⁄≠√gπG¥;TØé£\é”*_DVQù0Z	ãáÚπ…h±°	Eä'–Ù%Zx∆b‚=— âáÄ˚å¸w@†	r(_ı	!áâL,F.ç˜%XNÄ	Dà60MœàÚÈ*XH`ÊáJ0ì˚0BÉLª+{“ÑÓ◊Óﬁõ–}&i»ŸG»ÿ’°aûÌ©+Ë(ÿ :%là$ÒZ˝HFØï¸»	Õx¡B]$t.ÇÖCÀ˘µö¬Í¢ïoÚ)öØ~Ωˇûœ ëY®-u
é(O¡Sµp¥öˇ@¬h∞”È[+á™´®z¯\Y_√Åä≤W£äf™k˙ÂC˝‘nàƒ(a™ A˙ŒK◊∫ﬁYÅ©¸,¶ønÕ»\{Ryå9ƒa”93$A—vòÀ†)∑ì∞®”1óg™˜T ı˝@M“˝æDÂé”$÷dô¢÷ô`I9¶⁄*y≥ˇBbâë¸*®8l°∑∂Ì;v‚Ë«wG˜ﬁ9xıØ`Rn„x4¶&„(æxÕΩ∑∂^˚s‘È˝•ãf◊ÆŒX,dÁ®««ÊæÇzÉúà÷˜Ø©Ñ˙~}A‚Of=ƒ∞Z¿Œ’k0ÍF<DÛÏ ˜Ñ>~¥ÚCK≥–†aOvÔ<~È/O∫åhHNAÅá—t˜ˆ3]≠eÛyˆAvENüg¢ŸèŒ–ö≥327,M…®9˝pì‡è&ëÄr™®fPÅËOΩﬂ¬Eöƒ◊™n†qÀp8[pa4È®Ê…98ô∆ı√Yj¬˙	∏Aï˜†“˚1ægÂƒ°tnXM≥ΩÂ√ú8ö=€æ•uˇÒ®ÎªWa»îÚÂŸôo‹Ïêˇ%ùpê<{§ü˛
¶Ä™hÀ≥ΩmkÀÑMÙN¯©ö_™”Êsøæô<≥âË¬í{û≥≤ú#ÔÁ zì˘‰ƒ(\WGí/ì˜cº*∞œ!ÓˆÁ0ÿº~‘gÊπ›¬¶#Ù‡éûûïœÏZù#‡èÓã÷£óyˆ˘•V…8Ûç¨Åï”jØÙnH#wìLoï”î≠$ í◊Á4(‡¢,,™¿§`0“{!Ô8!¶Cê&@ì§OnÄ&y:ûË˘Ú	ÿgÕê«Õ8àcH“-;czŸoÕ|á'Ô7–”r‡˙9	óH—r	Vr§˜TÒõ4Ï≥ôkÌ)qvÄ‰ˆ-Ó√Ωá;:ˆÆZ0ﬂπ fs˛œ>[è7∏ª.^øæ+g^ZıíÙÙÍ˜ª˘ ≥⁄^a	S@ØÅC0ù√±}ø¯{¨kÇ≈∞í]á~π0nÆß"€a}W«æ˜ˆ	z¬˙§$ûx≠˙›ƒ§∫∏è∑]Ω’Ω}—å∑xcÖ¥ÿZqÙﬁ_≤ }S∂ë˛í≈—4H™ØWÃ≥á†Î'Rv»ç ∏¿…ç†n§Ò±ÍÎsÖ‰°¥ptﬁ*ΩWæ¿ﬁ˜™ ñ>F5,¶#ôbiÃ Wc*Õˆ}Ü:ÆÅæâw’$Sô+^¨~Y>}ÁÀ6@Í'ñï;#°é&yê˛ ®Á^MÿÓØ˘vÀÔØ‹7@Ù‘S®ÂÒMb∆qÁÈ€á]Û“ä ÑÙ$UÅ]Îp««ÁπR“Õ⁄k|rõOÑxüKºÛDÕ>ˆ©\'ópÉØÉW`qö±K⁄–≈<€ŸGaòå°—,ï-Õ,9≈êøÎŒû}z}O˛ÅπÔı…õ}‘e‚4É4íÀëPEÉı"È‚oCaDcûÄµv–ÙõxÚ8?´ ò$,†ôµ^¢’ÚO îƒ¨Ï$Ì˚˘≤	¥∏õ|ÿHÊç‰„6CumØ}ﬂ6í‹xÌ˚6√àÜ5æπïÆ~Â”ü$i¿Oˆ±§ö‰ÕL\–ãqòa≈Û]•QQY8ØdL·ŸÑÈ6Øc$ƒ—qC4DÇD=
»*¶1äh@eì9[ç§ëFçmYF0 .ÄWêh"£$c∂£≥ÿﬁ«T{Œ‹zçöÃôô∫^’≠˙ÓW˜ª˜÷oÈ∫≠Ü∫¡lQhÓl9ÿ^≠3!}ÆEVS√®{æº–<3teúwÊÑw¿ø¸z∑(¥ú?8'\ß\r7å2V„‹ÒË!,›‡Cª¡}p	uße‘ ê4Õ,ñó§2zÏ! ïM>^ÇŒ†Árü≤ÅΩÊä>Ïí˚lS∞UQ¨ª›YpìY)<ã°(wö÷Né’AÓ‰L÷Np√›‚àª5ó3í◊‰\éÆ"™€qX|a%⁄⁄E˚l~÷lº—»Õj0Í+8∆ÜÑâ≈à•’C∑kcåá¯$xìÆäW1uÁé˘]LS°_//√U%»J≠‚-
)SûêR€C`‰_:aÃ£»G‘CGw(ë–AÆó/üÌÃ¬ 1LóéHÉ√l°â8ÑBA/ﬂ§û˘'Æπk◊ﬂ‡Õ¿
áPÓ/Ã5àÇœ>S¡ˆΩ;˝ù…Në™ˇ;Nv{m ⁄&2oî¡+xû·ÚCµ∞ã\©Y5wfLºø.êPw´áµAÓ!Á≈Öòt€ÈÀπâyIÊ‘ﬂÅÁNídﬁZóÛµ∆≠o˝˝^GTÂ√ﬁ¬⁄À˜∞læwë©r?Qïÿ4WÇibX÷+Ùï@ä:Åßnóg¡4Q∏ûwª`‹˜âmÙ9,)ˆ'πÄ≤áOh
ÎØàBO[iÃàº¸fñ«ë^~ò¬ÛE8å¯P~º∑Íh <M‡≤ƒg•5vä≈ºíı˚P(JtÓaM—Û‡iÌw¸Í…‘To∞Kµ´
‡z\bÕ‚±˝±è¡B‡ˆ'aû(g!Yº_z¯ú9Ègøƒ1œÓôXûº€>ç¿˚ÒWV‘Q÷C\6Òêq*ÿ∑Ët∂‹e◊‡z€WòJnÀXèo[8Ä+3âpÃçd‚pö2±T«mGÓîKÏ1≈<VS˙òÉI‰Ôêıö≈Å°˛fÄÖ£â'Õò ùLT•6CB∞¨≥9Zç>WÛ∞@∆ﬂû‰uZÅGçá
NïaËídQ∫”ÔRnîGçc#§º-;©¯ÜíÚÜ¶¢µ—2¢7âoKú–¸Frt¥áÊΩÍÈ?_≠3∑1âH€◊móÚ”±{1Teóû“¿˘Å5]‘{¥◊2Í,n¿‘Çç»Ju–)+WÆØÆ?Yr∏}èX∏Ω4øŸQïg∞L∏è,‡ïÍ“Ñ%Ô5ÖıËvâúˆt\ËÿHù®”∆¿¿Äç‡$Rë‚åˆ&ÁL|de≠‘™ÓÃ∑†}ƒ∑îãàïñ&Ëå 1„∞«t|`WÜªé¬‹ œÖ5s{©@œ4ôÆÈ¬t	_‹ÇQ"º)RL‘ÇçmX ú?ÎË:≥;$B¸º£O·ÕÇ◊q·	ºÄ@séH%#iLà-é–",o¨
B’üÒÆµ∂¯T%«Åœ70¢ˇós’U<Lˇû£Si@"’`r’ÏBÂÎ¡µ£^‹!Rg273-6Jª(˝‚%]#ˇçC1jﬂπ∂sª£¶Á±gJ!®ˇßŸ©.7lﬂMWÂ†€˝o5ì*Ûû∫¸¸m9˘(±øÚBüimJÓZÌ§–’cu≥«wÛ™<:ˇá…‡ﬁdÅÔÔN`ŸI§/afçQ— ›rçZ®4ÚÌ…˙¢Z:6çé°.4≤Ìv¢±ÏxπŒ‰GBSóÖà¬ÒÙåù˘tB Ü¸LsëπéO∏Å:õzÈº* ªx°ÅV–:¨Püµ\h+\L_ÚLüøp·¶´_!ÁËA0c‹éÑàˆMËíé≤äÊ˙")L¥ÚË”hﬁ≤®yÍB˝¢íE#d∞G√ö‘Ô0úF£”ÃÒ¸|’≠ügÛ‘ÔÅ¸Øgv´É≤ígnŸf⁄"æŒÁ8ê≥OŒ’-?È‰ÎT‰üŸÂ)√¢Tõù≠»à0ëoπ<MÊ‡&…[ÿ«rÎhgî_`Äò ü†aaAT`f˛1~ô{.∂ø#Ö≈ÀG‰byÂâ∫ÇµKDÎp6Ê5ñµ¸?óûÛúô,âF“∂>™jæv·“‘≈±ÿxΩm‘ç∑Ò˜d§OË˘¸	ü+F¶Ñ'‡^Bœ%fÕ^f™~ªr¥É∏À1‘i`”òë'¬§÷˚(Õ¿®˚tF∂éN
CÁÎXñ∂ÛVW{Q(F´f]h»˚ü‹ÇaxçtÇ^xÙ
”Œ¿ˇì∂ãòíâ,≠®ëŒ	['Ù⁄¥∂Bäåg8Œ)^˛r˚£O∑ø∆>‰3ë‚Ê `,ˆ˘SÒ+ä√Ü§i”Âôö‚∆
ÏäT‘	Ù7ÉíëÑcå="\Éõ¸ı÷C'Õ99f‰ïœÕ‹úõ©éâãHd‹ªŒPÖ+ÏπîÇ3é‹ªÿ˛?ñÇü:çwo|cƒÒœÌ¿ıÆ>1•Ø∆ªúã*0îîij+‘|æ/)LÁ2‘N_§ØÜ¯NöUßøôÑ5o ñ;¸qiF¨fi¢¥Lø∂™Y,‚QÏü<erW§ûtä:¶µ;∞
û;RûóW)˛ÃÁlﬁî≥Iª|saÉN`.¿ﬁB‰m…MN}(i5kæP4tê&'Ë£◊∑ä2èW√¢e‘i˝wÁO<[¡≤W∏¢	ª≤ø=§¡xµëÃî’ˆÄ†≥÷p0ÖÄVÆQÍ,«ó’J≤x‚3·”Aa8ª‚!∂Sv¡Í¯•’ÖÉâô^–ﬁy¯¡H¸píé%sî¡|6¿›bmÁ~*á⁄CÜ<\˝.x)ßæBÕ¯2¨‰¿ù‹ø€‘è˝¢Pâœ93[°
∑…_Å‹D˝‘ÌFTïA¿I∏ 9lÛŸVG<È-ŸQŸq˙Ò¡÷¥ƒE⁄çsMu*øm‡ ù‡`wPVŸtïU‡@WX78ã’Å:¿2ûÆ¶7∞h7X@Íæﬂ}≈bWÅ6‰–¸[è_~ga6€E7]ÕˆÚ∑)Îk6çÔñ¨á&mﬂxVÍV‰e9`˝¸ÿUÙ(€ömmÒ	˘-)ÚløœÂà˛N¸nı€Í{"Z}”@û’ÔD äˇNî˚Œ"L˛Lﬂyæk!”oûﬂ™@¢5Å$Æ*«◊ÿtôÒœ9ÊΩ?^âö≥øı€Çµì˝˜Õﬂñ¨ÊÏ?dæß≥ﬁ`Ô˘£ z˘è≤3;®LVgøsÈB+íÔR¿ÙÒÏ˚åBı˜íøi¢–*ÜM¯⁄.v§ZÊ∞ñπÜQÀ‘Œ¸7Ûw–ÃÔJ3Ÿæ/ùÙh“üCìŸ´Ê¸åõÛ;k:P‰˝§?/ßs~Â˙.«}q˙Ùâ'N_Õ√ÛHOú<q"oﬂ˜ë≠¢  
ìendstreamendobj24 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA false/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj41 0 obj<</Length 32346>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 0.038 Tw 8 0 0 8 36 727.7881 Tm
[(Based on da)-10 (ta 7)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
6.199 0 Td
[(years after the last pa)-9.9 (tient was enrolled in the trial,)37 ( 44% were kno)-10 (wn)-10 ( )]TJ
0 Tw -6.199 -1.012 Td
[(to be alive,)37 ( 31% were kno)-9.9 (wn to ha)-10 (ve died,)37 ( and 25% had an unkno)-10 (wn sur)-17.9 (vival sta)-10 (tus.)]TJ
-0.005 Tw 0 -1.462 Td
[(By )0.5 (7)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
1.83 0 Td
[(years,)37 ( transforma)-10 (tion to )0.5 (either accelera)-10 (ted or blast phase occurred )0.5 (in nine pa)-9.9 (tients)-10 ( )]TJ
0 Tw -1.83 -1.012 Td
[(on trea)-10 (tment in the 100)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once-daily trea)-10 (tment group.)]TJ
/T1_1 1 Tf
0 -1.687 Td
[(Adv)16 (anced Phase CML and Ph)]TJ
0 Tc 11.248 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( ALL)Tj
/T1_2 1 Tf
0.01 Tw -11.838 -1.575 Td
(Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.447 Tw 1.377 0 Td
[(e-Optimiza)-10 (tion T)74 (rial:)]TJ
/T1_0 1 Tf
0.484 Tw /Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
7.785 0 Td
[( One randomized open-label trial \(NCT00123487\) was)-10 ( )]TJ
0.185 Tw -9.162 -1.012 Td
[(conducted in pa)-9.9 (tients with advanced phase CML \(accelera)-10 (ted phase CML,)37.1 ( myeloid)-10 ( )]TJ
0.068 Tw 0 -1.012 Td
[(blast phase CML,)37 ( or lymphoid blast phase CML\) to evalua)-10 (te the ef\037cac)20 (y and safety of)-9.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.126 Tw -31.5 -1.012 Td
[(SPR)18 (YCEL administered once daily compared with SPR)17.9 (YCEL administered twice daily)55 (.)27 ( )]TJ
0.081 Tw 0 -1.012 Td
[(The primar)-17.9 (y ef\037cac)20 (y endpoint was MaHR.)-3 ( )37.4 (A total of 6)40 (1)80 (1 pa)-10 (tients were randomized to)-9.9 ( )]TJ
0.131 Tw 0 -1.012 Td
[(either the SPR)18.1 (YCEL 1)60 (40)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
9.149 0 Td
(mg once-daily or 70)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
7.888 0 Td
[(mg twice-daily group.)37 ( Median dura)-9.9 (tion)-10 ( )]TJ
0.125 Tw -17.037 -1.012 Td
[(of trea)-9.9 (tment was a)-10 (pproxima)-10 (tely 6)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
12.871 0 Td
[(months for both trea)-9.9 (tment groups.)37 ( )36.8 (The once-daily)-10 ( )]TJ
0.478 Tw -12.871 -1.012 Td
[(schedule demonstra)-10 (ted comparable ef\037cac)20 (y \(non-inferiority\) to the twice-daily)-10 ( )]TJ
0.105 Tw 0 -1.012 Td
[(schedule on the primar)-18 (y ef\037cac)20 (y endpoint; ho)-10 (wever)73.9 (,)37.1 ( the 140-mg once-daily regimen)-10 ( )]TJ
0 Tw 0 -1.012 Td
[(demonstra)-9.9 (ted improved safety and tolerability)55 (.)]TJ
0 -1.552 Td
[(Response ra)-9.9 (tes for pa)-10 (tients in the 140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once-daily group are presented in )37 (T)74 (able)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(19.)Tj
ET
0 0 0 0 k
/GS0 gs
36 579.401 252 -17.348 re
36 562.053 47.88 -13.5 re
83.88 562.053 204.12 -13.5 re
36 548.553 47.88 -19.777 re
83.88 548.553 54 -19.777 re
137.88 548.553 54 -19.777 re
191.88 548.553 54 -19.777 re
245.88 548.553 42.12 -19.777 re
36 528.775 47.88 -19.472 re
83.88 528.775 54 -19.472 re
137.88 528.775 54 -19.472 re
191.88 528.775 54 -19.472 re
245.88 528.775 42.12 -19.472 re
36 509.303 47.88 -19.472 re
83.88 509.303 54 -19.472 re
137.88 509.303 54 -19.472 re
191.88 509.303 54 -19.472 re
245.88 509.303 42.12 -19.472 re
36 489.831 47.88 -19.472 re
83.88 489.831 54 -19.472 re
137.88 489.831 54 -19.472 re
191.88 489.831 54 -19.472 re
245.88 489.831 42.12 -19.472 re
36 470.359 47.88 -19.472 re
83.88 470.359 54 -19.472 re
137.88 470.359 54 -19.472 re
191.88 470.359 54 -19.472 re
245.88 470.359 42.12 -19.472 re
36 450.888 47.88 -19.472 re
83.88 450.888 54 -19.472 re
137.88 450.888 54 -19.472 re
191.88 450.888 54 -19.472 re
245.88 450.888 42.12 -19.472 re
36 431.416 252 -88.872 re
f
0 0 0 1 K
/GS2 gs
q 1 0 0 1 36 562.0526 cm
0 0 m
47.88 0 l
S
Q
0.5 w 
q 1 0 0 1 137.88 548.5526 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 191.88 548.5526 cm
0 0 m
54 0 l
S
Q
1 w 
q 1 0 0 1 83.88 562.0526 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 137.88 562.0526 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 191.88 562.0526 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 245.88 562.0526 cm
0 0 m
42.12 0 l
S
Q
0.505 w 
q 1 0 0 1 137.88 528.7751 cm
0 0 m
54 0 l
S
Q
1.01 w 
q 1 0 0 1 137.88 431.4156 cm
0 0 m
54 0 l
S
Q
0.5 w 
q 1 0 0 1 36 470.3594 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 137.88 470.3594 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 191.88 470.3594 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 83.88 548.5526 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 83.88 470.3594 cm
0 0 m
54 0 l
S
Q
0.505 w 
q 1 0 0 1 83.88 528.7751 cm
0 0 m
54 0 l
S
Q
1.01 w 
q 1 0 0 1 83.88 431.4156 cm
0 0 m
54 0 l
S
Q
0.5 w 
q 1 0 0 1 245.88 509.3033 cm
0 0 m
0 19.219 l
S
Q
q 1 0 0 1 245.88 489.8313 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 245.88 470.6094 cm
0 0 m
0 19.222 l
S
Q
q 1 0 0 1 245.88 470.3594 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 245.88 450.8875 cm
0 0 m
0 19.222 l
S
Q
q 1 0 0 1 245.88 431.9206 cm
0 0 m
0 18.967 l
S
Q
1.01 w 
q 1 0 0 1 245.88 431.4156 cm
0 0 m
42.12 0 l
S
Q
0.5 w 
q 1 0 0 1 245.88 548.5526 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 245.88 529.0276 cm
0 0 m
0 19.275 l
S
Q
0.505 w 
q 1 0 0 1 245.88 528.7751 cm
0 0 m
42.12 0 l
S
Q
1.01 w 
q 1 0 0 1 36 431.4156 cm
0 0 m
47.88 0 l
S
Q
0.505 w 
q 1 0 0 1 36 342.5437 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 83.88 342.5437 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 137.88 342.5437 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 191.88 342.5437 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 245.88 342.5437 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 36 528.7751 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 191.88 528.7751 cm
0 0 m
54 0 l
S
Q
1.01 w 
q 1 0 0 1 191.88 431.4156 cm
0 0 m
54 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0.542 Tw 8 0 0 8 36 573.6886 Tm
[(Table )518 (19:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(Efficacy of SPRYCEL in Imatinib-Resistant or -Intolerant)-10 ( )]TJ
0.024 Tw 0 -1 Td
(Advanced Phase CML and Ph)Tj
0 Tc 0 Tw 11.36 0.125 Td
(+)Tj
-0.01 Tc 0.024 Tw 0.59 -0.125 Td
( ALL \(2-Year Results\))Tj
-0.02 Tc 7.2 0 0 8 160.2689 551.4326 Tm
(140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
0.02 Tw -9.32 -1.347 Td
(Accelerated)Tj
0 Tc 0 Tw 7.2 0 0 8 125.7154 540.6552 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 98.597 532.6552 Tm
(\(n=158\))Tj
0.024 Tw 6.432 1 Td
(Myeloid Blast)Tj
0 Tc 0 Tw 7.2 0 0 8 181.9724 540.6552 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 154.253 532.6552 Tm
(\(n=75\))Tj
0.024 Tw 5.823 1 Td
(Lymphoid Blast)Tj
0 Tc 0 Tw 7.2 0 0 8 238.7012 540.6552 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 208.253 532.6552 Tm
(\(n=33\))Tj
0.024 Tw 6.546 1 Td
(Ph+ ALL)Tj
0 Tc 0 Tw 7.2 0 0 8 278.7469 540.6552 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 257.878 532.6552 Tm
(\(n=40\))Tj
-0.01 Tc 0.01 Tw -30.816 -1.559 Td
(MaHR)Tj
0 Tc 0 Tw 5.4 0 0 6 52.5094 522.9832 Tm
(a)Tj
/T1_0 1 Tf
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 512.1832 Tm
( )Tj
EMC 
1.262 0 Td
(\(95% CI\))Tj
-0.005 Tc 0.005 Tw 8.083 1 Td
(66%)Tj
-0.581 -1 Td
(\(59\22674\))Tj
8.081 1 Td
(28%)Tj
-0.581 -1 Td
(\(18\22640\))Tj
8.081 1 Td
(42%)Tj
-0.581 -1 Td
(\(26\22661\))Tj
7.474 1 Td
(38%)Tj
-0.581 -1 Td
(\(23\22654\))Tj
-0.01 Tc 0.01 Tw -30.656 -1.434 Td
(CHR)Tj
0 Tc 0 Tw 5.4 0 0 6 47.1238 503.5113 Tm
(a)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 492.7113 Tm
( )Tj
EMC 
1.262 0 Td
(\(95% CI\))Tj
-0.005 Tc 0.005 Tw 8.083 1 Td
(47%)Tj
-0.581 -1 Td
(\(40\22656\))Tj
8.081 1 Td
(17%)Tj
-0.581 -1 Td
(\(10\22628\))Tj
8.081 1 Td
(21%)Tj
-0.344 -1 Td
(\(9\22639\))Tj
7.236 1 Td
(33%)Tj
-0.581 -1 Td
(\(19\22649\))Tj
-0.01 Tc 0.01 Tw -30.656 -1.434 Td
(NEL)Tj
0 Tc 0 Tw 5.4 0 0 6 46.3174 484.0394 Tm
(a)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 473.2394 Tm
( )Tj
EMC 
1.262 0 Td
(\(95% CI\))Tj
-0.005 Tc 0.005 Tw 8.083 1 Td
(19%)Tj
-0.581 -1 Td
(\(13\22626\))Tj
8.081 1 Td
(11%)Tj
-0.344 -1 Td
(\(5\22620\))Tj
7.844 1 Td
(21%)Tj
-0.344 -1 Td
(\(9\22639\))Tj
7.474 1 Td
(5%)Tj
-0.581 -1 Td
(\(1\22617\))Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -30.894 -1.434 Td
(MCyR)Tj
0 Tc 0 Tw 5.4 0 0 6 52.1061 464.5675 Tm
(b)Tj
/T1_0 1 Tf
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 453.7675 Tm
( )Tj
EMC 
1.262 0 Td
(\(95% CI\))Tj
-0.005 Tc 0.005 Tw 8.083 1 Td
(39%)Tj
-0.581 -1 Td
(\(31\22647\))Tj
8.081 1 Td
(28%)Tj
-0.581 -1 Td
(\(18\22640\))Tj
8.082 1 Td
(52%)Tj
-0.581 -1 Td
(\(34\22669\))Tj
7.474 1 Td
(70%)Tj
-0.581 -1 Td
(\(54\22683\))Tj
-0.01 Tc 0.01 Tw -30.656 -1.434 Td
(CCyR)Tj
0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1 Td
( )Tj
EMC 
1.262 0 Td
(\(95% CI\))Tj
-0.005 Tc 0.005 Tw 8.083 1 Td
(32%)Tj
-0.581 -1 Td
(\(25\22640\))Tj
8.081 1 Td
(17%)Tj
-0.581 -1 Td
(\(10\22628\))Tj
8.082 1 Td
(39%)Tj
-0.581 -1 Td
(\(23\22658\))Tj
7.474 1 Td
(50%)Tj
-0.581 -1 Td
(\(34\22666\))Tj
5.4 0 0 6 36 424.9037 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.177 Tw 7.2 0 0 8 39.6 422.1037 Tm
[(Hema)-9.9 (tologic response criteria \(all responses confirmed after 4 weeks\):)36.9 ( Major hema)-9.9 (tologic)-5 ( )]TJ
0 Tw 0 -1 Td
[(response:)37 ( \(MaHR\) = complete hema)-9.9 (tologic response \(CHR\) + no evidence of leukemia \(NEL\).)]TJ
0.412 Tw /Span<</ActualText<FEFF0009>>> BDC 
-0.5 -1.225 Td
( )Tj
EMC 
0.5 0 Td
[(CHR:)37 ( )37.5 (WBC )0.5 (\034 )0.5 (institutional )0.6 (ULN,)37 ( )37.4 (ANC )0.5 (\0361000/mm)]TJ
0 Tc 0 Tw 5.4 0 0 6 179.0839 407.1037 Tm
(3)Tj
-0.005 Tc 0.412 Tw 7.2 0 0 8 181.6489 404.3037 Tm
[(,)37 ( )0.5 (pla)-10 (telets )0.5 (\036100,000/mm)]TJ
0 Tc 0 Tw 5.4 0 0 6 252.6971 407.1037 Tm
(3)Tj
-0.005 Tc 0.412 Tw 7.2 0 0 8 255.2621 404.3037 Tm
[(,)37 ( )0.5 (no )0.5 (blasts)-5 ( )]TJ
0.5 Tw -29.953 -1 Td
[(or promyeloc)20 (ytes in peripheral blood,)37 ( bone marro)-10 (w blasts \0345%,)37 ( <5% myeloc)20 (ytes)-5 ( )]TJ
0.31 Tw 0 -1 Td
[(plus metamyeloc)20 (ytes in peripheral blood,)37 ( basophils in peripheral blood <20%,)37 ( and no)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 288 388.3037 Tm
( )Tj
-0.005 Tc 7.2 0 0 8 39.6 380.3037 Tm
[(extramedullar)-18 (y involvement.)]TJ
0.008 Tw /Span<</ActualText<FEFF0009>>> BDC 
-0.5 -1.09 Td
( )Tj
EMC 
0.5 0 Td
[(NEL:)37 ( same criteria as for CHR but )36.6 (ANC \036500/mm)]TJ
0 Tc 0 Tw 5.4 0 0 6 167.9344 374.3837 Tm
(3)Tj
-0.005 Tc 0.008 Tw 7.2 0 0 8 170.4994 371.5837 Tm
( and <1000/mm)Tj
0 Tc 0 Tw 5.4 0 0 6 214.0129 374.3837 Tm
(3)Tj
-0.005 Tc 0.008 Tw 7.2 0 0 8 216.5779 371.5837 Tm
[(,)37 ( or pla)-10 (telets \03620,000/mm)]TJ
0 Tc 0 Tw 5.4 0 0 6 285.4081 374.3837 Tm
(3)Tj
7.2 0 0 8 288 371.5837 Tm
( )Tj
-0.005 Tc -34.5 -1 Td
(and \034100,000/mm)Tj
0 Tc 5.4 0 0 6 89.092 366.3837 Tm
(3)Tj
7.2 0 0 8 91.657 363.5837 Tm
(.)Tj
-0.005 Tc 0.005 Tw 5.4 0 0 6 36 357.6637 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 39.6 354.8637 Tm
(MCyR combines both complete \(0% Ph)Tj
0 Tc 14.21 0.125 Td
(+)Tj
-0.005 Tc 0.595 -0.125 Td
[( meta)-9.9 (phases\) and partial \(>0%\22635%\) responses.)]TJ
-15.305 -1.09 Td
[(CI = confidence inter)-18 (val)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
10 0 Td
(ULN = upper limit of normal range.)Tj
0.055 Tw 8 0 0 8 36 324.4732 Tm
[(In the SPR)18 (YCEL 140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
7.672 0 Td
[(mg once-daily group,)37 ( the median time to MaHR was 1)40 (.9)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
21.095 0 Td
[(months)-5 ( )]TJ
0.516 Tw -28.767 -1.012 Td
[(\(min-max:)37 ( 0.7-14.5\) for pa)-10 (tients with accelera)-9.9 (ted phase CML,)37 ( 1)60 (.9 months)-5 ( )]TJ
0.292 Tw 0 -1.012 Td
[(\(min-max:)37 ( 0.9-6.2\) for pa)-10 (tients with myeloid blast phase CML,)37 ( and 1)40 (.8)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
28.767 0 Td
[(months)-5 ( )]TJ
0 Tw -28.767 -1.012 Td
[(\(min-max:)37 ( 0.9-2.8\) for pa)-10 (tients with lymphoid blast phase CML.)]TJ
-0.01 Tc -0.023 Tw 0 -1.642 Td
[(In pa)-10 (tients with myeloid blast phase CML,)37 ( the median dura)-9.9 (tion of MaHR was 8.1)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
28.792 0 Td
[(months)-10 ( )]TJ
0.122 Tw -28.792 -1.012 Td
[(\(min-max:)37 ( 2.7-21.1\) and 9.0 \(min-max:)37 ( 1.8-23.1\) months for the 140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
26.223 0 Td
[(mg once-daily)-10 ( )]TJ
0.124 Tw -26.223 -1.012 Td
(group and the 70)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
6.787 0 Td
[(mg twice-daily group,)37 ( respectively)55 (.)37 ( In pa)-9.9 (tients with lymphoid blast)-10 ( )]TJ
0.168 Tw -6.787 -1.012 Td
[(phase CML,)37 ( the median dura)-9.9 (tion of MaHR was 4.7)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
19.679 0 Td
[(months \(min-max:)37 ( 3.0-9.0\) and)-10 ( )]TJ
0.003 Tw -19.679 -1.012 Td
[(7)40 (.9)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
1.36 0 Td
[(months )0.5 (\(min-max:)37 ( )0.6 (1.6-22.1\) )0.5 (for )0.6 (the )0.5 (140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
14.655 0 Td
[(mg )0.6 (once-daily )0.6 (group )0.6 (and )0.6 (the )0.6 (70 )0.5 (mg )0.5 (twice-)]TJ
0.148 Tw -16.015 -1.012 Td
[(daily group,)37 ( respectively)55 (.)37 ( In pa)-9.9 (tients with Ph)]TJ
0 Tc 0 Tw 16.61 0.125 Td
(+)Tj
-0.01 Tc 0.148 Tw 0.59 -0.125 Td
[( )36.9 (ALL who were trea)-10 (ted with SPR)18 (YCEL)-10 ( )]TJ
0.006 Tw -17.2 -1.012 Td
(140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
1.64 0 Td
[(mg once-daily)55 (,)37 ( the median dura)-10 (tion of MaHR was 4.6)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
19.437 0 Td
[(months \(min-max:)37 ( 1.4-10.2\).)27 ( )]TJ
-0.058 Tw -21.077 -1.012 Td
[(The medians of progression-free sur)-18 (vival for pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 21.509 0.125 Td
(+)Tj
-0.01 Tc -0.058 Tw 0.59 -0.125 Td
[( )37.1 (ALL trea)-9.9 (ted with SPR)18 (YCEL)-9.9 ( )]TJ
0.107 Tw -22.099 -1.012 Td
(140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
1.64 0 Td
(mg once-daily and 70)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
8.437 0 Td
(mg twice-daily were 4.0)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
9.313 0 Td
[(months \(min-max:)37 ( 0.4-11.1\) and)-10 ( )]TJ
0 Tw -19.39 -1.012 Td
(3.1)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(months \(min-max:)37 ( 0.3-20.8\),)37 ( respectively)55 (.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.8 Td
(14.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(CML in P)24 (ediatric P)24 (atients)]TJ
/T1_0 1 Tf
0.113 Tw -3.375 -1.395 Td
[(The ef\037cac)20 (y of SPR)18 (YCEL in pedia)-10 (tric pa)-10 (tients was evalua)-10 (ted in two pedia)-10 (tric studies)-10 ( )]TJ
0.116 Tw 0 -1.012 Td
[(of 97 pa)-10 (tients with chronic phase CML.)37 ( )37.2 (Among 97 pa)-10 (tients with chronic phase CML)-10 ( )]TJ
0.228 Tw 0 -1.012 Td
[(trea)-10 (ted in two pedia)-10 (tric studies,)37 ( an open-label,)36.9 ( non-randomized dose-ranging trial)-10 ( )]TJ
0.089 Tw 0 -1.012 Td
[(\(NCT00306202\) )0.5 (and )0.5 (an )0.5 (open-label,)37 ( )0.5 (non-randomized,)37 ( )0.5 (single-arm )0.6 (trial )0.6 (\(NCT00777036\),)27 ( )]TJ
0.067 Tw 0 -1.012 Td
[(51 pa)-10 (tients \(exc)19.9 (lusively from the single-arm trial\) had newly dia)-10 (gnosed chronic phase)-10 ( )]TJ
0.055 Tw 0 -1.012 Td
[(CML and 46 pa)-9.9 (tients \(17 from the dose-ranging trial and 29 from the single-arm trial\\))-10 ( )]TJ
0.099 Tw 0 -1.012 Td
[(were resistant or intolerant to previous trea)-10 (tment with ima)-9.9 (tinib.)37 ( Ninety-one of the 97)-10 ( )]TJ
0.063 Tw 0 -1.012 Td
[(pedia)-9.9 (tric pa)-10 (tients were trea)-10 (ted with SPR)18 (YCEL tablets 60 mg/m)]TJ
0 Tc 0 Tw 6 0 0 6 220.0596 134.7177 Tm
(2)Tj
-0.01 Tc 0.063 Tw 8 0 0 8 222.8796 131.9177 Tm
[( once daily \(maximum)-9.9 ( )]TJ
-0.046 Tw -23.36 -1.012 Td
[(dose of 100 mg once daily for pa)-10 (tients with high BSA\).)37 ( P)18 (a)-10 (tients were trea)-10 (ted until disease)-10 ( )]TJ
0 Tw 0 -1.012 Td
[(progression or unacceptable toxicity)55 (.)]TJ
0.044 Tw 0 -1.44 Td
[(Baseline demogra)-9.9 (phic characteristics of the 46 ima)-10 (tinib resistant or intolerant pa)-9.9 (tients)-9.9 ( )]TJ
0.236 Tw 0 -1.012 Td
[(were:)37 ( median a)-10 (ge 13.5 )0.5 (years )0.5 (\(range )0.5 (2 to )0.5 (20 years\),)37 ( 78.3% )37.4 (White,)37 ( 15.2% )37.4 (Asian,)27 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.157 Tw -31.5 -1.012 Td
[(4.4% Black,)37 ( 2.2% other)74 (,)37 ( and 52% female.)37 ( Baseline characteristics of the 51 newly)-10 ( )]TJ
-0.032 Tw 0 -1.012 Td
[(dia)-9.9 (gnosed pa)-10 (tients were:)37 ( median a)-9.9 (ge 12.8 years \(range 1.9 to 17.8 years\),)37 ( 60.8% )36.7 (White,)27 ( )]TJ
0 Tw 0 -1.012 Td
[(31.4% )37 (Asian,)37 ( 5.9% Black,)37 ( 2% Other)74 (,)37 ( and 49% female.)]TJ
0.106 Tw 0 -1.44 Td
[(Median dura)-10 (tion of follo)-10 (w-up was 5.2 years \(range 0.5 to 9.3 years\) for the ima)-10 (tinib)-10 ( )]TJ
0.145 Tw 0 -1.012 Td
[(resistant or intolerant pa)-9.9 (tients and 4.5 years \(range 1.3 to 6.4 years\) for the newly)-10 ( )]TJ
0.25 Tw 0 -1.012 Td
[(dia)-9.9 (gnosed pa)-10 (tients,)37 ( respectively)55 (.)37 ( Ef\037cac)20 (y results for the two pedia)-9.9 (tric studies are)-9.9 ( )]TJ
0 Tw 0 -1.012 Td
[(summarized in )37 (T)74 (able 20.)]TJ
0.07 Tw 36 86.406 Td
[(T)74 (able 20 sho)-10 (ws increasing trend for response for CCyR,)37 ( MCyR,)37 ( and MMR across time)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -0.027 Tw -31.5 -1.043 Td
[(\(3 months to 24 months\).)37 ( )37.1 (The increasing trend in response for all three endpoints is seen)-10 ( )]TJ
0 Tw 0 -1.043 Td
[(in both the newly dia)-10 (gnosed and ima)-10 (tinib resistant or intolerant pa)-9.9 (tients.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 700.133 252 -17.312 re
324 682.821 47.88 -12.912 re
371.88 682.821 54 -12.912 re
425.88 682.821 54 -12.912 re
479.88 682.821 54 -12.912 re
533.88 682.821 42.12 -12.912 re
324 669.91 47.88 -11.472 re
371.88 669.91 54 -11.472 re
425.88 669.91 54 -11.472 re
479.88 669.91 54 -11.472 re
533.88 669.91 42.12 -11.472 re
324 658.438 47.88 -11.472 re
371.88 658.438 54 -11.472 re
425.88 658.438 54 -11.472 re
479.88 658.438 54 -11.472 re
533.88 658.438 42.12 -11.472 re
324 646.966 47.88 -11.472 re
371.88 646.966 54 -11.472 re
425.88 646.966 54 -11.472 re
479.88 646.966 54 -11.472 re
533.88 646.966 42.12 -11.472 re
324 635.494 47.88 -11.472 re
371.88 635.494 54 -11.472 re
425.88 635.494 54 -11.472 re
479.88 635.494 54 -11.472 re
533.88 635.494 42.12 -11.472 re
324 624.022 47.88 -11.472 re
371.88 624.022 54 -11.472 re
425.88 624.022 54 -11.472 re
479.88 624.022 54 -11.472 re
533.88 624.022 42.12 -11.472 re
324 612.55 47.88 -11.472 re
371.88 612.55 54 -11.472 re
425.88 612.55 54 -11.472 re
479.88 612.55 54 -11.472 re
533.88 612.55 42.12 -11.472 re
324 601.078 47.88 -11.472 re
371.88 601.078 54 -11.472 re
425.88 601.078 54 -11.472 re
479.88 601.078 54 -11.472 re
533.88 601.078 42.12 -11.472 re
324 589.606 47.88 -11.472 re
371.88 589.606 54 -11.472 re
425.88 589.606 54 -11.472 re
479.88 589.606 54 -11.472 re
533.88 589.606 42.12 -11.472 re
324 578.134 47.88 -11.472 re
371.88 578.134 54 -11.472 re
425.88 578.134 54 -11.472 re
479.88 578.134 54 -11.472 re
533.88 578.134 42.12 -11.472 re
324 566.662 47.88 -11.472 re
371.88 566.662 54 -11.472 re
425.88 566.662 54 -11.472 re
479.88 566.662 54 -11.472 re
533.88 566.662 42.12 -11.472 re
324 555.19 47.88 -11.472 re
371.88 555.19 54 -11.472 re
425.88 555.19 54 -11.472 re
479.88 555.19 54 -11.472 re
533.88 555.19 42.12 -11.472 re
324 543.719 47.88 -11.472 re
371.88 543.719 54 -11.472 re
425.88 543.719 54 -11.472 re
479.88 543.719 54 -11.472 re
533.88 543.719 42.12 -11.472 re
324 532.247 47.88 -11.472 re
371.88 532.247 54 -11.472 re
425.88 532.247 54 -11.472 re
479.88 532.247 54 -11.472 re
533.88 532.247 42.12 -11.472 re
324 520.775 47.88 -11.472 re
371.88 520.775 54 -11.472 re
425.88 520.775 54 -11.472 re
479.88 520.775 54 -11.472 re
533.88 520.775 42.12 -11.472 re
324 509.303 47.88 -11.472 re
371.88 509.303 54 -11.472 re
425.88 509.303 54 -11.472 re
479.88 509.303 54 -11.472 re
533.88 509.303 42.12 -11.472 re
324 497.831 47.88 -11.472 re
371.88 497.831 54 -11.472 re
425.88 497.831 54 -11.472 re
479.88 497.831 54 -11.472 re
533.88 497.831 42.12 -11.472 re
324 486.359 47.88 -11.472 re
371.88 486.359 54 -11.472 re
425.88 486.359 54 -11.472 re
479.88 486.359 54 -11.472 re
533.88 486.359 42.12 -11.472 re
324 474.887 47.88 -11.472 re
371.88 474.887 54 -11.472 re
425.88 474.887 54 -11.472 re
479.88 474.887 54 -11.472 re
533.88 474.887 42.12 -11.472 re
324 463.415 252 -29.632 re
f
/GS2 gs
q 1 0 0 1 425.88 463.4151 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 371.88 463.4151 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 533.88 463.4151 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 479.88 463.4151 cm
0 0 m
54 0 l
S
Q
0.505 w 
q 1 0 0 1 324 669.9095 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 371.88 669.9095 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 425.88 669.9095 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 479.88 669.9095 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 533.88 669.9095 cm
0 0 m
42.12 0 l
S
Q
1 w 
q 1 0 0 1 324 682.8215 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 371.88 682.8215 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 425.88 682.8215 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 479.88 682.8215 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 533.88 682.8215 cm
0 0 m
42.12 0 l
S
Q
1.01 w 
q 1 0 0 1 324 463.4151 cm
0 0 m
47.88 0 l
S
Q
0.505 w 
q 1 0 0 1 324 433.7832 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 371.88 433.7832 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 425.88 433.7832 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 479.88 433.7832 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 533.88 433.7832 cm
0 0 m
42.12 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0.528 Tw 8 0 0 8 324 694.4214 Tm
[(Table )504 (20:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(Efficacy of SPRYCEL in Pediatric Patients with CP-CML)-10 ( )]TJ
0.059 Tw 0 -1 Td
(Cumulative Response Over Time by Minimum Follow-Up Period)Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 384.545 673.7895 Tm
(3 months)Tj
7.5 0 Td
(6 months)Tj
7.27 0 Td
(12 months)Tj
6.875 0 Td
(24 months)Tj
-0.01 Tc 0.01 Tw -30.054 -1.559 Td
(CCyR)Tj
0.024 Tw 0 -1.434 Td
(\(95% CI\))Tj
/T1_0 1 Tf
0 -1.434 Td
[(Newly dia)-10 (gnosed)]TJ
-0.005 Tc 0.005 Tw 8.991 0 Td
(43.1%)Tj
7.5 0 Td
(66.7%)Tj
7.5 0 Td
(96.1%)Tj
6.875 0 Td
(96.1%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=51\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 629.7018 Tm
(a)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 382.1259 626.9018 Tm
[(\(29.3,)37 ( 57.8\))]TJ
7.5 0 Td
[(\(52.1,)37 ( 79.2\))]TJ
7.5 0 Td
[(\(86.5,)37 ( 99.5\))]TJ
6.875 0 Td
[(\(86.5,)37 ( 99.5\))]TJ
-0.01 Tc -29.948 -1.434 Td
[(Prior ima)-9.9 (tinib)]TJ
-0.005 Tc 0.005 Tw 8.991 0 Td
(45.7%)Tj
7.5 0 Td
(71.7%)Tj
7.5 0 Td
(78.3%)Tj
6.875 0 Td
(82.6%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=46\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 606.758 Tm
(b)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 382.1259 603.958 Tm
[(\(30.9,)37 ( 61.0\))]TJ
7.5 0 Td
[(\(56.5,)37 ( 84.0\))]TJ
7.5 0 Td
[(\(63.6,)37 ( 89.1\))]TJ
6.875 0 Td
[(\(68.6,)37 ( 92.2\))]TJ
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -29.948 -1.434 Td
(MCyR)Tj
0.024 Tw 0 -1.434 Td
(\(95% CI\))Tj
/T1_0 1 Tf
0 -1.434 Td
[(Newly dia)-10 (gnosed)]TJ
-0.005 Tc 0.005 Tw 8.991 0 Td
(60.8%)Tj
7.5 0 Td
(90.2%)Tj
7.5 0 Td
(98.0%)Tj
6.875 0 Td
(98.0%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=51\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 560.8703 Tm
(a)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 382.1259 558.0703 Tm
[(\(46.1,)37 ( 74.2\))]TJ
7.5 0 Td
[(\(78.6,)37 ( 96.7\))]TJ
7.617 0 Td
[(\(89.6,)37 ( 100\))]TJ
6.875 0 Td
[(\(89.6,)37 ( 100\))]TJ
-0.01 Tc -30.066 -1.434 Td
[(Prior ima)-9.9 (tinib)]TJ
-0.005 Tc 0.005 Tw 8.991 0 Td
(60.9%)Tj
7.5 0 Td
(82.6%)Tj
7.5 0 Td
(89.1%)Tj
6.875 0 Td
(89.1%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=46\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 537.9265 Tm
(b)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 382.1259 535.1265 Tm
[(\(45.4,)37 ( 74.9\))]TJ
7.5 0 Td
[(\(68.6,)37 ( 92.2\))]TJ
7.5 0 Td
[(\(76.4,)37 ( 96.4\))]TJ
6.875 0 Td
[(\(76.4,)37 ( 96.4\))]TJ
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -29.948 -1.434 Td
(MMR)Tj
0.024 Tw 0 -1.434 Td
(\(95% CI\))Tj
/T1_0 1 Tf
0 -1.434 Td
[(Newly dia)-10 (gnosed)]TJ
-0.005 Tc 0.005 Tw 9.228 0 Td
(7.8%)Tj
7.263 0 Td
(31.4%)Tj
7.5 0 Td
(56.9%)Tj
6.875 0 Td
(74.5%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=51\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 492.0388 Tm
(a)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 383.8358 489.2388 Tm
[(\(2.2,)37 ( 18.9\))]TJ
7.262 0 Td
[(\(19.1,)37 ( 45.9\))]TJ
7.5 0 Td
[(\(42.2,)37 ( 70.7\))]TJ
6.875 0 Td
[(\(60.4,)37 ( 85.7\))]TJ
-0.01 Tc -29.948 -1.434 Td
[(Prior ima)-9.9 (tinib)]TJ
-0.005 Tc 0.005 Tw 8.991 0 Td
(15.2%)Tj
7.5 0 Td
(26.1%)Tj
7.5 0 Td
(39.1%)Tj
6.875 0 Td
(52.2%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=46\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 469.095 Tm
(b)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 383.8358 466.295 Tm
[(\(6.3,)37 ( 28.9\))]TJ
7.262 0 Td
[(\(14.3,)37 ( 41.1\))]TJ
7.5 0 Td
[(\(25.1,)37 ( 54.6\))]TJ
6.875 0 Td
[(\(36.9,)37 ( 67.1\))]TJ
0.005 Tw 5.4 0 0 6 324 456.9031 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 327.6 454.1031 Tm
[(P)18 (a)-10 (tients from pedia)-10 (tric stud)-10 (y of newly dia)-10 (gnosed CP-CML receiving oral tablet formula)-10 (tion)]TJ
0.005 Tw 5.4 0 0 6 324 448.1831 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.247 Tw 7.2 0 0 8 327.6 445.3831 Tm
[(P)18 (a)-10 (tients from pedia)-10 (tric studies of ima)-10 (tinib-resistant or -intolerant CP-CML receiving oral)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576 445.3831 Tm
( )Tj
-0.005 Tc 7.2 0 0 8 327.6 437.3831 Tm
[(tablet formula)-10 (tion)]TJ
-0.01 Tc -0.011 Tw 8 0 0 8 324 415.6457 Tm
[(With a median follo)-9.9 (w-up of 4.5 years in newly dia)-9.9 (gnosed pa)-10 (tients,)37 ( the median dura)-10 (tions)-10 ( )]TJ
-0.054 Tw 0 -1.043 Td
[(of CCyR,)37 ( MCyR,)37 ( MMR could not be estima)-10 (ted as more than half of the responding pa)-9.9 (tients)-10 ( )]TJ
-0.006 Tw 0 -1.043 Td
[(had not progressed a)-10 (t the time of da)-10 (ta cut-off.)37 ( Range of dura)-10 (tion of response was \(2.5)]TJ
0 Tc 0 Tw 30.9 0.125 Td
(+)Tj
0.6 -0.125 Td
( )Tj
-0.01 Tc -0.023 Tw -31.5 -1.043 Td
(to 66.5)Tj
0 Tc 0 Tw 2.53 0.125 Td
(+)Tj
-0.01 Tc -0.023 Tw 0.59 -0.125 Td
[( months for CCyR\),)37 ( \(1.4 to 66.5)]TJ
0 Tc 0 Tw 10.981 0.125 Td
(+)Tj
-0.01 Tc -0.023 Tw 0.59 -0.125 Td
[( months for MCyR\),)37 ( and \(5.4)]TJ
0 Tc 0 Tw 9.976 0.125 Td
(+)Tj
-0.01 Tc -0.023 Tw 0.59 -0.125 Td
( to 72.5)Tj
0 Tc 0 Tw 2.737 0.125 Td
(+)Tj
-0.01 Tc -0.023 Tw 0.59 -0.125 Td
[( months)-10 ( )]TJ
0.031 Tw -28.585 -1.043 Td
(for subjects who achieved MMR by month 24 and 0.03)Tj
0 Tc 0 Tw 20.02 0.125 Td
(+)Tj
-0.01 Tc 0.031 Tw 0.59 -0.125 Td
( to 72.5)Tj
0 Tc 0 Tw 2.846 0.125 Td
(+)Tj
-0.01 Tc 0.031 Tw 0.59 -0.125 Td
[( months for subjects)-10 ( )]TJ
0 Tw -24.046 -1.043 Td
[(who achieved MMR a)-9.9 (t an)-10 (y time\),)37 ( where )37 (\221)]TJ
0 Tc 14.683 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[(\222 indica)-10 (tes a censored obser)-18 (va)-9.9 (tion.)]TJ
0.074 Tw -15.273 -1.471 Td
[(With a median follo)-9.9 (w-up of 5.2 years in ima)-9.9 (tinib-resistant or - intolerant pa)-9.9 (tients,)37 ( the)-9.9 ( )]TJ
0.053 Tw 0 -1.043 Td
[(median )0.5 (dura)-10 (tions of CCyR,)37 ( MCyR,)37 ( and MMR could not )0.5 (be estima)-10 (ted as more )0.5 (than )0.5 (half)-9.9 ( )]TJ
-0.032 Tw 0 -1.043 Td
[(the responding pa)-10 (tients had not progressed a)-10 (t the time of da)-10 (ta cut-off.)37 ( Range of dura)-9.9 (tion)-10 ( )]TJ
0.028 Tw 0 -1.043 Td
(of response was \(2.4 to 86.9)Tj
0 Tc 0 Tw 10.454 0.125 Td
(+)Tj
-0.01 Tc 0.028 Tw 0.59 -0.125 Td
[( months for CCyR\),)37 ( \(2.4 to 86.9)]TJ
0 Tc 0 Tw 11.286 0.125 Td
(+)Tj
-0.01 Tc 0.028 Tw 0.59 -0.125 Td
[( months for MCyR\),)37 ( and)-10 ( )]TJ
0.01 Tw -22.919 -1.043 Td
(\(2.6)Tj
0 Tc 0 Tw 1.401 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( to 73.6)Tj
0 Tc 2.783 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( months for MMR\),)37 ( where )37 (\221)]TJ
0 Tc 9.576 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[(\222 indica)-10 (tes a censored obser)-18 (va)-9.9 (tion.)]TJ
0.279 Tw -15.53 -1.471 Td
[(The median time to response for MCyR was 2.9 months \(95% CI:)37 ( 2.8 months,)27 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.128 Tw -31.5 -1.043 Td
[(3.5 months\) in the pooled ima)-9.9 (tinib-resistant/intolerant CP-CML pa)-10 (tients.)37 ( )36.9 (The median)-10 ( )]TJ
0.1 Tw 0 -1.043 Td
[(time )0.5 (to )0.5 (response )0.6 (for )0.5 (CCyR )0.5 (was )0.5 (3.3 )0.5 (months )0.6 (\(95% )0.5 (CI:)37 ( )0.6 (2.8 )0.5 (months,)37 ( )0.5 (4.7 )0.5 (months\) )0.6 (in )0.5 (the)-10 ( )]TJ
0.213 Tw 0 -1.043 Td
[(pooled ima)-9.9 (tinib-resistant/intolerant CP-CML pa)-10 (tients.)37 ( )36.9 (The median time to response)-10 ( )]TJ
0.086 Tw 0 -1.043 Td
[(for MMR was 8.3 months \(95% CI:)37 ( 5.0 months,)37 ( 11.8 months\) in the pooled ima)-9.9 (tinib-)-10 ( )]TJ
0 Tw 0 -1.043 Td
[(resistant/intolerant CP-CML pa)-10 (tients.)]TJ
0.279 Tw 0 -1.471 Td
[(The median time to response for MCyR was 3.0 months \(95% CI:)37 ( 2.8 months,)27 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -0.01 Tw -31.5 -1.043 Td
[(4.3 months\) in the newly dia)-10 (gnosed trea)-9.9 (tment-na\357ve CP-CML pa)-10 (tients.)37 ( )37.1 (The median time)-10 ( )]TJ
0.064 Tw 0 -1.043 Td
[(to response for CCyR was 5.5 months \(95% CI:)37 ( 3.0 months,)37 ( 5.7 months\) in the newly)-10 ( )]TJ
-0.038 Tw 0 -1.043 Td
[(dia)-10 (gnosed trea)-10 (tment-na\357ve CP-CML pa)-9.9 (tients.)37.1 ( )37.2 (The median time to response for MMR was)-10 ( )]TJ
0.003 Tw 0 -1.043 Td
[(8.9 months \(95% CI:)37 ( 6.2 months,)37.1 ( 11.7 months\) in the newly dia)-9.9 (gnosed trea)-9.9 (tment-na\357ve)-10 ( )]TJ
0 Tw 0 -1.043 Td
[(CP-CML pa)-10 (tients.)]TJ
0.099 Tw 0 -1.471 Td
[(In the Phase II pedia)-9.9 (tric stud)-10 (y)55 (,)37 ( 1 newly dia)-10 (gnosed pa)-10 (tient and 2 ima)-9.9 (tinib-resistant or)-9.9 ( )]TJ
0 Tw 0 -1.043 Td
[(-intolerant pa)-10 (tients progressed to blast phase CML.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.741 Td
(14.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Ph)Tj
0 Tc 0 Tw 0.999 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( ALL in P)24 (ediatric P)24 (atients)]TJ
/T1_0 1 Tf
0.057 Tw -4.964 -1.426 Td
[(The ef\037cac)20 (y of SPR)18 (YCEL in combina)-10 (tion with chemothera)-9.9 (py was evalua)-10 (ted in a single)-10 ( )]TJ
0.149 Tw 0 -1.043 Td
[(cohort \(cohort 1\) of Stud)-10 (y CA180372 \(NCT01460160\),)37 ( a multicenter)74 (,)37 ( multiple-cohort)-10 ( )]TJ
0.16 Tw 0 -1.043 Td
[(stud)-10 (y of pedia)-10 (tric pa)-9.9 (tients with newly dia)-10 (gnosed B-cell precursor Ph)]TJ
0 Tc 0 Tw 25.972 0.125 Td
(+)Tj
-0.01 Tc 0.123 Tw 0.59 -0.125 Td
[( ALL.)37 ( The )-37.3 (78)-10 ( )]TJ
-0.003 Tw -26.562 -1.043 Td
[(pa)-10 (tients in cohort 1 received SPR)18 (YCEL a)-10 (t a daily dose of 60 mg/m)]TJ
0 Tc 0 Tw 6 0 0 6 512.9158 154.1236 Tm
(2)Tj
-0.01 Tc -0.003 Tw 8 0 0 8 515.7358 151.3236 Tm
[( for up to 24 months,)27 ( )]TJ
0.217 Tw -23.967 -1.043 Td
[(in combina)-9.9 (tion with chemothera)-10 (py)55 (.)37 ( )37 (The backbone chemothera)-10 (py regimen was the)-9.9 ( )]TJ
0 Tw 0 -1.043 Td
[(AIEOP-BFM )37 (ALL 2000 multi-a)-10 (gent chemothera)-9.9 (py protocol.)27 ( )]TJ
0.123 Tw 0 -1.471 Td
[(P)18 (a)-10 (tients had a median a)-10 (ge of 10.4 years \(range 2.6 to 17.9 years\) and inc)20 (luded 20)-10 ( )]TJ
0.114 Tw 0 -1.043 Td
[(pa)-10 (tients \(25%\) 2 to 6 years of a)-9.9 (ge,)37 ( 37 pa)-10 (tients \(46%\) 7 to 12 years of a)-9.9 (ge,)37 ( and 24)-10 ( )]TJ
0.078 Tw 0 -1.043 Td
[(pa)-10 (tients \(30%\) 13 to 17 years of a)-9.9 (ge.)37 ( Eighty-two percent of pa)-9.9 (tients were white,)37 ( and)-10 ( )]TJ
0.196 Tw 0 -1.043 Td
[(55% were male.)37 ( )37.3 (Thirty-two pa)-10 (tients \(41%\) had a white blood cell count \(WBC\) of)-10 ( )]TJ
0 Tw 0 -1.043 Td
[(\03650,000 mc)20 (l a)-9.9 (t dia)-9.9 (gnosis,)37 ( and 17 pa)-10 (tients \(22%\) had extramedullar)-17.9 (y disease.)27 ( )]TJ
0.117 Tw 0 -1.471 Td
[(Ef\037cac)20 (y was established on the basis of 3-year event-free sur)-17.9 (vival \(EFS\),)37 ( de\037ned as)-10 ( )]TJ
0.021 Tw 0 -1.043 Td
[(the time from the start of SPR)17.9 (YCEL to lack of complete response a)-9.9 (t the end of the third)-10 ( )]TJ
0.101 Tw 0 -1.043 Td
[(high risk block,)37 ( rela)-10 (pse,)37 ( secondar)-18 (y malignanc)20 (y)55 (,)37 ( or dea)-10 (th from an)-9.9 (y cause.)37 ( )37.1 (The 3-year)-10 ( )]TJ
0.001 Tw 0 -1.043 Td
[(EFS )0.5 (binar)-17.9 (y ra)-9.9 (te for pa)-10 (tients on )0.5 (Stud)-10 (y CA180372 was 64.1% \(95% CI:)37 ( )0.5 (52.4,)37 ( )0.5 (74.7\).)37 ( )37.4 (At the)-9.9 ( )]TJ
0.079 Tw 0 -1.043 Td
[(end of induction,)37 ( 75 pa)-9.9 (tients \(96%\) had a bone marro)-9.9 (w with <5% lymphoblasts,)37 ( and)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -31.5 -1.043 Td
[(76 pa)-9.9 (tients \(97%\) achieved this by the end of consolida)-9.9 (tion.)]TJ
ET
endstreamendobj39 0 obj<</Length 27641>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 0.005 Tw 8 0 0 8 36 727.248 Tm
[(Dasa)-9.9 (tinib was c)20 (lastogenic when tested )]TJ
/T1_1 1 Tf
(in vitro)Tj
/T1_0 1 Tf
[( in Chinese hamster ovar)-17.9 (y cells,)37 ( with and)-10 ( )]TJ
0.098 Tw 0 -1.001 Td
[(without metabolic activa)-9.9 (tion.)37 ( Dasa)-10 (tinib was not muta)-10 (genic when tested in an )]TJ
/T1_1 1 Tf
(in vitro)Tj
/T1_0 1 Tf
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.015 Tc -0.042 Tw -31.5 -1.001 Td
(bacterial cell assay \(Ames test\) and was not genotoxic in an )Tj
/T1_1 1 Tf
(in vivo)Tj
/T1_0 1 Tf
[( ra)-10 (t micronuc)20 (leus stud)-10 (y)55 (.)]TJ
-0.01 Tc 0.172 Tw 0 -1.563 Td
[(Dasa)-9.9 (tinib did not affect ma)-10 (ting or fertility in male and female ra)-10 (ts a)-9.9 (t plasma drug)-10 ( )]TJ
0.034 Tw 0 -1.001 Td
[(exposure \(AUC\) similar to the human exposure a)-9.9 (t 100 mg daily)55.1 (.)37 ( In repea)-9.9 (t dose studies,)27 ( )]TJ
0.073 Tw 0 -1.001 Td
[(administra)-10 (tion of dasa)-9.9 (tinib resulted in reduced size and secretion of seminal vesic)20 (les,)27.1 ( )]TJ
0.192 Tw 0 -1.001 Td
[(and )0.5 (imma)-9.9 (ture )0.5 (prosta)-9.9 (te,)37 ( )0.5 (seminal )0.5 (vesic)20 (le,)37 ( and testis.)37 ( )37.4 (The administra)-9.9 (tion )0.5 (of )0.5 (dasa)-10 (tinib)-10 ( )]TJ
0.035 Tw 0 -1.001 Td
[(resulted in uterine in\035amma)-10 (tion and mineraliza)-9.9 (tion in monkeys,)37 ( and c)20 (ystic ovaries and)-10 ( )]TJ
0 Tw 0 -1.001 Td
(ovarian hypertrophy in rodents.)Tj
/T1_2 1 Tf
0.01 Tw 0 -2.171 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(CLINIC)18 (AL STUDIES)]TJ
0.01 Tw -3.375 -1.653 Td
(14.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Newly Diagnosed Chronic Phase CML in Adults)Tj
/T1_0 1 Tf
0.103 Tw -3.375 -1.518 Td
[(DASISION )0.5 (\(Dasa)-10 (tinib vs Ima)-10 (tinib Stud)-10 (y in )37.4 (T)74 (rea)-9.9 (tment-Naive Chronic Myeloid Leukemia)-10 ( )]TJ
0 Tw 0 -1.001 Td
[(P)18 (a)-10 (tients\) )0.5 (\(NCT00481247\) was )0.5 (an open-label,)37 ( multicenter)74 (,)37 ( interna)-10 (tional,)37 ( randomized trial)-10 ( )]TJ
0.101 Tw 0 -1.001 Td
[(conducted in adult pa)-10 (tients with newly dia)-9.9 (gnosed chronic phase CML.)37 ( )37 (A total of 519)-10 ( )]TJ
0.134 Tw 0 -1.001 Td
[(pa)-10 (tients were randomized to receive either SPR)18 (YCEL 100 mg once daily or ima)-10 (tinib)-10 ( )]TJ
0.032 Tw 0 -1.001 Td
[(400 )0.5 (mg once daily)55 (.)37 ( P)18 (a)-10 (tients with a )0.5 (histor)-17.9 (y of cardiac disease )0.5 (were )0.5 (inc)20 (luded )0.5 (in this )0.5 (trial)-9.9 ( )]TJ
0.022 Tw 0 -1.001 Td
[(except those who had a myocardial infarction within 6 months,)37 ( congestive heart failure)-10 ( )]TJ
0.145 Tw 0 -1.001 Td
[(within 3 months,)37 ( signi\037cant arrhythmias,)37 ( or QTc prolonga)-10 (tion.)37 ( )36.8 (The primar)-18 (y endpoint)-10 ( )]TJ
0.136 Tw 0 -1.001 Td
[(was the ra)-10 (te of con\037rmed complete c)20 (ytogenetic response \(CCyR\) within 12 months.)27 ( )]TJ
0.061 Tw 0 -1.001 Td
[(Con\037rmed CCyR was de\037ned as a CCyR noted on two consecutive occasi\ons \(a)-9.9 (t least)-10 ( )]TJ
0 Tw 0 -1.001 Td
[(28 days a)-10 (part\).)]TJ
0.064 Tw 0 -1.563 Td
[(Median a)-9.9 (ge was 46 years in the SPR)18 (YCEL group and 49 years in the ima)-9.9 (tinib groups,)27 ( )]TJ
0.018 Tw 0 -1.001 Td
[(with 10% and 11% of pa)-9.9 (tients \03665 years of a)-10 (ge,)37 ( respectively)55 (.)37 ( )37.2 (There were slightly more)-10 ( )]TJ
0.18 Tw 0 -1.001 Td
[(male than female pa)-10 (tients in both groups \(59% vs 41%\).)37 ( F)18 (ifty-three percent of all)-9.9 ( )]TJ
0.075 Tw 0 -1.001 Td
[(pa)-10 (tients were Caucasian and 39% were )37 (Asian.)37 ( )37 (At baseline,)36.9 ( the distribution of Hasford)-10 ( )]TJ
0.07 Tw 0 -1.001 Td
[(scores was similar in the SPR)18 (YCEL and ima)-10 (tinib trea)-10 (tment groups \(lo)-10 (w risk:)37.1 ( 33% and)-9.9 ( )]TJ
0 -1.001 Td
[(34%; intermedia)-9.9 (te risk:)37 ( 48% and 47%; high risk:)37 ( 19% and 19%,)37 ( respectively\).)37 ( )36.7 (With a)-9.9 ( )]TJ
-0.001 Tw 0 -1.001 Td
[(minimum of 12 months follo)-9.9 (w-up,)37 ( 85% of pa)-10 (tients randomized to SPR)18 (YCEL and 81% of)-9.9 ( )]TJ
0 Tw 0 -1.001 Td
[(pa)-10 (tients randomized to ima)-10 (tinib were still on stud)-10 (y)55 (.)]TJ
0.024 Tw 0 -1.563 Td
[(With a minimum of 24 months follo)-10 (w-up,)37 ( 77% of pa)-10 (tients randomized to SPR)18 (YCEL and)-10 ( )]TJ
0.051 Tw 0 -1.001 Td
[(75% of pa)-9.9 (tients randomized to ima)-9.9 (tinib were still on stud)-10 (y and with a minimum of 60)-10 ( )]TJ
0.006 Tw 0 -1.001 Td
[(months follo)-10 (w-up,)37 ( 61% and 62% of pa)-9.9 (tients,)37 ( respectively)55 (,)37 ( were still on trea)-9.9 (tment a)-10 (t the)-10 ( )]TJ
0 Tw 0 -1.001 Td
[(time of stud)-10 (y c)20 (losure.)]TJ
0 -1.563 Td
[(Ef\037cac)20 (y results are summarized in )37.1 (T)73.9 (able 16.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 415.199 252 -17.312 re
36 397.887 95.4 -19.472 re
131.4 397.887 78.3 -19.472 re
209.7 397.887 78.3 -19.472 re
36 378.415 95.4 -11.472 re
131.4 378.415 78.3 -11.472 re
209.7 378.415 78.3 -11.472 re
36 366.943 95.4 -11.472 re
131.4 366.943 78.3 -11.472 re
209.7 366.943 78.3 -11.472 re
36 355.471 95.4 -11.472 re
131.4 355.471 156.6 -11.472 re
36 343.999 95.4 -11.472 re
131.4 343.999 156.6 -11.472 re
36 332.527 95.4 -11.472 re
131.4 332.527 78.3 -11.472 re
209.7 332.527 78.3 -11.472 re
36 321.055 95.4 -11.472 re
131.4 321.055 156.6 -11.472 re
36 309.583 95.4 -11.472 re
131.4 309.583 78.3 -11.472 re
209.7 309.583 78.3 -11.472 re
36 298.111 252 -64.152 re
f
0 0 0 1 K
/GS2 gs
q 1 0 0 1 36 397.8868 cm
0 0 m
95.4 0 l
S
Q
0.5 w 
q 1 0 0 1 36 378.4149 cm
0 0 m
95.4 0 l
S
Q
1 w 
q 1 0 0 1 36 298.1115 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4 298.1115 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7 298.1115 cm
0 0 m
78.3 0 l
S
Q
0.5 w 
q 1 0 0 1 36 343.9991 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4 343.9991 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7 343.9991 cm
0 0 m
78.3 0 l
S
Q
1 w 
q 1 0 0 1 131.4 397.8868 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7 397.8868 cm
0 0 m
78.3 0 l
S
Q
0.5 w 
q 1 0 0 1 131.4 378.4149 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7 378.4149 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 36 233.9596 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4 233.9596 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7 233.9596 cm
0 0 m
78.3 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
0.265 Tw 8 0 0 8 36 409.4868 Tm
[(Table )241 (16:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Efficacy Results in a Randomized Newly Diagnosed Chronic)-10 ( )]TJ
0.024 Tw 0 -1 Td
(Phase CML Trial)Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 158.0402 389.2948 Tm
(SPRYCEL)Tj
0 Tc 0 Tw 7.2 0 0 8 183.0598 389.2948 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 159.707 381.2948 Tm
(\(n=259\))Tj
10.815 1 Td
(Imatinib)Tj
0 Tc 0 Tw 7.2 0 0 8 260.1286 389.2948 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 238.007 381.2948 Tm
(\(n=260\))Tj
-0.01 Tc 0.024 Tw -28.057 -1.434 Td
(Confirmed CCyR)Tj
0 Tc 0 Tw 5.4 0 0 6 81.3951 372.6229 Tm
(a)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 358.351 Tm
( )Tj
EMC 
1.25 0 Td
(Within 12 months \(95% CI\))Tj
/T1_0 1 Tf
-0.005 Tc 13.955 0 Td
(76.8% \(71.2\22681.8\))Tj
11.125 0 Td
(66.2% \(60.1\22671.9\))Tj
/T1_2 1 Tf
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.33 -1.434 Td
( )Tj
EMC 
[(P-v)16.1 (alue)-10 ( )]TJ
/T1_0 1 Tf
-0.005 Tc 0.005 Tw 22.882 0 Td
(0.007*)Tj
/T1_2 1 Tf
-0.01 Tc 0.024 Tw -22.882 -1.434 Td
(Major Molecular Response)Tj
0 Tc 0 Tw 5.4 0 0 6 110.533 338.2072 Tm
(b)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 323.9353 Tm
( )Tj
EMC 
1.25 0 Td
(12 months \(95% CI\))Tj
/T1_0 1 Tf
-0.005 Tc 13.955 0 Td
(52.1% \(45.9\22658.3\))Tj
11.125 0 Td
(33.8% \(28.1\22639.9\))Tj
/T1_2 1 Tf
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.33 -1.434 Td
( )Tj
EMC 
[(P-v)16.1 (alue)]TJ
/T1_0 1 Tf
-0.005 Tc 0.005 Tw 22.52 0 Td
(<0.0001)Tj
/T1_2 1 Tf
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-22.52 -1.434 Td
( )Tj
EMC 
1.25 0 Td
(60 months \(95% CI\))Tj
/T1_0 1 Tf
-0.005 Tc 13.955 0 Td
(76.4% \(70.8\22681.5\))Tj
11.125 0 Td
(64.2% \(58.1\22670.1\))Tj
0.005 Tw 5.4 0 0 6 36 291.5995 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.01 Tc -0.043 Tw 7.2 0 0 8 41 288.7995 Tm
[(Confirmed CCyR is defined as a CCyR noted on two consecutive occasions a\)-10 (t least 28)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
30.369 0 Td
[(days a)-9.9 (part.)]TJ
-0.005 Tc 0.005 Tw 5.4 0 0 6 36 281.7995 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.047 Tw 7.2 0 0 8 41 278.9995 Tm
[(Major molecular response \(a)-9.9 (t an)-10 (y time\) was defined as BCR-ABL ra)-10 (tios \0340.1% by RQ-PCR in)-5 ( )]TJ
0.043 Tw 0 -1 Td
[(peripheral blood samples standardized on the Interna)-10 (tional scale.)37 ( )36.5 (These are cumula)-10 (tive ra)-9.9 (tes)-5 ( )]TJ
0 Tw 0 -1 Td
[(representing minimum follo)-10 (w up for the time frame specified.)]TJ
0.004 Tw -0.694 -1.09 Td
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.694 0 Td
[(Adjusted for Hasford score and indica)-10 (ted sta)-9.9 (tistical significance a)-10 (t a pre-defined nominal level)-5 ( )]TJ
0 Tw 0 -1 Td
(of significance.)Tj
-0.694 -1.09 Td
[(CI = confidence inter)-18 (val.)]TJ
-0.01 Tc 0.068 Tw 8 0 0 8 36 218.8646 Tm
[(The con\037rmed CCyR within 24,)37 ( 36,)37 ( and 60)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
15.948 0 Td
[(months for SPR)18 (YCEL versus ima)-9.9 (tinib arms)-9.9 ( )]TJ
-0.004 Tw -15.948 -1.001 Td
[(were 80% versus 74%,)37 ( 83% versus 77%,)37 ( and 83% versus 79%,)37 ( respectively)55 (.)37 ( )37.2 (The MMR)-9.9 ( )]TJ
-0.035 Tw 0 -1.001 Td
[(a)-10 (t 24 and 36)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.729 0 Td
[(months for SPR)18 (YCEL versus ima)-10 (tinib arms were 65% versus 50% and 69%)-10 ( )]TJ
0 Tw -4.729 -1.001 Td
[(versus 56%,)37 ( respectively)55 (.)]TJ
0.341 Tw 0 -1.496 Td
(After 60)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
3.449 0 Td
[(months follo)-10 (w-up,)37 ( median time to con\037rmed CCyR was 3.)120 (1)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
24.125 0 Td
[(months in)-10 ( )]TJ
0 Tc 0 Tw 3.926 0 Td
( )Tj
-0.01 Tc 0.072 Tw -31.5 -1.001 Td
[(21)40 (5 SPR)18 (YCEL responders and 5.8)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
12.645 0 Td
(months in 204)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
5.589 0 Td
[(ima)-9.9 (tinib responders.)37 ( Median time to)-9.9 ( )]TJ
0 Tc 0 Tw 13.265 0 Td
( )Tj
-0.01 Tc 0.208 Tw -31.5 -1.001 Td
(MMR after 60)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
5.595 0 Td
[(months follo)-10 (w-up was 9.3)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
10.282 0 Td
[(months in 198 SPR)18 (YCEL responders and)-10 ( )]TJ
0 Tw -15.877 -1.001 Td
[(1)20 (5.0)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(months in 167)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(ima)-10 (tinib responders.)]TJ
0.102 Tw 0 -1.451 Td
(At 60)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.241 0 Td
[(months,)37 ( 8 pa)-10 (tients \(3%\) on the dasa)-9.9 (tinib arm progressed to either accelera)-10 (ted)-10 ( )]TJ
0.09 Tw -2.241 -1.001 Td
[(phase or blast crisis )0.5 (while )0.5 (15 )0.5 (pa)-10 (tients \(6%\) )0.5 (on the ima)-10 (tinib )0.5 (arm progressed to either)-10 ( )]TJ
0 Tw 0 -1.001 Td
[(accelera)-10 (ted phase or blast crisis.)]TJ
-0.028 Tw 0 -1.451 Td
[(The estima)-9.9 (ted 60-month sur)-18 (vival ra)-10 (tes for SPR)18 (YCEL- and ima)-10 (tinib-trea)-9.9 (ted pa)-10 (tients were)-9.9 ( )]TJ
0.051 Tw 0 -1.001 Td
[(90.9% \(CI:)37 ( 86.6%\22693.8%\) and 89.6% \(CI:)37 ( 85.2%\22692.8%\),)37 ( respectively)54.9 (.)37.1 ( Based on da)-9.9 (ta)-10 ( )]TJ
0.074 Tw 0 -1.001 Td
(5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
0.7 0 Td
[(years after the last pa)-10 (tient was enrolled in the trial,)37 ( 83% and 77% of pa)-10 (tients were)-10 ( )]TJ
-0.039 Tw -0.7 -1.001 Td
[(kno)-9.9 (wn to be alive in the dasa)-10 (tinib and ima)-10 (tinib trea)-10 (tment groups,)37 ( respectively)55 (,)37 ( 10% were)-9.9 ( )]TJ
0.033 Tw 0 -1.001 Td
[(kno)-9.9 (wn to ha)-9.9 (ve died in both trea)-10 (tment groups,)37 ( and 7% and 13% had unkno)-10 (wn sur)-18 (vival)-10 ( )]TJ
0 Tw 0 -1.001 Td
[(sta)-9.9 (tus in the dasa)-9.9 (tinib and ima)-10 (tinib trea)-10 (tment groups,)37 ( respectively)55.1 (.)]TJ
-0.011 Tc 0.049 Tw 0 -1.451 Td
(At 60)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.182 0 Td
[(months follo)-10 (w-up in the SPR)18 (YCEL arm,)37 ( the ra)-10 (te of MMR a)-10 (t an)-10 (y time in each risk)-11 ( )]TJ
0.108 Tw -2.182 -1.001 Td
[(group determined by Hasford score was 90% \(lo)-10 (w risk\),)37 ( 71% \(intermedia)-9.9 (te risk\) and)-11 ( )]TJ
0.099 Tw 0 -1.001 Td
[(67% \(high risk\).)37 ( In the ima)-10 (tinib arm,)37 ( the ra)-10 (te of MMR a)-10 (t an)-10 (y time in each risk group)-11.1 ( )]TJ
0.124 Tw 0 -1.001 Td
[(determined by Hasford score was 69% \(lo)-10 (w risk\),)37 ( 65% \(intermedia)-10 (te risk\),)37 ( and 54%)-11 ( )]TJ
0 Tw 0 -1.001 Td
(\(high risk\).)Tj
-0.01 Tc 0.18 Tw 36 86.406 Td
[(BCR-ABL sequencing was performed on blood samples from pa)-9.9 (tients in the newly)-10 ( )]TJ
-0.018 Tw 0 -1.002 Td
[(dia)-9.9 (gnosed trial who discontinued dasa)-9.9 (tinib or ima)-10 (tinib thera)-10 (py)55 (.)37 ( )37.2 (Among dasa)-10 (tinib-trea)-10 (ted)-10 ( )]TJ
0 Tw 0 -1.002 Td
[(pa)-10 (tients the muta)-9.9 (tions detected were )37 (T315I,)37 ( F317I/L,)37 ( and )37 (V299L.)]TJ
-0.038 Tw 0 -1.452 Td
[(Dasa)-9.9 (tinib does not a)-9.9 (ppear to be active a)-9.9 (gainst the )37.1 (T315I muta)-10 (tion,)37 ( based on )]TJ
/T1_1 1 Tf
(in vitro)Tj
/T1_0 1 Tf
[( da)-10 (ta.)]TJ
/T1_2 1 Tf
0.01 Tw 0 -1.789 Td
(14.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Imatinib-Resistant or -Intolerant CML or Ph)Tj
0 Tc 16.735 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( ALL in Adults)Tj
/T1_0 1 Tf
0.12 Tw -20.7 -1.497 Td
[(The ef\037cac)20 (y and safety of SPR)18 (YCEL were investiga)-10 (ted in adult pa)-10 (tients with CML or)-10 ( )]TJ
0.01 Tw 0 -1.002 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.125 Td
(+)Tj
-0.01 Tc 0.174 Tw 0.59 -0.125 Td
[( )37.5 (ALL )0.5 (whose )0.5 (disease )0.5 (was )0.5 (resistant )0.5 (to )0.5 (or )0.5 (who )0.5 (were )0.5 (intolerant )0.5 (to )0.5 (ima)-9.9 (tinib:)37 ( )0.5 (1158)-9.9 ( )]TJ
0.125 Tw -1.514 -1.002 Td
[(pa)-10 (tients )0.5 (had chronic )0.5 (phase )0.5 (CML,)37 ( )0.6 (858 )0.5 (pa)-10 (tients )0.5 (had )0.5 (accelera)-9.9 (ted )0.5 (phase,)37 ( )0.5 (myeloid )0.5 (blast)-10 ( )]TJ
0.01 Tw 0 -1.002 Td
[(phase,)37 ( or lymphoid blast phase CML,)37 ( and 130 pa)-10 (tients had Ph)]TJ
0 Tc 0 Tw 22.387 0.125 Td
(+)Tj
-0.01 Tc 0.01 Tw 0.59 -0.125 Td
[( )37.1 (ALL.)37 ( In a c)20 (linical trial in)-10 ( )]TJ
0.012 Tw -22.977 -1.002 Td
[(chronic )0.5 (phase )0.5 (CML,)37 ( resistance )0.5 (to )0.5 (ima)-9.9 (tinib )0.5 (was de\037ned )0.5 (as )0.5 (failure )0.5 (to )0.5 (achieve )0.5 (a complete)-10 ( )]TJ
0.056 Tw 0 -1.002 Td
[(hema)-10 (tologic response \(CHR; after 3 months\),)37 ( major c)20 (ytogenetic response \(MCyR; after)-9.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.159 Tw -31.5 -1.002 Td
[(6\032)-159.4 (months\),)37 ( or complete c)20 (ytogenetic response \(CCyR; after 12 months\); or loss of a)-10 ( )]TJ
0.185 Tw 0 -1.002 Td
(previous molecular response \(with concurrent \03610% increase in Ph)Tj
0 Tc 0 Tw 25.654 0.125 Td
(+)Tj
-0.01 Tc 0.185 Tw 0.59 -0.125 Td
[( meta)-10 (phases\),)27 ( )]TJ
0.151 Tw -26.244 -1.002 Td
[(c)20 (ytogenetic response,)37 ( or hema)-10 (tologic response.)37 ( Ima)-10 (tinib intolerance was de\037ned as)-10 ( )]TJ
0.082 Tw 0 -1.002 Td
[(inability to tolera)-10 (te 400 mg or more of ima)-10 (tinib per day or discontinua)-9.9 (tion of ima)-10 (tinib)-10 ( )]TJ
0 Tw 0 -1.002 Td
[(because of toxicity)55 (.)]TJ
0.004 Tw 0 -1.452 Td
[(Results described belo)-10 (w are based on a minimum of 2 years follo)-9.9 (w-up after the start of)-10 ( )]TJ
0.015 Tw 0 -1.002 Td
[(SPR)18 (YCEL thera)-10 (py )0.5 (in pa)-10 (tients with a )0.5 (median time from )0.5 (initial dia)-9.9 (gnosis )0.5 (of a)-9.9 (pproxima)-10 (tely)-9.9 ( )]TJ
0.047 Tw 0 -1.002 Td
[(5 years.)37 ( )36.8 (Across all studies,)37 ( 48% of pa)-10 (tients were women,)37 ( 81% were white,)37 ( 15% were)-10 ( )]TJ
0.088 Tw 0 -1.002 Td
[(black or )37.2 (Asian,)37 ( 25% were 65 years of a)-10 (ge or older)74 (,)37 ( and 5% were 75 years of a)-10 (ge or)-10 ( )]TJ
0.02 Tw 0 -1.002 Td
[(older)74 (.)37 ( Most pa)-10 (tients had long disease histories with extensive prior trea)-10 (tment,)37 ( inc)20 (luding)-10 ( )]TJ
0.076 Tw 0 -1.002 Td
[(ima)-9.9 (tinib,)37 ( c)19.9 (ytotoxic chemothera)-10 (py)55 (,)37 ( interferon,)37 ( and stem cell transplant.)37 ( Overall,)37.1 ( 80% of)-10 ( )]TJ
0.014 Tw 0 -1.002 Td
[(pa)-10 (tients had ima)-10 (tinib-resistant disease and 20% of pa)-10 (tients were intolerant to ima)-10 (tinib.)27 ( )]TJ
0.057 Tw 0 -1.002 Td
[(The maximum ima)-10 (tinib dose had been 400\226600 mg/day in about 60% of the pa)-10 (tients)-10 ( )]TJ
0 Tw 0 -1.002 Td
[(and >600 mg/day in 40% of the pa)-10 (tients.)]TJ
0.031 Tw 0 -1.452 Td
[(The primar)-18 (y ef\037cac)20 (y endpoint in chronic phase CML was MCyR,)37 ( de\037ned as elimina)-9.9 (tion)-10 ( )]TJ
0.042 Tw 0 -1.002 Td
[(\(CCyR\) or substantial diminution \(by )0.5 (a)-10 (t )0.5 (least )0.5 (65%,)37 ( )0.5 (partial c)20 (ytogenetic response\) )0.5 (of Ph)]TJ
0 Tc 0 Tw 30.9 0.125 Td
(+)Tj
0.6 -0.125 Td
( )Tj
-0.01 Tc 0.053 Tw -31.5 -1.002 Td
[(hema)-10 (topoietic cells.)37 ( )36.9 (The primar)-18 (y ef\037cac)20 (y endpoint in accelera)-10 (ted phase,)37 ( myeloid blast)-10 ( )]TJ
0.197 Tw 0 -1.002 Td
[(phase,)37 ( lymphoid blast phase CML,)37 ( and Ph)]TJ
0 Tc 0 Tw 16.209 0.125 Td
(+)Tj
-0.01 Tc 0.197 Tw 0.59 -0.125 Td
[( )36.7 (ALL was major hema)-10 (tologic response)-10 ( )]TJ
0 Tw -16.799 -1.002 Td
[(\(MaHR\),)37 ( de\037ned as either a CHR or no evidence of leukemia \(NEL\).)]TJ
/T1_2 1 Tf
0 -1.587 Td
(Chronic Phase CML)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.497 Td
(Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.014 Tw 1.377 0 Td
[(e-Optimiza)-9.9 (tion T)74 (rial:)]TJ
/T1_0 1 Tf
0.023 Tw /Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
7.325 0 Td
[( )37.3 (A randomized,)37 ( open-label trial \(NCT00123474\) was conducted)-10 ( )]TJ
-0.01 Tw -8.702 -1.002 Td
[(in adult pa)-10 (tients with chronic phase CML to evalua)-10 (te the ef\037cac)20 (y and safety of SPR)18 (YCEL)-9.9 ( )]TJ
-0.021 Tw 0 -1.002 Td
[(administered once daily compared with SPR)18 (YCEL administered twice daily)55 (.)37 ( P)18 (a)-10 (tients with)-10 ( )]TJ
-0.022 Tw 0 -1.002 Td
[(signi\037cant cardiac diseases,)37 ( inc)20 (luding myocardial infarction within 6 months,)37 ( congestive)-9.9 ( )]TJ
-0.044 Tw 0 -1.002 Td
[(heart failure within 3 months,)37.1 ( signi\037cant arrhythmias,)37 ( or QTc prolonga)-9.9 (tion were exc)20 (luded)-10 ( )]TJ
0.21 Tw 0 -1.002 Td
[(from the )0.5 (trial.)37 ( )37.5 (The )0.5 (primar)-18 (y )0.5 (ef\037cac)20 (y endpoint )0.5 (was )0.5 (MCyR )0.5 (in )0.5 (pa)-10 (tients )0.5 (with )0.5 (ima)-9.9 (tinib-)]TJ
-0.025 Tw 0 -1.002 Td
[(resistant CML.)37 ( )36.7 (A total of 670 pa)-10 (tients,)37 ( of whom 497 had ima)-10 (tinib-resistant disease,)37 ( were)-9.9 ( )]TJ
0.022 Tw 0 -1.002 Td
[(randomized to the SPR)18.1 (YCEL 100 mg once-daily)55 (,)37 ( 140 mg once-daily)55 (,)37 ( 50 mg twice-daily)55 (,)27 ( )]TJ
0 Tw 0 -1.002 Td
[(or 70 mg twice-daily group.)37.1 ( Median dura)-10 (tion of trea)-10 (tment was 22 months.)]TJ
-0.059 Tw 0 -1.452 Td
[(Ef\037cac)20 (y was achieved across all SPR)18 (YCEL trea)-9.9 (tment groups with the once-daily schedule)-10 ( )]TJ
0.072 Tw 0 -1.002 Td
[(demonstra)-10 (ting comparable ef\037cac)20 (y \(non-inferiority\) to the twice-daily schedule on the)-10 ( )]TJ
-0.017 Tw 0 -1.002 Td
[(primar)-18 (y ef\037cac)20 (y endpoint \(difference in MCyR 1.9%; 95% CI [\0316.8%\22610.6%]\); ho)-10 (wever)74 (,)27 ( )]TJ
0 Tw 0 -1.002 Td
[(the 100-mg once-daily regimen demonstra)-9.9 (ted improved safety and tolerability)55 (.)]TJ
0.015 Tw 0 -1.452 Td
[(Ef\037cac)20 (y results are presented in )36.7 (T)74 (ables 17 and 18 for adult pa)-10 (tients with chronic phase)-9.9 ( )]TJ
0 Tw 0 -1.002 Td
[(CML who received the recommended starting dose of 100 mg once daily)55.1 (.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 318.944 252 -17.312 re
324 301.632 138.96 -19.88 re
462.96 301.632 113.04 -19.88 re
324 281.752 138.96 -11.472 re
462.96 281.752 113.04 -11.472 re
324 270.28 138.96 -11.472 re
462.96 270.28 113.04 -11.472 re
324 258.808 138.96 -11.472 re
462.96 258.808 113.04 -11.472 re
324 247.336 138.96 -11.472 re
462.96 247.336 113.04 -11.472 re
324 235.865 138.96 -11.472 re
462.96 235.865 113.04 -11.472 re
324 224.393 252 -38.712 re
f
1 w 
/GS2 gs
q 1 0 0 1 323.9999 301.6322 cm
0 0 m
138.96 0 l
S
Q
0.5 w 
q 1 0 0 1 323.9999 281.7522 cm
0 0 m
138.96 0 l
S
Q
1 w 
q 1 0 0 1 462.96 301.6322 cm
0 0 m
113.04 0 l
S
Q
0.5 w 
q 1 0 0 1 462.96 281.7522 cm
0 0 m
113.04 0 l
S
Q
1 w 
q 1 0 0 1 323.9999 224.3927 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 462.96 224.3927 cm
0 0 m
113.04 0 l
S
Q
0.5 w 
q 1 0 0 1 323.9999 185.6808 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 462.96 185.6808 cm
0 0 m
113.04 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.02 Tc 0.087 Tw 8 0 0 8 323.9999 313.2322 Tm
[(T)-10 (a)-10 (b)-10 (l)-10 (e)-10 ( )53 (1)-10 (7)-10 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.538 0 Td
( )Tj
EMC 
3.087 0 Td
[(Efficacy of SPRYCEL in Adult Patients with Imatinib-Resistant or)-20 ( )]TJ
-0.025 Tc 0.024 Tw 0 -1 Td
[(-)-5 (Intolerant )0.5 (Chronic Phase )0.5 (CML )0.5 (\(minimum of )0.5 (24 months )0.5 (follow-up\))]TJ
-0.01 Tc 7.2 0 0 8 323.9999 293.0403 Tm
[(All P)24 (atients)]TJ
-0.02 Tc 23.585 0 Td
(100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
0 Tc 0 Tw 7.2 0 0 8 545.1511 293.0403 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 508.6369 285.0403 Tm
(\(n=167\))Tj
-0.01 Tc 0.024 Tw -25.644 -1.485 Td
(Hematologic Response Rate % \(95% CI\))Tj
/T1_0 1 Tf
1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
(CHR)Tj
0 Tc 0 Tw 5.4 0 0 6 344.1238 264.4884 Tm
(a)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 502.0742 261.6884 Tm
(92% \(86\22695\))Tj
/T1_2 1 Tf
-0.01 Tc -24.733 -1.434 Td
(Cytogenetic Response Rate % \(95% CI\))Tj
/T1_0 1 Tf
1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
(MCyR)Tj
0 Tc 0 Tw 5.4 0 0 6 348.1775 241.5446 Tm
(b)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 502.0743 238.7446 Tm
(63% \(56\22671\))Tj
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.733 -1.434 Td
( )Tj
EMC 
(CCyR)Tj
-0.005 Tc 0.024 Tw 24.733 0 Td
(50% \(42\22658\))Tj
0.005 Tw 5.4 0 0 6 324.0001 217.8808 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.01 Tw 7.2 0 0 8 327.6001 215.0807 Tm
[(CHR \(response confirmed after 4 weeks\):)37 ( )36.7 (WBC \034 institutional ULN,)37 ( pla)-10 (telets <450,000/mm)]TJ
0 Tc 0 Tw 5.4 0 0 6 563.8937 217.8808 Tm
(3)Tj
-0.042 Tc 0.027 Tw 7.2 0 0 8 566.4587 215.0807 Tm
[(, n)-37 (o)-42 ( )]TJ
-0.005 Tc -0.043 Tw -33.175 -1 Td
[(blasts or promyeloc)20 (ytes in peripheral blood,)37 ( <5% myeloc)20 (ytes plus metamyeloc)20 (ytes in peripheral)-5 ( )]TJ
0 Tw 0 -1 Td
[(blood,)37 ( basophils in peripheral blood <20%,)37 ( and no extramedullar)-18 (y involvement.)]TJ
0.005 Tw 5.4 0 0 6 324.0001 192.0807 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 327.6001 189.2807 Tm
(MCyR combines both complete \(0% Ph)Tj
0 Tc 14.21 0.125 Td
(+)Tj
-0.005 Tc 0.595 -0.125 Td
[( meta)-9.9 (phases\) and partial \(>0%\22635%\) responses.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 169.218 252 -25.312 re
324 143.906 101.52 -11.472 re
425.52 143.906 150.48 -11.472 re
324 132.434 101.52 -11.472 re
425.52 132.434 50.16 -11.472 re
475.68 132.434 50.16 -11.472 re
525.84 132.434 50.16 -11.472 re
324 120.962 101.52 -13.5 re
425.52 120.962 50.16 -13.5 re
475.68 120.962 50.16 -13.5 re
525.84 120.962 50.16 -13.5 re
324 107.462 101.52 -13.5 re
425.52 107.462 50.16 -13.5 re
475.68 107.462 50.16 -13.5 re
525.84 107.462 50.16 -13.5 re
324 93.962 101.52 -13.5 re
425.52 93.962 50.16 -13.5 re
475.68 93.962 50.16 -13.5 re
525.84 93.962 50.16 -13.5 re
324 80.462 101.52 -13.5 re
425.52 80.462 50.16 -13.5 re
475.68 80.462 50.16 -13.5 re
525.84 80.462 50.16 -13.5 re
324 66.962 252 -30.712 re
f
1 w 
/GS2 gs
q 1 0 0 1 425.5201 143.9057 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 475.6801 143.9057 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 525.8401 143.9057 cm
0 0 m
50.16 0 l
S
Q
0.5 w 
q 1 0 0 1 425.5201 132.4338 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 475.6801 132.4338 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 525.8401 132.4338 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 324.0001 120.9619 cm
0 0 m
101.52 0 l
S
Q
q 1 0 0 1 525.8401 120.9619 cm
0 0 m
50.16 0 l
S
Q
1 w 
q 1 0 0 1 525.8401 66.9619 cm
0 0 m
50.16 0 l
S
Q
0.5 w 
q 1 0 0 1 425.5201 120.9619 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 475.6801 120.9619 cm
0 0 m
50.16 0 l
S
Q
0 0 0 0 K
/GS3 gs
q 1 0 0 1 525.8401 107.4619 cm
0 0 m
0 13.25 l
S
Q
q 1 0 0 1 525.8401 93.9619 cm
0 0 m
0 13.5 l
S
Q
q 1 0 0 1 525.8401 80.4619 cm
0 0 m
0 13.5 l
S
Q
q 1 0 0 1 525.8401 67.4619 cm
0 0 m
0 13 l
S
Q
0 0 0 1 K
1 w 
/GS2 gs
q 1 0 0 1 425.5201 66.9619 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 475.6801 66.9619 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 324.0001 66.9619 cm
0 0 m
101.52 0 l
S
Q
0.5 w 
q 1 0 0 1 324.0001 36.2499 cm
0 0 m
101.52 0 l
S
Q
q 1 0 0 1 425.5201 36.2499 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 475.6801 36.2499 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 525.8401 36.2499 cm
0 0 m
50.16 0 l
S
Q
1 w 
q 1 0 0 1 324.0001 143.9057 cm
0 0 m
101.52 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.01 Tc 0.577 Tw 8 0 0 8 324.0001 163.5057 Tm
[(Table )553 (18:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Long-T)74 (erm MMR of SPR)18 (YCEL in the Dose Optimization)-10 ( )]TJ
0 Tc 0 Tw 24.875 0 Td
( )Tj
-0.01 Tc 0.441 Tw -24.875 -1 Td
[(T)74 (rial: Adult P)24 (atients with Imatinib-Resistant or -Intolerant)-10 ( )]TJ
0.024 Tw 0 -1 Td
(Chronic Phase CML)Tj
0 Tc 0 Tw 6 0 0 6 437.4631 150.3057 Tm
(a)Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 463.623 135.3138 Tm
(Minimum Follow-up Period)Tj
0 Tc 0 Tw -19.392 -1.434 Td
( )Tj
-0.02 Tc 0.024 Tw 16.151 0 Td
(2)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years)Tj
6.967 0 Td
(5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years)Tj
6.967 0 Td
(7)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years)Tj
-0.01 Tc -30.084 -1.434 Td
(Major Molecular Response)Tj
0 Tc 0 Tw 5.4 0 0 6 398.5331 115.1699 Tm
(b)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 401.1791 112.3699 Tm
( % \(n/N\))Tj
/T1_0 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
-10.719 -1.687 Td
( )Tj
EMC 
1.25 0 Td
[(All P)18.1 (a)-10 (tients Randomized)-10 ( )]TJ
-0.005 Tc 13.789 0 Td
(34% \(57/167\))Tj
6.949 0 Td
(43% \(71/167\))Tj
7.234 0 Td
(44% \(73/167\))Tj
-0.01 Tc /Span<</ActualText<FEFF0009>>> BDC 
-29.223 -1.687 Td
( )Tj
EMC 
1.25 0 Td
[(Ima)-9.9 (tinib-Resistant P)18 (a)-10 (tients)]TJ
-0.005 Tc 13.789 0 Td
(33% \(41/124\))Tj
6.949 0 Td
(40% \(50/124\))Tj
7.234 0 Td
(41% \(51/124\))Tj
-0.01 Tc /Span<</ActualText<FEFF0009>>> BDC 
-29.223 -1.687 Td
( )Tj
EMC 
1.25 0 Td
[(Ima)-9.9 (tinib-Intolerant P)18 (a)-9.9 (tients)]TJ
-0.005 Tc 14.027 0 Td
(37% \(16/43\))Tj
6.949 0 Td
(49% \(21/43\))Tj
7.234 0 Td
(51% \(22/43\))Tj
0.005 Tw 5.4 0 0 6 324.0001 60.4499 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 329.0001 57.6499 Tm
(Results reported in recommended starting dose of 100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily)55 (.)]TJ
0.005 Tw 5.4 0 0 6 324.0001 50.6499 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.04 Tw 7.2 0 0 8 329.0001 47.8499 Tm
[(Major molecular response criteria:)36.9 ( Defined as BCR-ABL/control transcripts \0340.1% by RQ-PCR)-5 ( )]TJ
0 Tw 0 -1 Td
(in peripheral blood samples.)Tj
ET
endstreamendobj40 0 obj<</AIS false/BM/Normal/CA 1.0/OP false/OPM 1/SA false/SMask/None/Type/ExtGState/ca 1.0/op false>>endobj33 0 obj<</Length 23153>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.005 Tc -0.042 Tw 8 0 0 8 36 727.2481 Tm
[(Acute overdose in animals was associa)-10 (ted with cardiotoxicity)55 (.)37 ( Evidence of cardiotoxicity)-5 ( )]TJ
-0.025 Tw 0 -1.019 Td
[(inc)20 (luded ventricular necrosis and valvular/ventricular/a)-10 (trial hemorrha)-9.9 (ge a)-9.9 (t single doses)-5 ( )]TJ
0.022 Tw 0 -1.019 Td
(\036100 mg/kg \(600 mg/m)Tj
0 Tc 0 Tw 6 0 0 6 106.8661 713.7367 Tm
(2)Tj
-0.005 Tc 0.022 Tw 8 0 0 8 109.716 710.9367 Tm
[(\) in rodents.)37 ( )37.2 (There was a tendenc)20 (y for increased systolic and)-5 ( )]TJ
0 Tw -9.215 -1.019 Td
[(diastolic blood pressure in monkeys a)-10 (t single doses \03610 mg/kg \(120 mg/m)]TJ
0 Tc 6 0 0 6 254.6435 705.5811 Tm
(2)Tj
-0.005 Tc 0.005 Tw 8 0 0 8 257.4935 702.7811 Tm
(\).)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -27.687 -1.919 Td
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(DESCRIPTION)Tj
/T1_0 1 Tf
0.373 Tw -3.375 -1.312 Td
[(SPR)18 (YCEL \(dasa)-10 (tinib\) is a kinase inhibitor)74 (.)37 ( )36.6 (The chemical name for dasa)-9.9 (tinib is)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.012 Tc -0.012 Tw -31.5 -1.019 Td
[(N-\(2-chloro-6-methylphen)-10.3 (yl\)-2-[[6-[4-\(2-hydroxyethyl\)-1-piperazin)-10.3 (yl]-2-methyl-4-)]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.353 Tw -31.5 -1.019 Td
[(pyrimidin)-10 (yl]amino]-5-thiazolecarboxamide,)37 ( )0.5 (monohydra)-10 (te.)37 ( )37.5 (The )0.5 (molecular )0.5 (formula )0.5 (is)]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-31.5 -1.019 Td
(C)Tj
-0.01 Tc 0.01 Tw 6 0 0 6 40.072 650.9626 Tm
(22)Tj
0 Tc 0 Tw 8 0 0 8 45.7119 652.4626 Tm
(H)Tj
-0.01 Tc 0.01 Tw 6 0 0 6 49.9278 650.9626 Tm
(26)Tj
8 0 0 8 55.5678 652.4626 Tm
(ClN)Tj
0 Tc 0 Tw 6 0 0 6 65.5597 650.9626 Tm
(7)Tj
8 0 0 8 68.3797 652.4626 Tm
(O)Tj
6 0 0 6 72.7477 650.9626 Tm
(2)Tj
-0.01 Tc 0.549 Tw 8 0 0 8 75.5677 652.4626 Tm
(S \225 H)Tj
0 Tc 0 Tw 6 0 0 6 100.081 650.9626 Tm
(2)Tj
-0.01 Tc 0.549 Tw 8 0 0 8 102.9009 652.4626 Tm
[(O,)37 ( which corresponds to a formula )0.5 (weight )0.5 (of 506.02)-10 ( )]TJ
0 Tc 0 Tw 23.137 0 Td
( )Tj
-0.01 Tc 0.078 Tw -31.5 -1.019 Td
[(\(monohydra)-10 (te\).)37 ( )36.9 (The anhydrous free base has a molecular weight of 488.01.)37 ( Dasa)-10 (tinib)-10 ( )]TJ
0 Tw 0 -1.019 Td
[(has the follo)-10 (wing chemical structure:)]TJ
ET
/PlacedGraphic /MC0 BDC 
EMC 
0 0 0 1 K
0.9 w 4 M 
/GS0 gs
q 1 0 0 1 133.0782 583.7868 cm
0 0 m
4.743 -3.23 l
B
Q
1 J 
q 1 0 0 1 86.9958 618.6249 cm
0 0 m
5.855 -2.813 l
0 0 m
-10.722 -5.323 l
-17.298 -1.386 m
-10.722 -5.323 l
S
Q
0 J 
q 1 0 0 1 170.5645 595.6603 cm
0 0 m
1.369 -6.007 l
S
Q
q 1 0 0 1 185.0131 595.6603 cm
0 0 m
-2.89 -9.581 l
B
Q
BT
/CS0 cs 1  scn
/T1_2 1 Tf
0 Tc 8.955 0 0 8.865 251.632 588.5729 Tm
(\267)Tj
0.302 0 Td
( )Tj
0.201 0 Td
( )Tj
/T1_3 1 Tf
0.302 0 Td
(H)Tj
6.8058 0 0 6.7374 265.0996 586.7404 Tm
(2)Tj
8.955 0 0 8.865 269.7958 588.5729 Tm
(O)Tj
8.0595 0 0 7.9785 124.7185 582.2588 Tm
(N)Tj
2.457 -0.063 Td
(N)Tj
-3.713 2.185 Td
(N)Tj
-2.54 1.487 Td
(N)Tj
ET
q
36 560.087 252 63.209 re
W n
BT
0.06 Tc -0.06 Tw 8.0595 0 0 7.9785 56.3185 616.4579 Tm
(HO)Tj
ET
Q
BT
8.0595 0 0 7.9785 155.0701 607.5546 Tm
(H)Tj
0.004 -1.027 Td
(N)Tj
1.59 -2.143 Td
(N)Tj
1.005 2.369 Td
(S)Tj
3.462 -1.579 Td
(N)Tj
0 -1.015 Td
(H)Tj
0.803 Tc -0.803 Tw -0.67 3.497 Td
(OC)Tj
0 Tc 0 Tw 2.345 0 Td
(l)Tj
-1.452 -5.108 Td
(H)Tj
6.6267 0 0 6.5601 211.9969 566.6881 Tm
(3)Tj
8.0595 0 0 7.9785 216.0973 567.6083 Tm
(C)Tj
-0.052 Tc 0.052 Tw -10.11 -0.533 Td
(CH)Tj
ET
q
36 560.087 252 63.209 re
W n
BT
0 Tc 0 Tw 6.6267 0 0 6.5601 146.2965 561.5368 Tm
(3)Tj
ET
Q
1 J 
q 1 0 0 1 113.6016 599.1022 cm
0 0 m
-6.508 -2.878 l
-16.442 2.535 l
-16.442 10.344 l
-12.404 16.337 m
-6.508 19.524 l
4.247 14.181 l
4.247 6.234 l
34.331 -10.765 m
34.331 -2.961 l
24.342 2.641 l
14.226 -3.064 l
7.434 0.039 l
84.615 0.1 m
73.844 -2.758 l
67.913 2.033 l
14.153 -10.765 m
14.153 -3.093 l
S
Q
0 J 
q 1 0 0 1 146.5489 594.6473 cm
0 0 m
0 -6.31 l
-17.274 0.177 m
-8.7 5.268 l
S
Q
0 0 0 1 k
q 1 0 0 1 147.9088 596.2365 cm
0 0 m
6.389 3.002 l
B
Q
1 J 
q 1 0 0 1 131.7981 582.1389 cm
0 0 m
5.762 -3.97 l
5.762 -11.142 l
S
Q
0 J 
q 1 0 0 1 143.5526 582.2548 cm
0 0 m
-5.992 -4.086 l
B
Q
1 J 
q 1 0 0 1 161.4979 599.2388 cm
0 0 m
6.716 -3.061 l
8.459 -10.422 l
6.716 -3.061 l
13.301 1.786 l
22.151 -14.808 m
25.955 -2.961 l
22.151 -14.808 l
h
13.722 -14.808 m
22.151 -14.808 l
42.062 -5.168 m
37.05 -0.385 l
S
Q
10 M 0 J 
q 1 0 0 1 199.54 607.2835 cm
0 0 m
-2.204 -8.228 l
S
Q
1 J 
q 1 0 0 1 221.3056 606.7649 cm
0 0 m
3.537 -6.057 l
-2.679 -15.96 l
-11.123 -15.895 l
3.748 -25.916 m
-2.679 -15.96 l
3.748 -25.916 l
h
-0.098 -32.237 m
3.748 -25.916 l
15.337 -25.864 l
20.597 -15.961 l
15.052 -6.058 l
3.537 -6.057 l
S
Q
0 J 
q 1 0 0 1 225.6247 582.6398 cm
0 0 m
-4.747 8.165 l
14.433 8.165 m
9.911 -0.053 l
S
Q
4 M 
q 1 0 0 1 236.2213 598.9172 cm
0 0 m
-10.823 0 l
S
Q
10 M 
q 1 0 0 1 201.1564 606.696 cm
0 0 m
-2.205 -8.228 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 0.05 Tw 8 0 0 8 36 542.9514 Tm
[(Dasa)-9.9 (tinib )0.6 (is )0.5 (a )0.6 (white )0.6 (to )0.6 (off-white )0.6 (po)-10 (wder)74 (.)37 ( )37.6 (The )0.6 (drug )0.5 (substance )0.6 (is )0.5 (insoluble )0.6 (in )0.5 (wa)-10 (ter )0.6 (and)-10 ( )]TJ
0 Tw 0 -1.019 Td
[(slightly soluble in ethanol and methanol.)27.1 ( )]TJ
0.314 Tw 0 -1.312 Td
[(SPR)18 (YCEL tablets are white to off-white,)37 ( biconvex,)37 ( \037lm-coa)-9.9 (ted tablets containing)-10 ( )]TJ
0.012 Tw 0 -1.019 Td
[(dasa)-9.9 (tinib,)37 ( with the follo)-10 (wing inactive ingredients:)37 ( lactose monohydra)-10 (te,)37 ( microcr)-18 (ystalline)-10 ( )]TJ
0.164 Tw 0 -1.019 Td
[(cellulose,)37 ( croscarmellose sodium,)37.1 ( hydroxypropyl cellulose,)37 ( and ma)-10 (gnesium steara)-10 (te.)27 ( )]TJ
0 Tw 0 -1.019 Td
[(The tablet coa)-10 (ting consists of hypromellose,)37 ( titanium dioxide,)37 ( and polyethylene glycol.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -2.144 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(CLINIC)18 (AL PHARMACOLOGY)]TJ
0.01 Tw -3.375 -1.942 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Mechanism of Action)Tj
/T1_0 1 Tf
0.102 Tw -3.375 -1.402 Td
[(Dasa)-9.9 (tinib,)37 ( a)-10 (t nanomolar concentra)-9.9 (tions,)37 ( inhibits the follo)-9.9 (wing kinases:)37 ( BCR-ABL,)37 ( SRC)-10 ( )]TJ
0.101 Tw 0 -1.019 Td
[(family \(SRC,)37 ( LCK,)37 ( )36.7 (YES,)37 ( FYN\),)37 ( c-KIT)92 (,)37 ( EPHA2,)37 ( and PDGFR)]TJ
/T1_4 1 Tf
0 Tc 0 Tw (\037)Tj
/T1_0 1 Tf
-0.01 Tc 0.101 Tw 20.761 0 Td
[(.)37 ( Based on modeling studies,)27 ( )]TJ
0 Tw -20.761 -1.019 Td
[(dasa)-9.9 (tinib is predicted to bind to multiple conforma)-10 (tions of the )37 (ABL kinase.)]TJ
/T1_5 1 Tf
0.141 Tw 0 -1.312 Td
(In vitro)Tj
/T1_0 1 Tf
[(,)37 ( dasa)-9.9 (tinib was active in leukemic cell lines representing variants of ima)-10 (tinib)-10 ( )]TJ
0.594 Tw 0 -1.019 Td
[(mesyla)-10 (te-sensitive and )0.5 (resistant disease.)37 ( )0.5 (Dasa)-10 (tinib inhibited the gro)-9.9 (wth of)-10 ( )]TJ
0.201 Tw 0 -1.019 Td
[(chronic myeloid leukemia \(CML\) and acute lymphoblastic leukemia \(ALL\)\ cell lines)-10 ( )]TJ
0.007 Tw 0 -1.019 Td
[(overexpressing BCR-ABL.)37 ( Under the conditions of the assays,)37 ( dasa)-10 (tinib could overcome)-10 ( )]TJ
0.338 Tw 0 -1.019 Td
[(ima)-9.9 (tinib resistance resulting )0.5 (from BCR-ABL )0.5 (kinase )0.5 (domain muta)-9.9 (tions,)37 ( )0.5 (activa)-9.9 (tion)-10 ( )]TJ
0.239 Tw 0 -1.019 Td
[(of )0.5 (alterna)-10 (te signaling pa)-9.9 (thways involving the SRC family kinases \(L)92 (YN,)37 ( HCK\),)37 ( and)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -31.5 -1.019 Td
(multi-drug resistance gene overexpression.)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.582 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacodynamics)Tj
0 Tw -3.375 -1.469 Td
[(Cardiac Electrophysiolog)-10 (y)]TJ
/T1_0 1 Tf
0.044 Tw 0 -1.312 Td
[(Of 2440 pa)-9.9 (tients trea)-10 (ted with SPR)18 (YCEL a)-10 (t all doses tested in c)20 (linical trials,)37 ( 16 pa)-10 (tients)-10 ( )]TJ
0.005 Tw 0 -1.019 Td
[(\(<1%\) had QTc )0.5 (prolonga)-9.9 (tion reported as an adverse reaction.)37 ( )37.4 (T)74 (wenty-two pa)-10 (tients \(1%\))-10 ( )]TJ
0.135 Tw 0 -1.019 Td
[(experienced a QTcF >500 ms.)37.1 ( In 865 pa)-10 (tients with leukemia trea)-10 (ted with SPR)18 (YCEL)-9.9 ( )]TJ
0.067 Tw 0 -1.019 Td
[(70 mg BID in \037ve Phase 2 studies,)37 ( the maximum mean changes in QTcF \(90% upper)-10 ( )]TJ
0 Tw 0 -1.019 Td
(bound CI\) from baseline ranged from 7 ms to 13.4 ms.)Tj
0.049 Tw 0 -1.447 Td
[(An analysis of the da)-9.9 (ta from \037ve Phase 2 studies in pa)-10 (tients \(70 mg BID\) and a Phase)-10 ( )]TJ
0.113 Tw 0 -1.019 Td
[(1 stud)-10 (y in healthy subjects \(100 mg single dose\) suggests tha)-10 (t there is a maximum)-10 ( )]TJ
0.123 Tw 0 -1.019 Td
[(increase of 3 to 6 milliseconds in F)20 (ridericia corrected QTc inter)-18 (val from baseline for)-10 ( )]TJ
-0.049 Tw 0 -1.019 Td
[(subjects receiving thera)-10 (peutic doses of dasa)-10 (tinib,)37 ( with associa)-10 (ted upper 95% con\037dence)-10 ( )]TJ
0 Tw 0 -1.019 Td
[(inter)-18 (vals <10 msec.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.717 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacokinetics)Tj
/T1_0 1 Tf
0.181 Tw -3.375 -1.402 Td
[(The pharmacokinetics of dasa)-10 (tinib exhibits dose proportional increases in )37.1 (AUC and)-10 ( )]TJ
0.144 Tw 0 -1.019 Td
[(linear elimina)-9.9 (tion characteristics over the dose range of 15 mg/day \(0.15 times the)-10 ( )]TJ
0.069 Tw 0 -1.019 Td
[(lo)-10 (west a)-10 (pproved recommended dose\) to 240 mg/day \(1.7 times the highest a)-9.9 (pproved)-10 ( )]TJ
0 Tw 0 -1.019 Td
(recommended dose\).)Tj
0.209 Tw 0 -1.447 Td
[(At 100 mg QD,)37 ( the maximum concentra)-10 (tion a)-10 (t stead)-10 (y sta)-10 (te \(C)]TJ
0.01 Tw 6 0 0 6 229.8712 206.9623 Tm
(max)Tj
0.209 Tw 8 0 0 8 239.123 207.4623 Tm
[(\) is 82.2 ng/mL)-9.9 ( )]TJ
0 Tc 0 Tw 6.11 0 Td
( )Tj
-0.01 Tc 0.433 Tw -31.5 -1.019 Td
[(\(CV% 69%\),)37 ( area under the plasma drug concentra)-9.9 (tion time cur)-18 (ve \(AUC\) is)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.142 Tw -31.5 -1.019 Td
[(397 ng/mL*hr \(CV% 55%\).)37 ( )36.7 (The c)20 (learance of dasa)-9.9 (tinib is found to be time-invariant.)27 ( )]TJ
0.037 Tw 0 -1.019 Td
[(When )0.5 (administered )0.5 (to )0.5 (adult )0.5 (healthy )0.6 (subjects )0.6 (as )0.6 (dispersed )0.5 (tablets )0.6 (in )0.5 (juice,)37 ( )0.5 (the )0.5 (adjusted)-10 ( )]TJ
0.211 Tw 0 -1.019 Td
[(geometric mean ra)-9.9 (tio was 0.97 \(90% CI:)37.1 ( 0.85,)37 ( 1.10\) for C)]TJ
0.01 Tw 6 0 0 6 218.1775 174.3396 Tm
(max)Tj
0.211 Tw 8 0 0 8 227.4292 174.8396 Tm
[( and 0.84 \(90% CI:)27 ( )]TJ
0 Tc 0 Tw 7.571 0 Td
( )Tj
-0.01 Tc -31.5 -1.019 Td
[(0.78,)37 ( 0.91\) for )37 (AUC as compared to intact tablets.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.604 Td
(Absorption)Tj
/T1_0 1 Tf
0.322 Tw 0 -1.312 Td
[(The maximum plasma concentra)-9.9 (tions \(C)]TJ
0.01 Tw 6 0 0 6 162.687 142.8525 Tm
(max)Tj
0.322 Tw 8 0 0 8 171.9387 143.3525 Tm
[(\) of dasa)-9.9 (tinib are obser)-18 (ved between)-10 ( )]TJ
0 Tw -16.992 -1.019 Td
(0.5 hours and 6 hours \(T)Tj
0.01 Tw 6 0 0 6 106.8787 134.6968 Tm
(max)Tj
0 Tw 8 0 0 8 116.1305 135.1968 Tm
[(\) follo)-10 (wing oral administra)-10 (tion.)]TJ
/T1_6 1 Tf
-10.016 -1.469 Td
(Food Effect)Tj
/T1_0 1 Tf
0.004 Tw 0 -1.312 Td
[(A high-fa)-10 (t meal increased the mean )37.2 (AUC of dasa)-10 (tinib follo)-9.9 (wing a single dose of 100 mg)-10 ( )]TJ
-0.024 Tw 0 -1.019 Td
[(by 14%.)37 ( )36.6 (The total calorie content of the high-fa)-10 (t meal was 985 kcal.)37 ( )36.7 (The calories derived)-10 ( )]TJ
0 Tw 0 -1.019 Td
[(from fa)-10 (t,)37 ( carbohydra)-10 (tes,)37 ( and protein were 52%,)37 ( 34%,)37 ( and 14% for the high-fa)-10 (t meal.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.604 Td
(Distribution)Tj
/T1_0 1 Tf
0 Tw 0 -1.312 Td
[(The a)-9.9 (pparent volume of distribution is 2505 L \(CV% 93%\).)]TJ
0.05 Tw 0 -1.312 Td
[(Binding of dasa)-10 (tinib to human plasma proteins )]TJ
/T1_5 1 Tf
(in vitro)Tj
/T1_0 1 Tf
[( was a)-9.9 (pproxima)-10 (tely 96% and of)-10 ( )]TJ
0.121 Tw 0 -1.019 Td
[(its active metabolite was 93%,)37 ( with no concentra)-10 (tion dependence over the range of)-10 ( )]TJ
0 Tw 0 -1.019 Td
(100 ng/mL to 500 ng/mL.)Tj
0 -1.312 Td
[(Dasa)-9.9 (tinib is a P-gp substra)-9.9 (te )]TJ
/T1_5 1 Tf
(in vitro)Tj
/T1_0 1 Tf
0 Tc (.)Tj
ET
0.5 w 
q 1 0 0 1 324 331.5566 cm
0 0 m
79.262 0 l
S
Q
q 1 0 0 1 324 252.7828 cm
0 0 m
84.263 0 l
S
Q
q 1 0 0 1 324 130.4679 cm
0 0 m
36.063 0 l
S
Q
BT
/T1_1 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 324 727.248 Tm
(Elimination)Tj
/T1_0 1 Tf
0.045 Tw 0 -1.296 Td
[(The mean terminal half-life of dasa)-10 (tinib is 3 hours to 5 hours.)37 ( )37.3 (The mean a)-9.9 (pparent oral)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(c)20 (learance is 363.8 L/hr \(CV% 81.3%\).)]TJ
/T1_6 1 Tf
0.01 Tw 0 -1.453 Td
(Metabolism)Tj
/T1_0 1 Tf
-0.047 Tw 0 -1.296 Td
[(Dasa)-9.9 (tinib is metabolized in humans,)37 ( primarily by CYP3A4.)37 ( CYP3A4 is the primar)-17.9 (y enzyme)-10 ( )]TJ
-0.027 Tw 0 -1.003 Td
[(responsible for the forma)-10 (tion of the active metabolite.)37 ( Fla)-10 (vin-containing monooxygenase)-10 ( )]TJ
0.16 Tw 0 -1.003 Td
[(3 \(FMO-3\) and uridine diphospha)-9.9 (te-glucuronosyltransferase \(UGT\) enzymes are also)-9.9 ( )]TJ
0 Tw 0 -1.003 Td
[(involved in the forma)-10 (tion of dasa)-10 (tinib metabolites.)]TJ
0.172 Tw 0 -1.296 Td
[(The exposure of the active metabolite,)37 ( which is equipotent to dasa)-10 (tinib,)37 ( represents)-10 ( )]TJ
0.019 Tw 0 -1.003 Td
[(a)-10 (pproxima)-9.9 (tely 5% of the )37.1 (AUC of dasa)-9.9 (tinib.)37 ( )37.1 (The active metabolite of dasa)-9.9 (tinib is unlikely)-9.9 ( )]TJ
-0.033 Tw 0 -1.003 Td
[(to play a major role in the obser)-18 (ved pharmacolog)-9.9 (y of the drug.)37 ( Dasa)-10 (tinib also has several)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(other inactive oxida)-10 (tive metabolites.)]TJ
/T1_6 1 Tf
0.01 Tw 0 -1.453 Td
(Excretion)Tj
/T1_0 1 Tf
0.218 Tw 0 -1.296 Td
[(Elimina)-10 (tion )0.5 (is )0.5 (primarily )0.5 (via )0.5 (the )0.5 (feces.)37.1 ( F)20 (ollo)-10 (wing )0.5 (a )0.5 (single )0.5 (radiolabeled dose of oral)-10 ( )]TJ
0.05 Tw 0 -1.003 Td
[(dasa)-9.9 (tinib,)37 ( 4% of the administered radioactivity was recovered in the urine and 85%\ in)-10 ( )]TJ
0.017 Tw 0 -1.003 Td
[(the feces within 10 days.)37 ( Unchanged dasa)-9.9 (tinib accounted for 0.1% of the administered)-10 ( )]TJ
0.03 Tw 0 -1.003 Td
[(dose in the urine and 19% of the administered dose in the feces with the\ remainder of)-9.9 ( )]TJ
0 Tw 0 -1.003 Td
(the dose being metabolites.)Tj
/T1_1 1 Tf
0 -1.588 Td
[(Speci\037c P)24 (opulations)]TJ
/T1_0 1 Tf
-0.028 Tw 0 -1.296 Td
[(Age )0.6 (\(15 )0.5 (to )0.5 (86 )0.6 (years )0.6 (old\),)37 ( )0.6 (sex,)37 ( )0.5 (and )0.5 (renal )0.5 (impairment )0.5 (\(crea)-9.9 (tinine )0.5 (c)20 (learance )0.5 (21.6 )0.5 (mL/min )0.5 (to)-10 ( )]TJ
0.019 Tw 0 -1.003 Td
[(342.3 mL/min as estima)-9.9 (ted by Cockcroft Gault\) ha)-10 (ve no c)20 (linically relevant effect on the)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(pharmacokinetics of dasa)-9.9 (tinib.)]TJ
/T1_6 1 Tf
0 -1.588 Td
[(P)24 (ediatric P)24 (atients)]TJ
/T1_0 1 Tf
-0.038 Tw 0 -1.296 Td
[(The pharmacokinetics of dasa)-9.9 (tinib were evalua)-10 (ted in 43 pedia)-10 (tric pa)-9.9 (tients with leukemia)-10 ( )]TJ
0.065 Tw 0 -1.003 Td
[(or solid tumors a)-10 (t oral doses ranging from 60 mg/m)]TJ
0 Tc 0 Tw 6 0 0 6 477.8126 506.8668 Tm
(2)Tj
-0.01 Tc 0.065 Tw 8 0 0 8 480.6326 504.0668 Tm
( to 120 mg/m)Tj
0 Tc 0 Tw 6 0 0 6 521.6185 506.8668 Tm
(2)Tj
-0.01 Tc 0.065 Tw 8 0 0 8 524.4385 504.0668 Tm
[( once daily)55 (,)37 ( taken)-10 ( )]TJ
0.079 Tw -25.055 -1.003 Td
[(with or without food.)37 ( )36.9 (The pharmacokinetics sho)-10 (wed dose proportionality with a dose-)]TJ
0.146 Tw 0 -1.003 Td
[(rela)-10 (ted increase in exposure.)37 ( )37.1 (The mean )37 (T)]TJ
0.01 Tw 6 0 0 6 449.41 487.5183 Tm
(max)Tj
0.146 Tw 8 0 0 8 458.6617 488.0183 Tm
[( was obser)-18 (ved between 0.5 hours and)-10 ( )]TJ
0.123 Tw -16.833 -1.003 Td
[(6 hours and the mean half-life was 2 hours to 5 hours.)37 ( )37 (The geometric mean \(CV%\))-9.9 ( )]TJ
0.15 Tw 0 -1.003 Td
[(of )0.5 (bod)-10 (y )0.5 (weight normalized c)20 (learance in )0.5 (these 43 )0.5 (pedia)-9.9 (tric )0.5 (pa)-10 (tients is 5.98 \(41.5%\))-10 ( )]TJ
0.064 Tw 0 -1.003 Td
[(L/h/kg.)37 ( In pedia)-9.9 (tric pa)-10 (tients with a dosing regimen of 60 mg/m)]TJ
0 Tc 0 Tw 6 0 0 6 509.3609 466.7456 Tm
(2)Tj
-0.01 Tc 0.064 Tw 8 0 0 8 512.1809 463.9456 Tm
[(,)37 ( the model simula)-9.9 (ted)-10 ( )]TJ
0.06 Tw -23.523 -1.003 Td
[(geometric mean \(CV%\) stead)-9.9 (y-sta)-10 (te plasma a)-10 (vera)-9.9 (ge concentra)-10 (tions of dasa)-10 (tinib were)-10 ( )]TJ
-0.014 Tw 0 -1.003 Td
[(14.7 \(64.6%\) ng/mL \(for 2 to <6 years old\),)37 ( 16.3 \(97.5%\) ng/mL \(for 6 to <12 years old\),)26.9 ( )]TJ
0.007 Tw 0 -1.003 Td
(and 18.2 \(67.7%\) ng/mL \(for 12 years and older\) )Tj
/T1_5 1 Tf
0 Tc 0 Tw ([)Tj
17.991 0 Td
(s)Tj
-0.01 Tc 0.007 Tw 0.397 0 Td
(ee Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.03 Tw 2.482 0 Td
[(a)-10 (ge )-36.9 (and Admini)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.007 Tw 6.001 0 Td
[(tra)-9.9 (tion \(2.2\)])]TJ
/T1_0 1 Tf
-0.037 Tc 0.037 Tw (. )Tj
-0.01 Tc 0.122 Tw -26.87 -1.003 Td
[(Dasa)-9.9 (tinib c)20 (learance and volume of distribution change with bod)-10 (y weight in pedia)-10 (tric)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(pa)-10 (tients.)37 ( Dasa)-10 (tinib has not been studied in pa)-10 (tients < 1 year old.)]TJ
0.084 Tw 0 -1.431 Td
[(The )0.5 (bioa)-9.9 (vailability )0.5 (of dispersed )0.5 (tablets in pedia)-10 (tric pa)-10 (tients )0.5 (was )0.5 (estima)-9.9 (ted )0.5 (to )0.5 (be 36%)-9.9 ( )]TJ
0 Tw 0 -1.003 Td
[(lo)-10 (wer than tha)-10 (t of intact tablets.)]TJ
/T1_6 1 Tf
0 -1.588 Td
[(P)24 (atients with Hepatic Impairment)]TJ
/T1_0 1 Tf
0.266 Tw 0 -1.296 Td
[(Compared to subjects with normal liver function,)37 ( pa)-9.9 (tients with modera)-10 (te hepa)-9.9 (tic)-10 ( )]TJ
0.02 Tw 0 -1.003 Td
(impairment \(Child Pugh B\) had decreases in mean C)Tj
0.01 Tw 6 0 0 6 475.5179 372.7635 Tm
(max)Tj
0.02 Tw 8 0 0 8 484.7697 373.2635 Tm
[( by 47% and mean )36.8 (AUC by 8%.)27 ( )]TJ
0.101 Tw -20.096 -1.003 Td
[(P)18 (a)-10 (tients )0.5 (with )0.5 (severe hepa)-10 (tic )0.5 (impairment )0.5 (\(Child Pugh C\) )0.5 (had )0.5 (decreases )0.5 (in mean )0.5 (C)]TJ
0.01 Tw 6 0 0 6 566.6883 364.7392 Tm
(max)Tj
0 Tc 0 Tw 8 0 0 8 576.0001 365.2392 Tm
( )Tj
-0.01 Tc -31.5 -1.003 Td
[(by 43% and in mean )37 (AUC by 28% compared to the subjects with normal liver function.)]TJ
/T1_1 1 Tf
0 -1.588 Td
(Drug Interaction Studies)Tj
/T1_5 1 Tf
0 -1.363 Td
(Cytochrome P450 Enzymes)Tj
/T1_0 1 Tf
-0.03 Tw 0 -1.476 Td
[(The coadministra)-9.9 (tion of ketoconazole \(strong CYP3A4 inhibitor\) twice daily increased t\he)-10 ( )]TJ
0.052 Tw 0 -1.003 Td
(mean C)Tj
0.01 Tw 6 0 0 6 346.5944 313.2781 Tm
(max)Tj
0.052 Tw 8 0 0 8 355.8461 313.7781 Tm
[( of dasa)-10 (tinib by 4-fold and the mean )36.7 (AUC of dasa)-10 (tinib by 5-fold follo)-10 (wing a)-10 ( )]TJ
0 Tw -3.981 -1.003 Td
(single oral dose of 20 mg.)Tj
0.163 Tw 0 -1.431 Td
[(The coadministra)-9.9 (tion of rifampin \(strong CYP3A4 inducer\) once daily decreased the)-10 ( )]TJ
0 Tw 0 -1.003 Td
(mean C)Tj
0.01 Tw 6 0 0 6 346.1756 285.7855 Tm
(max)Tj
0 Tw 8 0 0 8 355.4273 286.2855 Tm
[( of dasa)-10 (tinib by 81% and the mean )37 (AUC of dasa)-10 (tinib by 82%.)]TJ
0.065 Tw -3.928 -1.431 Td
[(Dasa)-9.9 (tinib is a time-dependent inhibitor of CYP3A4.)37 ( Dasa)-10 (tinib does not inhibit CYP1A2,)27 ( )]TJ
0 Tw 0 -1.003 Td
[(2A6,)37 ( 2B6,)37 ( 2C8,)37 ( 2C9,)37 ( 2C19,)37 ( 2D6,)37 ( or 2E1.)37 ( Dasa)-10 (tinib does not induce CYP enzymes.)]TJ
/T1_5 1 Tf
-0.037 Tw 0 -1.498 Td
[(Gastric Acid )-36.9 (Reducing Agents)]TJ
/T1_0 1 Tf
-0.022 Tw 0 -1.476 Td
[(The administra)-10 (tion )0.5 (of 30 mL )0.5 (of aluminum hydroxide/ma)-9.9 (gnesium hydroxide 2 hours prior)-10 ( )]TJ
-0.023 Tw 0 -1.003 Td
[(to a single dose of SPR)18 (YCEL was associa)-9.9 (ted with no relevant change in the mean )36.9 (AUC of)-9.9 ( )]TJ
0 Tw 0 -1.003 Td
[(dasa)-9.9 (tinib; ho)-10 (wever)74.1 (,)37 ( the mean C)]TJ
0.01 Tw 6 0 0 6 414.422 226.4801 Tm
(max)Tj
0 Tw 8 0 0 8 423.6737 226.9801 Tm
[( of dasa)-10 (tinib was increased by 26%.)]TJ
-0.049 Tw -12.459 -1.431 Td
[(The simultaneous administra)-10 (tion of 30 mL of aluminum hydroxide/ma)-10 (gnesium hydroxide)-10 ( )]TJ
-0.019 Tw 0 -1.003 Td
[(with a single dose of SPR)18 (YCEL was associa)-9.9 (ted with a 55% reduction in the mean )37 (AUC of)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(dasa)-9.9 (tinib and a 58% reduction in the mean C)]TJ
0.01 Tw 6 0 0 6 454.1652 198.9875 Tm
(max)Tj
0 Tw 8 0 0 8 463.4169 199.4875 Tm
[( of dasa)-10 (tinib.)]TJ
0.319 Tw -17.427 -1.431 Td
[(The administra)-10 (tion of a single dose of SPR)18 (YCEL 10 hours follo)-9.9 (wing famotidine)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.01 Tw -31.5 -1.003 Td
(\(H)Tj
0 Tc 0 Tw 6 0 0 6 330.0639 179.519 Tm
(2)Tj
-0.01 Tc 0.161 Tw 8 0 0 8 332.8839 180.019 Tm
[( anta)-10 (gonist\) reduced the mean )37.2 (AUC of dasa)-10 (tinib by 61% and the mean C)]TJ
0.01 Tw 6 0 0 6 558.0785 179.519 Tm
(max)Tj
0.161 Tw 8 0 0 8 567.3303 180.019 Tm
[( of)-10 ( )]TJ
0 Tw -30.416 -1.003 Td
[(dasa)-9.9 (tinib by 63%.)]TJ
-0.042 Tw 0 -1.431 Td
[(The administra)-10 (tion of a single 100 mg dose of SPR)18 (YCEL 22 hours follo)-9.9 (wing a 40 mg dose)-9.9 ( )]TJ
-0.038 Tw 0 -1.003 Td
[(of omeprazole \(proton pump inhibitor\) a)-10 (t stead)-9.9 (y sta)-9.9 (te reduced the mean )36.7 (AUC of dasa)-10 (tinib)-9.9 ( )]TJ
0 Tw 0 -1.003 Td
(by 43% and the mean C)Tj
0.01 Tw 6 0 0 6 393.6466 144.0021 Tm
(max)Tj
0 Tw 8 0 0 8 402.8984 144.5021 Tm
[( of dasa)-10 (tinib by 42%.)]TJ
/T1_5 1 Tf
0.01 Tw -9.862 -1.498 Td
[(T)74 (ransporters)]TJ
/T1_0 1 Tf
0 Tw 0 -1.476 Td
[(Dasa)-9.9 (tinib is not an inhibitor of P-gp )]TJ
/T1_5 1 Tf
(in vitro)Tj
/T1_0 1 Tf
0 Tc (.)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw 0 -2.263 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(NONCLINIC)18 (AL TOXICOLOGY)]TJ
0.01 Tw -3.375 -1.791 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Carcinogenesis,)37 ( Mutagenesis,)37 ( Impairment of F)20 (ertility)]TJ
/T1_0 1 Tf
0.15 Tw -3.375 -1.521 Td
[(In a 2-year carcinogenicity stud)-10 (y)55 (,)37 ( ra)-10 (ts were administered oral doses of dasa)-9.9 (tinib a)-9.9 (t)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -0.044 Tw -31.5 -1.003 Td
[(0.3,)37 ( 1,)37 ( and 3)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.624 0 Td
[(mg/kg/day)55 (.)37 ( )37.1 (The highest dose resulted in a plasma drug exposure \(AUC\) level)-9.9 ( )]TJ
0.054 Tw -4.624 -1.003 Td
[(a)-10 (pproxima)-9.9 (tely 60% of the human exposure a)-10 (t 100)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
18.707 0 Td
[(mg once daily)55 (.)37 ( Dasa)-10 (tinib induced a)-10 ( )]TJ
-0.017 Tw -18.707 -1.003 Td
[(sta)-10 (tistically signi\037cant increase in the combined incidence of squamous \cell carcinomas)-10 ( )]TJ
0.022 Tw 0 -1.003 Td
[(and )0.5 (pa)-9.9 (pillomas )0.5 (in )0.5 (the )0.5 (uterus )0.5 (and )0.5 (cer)-18 (vix )0.5 (of )0.5 (high-dose )0.5 (females )0.5 (and )0.5 (prosta)-10 (te )0.5 (adenoma )0.5 (in)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(lo)-10 (w-dose males.)]TJ
ET
endstreamendobj38 0 obj<</Metadata 93 0 R>>endobj93 0 obj<</Length 1623/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#">
         <dc:format>application/postscript</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">chemstruct</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Seq>
               <rdf:li>Bristol Myers</rdf:li>
            </rdf:Seq>
         </dc:creator>
         <xmp:CreatorTool>Adobe Illustrator CS2</xmp:CreatorTool>
         <xmp:CreateDate>2007-10-09T10:48:45-04:00</xmp:CreateDate>
         <xmp:ModifyDate>2007-11-14T13:12:37-05:00</xmp:ModifyDate>
         <xmp:MetadataDate>2007-11-14T13:12:37-05:00</xmp:MetadataDate>
         <xmpMM:DocumentID>uuid:89F5A43B77E711DCBAA69278F1D14B3D</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:AC14BEB3944411DC9D20ACAF37F3B60D</xmpMM:InstanceID>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:8222C0B274C411DC8FAD99C84716D7A7</stRef:instanceID>
            <stRef:documentID>uuid:8222C0B174C411DC8FAD99C84716D7A7</stRef:documentID>
         </xmpMM:DerivedFrom>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj35 0 obj<</BaseFont/NXSWOC+Geneva/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 94 0 R/LastChar 183/Subtype/Type1/Type/Font/Widths[333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667]>>endobj36 0 obj<</BaseFont/NXSWOC+HelveticaNeue-Medium/Encoding/WinAnsiEncoding/FirstChar 50/FontDescriptor 95 0 R/LastChar 108/Subtype/Type1/Type/Font/Widths[556 556 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 0 722 0 0 0 0 0 722 760 0 0 0 648 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 241]>>endobj37 0 obj<</BaseFont/NXSWOC+SymbolStd/Encoding 96 0 R/FirstChar 31/FontDescriptor 97 0 R/LastChar 31/Subtype/Type1/ToUnicode 98 0 R/Type/Font/Widths[549]>>endobj31 0 obj<</BaseFont/NXSWOC+HelveticaNeueLTStd-BdCnO/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 99 0 R/LastChar 121/Subtype/Type1/ToUnicode 100 0 R/Type/Font/Widths[240 0 0 0 0 0 0 0 0 0 0 0 240 370 0 0 0 0 0 0 0 0 0 0 0 0 240 0 0 0 0 0 0 556 556 537 574 481 463 556 556 258 0 0 463 740 574 0 519 0 556 519 480 538 519 0 0 0 0 0 0 0 0 0 0 481 500 463 500 463 296 500 500 240 240 500 240 758 500 480 500 0 333 444 296 500 444 704 462 444]>>endobj99 0 obj<</Ascent 961/CapHeight 714/CharSet(/space/comma/hyphen/colon/A/B/C/D/E/F/G/H/I/L/M/N/P/R/S/T/U/V/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/r/s/t/u/v/w/x/y)/Descent -271/Flags 96/FontBBox[-171 -271 1116 961]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 101 0 R/FontName/NXSWOC+HelveticaNeueLTStd-BdCnO/FontStretch/Condensed/FontWeight 700/ItalicAngle -12/StemV 140/Type/FontDescriptor/XHeight 538>>endobj100 0 obj<</Filter/FlateDecode/Length 439>>stream
Hâ\ìÕn£@ÑÔÛsL6f∫	YJÏDÚa¥ﬁ} c)–¸ˆ€EEYië|¶ÙnäÕnªK˝‰ãüyh˜qÚ«>u9^Ükn£?ƒSü‹≤Ù]ﬂNüWÛo{nFWÿÊ˝Ì2≈Û.W◊æ¯e7/Sæ˘ªÁn8ƒ{W¸»]Ã}:˘ª?õ˝Ω/ˆ◊q¸àÁò&øÎµÔ‚—Çæ5„˜Ê}1o{ÿuvøün∂ÁﬂøocÙÂ|Ω§L;tÒ26mÃM:EW/ÏX˚˙Õéµã©˚Ô~%‹v8∂ÔMvuâá[å7‰xKﬁØûg∂≈’’rf[åKr	^ëW‡ä\Å9ÄÖ,`%+¯ë¸~"?ÅÈS¡ß¢OüÍï¸jË‡Ë‡Ë‡Ë‡Ë‡Ë‡#Ï%Ë%Ã‰s9¬Aé0Gê#Ãë9áΩΩÑΩΩÑΩΩÑÔS>ÂÖ¸f_A_a_A_a_A_y#€ü[+ª+∫+ùŒJgÖ≥“Y·¨tV8+ùŒJgÖ≥“Y·¨t∂ÉÙ91)õ|ˇ5ØÌ5g’˘Ûòg”Ÿß¯ıç√ËmN˜WÄ »]Ÿ1endstreamendobj101 0 obj<</Filter/FlateDecode/Length 3357/Subtype/Type1C>>stream
HâlUkPWÓaËÀÄ0⁄°¿V∫*àDcv)ç/Wƒ8
&t`f∞gD£	(:(æ–`| Úÿe5Æñ‡àÇ∫‡Cb‘d5eeC≠‘Íxö‹Ÿ ﬁíç?∂∫n›{nüs˙ªÁ|ﬂmÂÈA)
~ŸjmZ Ç»D¡h¨Ül›2°HX∫Rk’OüØ_`Jë}^óXÖ4ŒÛ_iÇØœ≈'~˛qè∆ÇÙ⁄Ω	c3(Ö‚üœòKDCnûï#..&äü3ìüß7g	º∂ƒb
,|í)€,öEùU–GÛÛåF~Ö`·WA¥…õˇC¬,ºé∑ä:ΩP†◊ÒÊÚŒ†åYÇò+à¸B±({]ÅŒíùg0	&~ﬁ‚(^ÿêm,≤lÇ±Ñ7≤ìE–Û÷<—\îõ«/5òÃ÷íBÅ,≤DùX¬/.»Jå‚u&=_†+·	JQ»5ú"	2ò¯lA¥Í»ú_$,zC∂’`6Y¢g$hW Iﬁ‰ıBE)»C˘)(ñ¢^WQ”=®7(jñ'5,•ı¢fêSI‘ JUSm‘s≈{ä?+˛Â1›cç«]•J9Yô§‹ßºÂÈÎπÖ¶ÈY¥ï>Åf£zÙ¬+›Î3ïØ™IıÉ7„ùÍ]„} áı…ˆπ0&tLÓÏªÿ∑⁄˜≤ﬂxøTøÉ0◊—)u*`J†T9≤‹Uâ`æÆ¡s`Û¯äd√µ◊ÀÖ2›kòÉâç§ÀyÖeK≠v@å‚(§+øÉM>é°/£ “èrƒ‹‹ä‡≤E†®9wøﬁ‹Å¥öáç‡£Ä%¯¿∞Fƒ>4|ä¿áñìÄ@u¡6eW °ìC„ tÕØñ˙õ:Dí‡Ø¿ﬂQ‡êÆ0û0›ÜHV†*L¶i(g$ì∆	àË≈˛öùd˜+Û$ÿ·Ñuœ ≈ ÕÇiìa3‹€ƒ?œzÆÓ©ægÓ’NØ˚«:ˇÚ…C3 ˇˆyÏ√‚
~ì4ó—Õ‚‚2.—Æ+åg≥ê-B√ﬂ@7[-±%\Ï∆41Å’"uè›)59O >Ñ•4$hû?ë8ã≈∆ç282*p4YxÁCÙIá!ùø∂0çM.:∆ãd∂˝Èﬁ=ˆˆ¡Ã–"N=‰pJ;ú
iÑ+ØB1Ì◊Ä`O9 a"NgÒf7 ^€bÒ[yNÕ _¡˛©´§h+…à'Ëî⁄ïê9í©¡Qˇ…§•ÈÓ‡#Ë¨§°|‘*Gß!ûÜ}£›±ì≤ﬂ|%öî-›Åõˇﬂ›JjmwŒ¯ûî∂8æá©∞BôIívh`rK˙#<ì≈K„X\æö√é‘Ω8±}]'Æ^‰v"¶ÃûD;—cICc;≤N¢ü¢≤˘4”1gcréÅç›º}öÉÑ3m_ˆ≥◊kS7snbÙÉ?4Ä/FˆA?Ò(ì)AîÃä0Ùn§q<∫ç≤•∆Ê:€Hf±‚t(!#/wi‘vR6i@NØîV∫è∫#¸Íü‘Ÿ§>S¿≠ü(√fJyE¶/¯I}ÙN¥«’GÉ'Ç*∑Ö˝d3Ëg(Ñs\UÙv¥[™¢q>Rç"ÈAØ¥á∏;•J‹Ô™§!ˆÁÿ Í≤ì–EíùV∑í≥üqBaáûŒ}ˆ^8C?D0·ELi·^÷æƒ·,ﬁÌ&H˙ÚXˆ¢2n~iÜaÖÃπx›œ ã√"2!äÜ“3p›nŒO≤ssJ3
ÿÑK\·í˛t”ÃCt˝àAªÖÒƒ≠Ê ¬ö‚`àAU{,µªœ÷ﬁnÅ»m]Q==9¸Ÿ≠∫ß≤û‘çÀo»z:ä‘≠nô\Ö)ã!rfEÜ¸˝s∞h*L‰|Êˆπñy1Œªyí;Ú]i˜‘K·ÌA⁄∆Ú¶öÛ*Ê^Îæ∆s∑ŸÓC˙D;!®˙M‘˙€n<é≈"bÆÄ¿”û
>k»áˇñﬂl±/Q•|æy;wK[_-W]G´wë÷N')!ñ‘‹}'≈ Ã∏‹§ë[Ml∑
zÌŒèb≈◊DÅ∞ä¯Nrm•±6Îﬂzf¡¸⁄a…YŒ)mïπ!ø[XfNMd+Æ|q»Ω-7Jn0Ã˛â⁄Eà3HíÉrèì|.∑u*¬&W]âH¥∫⁄>¯ªøBüÌ…`¿òc 8BòKÑLﬁö]áË÷˝ÕÕ≠Ï≈è≈¨πÚ‹í“µõcmAÎﬂÕ≤Ö´îé˚Åe:Ó¥÷^=ÔñTâ√∂{caSyKU˝ÅŒ8ƒ\™€x«≤°”uÿ=Wπâ=Œ—,ﬂîj…as>:un?W”ﬁ‹t˝‡ëÍÜ˝«kUÍz∑™_:·≠‚ Xyœt@◊ÄwCCO/€≥#{ãñîvô£áÏsLN√«ÂkúÈ8xçP˘›£ßl],–˝ﬂBz+ÈmyﬂböM”€÷
‹v‘6á µ›>(©û)˙`$A∞R⁄C`öﬁ{Ñ3°…x}:áç]â¬B¯Éo`“9"å77òÙl≤£Çõ9o<—sóΩº]õF.âW·ﬂéŸ ~Åﬁ√ˆæ}õ2
}p˜®ËB–˚ÿFD◊Vl¨Kc1ùã”◊rÃúÆ;4€’Z◊yé[FÒèa‹†‚6ø4JiTiˆ¥–˜È&†l/”‚Ò8Ã»·Òfë¸“YºﬂØµpÿ%≠œÀ`Woªq≥ñ€ﬂF~¨Ÿ]Gw÷4_ÎfØUeƒïqjúDòª|œ*ãHÑ‡â•ˇ^ıAQUQ|◊ù˚Xwlk÷mx¢mNÑíZMZn„Ë†»á°¥¢àÕ–¢ÑÄªƒáª|ôÆ∞µÀ"<Wæ‚S$@â»†“4G'-l?rÇ,ô©ÅÛËÓ›˚X˝ß©˛zÔﬁwÔπÁ¸Œ˘˝Óy[–MŒ3é¬πÚ>‘Í:^—Ö›Ó£v∑¿Úwƒèïfdî§„∞M)ÀÃ¬¡ÕËMŒÇF8Mâ∏˚"üõÑ;øÑNjõ·Èï ¿ÎÛ&>CZ'uË¯6k$|(ogÕ;ò,€NÙDõ&êÌâ]kaÓÌoÏ>M„Œ5 æ=÷ñöÉ≥sùnõ¿g⁄‹áDGçö¶%4k0éÒd’√‘"ÄB*C|
˘ôt—°•∂ˇ"t∆ì'“ÑÂñ}Q8 qÂª„4c4Ãhñ/•¥ñ®Œ±(o¿4∫PŸ÷‹á{*Õ[m¬´^?DßoIã—dÌÓæU8*.sG2-§~»ëâ⁄Ë∞‹¶4Ä^’ 3ú‘¡>âWtt$À:]G“_Ú¬Mí^uæ\∑≈jKã«ÖEGKãÛ≥»ÓÒÿècX–€ÔÑ È⁄?M‘…g¡6ãr@:£ÇùèT<ê∂0+.]æJˆ#xû#J#$#Bﬂ7ê€õ“|§ô’á8Îs”Wv8≈p`πô^¡¸∞å√uòBﬂTv¥Ù‚.wzBÅÓıGˇ>˝ìÑﬂ˘gÌﬁ/ó„ç1©—&
–‡·§÷e¥ƒ'–?|lPn≤Í∆0˜ˆ†Ûù>ÿc3ﬁJíÌT^íÌ8(Å5„ ´H9®∫EπñD"ÙÓPCÿı—%tCd˙~XM¬÷ÍIƒ*ÂaN}ÌËU<‰ä%O•2ÇÏãç¡Îèç¬ú:Z$‘´'aJvp)†±ˇ íÎçbYb R Ì:—j˛¸ë˙–+∆ß?[Õ€w3ˇ«®H1ˇI0‚eò'Z¥Á§`æSÇÜËZ’◊üb± næ≥	°í¬ÇíBΩ„›∏=2U◊d&*ü¡∫êqmˇå¢ÿ¶òôÈ∂)( Z‡€/ÄA˜A‚{Ç4ØáPÍ˚CÄÍÖÍÙæ“¨Ê€_k⁄Uï_Îl|Úì≤Sû\'t
¸∑Æº£ñ‚45,‡>™•î˚Õc"ècdx#,K»Y”lIªóº®>ﬂìSî¨Ê{vÂßò±Ò˝÷ær¡QÉ®xO¿„ _AØÇhJoül$QfVö@Å€öéV¡sŸlvN:T}∆-\Ñﬁá˙“/Ã<ìT)⁄¢°•í◊Âﬁ««Æ5dEZSRçxwﬁ…/é	£íõ~…ÀjÊôÃ„m¸’`˝˘n&ô&ô8 E!≈HëœnGBtG∏YÃ5x;¨‰†t÷¥,ÙèÅ`≥§ÖÂÙO`FëÕˆY)∂Îßx#,XHÛ{A/ii∆ÛΩZ+8»fõÈ-TMñ“ô#\9˝JñqD/èjÿàöŒ•›–ÄDã“%ùW¡e…_ó´ô∑àHIã‹Ã√Yb`Ø+°‚@îªI”¨Ü(›Rè M∫!N7¬Êªÿ$;3OûÛ™ÈavIÕ6t“∞ﬁŒKo∂ZKJ≠Ç&OúNI¥A"çÆ;.Ô`ô_vıtB51U®ÈÃÑÀ;^1wr>6RQ·t:+⁄¸˝'Ë”YÊt˙œ/Ò◊@QÄ¥_˜∑  ö3N#endstreamendobj96 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[31/uni03B2]/Type/Encoding>>endobj97 0 obj<</Ascent 1010/CapHeight 688/CharSet(/uni03B2)/Descent -293/Flags 4/FontBBox[-180 -293 1090 1010]/FontFamily(Symbol Std)/FontFile3 102 0 R/FontName/NXSWOC+SymbolStd/FontStretch/Normal/FontWeight 500/ItalicAngle 0/StemV 75/Type/FontDescriptor/XHeight 502>>endobj98 0 obj<</Filter/FlateDecode/Length 235>>stream
Hâ\êœjƒ ∆Ô>≈wãâΩJ†›≤êCˇ–¥`tí
ç ƒÚˆ›ePæÔ7|é<˜œ}‰;E;`Ü…G∏∆ç,¬à≥¢U‡ºÕ∑Æﬁv1IHÜá}Õ∏ÙaäBkê,Æôv8<∫8‚Q»7rH>Ãp¯:Gê√ñ“.24–u‡p‚A/&ΩöAVÏ‘;÷}ﬁOÃ¸9>˜Ñ†jﬂ^√ÿËpM∆"ô0£–W˙¬’	ÓüÆÆ‘8ŸoCB∑ˆ6O™+§*d}
yÛî¸U∏¥g´˚®°Jæ≤0Ué¯` cƒq˝endstreamendobj102 0 obj<</Filter/FlateDecode/Length 467/Subtype/Type1C>>stream
Hâbd`ab`ddÙã˜w÷ÆÃM œ	.I	*˛êa¸!ŒÚCñGÙ∑«ÔùøÆ˝jc˝ƒˇ=T‡{Ñ‡å…BÃååŸ•yô∆NFŒ˘ïEôÈ%
Üñ¶: “LZÇHK0	1200R S∆é)˘I©
¡ï≈%©π≈
ûy…˘E˘Eâ%©)z
é99
`„ääRãSã ÄÇ˙n¡!ï©
&
)©iåÌåIL@/0¯12ˇËËﬁ˚„Õ^F ©≤óπõÂG«œÄ?lﬂ˚~˝m˜}2Î˜lø~˝‚¸ôƒ˛á-Ã˛n˜»g˚±_ƒ˙‚Ò˝ÿYµ+~˚ñìﬂª◊
›∏˘}Í'·=¬5ﬂç6ànÕ[Y≥µeKÀ÷æµ”óN9øf…áÈª€7l,æõ≤≈gÂÜUkóMª4ıt‚Æ≤9.G’¶∏ß C( €RÍØ2{DCd[Ñ‹#∂æ%ñ,ëÍ˙Y+∫}›Œu3ÂMY◊≥>ˇBH’oé¢ÏÊ∆∆ ÍﬁÚæ§i’MÕÂ≈´´f7-ô0ØwEﬂ‘ñYU¬{éxœ˛ÕR„‹öSìû\ö^;!~NŒÙöπs9¯*Ê˝4ùı;v€sÆ‹  ›-ÕFendstreamendobj95 0 obj<</Ascent 952/CapHeight 714/CharSet(/two/three/C/H/N/O/S/l)/Descent -221/Flags 32/FontBBox[-165 -221 1066 952]/FontFamily(Helvetica 65 Medium)/FontFile3 103 0 R/FontName/NXSWOC+HelveticaNeue-Medium/FontStretch/Normal/FontWeight 500/ItalicAngle 0/StemV 116/Type/FontDescriptor/XHeight 500>>endobj103 0 obj<</Filter/FlateDecode/Length 871/Subtype/Type1C>>stream
HâlílSU«ﬂmªª≤‚É∑∑Œ¶›˙.õ†ÕÏ6qõM! Ñ1~.16Î÷7}u[Îk;Ç"	∆1¨Å §qâQHúÜê¯J≤¯«6cpåi∆ôÿƒ-.dÒèÛ∫”?ºC£1zˇ8ﬂõsœ˝ﬁœ9πD∞òBHISÎæñ]õ+∂©]Ωj\Î6©	’ªSiâÓ•s∑·"∆££dy16‡+ã_.6Ê¡¿
în-*ÖÇâêsW6G¢}∫ˆ‚KqˆDáá=’P_ˇ$è’„”Ãä¥´l__,Æv«ÿˆûéàçË¡∏™dÃﬂ’≈ˆ.›ç±ΩjL’{yˆo¶≈Xê≈ı`HÌÍ/≥H'k‘z"Òæ®ÍÂE]ÃˇˆÑ™":”∏A,—”BZP◊‘XÂˇ6ƒó,	è	°J®jÑù¬2>¡"Óí
“BNêiSã©;gŸ¿Çëö#_Ö„@ÕFj¡é≥Ù˝—ô˜G¨˜Fæøfg¶$ÙauÊcï(ùO~ÙC∆5?‰?pRÈGÇ˚´∑{w◊úƒ|´°SëùÉ∑f^ÔÖ7Á
Ø ]√Õ@kÅ £p“ˆÃ;øE‚|vO¿∑ˆÖÒô§)≈5…˚®sÅËè‡P‰UôÁoØœ˝væ\˜ÌWGæs¬J¥åÒ◊V’≠∆íKw˙?üòvç}—±[ë7’Æè˙ínÒÇq}Å|íQ¢9Î3^µÅJî¡⁄SVcnƒ6lÆ?<‡{WAëñø—TèfzwÄJ°túã˜˜[ªÜq®¶@Ä·Éd$HÉdû,Êõ)H„HŸ J8åiFâÚ⁄l‡ ô ÃÇÕ<Q6„BíB:w!º‘ñªÿOq⁄∏òá*˛ˆVnk¨ÃFÏˇ¡ClÑ6hCÆVV[¿;é.,≈“\ºˇfVƒ#MØÅ‰·î‹ª$˘“58n«-IplÄg\Pe„Ps7pœ{Yë[;œ·⁄Î«í÷÷îv˘¶ÛŒ‰–◊?èjUß› Q†4ç¥£cñ˚?ıÉvÀóÊ£ﬂºvÛêı„cü$ˆ;õ€õ—Ù¯∫`rãπuN`åˇß±b†ºeJ≈√ÉŸ¿ ÜS∞aÄ¬‡Ÿgs?•ÚˇJû∑¬ágú…Õû_ñ) j;µ\Ãve+Ï0 Ír∏∑endstreamendobj94 0 obj<</Ascent 997/CapHeight 700/CharSet(/space/periodcentered)/Descent -430/Flags 32/FontBBox[-280 -430 1280 997]/FontFile3 104 0 R/FontName/NXSWOC+Geneva/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 75/Type/FontDescriptor/XHeight 500>>endobj104 0 obj<</Filter/FlateDecode/Length 140/Subtype/Type1C>>stream
Hâbd`ad`dd‰Ûã˜w÷vOÕK-KâHˇêÊ˝!√#ˆ{Õ'VÜ_ï¨∑˘ˆ}ób`j—w©,HU0PHIMÉÍFÜ"fFF)Yù?¸vâ˛aˇ€ıÉùÕÈäËÔ“?æó≤Ò}»˜Sˇá“˜T—Ô¢øÅêùØªõ ¿ ì&.]endstreamendobj34 0 obj[/Separation/Black/DeviceCMYK<</C0[0.0 0.0 0.0 0.0]/C1[0.0 0.0 0.0 1.0]/Domain[0 1]/FunctionType 2/N 1.0/Range[0.0 1.0 0.0 1.0 0.0 1.0 0.0 1.0]>>]endobj32 0 obj<</Length 22414>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 273.9181 cm
0 0 m
42.279 0 l
S
Q
q 1 0 0 1 36 166.9381 cm
0 0 m
65.351 0 l
S
Q
q 1 0 0 1 36 92.138 cm
0 0 m
13.544 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.005 Tc -0.08 Tw 8 0 0 8 36 727.248 Tm
(Ear and Labyrinth Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc -0.08 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
( tinnitus; )Tj
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( vertigo,)37 ( hearing loss.)]TJ
/T1_0 1 Tf
0 Tw 0 -1.427 Td
[(Hepatobiliar)-18 (y Disorders:)]TJ
/T1_1 1 Tf
0 Tc /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc (0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( cholestasis,)37 ( cholec)20 (ystitis,)37 ( hepa)-9.9 (titis.)]TJ
/T1_0 1 Tf
0.436 Tw 0 -1.427 Td
[(Renal and Urinar)-18 (y Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.436 Tw (0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( urinar)-18 (y frequenc)20 (y)55 (,)37 ( renal failure,)32 ( )]TJ
0.005 Tw 0 -1 Td
(proteinuria; )Tj
/T1_2 1 Tf
4.395 0 Td
(<0.1% )Tj
/T1_1 1 Tf
0 Tw 2.769 0 Td
(\226 renal impairment.)Tj
/T1_0 1 Tf
0.393 Tw -7.164 -1.427 Td
[(Immune System )0.5 (Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.393 Tw (0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( )0.5 (hypersensitivity \(inc)20 (luding er)-18 (ythema)-5 ( )]TJ
0.005 Tw 0 -1 Td
(nodosum\).)Tj
/T1_0 1 Tf
0.379 Tw 0 -1.427 Td
(Endocrine Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.379 Tw (0.1%\226<1% \226)Tj
/T1_1 1 Tf
( hypothyroidism; )Tj
/T1_2 1 Tf
0.005 Tw (<0.1% )Tj
/T1_1 1 Tf
0.379 Tw 24.323 0 Td
[(\226 hyperthyroidism,)32 ( )]TJ
0.005 Tw -24.323 -1 Td
(thyroiditis.)Tj
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -1.697 Td
(6.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(P)24 (ostmarketing Experience)]TJ
/T1_1 1 Tf
-0.005 Tc 0.083 Tw -3.375 -1.383 Td
[(The follo)-9.9 (wing additional adverse reactions ha)-10 (ve been identi\037ed during post a)-10 (pproval)-5 ( )]TJ
0.007 Tw 0 -1 Td
[(use of SPR)18 (YCEL.)37 ( Because these reactions are reported voluntarily from a popula)-9.9 (tion of)-5 ( )]TJ
-0.002 Tw 0 -1 Td
[(uncertain size,)37 ( it is not al)-10 (ways possible to reliably estima)-10 (te their frequenc)20 (y or establish)-5 ( )]TJ
0 Tw 0 -1 Td
[(a causal rela)-9.9 (tionship to drug exposure.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -1.383 Td
(Infections:)Tj
/T1_1 1 Tf
0 Tw /Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
4.393 0 Td
[(hepa)-9.9 (titis B virus reactiva)-10 (tion)]TJ
/T1_3 1 Tf
-4.393 -1.427 Td
(Cardiac disorders:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
7.395 0 Td
[(a)-10 (trial \037brilla)-10 (tion/a)-10 (trial \035utter)]TJ
/T1_3 1 Tf
-0.064 Tw -7.395 -1.427 Td
[(Respirator)-18 (y)55 (,)37 ( thoracic,)37 ( and mediastinal disorders:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
18.832 0 Td
[(interstitial lung disease,)37 ( chylothorax)]TJ
/T1_3 1 Tf
0 Tw -18.832 -1.427 Td
(Skin and subcutaneous tissue disorders:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
16.068 0 Td
(Stevens-Johnson syndrome)Tj
/T1_3 1 Tf
-16.068 -1.427 Td
[(Renal and urinar)-18 (y disorders:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
11.31 0 Td
(nephrotic syndrome)Tj
/T1_3 1 Tf
-11.31 -1.427 Td
(Blood and lymphatic system disorders:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
15.398 0 Td
[(thrombotic microangiopa)-9.9 (thy)]TJ
/T1_3 1 Tf
-15.398 -1.427 Td
[(Hepatobiliar)-17.9 (y disorders:)]TJ
/T1_1 1 Tf
0.093 Tw /Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
[(hepa)-9.9 (totoxicity)]TJ
/T1_3 1 Tf
0.01 Tw 0 -2.035 Td
(7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(DR)-10 (UG INTERACTIONS)]TJ
0.01 Tw -3.375 -1.923 Td
(7.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Effect of Other Drugs on Dasatinib)Tj
-3.375 -1.653 Td
(Strong CYP3A4 Inhibitors)Tj
/T1_1 1 Tf
-0.005 Tc 0.574 Tw 0 -1.337 Td
[(The coadministra)-9.9 (tion with strong CYP3A inhibitors may increase dasa)-10 (tinib)-5 ( )]TJ
0.005 Tw 0 -1 Td
[(concentra)-10 (tions )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 5.659 0 Td
([)Tj
0.254 0 Td
(s)Tj
-0.005 Tc 0.042 Tw 0.402 0 Td
[(ee Clinical Pharmacolog)-10 (y \(12.3\))]TJ
0 Tc 0 Tw (])Tj
/T1_1 1 Tf
-0.005 Tc 0.042 Tw 11.909 0 Td
[(.)37 ( Increased dasa)-10 (tinib concentra)-10 (tions)-5 ( )]TJ
0.079 Tw -18.223 -1 Td
[(may increase the risk of toxicity)55 (.)37 ( )36.9 (Avoid concomitant use of strong CYP3A4 inhibitors.)32 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.005 Tc -0.005 Tw -31.5 -1 Td
[(If concomitant administra)-10 (tion of a strong CYP3A4 inhibitor cannot be a)-10 (voided,)37 ( consider)-5 ( )]TJ
0 Tw 0 -1 Td
[(a SPR)18 (YCEL dose reduction )]TJ
/T1_2 1 Tf
0 Tc ([)Tj
10.123 0 Td
(s)Tj
-0.005 Tc 0.402 0 Td
(ee Do)Tj
0 Tc (s)Tj
-0.005 Tc -0.037 Tw 2.505 0 Td
[(a)-10 (ge )-37 (and Admini)]TJ
0 Tc 0 Tw (s)Tj
-0.005 Tc 6.062 0 Td
[(tra)-10 (tion \(2.5\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
/T1_3 1 Tf
-0.01 Tc -19.092 -1.653 Td
(Strong CYP3A4 Inducers)Tj
/T1_1 1 Tf
-0.005 Tc 0.009 Tw 0 -1.337 Td
[(The coadministra)-10 (tion of SPR)18 (YCEL with strong CYP3A inducers may decrease dasa)-10 (tinib)-5 ( )]TJ
0.005 Tw 0 -1 Td
[(concentra)-10 (tions )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 5.611 0 Td
([)Tj
0.254 0 Td
(s)Tj
-0.005 Tc -0.006 Tw 0.402 0 Td
[(ee Clinical Pharmacolog)-10 (y \(12.3\))]TJ
0 Tc 0 Tw (])Tj
/T1_1 1 Tf
-0.005 Tc -0.006 Tw 11.766 0 Td
[(.)37 ( Decreased dasa)-9.9 (tinib concentra)-10 (tions)-5 ( )]TJ
0.052 Tw -18.033 -1 Td
[(may reduce ef\037cac)20 (y)55 (.)37 ( Consider alterna)-9.9 (tive drugs with less enzyme induction potential.)32 ( )]TJ
0.016 Tw 0 -1 Td
[(If concomitant administra)-10 (tion of a strong CYP3A4 inducer cannot be a)-9.9 (voided,)37 ( consider)-5 ( )]TJ
0 Tw 0 -1 Td
[(a SPR)18 (YCEL dose increase.)]TJ
/T1_3 1 Tf
-0.01 Tc 0 -1.653 Td
(Gastric Acid Reducing Agents)Tj
/T1_1 1 Tf
-0.004 Tc -0.01 Tw 0 -1.427 Td
[(The coadministra)-10 (tion of SPR)18 (YCEL with a gastric acid reducing a)-9.9 (gent may decrease the)-3.9 ( )]TJ
0 Tw 0 -1 Td
[(concentra)-10 (tions of dasa)-9.9 (tinib.)37 ( Decreased dasa)-9.9 (tinib concentra)-10 (tions may reduce ef\037cac)20 (y)55 (.)]TJ
0.437 Tw 0 -1.383 Td
(Do not administer H)Tj
0 Tc 0 Tw 6 0 0 6 104.5191 341.648 Tm
(2)Tj
-0.004 Tc 0.437 Tw 8 0 0 8 107.3751 342.148 Tm
[( anta)-10 (gonists or proton pump inhibitors with SPR)17.9 (YCEL.)33 ( )]TJ
0.14 Tw -8.922 -1 Td
(Consider the use of antacids in place of H)Tj
0 Tc 0 Tw 6 0 0 6 166.369 333.648 Tm
(2)Tj
-0.004 Tc 0.14 Tw 8 0 0 8 169.2249 334.148 Tm
[( anta)-10 (gonists or proton pump inhibitors.)33 ( )]TJ
0.034 Tw -16.653 -1 Td
[(Administer the antacid a)-10 (t least 2 hours prior to or 2 hours after the dose of SPR)18 (YCEL.)33 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.004 Tc -31.5 -1 Td
[(Avoid simultaneous administra)-10 (tion of SPR)18 (YCEL with antacids.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -1.99 Td
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(USE IN SPECIFIC POPULA)55 (TIONS)]TJ
0.01 Tw -3.375 -1.923 Td
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(Pregnanc)10 (y)]TJ
/T1_1 1 Tf
0 Tw -3.375 -1.45 Td
[(Risk Summar)-17.9 (y)]TJ
0.114 Tw 0 -1.292 Td
[(Based on limited human da)-10 (ta,)37 ( SPR)18 (YCEL can cause fetal harm when administered to)-10 ( )]TJ
0.255 Tw 0 -1 Td
[(a pregnant woman.)37 ( )37.1 (Adverse pharmacologic effects inc)20 (luding hydrops fetalis,)37 ( fetal)-10 ( )]TJ
0.048 Tw 0 -1 Td
[(leukopenia,)37 ( and fetal thromboc)20 (ytopenia ha)-10 (ve been reported with ma)-9.9 (ternal exposure to)-10 ( )]TJ
0.12 Tw 0 -1 Td
[(SPR)18 (YCEL.)37 ( )36.7 (Animal reproduction studies in ra)-10 (ts ha)-9.9 (ve demonstra)-9.9 (ted extensive mortality)-10 ( )]TJ
0.098 Tw 0 -1 Td
[(during organogenesis,)37 ( the fetal period,)37 ( and in neona)-10 (tes.)37 ( Skeletal malforma)-9.9 (tions were)-10 ( )]TJ
0.091 Tw 0 -1 Td
[(obser)-18 (ved in a limited number of sur)-18 (viving ra)-10 (t and rabbit conceptuses.)37 ( )36.9 (These \037ndings)-10 ( )]TJ
0.378 Tw 0 -1 Td
[(occurred a)-10 (t dasa)-10 (tinib plasma concentra)-10 (tions belo)-10 (w those in humans receiving)-10 ( )]TJ
0.117 Tw 0 -1 Td
[(thera)-10 (peutic doses of dasa)-9.9 (tinib )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
11.772 0 Td
(s)Tj
-0.01 Tc 0.117 Tw 0.397 0 Td
[(ee Da)-10 (ta])]TJ
/T1_1 1 Tf
[(.)37 ( )36.7 (Advise a pregnant woman of the potential)-9.9 ( )]TJ
0 Tw -12.169 -1 Td
(risk to a fetus.)Tj
-0.005 Tc 0.098 Tw 0 -1.427 Td
[(The )0.5 (estima)-10 (ted )0.5 (background risk )0.5 (in the U.S.)37 ( )0.5 (general popula)-9.9 (tion of major )0.5 (birth )0.5 (defects)-5 ( )]TJ
0 Tw 0 -1 Td
[(is 2% to 4% and of miscarria)-10 (ge is 15% to 20% of c)20 (linically recognized pregnancies.)]TJ
-0.01 Tc 0 -1.653 Td
[(Clinical Considera)-10 (tions)]TJ
/T1_2 1 Tf
-0.037 Tw 0 -1.36 Td
[(F)24 (etal/Neona)-9.9 (tal Adverse )-37 (Reactions)]TJ
/T1_1 1 Tf
-0.005 Tc 0.052 Tw 0 -1.292 Td
[(T)74 (ransplacental transfer of dasa)-10 (tinib has been reported.)37 ( Dasa)-10 (tinib has been measured)-5 ( )]TJ
0.063 Tw 0 -1 Td
[(in fetal plasma and amniotic \035uid a)-9.9 (t concentra)-10 (tions comparable to those in ma)-10 (ternal)-5 ( )]TJ
0.265 Tw 0 -1 Td
[(plasma.)37 ( Hydrops fetalis,)36.9 ( fetal leukopenia,)37 ( and fetal thromboc)20 (ytopenia ha)-10 (ve been)-5 ( )]TJ
-0.002 Tw 0 -1 Td
[(reported with ma)-10 (ternal exposure to dasa)-10 (tinib.)37 ( )37.3 (These adverse pharmacologic effects on)-5 ( )]TJ
0.028 Tw 0 -1 Td
[(the fetus are similar to adverse reactions obser)-18 (ved in adult pa)-10 (tients and may result in)-5 ( )]TJ
0 Tw 0 -1 Td
[(fetal harm or neona)-10 (tal dea)-9.9 (th )]TJ
/T1_2 1 Tf
0 Tc ([)Tj
10.842 0 Td
(s)Tj
-0.005 Tc -0.037 Tw 0.402 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.005 Tc 4.48 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.005 Tc 6.101 0 Td
[( \(5.1,)37 ( 5.3\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -21.824 -1.697 Td
[(Da)-10 (ta)]TJ
/T1_2 1 Tf
0 Tw 0 -1.36 Td
[(Human Da)-10 (ta)]TJ
/T1_1 1 Tf
-0.005 Tc -0.043 Tw 0 -1.292 Td
[(Based on human experience,)37 ( dasa)-10 (tinib )0.5 (is suspected )0.5 (to cause )0.5 (congenital malforma)-10 (tions,)32 ( )]TJ
0.033 Tw 0 -1 Td
[(inc)20 (luding neural tube defects,)37 ( and harmful pharmacological effects on the fetus when)-5 ( )]TJ
0 Tw 0 -1 Td
[(administered during pregnanc)20 (y)54.9 (.)]TJ
ET
q 1 0 0 1 324 578.9042 cm
0 0 m
42.279 0 l
S
Q
q 1 0 0 1 324 486.6914 cm
0 0 m
40.143 0 l
S
Q
q 1 0 0 1 324 446.428 cm
0 0 m
24.895 0 l
S
Q
q 1 0 0 1 324 398.0645 cm
0 0 m
77.375 0 l
S
Q
q 1 0 0 1 324 343.2494 cm
0 0 m
24.68 0 l
S
Q
q 1 0 0 1 324 249.2507 cm
0 0 m
147.877 0 l
S
Q
BT
/T1_2 1 Tf
-0.01 Tc 8 0 0 8 324 727.248 Tm
[(Animal Da)-10 (ta)]TJ
/T1_1 1 Tf
-0.005 Tc 0.215 Tw 0 -1.303 Td
[(In nonc)20 (linical studies a)-10 (t plasma concentra)-10 (tions belo)-10 (w those obser)-18 (ved in humans)-5 ( )]TJ
0.026 Tw 0 -1.011 Td
[(receiving thera)-10 (peutic doses of dasa)-10 (tinib,)37 ( embr)-18 (yo-fetal toxicities were obser)-18 (ved in ra)-10 (ts)-5 ( )]TJ
-0.024 Tw 0 -1.011 Td
[(and rabbits.)37 ( F)24 (etal dea)-10 (th was obser)-18 (ved in ra)-10 (ts.)37 ( In both ra)-10 (ts and rabbits,)37 ( the lo)-10 (west doses)-5 ( )]TJ
0.166 Tw 0 -1.011 Td
[(of dasa)-10 (tinib tested \(ra)-10 (t:)37 ( 2.5 mg/kg/day [15 mg/m)]TJ
0 Tc 0 Tw 6 0 0 6 475.6635 695.3646 Tm
(2)Tj
-0.005 Tc 0.166 Tw 8 0 0 8 478.5134 692.5646 Tm
[(/day] and rabbit:)37 ( 0.5 mg/kg/day)-5 ( )]TJ
0.156 Tw -19.314 -1.011 Td
([6 mg/m)Tj
0 Tc 0 Tw 6 0 0 6 350.2808 687.2787 Tm
(2)Tj
-0.005 Tc 0.156 Tw 8 0 0 8 353.1308 684.4787 Tm
[(/day]\) resulted in embr)-18 (yo-fetal toxicities.)36.9 ( )36.9 (These doses produced ma)-10 (ternal)-5 ( )]TJ
0.045 Tw -3.641 -1.011 Td
[(AUCs of 105 ng\225h/mL and 44 ng\225h/mL \(0.1-fold the human )36.8 (AUC\) in ra)-10 (ts and rabbits,)32 ( )]TJ
0.094 Tw 0 -1.011 Td
[(respectively)55 (.)37 ( Embr)-18 (yo-fetal toxicities inc)20 (luded skeletal malforma)-10 (tions a)-10 (t multiple sites)-5 ( )]TJ
0.153 Tw 0 -1.011 Td
[(\(sca)-10 (pula,)37 ( )0.5 (humerus,)37 ( )0.5 (femur)74 (,)37 ( )0.5 (radius,)37 ( )0.5 (ribs,)37 ( )0.5 (and )0.5 (c)20 (la)-10 (vic)20 (le\),)37 ( )0.5 (reduced )0.5 (ossi\037ca)-9.9 (tion )0.5 (\(sternum;)-5 ( )]TJ
0.131 Tw 0 -1.011 Td
[(thoracic,)37 ( lumbar)74 (,)37 ( and sacral vertebrae; forepa)-10 (w phalanges; pelvis; and hyoid bod)-10 (y\),)32 ( )]TJ
0.33 Tw 0 -1.011 Td
[(edema,)37 ( and microhepa)-10 (tia.)37 ( In a pre- and postna)-10 (tal development stud)-10 (y in ra)-9.9 (ts,)31.9 ( )]TJ
0.063 Tw 0 -1.011 Td
[(administra)-10 (tion of dasa)-9.9 (tinib from gesta)-10 (tion day \(GD\) 16 through lacta)-9.9 (tion day \(LD\) 20,)32 ( )]TJ
0.094 Tw 0 -1.011 Td
[(GD 21 through LD 20,)36.9 ( or LD 4 through LD 20 resulted in extensive pup mortality a)-10 (t)-5 ( )]TJ
-0.027 Tw 0 -1.011 Td
[(ma)-10 (ternal exposures tha)-9.9 (t were belo)-9.9 (w the exposures in pa)-10 (tients trea)-9.9 (ted with dasa)-9.9 (tinib a)-9.9 (t)-5 ( )]TJ
0 Tw 0 -1.011 Td
(the recommended labeling dose.)Tj
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -2.271 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Lactation)Tj
/T1_1 1 Tf
0 Tw -3.375 -1.663 Td
[(Risk Summar)-17.9 (y)]TJ
-0.005 Tc -0.001 Tw 0 -1.303 Td
[(No da)-10 (ta are a)-10 (vailable regarding the presence of dasa)-9.9 (tinib in human milk,)37 ( the effects of)-5 ( )]TJ
0.003 Tw 0 -1.011 Td
[(the drug on the breastfed child,)37 ( or the effects of the drug on milk production.)37 ( Ho)-9.9 (wever)74 (,)32 ( )]TJ
0.076 Tw 0 -1.011 Td
[(dasa)-10 (tinib is present in the milk of lacta)-10 (ting ra)-10 (ts.)37 ( Because of the potential for serious)-5 ( )]TJ
-0.062 Tw 0 -1.011 Td
[(adverse reactions in nursing children from SPR)17.9 (YCEL,)37 ( breastfeeding is not recommended)-5 ( )]TJ
0 Tw 0 -1.011 Td
[(during trea)-10 (tment with SPR)18 (YCEL and for 2 weeks after the last dose.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -2.271 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(F)20 (emales and Males of Reproductive P)24 (otential)]TJ
/T1_1 1 Tf
0.088 Tw -3.375 -1.393 Td
[(SPR)18 (YCEL can cause fetal harm when administered to a pregnant woman )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
27.602 0 Td
(s)Tj
-0.01 Tc 0.088 Tw 0.397 0 Td
(ee U)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.088 Tw 2.092 0 Td
[(e in)-10 ( )]TJ
0 Tw -30.091 -1.011 Td
[(Speci\037c P)18 (opula)-9.9 (tion)]TJ
0 Tc (s)Tj
-0.01 Tc 7.244 0 Td
( \(8.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -7.244 -1.506 Td
(Contraception)Tj
-0.017 Tw 0 -1.303 Td
[(Advise females of reproductive potential and males with female partners \of reproductive)-10 ( )]TJ
0.012 Tw 0 -1.011 Td
[(potential to use effective contraception during trea)-9.9 (tment with SPR)18 (YCEL and for 30 days)-10 ( )]TJ
0 Tw 0 -1.011 Td
(after the last dose.)Tj
0.01 Tw 0 -1.708 Td
(Infertility)Tj
-0.005 Tc -0.028 Tw 0 -1.303 Td
[(Based on animal da)-10 (ta,)37 ( dasa)-10 (tinib may result in dama)-10 (ge to female and male reproductive)-5 ( )]TJ
0.005 Tw 0 -1.011 Td
(tissues )Tj
/T1_2 1 Tf
0 Tc 0 Tw 2.791 0 Td
([)Tj
0.254 0 Td
(s)Tj
-0.005 Tc 0.402 0 Td
[(ee Nonc)20 (linical )37 (T)74 (oxicolog)-10 (y \(13.1\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
/T1_3 1 Tf
-0.01 Tc 0.01 Tw -3.447 -2.271 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(P)24 (ediatric Use)]TJ
/T1_1 1 Tf
0.01 Tw -3.375 -1.461 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( CML in Chronic Phase)Tj
-0.005 Tc 0.136 Tw -1.514 -1.303 Td
[(The safety and effectiveness of SPR)18 (YCEL monothera)-10 (py ha)-9.9 (ve been demonstra)-10 (ted in)-5 ( )]TJ
0.221 Tw 0 -1.011 Td
[(pedia)-10 (tric pa)-10 (tients with newly dia)-9.9 (gnosed chronic phase CML )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
23.97 0 Td
(s)Tj
-0.005 Tc 0.221 Tw 0.402 0 Td
(ee Clinical Studie)Tj
0 Tc 0 Tw (s)Tj
( )Tj
-0.005 Tc 0.005 Tw -24.372 -1.011 Td
(\(14.3\)])Tj
/T1_1 1 Tf
-0.014 Tw [(.)37 ( )36.6 (There are no da)-10 (ta in children under 1 year of a)-10 (ge.)37 ( )36.6 (Adverse reactions associa)-9.9 (ted)-5 ( )]TJ
-0.034 Tw 0 -1.011 Td
[(with bone gro)-9.9 (wth and development were reported in 5 \(5.2%\) of )0.5 (pa)-9.9 (tients )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
26.647 0 Td
(s)Tj
-0.005 Tc -0.071 Tw 0.402 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
( )Tj
-0.005 Tc -27.049 -1.011 Td
(and Precaution)Tj
0 Tc (s)Tj
-0.005 Tc 5.866 0 Td
( \(5.10\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -5.866 -1.506 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.125 Td
(+)Tj
-0.01 Tc -0.037 Tw 0.59 -0.125 Td
( ALL)Tj
-0.005 Tc -0.026 Tw -1.514 -1.303 Td
[(The safety and effectiveness of SPR)17.9 (YCEL in combina)-9.9 (tion with chemothera)-9.9 (py ha)-10 (ve been)-5 ( )]TJ
0.044 Tw 0 -1.011 Td
[(demonstra)-9.9 (ted in pedia)-10 (tric pa)-10 (tients one year and over with newly dia)-9.9 (gnosed Ph)]TJ
0 Tc 0 Tw 29.087 0.125 Td
(+)Tj
-0.005 Tc 0.007 Tw 0.595 -0.125 Td
[( ALL.)32 ( )]TJ
-0.029 Tw -29.682 -1.011 Td
[(Use of SPR)18 (YCEL in pedia)-9.9 (tric pa)-10 (tients is supported )0.5 (by evidence from one )0.5 (pedia)-10 (tric stud)-10 (y)55 (.)32 ( )]TJ
-0.004 Tw 0 -1.011 Td
[(There are no da)-10 (ta in children under 1 year of a)-10 (ge.)37 ( One case of grade 1 osteopenia was)-5 ( )]TJ
0.005 Tw 0 -1.011 Td
(reported.)Tj
0.008 Tw 0 -1.438 Td
[(The safety pro\037le of SPR)18 (YCEL in pedia)-10 (tric subjects was comparable to tha)-10 (t reported in)-5 ( )]TJ
-0.017 Tw 0 -1.011 Td
(studies in adult subjects )Tj
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
9.234 0 Td
(s)Tj
-0.005 Tc -0.054 Tw 0.402 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc -0.017 Tw 3.545 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc -0.017 Tw 4.222 0 Td
( \(6.1\) and Clinical Studie)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc -0.017 Tw 9.215 0 Td
[( \(14.3,)37 ( 14.4\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.005 Tc 0.297 Tw -26.618 -1.438 Td
[(Monitor bone gro)-9.9 (wth and development in pedia)-10 (tric pa)-10 (tients )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
24.429 0 Td
(s)Tj
-0.005 Tc 0.26 Tw 0.402 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.005 Tc 0.297 Tw 4.777 0 Td
[( and)-5 ( )]TJ
0.005 Tw -29.608 -1.011 Td
(Precaution)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc 4.276 0 Td
( \(5.10\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc -4.276 -1.506 Td
[(P)18 (edia)-9.9 (tric P)18.1 (a)-10 (tients with Dif\037culty Swallo)-10 (wing )37 (T)74 (ablets)]TJ
-0.005 Tc 0.22 Tw 0 -1.303 Td
[(F)18 (ive pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 8.227 0.125 Td
(+)Tj
-0.005 Tc 0.22 Tw 0.595 -0.125 Td
[( )36.7 (ALL 2 to 10 years of a)-9.9 (ge received a)-10 (t least one dose of)-5 ( )]TJ
0.128 Tw -8.822 -1.011 Td
[(SPR)18 (YCEL tablet dispersed in juice on Stud)-10 (y CA180372.)37 ( )36.9 (The exposure for dispersed)-5 ( )]TJ
0.017 Tw 0 -1.011 Td
[(tablets was 36% lo)-10 (wer as compared to intact tablets in pedia)-10 (tric pa)-9.9 (tients )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
27.335 0 Td
(s)Tj
-0.005 Tc 0.017 Tw 0.402 0 Td
[(ee Clinical)-5 ( )]TJ
0.074 Tw -27.737 -1.011 Td
[(Pharmacolog)-10 (y \(12.3\))]TJ
0 Tc 0 Tw (])Tj
/T1_1 1 Tf
-0.005 Tc 0.074 Tw 7.882 0 Td
[(.)37 ( Due to the limited a)-9.9 (vailable c)20 (linical da)-10 (ta,)37 ( it is unc)20 (lear whether)-4.9 ( )]TJ
0 Tw -7.882 -1.011 Td
[(dispersing SPR)18 (YCEL tablets signi\037cantly alters the safety and/or ef\037cac)20 (y of SPR)18 (YCEL.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -1.708 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Geriatric Use)Tj
/T1_1 1 Tf
-0.005 Tc 0.055 Tw -3.375 -1.393 Td
[(Of )0.5 (the )0.5 (2712 )0.5 (pa)-10 (tients )0.5 (in )0.5 (c)20 (linical )0.5 (studies )0.5 (of )0.5 (SPR)18 (YCEL,)37 ( )0.5 (617 )0.5 (\(23%\) )0.5 (were )0.5 (65 )0.5 (years )0.5 (of )0.5 (a)-10 (ge)-5 ( )]TJ
0.048 Tw 0 -1.011 Td
[(and older)74 (,)37 ( and 123 \(5%\) were 75 years of a)-10 (ge and older)74 (.)37 ( No differences in con\037rmed)-5 ( )]TJ
0.209 Tw 0 -1.011 Td
[(Complete Cytogenetic Response \(cCCyR\) and MMR were obser)-18 (ved between older)-5 ( )]TJ
0.085 Tw 0 -1.011 Td
[(and younger pa)-10 (tients.)37 ( )37.1 (While the safety pro\037le of SPR)18 (YCEL in the geria)-10 (tric popula)-9.9 (tion)-5 ( )]TJ
0.101 Tw 0 -1.011 Td
[(was similar to tha)-10 (t in the younger popula)-10 (tion,)37 ( pa)-10 (tients a)-10 (ged 65 years and older are)-5 ( )]TJ
0.308 Tw 0 -1.011 Td
[(more likely to experience the commonly reported adverse reactions of fa)-10 (tigue,)32 ( )]TJ
0.191 Tw 0 -1.011 Td
[(pleural effusion,)37 ( diarrhea,)37 ( d)-10 (yspnea,)37 ( cough,)37 ( lo)-10 (wer gastrointestinal hemorrha)-10 (ge,)37 ( and)-5.1 ( )]TJ
0.261 Tw 0 -1.011 Td
[(a)-10 (ppetite disturbance,)37 ( and more likely to experience the less frequently reported)-5 ( )]TJ
0.098 Tw 0 -1.011 Td
[(adverse )0.5 (reactions of )0.5 (abdominal distention,)36.9 ( )0.5 (dizziness,)37 ( pericardial )0.5 (effusion,)37 ( congestive)-5 ( )]TJ
0.133 Tw 0 -1.011 Td
[(heart failure,)37 ( hypertension,)37 ( pulmonar)-18 (y edema,)37 ( and weight decrease,)37 ( and should be)-5 ( )]TJ
0 Tw 0 -1.011 Td
[(monitored c)19.9 (losely)55 (.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -1.911 Td
(10)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(OVERDOSAGE)Tj
/T1_1 1 Tf
-0.005 Tc 0.092 Tw -3.375 -1.303 Td
[(Experience with overdose of SPR)17.9 (YCEL in c)20 (linical studies is limited to isola)-10 (ted cases.)32 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.005 Tc -0.032 Tw -31.5 -1.011 Td
[(The highest overdosa)-9.9 (ge of 280 mg per day for 1 week was reported in two pa)-9.9 (tients and)-5 ( )]TJ
0.058 Tw 0 -1.011 Td
[(both developed severe myelosuppression and bleeding.)37 ( Since SPR)18 (YCEL is associa)-10 (ted)-5 ( )]TJ
0.265 Tw 0 -1.011 Td
(with severe myelosuppression )Tj
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
12.319 0 Td
(s)Tj
-0.005 Tc 0.228 Tw 0.402 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.005 Tc 0.265 Tw 4.745 0 Td
( and Precaution)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc 0.265 Tw 6.63 0 Td
( \(5.1\))Tj
0 Tc 0 Tw ( )Tj
-0.005 Tc 0.005 Tw 2.656 0 Td
(and)Tj
0 Tc 0 Tw ( )Tj
-0.005 Tc 0.005 Tw 1.818 0 Td
(Adver)Tj
0 Tc 0 Tw (s)Tj
2.486 0 Td
(e )Tj
-0.005 Tc 0.005 Tw -31.056 -1.011 Td
(Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc 0.145 Tw 3.565 0 Td
[( )0.5 (\(6.1\)])]TJ
/T1_1 1 Tf
[(,)37 ( )0.6 (monitor )0.6 (pa)-10 (tients )0.5 (who )0.6 (ingest )0.5 (more )0.5 (than )0.6 (the )0.5 (recommended )0.5 (dosa)-10 (ge)-5 ( )]TJ
0 Tw -3.565 -1.011 Td
[(c)20 (losely for myelosuppression and give a)-10 (ppropria)-10 (te supportive trea)-9.9 (tment.)]TJ
ET
endstreamendobj30 0 obj<</Length 28781>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 0 k
/GS0 gs
36 732.96 252 -25.312 re
36 707.648 97.92 -12.912 re
133.92 707.648 154.08 -12.912 re
36 694.736 97.92 -12.912 re
133.92 694.736 77.04 -12.912 re
210.96 694.736 77.04 -12.912 re
36 681.824 97.92 -11.981 re
133.92 681.824 77.04 -11.981 re
210.96 681.824 77.04 -11.981 re
36 669.843 97.92 -11.731 re
133.92 669.843 77.04 -11.731 re
210.96 669.843 77.04 -11.731 re
36 658.112 97.92 -11.731 re
133.92 658.112 77.04 -11.731 re
210.96 658.112 77.04 -11.731 re
36 646.381 97.92 -11.731 re
133.92 646.381 77.04 -11.731 re
210.96 646.381 77.04 -11.731 re
36 634.65 97.92 -11.731 re
133.92 634.65 77.04 -11.731 re
210.96 634.65 77.04 -11.731 re
36 622.919 97.92 -11.731 re
133.92 622.919 77.04 -11.731 re
210.96 622.919 77.04 -11.731 re
36 611.188 97.92 -11.731 re
133.92 611.188 77.04 -11.731 re
210.96 611.188 77.04 -11.731 re
36 599.456 97.92 -11.731 re
133.92 599.456 77.04 -11.731 re
210.96 599.456 77.04 -11.731 re
36 587.725 97.92 -11.731 re
133.92 587.725 77.04 -11.731 re
210.96 587.725 77.04 -11.731 re
36 575.994 97.92 -11.731 re
133.92 575.994 77.04 -11.731 re
210.96 575.994 77.04 -11.731 re
36 564.263 97.92 -11.731 re
133.92 564.263 77.04 -11.731 re
210.96 564.263 77.04 -11.731 re
36 552.532 97.92 -11.731 re
133.92 552.532 77.04 -11.731 re
210.96 552.532 77.04 -11.731 re
36 540.801 97.92 -11.731 re
133.92 540.801 77.04 -11.731 re
210.96 540.801 77.04 -11.731 re
36 529.07 97.92 -11.731 re
133.92 529.07 77.04 -11.731 re
210.96 529.07 77.04 -11.731 re
36 517.339 97.92 -11.731 re
133.92 517.339 77.04 -11.731 re
210.96 517.339 77.04 -11.731 re
36 505.608 97.92 -11.731 re
133.92 505.608 77.04 -11.731 re
210.96 505.608 77.04 -11.731 re
36 493.876 97.92 -11.731 re
133.92 493.876 77.04 -11.731 re
210.96 493.876 77.04 -11.731 re
36 482.145 97.92 -11.731 re
133.92 482.145 77.04 -11.731 re
210.96 482.145 77.04 -11.731 re
36 470.414 97.92 -11.731 re
133.92 470.414 77.04 -11.731 re
210.96 470.414 77.04 -11.731 re
36 458.683 97.92 -11.731 re
133.92 458.683 77.04 -11.731 re
210.96 458.683 77.04 -11.731 re
36 446.952 97.92 -11.731 re
133.92 446.952 77.04 -11.731 re
210.96 446.952 77.04 -11.731 re
36 435.221 97.92 -11.731 re
133.92 435.221 77.04 -11.731 re
210.96 435.221 77.04 -11.731 re
36 423.49 97.92 -11.731 re
133.92 423.49 77.04 -11.731 re
210.96 423.49 77.04 -11.731 re
36 411.759 97.92 -11.731 re
133.92 411.759 77.04 -11.731 re
210.96 411.759 77.04 -11.731 re
36 400.027 97.92 -11.731 re
133.92 400.027 77.04 -11.731 re
210.96 400.027 77.04 -11.731 re
36 388.296 97.92 -11.731 re
133.92 388.296 77.04 -11.731 re
210.96 388.296 77.04 -11.731 re
36 376.565 97.92 -11.731 re
133.92 376.565 77.04 -11.731 re
210.96 376.565 77.04 -11.731 re
36 364.834 97.92 -11.731 re
133.92 364.834 77.04 -11.731 re
210.96 364.834 77.04 -11.731 re
36 353.103 97.92 -11.731 re
133.92 353.103 77.04 -11.731 re
210.96 353.103 77.04 -11.731 re
36 341.372 97.92 -11.731 re
133.92 341.372 77.04 -11.731 re
210.96 341.372 77.04 -11.731 re
36 329.641 97.92 -11.731 re
133.92 329.641 77.04 -11.731 re
210.96 329.641 77.04 -11.731 re
36 317.91 97.92 -11.731 re
133.92 317.91 77.04 -11.731 re
210.96 317.91 77.04 -11.731 re
36 306.179 97.92 -11.731 re
133.92 306.179 77.04 -11.731 re
210.96 306.179 77.04 -11.731 re
36 294.447 97.92 -11.731 re
133.92 294.447 77.04 -11.731 re
210.96 294.447 77.04 -11.731 re
36 282.716 97.92 -11.731 re
133.92 282.716 77.04 -11.731 re
210.96 282.716 77.04 -11.731 re
36 270.985 97.92 -11.731 re
133.92 270.985 77.04 -11.731 re
210.96 270.985 77.04 -11.731 re
36 259.254 97.92 -11.731 re
133.92 259.254 77.04 -11.731 re
210.96 259.254 77.04 -11.731 re
36 247.523 97.92 -11.731 re
133.92 247.523 77.04 -11.731 re
210.96 247.523 77.04 -11.731 re
36 235.792 97.92 -11.731 re
133.92 235.792 77.04 -11.731 re
210.96 235.792 77.04 -11.731 re
f
0 0 0 1 K
1.01 w 
/GS1 gs
q 1 0 0 1 36 224.0608 cm
0 0 m
97.92 0 l
S
Q
q 1 0 0 1 133.92 224.0608 cm
0 0 m
77.04 0 l
S
Q
0.5 w 
q 1 0 0 1 210.96 669.8431 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 658.112 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 646.3809 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 634.6498 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 622.9186 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 611.1876 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 587.7253 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 575.9942 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 564.2631 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 552.532 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 540.8008 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 529.0697 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 517.3386 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 505.6075 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 493.8764 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 482.1453 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 470.4142 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 458.683 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 446.9519 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 435.2208 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 423.4897 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 411.7586 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 400.0275 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 388.2964 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 376.5652 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 364.8341 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 353.103 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 341.3719 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 329.6408 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 317.9097 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 306.1786 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 294.4474 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 282.7163 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 270.9852 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 259.2541 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 247.523 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 235.7919 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 224.5658 cm
0 0 m
0 11.226 l
S
Q
1.01 w 
q 1 0 0 1 210.96 224.0608 cm
0 0 m
77.04 0 l
S
Q
0.5 w 
q 1 0 0 1 36 681.8242 cm
0 0 m
97.92 0 l
S
Q
q 1 0 0 1 210.96 681.8242 cm
0 0 m
77.04 0 l
S
Q
q 1 0 0 1 210.96 694.7361 cm
0 0 m
77.04 0 l
S
Q
1 w 
q 1 0 0 1 36 707.6481 cm
0 0 m
97.92 0 l
S
Q
q 1 0 0 1 133.92 707.6481 cm
0 0 m
77.04 0 l
S
Q
q 1 0 0 1 210.96 707.6481 cm
0 0 m
77.04 0 l
S
Q
0.5 w 
q 1 0 0 1 133.92 694.7361 cm
0 0 m
77.04 0 l
S
Q
q 1 0 0 1 210.96 682.0742 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 133.92 681.8242 cm
0 0 m
77.04 0 l
S
Q
q 1 0 0 1 210.96 599.4564 cm
0 0 m
0 11.731 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.01 Tc 0.35 Tw 8 0 0 8 36 727.248 Tm
[(Table )326 (14:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(Adverse Reactions )0.5 (Reported )0.5 (in \03620% )0.5 (of Pediatric )0.5 (Patients)-10 ( )]TJ
0.341 Tw 0 -1 Td
(with Ph)Tj
0 Tc 0 Tw 3.27 0.125 Td
(+)Tj
-0.01 Tc 0.341 Tw 0.59 -0.125 Td
[( ALL Treated with SPRYCEL in Combination with)-10 ( )]TJ
0.024 Tw -3.86 -1 Td
(Chemotherapy CA180372 \(N=81\))Tj
-0.02 Tc 7.2 0 0 8 179.3743 698.3361 Tm
(Percent \(%\) of Patients)Tj
-0.01 Tc -19.913 -1.614 Td
(Adverse Reaction)Tj
-0.02 Tc 16.984 0 Td
(All Grades)Tj
10.819 0 Td
(Grade 3/4)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -27.803 -1.571 Td
(Mucositis)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(93)Tj
10.97 0 Td
(60)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(F)24 (ebrile neutropenia)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(86)Tj
10.97 0 Td
(86)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Pyrexia)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(85)Tj
10.97 0 Td
(17)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(84)Tj
10.97 0 Td
(31)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Nausea)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(84)Tj
10.97 0 Td
(11)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
[(V)18 (omiting)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(83)Tj
10.97 0 Td
(17)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
(Musculoskeletal pain)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(83)Tj
10.97 0 Td
(25)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
(Abdominal pain)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(78)Tj
10.97 0 Td
(17)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Cough)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(78)Tj
0 Tc 0 Tw 11.207 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(77)Tj
10.97 0 Td
(15)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Rash)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(68)Tj
0 Tc 0 Tw 11.207 0 Td
(7)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
[(F)20 (a)-10 (tigue)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(59)Tj
0 Tc 0 Tw 11.207 0 Td
(3)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
[(Constipa)-10 (tion)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(57)Tj
0 Tc 0 Tw 11.207 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
(Arrhythmia)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(47)Tj
10.97 0 Td
(12)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Hypertension)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(47)Tj
10.97 0 Td
(10)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Edema)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(47)Tj
0 Tc 0 Tw 11.207 0 Td
(6)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
(Viral infection)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(40)Tj
10.97 0 Td
(12)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Hypotension)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(40)Tj
10.97 0 Td
(26)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(Decreased a)-10 (ppetite)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(38)Tj
10.97 0 Td
(22)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Hypersensitivity)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(36)Tj
10.97 0 Td
(20)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(Upper respira)-10 (tor)-17.9 (y tract infection)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(36)Tj
10.97 0 Td
(10)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Dyspnea)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(35)Tj
10.97 0 Td
(10)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Epistaxis)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(31)Tj
0 Tc 0 Tw 11.207 0 Td
(6)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
[(P)18 (eripheral neuropa)-10 (thy)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(31)Tj
0 Tc 0 Tw 11.207 0 Td
(7)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
[(Sepsis \(exc)20 (luding fungal\))]TJ
-0.005 Tc 0.005 Tw 18.345 0 Td
(n/a)Tj
11.08 0 Td
(31)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(Altered sta)-10 (te of consciousness)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(30)Tj
0 Tc 0 Tw 11.207 0 Td
(4)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
(Fungal infection)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(30)Tj
10.97 0 Td
(11)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(Pneumonia \(exc)20 (luding fungal\))]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(28)Tj
10.97 0 Td
(25)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Pruritus)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(28)Tj
0 Tc 0 Tw 11.271 0 Td
(-)Tj
-0.01 Tc 0.024 Tw -29.727 -1.466 Td
[(Clostridial infection \(exc)20 (luding sepsis\))]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(25)Tj
10.97 0 Td
(14)Tj
-0.01 Tc -0.013 Tw -29.425 -1.466 Td
[(Urinar)-18 (y T)74 (ract )-37 (Infection)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(24)Tj
10.97 0 Td
(14)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(Bacteremia \(exc)20 (luding fungal\))]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(22)Tj
10.97 0 Td
(20)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
[(Er)-18 (ythema)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(22)Tj
0 Tc 0 Tw 11.207 0 Td
(6)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
(Chills)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(21)Tj
0 Tc 0 Tw 11.271 0 Td
(-)Tj
-0.01 Tc 0.024 Tw -29.727 -1.466 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(21)Tj
0 Tc 0 Tw 11.207 0 Td
(9)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
(Sinusitis)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(21)Tj
10.97 0 Td
(10)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
[(Dehydra)-10 (tion)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(20)Tj
0 Tc 0 Tw 11.207 0 Td
(9)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
[(Renal insufficienc)20 (y)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(20)Tj
0 Tc 0 Tw 11.207 0 Td
(9)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
(Visual impairment)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(20)Tj
0 Tc 0 Tw 11.271 0 Td
(-)Tj
-0.01 Tc 0.053 Tw 8 0 0 8 36 203.6964 Tm
[(The incidence of common adverse reactions a)-10 (ttributed by the investiga)-10 (tor to SPR)18 (YCEL)-10 ( )]TJ
0.159 Tw 0 -1.065 Td
[(\(reported a)-9.9 (t a frequenc)20 (y of \03610%,)37 ( all grades and grade 3/4,)37 ( respectively\) on stud)-10 (y)-10 ( )]TJ
0.112 Tw 0 -1.065 Td
[(\(N=81\),)37.1 ( inc)20 (luded febrile neutropenia \(23%,)37 ( 23%\),)37 ( nausea \(21%,)37 ( 4%\),)37.1 ( vomiting \(19%,)27 ( )]TJ
-0.005 Tw 0 -1.065 Td
[(4%\),)37 ( mucositis \(17%,)37 ( 6%\),)37 ( musculoskeletal pain \(17%,)37 ( 2%\),)37 ( abdominal pain \(16%,)37 ( 5%\),)27 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.23 Tw -31.5 -1.065 Td
[(diarrhea )0.6 (\(16%,)37 ( )0.6 (7%\),)37 ( )0.6 (rash )0.6 (\(15%,)37 ( )0.6 (0%\),)37 ( )0.5 (fa)-10 (tigue )0.6 (\(12%,)37 ( )0.6 (0%\),)37 ( )0.6 (pyrexia )0.5 (\(12%,)37 ( )0.5 (6%\),)37 ( )0.5 (and)-10 ( )]TJ
0 Tw 0 -1.065 Td
[(headache \(12%,)37 ( 5%\).)]TJ
-0.045 Tw 0 -1.492 Td
[(CTCAE grade 3/4 labora)-9.9 (tor)-18 (y abnormalities in pedia)-10 (tric pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 24.942 0.125 Td
(+)Tj
-0.01 Tc -0.045 Tw 0.59 -0.125 Td
[( )37.2 (ALL trea)-10 (ted with)-10 ( )]TJ
0 Tw -25.532 -1.065 Td
[(SPR)18 (YCEL in combina)-10 (tion with chemothera)-10 (py are sho)-10 (wn in )37 (T)74 (able 15.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 130.041 252 -25.312 re
36 104.729 105.84 -13.635 re
141.84 104.729 146.16 -13.635 re
36 91.094 105.84 -11.731 re
141.84 91.094 146.16 -11.731 re
36 79.363 105.84 -11.731 re
141.84 79.363 146.16 -11.731 re
36 67.632 105.84 -11.731 re
141.84 67.632 146.16 -11.731 re
36 55.901 105.84 -11.731 re
141.84 55.901 146.16 -11.731 re
f
1 w 
/GS1 gs
q 1 0 0 1 36 104.7294 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 141.84 104.7294 cm
0 0 m
146.16 0 l
S
Q
0.505 w 
q 1 0 0 1 36 91.0944 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 141.84 91.0944 cm
0 0 m
146.16 0 l
S
Q
0.5 w 
q 1 0 0 1 36 44.17 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 141.84 44.17 cm
0 0 m
146.16 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
0.022 Tw 8 0 0 8 36 124.3294 Tm
[(Table )-2 (15:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(CTCAE Grade 3/4 Laboratory Abnormalities in \03610% of Pediatric)-10 ( )]TJ
0.158 Tw 0 -1 Td
(Patients with Ph)Tj
0 Tc 0 Tw 6.634 0.125 Td
(+)Tj
-0.01 Tc 0.158 Tw 0.59 -0.125 Td
[( ALL Treated with SPRYCEL in Combination)-10 ( )]TJ
0.024 Tw -7.224 -1 Td
(with Chemotherapy CA180372 \(N=81\))Tj
7.2 0 0 8 182.715 95.056 Tm
[(P)24 (ercent \(%\) of P)24 (atients)]TJ
-20.377 -1.585 Td
[(Hematolog)-10 (y P)24 (arameters)]TJ
/T1_1 1 Tf
1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.466 Td
( )Tj
EMC 
1.262 0 Td
(Neutropenia)Tj
-0.005 Tc 0.005 Tw 23.11 0 Td
(96)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.373 -1.466 Td
( )Tj
EMC 
1.262 0 Td
[(Thromboc)20 (ytopenia)]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(88)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.373 -1.466 Td
( )Tj
EMC 
1.262 0 Td
(Anemia)Tj
-0.005 Tc 0.005 Tw 23.11 0 Td
(82)Tj
/T1_2 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 253.872 35.8177 Tm
(\(Continued\))Tj
ET
q 1 0 0 1 324 561.7136 cm
0 0 m
119.269 0 l
S
Q
0 0 0 0 k
/GS0 gs
324 732.96 252 -25.312 re
324 707.648 105.84 -13.635 re
429.84 707.648 146.16 -13.635 re
324 694.013 252 -5.964 re
324 688.049 105.84 -11.472 re
429.84 688.049 146.16 -11.472 re
324 676.577 105.84 -11.472 re
429.84 676.577 146.16 -11.472 re
324 665.105 105.84 -11.472 re
429.84 665.105 146.16 -11.472 re
324 653.633 105.84 -11.472 re
429.84 653.633 146.16 -11.472 re
324 642.161 105.84 -11.472 re
429.84 642.161 146.16 -11.472 re
324 630.689 105.84 -11.472 re
429.84 630.689 146.16 -11.472 re
324 619.217 105.84 -11.472 re
429.84 619.217 146.16 -11.472 re
324 607.745 105.84 -11.472 re
429.84 607.745 146.16 -11.472 re
324 596.273 252 -12.912 re
f
1 w 
/GS1 gs
q 1 0 0 1 324 707.6481 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 429.84 707.6481 cm
0 0 m
146.16 0 l
S
Q
0.505 w 
q 1 0 0 1 324 694.0131 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 429.84 694.0131 cm
0 0 m
146.16 0 l
S
Q
1.01 w 
q 1 0 0 1 324 596.2733 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 429.84 596.2733 cm
0 0 m
146.16 0 l
S
Q
0.505 w 
q 1 0 0 1 324 583.3614 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 429.84 583.3614 cm
0 0 m
146.16 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
0.022 Tw 8 0 0 8 324 727.248 Tm
[(Table )-2 (15:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(CTCAE Grade 3/4 Laboratory Abnormalities in \03610% of Pediatric)-10 ( )]TJ
0.158 Tw 0 -1 Td
(Patients with Ph)Tj
0 Tc 0 Tw 6.634 0.125 Td
(+)Tj
-0.01 Tc 0.158 Tw 0.59 -0.125 Td
[( ALL Treated with SPRYCEL in Combination)-10 ( )]TJ
0.024 Tw -7.224 -1 Td
(with Chemotherapy CA180372 \(N=81\))Tj
7.2 0 0 8 470.715 697.9745 Tm
[(P)24 (ercent \(%\) of P)24 (atients)]TJ
-0.02 Tc -20.377 -2.315 Td
[(Biochemistr)-18 (y P)24 (arameters)]TJ
/T1_1 1 Tf
-0.01 Tc /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGPT \(AL)94.1 (T\))]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(47)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
(Hypokalemia)Tj
-0.005 Tc 0.005 Tw 23.11 0 Td
(40)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGOT \(AST\))]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(26)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
(Hypocalcemia)Tj
-0.005 Tc 0.005 Tw 23.11 0 Td
(19)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
[(Hypona)-10 (tremia)]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(19)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted Bilirubin)]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(11)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
[(Hypophospha)-9.9 (temia)]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(11)Tj
0 Tw -24.372 -1.524 Td
[(T)74 (oxicity grading is per CTCAE version 4.)]TJ
-0.01 Tc 8 0 0 8 324 563.0436 Tm
[(Additional P)18 (ooled Da)-9.9 (ta from Clinical )37 (T)74 (rials)]TJ
-0.005 Tc -0.025 Tw 0 -1.316 Td
[(The follo)-9.9 (wing additional adverse reactions were reported in adult and pedia)-10 (tric pa)-10 (tients)-5 ( )]TJ
0.197 Tw 0 -1.023 Td
[(\(n=2809\) in SPR)18 (YCEL CML c)20 (linical studies and adult pa)-9.9 (tients in Ph)]TJ
0 Tc 0 Tw 26.185 0.125 Td
(+)Tj
-0.005 Tc 0.16 Tw 0.595 -0.125 Td
[( ALL )-37.2 (c)20 (linical)-5 ( )]TJ
0 Tc 0 Tw 4.72 0 Td
( )Tj
-0.005 Tc 0.119 Tw -31.5 -1.023 Td
[(studies )0.5 (a)-10 (t )0.5 (a )0.5 (frequenc)20 (y )0.5 (of )0.5 (\03610%,)37 ( )0.5 (1%\226<10%,)37 ( )0.5 (0.1%\226<1%,)37 ( )0.5 (or )0.5 (<0.1%.)37 ( )37.5 (These )0.5 (adverse)-5 ( )]TJ
0 Tw 0 -1.023 Td
[(reactions are inc)20 (luded based on c)20 (linical relevance.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.059 Tw 0 -1.451 Td
(Gastrointestinal Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.01 Tc 0.059 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( mucosal in\035amma)-9.9 (tion \(inc)20 (luding mucositis/)]TJ
0.193 Tw 0 -1.023 Td
[(stoma)-10 (titis\),)37 ( d)-10 (yspepsia,)37.1 ( abdominal distension,)37 ( constipa)-10 (tion,)37.1 ( gastritis,)37 ( colitis \(inc)20 (luding)-10 ( )]TJ
0.165 Tw 0 -1.023 Td
[(neutropenic )0.6 (colitis\),)37 ( )0.5 (oral )0.5 (soft )0.6 (tissue )0.6 (disorder; )]TJ
/T1_2 1 Tf
17.095 0 Td
[(0.1%\226<1% )0.5 (\226)]TJ
/T1_1 1 Tf
[( )0.5 (ascites,)37 ( )0.5 (d)-10 (yspha)-10 (gia,)37 ( )0.5 (anal)-9.9 ( )]TJ
0.098 Tw -17.095 -1.023 Td
[(\037ssure,)37 ( upper gastrointestinal ulcer)74 (,)37 ( esopha)-10 (gitis,)37 ( pancrea)-10 (titis,)37 ( gastroesopha)-9.9 (geal re\035ux)-10 ( )]TJ
0.01 Tw 0 -1.023 Td
(disease; )Tj
/T1_2 1 Tf
3.181 0 Td
(<0.1% )Tj
/T1_1 1 Tf
-0.022 Tw 2.717 0 Td
[(\226 protein losing gastroenteropa)-10 (thy)55.1 (,)36.9 ( ileus,)37.1 ( acute pancrea)-10 (titis,)37 ( anal \037stula.)]TJ
/T1_3 1 Tf
0.075 Tw -5.898 -1.451 Td
(General Disorders and Administration-Site Conditions:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.01 Tc 0.01 Tw (\03610%)Tj
/T1_1 1 Tf
0.075 Tw [( \226 peripheral edema,)27 ( )]TJ
0.155 Tw 0 -1.023 Td
(face edema; )Tj
/T1_2 1 Tf
(1%\226<10% \226)Tj
/T1_1 1 Tf
[( asthenia,)37 ( chest pain,)37 ( chills; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( malaise,)37 ( other)-10 ( )]TJ
0 Tw 0 -1.023 Td
[(super\037cial edema,)37 ( peripheral s)-10 (welling; )]TJ
/T1_2 1 Tf
0.01 Tw (<0.1% )Tj
/T1_1 1 Tf
0 Tw 16.851 0 Td
(\226 gait disturbance.)Tj
/T1_3 1 Tf
0.18 Tw -16.851 -1.451 Td
[(Skin and Subcutaneous T)18 (issue Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.01 Tc 0.18 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( alopecia,)37 ( acne,)37 ( dr)-18 (y skin,)27 ( )]TJ
0.276 Tw 0 -1.023 Td
[(hyperhidrosis,)37.1 ( urticaria,)37 ( derma)-10 (titis \(inc)20 (luding eczema\); )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( pigmenta)-10 (tion)-9.9 ( )]TJ
0.314 Tw 0 -1.023 Td
[(disorder)74 (,)37 ( skin ulcer)74 (,)37 ( bullous conditions,)37 ( photosensitivity)55 (,)37 ( )0.5 (nail disorder)74 (,)37 ( )0.5 (neutrophilic)-10 ( )]TJ
0.204 Tw 0 -1.023 Td
[(derma)-10 (tosis,)37 ( panniculitis,)37.1 ( palmar)37 (-plantar er)-18 (ythrod)-10 (ysesthesia syndrome,)37 ( hair disorder;)-10 ( )]TJ
/T1_2 1 Tf
0.01 Tw 0 -1.023 Td
(<0.1%)Tj
/T1_1 1 Tf
0 Tw [( \226 leukoc)20 (ytoc)20 (lastic vasculitis,)37 ( skin \037brosis.)]TJ
/T1_3 1 Tf
0.247 Tw 0 -1.451 Td
[(Respirator)-18 (y)55.1 (,)37 ( Thoracic,)37 ( and Mediastinal Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.01 Tc 0.247 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( lung in\037ltra)-10 (tion,)27 ( )]TJ
0.289 Tw 0 -1.023 Td
[(pneumonitis,)37 ( cough; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( asthma,)37 ( bronchospasm,)37 ( d)-10 (ysphonia,)37 ( pulmonar)-18 (y)-10 ( )]TJ
0.377 Tw 0 -1.023 Td
(arterial hypertension; )Tj
/T1_2 1 Tf
0.01 Tw (<0.1% )Tj
/T1_1 1 Tf
0.377 Tw 11.706 0 Td
[(\226 acute respira)-9.9 (tor)-17.9 (y distress syndrome,)37 ( pulmonar)-18 (y)-10 ( )]TJ
0.01 Tw -11.706 -1.023 Td
(embolism.)Tj
/T1_3 1 Tf
-0.005 Tc 0.652 Tw 0 -1.451 Td
[(Ner)-18 (vous System Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.652 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( neuropa)-9.9 (thy \(inc)20 (luding peripheral)-5 ( )]TJ
0.383 Tw 0 -1.023 Td
[(neuropa)-10 (thy\),)37 ( dizziness,)37 ( d)-9.9 (ysgeusia,)37 ( somnolence; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( amnesia,)37 ( tremor)74 (,)32 ( )]TJ
0.116 Tw 0 -1.023 Td
[(syncope,)37 ( balance disorder; )]TJ
/T1_2 1 Tf
0.005 Tw (<0.1% )Tj
/T1_1 1 Tf
0.116 Tw 13.217 0 Td
[(\226 convulsion,)37 ( cerebrovascular accident,)37 ( transient)-5 ( )]TJ
0 Tw -13.217 -1.023 Td
[(ischemic a)-10 (ttack,)37 ( optic neuritis,)37 ( )37 (VIIth ner)-18 (ve paralysis,)37 ( dementia,)37 ( a)-10 (taxia.)]TJ
/T1_3 1 Tf
0.635 Tw 0 -1.451 Td
[(Blood and L)37 (ymphatic System Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.635 Tw (0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( lymphadenopa)-9.9 (thy)55 (,)31.9 ( )]TJ
0.005 Tw 0 -1.023 Td
(lymphopenia; )Tj
/T1_2 1 Tf
5.135 0 Td
(<0.1% )Tj
/T1_1 1 Tf
0 Tw 2.769 0 Td
[(\226 a)-10 (plasia pure red cell.)]TJ
/T1_3 1 Tf
0.532 Tw -7.904 -1.451 Td
[(Musculoskeletal and Connective T)18 (issue Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.532 Tw 22.058 0 Td
(1%\226<10% \226)Tj
/T1_1 1 Tf
[( muscular)-5 ( )]TJ
-0.034 Tw -22.058 -1.023 Td
[(weakness,)37 ( musculoskeletal stiffness; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( rhabdomyolysis,)37 ( tendonitis,)37 ( musc)20 (le)-5 ( )]TJ
0.046 Tw 0 -1.023 Td
[(in\035amma)-10 (tion,)37 ( osteonecrosis,)37 ( arthritis; )]TJ
/T1_2 1 Tf
0.005 Tw (<0.1%)Tj
/T1_1 1 Tf
0.046 Tw [( \226 epiphyses delayed fusion \(reported a)-10 (t)-5 ( )]TJ
/T1_2 1 Tf
0.005 Tw 0 -1.023 Td
(1%\226<10%)Tj
/T1_1 1 Tf
0.046 Tw [( in the pedia)-10 (tric studies\),)37 ( gro)-10 (wth retarda)-10 (tion \(reported a)-10 (t )]TJ
/T1_2 1 Tf
0.005 Tw (1%\226<10%)Tj
/T1_1 1 Tf
0.046 Tw [( in the)-4.9 ( )]TJ
0 Tw 0 -1.023 Td
[(pedia)-10 (tric studies\).)]TJ
/T1_3 1 Tf
0.005 Tw 0 -1.451 Td
(Investigations:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc -0.038 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( weight increased,)37 ( weight decreased; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( blood)-5 ( )]TJ
0 Tw 0 -1.023 Td
[(crea)-10 (tine phosphokinase increased,)37 ( gamma-glutamyltransferase increased.)]TJ
/T1_3 1 Tf
0.316 Tw 0 -1.451 Td
(Infections and Infestations:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.316 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( pneumonia \(inc)20 (luding bacterial,)37 ( viral,)32 ( )]TJ
0.241 Tw 0 -1.023 Td
[(and fungal\),)37 ( upper respira)-10 (tor)-17.9 (y tract infection/in\035amma)-10 (tion,)37 ( herpes virus infection,)32 ( )]TJ
0 Tw 0 -1.023 Td
[(enterocolitis infection,)37 ( sepsis \(inc)20 (luding fa)-10 (tal outcomes [0.2%]\).)]TJ
/T1_3 1 Tf
0.671 Tw 0 -1.451 Td
(Metabolism and Nutrition Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.671 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( a)-10 (ppetite disturbances,)32 ( )]TJ
0.005 Tw 0 -1.023 Td
(hyperuricemia; )Tj
/T1_2 1 Tf
0.13 Tw 5.81 0 Td
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( hypoalbuminemia,)37 ( tumor lysis syndrome,)37 ( dehydra)-10 (tion,)31.9 ( )]TJ
0.005 Tw -5.81 -1.023 Td
(hypercholesterolemia; )Tj
/T1_2 1 Tf
8.291 0 Td
(<0.1% )Tj
/T1_1 1 Tf
0 Tw 2.769 0 Td
(\226 diabetes mellitus.)Tj
/T1_3 1 Tf
0.293 Tw -11.06 -1.451 Td
(Cardiac Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.293 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( arrhythmia \(inc)20 (luding tachycardia\),)37 ( palpita)-10 (tions;)-5 ( )]TJ
/T1_2 1 Tf
0.351 Tw 0 -1.023 Td
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( angina pectoris,)37 ( cardiomegaly)55 (,)36.9 ( pericarditis,)37 ( ventricular arrhythmia)-5 ( )]TJ
0.357 Tw 0 -1.023 Td
[(\(inc)20 (luding ventricular tachycardia\),)37 ( electrocardiogram )36.6 (T)55 (-wa)-10 (ve abnormal,)37 ( troponin)-5 ( )]TJ
0.005 Tw 0 -1.023 Td
(increased; )Tj
/T1_2 1 Tf
4.162 0 Td
(<0.1% )Tj
/T1_1 1 Tf
0.147 Tw 2.915 0 Td
[(\226 )0.5 (cor )0.5 (pulmonale,)37 ( )0.5 (myocarditis,)37 ( )0.5 (acute )0.5 (coronar)-18 (y )0.5 (syndrome,)37 ( )0.5 (cardiac)-5 ( )]TJ
0 Tw -7.078 -1.023 Td
[(arrest,)37 ( electrocardiogram PR prolonga)-10 (tion,)37 ( coronar)-18 (y arter)-18 (y disease,)37 ( pleuropericarditis.)]TJ
/T1_3 1 Tf
0.277 Tw 0 -1.451 Td
(Eye Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.277 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( visual disorder \(inc)20 (luding visual disturbance,)37.1 ( vision)-5 ( )]TJ
0.284 Tw 0 -1.023 Td
[(blurred,)37 ( and visual acuity reduced\),)37 ( dr)-18 (y eye; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( conjunctivitis,)37 ( visual)-5 ( )]TJ
0 Tw 0 -1.023 Td
[(impairment,)36.9 ( lacrima)-10 (tion increased,)37 ( )]TJ
/T1_2 1 Tf
0.005 Tw (<0.1%)Tj
/T1_1 1 Tf
0 Tw ( \226 photophobia.)Tj
/T1_3 1 Tf
0.045 Tw 0 -1.451 Td
[(V)18 (ascular Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.045 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( \035ushing,)37 ( hypertension; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( hypotension,)32 ( )]TJ
0.313 Tw 0 -1.023 Td
[(thrombophlebitis,)37 ( )0.6 (thrombosis; )]TJ
/T1_2 1 Tf
0.005 Tw 11.709 0 Td
(<0.1% )Tj
/T1_1 1 Tf
0.313 Tw 3.081 0 Td
[(\226 )0.6 (livedo )0.5 (reticularis,)37 ( )0.5 (deep )0.6 (vein )0.6 (thrombosis,)32 ( )]TJ
0.005 Tw -14.79 -1.023 Td
(embolism.)Tj
/T1_3 1 Tf
0.215 Tw 0 -1.451 Td
(Psychiatric Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.215 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( insomnia,)37 ( depression; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( anxiety)55 (,)32 ( )]TJ
0 Tw 0 -1.023 Td
[(affect lability)55 (,)37 ( confusional sta)-10 (te,)37 ( libido decreased.)]TJ
/T1_3 1 Tf
0 -1.451 Td
[(Pregnanc)10 (y)55 (,)37 ( Puerperium,)37 ( and P)24 (erinatal Conditions:)]TJ
/T1_1 1 Tf
0 Tc /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.005 Tw (<0.1% )Tj
/T1_1 1 Tf
0 Tw 22.349 0 Td
(\226 abortion.)Tj
/T1_3 1 Tf
-0.022 Tw -22.349 -1.451 Td
(Reproductive System and Breast Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc -0.022 Tw (0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( g)-10 (ynecomastia,)37 ( menstrual)-5 ( )]TJ
0.005 Tw 0 -1.023 Td
[(disorder)74 (.)]TJ
/T1_3 1 Tf
0 Tw 0 -1.451 Td
[(Injur)-18 (y)55 (,)37 ( P)24 (oisoning,)37 ( and Procedural Complications:)]TJ
/T1_1 1 Tf
0 Tc /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc (1%\226<10% \226)Tj
/T1_1 1 Tf
( contusion.)Tj
/T1_2 1 Tf
-0.01 Tc 0.01 Tw 0 85.428 Td
(\(Continued\))Tj
ET
endstreamendobj22 0 obj<</Length 32770>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 0 k
/GS0 gs
36 732.96 251.937 -17.312 re
36 715.648 88.497 -12.912 re
124.497 715.648 81.72 -12.912 re
206.217 715.648 81.72 -12.912 re
36 702.736 88.497 -12.912 re
124.497 702.736 163.44 -12.912 re
36 689.824 88.497 -10.282 re
124.497 689.824 81.72 -10.282 re
206.217 689.824 81.72 -10.282 re
36 679.542 88.497 -10.032 re
124.497 679.542 81.72 -10.032 re
206.217 679.542 81.72 -10.032 re
36 669.51 88.497 -10.032 re
124.497 669.51 81.72 -10.032 re
206.217 669.51 81.72 -10.032 re
36 659.478 88.497 -10.032 re
124.497 659.478 81.72 -10.032 re
206.217 659.478 81.72 -10.032 re
36 649.447 88.497 -10.032 re
124.497 649.447 81.72 -10.032 re
206.217 649.447 81.72 -10.032 re
36 639.415 88.497 -10.032 re
124.497 639.415 81.72 -10.032 re
206.217 639.415 81.72 -10.032 re
36 629.383 88.497 -10.032 re
124.497 629.383 81.72 -10.032 re
206.217 629.383 81.72 -10.032 re
36 619.351 88.497 -10.032 re
124.497 619.351 81.72 -10.032 re
206.217 619.351 81.72 -10.032 re
36 609.319 88.497 -10.752 re
124.497 609.319 81.72 -10.752 re
206.217 609.319 81.72 -10.752 re
f
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 689.8242 cm
0 0 m
88.497 0 l
S
Q
q 1 0 0 1 124.4975 689.8242 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 206.2175 689.8242 cm
0 0 m
81.72 0 l
S
Q
1 w 
q 1 0 0 1 36 598.567 cm
0 0 m
88.497 0 l
S
Q
q 1 0 0 1 206.2175 598.567 cm
0 0 m
81.72 0 l
S
Q
0.5 w 
q 1 0 0 1 206.2175 679.5423 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 669.5104 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 659.4785 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 649.4465 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 639.4147 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 629.3828 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 619.3508 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 609.3189 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 599.067 cm
0 0 m
0 10.252 l
S
Q
1 w 
q 1 0 0 1 124.4975 598.567 cm
0 0 m
81.72 0 l
S
Q
0.5 w 
q 1 0 0 1 206.2175 702.7361 cm
0 0 m
81.72 0 l
S
Q
1 w 
q 1 0 0 1 36 715.6481 cm
0 0 m
88.497 0 l
S
Q
q 1 0 0 1 206.2175 715.6481 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 124.4975 715.6481 cm
0 0 m
81.72 0 l
S
Q
0.5 w 
q 1 0 0 1 206.2175 702.9861 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 124.4975 702.7361 cm
0 0 m
81.72 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.015 Tc 0.44 Tw 8 0 0 8 36 727.248 Tm
[(T)-5 (a)-5 (b)-5 (l)-5 (e)-5 ( )411 (1)-5 (1)-4.9 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.538 0 Td
( )Tj
EMC 
3.087 0 Td
[(Adverse )0.5 (Reactions )0.5 (Reported in )0.5 (\03610% of Dasatinib-Treated)-15 ( )]TJ
0.024 Tw 0 -1 Td
(Pediatric Patients with Chronic Phase CML \(n=97\))Tj
-0.02 Tc 7.2 0 0 8 151.2036 706.3361 Tm
(All Grades)Tj
11.469 0 Td
(Grade 3/4)Tj
-0.01 Tc -27.469 -1.614 Td
(Adverse Reaction)Tj
-0.02 Tc 19.254 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -19.254 -1.465 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(28)Tj
0 Tc 0 Tw 11.622 0 Td
(3)Tj
-0.01 Tc 0.01 Tw -29.094 -1.254 Td
(Nausea)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(20)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -29.094 -1.254 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(21)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -29.094 -1.254 Td
(Skin rash)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(19)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -29.094 -1.254 Td
[(V)18 (omiting)]TJ
-0.005 Tc 0.005 Tw 17.471 0 Td
(13)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -29.094 -1.254 Td
[(P)18 (ain in extremity)]TJ
-0.005 Tc 0.005 Tw 17.471 0 Td
(19)Tj
0 Tc 0 Tw 11.622 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -29.094 -1.254 Td
(Abdominal pain)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(16)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -29.094 -1.254 Td
[(F)20 (a)-10 (tigue)]TJ
-0.005 Tc 0.005 Tw 17.471 0 Td
(10)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -29.094 -1.254 Td
(Arthralgia)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(10)Tj
0 Tc 0 Tw 11.622 0 Td
(1)Tj
-0.01 Tc 0.187 Tw 8 0 0 8 36 577.4811 Tm
[(Adverse reactions associa)-10 (ted with bone gro)-10 (wth and development were reported in)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.067 Tw -31.5 -1.156 Td
[(5 \(5.2%\) of pedia)-9.9 (tric pa)-10 (tients with chronic phase CML )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
20.446 0 Td
(s)Tj
-0.01 Tc 0.03 Tw 0.397 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.067 Tw 4.492 0 Td
( and Precaution)Tj
0 Tc 0 Tw (s)Tj
( )Tj
-0.01 Tc 0.01 Tw -25.335 -1.156 Td
(\(5.10\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_2 1 Tf
-0.01 Tc -0.037 Tw 0 -2.078 Td
[(Labora)-10 (tor)-18 (y Abnormalities)]TJ
/T1_1 1 Tf
0.029 Tw 8.08 0 0 8.08 36 530.6743 Tm
[(Myelosuppression was commonly reported in all pa)-10 (tient popula)-10 (tions.)37 ( )36.9 (The frequenc)20 (y of)-10 ( )]TJ
0.058 Tw 0 -1.154 Td
[(Grade 3 or 4 neutropenia,)37.1 ( thromboc)20 (ytopenia,)37 ( and anemia was higher in pa)-9.9 (tients with)-10 ( )]TJ
-0.019 Tw 0 -1.154 Td
[(advanced phase CML than in chronic phase CML \(T)74 (ables 12 and 13\).)37 ( Myelosuppression)-9.9 ( )]TJ
0.043 Tw 0 -1.154 Td
[(was )0.5 (reported in )0.5 (pa)-9.9 (tients with )0.5 (normal baseline labora)-10 (tor)-18 (y )0.5 (values )0.5 (as )0.5 (well )0.5 (as )0.5 (in )0.5 (pa)-9.9 (tients)-10 ( )]TJ
0 Tw 0 -1.154 Td
[(with pre-existing labora)-9.9 (tor)-18 (y abnormalities.)]TJ
0.157 Tw 0 -1.447 Td
[(In pa)-10 (tients who experienced severe myelosuppression,)37 ( recover)-17.9 (y generally occurred)-10 ( )]TJ
0.292 Tw 0 -1.154 Td
[(follo)-10 (wing dose interruption or reduction; permanent discontinua)-10 (tion of trea)-10 (tment)-9.9 ( )]TJ
0.036 Tw 0 -1.154 Td
[(occurred in 2% of adult pa)-9.9 (tients with newly dia)-10 (gnosed chronic phase CML and 5% of)-9.9 ( )]TJ
-0.024 Tw 0 -1.154 Td
[(adult pa)-9.9 (tients with resistance or intolerance to prior ima)-10 (tinib thera)-10 (py )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
24.835 0 Td
(s)Tj
-0.01 Tc -0.061 Tw 0.397 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.024 Tw 4.401 0 Td
[( and)-10 ( )]TJ
0.01 Tw -29.632 -1.154 Td
(Precaution)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.221 0 Td
( \(5.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.049 Tw -4.221 -1.447 Td
[(Grade 3 or 4 eleva)-10 (tions of transaminases or bilirubin and Grade 3 or 4 hypocalcemia,)27 ( )]TJ
0.01 Tw 0 -1.154 Td
[(hypokalemia,)37 ( and hypophospha)-9.9 (temia were reported in pa)-10 (tients with all phases of CML)-9.9 ( )]TJ
0.091 Tw 0 -1.154 Td
[(but )0.5 (were )0.5 (reported )0.5 (with )0.5 (an increased frequenc)20 (y in )0.5 (pa)-10 (tients with myeloid )0.5 (or )0.5 (lymphoid)-10 ( )]TJ
0.048 Tw 0 -1.154 Td
[(blast phase CML.)37 ( Eleva)-9.9 (tions in transaminases or bilirubin were usually mana)-9.9 (ged with)-10 ( )]TJ
0.062 Tw 0 -1.154 Td
[(dose reduction or interruption.)37 ( P)18.1 (a)-10 (tients developing Grade 3 or 4 hypocalcemia during)-10 ( )]TJ
0 Tw 0 -1.154 Td
[(SPR)18 (YCEL thera)-10 (py often had recover)-18 (y with oral calcium supplementa)-10 (tion.)]TJ
-0.006 Tw 8 0 0 8 36 374.4735 Tm
[(Labora)-10 (tor)-18 (y abnormalities )0.5 (reported in adult pa)-10 (tients )0.5 (with )0.5 (newly )0.5 (dia)-10 (gnosed chronic phase)-10 ( )]TJ
0.018 Tw 0 -1.156 Td
[(CML are sho)-9.9 (wn in )37.1 (T)74 (able 12.)37 ( )37.1 (There were no discontinua)-10 (tions of SPR)18 (YCEL thera)-10 (py in this)-10 ( )]TJ
0 Tw 0 -1.156 Td
[(pa)-10 (tient popula)-10 (tion due to biochemical labora)-9.9 (tor)-18 (y parameters.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 344.656 252 -25.312 re
36 319.344 81.72 -21.226 re
117.72 319.344 85.14 -21.226 re
202.86 319.344 85.14 -21.226 re
36 298.118 81.72 -13.635 re
117.72 298.118 170.28 -13.635 re
36 284.483 81.72 -12.192 re
117.72 284.483 85.14 -12.192 re
202.86 284.483 85.14 -12.192 re
36 272.291 81.72 -12.192 re
117.72 272.291 85.14 -12.192 re
202.86 272.291 85.14 -12.192 re
36 260.099 81.72 -12.192 re
117.72 260.099 85.14 -12.192 re
202.86 260.099 85.14 -12.192 re
36 247.907 81.72 -12.192 re
117.72 247.907 85.14 -12.192 re
202.86 247.907 85.14 -12.192 re
36 235.715 81.72 -12.192 re
117.72 235.715 85.14 -12.192 re
202.86 235.715 85.14 -12.192 re
36 223.523 81.72 -12.192 re
117.72 223.523 85.14 -12.192 re
202.86 223.523 85.14 -12.192 re
36 211.332 81.72 -12.192 re
117.72 211.332 85.14 -12.192 re
202.86 211.332 85.14 -12.192 re
36 199.14 81.72 -12.192 re
117.72 199.14 85.14 -12.192 re
202.86 199.14 85.14 -12.192 re
36 186.948 81.72 -12.192 re
117.72 186.948 85.14 -12.192 re
202.86 186.948 85.14 -12.192 re
36 174.756 81.72 -12.192 re
117.72 174.756 85.14 -12.192 re
202.86 174.756 85.14 -12.192 re
36 162.564 81.72 -12.192 re
117.72 162.564 85.14 -12.192 re
202.86 162.564 85.14 -12.192 re
36 150.372 81.72 -12.192 re
117.72 150.372 85.14 -12.192 re
202.86 150.372 85.14 -12.192 re
36 138.18 252 -62.85 re
f
1.01 w 
/GS1 gs
q 1 0 0 1 36 138.1801 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 138.1801 cm
0 0 m
85.14 0 l
S
Q
0.505 w 
q 1 0 0 1 36 75.33 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 75.33 cm
0 0 m
85.14 0 l
S
Q
q 1 0 0 1 202.86 75.33 cm
0 0 m
85.14 0 l
S
Q
q 1 0 0 1 117.72 298.118 cm
0 0 m
85.14 0 l
S
Q
q 1 0 0 1 36 284.483 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 284.483 cm
0 0 m
85.14 0 l
S
Q
1 w 
q 1 0 0 1 36 319.344 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 319.344 cm
0 0 m
85.14 0 l
S
Q
0.505 w 
q 1 0 0 1 202.86 284.483 cm
0 0 m
85.14 0 l
S
Q
0.5 w 
q 1 0 0 1 202.86 272.2911 cm
0 0 m
0 11.939 l
S
Q
q 1 0 0 1 202.86 260.0992 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 247.9073 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 223.5235 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 202.86 211.3315 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 199.1396 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 186.9477 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 174.7558 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 162.5639 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 150.372 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 138.6851 cm
0 0 m
0 11.687 l
S
Q
1.01 w 
q 1 0 0 1 202.86 138.1801 cm
0 0 m
85.14 0 l
S
Q
1 w 
q 1 0 0 1 202.86 319.344 cm
0 0 m
85.14 0 l
S
Q
0.5 w 
q 1 0 0 1 202.86 298.3705 cm
0 0 m
0 20.473 l
S
Q
0.505 w 
q 1 0 0 1 202.86 298.118 cm
0 0 m
85.14 0 l
S
Q
0.5 w 
q 1 0 0 1 202.86 235.9654 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 36 235.7154 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 235.7154 cm
0 0 m
85.14 0 l
S
Q
q 1 0 0 1 202.86 235.7154 cm
0 0 m
85.14 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
0.085 Tw 8 0 0 8 36 338.944 Tm
[(Table )61 (12:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(CTC Grade 3/4 Laboratory Abnormalities in Adult Patients with)-10 ( )]TJ
0.107 Tw 0 -1 Td
[(Newly Diagnosed Chronic Phase CML \(minimum of 60 months)-10 ( )]TJ
0.01 Tw 0 -1 Td
(follow-up\))Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 147.6552 309.8751 Tm
(SPRYCEL)Tj
0 Tc 0 Tw 7.2 0 0 8 172.6748 309.8751 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 149.322 301.8751 Tm
(\(n=258\))Tj
11.799 1 Td
(Imatinib)Tj
0 Tc 0 Tw 7.2 0 0 8 256.8336 309.8751 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 234.712 301.8751 Tm
(\(n=258\))Tj
0.024 Tw -8.811 -1.634 Td
(Percent \(%\) of Patients)Tj
-0.01 Tc -18.788 -1.659 Td
[(Hematolog)-10 (y P)24 (arameters)]TJ
/T1_1 1 Tf
1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Neutropenia)Tj
-0.005 Tc 0.005 Tw 15.505 0 Td
(29)Tj
12.095 0 Td
(24)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.862 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Thromboc)20 (ytopenia)]TJ
-0.005 Tc 0.005 Tw 15.505 0 Td
(22)Tj
12.095 0 Td
(14)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.862 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Anemia)Tj
-0.005 Tc 0.005 Tw 15.505 0 Td
(13)Tj
0 Tc 0 Tw 12.332 0 Td
(9)Tj
/T1_0 1 Tf
-0.01 Tc 0.024 Tw -29.1 -1.524 Td
[(Biochemistr)-17.9 (y P)24 (arameters)]TJ
/T1_1 1 Tf
1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Hypophospha)-9.9 (temia)]TJ
0 Tc 0 Tw 15.743 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 11.857 0 Td
(31)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.862 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Hypokalemia)Tj
0 Tc 0 Tw 15.743 0 Td
(0)Tj
12.095 0 Td
(3)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.1 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Hypocalcemia)Tj
0 Tc 0 Tw 15.743 0 Td
(4)Tj
12.095 0 Td
(3)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.1 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGPT \(AL)94.1 (T\))]TJ
-0.005 Tc 0.005 Tw 15.445 0 Td
(<1)Tj
0 Tc 0 Tw 12.392 0 Td
(2)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.1 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGOT \(AST\))]TJ
-0.005 Tc 0.005 Tw 15.445 0 Td
(<1)Tj
0 Tc 0 Tw 12.392 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.1 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted Bilirubin)]TJ
0 Tc 0 Tw 15.743 0 Td
(1)Tj
12.095 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.1 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted Crea)-10 (tinine)]TJ
0 Tc 0 Tw 15.743 0 Td
(1)Tj
12.095 0 Td
(1)Tj
-0.005 Tc -0.022 Tw -29.1 -1.811 Td
[(CTC grades:)37 ( neutropenia \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.773 0 Td
(3 \0360.5\226<1.0 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 168.3716 129.7301 Tm
(9)Tj
-0.005 Tc -0.022 Tw 7.2 0 0 8 170.9366 126.9301 Tm
[(/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
3.517 0 Td
(4 <0.5 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 228.2297 129.7301 Tm
(9)Tj
-0.005 Tc -0.022 Tw 7.2 0 0 8 230.7947 126.9301 Tm
[(/L\); thromboc)20 (ytopenia)-5 ( )]TJ
0.034 Tw -27.055 -1 Td
(\(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.63 0 Td
[(3 \03625\226<50 )0.5 (\327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 100.3503 121.7301 Tm
(9)Tj
-0.005 Tc 0.034 Tw 7.2 0 0 8 102.9152 118.9301 Tm
[(/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
3.572 0 Td
[(4 <25 )0.5 (\327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 160.1055 121.7301 Tm
(9)Tj
-0.005 Tc 0.034 Tw 7.2 0 0 8 162.6705 118.9301 Tm
(/L\); anemia \(hemoglobin Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.573 0 Td
(3 \03665\226<80)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.461 0 Td
[(g/L,)32 ( )]TJ
-0.062 Tw -33.627 -1 Td
(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.394 0 Td
(4 <65)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.428 0 Td
[(g/L\); eleva)-10 (ted crea)-9.9 (tinine \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.474 0 Td
[(3 >3\2266 \327 upper limit of normal range \(ULN\),)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
18.225 0 Td
[(4)-5 ( )]TJ
0.073 Tw -34.52 -1 Td
[(>6 \327 ULN\); eleva)-10 (ted bilirubin \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
13.805 0 Td
[(3 >3\22610 \327 )0.5 (ULN,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
8.911 0 Td
[(4 >10 \327 )0.5 (ULN\); eleva)-10 (ted )0.5 (SGOT or)-5 ( )]TJ
0.107 Tw -22.716 -1 Td
(SGPT \(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.933 0 Td
[(3 >5\22620 \327 ULN,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
9.048 0 Td
(4 >20 \327 ULN\); hypocalcemia \(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
13.959 0 Td
(3 <7.0\2266.0)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.512 0 Td
[(mg/dL,)32 ( )]TJ
0.274 Tw -32.452 -1 Td
(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.394 0 Td
[(4 <6.0 mg/dL\); hypophospha)-10 (temia \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
16.662 0 Td
(3 <2.0\2261.0)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.679 0 Td
[(mg/dL,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
5.446 0 Td
(4 <1.0)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.999 0 Td
[(mg/dL\);)-5 ( )]TJ
0 Tw -32.179 -1 Td
(hypokalemia \(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(3 <3.0\2262.5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mmol/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(4 <2.5 mmol/L\).)Tj
-0.01 Tc -0.024 Tw 8 0 0 8 36.0001 54.4917 Tm
[(Labora)-10 (tor)-18 (y abnormalities reported in pa)-9.9 (tients with CML resistant or intolerant to ima)-10 (tinib)-10 ( )]TJ
-0.026 Tw 0 -1.156 Td
[(who received the recommended starting doses of SPR)18 (YCEL are sho)-9.9 (wn by disease phase)-10 ( )]TJ
-0.037 Tw 0 -1.156 Td
[(in T)74 (able)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.964 0 Td
(13.)Tj
ET
0 0 0 0 k
/GS0 gs
324 732.96 252 -28.726 re
324 704.234 69.75 -20.912 re
393.75 704.234 63.45 -20.912 re
457.2 704.234 118.8 -20.912 re
324 683.322 69.75 -28.912 re
393.75 683.322 63.45 -28.912 re
457.2 683.322 39.84 -28.912 re
497.04 683.322 39.48 -28.912 re
536.52 683.322 39.48 -28.912 re
324 654.41 252 -13.635 re
324 640.775 69.75 -12.192 re
393.75 640.775 63.45 -12.192 re
457.2 640.775 39.84 -12.192 re
497.04 640.775 39.48 -12.192 re
536.52 640.775 39.48 -12.192 re
324 628.583 69.75 -12.192 re
393.75 628.583 63.45 -12.192 re
457.2 628.583 39.84 -12.192 re
497.04 628.583 39.48 -12.192 re
536.52 628.583 39.48 -12.192 re
324 616.391 69.75 -12.192 re
393.75 616.391 63.45 -12.192 re
457.2 616.391 39.84 -12.192 re
497.04 616.391 39.48 -12.192 re
536.52 616.391 39.48 -12.192 re
324 604.199 69.75 -12.192 re
393.75 604.199 63.45 -12.192 re
457.2 604.199 39.84 -12.192 re
497.04 604.199 39.48 -12.192 re
536.52 604.199 39.48 -12.192 re
324 592.007 69.75 -12.192 re
393.75 592.007 63.45 -12.192 re
457.2 592.007 39.84 -12.192 re
497.04 592.007 39.48 -12.192 re
536.52 592.007 39.48 -12.192 re
324 579.816 69.75 -12.192 re
393.75 579.816 63.45 -12.192 re
457.2 579.816 39.84 -12.192 re
497.04 579.816 39.48 -12.192 re
536.52 579.816 39.48 -12.192 re
324 567.624 69.75 -12.192 re
393.75 567.624 63.45 -12.192 re
457.2 567.624 39.84 -12.192 re
497.04 567.624 39.48 -12.192 re
536.52 567.624 39.48 -12.192 re
324 555.432 69.75 -12.192 re
393.75 555.432 63.45 -12.192 re
457.2 555.432 39.84 -12.192 re
497.04 555.432 39.48 -12.192 re
536.52 555.432 39.48 -12.192 re
324 543.24 69.75 -12.192 re
393.75 543.24 63.45 -12.192 re
457.2 543.24 39.84 -12.192 re
497.04 543.24 39.48 -12.192 re
536.52 543.24 39.48 -12.192 re
324 531.048 69.75 -12.192 re
393.75 531.048 63.45 -12.192 re
457.2 531.048 39.84 -12.192 re
497.04 531.048 39.48 -12.192 re
536.52 531.048 39.48 -12.192 re
324 518.856 69.75 -12.192 re
393.75 518.856 63.45 -12.192 re
457.2 518.856 39.84 -12.192 re
497.04 518.856 39.48 -12.192 re
536.52 518.856 39.48 -12.192 re
324 506.664 69.75 -12.192 re
393.75 506.664 63.45 -12.192 re
457.2 506.664 39.84 -12.192 re
497.04 506.664 39.48 -12.192 re
536.52 506.664 39.48 -12.192 re
324 494.472 252 -78.73 re
f
1 w 
/GS1 gs
q 1 0 0 1 324 704.2339 cm
0 0 m
69.75 0 l
S
Q
q 1 0 0 1 457.2 704.2339 cm
0 0 m
39.84 0 l
S
Q
q 1 0 0 1 497.04 704.2339 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 704.2339 cm
0 0 m
39.48 0 l
S
Q
0.5 w 
q 1 0 0 1 457.2 683.322 cm
0 0 m
39.84 0 l
S
Q
q 1 0 0 1 497.04 683.322 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 683.322 cm
0 0 m
39.48 0 l
S
Q
0.505 w 
q 1 0 0 1 457.2 654.4102 cm
0 0 m
39.84 0 l
S
Q
q 1 0 0 1 497.04 654.4102 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 654.4102 cm
0 0 m
39.48 0 l
S
Q
1 w 
q 1 0 0 1 393.75 704.2339 cm
0 0 m
63.45 0 l
S
Q
0.5 w 
q 1 0 0 1 457.2 683.572 cm
0 0 m
0 20.162 l
S
Q
q 1 0 0 1 393.75 683.322 cm
0 0 m
63.45 0 l
S
Q
q 1 0 0 1 457.2 654.6627 cm
0 0 m
0 28.409 l
S
Q
0.505 w 
q 1 0 0 1 393.75 654.4102 cm
0 0 m
63.45 0 l
S
Q
q 1 0 0 1 457.2 640.7751 cm
0 0 m
39.84 0 l
S
Q
0.5 w 
q 1 0 0 1 457.2 628.5833 cm
0 0 m
0 11.939 l
S
Q
q 1 0 0 1 457.2 616.3913 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 604.1994 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 579.8156 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 457.2 567.6237 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 555.4318 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 543.2398 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 531.0479 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 518.856 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 506.6641 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 494.9772 cm
0 0 m
0 11.687 l
S
Q
1.01 w 
q 1 0 0 1 457.2 494.4722 cm
0 0 m
39.84 0 l
S
Q
0.5 w 
q 1 0 0 1 457.2 592.2574 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 324 592.0074 cm
0 0 m
69.75 0 l
S
Q
q 1 0 0 1 393.75 592.0074 cm
0 0 m
63.45 0 l
S
Q
q 1 0 0 1 457.2 592.0074 cm
0 0 m
39.84 0 l
S
Q
q 1 0 0 1 497.04 592.0074 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 592.0074 cm
0 0 m
39.48 0 l
S
Q
1.01 w 
q 1 0 0 1 324 494.4722 cm
0 0 m
69.75 0 l
S
Q
q 1 0 0 1 393.75 494.4722 cm
0 0 m
63.45 0 l
S
Q
0.505 w 
q 1 0 0 1 324 415.7422 cm
0 0 m
69.75 0 l
S
Q
q 1 0 0 1 393.75 415.7422 cm
0 0 m
63.45 0 l
S
Q
q 1 0 0 1 457.2 415.7422 cm
0 0 m
39.84 0 l
S
Q
q 1 0 0 1 497.04 415.7422 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 415.7422 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 324 640.7751 cm
0 0 m
69.75 0 l
S
Q
q 1 0 0 1 393.75 640.7751 cm
0 0 m
63.45 0 l
S
Q
q 1 0 0 1 497.04 640.7751 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 640.7751 cm
0 0 m
39.48 0 l
S
Q
1.01 w 
q 1 0 0 1 497.04 494.4722 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 494.4722 cm
0 0 m
39.48 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
0.294 Tw 8 0 0 8 324 723.8699 Tm
[(Table )270 (13:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(CTC )0.5 (Grade 3/4 Laboratory )0.5 (Abnormalities )0.5 (in Clinical Studies)-10 ( )]TJ
0.18 Tw 0 -1 Td
[(of CML in Adults: Resistance or Intolerance to Prior Imatinib)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Therapy)Tj
-0.015 Tc 0.024 Tw 7.2 0 0 8 398.3937 694.9221 Tm
(Chronic Phase CML)Tj
0 Tc 0 Tw 7.2 0 0 8 452.3063 694.9221 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 399.6789 686.9221 Tm
(100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
12.135 1 Td
(Advanced Phase CML)Tj
0 Tc 0 Tw 7.2 0 0 8 546.3958 694.9221 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 491.0539 686.9221 Tm
(140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
0.02 Tw -10.632 -3.489 Td
(\(n=165\))Tj
6.486 2 Td
(Accelerated)Tj
0 Tc 0 Tw 7.2 0 0 8 493.7553 675.0101 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 469.1029 667.0101 Tm
(Phase)Tj
0 Tc 0 Tw 7.2 0 0 8 485.857 667.0101 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 466.637 659.0101 Tm
(\(n=157\))Tj
5.471 2 Td
(Myeloid)Tj
0 Tc 0 Tw 7.2 0 0 8 527.533 675.0101 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 500.6236 667.0101 Tm
(Blast Phase)Tj
0 Tc 0 Tw 7.2 0 0 8 532.9364 667.0101 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 507.5929 659.0101 Tm
(\(n=74\))Tj
4.887 2 Td
[(Lymphoid)-20 ( )]TJ
0.024 Tw -0.371 -1 Td
(Blast Phase)Tj
0 Tc 0 Tw 7.2 0 0 8 572.4164 667.0101 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 547.073 659.0101 Tm
(\(n=33\))Tj
-0.01 Tc 0.024 Tw -17.955 -1.739 Td
[(P)24 (ercent \(%\) of P)24 (atients)]TJ
0.013 Tw -13.027 -1.659 Td
[(Hematolog)-10 (y P)24 (arameters*)]TJ
/T1_1 1 Tf
1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Neutropenia)Tj
-0.005 Tc 0.005 Tw 12.336 0 Td
(36)Tj
7.24 0 Td
(58)Tj
5.458 0 Td
(77)Tj
5.483 0 Td
(79)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.781 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Thromboc)20 (ytopenia)]TJ
-0.005 Tc 0.005 Tw 12.336 0 Td
(24)Tj
7.24 0 Td
(63)Tj
5.458 0 Td
(78)Tj
5.483 0 Td
(85)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.781 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Anemia)Tj
-0.005 Tc 0.005 Tw 12.336 0 Td
(13)Tj
7.24 0 Td
(47)Tj
5.458 0 Td
(74)Tj
5.483 0 Td
(52)Tj
/T1_0 1 Tf
-0.02 Tc 0.024 Tw -31.781 -1.524 Td
[(Biochemistr)-18 (y P)24 (arameters)]TJ
/T1_1 1 Tf
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Hypophospha)-9.9 (temia)]TJ
-0.005 Tc 0.005 Tw 12.336 0 Td
(10)Tj
7.24 0 Td
(13)Tj
5.458 0 Td
(12)Tj
5.483 0 Td
(18)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.781 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Hypokalemia)Tj
0 Tc 0 Tw 12.574 0 Td
(2)Tj
7.24 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 5.221 0 Td
(11)Tj
5.483 0 Td
(15)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.781 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Hypocalcemia)Tj
-0.005 Tc 0.005 Tw 12.276 0 Td
(<1)Tj
0 Tc 0 Tw 7.538 0 Td
(4)Tj
5.458 0 Td
(9)Tj
-0.005 Tc 0.005 Tw 5.246 0 Td
(12)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.781 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGPT \(AL)94.1 (T\))]TJ
0 Tc 0 Tw 12.574 0 Td
(0)Tj
7.24 0 Td
(2)Tj
5.458 0 Td
(5)Tj
5.483 0 Td
(3)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.018 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGOT \(AST\))]TJ
-0.005 Tc 0.005 Tw 12.276 0 Td
(<1)Tj
0 Tc 0 Tw 7.538 0 Td
(0)Tj
5.458 0 Td
(4)Tj
5.483 0 Td
(3)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.018 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted Bilirubin)]TJ
-0.005 Tc 0.005 Tw 12.276 0 Td
(<1)Tj
0 Tc 0 Tw 7.538 0 Td
(1)Tj
5.458 0 Td
(3)Tj
5.483 0 Td
(6)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.018 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted Crea)-10 (tinine)]TJ
0 Tc 0 Tw 12.574 0 Td
(0)Tj
7.24 0 Td
(2)Tj
5.458 0 Td
(8)Tj
5.483 0 Td
(0)Tj
-0.005 Tc -0.022 Tw -32.018 -1.569 Td
[(CTC grades:)37 ( neutropenia \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.773 0 Td
(3 \0360.5\226<1.0 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 456.3716 487.9602 Tm
(9)Tj
-0.005 Tc -0.022 Tw 7.2 0 0 8 458.9366 485.1602 Tm
[(/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
3.517 0 Td
(4 <0.5 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 516.2297 487.9602 Tm
(9)Tj
-0.005 Tc -0.022 Tw 7.2 0 0 8 518.7947 485.1602 Tm
[(/L\); thromboc)20 (ytopenia)-5 ( )]TJ
0.031 Tw -27.055 -1 Td
(\(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.63 0 Td
(3 \03625\226<50 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 388.2899 479.9602 Tm
(9)Tj
-0.005 Tc 0.031 Tw 7.2 0 0 8 390.8548 477.1602 Tm
[(/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
3.57 0 Td
(4 <25 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 447.9646 479.9602 Tm
(9)Tj
-0.005 Tc 0.031 Tw 7.2 0 0 8 450.5295 477.1602 Tm
(/L\); anemia \(hemoglobin Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.565 0 Td
[(3 \03665\226<80 g/L,)32 ( )]TJ
0.177 Tw -29.139 -1 Td
(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.394 0 Td
[(4 )0.6 (<65 )0.5 (g/L\); )0.6 (eleva)-10 (ted )0.5 (crea)-9.9 (tinine )0.5 (\(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
15.033 0 Td
[(3 )0.6 (>3\2266 )0.5 (\327 )0.6 (upper )0.5 (limit )0.5 (of )0.6 (normal )0.5 (range )0.6 (\(ULN\),)32 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576.0001 469.1602 Tm
( )Tj
-0.005 Tc 0.349 Tw 7.2 0 0 8 324.0001 461.1602 Tm
(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.394 0 Td
[(4 >6 \327 ULN\); eleva)-10 (ted bilirubin \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
16.244 0 Td
[(3 >3\22610 \327 ULN,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
10.016 0 Td
[(4 >10 \327 ULN\);)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576.0001 461.1602 Tm
( )Tj
-0.005 Tc 0.37 Tw 7.2 0 0 8 324.0001 453.1602 Tm
[(eleva)-10 (ted SGOT or SGPT \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
12.855 0 Td
[(3 >5\22620 \327 ULN,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
10.101 0 Td
[(4 >20 \327 ULN\); hypocalcemia)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576.0001 453.1602 Tm
( )Tj
-0.005 Tc 7.2 0 0 8 324.0001 445.1602 Tm
(\(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(3 )-45.6 (<7.0\2266.0)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg/dL,)36.9 ( )-45.6 (Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(4 )-45.7 (<6.0)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg/dL\); )-45.6 (hypophospha)-10 (temia )-45.7 (\(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(3 )-45.7 (<2.0\2261.0)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg/dL,)32 ( )]TJ
0 -1 Td
(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(4 <1.0)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg/dL\); hypokalemia \(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(3 <3.0\2262.5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mmol/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(4 <2.5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mmol/L\).)Tj
-0.02 Tw 0 -1.227 Td
(* )Tj
/Span<</ActualText<FEFF0007>>> BDC 
0.582 0 Td
( )Tj
EMC 
T*
[(Hema)-9.9 (tolog)-10 (y parameters for 100)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.794 0 Td
[(mg once-daily dosing in chronic phase CML reflects 60-month)-5 ( )]TJ
0 Tw -11.794 -1 Td
[(minimum follo)-10 (w-up.)]TJ
0.072 Tw 8 0 0 8 324.0001 398.4897 Tm
[(Among adult pa)-10 (tients with chronic phase CML with resistance or intolerance to prior)-5 ( )]TJ
0.101 Tw 0 -1 Td
[(ima)-10 (tinib thera)-10 (py)55 (,)37 ( cumula)-9.9 (tive Grade 3 or 4 c)20 (ytopenias were similar a)-10 (t 2 and 5 years)-5 ( )]TJ
0.098 Tw 0 -1 Td
[(inc)20 (luding:)37 ( neutropenia \(36% )0.5 (vs 36%\),)36.9 ( )0.5 (thromboc)20 (ytopenia \(23% )0.5 (vs 24%\),)36.9 ( )0.5 (and )0.5 (anemia)-5 ( )]TJ
0 Tw 0 -1 Td
(\(13% vs 13%\).)Tj
0.063 Tw 0 -1.427 Td
[(In the pedia)-10 (tric studies in CML,)37 ( the ra)-10 (tes of labora)-9.9 (tor)-18 (y abnormalities were consistent)-5 ( )]TJ
0 Tw 0 -1 Td
[(with the kno)-9.9 (wn pro\037le for labora)-9.9 (tor)-18 (y parameters in adults.)]TJ
/T1_0 1 Tf
-0.01 Tc 0.257 Tw 0 -1.495 Td
[(Philadelphia Chromosome-P)24 (ositive Acute L)37 (ymphoblastic Leukemia \(Ph)]TJ
0 Tc 0 Tw 28.675 0.125 Td
(+)Tj
-0.01 Tc 0.257 Tw 0.59 -0.125 Td
[( ALL\))-10 ( )]TJ
0 Tc 0 Tw 2.235 0 Td
( )Tj
-0.01 Tc -31.5 -1 Td
(in Adults)Tj
/T1_1 1 Tf
-0.005 Tc -0.042 Tw 0 -1.292 Td
[(A total of 135 adult pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 12.756 0.125 Td
(+)Tj
-0.005 Tc -0.042 Tw 0.595 -0.125 Td
[( )37.3 (ALL were trea)-10 (ted with SPR)18 (YCEL in c)20 (linical studies.)32 ( )]TJ
0.048 Tw -13.351 -1 Td
[(The median dura)-10 (tion of trea)-10 (tment was 3 months \(range 0.03\22631 months\).)37 ( )37.1 (The safety)-4.9 ( )]TJ
0.043 Tw 0 -1 Td
[(pro\037le of pa)-9.9 (tients with Ph)]TJ
0 Tc 0 Tw 9.489 0.125 Td
(+)Tj
-0.005 Tc 0.043 Tw 0.595 -0.125 Td
[( )37.1 (ALL was similar to those with lymphoid blast phase CML.)32 ( )]TJ
0.084 Tw -10.084 -1 Td
[(The most frequently reported adverse reactions inc)20 (luded \035uid retention events,)37 ( such)-5 ( )]TJ
0.024 Tw 0 -1 Td
[(as pleural effusion \(24%\) and super\037cial edema \(19%\),)37 ( and gastrointestinal disorders,)32 ( )]TJ
0.243 Tw 0 -1 Td
[(such as diarrhea \(31%\),)37 ( nausea \(24%\),)37 ( and vomiting \(16%\).)37 ( Hemorrha)-10 (ge \(19%\),)32 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.005 Tc 0.038 Tw -31.5 -1 Td
[(pyrexia \(17%\),)37 ( rash \(16%\),)37 ( and d)-10 (yspnea \(16%\) were also frequently reported.)37 ( Serious)-5 ( )]TJ
0.305 Tw 0 -1 Td
[(adverse reactions reported in \0365% of pa)-9.9 (tients inc)20 (luded pleural effusion \(11%\),)32.1 ( )]TJ
0 Tw 0 -1 Td
[(gastrointestinal bleeding \(7%\),)37 ( febrile neutropenia \(6%\),)37 ( and infection \(5%\).)]TJ
/T1_0 1 Tf
-0.01 Tc 0.084 Tw 0 -1.495 Td
[(Philadelphia Chromosome-P)24 (ositive Acute L)37 (ymphoblastic Leukemia \(Ph)]TJ
0 Tc 0 Tw 27.813 0.125 Td
(+)Tj
-0.01 Tc 0.084 Tw 0.59 -0.125 Td
[( ALL\) in)-10 ( )]TJ
0 Tw -28.403 -1 Td
[(P)24 (ediatric P)24 (atients)]TJ
/T1_1 1 Tf
0.252 Tw 0 -1.292 Td
[(The safety of SPR)18.1 (YCEL administered continuously in combina)-9.9 (tion with multia)-9.9 (gent)-10 ( )]TJ
-0.032 Tw 0 -1 Td
[(chemothera)-9.9 (py was determined in a multicohort stud)-9.9 (y of 81 pedia)-9.9 (tric pa)-9.9 (tients with newly)-10 ( )]TJ
0.071 Tw 0 -1 Td
[(dia)-9.9 (gnosed Ph)]TJ
0 Tc 0 Tw 4.94 0.125 Td
(+)Tj
-0.01 Tc 0.034 Tw 0.59 -0.125 Td
[( ALL.)37 ( )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 2.117 0 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc 0.071 Tw 0.397 0 Td
(ee Clinical Studie)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.071 Tw 6.728 0 Td
( \(14.4\)])Tj
/T1_1 1 Tf
[(.)37 ( )36.7 (The median dura)-10 (tion of thera)-10 (py was)-10 ( )]TJ
0 Tc 0 Tw 16.479 0 Td
( )Tj
-0.01 Tc -31.5 -1 Td
[(24 months \(range 2 to 27 months\).)27 ( )]TJ
0.016 Tw 0 -1.427 Td
[(F)20 (a)-10 (tal adverse reactions occurred in 3 pa)-9.9 (tients \(4%\),)37 ( all of which were due to infections.)27 ( )]TJ
-0.044 Tw 0 -1 Td
[(Eight \(10%\) pa)-9.9 (tients experienced adverse reactions leading to trea)-10 (tment discontinua)-9.9 (tion,)27 ( )]TJ
0.239 Tw 0 -1 Td
[(inc)20 (luding )0.5 (fungal )0.5 (sepsis,)37 ( )0.5 (hepa)-10 (totoxicity )0.5 (in )0.5 (the )0.5 (setting )0.5 (of )0.5 (graft )0.5 (versus )0.5 (host )0.6 (disease,)27 ( )]TJ
-0.066 Tw 0 -1 Td
[(thromboc)20 (ytopenia,)37 ( CMV infection,)37 ( pneumonia,)37 ( nausea,)37 ( enteritis and drug hypersensitivity)55 (.)27 ( )]TJ
0.127 Tw 0 -1.427 Td
[(The )0.6 (most )0.6 (common )0.5 (serious )0.6 (adverse )0.5 (reactions )0.5 (\(incidence )0.6 (\03610%\) )0.6 (were )0.6 (pyrexia,)37 ( )0.5 (febrile)-10 ( )]TJ
0.443 Tw 0 -1 Td
[(neutropenia,)37 ( mucositis,)37 ( diarrhea,)37 ( sepsis,)37 ( hypotension,)37 ( infections \(bacterial,)37 ( viral)-10 ( )]TJ
0.426 Tw 0 -1 Td
[(and )0.5 (fungal\),)37 ( hypersensitivity)55 (,)37 ( vomiting,)37 ( renal insuf\037cienc)20 (y)55.1 (,)36.9 ( )0.5 (abdominal )0.5 (pain,)37 ( )0.5 (and)-10 ( )]TJ
0 Tw 0 -1 Td
[(musculoskeletal pain.)27 ( )]TJ
0.071 Tw 0 -1.427 Td
[(The incidence of common adverse reactions \(incidence \03620%\) on stud)-10 (y are sho)-10 (wn in)-10 ( )]TJ
0 Tw 0 -1 Td
[(T)74 (able 14:)]TJ
ET
endstreamendobj5 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 105 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 25 0 R/GS1 23 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300032005A>/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 5192>>/PageWidthList<</0 612.0>>>>>>>>endobj6 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 106 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 25 0 R/GS1 23 0 R/GS2 24 0 R>>/Font<</T1_0 107 0 R/T1_1 26 0 R/T1_2 27 0 R/T1_3 28 0 R>>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300033005A>/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 19653>>/PageWidthList<</0 612.0>>>>>>>>endobj7 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 108 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R/GS2 24 0 R>>/Font<</T1_0 27 0 R/T1_1 26 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300033005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 3912>>/PageWidthList<</0 612.0>>>>>>>>endobj8 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 109 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R/GS2 24 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300033005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 3929>>/PageWidthList<</0 612.0>>>>>>>>endobj9 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 110 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R/GS3 40 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200340030003800300036003100300030003900300033005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 3946>>/PageWidthList<</0 612.0>>>>>>>>endobj110 0 obj<</Length 47116>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 0 k
/GS0 gs
36 732.96 252 -25.312 re
36 707.648 81.72 -20.192 re
117.72 707.648 85.14 -20.192 re
202.86 707.648 85.14 -20.192 re
36 687.456 81.72 -12.192 re
117.72 687.456 42.57 -12.192 re
160.29 687.456 42.57 -12.192 re
202.86 687.456 42.57 -12.192 re
245.43 687.456 42.57 -12.192 re
36 675.264 81.72 -12.192 re
117.72 675.264 170.28 -12.192 re
36 663.072 81.72 -11.112 re
117.72 663.072 42.57 -11.112 re
160.29 663.072 42.57 -11.112 re
202.86 663.072 42.57 -11.112 re
245.43 663.072 42.57 -11.112 re
36 651.96 81.72 -11.112 re
117.72 651.96 42.57 -11.112 re
160.29 651.96 42.57 -11.112 re
202.86 651.96 42.57 -11.112 re
245.43 651.96 42.57 -11.112 re
36 640.849 81.72 -11.112 re
117.72 640.849 42.57 -11.112 re
160.29 640.849 42.57 -11.112 re
202.86 640.849 42.57 -11.112 re
245.43 640.849 42.57 -11.112 re
36 629.737 81.72 -11.112 re
117.72 629.737 42.57 -11.112 re
160.29 629.737 42.57 -11.112 re
202.86 629.737 42.57 -11.112 re
245.43 629.737 42.57 -11.112 re
36 618.625 81.72 -11.112 re
117.72 618.625 42.57 -11.112 re
160.29 618.625 42.57 -11.112 re
202.86 618.625 42.57 -11.112 re
245.43 618.625 42.57 -11.112 re
36 607.513 81.72 -11.112 re
117.72 607.513 42.57 -11.112 re
160.29 607.513 42.57 -11.112 re
202.86 607.513 42.57 -11.112 re
245.43 607.513 42.57 -11.112 re
36 596.401 81.72 -19.112 re
117.72 596.401 42.57 -19.112 re
160.29 596.401 42.57 -19.112 re
202.86 596.401 42.57 -19.112 re
245.43 596.401 42.57 -19.112 re
36 577.289 81.72 -11.112 re
117.72 577.289 42.57 -11.112 re
160.29 577.289 42.57 -11.112 re
202.86 577.289 42.57 -11.112 re
245.43 577.289 42.57 -11.112 re
36 566.177 81.72 -11.112 re
117.72 566.177 42.57 -11.112 re
160.29 566.177 42.57 -11.112 re
202.86 566.177 42.57 -11.112 re
245.43 566.177 42.57 -11.112 re
36 555.065 81.72 -11.112 re
117.72 555.065 42.57 -11.112 re
160.29 555.065 42.57 -11.112 re
202.86 555.065 42.57 -11.112 re
245.43 555.065 42.57 -11.112 re
36 543.953 81.72 -11.112 re
117.72 543.953 42.57 -11.112 re
160.29 543.953 42.57 -11.112 re
202.86 543.953 42.57 -11.112 re
245.43 543.953 42.57 -11.112 re
36 532.841 81.72 -11.112 re
117.72 532.841 42.57 -11.112 re
160.29 532.841 42.57 -11.112 re
202.86 532.841 42.57 -11.112 re
245.43 532.841 42.57 -11.112 re
36 521.729 81.72 -11.112 re
117.72 521.729 42.57 -11.112 re
160.29 521.729 42.57 -11.112 re
202.86 521.729 42.57 -11.112 re
245.43 521.729 42.57 -11.112 re
36 510.617 81.72 -11.112 re
117.72 510.617 42.57 -11.112 re
160.29 510.617 42.57 -11.112 re
202.86 510.617 42.57 -11.112 re
245.43 510.617 42.57 -11.112 re
36 499.505 81.72 -11.112 re
117.72 499.505 42.57 -11.112 re
160.29 499.505 42.57 -11.112 re
202.86 499.505 42.57 -11.112 re
245.43 499.505 42.57 -11.112 re
36 488.394 252 -38.712 re
f
0 0 0 1 K
/GS1 gs
q 1 0 0 1 202.86 707.6481 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 245.43 707.6481 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 202.86 687.4561 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 245.43 687.4561 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 675.2642 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 245.43 675.2642 cm
0 0 m
42.57 0 l
S
Q
1 w 
q 1 0 0 1 36 488.3936 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 488.3936 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 160.29 488.3936 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 36 449.6817 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 449.6817 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 160.29 449.6817 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 449.6817 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 245.43 449.6817 cm
0 0 m
42.57 0 l
S
Q
1 w 
q 1 0 0 1 117.72 707.6481 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 160.29 707.6481 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 202.86 687.7061 cm
0 0 m
0 19.442 l
S
Q
1 w 
q 1 0 0 1 36 707.6481 cm
0 0 m
81.72 0 l
S
Q
0.5 w 
q 1 0 0 1 117.72 687.4561 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 117.72 675.2642 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 36 663.0723 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 663.0723 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 160.29 663.0723 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 663.0723 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 651.9604 cm
0 0 m
0 10.862 l
S
Q
q 1 0 0 1 245.43 663.0723 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 640.8485 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 629.7366 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 618.6246 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 596.4008 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 577.2889 cm
0 0 m
0 19.112 l
S
Q
q 1 0 0 1 202.86 566.177 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 555.0651 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 543.9532 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 532.8412 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 521.7294 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 510.6174 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 499.5055 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 488.8936 cm
0 0 m
0 10.612 l
S
Q
1 w 
q 1 0 0 1 202.86 488.3936 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 245.43 488.3936 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 160.29 687.4561 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 675.5142 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 160.29 675.2642 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 607.5128 cm
0 0 m
0 11.112 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.01 Tc 0.248 Tw 8 0 0 8 36 727.248 Tm
[(Table )224 (7:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Adverse Reactions Reported in \03610% of Adult Patients with)-10 ( )]TJ
0.154 Tw 0 -1 Td
[(Newly Diagnosed Chronic Phase CML in the SPR)40 (Y)40 (CEL-T)40 (reated)-10 ( )]TJ
0.024 Tw 0 -1 Td
[(Arm \(n=25)20 (8\))]TJ
-0.02 Tc 7.2 0 0 8 134.0259 698.6961 Tm
(Minimum of 1)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(Year)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 187.9168 698.6961 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 146.424 690.6961 Tm
(Follow-up)Tj
0.024 Tw 9.926 1 Td
(Minimum of 5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(Years)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 274.8331 698.6961 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 231.814 690.6961 Tm
(Follow-up)Tj
0.024 Tw -14.839 -1.524 Td
(All Grades)Tj
5.979 0 Td
(Grade 3/4)Tj
5.863 0 Td
(All Grades)Tj
5.979 0 Td
(Grade 3/4)Tj
-0.01 Tc -30.179 -1.524 Td
[(Adverse Reaction)-10 ( )]TJ
-0.02 Tc 18.788 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc -18.788 -1.456 Td
(Fluid retention)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(19)Tj
0 Tc 0 Tw 6.133 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(38)Tj
0 Tc 0 Tw 6.15 0 Td
(5)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 12.579 0 Td
(10)Tj
0 Tc 0 Tw 6.133 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(28)Tj
0 Tc 0 Tw 6.15 0 Td
(3)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Superficial localized edema)Tj
0 Tc 0 Tw 12.816 0 Td
(9)Tj
5.895 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(14)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y hypertension)]TJ
0 Tc 0 Tw 12.816 0 Td
(1)Tj
5.895 0 Td
(0)Tj
6.18 0 Td
(5)Tj
5.912 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Generalized edema)Tj
0 Tc 0 Tw 12.816 0 Td
(2)Tj
5.895 0 Td
(0)Tj
6.18 0 Td
(4)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
[(P)18 (ericardial effusion)]TJ
0 Tc 0 Tw 12.816 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 5.598 0 Td
(<1)Tj
0 Tc 0 Tw 6.477 0 Td
(4)Tj
5.912 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Congestive heart failure/)Tj
0 Tc 0 Tw 7.2 0 0 8 108.6389 587.9889 Tm
( )Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF00090009>>> BDC 
7.2 0 0 8 36 579.9889 Tm
[( )-996 ( )]TJ
EMC 
2.083 0 Td
[(cardiac d)-10 (ysfunction)]TJ
0 Tc 0 Tw 5.4 0 0 6 101.7155 582.7889 Tm
(a)Tj
7.2 0 0 8 137.277 583.9889 Tm
(2)Tj
-0.005 Tc 0.005 Tw 5.598 0 Td
(<1)Tj
0 Tc 0 Tw 6.477 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.756 -1.889 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y edema)]TJ
-0.005 Tc 0.005 Tw 12.519 0 Td
(<1)Tj
0 Tc 0 Tw 6.193 0 Td
(0)Tj
6.18 0 Td
(1)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.389 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(17)Tj
5.835 0 Td
(<1)Tj
6.24 0 Td
(22)Tj
0 Tc 0 Tw 6.15 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -32.054 -1.389 Td
(Musculoskeletal pain)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(11)Tj
0 Tc 0 Tw 6.133 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(14)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.389 Td
(Rash)Tj
0 Tc 0 Tw 5.4 0 0 6 48.9094 538.3412 Tm
(b)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 135.5671 535.5413 Tm
(11)Tj
0 Tc 0 Tw 6.133 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(14)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.389 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(12)Tj
0 Tc 0 Tw 6.133 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(14)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -32.054 -1.389 Td
(Abdominal pain)Tj
0 Tc 0 Tw 14.066 0 Td
(7)Tj
5.895 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(11)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.389 Td
[(F)20 (a)-10 (tigue)]TJ
0 Tc 0 Tw 14.066 0 Td
(8)Tj
-0.005 Tc 0.005 Tw 5.598 0 Td
(<1)Tj
6.24 0 Td
(11)Tj
5.853 0 Td
(<1)Tj
-0.01 Tc 0.01 Tw -31.756 -1.389 Td
(Nausea)Tj
0 Tc 0 Tw 14.066 0 Td
(8)Tj
5.895 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(10)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.4 0 0 6 36.0001 481.8817 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.047 Tw 7.2 0 0 8 41.0001 479.0817 Tm
[(Inc)20 (ludes cardiac failure acute,)37 ( cardiac failure congestive,)37 ( cardiomyopa)-10 (thy)55 (,)37 ( diastolic d)-10 (ysfunction,)32 ( )]TJ
0 Tw 0 -1 Td
[(ejection fraction decreased,)36.9 ( and left ventricular d)-10 (ysfunction.)]TJ
0.005 Tw 5.4 0 0 6 36.0001 464.0817 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.074 Tw 7.2 0 0 8 41.0001 461.2817 Tm
[(Inc)20 (ludes er)-18 (ythema,)37 ( er)-18 (ythema multiforme,)37 ( rash,)37 ( rash generalized,)37 ( rash macular)74 (,)37 ( rash pa)-9.9 (pular)74 (,)32 ( )]TJ
0 Tw 0 -1 Td
[(rash pustular)74 (,)37 ( skin exfolia)-10 (tion,)37 ( and rash vesicular)74 (.)]TJ
-0.01 Tc 0.194 Tw 8 0 0 8 36.0001 434.3896 Tm
[(At 60 months,)37 ( there were 26 dea)-10 (ths in dasa)-10 (tinib-trea)-10 (ted pa)-10 (tients \(10.1%\) and 26)-10 ( )]TJ
0.107 Tw 0 -1.025 Td
[(dea)-9.9 (ths in ima)-10 (tinib-trea)-9.9 (ted pa)-9.9 (tients \(10.1%\); 1 dea)-9.9 (th in each group was assessed by)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -31.5 -1.025 Td
[(the investiga)-10 (tor as rela)-9.9 (ted to stud)-10 (y thera)-9.9 (py)55 (.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 407.704 252 -25.312 re
36 382.392 95.4 -12.192 re
131.4 382.392 156.6 -12.192 re
36 370.2 95.4 -20.192 re
131.4 370.2 156.6 -20.192 re
36 350.008 95.4 -12.192 re
131.4 350.008 78.3 -12.192 re
209.7 350.008 78.3 -12.192 re
36 337.816 95.4 -12.192 re
131.4 337.816 156.6 -12.192 re
36 325.624 95.4 -11.112 re
131.4 325.624 78.3 -11.112 re
209.7 325.624 78.3 -11.112 re
36 314.512 95.4 -11.112 re
131.4 314.512 78.3 -11.112 re
209.7 314.512 78.3 -11.112 re
36 303.4 95.4 -11.112 re
131.4 303.4 78.3 -11.112 re
209.7 303.4 78.3 -11.112 re
36 292.288 95.4 -11.112 re
131.4 292.288 78.3 -11.112 re
209.7 292.288 78.3 -11.112 re
36 281.176 95.4 -11.112 re
131.4 281.176 78.3 -11.112 re
209.7 281.176 78.3 -11.112 re
36 270.064 95.4 -11.112 re
131.4 270.064 78.3 -11.112 re
209.7 270.064 78.3 -11.112 re
36 258.953 95.4 -11.112 re
131.4 258.953 78.3 -11.112 re
209.7 258.953 78.3 -11.112 re
36 247.841 95.4 -11.112 re
131.4 247.841 78.3 -11.112 re
209.7 247.841 78.3 -11.112 re
36 236.729 95.4 -11.112 re
131.4 236.729 78.3 -11.112 re
209.7 236.729 78.3 -11.112 re
36 225.617 95.4 -11.112 re
131.4 225.617 78.3 -11.112 re
209.7 225.617 78.3 -11.112 re
36 214.505 95.4 -11.112 re
131.4 214.505 78.3 -11.112 re
209.7 214.505 78.3 -11.112 re
36 203.393 95.4 -11.112 re
131.4 203.393 78.3 -11.112 re
209.7 203.393 78.3 -11.112 re
36 192.281 95.4 -11.112 re
131.4 192.281 78.3 -11.112 re
209.7 192.281 78.3 -11.112 re
36 181.169 95.4 -11.112 re
131.4 181.169 78.3 -11.112 re
209.7 181.169 78.3 -11.112 re
36 170.057 95.4 -11.112 re
131.4 170.057 78.3 -11.112 re
209.7 170.057 78.3 -11.112 re
36 158.945 95.4 -19.112 re
131.4 158.945 78.3 -19.112 re
209.7 158.945 78.3 -19.112 re
36 139.833 95.4 -11.112 re
131.4 139.833 78.3 -11.112 re
209.7 139.833 78.3 -11.112 re
36 128.721 95.4 -11.112 re
131.4 128.721 78.3 -11.112 re
209.7 128.721 78.3 -11.112 re
36 117.61 95.4 -11.112 re
131.4 117.61 78.3 -11.112 re
209.7 117.61 78.3 -11.112 re
36 106.498 95.4 -11.112 re
131.4 106.498 78.3 -11.112 re
209.7 106.498 78.3 -11.112 re
36 95.386 95.4 -11.112 re
131.4 95.386 78.3 -11.112 re
209.7 95.386 78.3 -11.112 re
36 84.274 95.4 -11.112 re
131.4 84.274 78.3 -11.112 re
209.7 84.274 78.3 -11.112 re
36 73.162 252 -36.912 re
f
/GS1 gs
q 1 0 0 1 209.7001 325.624 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 314.5121 cm
0 0 m
0 10.862 l
S
Q
q 1 0 0 1 209.7001 303.4001 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 292.2882 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 281.1763 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 270.0644 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 258.9525 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 247.8406 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 236.7287 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 225.6168 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 214.5048 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 203.3929 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 192.281 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 181.1691 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 170.0572 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 139.8333 cm
0 0 m
0 19.112 l
S
Q
q 1 0 0 1 209.7001 128.7214 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 117.6095 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 106.4976 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 95.3857 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 84.2738 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 73.6619 cm
0 0 m
0 10.612 l
S
Q
1 w 
q 1 0 0 1 209.7001 73.1619 cm
0 0 m
78.3 0 l
S
Q
0.5 w 
q 1 0 0 1 209.7001 350.0078 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 338.0659 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 209.7001 337.8159 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 158.9453 cm
0 0 m
0 11.112 l
S
Q
1 w 
q 1 0 0 1 36.0001 73.1619 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4001 73.1619 cm
0 0 m
78.3 0 l
S
Q
0.5 w 
q 1 0 0 1 36.0001 36.25 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4001 36.25 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 36.25 cm
0 0 m
78.3 0 l
S
Q
1 w 
q 1 0 0 1 131.4001 382.3916 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 382.3916 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 36.0001 382.3916 cm
0 0 m
95.4 0 l
S
Q
0.5 w 
q 1 0 0 1 131.4001 370.1997 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 370.1997 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 131.4001 350.0078 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 131.4001 337.8159 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 36.0001 325.624 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4001 325.624 cm
0 0 m
78.3 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
0.248 Tw 8 0 0 8 36.0001 401.9916 Tm
[(Table )224 (8:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Adverse Reactions Reported in \03610% of Adult Patients with)-10 ( )]TJ
0.25 Tw 0 -1 Td
[(Chronic Phase CML Resistant or Intolerant to Prior Imatinib)-10 ( )]TJ
0.024 Tw 0 -1 Td
(Therapy \(minimum of 84 months follow-up\))Tj
-0.02 Tc 7.2 0 0 8 184.029 373.4397 Tm
(100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
0.02 Tw 2.099 -1.524 Td
(Chronic)Tj
0 Tc 0 Tw 7.2 0 0 8 220.2588 361.2478 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 198.8571 353.2478 Tm
(\(n=165\))Tj
0.024 Tw -5.897 -1.524 Td
(All Grades)Tj
10.994 0 Td
(Grade 3/4)Tj
-0.01 Tc -27.715 -1.524 Td
[(Adverse Reaction)-10 ( )]TJ
-0.02 Tc 19.738 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc -19.738 -1.456 Td
(Fluid retention)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(48)Tj
0 Tc 0 Tw 11.38 0 Td
(7)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Superficial localized edema)Tj
-0.005 Tc 0.005 Tw 16.943 0 Td
(22)Tj
0 Tc 0 Tw 11.38 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 16.943 0 Td
(28)Tj
0 Tc 0 Tw 11.38 0 Td
(5)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Generalized edema)Tj
0 Tc 0 Tw 17.18 0 Td
(4)Tj
11.142 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
[(P)18 (ericardial effusion)]TJ
0 Tc 0 Tw 17.18 0 Td
(3)Tj
11.142 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y hypertension)]TJ
0 Tc 0 Tw 17.18 0 Td
(2)Tj
11.142 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(33)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(28)Tj
0 Tc 0 Tw 11.38 0 Td
(2)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
[(F)20 (a)-10 (tigue)]TJ
-0.005 Tc 0.005 Tw 18.193 0 Td
(26)Tj
0 Tc 0 Tw 11.38 0 Td
(4)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Dyspnea)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(24)Tj
0 Tc 0 Tw 11.38 0 Td
(2)Tj
-0.01 Tc 0.024 Tw -29.573 -1.389 Td
(Musculoskeletal pain)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(22)Tj
0 Tc 0 Tw 11.38 0 Td
(2)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Nausea)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(18)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -29.573 -1.389 Td
(Skin rash)Tj
0 Tc 0 Tw 5.4 0 0 6 60.4436 186.6691 Tm
(a)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 166.9872 183.8691 Tm
(18)Tj
0 Tc 0 Tw 11.38 0 Td
(2)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
[(My)-10 (algia)]TJ
-0.005 Tc 0.005 Tw 18.193 0 Td
(13)Tj
0 Tc 0 Tw 11.38 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Arthralgia)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(13)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -29.573 -1.389 Td
[(Infection \(inc)20 (luding bacterial,)37 ( viral,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 126.3578 150.5334 Tm
( )Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36.0001 142.5334 Tm
( )Tj
EMC 
1.25 0 Td
[(fungal,)37 ( and non-specified\))]TJ
-0.005 Tc 0.005 Tw 16.943 0.5 Td
(13)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -29.573 -1.889 Td
(Abdominal pain)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(12)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
[(Hemorrha)-9.9 (ge)]TJ
-0.005 Tc 0.005 Tw 18.193 0 Td
(12)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Gastrointestinal bleeding)Tj
0 Tc 0 Tw 17.18 0 Td
(2)Tj
11.142 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Pruritus)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(12)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
[(P)18 (ain)]TJ
-0.005 Tc 0.005 Tw 18.193 0 Td
(11)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
[(Constipa)-10 (tion)]TJ
-0.005 Tc 0.005 Tw 18.193 0 Td
(10)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 5.4 0 0 6 36.0001 66.6499 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.046 Tw 7.2 0 0 8 41.0001 63.8499 Tm
[(Inc)20 (ludes drug eruption,)37 ( er)-18 (ythema,)37 ( er)-18 (ythema multiforme,)37 ( er)-18 (ythrosis,)37 ( exfolia)-9.9 (tive rash,)37 ( generalized)-5 ( )]TJ
0.318 Tw 0 -1 Td
[(er)-18 (ythema,)37 ( )0.5 (genital )0.5 (rash,)37 ( )0.5 (hea)-9.9 (t )0.5 (rash,)37 ( )0.5 (milia,)37 ( )0.5 (rash,)37 ( )0.5 (rash )0.5 (er)-18 (ythema)-9.9 (tous,)37 ( )0.5 (rash )0.5 (follicular)74 (,)37 ( )0.5 (rash)-5 ( )]TJ
0.046 Tw 0 -1 Td
[(generalized,)36.9 ( rash macular)74 (,)37 ( rash maculopa)-10 (pular)74 (,)37 ( rash pa)-9.9 (pular)73.9 (,)37.1 ( rash pruritic,)37 ( rash pustular)74 (,)37 ( skin)-5 ( )]TJ
0 Tw 0 -1 Td
[(exfolia)-9.9 (tion,)37 ( skin irrita)-10 (tion,)37 ( urticaria vesiculosa,)36.9 ( and rash vesicular)74 (.)]TJ
-0.01 Tc 0.015 Tw 8 0 0 8 324 727.248 Tm
[(Cumula)-10 (tive ra)-9.9 (tes of selected adverse reactions tha)-10 (t were reported over time in pa)-10 (tients)-10 ( )]TJ
0.021 Tw 0 -1.024 Td
[(trea)-10 (ted with the 100 mg once daily recommended starting dose in a randomized\ dose-)]TJ
-0.024 Tw 0 -1.024 Td
[(optimiza)-10 (tion trial of ima)-10 (tinib-resistant or -intolerant pa)-10 (tients with chronic phase CML are)-9.9 ( )]TJ
0 Tw 0 -1.024 Td
[(sho)-10 (wn in )37 (T)74 (able 9.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 692.407 252 -17.312 re
324 675.095 65.88 -20.912 re
389.88 675.095 62.04 -20.912 re
451.92 675.095 62.04 -20.912 re
513.96 675.095 62.04 -20.912 re
324 654.183 65.88 -21.57 re
389.88 654.183 31.02 -21.57 re
420.9 654.183 31.02 -21.57 re
451.92 654.183 31.02 -21.57 re
482.94 654.183 31.02 -21.57 re
513.96 654.183 31.02 -21.57 re
544.98 654.183 31.02 -21.57 re
324 632.613 65.88 -13.5 re
389.88 632.613 186.12 -13.5 re
324 619.113 65.88 -11.472 re
389.88 619.113 31.02 -11.472 re
420.9 619.113 31.02 -11.472 re
451.92 619.113 31.02 -11.472 re
482.94 619.113 31.02 -11.472 re
513.96 619.113 31.02 -11.472 re
544.98 619.113 31.02 -11.472 re
324 607.641 65.88 -11.472 re
389.88 607.641 31.02 -11.472 re
420.9 607.641 31.02 -11.472 re
451.92 607.641 31.02 -11.472 re
482.94 607.641 31.02 -11.472 re
513.96 607.641 31.02 -11.472 re
544.98 607.641 31.02 -11.472 re
324 596.169 65.88 -11.472 re
389.88 596.169 31.02 -11.472 re
420.9 596.169 31.02 -11.472 re
451.92 596.169 31.02 -11.472 re
482.94 596.169 31.02 -11.472 re
513.96 596.169 31.02 -11.472 re
544.98 596.169 31.02 -11.472 re
324 584.697 65.88 -11.472 re
389.88 584.697 31.02 -11.472 re
420.9 584.697 31.02 -11.472 re
451.92 584.697 31.02 -11.472 re
482.94 584.697 31.02 -11.472 re
513.96 584.697 31.02 -11.472 re
544.98 584.697 31.02 -11.472 re
324 573.225 65.88 -11.472 re
389.88 573.225 31.02 -11.472 re
420.9 573.225 31.02 -11.472 re
451.92 573.225 31.02 -11.472 re
482.94 573.225 31.02 -11.472 re
513.96 573.225 31.02 -11.472 re
544.98 573.225 31.02 -11.472 re
324 561.753 65.88 -11.472 re
389.88 561.753 31.02 -11.472 re
420.9 561.753 31.02 -11.472 re
451.92 561.753 31.02 -11.472 re
482.94 561.753 31.02 -11.472 re
513.96 561.753 31.02 -11.472 re
544.98 561.753 31.02 -11.472 re
324 550.282 65.88 -19.472 re
389.88 550.282 31.02 -19.472 re
420.9 550.282 31.02 -19.472 re
451.92 550.282 31.02 -19.472 re
482.94 550.282 31.02 -19.472 re
513.96 550.282 31.02 -19.472 re
544.98 550.282 31.02 -19.472 re
324 530.81 65.88 -11.472 re
389.88 530.81 31.02 -11.472 re
420.9 530.81 31.02 -11.472 re
451.92 530.81 31.02 -11.472 re
482.94 530.81 31.02 -11.472 re
513.96 530.81 31.02 -11.472 re
544.98 530.81 31.02 -11.472 re
324 519.338 65.88 -19.472 re
389.88 519.338 31.02 -19.472 re
420.9 519.338 31.02 -19.472 re
451.92 519.338 31.02 -19.472 re
482.94 519.338 31.02 -19.472 re
513.96 519.338 31.02 -19.472 re
544.98 519.338 31.02 -19.472 re
324 499.866 252 -20.912 re
f
1 w 
/GS1 gs
q 1 0 0 1 389.88 675.095 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 420.9 675.095 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 675.095 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 544.98 675.095 cm
0 0 m
31.02 0 l
S
Q
0.5 w 
q 1 0 0 1 451.92 654.433 cm
0 0 m
0 20.162 l
S
Q
q 1 0 0 1 389.88 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 420.9 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 632.863 cm
0 0 m
0 21.07 l
S
Q
q 1 0 0 1 482.94 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 632.863 cm
0 0 m
0 21.07 l
S
Q
q 1 0 0 1 389.88 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 420.9 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 482.94 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 544.98 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 324 619.113 cm
0 0 m
65.88 0 l
S
Q
q 1 0 0 1 389.88 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 482.94 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 420.9 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 607.6411 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 451.92 596.1692 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 584.6973 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 573.2253 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 561.7535 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 550.2816 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 530.8096 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 451.92 519.3377 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 500.3658 cm
0 0 m
0 18.972 l
S
Q
1 w 
q 1 0 0 1 420.9 499.8658 cm
0 0 m
31.02 0 l
S
Q
0.5 w 
q 1 0 0 1 513.96 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 544.98 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 607.6411 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 544.98 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 596.1692 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 584.6973 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 573.2253 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 561.7535 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 550.2816 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 530.8096 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 513.96 519.3377 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 500.3658 cm
0 0 m
0 18.972 l
S
Q
1 w 
q 1 0 0 1 513.96 499.8658 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 544.98 499.8658 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 324 499.8658 cm
0 0 m
65.88 0 l
S
Q
q 1 0 0 1 389.88 499.8658 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 499.8658 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 482.94 499.8658 cm
0 0 m
31.02 0 l
S
Q
0.5 w 
q 1 0 0 1 324 478.9539 cm
0 0 m
65.88 0 l
S
Q
q 1 0 0 1 389.88 478.9539 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 420.9 478.9539 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 478.9539 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 482.94 478.9539 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 478.9539 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 544.98 478.9539 cm
0 0 m
31.02 0 l
S
Q
1 w 
q 1 0 0 1 451.92 675.095 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 482.94 675.095 cm
0 0 m
31.02 0 l
S
Q
0.5 w 
q 1 0 0 1 513.96 654.433 cm
0 0 m
0 20.162 l
S
Q
1 w 
q 1 0 0 1 324 675.095 cm
0 0 m
65.88 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.018 Tw 8 0 0 8 324 686.6949 Tm
[(Table )-42 (9:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Selected Adverse Reactions Reported in Adult Dose Optimization)-10 ( )]TJ
0.024 Tw 0 -1 Td
(Trial \(Imatinib-Intolerant or -Resistant Chronic Phase CML\))Tj
0 Tc 0 Tw 6 0 0 6 560.6205 681.4949 Tm
(a)Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 404.2297 665.783 Tm
[(Minimum of)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 438.9331 665.783 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 395.9139 657.783 Tm
(2)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years Follow-up)Tj
9.789 1 Td
[(Minimum of)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 501.0981 665.783 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 458.0789 657.783 Tm
(5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years Follow-up)Tj
9.789 1 Td
[(Minimum of)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 563.2631 665.783 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 520.2439 657.783 Tm
(7)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years Follow-up)Tj
0.02 Tw -16.45 -1.655 Td
(All)Tj
0 Tc 0 Tw 7.2 0 0 8 408.9755 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 395.753 636.5421 Tm
(Grades)Tj
4.503 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 446.0084 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 431.7779 636.5421 Tm
(3/4)Tj
4.471 1 Td
(All)Tj
0 Tc 0 Tw 7.2 0 0 8 471.1405 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 457.9179 636.5421 Tm
(Grades)Tj
4.486 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 508.0484 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 493.8179 636.5421 Tm
(3/4)Tj
4.471 1 Td
(All)Tj
0 Tc 0 Tw 7.2 0 0 8 533.1805 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 519.958 636.5421 Tm
(Grades)Tj
4.503 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 570.2134 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 555.9828 636.5421 Tm
(3/4)Tj
-0.01 Tc 0.024 Tw -32.22 -1.692 Td
[(Adverse Reaction)-10 ( )]TJ
-0.02 Tc 17.688 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -17.688 -1.561 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 10.827 0 Td
(27)Tj
0 Tc 0 Tw 4.528 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 4.106 0 Td
(28)Tj
0 Tc 0 Tw 4.511 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 4.338 0 Td
(28)Tj
0 Tc 0 Tw 4.546 0 Td
(2)Tj
-0.01 Tc 0.024 Tw -32.856 -1.434 Td
(Fluid retention)Tj
-0.005 Tc 0.005 Tw 10.827 0 Td
(34)Tj
0 Tc 0 Tw 4.528 0 Td
(4)Tj
-0.005 Tc 0.005 Tw 4.106 0 Td
(42)Tj
0 Tc 0 Tw 4.511 0 Td
(6)Tj
-0.005 Tc 0.005 Tw 4.338 0 Td
(48)Tj
0 Tc 0 Tw 4.546 0 Td
(7)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
1.25 0 Td
(Superficial edema)Tj
-0.005 Tc 0.005 Tw 9.577 0 Td
(18)Tj
0 Tc 0 Tw 4.528 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 4.106 0 Td
(21)Tj
0 Tc 0 Tw 4.511 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 4.338 0 Td
(22)Tj
0 Tc 0 Tw 4.546 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
1.25 0 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 9.577 0 Td
(18)Tj
0 Tc 0 Tw 4.528 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 4.106 0 Td
(24)Tj
0 Tc 0 Tw 4.511 0 Td
(4)Tj
-0.005 Tc 0.005 Tw 4.338 0 Td
(28)Tj
0 Tc 0 Tw 4.546 0 Td
(5)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
1.25 0 Td
(Generalized edema)Tj
0 Tc 0 Tw 9.814 0 Td
(3)Tj
4.291 0 Td
(0)Tj
4.343 0 Td
(4)Tj
4.274 0 Td
(0)Tj
4.576 0 Td
(4)Tj
4.308 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
1.25 0 Td
[(P)18 (ericardial effusion)]TJ
0 Tc 0 Tw 9.814 0 Td
(2)Tj
4.291 0 Td
(1)Tj
4.343 0 Td
(2)Tj
4.274 0 Td
(1)Tj
4.576 0 Td
(3)Tj
4.308 0 Td
(1)Tj
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
[(Pulmonar)-17.9 (y)]TJ
0 Tc 0 Tw 7.2 0 0 8 360.7984 541.6896 Tm
( )Tj
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 324 533.6896 Tm
( )Tj
EMC 
(hypertension)Tj
0 Tc 0 Tw 11.064 0.5 Td
(0)Tj
4.291 0 Td
(0)Tj
4.343 0 Td
(0)Tj
4.274 0 Td
(0)Tj
4.576 0 Td
(2)Tj
4.308 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -32.856 -1.934 Td
[(Hemorrha)-9.9 (ge)]TJ
-0.005 Tc 0.005 Tw 10.827 0 Td
(11)Tj
0 Tc 0 Tw 4.528 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 4.106 0 Td
(11)Tj
0 Tc 0 Tw 4.511 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 4.338 0 Td
(12)Tj
0 Tc 0 Tw 4.546 0 Td
(1)Tj
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
[(Gastrointestinal)-9.9 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 374.9891 510.7458 Tm
( )Tj
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 324 502.7458 Tm
( )Tj
EMC 
(bleeding)Tj
0 Tc 0 Tw 11.064 0.5 Td
(2)Tj
4.291 0 Td
(1)Tj
4.343 0 Td
(2)Tj
4.274 0 Td
(1)Tj
4.576 0 Td
(2)Tj
4.308 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 5.4 0 0 6 324 493.3539 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.175 Tw 7.2 0 0 8 329 490.5539 Tm
[(Randomized dose-optimiza)-10 (tion trial results reported in the recommended starting dose of)-5 ( )]TJ
0 Tw 0 -1 Td
(100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily \(n=165\) popula)-10 (tion.)]TJ
ET
0 0 0 0 k
/GS0 gs
324.062 465.014 251.937 -25.312 re
324.062 439.702 88.497 -12.912 re
412.56 439.702 163.44 -12.912 re
324.062 426.79 88.497 -20.912 re
412.56 426.79 54.48 -20.912 re
467.04 426.79 54.48 -20.912 re
521.52 426.79 54.48 -20.912 re
324.062 405.878 88.497 -20.912 re
412.56 405.878 27.24 -20.912 re
439.8 405.878 27.24 -20.912 re
467.04 405.878 27.24 -20.912 re
494.28 405.878 27.24 -20.912 re
521.52 405.878 27.24 -20.912 re
548.76 405.878 27.24 -20.912 re
324.062 384.966 88.497 -12.912 re
412.56 384.966 163.44 -12.912 re
324.062 372.054 88.497 -11.902 re
412.56 372.054 27.24 -11.902 re
439.8 372.054 27.24 -11.902 re
467.04 372.054 27.24 -11.902 re
494.28 372.054 27.24 -11.902 re
521.52 372.054 27.24 -11.902 re
548.76 372.054 27.24 -11.902 re
324.062 360.152 88.497 -11.652 re
412.56 360.152 27.24 -11.652 re
439.8 360.152 27.24 -11.652 re
467.04 360.152 27.24 -11.652 re
494.28 360.152 27.24 -11.652 re
521.52 360.152 27.24 -11.652 re
548.76 360.152 27.24 -11.652 re
324.062 348.5 88.497 -11.652 re
412.56 348.5 27.24 -11.652 re
439.8 348.5 27.24 -11.652 re
467.04 348.5 27.24 -11.652 re
494.28 348.5 27.24 -11.652 re
521.52 348.5 27.24 -11.652 re
548.76 348.5 27.24 -11.652 re
324.062 336.848 88.497 -11.652 re
412.56 336.848 27.24 -11.652 re
439.8 336.848 27.24 -11.652 re
467.04 336.848 27.24 -11.652 re
494.28 336.848 27.24 -11.652 re
521.52 336.848 27.24 -11.652 re
548.76 336.848 27.24 -11.652 re
324.062 325.196 88.497 -11.652 re
412.56 325.196 27.24 -11.652 re
439.8 325.196 27.24 -11.652 re
467.04 325.196 27.24 -11.652 re
494.28 325.196 27.24 -11.652 re
521.52 325.196 27.24 -11.652 re
548.76 325.196 27.24 -11.652 re
324.062 313.544 88.497 -19.652 re
412.56 313.544 27.24 -19.652 re
439.8 313.544 27.24 -19.652 re
467.04 313.544 27.24 -19.652 re
494.28 313.544 27.24 -19.652 re
521.52 313.544 27.24 -19.652 re
548.76 313.544 27.24 -19.652 re
324.062 293.893 88.497 -11.652 re
412.56 293.893 27.24 -11.652 re
439.8 293.893 27.24 -11.652 re
467.04 293.893 27.24 -11.652 re
494.28 293.893 27.24 -11.652 re
521.52 293.893 27.24 -11.652 re
548.76 293.893 27.24 -11.652 re
324.062 282.241 88.497 -11.652 re
412.56 282.241 27.24 -11.652 re
439.8 282.241 27.24 -11.652 re
467.04 282.241 27.24 -11.652 re
494.28 282.241 27.24 -11.652 re
521.52 282.241 27.24 -11.652 re
548.76 282.241 27.24 -11.652 re
324.062 270.589 88.497 -11.652 re
412.56 270.589 27.24 -11.652 re
439.8 270.589 27.24 -11.652 re
467.04 270.589 27.24 -11.652 re
494.28 270.589 27.24 -11.652 re
521.52 270.589 27.24 -11.652 re
548.76 270.589 27.24 -11.652 re
324.062 258.937 88.497 -11.652 re
412.56 258.937 27.24 -11.652 re
439.8 258.937 27.24 -11.652 re
467.04 258.937 27.24 -11.652 re
494.28 258.937 27.24 -11.652 re
521.52 258.937 27.24 -11.652 re
548.76 258.937 27.24 -11.652 re
324.062 247.285 88.497 -11.652 re
412.56 247.285 27.24 -11.652 re
439.8 247.285 27.24 -11.652 re
467.04 247.285 27.24 -11.652 re
494.28 247.285 27.24 -11.652 re
521.52 247.285 27.24 -11.652 re
548.76 247.285 27.24 -11.652 re
324.062 235.633 88.497 -11.652 re
412.56 235.633 27.24 -11.652 re
439.8 235.633 27.24 -11.652 re
467.04 235.633 27.24 -11.652 re
494.28 235.633 27.24 -11.652 re
521.52 235.633 27.24 -11.652 re
548.76 235.633 27.24 -11.652 re
324.062 223.981 88.497 -11.652 re
412.56 223.981 27.24 -11.652 re
439.8 223.981 27.24 -11.652 re
467.04 223.981 27.24 -11.652 re
494.28 223.981 27.24 -11.652 re
521.52 223.981 27.24 -11.652 re
548.76 223.981 27.24 -11.652 re
324.062 212.329 88.497 -11.652 re
412.56 212.329 27.24 -11.652 re
439.8 212.329 27.24 -11.652 re
467.04 212.329 27.24 -11.652 re
494.28 212.329 27.24 -11.652 re
521.52 212.329 27.24 -11.652 re
548.76 212.329 27.24 -11.652 re
324.062 200.677 88.497 -11.652 re
412.56 200.677 27.24 -11.652 re
439.8 200.677 27.24 -11.652 re
467.04 200.677 27.24 -11.652 re
494.28 200.677 27.24 -11.652 re
521.52 200.677 27.24 -11.652 re
548.76 200.677 27.24 -11.652 re
324.062 189.025 88.497 -19.652 re
412.56 189.025 27.24 -19.652 re
439.8 189.025 27.24 -19.652 re
467.04 189.025 27.24 -19.652 re
494.28 189.025 27.24 -19.652 re
521.52 189.025 27.24 -19.652 re
548.76 189.025 27.24 -19.652 re
324.062 169.373 88.497 -11.652 re
412.56 169.373 27.24 -11.652 re
439.8 169.373 27.24 -11.652 re
467.04 169.373 27.24 -11.652 re
494.28 169.373 27.24 -11.652 re
521.52 169.373 27.24 -11.652 re
548.76 169.373 27.24 -11.652 re
324.062 157.721 88.497 -11.652 re
412.56 157.721 27.24 -11.652 re
439.8 157.721 27.24 -11.652 re
467.04 157.721 27.24 -11.652 re
494.28 157.721 27.24 -11.652 re
521.52 157.721 27.24 -11.652 re
548.76 157.721 27.24 -11.652 re
324.062 146.07 88.497 -11.652 re
412.56 146.07 27.24 -11.652 re
439.8 146.07 27.24 -11.652 re
467.04 146.07 27.24 -11.652 re
494.28 146.07 27.24 -11.652 re
521.52 146.07 27.24 -11.652 re
548.76 146.07 27.24 -11.652 re
324.062 134.418 88.497 -11.652 re
412.56 134.418 27.24 -11.652 re
439.8 134.418 27.24 -11.652 re
467.04 134.418 27.24 -11.652 re
494.28 134.418 27.24 -11.652 re
521.52 134.418 27.24 -11.652 re
548.76 134.418 27.24 -11.652 re
324.062 122.766 88.497 -11.652 re
412.56 122.766 27.24 -11.652 re
439.8 122.766 27.24 -11.652 re
467.04 122.766 27.24 -11.652 re
494.28 122.766 27.24 -11.652 re
521.52 122.766 27.24 -11.652 re
548.76 122.766 27.24 -11.652 re
324.062 111.114 88.497 -12.152 re
412.56 111.114 27.24 -12.152 re
439.8 111.114 27.24 -12.152 re
467.04 111.114 27.24 -12.152 re
494.28 111.114 27.24 -12.152 re
521.52 111.114 27.24 -12.152 re
548.76 111.114 27.24 -12.152 re
324.062 98.962 251.937 -62.712 re
f
/GS1 gs
q 1 0 0 1 324.0625 439.7016 cm
0 0 m
88.497 0 l
S
Q
q 1 0 0 1 412.56 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 324 98.9619 cm
0 0 m
88.56 0 l
S
Q
q 1 0 0 1 412.56 98.9619 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 98.9619 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 98.9619 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 98.9619 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 98.9619 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 98.9619 cm
0 0 m
27.24 0 l
S
Q
0 0 0 0 K
0.125 w 
/GS3 gs
q 1 0 0 1 324.0625 36.5 cm
0 0 m
0 61.962 l
S
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 324 36.25 cm
0 0 m
88.56 0 l
S
Q
q 1 0 0 1 412.56 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 412.56 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 324.0625 372.054 cm
0 0 m
88.497 0 l
S
Q
q 1 0 0 1 412.56 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 412.56 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 412.56 384.9659 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 384.9659 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 384.9659 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 384.9659 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 384.9659 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 384.9659 cm
0 0 m
27.24 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.015 Tc 0.282 Tw 8 0 0 8 324.0625 459.3016 Tm
[(T)-5 (a)-5 (b)-5 (l)-5 (e)-5 ( )253 (1)-5 (0)-5 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.538 0 Td
( )Tj
EMC 
3.087 0 Td
[(Adverse Reactions Reported in \03610% of Adult Patients with)-15 ( )]TJ
0.181 Tw 0 -1 Td
[(Advanced )0.5 (Phase CML Resistant or )0.5 (Intolerant )0.5 (to Prior Imatinib)-15 ( )]TJ
0.015 Tw 0 -1 Td
(Therapy)Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 468.7529 430.3897 Tm
[(1)40 (40)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
0.02 Tw -6.282 -1.614 Td
(Accelerated)Tj
0 Tc 0 Tw 7.2 0 0 8 456.0753 417.4778 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 428.957 409.4778 Tm
(\(n=157\))Tj
0.024 Tw 6.499 1 Td
(Myeloid Blast)Tj
0 Tc 0 Tw 7.2 0 0 8 512.8123 417.4778 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 485.0929 409.4778 Tm
(\(n=74\))Tj
0.024 Tw 5.89 1 Td
(Lymphoid Blast)Tj
0 Tc 0 Tw 7.2 0 0 8 570.0212 417.4778 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 539.573 409.4778 Tm
(\(n=33\))Tj
-16.247 -1.614 Td
[(All)-20 ( )]TJ
-0.84 -1 Td
(Grades)Tj
3.995 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 463.1434 396.5659 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 448.9129 388.5659 Tm
(3/4)Tj
3.911 1 Td
[(All)-20 ( )]TJ
-0.84 -1 Td
(Grades)Tj
3.995 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 517.6234 396.5659 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 503.3929 388.5659 Tm
(3/4)Tj
3.911 1 Td
[(All)-20 ( )]TJ
-0.84 -1 Td
(Grades)Tj
3.995 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 572.1034 396.5659 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 557.8729 388.5659 Tm
(3/4)Tj
-0.01 Tc 0.024 Tw -32.474 -1.614 Td
(Adverse Reaction)Tj
-0.02 Tc 19.254 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc -19.254 -1.578 Td
(Fluid retention)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(35)Tj
0 Tc 0 Tw 4.021 0 Td
(8)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(34)Tj
0 Tc 0 Tw 4.021 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(21)Tj
0 Tc 0 Tw 4.021 0 Td
(6)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
8 0 0 8 324.0625 351.3802 Tm
( )Tj
EMC 
1.125 0 Td
(Super\037cial localized edema)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 422.742 351.3802 Tm
(18)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(14)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
3.783 0 Td
(3)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 12.455 0 Td
(21)Tj
0 Tc 0 Tw 4.021 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(20)Tj
0 Tc 0 Tw 4.021 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(21)Tj
0 Tc 0 Tw 4.021 0 Td
(6)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
(Generalized edema)Tj
0 Tc 0 Tw 12.693 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(3)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
[(P)18 (ericardial effusion)]TJ
0 Tc 0 Tw 12.693 0 Td
(3)Tj
3.783 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
(Congestive heart failure/)Tj
0 Tc 0 Tw 7.2 0 0 8 396.7015 304.7725 Tm
( )Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF00090009>>> BDC 
7.2 0 0 8 324.0625 296.7725 Tm
[( )-996 ( )]TJ
EMC 
2.222 0 Td
[(cardiac d)-10 (ysfunction)]TJ
0 Tc 0 Tw 5.4 0 0 6 390.7781 299.5725 Tm
(a)Tj
7.2 0 0 8 424.452 304.7725 Tm
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(4)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -2.456 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y edema)]TJ
0 Tc 0 Tw 12.693 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(4)Tj
3.783 0 Td
(3)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(27)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(18)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(15)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(31)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(20)Tj
0 Tc 0 Tw 4.021 0 Td
(5)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(18)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
[(F)20 (a)-10 (tigue)]TJ
-0.005 Tc 0.005 Tw 13.705 0 Td
(19)Tj
0 Tc 0 Tw 4.021 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(20)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
3.783 0 Td
(9)Tj
3.783 0 Td
(3)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Dyspnea)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(20)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(15)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
3.783 0 Td
(3)Tj
3.783 0 Td
(3)Tj
-0.01 Tc 0.024 Tw -32.86 -1.456 Td
(Musculoskeletal pain)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(11)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
3.783 0 Td
(8)Tj
3.783 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Nausea)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(19)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(23)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(21)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
-0.01 Tc 0.024 Tw -32.86 -1.456 Td
(Skin rash)Tj
0 Tc 0 Tw 5.4 0 0 6 348.506 206.3572 Tm
(b)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 422.742 203.5572 Tm
(15)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(16)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(21)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Arthralgia)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(10)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
3.783 0 Td
(5)Tj
3.783 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.019 Tw -32.86 -1.456 Td
[(Infection \(inc)20 (luding bacterial,)37 ( viral,)]TJ
0 Tc 0 Tw 7.2 0 0 8 412.56 180.2534 Tm
( )Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 324.0625 172.2534 Tm
( )Tj
EMC 
1.25 0 Td
[(fungal,)37 ( and non-specified\))]TJ
-0.005 Tc 0.005 Tw 12.455 1 Td
(10)Tj
0 Tc 0 Tw 4.021 0 Td
(6)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(14)Tj
0 Tc 0 Tw 4.021 0 Td
(7)Tj
3.783 0 Td
(9)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -2.456 Td
[(Hemorrha)-9.9 (ge)]TJ
-0.005 Tc 0.005 Tw 13.705 0 Td
(26)Tj
0 Tc 0 Tw 4.021 0 Td
(8)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(19)Tj
0 Tc 0 Tw 4.021 0 Td
(9)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(24)Tj
0 Tc 0 Tw 4.021 0 Td
(9)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
(Gastrointestinal bleeding)Tj
0 Tc 0 Tw 12.693 0 Td
(8)Tj
3.783 0 Td
(6)Tj
3.783 0 Td
(9)Tj
3.783 0 Td
(7)Tj
3.783 0 Td
(9)Tj
3.783 0 Td
(3)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
(CNS bleeding)Tj
0 Tc 0 Tw 12.693 0 Td
(1)Tj
3.783 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(3)Tj
3.783 0 Td
(3)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
[(V)18 (omiting)]TJ
-0.005 Tc 0.005 Tw 13.705 0 Td
(11)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(12)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(15)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Pyrexia)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(11)Tj
0 Tc 0 Tw 4.021 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(18)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
3.783 0 Td
(6)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -32.86 -1.456 Td
[(F)24 (ebrile neutropenia)]TJ
0 Tc 0 Tw 13.943 0 Td
(4)Tj
3.783 0 Td
(4)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(12)Tj
3.783 0 Td
(12)Tj
3.783 0 Td
(12)Tj
3.783 0 Td
(12)Tj
5.4 0 0 6 324.125 92.45 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.145 Tw 7.2 0 0 8 327.725 89.65 Tm
[(Inc)20 (ludes ventricular d)-10 (ysfunction,)37 ( cardiac failure,)37 ( cardiac failure congestive,)37 ( cardiomyopa)-10 (thy)55 (,)32 ( )]TJ
0.656 Tw 0 -1 Td
[(congestive cardiomyopa)-10 (thy)55 (,)37 ( diastolic d)-10 (ysfunction,)37 ( ejection fraction decreased,)37 ( and)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576 81.65 Tm
( )Tj
-0.005 Tc 7.2 0 0 8 327.725 73.65 Tm
(ventricular failure.)Tj
0.005 Tw 5.4 0 0 6 324.125 66.65 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.027 Tw 7.2 0 0 8 327.725 63.85 Tm
[(Inc)20 (ludes drug eruption,)37 ( er)-18 (ythema,)37 ( er)-18 (ythema multiforme,)37 ( er)-18 (ythrosis,)37 ( exfolia)-10 (tive rash,)37 ( generalized)-5 ( )]TJ
0.334 Tw 0 -1 Td
[(er)-18 (ythema,)37 ( genital rash,)37 ( )0.5 (hea)-10 (t rash,)37 ( milia,)37 ( rash,)37 ( rash er)-17.9 (ythema)-10 (tous,)37 ( rash )0.5 (follicular)74 (,)37 ( rash)-5 ( )]TJ
0.062 Tw 0 -1 Td
[(generalized,)36.9 ( rash macular)74 (,)37 ( rash maculopa)-10 (pular)74 (,)37 ( rash pa)-10 (pular)74 (,)37 ( rash pruritic,)37 ( rash pustular)74 (,)37 ( skin)-5 ( )]TJ
0 Tw 0 -1 Td
[(exfolia)-9.9 (tion,)37 ( skin irrita)-10 (tion,)37 ( urticaria vesiculosa,)36.9 ( and rash vesicular)74 (.)]TJ
ET
endstreamendobj109 0 obj<</Length 30380>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 36 727.248 Tm
(5.8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(T)74 (umor L)37.1 (ysis Syndrome)]TJ
/T1_1 1 Tf
0.105 Tw -3.375 -1.36 Td
[(T)74 (umor lysis syndrome has been reported in pa)-10 (tients with resistance to prior ima)-9.9 (tinib)-10 ( )]TJ
-0.012 Tw 0 -1 Td
[(thera)-10 (py)55 (,)37 ( primarily in advanced phase disease.)37 ( Due to potential for tumor lysis syndrome,)27 ( )]TJ
0.168 Tw 0 -1 Td
[(maintain adequa)-9.9 (te hydra)-10 (tion,)37 ( correct uric acid levels prior to initia)-10 (ting thera)-10 (py with)-10 ( )]TJ
0.071 Tw 0 -1 Td
[(SPR)18 (YCEL,)37 ( and monitor electrolyte )0.5 (levels.)37 ( P)18 (a)-10 (tients )0.5 (with )0.5 (advanced sta)-9.9 (ge disease )0.5 (and/or)-9.9 ( )]TJ
0.048 Tw 0 -1 Td
[(high tumor burden may be a)-9.9 (t increased risk and should be monitored more frequently)-10 ( )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 0 -1 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 3.517 0 Td
(e Reaction)Tj
0 Tc (s)Tj
-0.01 Tc 4.184 0 Td
( \(6.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -8.347 -1.697 Td
(5.9)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Embr)-17.9 (yo-F)20 (etal T)74 (oxicity)]TJ
/T1_1 1 Tf
0.055 Tw -3.375 -1.36 Td
[(Based )0.5 (on )0.5 (limited )0.5 (human )0.5 (da)-9.9 (ta,)37 ( )0.5 (SPR)18 (YCEL )0.5 (can )0.5 (cause )0.5 (fetal )0.5 (harm )0.5 (when )0.5 (administered )0.5 (to )0.5 (a)-10 ( )]TJ
0.034 Tw 0 -1 Td
[(pregnant woman.)37 ( )37.1 (Adverse pharmacologic effects of SPR)18 (YCEL inc)20 (luding hydrops fetalis,)27 ( )]TJ
-0.04 Tw 0 -1 Td
[(fetal leukopenia,)37 ( and fetal thromboc)20 (ytopenia ha)-10 (ve been reported with ma)-10 (ternal exposure)-10 ( )]TJ
-0.006 Tw 0 -1 Td
[(to SPR)18 (YCEL.)37 ( )36.7 (Advise females of reproductive potential and males with female partners \of)-10 ( )]TJ
-0.029 Tw 0 -1 Td
[(reproductive potential )0.5 (to use effective contraception during trea)-10 (tment with )0.5 (SPR)18 (YCEL )0.5 (and)-10 ( )]TJ
0 Tw 0 -1 Td
(for 30 days after the last dose )Tj
/T1_2 1 Tf
0 Tc ([)Tj
11.228 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
(ee U)Tj
0 Tc (s)Tj
-0.01 Tc 2.004 0 Td
[(e in Speci\037c P)18 (opula)-10 (tion)]TJ
0 Tc (s)Tj
-0.01 Tc 8.785 0 Td
[( \(8.1,)37 ( 8.3\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -22.413 -1.697 Td
(5.10)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Effects on Growth and Development in P)24 (ediatric P)23.9 (atients)]TJ
/T1_1 1 Tf
0.038 Tw -3.375 -1.383 Td
[(In pedia)-10 (tric trials of SPR)18 (YCEL in chronic phase CML after a)-10 (t least 2 years of trea)-10 (tment,)27 ( )]TJ
0.192 Tw 0 -1 Td
[(adverse reactions associa)-10 (ted with bone gro)-9.9 (wth and development were reported in)-10 ( )]TJ
0.07 Tw 0 -1 Td
[(5\032)-70.3 (\(5.2%\) pa)-10 (tients,)37 ( one of which was severe in intensity \(Gro)-9.9 (wth Retarda)-10 (tion Grade\032)-70.4 (3\).)27 ( )]TJ
0.327 Tw 0 -1 Td
[(These 5 cases inc)20 (luded cases of epiphyses delayed fusion,)37 ( osteopenia,)37 ( gro)-10 (wth)-10 ( )]TJ
0.302 Tw 0 -1 Td
[(retarda)-10 (tion,)37 ( and g)-10 (ynecomastia )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
12.311 0 Td
(s)Tj
-0.01 Tc 0.265 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.302 Tw 3.819 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.302 Tw 4.486 0 Td
( \(6.1\) and U)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.302 Tw 5.475 0 Td
[(e in Speci\037c)-10 ( )]TJ
0.01 Tw -26.488 -1 Td
[(P)18 (opula)-10 (tion)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.043 Tw 4.158 0 Td
[( )0.5 (\(8.4\)])]TJ
/T1_1 1 Tf
[(.)37 ( )0.5 (Of )0.5 (these 5 )0.5 (cases,)37 ( 1 )0.5 (case of osteopenia and 1 )0.5 (case of g)-10 (ynecomastia)-10 ( )]TJ
0 Tw -4.158 -1 Td
[(resolved during trea)-10 (tment.)]TJ
0 -1.427 Td
[(Monitor bone gro)-10 (wth and development in pedia)-10 (tric pa)-10 (tients.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.697 Td
(5.11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Hepatotoxicity)Tj
/T1_1 1 Tf
0.121 Tw -3.375 -1.383 Td
[(SPR)18 (YCEL may cause hepa)-10 (totoxicity as measured by eleva)-10 (tions in bilirubin,)37 ( asparta)-10 (te)-9.9 ( )]TJ
0.03 Tw 0 -1 Td
[(aminotransferase \(AST\),)37 ( alanine aminotransferase \(AL)94 (T\),)37 ( and alkaline phospha)-9.9 (tase )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
30.225 0 Td
(s)Tj
-0.01 Tc 0.01 Tw 0.397 0 Td
[(ee)-10 ( )]TJ
-30.622 -1 Td
(Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.007 Tw 2.456 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.007 Tw 4.177 0 Td
( \(6.1\)])Tj
/T1_1 1 Tf
[(.)37 ( Monitor transaminases a)-9.9 (t baseline and monthly or as c)20 (linically)-10 ( )]TJ
-0.043 Tw -6.633 -1 Td
[(indica)-9.9 (ted during trea)-9.9 (tment.)37 ( Reduce dose,)37 ( withhold,)37 ( or permanently discontinue SPR)18 (YCEL)-9.9 ( )]TJ
-0.026 Tw 0 -1 Td
(based on severity )Tj
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
6.706 0 Td
(s)Tj
-0.01 Tc -0.026 Tw 0.397 0 Td
(ee Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.063 Tw 2.449 0 Td
[(a)-10 (ge )-37.3 (and Admini)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.026 Tw 5.935 0 Td
[(tra)-9.9 (tion \(2.5\)])]TJ
/T1_1 1 Tf
[(.)37 ( )36.7 (When SPR)18 (YCEL is administered)-9.9 ( )]TJ
0.069 Tw -15.487 -1 Td
[(in )0.5 (combina)-10 (tion )0.5 (with )0.5 (chemothera)-9.9 (py)55 (,)37 ( )0.5 (liver )0.5 (toxicity )0.5 (in the )0.5 (form )0.5 (of )0.5 (transaminase )0.5 (eleva)-10 (tion)-10 ( )]TJ
0.047 Tw 0 -1 Td
[(and hyperbilirubinemia has been obser)-18 (ved.)37 ( Monitor hepa)-9.9 (tic function when SPR)18 (YCEL is)-10 ( )]TJ
0 Tw 0 -1 Td
[(used in combina)-10 (tion with chemothera)-10 (py)55 (.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -2.17 Td
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(ADVERSE REACTIONS)Tj
/T1_1 1 Tf
0.081 Tw -3.375 -1.653 Td
[(The follo)-9.9 (wing c)20 (linically signi\037cant adverse reactions are discussed in grea)-10 (ter detail in)-10 ( )]TJ
0 Tw 0 -1 Td
(other sections of the labeling:)Tj
-0.018 Tc 0.018 Tw 0 -1.171 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.625 0 Td
(Myelosuppression )Tj
/T1_2 1 Tf
0.464 Tw 7.06 0 Td
[([see )0.5 (Dosa)-10 (ge and )37.5 (Administra)-10 (tion )0.5 (\(2.5\) and )37.4 (W)18 (arnings )0.5 (and)-18 ( )]TJ
0 Tw -7.06 -1 Td
(Precautions \(5.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(Bleeding-rela)-10 (ted events )]TJ
/T1_2 1 Tf
[([see )37 (W)18 (arnings and Precautions \(5.2\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
(Fluid retention )Tj
/T1_2 1 Tf
[([see )37 (W)18 (arnings and Precautions \(5.3\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
(Cardiovascular toxicity )Tj
/T1_2 1 Tf
[([see )37 (W)18 (arnings and Precautions \(5.4\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(Pulmonar)-18 (y arterial hypertension )]TJ
/T1_2 1 Tf
[([see )36.9 (W)18.1 (arnings and Precautions \(5.5\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(QT prolonga)-9.9 (tion )]TJ
/T1_2 1 Tf
[([see )37 (W)18 (arnings and Precautions \(5.6\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(Severe derma)-10 (tologic reactions )]TJ
/T1_2 1 Tf
[([see )37 (W)18.1 (arnings and Precautions \(5.7\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(T)74 (umor lysis syndrome )]TJ
/T1_2 1 Tf
[([see )37 (W)18.1 (arnings and Precautions \(5.8\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.29 Tw 1.625 0 Td
[(Effects on gro)-9.9 (wth and development in pedia)-10 (tric pa)-10 (tients )]TJ
/T1_2 1 Tf
0.253 Tw [([see W)18 (arnings )-36.9 (and)-10 ( )]TJ
0 Tw 0 -1 Td
(Precautions \(5.10\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.625 0 Td
[(Hepa)-10 (totoxicity )]TJ
/T1_2 1 Tf
0 Tw 5.299 0 Td
[([see )37 (W)18 (arnings and Precautions \(5.11\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -6.924 -1.643 Td
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Clinical T)74 (rials Experience)]TJ
/T1_1 1 Tf
0.004 Tw 8.08 0 0 8.08 36 275.308 Tm
[(Because c)20 (linical trials )0.5 (are conducted )0.5 (under )0.5 (widely )0.5 (var)-18 (ying conditions,)37 ( )0.5 (adverse reaction)-10 ( )]TJ
-0.015 Tw 0 -1 Td
[(ra)-10 (tes obser)-17.9 (ved in the c)20.1 (linical trials of a drug cannot be directly compared to ra)-10 (tes in the)-10 ( )]TJ
0 Tw 0 -1 Td
[(c)20 (linical trials of another drug and may not re\035ect the ra)-10 (tes obser)-18 (ved in practice.)]TJ
0.071 Tw 0 -1.512 Td
[(The da)-10 (ta described belo)-10 (w re\035ect exposure to SPR)18 (YCEL administered as single-a)-9.9 (gent)-10 ( )]TJ
0.106 Tw 0 -1 Td
[(thera)-10 (py a)-10 (t all doses tested in c)20 (linical studies \(n=2809\),)37 ( inc)20 (luding 324 adult pa)-10 (tients)-10 ( )]TJ
-0.044 Tw 0 -1 Td
[(with newly dia)-9.9 (gnosed chronic phase CML,)37 ( 2388 adult pa)-10 (tients with ima)-10 (tinib-resistant or)-10 ( )]TJ
0.02 Tw 0 -1 Td
(-intolerant chronic or advanced phase CML or Ph)Tj
0 Tc 0 Tw 17.766 0.124 Td
(+)Tj
-0.01 Tc 0.02 Tw 0.59 -0.124 Td
[( )37.3 (ALL,)37 ( and 97 pedia)-10 (tric pa)-9.9 (tients with)-10 ( )]TJ
0.079 Tw -18.356 -1 Td
[(chronic )0.5 (phase )0.5 (CML.)37 ( )37.5 (The )0.5 (median )0.5 (dura)-9.9 (tion )0.6 (of )0.5 (thera)-10 (py )0.5 (in )0.5 (a )0.5 (total )0.5 (of )0.5 (2712 )0.6 (adult )0.5 (pa)-9.9 (tients)-10 ( )]TJ
-0.008 Tw 0 -1 Td
[(was 19.2 months \(range 0 to 93.2 months\).)37.1 ( In a randomized trial in pa)-9.9 (tients with newly)-10 ( )]TJ
0.055 Tw 0 -1 Td
[(dia)-9.9 (gnosed chronic phase CML,)37 ( the median dura)-10 (tion of thera)-10 (py was a)-10 (pproxima)-9.9 (tely 60)-10 ( )]TJ
-0.017 Tw 0 -1 Td
[(months.)37 ( )37.4 (The median dura)-10 (tion of thera)-10 (py in 1618 adult pa)-9.9 (tients with chronic phase CML)-9.9 ( )]TJ
0 Tw 0 -1 Td
(was 29 months \(range 0 to 92.9 months\).)Tj
0.084 Tw 0 -1.512 Td
[(The )0.5 (median )0.5 (dura)-10 (tion of thera)-10 (py )0.5 (in 1094 adult pa)-9.9 (tients )0.5 (with advanced )0.5 (phase CML or)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.124 Td
(+)Tj
-0.01 Tc 0.59 -0.124 Td
[( )37 (ALL was 6.2 months \(range 0 to 93.2 months\).)]TJ
0.312 Tw -1.514 -1.512 Td
[(In two non-randomized trials in 97 pedia)-10 (tric pa)-9.9 (tients with chronic phase CML)-9.9 ( )]TJ
0 Tc 0 Tw 8.08 0 0 8.08 288 149.7681 Tm
( )Tj
-0.01 Tc 0.245 Tw 8.08 0 0 8.08 36 141.688 Tm
[(\(51 pa)-10 (tients newly dia)-9.9 (gnosed and 46 pa)-10 (tients resistant or intolerant to previous)-10 ( )]TJ
0.183 Tw 0 -1 Td
[(trea)-10 (tment with ima)-9.9 (tinib\),)37 ( the median dura)-10 (tion of thera)-10 (py was 51.1 months \(range)-10 ( )]TJ
0 Tc 0 Tw 8.08 0 0 8.08 288 133.608 Tm
( )Tj
-0.01 Tc 8.08 0 0 8.08 36 125.5281 Tm
(1.9 to 99.6 months\).)Tj
0.052 Tw 0 -1.512 Td
[(In the overall popula)-10 (tion of 2712 adult pa)-10 (tients,)37 ( 88% of pa)-10 (tients experienced adverse)-10 ( )]TJ
0.067 Tw 0 -1 Td
[(reactions a)-10 (t some time and 19% experienced adverse reactions leading to trea)-9.9 (tment)-10 ( )]TJ
0.01 Tw 0 -1 Td
[(discontinua)-10 (tion.)]TJ
-0.011 Tw 0 -1.512 Td
[(In the randomized )0.5 (trial in adult )0.5 (pa)-10 (tients with )0.5 (newly dia)-9.9 (gnosed chronic phase CML,)37 ( drug)-10 ( )]TJ
-0.057 Tw 0 -1 Td
[(was )0.5 (discontinued )0.5 (for )0.5 (adverse reactions in )0.5 (16% )0.5 (of pa)-10 (tients with a )0.5 (minimum of 60 )0.5 (months)-9.9 ( )]TJ
-0.045 Tw 0 -1 Td
[(of follo)-10 (w-up.)37 ( )37.1 (After a minimum of 60 months of follo)-9.9 (w-up,)37 ( the cumula)-10 (tive discontinua)-10 (tion)-10 ( )]TJ
-0.02 Tw 0 -1 Td
[(ra)-10 (te was 39%.)37 ( )37.1 (Among the 1618 pa)-10 (tients with chronic phase CML,)37 ( drug-rela)-10 (ted adverse)-10 ( )]TJ
0.012 Tw 0 -1 Td
[(reactions leading to discontinua)-10 (tion were reported in 329 \(20.3%\) pa)-10 (tients; among the)-10 ( )]TJ
0.066 Tw 0 -1 Td
[(1094 )0.5 (pa)-9.9 (tients )0.5 (with advanced phase )0.5 (CML )0.5 (or Ph)]TJ
0 Tc 0 Tw 17.28 0.124 Td
(+)Tj
-0.01 Tc 0.066 Tw 0.59 -0.124 Td
[( )37.5 (ALL,)37 ( )0.5 (drug-rela)-10 (ted )0.5 (adverse )0.5 (reactions)-10 ( )]TJ
0 Tw -17.87 -1 Td
[(leading to discontinua)-10 (tion were reported in 191 \(17.5%\) pa)-9.9 (tients.)]TJ
0.475 Tw 35.644 85.488 Td
[(Among the 97 pedia)-10 (tric subjects,)37 ( drug-rela)-10 (ted adverse reactions leading to)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(discontinua)-10 (tion were reported in 1 pa)-9.9 (tient \(1%\).)]TJ
0.07 Tw 0 -1.518 Td
[(Adverse reactions reported in \03610% of adult pa)-10 (tients,)37 ( and other adverse reactions of)-10 ( )]TJ
-0.005 Tw 0 -1.006 Td
[(interest,)37 ( in a randomized trial in pa)-10 (tients with newly dia)-10 (gnosed chronic phase CML a)-9.9 (t a)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(median follo)-10 (w-up of a)-10 (pproxima)-9.9 (tely 60 months are presented in )37 (T)74 (able 6.)]TJ
-0.023 Tw 0 -1.518 Td
[(Adverse reactions reported in \03610% of adult pa)-10 (tients trea)-10 (ted a)-10 (t the recommended dose)-10 ( )]TJ
-0.002 Tw 0 -1.006 Td
[(of 100 mg once daily \(n=165\),)37 ( and other adverse reactions of interest,)37 ( in a randomized)-10 ( )]TJ
0.129 Tw 0 -1.006 Td
[(dose-optimiza)-10 (tion trial of pa)-10 (tients with chronic phase CML resistant or intolerant to)-10 ( )]TJ
-0.017 Tw 0 -1.006 Td
[(prior ima)-10 (tinib thera)-10 (py a)-10 (t a median follo)-9.9 (w-up of a)-10 (pproxima)-10 (tely 84 months are presented)-10 ( )]TJ
-0.037 Tw 0 -1.006 Td
[(in T)74 (able )-37 (8.)]TJ
0.151 Tw 0 -1.518 Td
[(Adverse reactions reported in \03610% of pedia)-10 (tric pa)-10 (tients a)-9.9 (t a median follo)-9.9 (w-up of)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(a)-10 (pproxima)-9.9 (tely 51.1 months are presented in )37 (T)74 (able 11.)]TJ
-0.047 Tw 0 -1.518 Td
[(Drug-rela)-10 (ted serious adverse reactions \(SARs\) were reported for 16.7% of adult \pa)-10 (tients)-10 ( )]TJ
0.066 Tw 0 -1.006 Td
[(in )0.5 (the )0.5 (randomized )0.5 (trial )0.5 (of )0.5 (pa)-10 (tients )0.5 (with )0.6 (newly )0.5 (dia)-10 (gnosed )0.5 (chronic )0.5 (phase )0.5 (CML.)37.1 ( )0.5 (Serious)-9.9 ( )]TJ
0 Tw 0 -1.006 Td
[(adverse reactions reported in \0365% of pa)-10 (tients inc)20.1 (luded pleural effusion \(5%\).)]TJ
0.078 Tw 0 -1.518 Td
[(Drug-rela)-10 (ted SARs were reported for 26.1% of pa)-9.9 (tients trea)-10 (ted a)-10 (t the recommended)-9.9 ( )]TJ
0.05 Tw 0 -1.006 Td
[(dose of 100 mg once )0.5 (daily in the randomized dose-optimiza)-10 (tion trial of adult )0.5 (pa)-10 (tients)-10 ( )]TJ
-0.031 Tw 0 -1.006 Td
[(with chronic phase CML resistant or intolerant to prior ima)-10 (tinib thera)-9.9 (py)55.1 (.)37 ( Serious adverse)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(reactions reported in \0365% of pa)-10 (tients inc)20 (luded pleural effusion \(10%\).)]TJ
0 -1.518 Td
[(Drug-rela)-10 (ted SARs were reported for 14.4% of pedia)-9.9 (tric pa)-10 (tients.)]TJ
/T1_0 1 Tf
8 0 0 8 324 535.2371 Tm
(Chronic Myeloid Leukemia \(CML\))Tj
/T1_1 1 Tf
0.366 Tw 0 -1.298 Td
[(Adverse reactions \(exc)20.1 (luding labora)-9.9 (tor)-18 (y abnormalities\) tha)-9.9 (t were reported in a)-10 (t)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.13 Tw -31.5 -1.006 Td
[(least 10% of adult pa)-9.9 (tients are sho)-10 (wn in )37.3 (T)74 (able 6 for newly dia)-10 (gnosed pa)-9.9 (tients with)-10 ( )]TJ
0.004 Tw 0 -1.006 Td
[(chronic phase CML and )36.8 (T)74 (ables 8 and 10 for CML pa)-10 (tients with resistance or intolerance)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(to prior ima)-10 (tinib thera)-9.9 (py)55 (.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 491.669 252 -25.312 re
324 466.357 81.72 -12.912 re
405.72 466.357 85.14 -12.912 re
490.86 466.357 85.14 -12.912 re
324 453.445 81.72 -20.912 re
405.72 453.445 42.57 -20.912 re
448.29 453.445 42.57 -20.912 re
490.86 453.445 42.57 -20.912 re
533.43 453.445 42.57 -20.912 re
324 432.533 81.72 -12.912 re
405.72 432.533 170.28 -12.912 re
324 419.621 81.72 -11.688 re
405.72 419.621 42.57 -11.688 re
448.29 419.621 42.57 -11.688 re
490.86 419.621 42.57 -11.688 re
533.43 419.621 42.57 -11.688 re
324 407.933 81.72 -11.688 re
405.72 407.933 42.57 -11.688 re
448.29 407.933 42.57 -11.688 re
490.86 407.933 42.57 -11.688 re
533.43 407.933 42.57 -11.688 re
324 396.245 81.72 -11.688 re
405.72 396.245 42.57 -11.688 re
448.29 396.245 42.57 -11.688 re
490.86 396.245 42.57 -11.688 re
533.43 396.245 42.57 -11.688 re
324 384.557 81.72 -11.688 re
405.72 384.557 42.57 -11.688 re
448.29 384.557 42.57 -11.688 re
490.86 384.557 42.57 -11.688 re
533.43 384.557 42.57 -11.688 re
324 372.869 81.72 -11.688 re
405.72 372.869 42.57 -11.688 re
448.29 372.869 42.57 -11.688 re
490.86 372.869 42.57 -11.688 re
533.43 372.869 42.57 -11.688 re
324 361.181 81.72 -11.688 re
405.72 361.181 42.57 -11.688 re
448.29 361.181 42.57 -11.688 re
490.86 361.181 42.57 -11.688 re
533.43 361.181 42.57 -11.688 re
324 349.493 81.72 -19.688 re
405.72 349.493 42.57 -19.688 re
448.29 349.493 42.57 -19.688 re
490.86 349.493 42.57 -19.688 re
533.43 349.493 42.57 -19.688 re
324 329.806 81.72 -11.688 re
405.72 329.806 42.57 -11.688 re
448.29 329.806 42.57 -11.688 re
490.86 329.806 42.57 -11.688 re
533.43 329.806 42.57 -11.688 re
324 318.118 81.72 -11.688 re
405.72 318.118 42.57 -11.688 re
448.29 318.118 42.57 -11.688 re
490.86 318.118 42.57 -11.688 re
533.43 318.118 42.57 -11.688 re
324 306.43 81.72 -11.688 re
405.72 306.43 42.57 -11.688 re
448.29 306.43 42.57 -11.688 re
490.86 306.43 42.57 -11.688 re
533.43 306.43 42.57 -11.688 re
324 294.742 81.72 -11.688 re
405.72 294.742 42.57 -11.688 re
448.29 294.742 42.57 -11.688 re
490.86 294.742 42.57 -11.688 re
533.43 294.742 42.57 -11.688 re
324 283.054 81.72 -11.688 re
405.72 283.054 42.57 -11.688 re
448.29 283.054 42.57 -11.688 re
490.86 283.054 42.57 -11.688 re
533.43 283.054 42.57 -11.688 re
324 271.366 81.72 -11.688 re
405.72 271.366 42.57 -11.688 re
448.29 271.366 42.57 -11.688 re
490.86 271.366 42.57 -11.688 re
533.43 271.366 42.57 -11.688 re
324 259.678 81.72 -11.688 re
405.72 259.678 42.57 -11.688 re
448.29 259.678 42.57 -11.688 re
490.86 259.678 42.57 -11.688 re
533.43 259.678 42.57 -11.688 re
324 247.99 81.72 -11.688 re
405.72 247.99 42.57 -11.688 re
448.29 247.99 42.57 -11.688 re
490.86 247.99 42.57 -11.688 re
533.43 247.99 42.57 -11.688 re
324 236.302 81.72 -11.688 re
405.72 236.302 42.57 -11.688 re
448.29 236.302 42.57 -11.688 re
490.86 236.302 42.57 -11.688 re
533.43 236.302 42.57 -11.688 re
324 224.614 81.72 -11.688 re
405.72 224.614 42.57 -11.688 re
448.29 224.614 42.57 -11.688 re
490.86 224.614 42.57 -11.688 re
533.43 224.614 42.57 -11.688 re
324 212.926 81.72 -11.688 re
405.72 212.926 42.57 -11.688 re
448.29 212.926 42.57 -11.688 re
490.86 212.926 42.57 -11.688 re
533.43 212.926 42.57 -11.688 re
324 201.239 81.72 -11.688 re
405.72 201.239 42.57 -11.688 re
448.29 201.239 42.57 -11.688 re
490.86 201.239 42.57 -11.688 re
533.43 201.239 42.57 -11.688 re
324 189.551 81.72 -11.688 re
405.72 189.551 42.57 -11.688 re
448.29 189.551 42.57 -11.688 re
490.86 189.551 42.57 -11.688 re
533.43 189.551 42.57 -11.688 re
324 177.863 81.72 -11.688 re
405.72 177.863 42.57 -11.688 re
448.29 177.863 42.57 -11.688 re
490.86 177.863 42.57 -11.688 re
533.43 177.863 42.57 -11.688 re
324 166.175 81.72 -11.688 re
405.72 166.175 42.57 -11.688 re
448.29 166.175 42.57 -11.688 re
490.86 166.175 42.57 -11.688 re
533.43 166.175 42.57 -11.688 re
324 154.487 81.72 -11.688 re
405.72 154.487 42.57 -11.688 re
448.29 154.487 42.57 -11.688 re
490.86 154.487 42.57 -11.688 re
533.43 154.487 42.57 -11.688 re
324 142.799 252 -71.072 re
f
0 0 0 1 K
0.5 w 
/GS2 gs
q 1 0 0 1 490.86 419.621 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 407.9331 cm
0 0 m
0 11.438 l
S
Q
q 1 0 0 1 533.43 419.621 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 396.2451 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 384.5573 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 372.8693 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 349.4935 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 329.8056 cm
0 0 m
0 19.688 l
S
Q
q 1 0 0 1 490.86 318.1177 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 306.4297 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 271.366 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 259.6781 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 247.9902 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 236.3023 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 224.6143 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 212.9265 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 201.2385 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 189.5506 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 177.8627 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 166.1748 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 154.4869 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 143.299 cm
0 0 m
0 11.188 l
S
Q
1 w 
q 1 0 0 1 490.86 142.799 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 533.43 142.799 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 466.3567 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 533.43 466.3567 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 490.86 361.1814 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 453.4448 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 533.43 453.4448 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 432.5329 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 533.43 432.5329 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 283.0539 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 294.7418 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 448.29 453.4448 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 432.7829 cm
0 0 m
0 20.412 l
S
Q
q 1 0 0 1 448.29 432.5329 cm
0 0 m
42.57 0 l
S
Q
1 w 
q 1 0 0 1 324 142.799 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 405.72 142.799 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 448.29 142.799 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 324 71.7271 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 405.72 71.7271 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 448.29 71.7271 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 71.7271 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 533.43 71.7271 cm
0 0 m
42.57 0 l
S
Q
1 w 
q 1 0 0 1 405.72 466.3567 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 448.29 466.3567 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 490.86 453.6948 cm
0 0 m
0 12.162 l
S
Q
1 w 
q 1 0 0 1 324 466.3567 cm
0 0 m
81.72 0 l
S
Q
0.5 w 
q 1 0 0 1 405.72 453.4448 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 405.72 432.5329 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 324 419.621 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 405.72 419.621 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 448.29 419.621 cm
0 0 m
42.57 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0.248 Tw 8 0 0 8 324 485.9567 Tm
[(Table )224 (6:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Adverse Reactions Reported in \03610% of Adult Patients with)-10 ( )]TJ
-0.025 Tc 0.206 Tw 0 -1 Td
[(N)-15 (e)-15 (w)-15 (l)-15 (y)-14.9 ( )-14.6 (Diagnosed )0.5 (Chronic Phase )0.5 (CML )0.5 (\(minimum of 60 )0.5 (months)-25 ( )]TJ
0.025 Tw 0 -1 Td
(follow-up\))Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 434.1361 457.0448 Tm
(All Grades)Tj
11.944 0 Td
(Grade 3/4)Tj
0.02 Tw -14.672 -1.614 Td
(SPRYCEL)Tj
0 Tc 0 Tw 7.2 0 0 8 439.5148 444.1329 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 416.162 436.1329 Tm
(\(n=258\))Tj
5.835 1 Td
(Imatinib)Tj
0 Tc 0 Tw 7.2 0 0 8 480.7286 444.1329 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 458.607 436.1329 Tm
(\(n=258\))Tj
5.716 1 Td
(SPRYCEL)Tj
0 Tc 0 Tw 7.2 0 0 8 524.7798 444.1329 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 501.427 436.1329 Tm
(\(n=258\))Tj
5.835 1 Td
(Imatinib)Tj
0 Tc 0 Tw 7.2 0 0 8 565.9936 444.1329 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 543.8719 436.1329 Tm
(\(n=258\))Tj
-0.01 Tc 0.024 Tw -30.538 -1.614 Td
[(Adverse Reaction)-10 ( )]TJ
-0.02 Tc 18.788 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc -18.788 -1.537 Td
(Fluid retention)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(38)Tj
5.895 0 Td
(45)Tj
0 Tc 0 Tw 6.417 0 Td
(5)Tj
5.913 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 12.579 0 Td
(28)Tj
0 Tc 0 Tw 6.133 0 Td
(1)Tj
6.18 0 Td
(3)Tj
5.913 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Superficial localized edema)Tj
-0.005 Tc 0.005 Tw 12.579 0 Td
(14)Tj
5.895 0 Td
(38)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.756 -1.461 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y hypertension)]TJ
0 Tc 0 Tw 12.816 0 Td
(5)Tj
-0.005 Tc 0.005 Tw 5.598 0 Td
(<1)Tj
0 Tc 0 Tw 6.477 0 Td
(1)Tj
5.913 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Generalized edema)Tj
0 Tc 0 Tw 12.816 0 Td
(4)Tj
5.895 0 Td
(7)Tj
6.18 0 Td
(0)Tj
5.913 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
[(P)18 (ericardial effusion)]TJ
0 Tc 0 Tw 12.816 0 Td
(4)Tj
5.895 0 Td
(1)Tj
6.18 0 Td
(1)Tj
5.913 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Congestive heart failure/)Tj
0 Tc 0 Tw 7.2 0 0 8 396.639 340.7936 Tm
( )Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF00090009>>> BDC 
7.2 0 0 8 324 332.7936 Tm
[( )-996 ( )]TJ
EMC 
2.083 0 Td
[(cardiac d)-10 (ysfunction)]TJ
0 Tc 0 Tw 5.4 0 0 6 389.7156 335.5936 Tm
(a)Tj
7.2 0 0 8 425.277 340.7936 Tm
(2)Tj
5.895 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 5.882 0 Td
(<1)Tj
5.912 0 Td
(<1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.756 -2.461 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y edema)]TJ
0 Tc 0 Tw 12.816 0 Td
(1)Tj
5.895 0 Td
(0)Tj
6.18 0 Td
(0)Tj
5.913 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(22)Tj
5.895 0 Td
(23)Tj
0 Tc 0 Tw 6.417 0 Td
(1)Tj
5.913 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -32.054 -1.461 Td
(Musculoskeletal pain)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(14)Tj
5.895 0 Td
(17)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.01 Tw -31.756 -1.461 Td
(Rash)Tj
0 Tc 0 Tw 5.4 0 0 6 336.9094 288.8419 Tm
(b)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 423.5671 286.0419 Tm
(14)Tj
5.895 0 Td
(18)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
5.912 0 Td
(2)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(14)Tj
5.895 0 Td
(11)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -32.054 -1.461 Td
(Abdominal pain)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(11)Tj
0 Tc 0 Tw 6.133 0 Td
(8)Tj
6.18 0 Td
(0)Tj
5.912 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
[(F)20 (a)-10 (tigue)]TJ
-0.005 Tc 0.005 Tw 13.829 0 Td
(11)Tj
5.895 0 Td
(12)Tj
6.12 0 Td
(<1)Tj
0 Tc 0 Tw 6.21 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
(Nausea)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(10)Tj
5.895 0 Td
(25)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
[(My)-10 (algia)]TJ
0 Tc 0 Tw 14.066 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 5.658 0 Td
(12)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
(Arthralgia)Tj
0 Tc 0 Tw 14.066 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 5.658 0 Td
(10)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.01 Tw -31.756 -1.461 Td
[(Hemorrha)-9.9 (ge)]TJ
0 Tc 0 Tw 5.4 0 0 6 356.1327 207.0265 Tm
(c)Tj
7.2 0 0 8 425.277 204.2265 Tm
(8)Tj
5.895 0 Td
(8)Tj
6.18 0 Td
(1)Tj
5.912 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Gastrointestinal bleeding)Tj
0 Tc 0 Tw 12.816 0 Td
(2)Tj
5.895 0 Td
(2)Tj
6.18 0 Td
(1)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Other bleeding)Tj
0 Tc 0 Tw 5.4 0 0 6 371.0872 183.6507 Tm
(d)Tj
7.2 0 0 8 425.277 180.8507 Tm
(6)Tj
5.895 0 Td
(6)Tj
6.18 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.756 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(CNS bleeding)Tj
-0.005 Tc 0.005 Tw 12.519 0 Td
(<1)Tj
5.895 0 Td
(<1)Tj
0 Tc 0 Tw 6.477 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.01 Tw -31.756 -1.461 Td
[(V)18 (omiting)]TJ
0 Tc 0 Tw 14.066 0 Td
(5)Tj
-0.005 Tc 0.005 Tw 5.658 0 Td
(12)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -32.054 -1.461 Td
[(Musc)20 (le spasms)]TJ
0 Tc 0 Tw 14.066 0 Td
(5)Tj
-0.005 Tc 0.005 Tw 5.658 0 Td
(21)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
5.4 0 0 6 324 136.2871 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.047 Tw 7.2 0 0 8 329 133.4871 Tm
[(Inc)20 (ludes cardiac failure acute,)37 ( cardiac failure congestive,)37 ( cardiomyopa)-10 (thy)55 (,)37 ( diastolic d)-10 (ysfunction,)32 ( )]TJ
0 Tw 0 -1 Td
[(ejection fraction decreased,)36.9 ( and left ventricular d)-10 (ysfunction.)]TJ
0.005 Tw 5.4 0 0 6 324 119.5671 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.074 Tw 7.2 0 0 8 329 116.7671 Tm
[(Inc)20 (ludes er)-18 (ythema,)37 ( er)-18 (ythema multiforme,)37 ( rash,)37 ( rash generalized,)37 ( rash macular)74 (,)37 ( rash pa)-9.9 (pular)74 (,)32 ( )]TJ
0 Tw 0 -1 Td
[(rash pustular)74 (,)37 ( skin exfolia)-10 (tion,)37 ( and rash vesicular)74 (.)]TJ
0.005 Tw 5.4 0 0 6 324 102.8471 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 329 100.0471 Tm
[(Adverse reaction of special interest with <10% frequenc)20 (y)55 (.)]TJ
0.005 Tw 5.4 0 0 6 324 94.1271 Tm
(d)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.102 Tw 7.2 0 0 8 329 91.3271 Tm
[(Inc)20 (ludes conjunctival hemorrha)-10 (ge,)37 ( ear hemorrha)-9.9 (ge,)36.9 ( ecchymosis,)37 ( epistaxis,)37 ( eye hemorrha)-10 (ge,)32 ( )]TJ
0.073 Tw 0 -1 Td
[(gingival bleeding,)37 ( hema)-9.9 (toma,)37 ( hema)-10 (turia,)37 ( hemoptysis,)37 ( intra-abdominal hema)-10 (toma,)36.9 ( petechiae,)32 ( )]TJ
0 Tw 0 -1 Td
[(sc)20 (leral hemorrha)-10 (ge,)37 ( uterine hemorrha)-10 (ge,)37 ( and va)-9.9 (ginal hemorrha)-10 (ge.)]TJ
-0.01 Tc -0.03 Tw 8 0 0 8 324 52.0914 Tm
[(A )0.5 (comparison )0.5 (of )0.5 (cumula)-10 (tive )0.5 (ra)-10 (tes )0.5 (of )0.5 (adverse )0.5 (reactions )0.5 (reported )0.5 (in )0.5 (\03610% )0.5 (of )0.5 (pa)-9.9 (tients )0.5 (with)-10 ( )]TJ
0.034 Tw 0 -1.006 Td
[(minimum follo)-9.9 (w-up of 1 and 5 years in a randomized trial of newly dia)-9.9 (gnosed pa)-10 (tients)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(with chronic phase CML trea)-9.9 (ted with SPR)18 (YCEL are sho)-10 (wn in )37 (T)74 (able 7.)]TJ
ET
endstreamendobj108 0 obj<</Length 24855>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 0.465 Tw 8 0 0 8 36 727.2481 Tm
[(F)20 (or pedia)-10 (tric pa)-9.9 (tients with chronic phase CML,)37 ( if Grade \0363 neutropenia or)-9.9 ( )]TJ
0.366 Tw 0 -1.006 Td
[(thromboc)20 (ytopenia recurs during complete hema)-10 (tologic response \(CHR\),)36.9 ( interrupt)-10 ( )]TJ
0.15 Tw 0 -1.006 Td
[(SPR)18 (YCEL )0.5 (and )0.5 (resume )0.5 (a)-10 (t )0.5 (a )0.5 (reduced )0.5 (dose.)37 ( )0.5 (Implement )0.5 (temporar)-18 (y )0.5 (dose )0.5 (reductions )0.5 (for)-9.9 ( )]TJ
0 Tw 0 -1.006 Td
[(intermedia)-9.9 (te degrees of c)20 (ytopenia and disease response as needed.)]TJ
0.036 Tw 0 -1.434 Td
[(F)20 (or pedia)-9.9 (tric pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 10.652 0.125 Td
(+)Tj
-0.01 Tc 0.036 Tw 0.59 -0.125 Td
[( )36.9 (ALL,)37 ( if neutropenia and/or thromboc)20 (ytopenia result in a)-9.9 ( )]TJ
0 Tc 0 Tw 20.258 0 Td
( )Tj
-0.01 Tc 0.148 Tw -31.5 -1.006 Td
[(delay of the next block of trea)-10 (tment by more than 14 days,)37 ( interrupt SPR)18 (YCEL and)-10 ( )]TJ
-0.026 Tw 0 -1.006 Td
[(resume a)-10 (t the same dose level once the next block of trea)-9.9 (tment is started.)37 ( If neutropenia)-9.9 ( )]TJ
0.136 Tw 0 -1.006 Td
[(and/or thromboc)20 (ytopenia persist and the next block of trea)-9.9 (tment is delayed another)-9.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.13 Tw -31.5 -1.006 Td
[(7 days,)37 ( perform a bone marro)-9.9 (w assessment to assess cellularity and percenta)-10 (ge of)-10 ( )]TJ
0.222 Tw 0 -1.006 Td
[(blasts.)37 ( If marro)-10 (w cellularity is <10%,)37 ( interrupt trea)-10 (tment with SPR)18 (YCEL until )37 (ANC)-9.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.013 Tw -31.5 -1.006 Td
(>500/\033L \(0.5 x 10)Tj
0 Tc 0 Tw 6 0 0 6 88.958 646.1302 Tm
(9)Tj
-0.01 Tc 0.013 Tw 8 0 0 8 91.7779 643.3302 Tm
[(/L\),)37 ( a)-9.9 (t which time trea)-9.9 (tment may be resumed a)-9.9 (t full dose.)37 ( If marro)-10 (w)-10 ( )]TJ
0 Tw -6.972 -1.006 Td
[(cellularity is >10%,)37.1 ( resumption of trea)-9.9 (tment with SPR)18 (YCEL may be considered.)]TJ
/T1_1 1 Tf
0 -1.501 Td
(Non-Hematologic Adverse Reactions)Tj
/T1_0 1 Tf
0.114 Tw 0 -1.299 Td
[(F)20 (or adults with Ph)]TJ
0 Tc 0 Tw 6.805 0.125 Td
(+)Tj
-0.01 Tc 0.114 Tw 0.59 -0.125 Td
[( CML and )36.7 (ALL,)37 ( and pedia)-10 (tric pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 17.04 0.125 Td
(+)Tj
-0.01 Tc 0.114 Tw 0.59 -0.125 Td
[( CML,)37 ( if a severe)-10 ( )]TJ
0 Tc 0 Tw 6.475 0 Td
( )Tj
-0.01 Tc 0.208 Tw -31.5 -1.006 Td
[(non-hema)-10 (tologic adverse reaction develops with SPR)18 (YCEL use,)37.1 ( trea)-9.9 (tment must be)-9.9 ( )]TJ
0.182 Tw 0 -1.006 Td
[(withheld until the adverse reaction has resolved or improved.)37 ( )37.2 (Thereafter)74 (,)37 ( trea)-10 (tment)-10 ( )]TJ
0.191 Tw 0 -1.006 Td
[(can )0.5 (be resumed as )0.5 (a)-10 (ppropria)-10 (te )0.5 (a)-10 (t a )0.5 (reduced dose depending on the severity and)-9.9 ( )]TJ
0.01 Tw 0 -1.006 Td
(recurrence)Tj
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
4.147 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
[(ee W)18.1 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.425 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.139 Tw -14.99 -1.299 Td
[(F)20 (or pedia)-10 (tric pa)-9.9 (tients with Ph)]TJ
0 Tc 0 Tw 11.066 0.125 Td
(+)Tj
-0.01 Tc 0.139 Tw 0.59 -0.125 Td
[( )36.6 (ALL,)37 ( interrupt trea)-10 (tment for cases of grade \0363 non-)]TJ
0.103 Tw -11.656 -1.006 Td
[(hema)-10 (tologic adverse reactions with the exception of liver function test abno\rmalities,)27 ( )]TJ
0.033 Tw 0 -1.006 Td
[(and resume a)-9.9 (t a reduced dose when resolved to grade \0341.)37 ( F)20 (or eleva)-10 (ted direct bilirubin)-10 ( )]TJ
0.198 Tw 0 -1.006 Td
[(over )0.5 (5 )0.6 (times )0.6 (the )0.5 (institutional )0.6 (upper )0.5 (limit )0.6 (of )0.5 (normal )0.6 (\(ULN\),)37 ( )0.5 (interrupt )0.5 (trea)-10 (tment )0.5 (until)-10 ( )]TJ
-0.057 Tw 0 -1.006 Td
[(improvement to baseline or grade \0341.)37 ( F)20 (or eleva)-10 (ted )36.9 (AST/AL)94 (T over 15 times the institutional)-10 ( )]TJ
0.045 Tw 0 -1.006 Td
[(ULN,)37 ( interrupt trea)-10 (tment until improvement to baseline or grade <1.)37 ( F)20 (or recurrent liver)-9.9 ( )]TJ
0.116 Tw 0 -1.006 Td
[(function )0.5 (test )0.5 (abnormalities )0.6 (as )0.5 (above,)37 ( )0.6 (reduce )0.6 (the )0.5 (dose )0.5 (if )0.5 (this )0.6 (adverse )0.5 (reaction )0.6 (recurs)-10 ( )]TJ
-0.016 Tw 0 -1.006 Td
[(after reinitia)-9.9 (tion of SPR)18 (YCEL.)37 ( Dose reduction recommenda)-9.9 (tions are described in )36.9 (T)74 (able 5.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 495.894 252 -17.312 re
36 478.582 67.68 -16.965 re
103.68 478.582 30.72 -16.965 re
134.4 478.582 153.6 -16.965 re
36 461.617 67.68 -92.912 re
103.68 461.617 30.72 -26.456 re
134.4 461.617 51.2 -26.456 re
185.6 461.617 51.2 -26.456 re
236.8 461.617 51.2 -26.456 re
103.68 435.161 30.72 -66.456 re
134.4 435.161 51.2 -12.912 re
185.6 435.161 51.2 -12.912 re
236.8 435.161 51.2 -12.912 re
134.4 422.249 51.2 -13.386 re
185.6 422.249 51.2 -13.386 re
236.8 422.249 51.2 -13.386 re
134.4 408.863 51.2 -13.386 re
185.6 408.863 51.2 -13.386 re
236.8 408.863 51.2 -13.386 re
134.4 395.477 51.2 -13.386 re
185.6 395.477 51.2 -13.386 re
236.8 395.477 51.2 -13.386 re
134.4 382.091 51.2 -13.386 re
185.6 382.091 51.2 -13.386 re
236.8 382.091 51.2 -13.386 re
36 368.705 67.68 -52.912 re
103.68 368.705 30.72 -52.912 re
134.4 368.705 51.2 -12.912 re
185.6 368.705 51.2 -12.912 re
236.8 368.705 51.2 -12.912 re
134.4 355.793 51.2 -12.912 re
185.6 355.793 51.2 -12.912 re
236.8 355.793 51.2 -12.912 re
134.4 342.881 51.2 -12.912 re
185.6 342.881 51.2 -12.912 re
236.8 342.881 51.2 -12.912 re
134.4 329.969 51.2 -14.176 re
185.6 329.969 51.2 -14.176 re
236.8 329.969 51.2 -14.176 re
36 315.793 67.68 -84.912 re
103.68 315.793 81.92 -84.912 re
185.6 315.793 51.2 -84.912 re
236.8 315.793 51.2 -84.912 re
36 230.881 252 -12.912 re
f
0 0 0 1 K
1.01 w 
/GS2 gs
q 1 0 0 1 36 230.881 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 103.68 230.881 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 134.4 230.881 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 185.6 230.881 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 236.8 230.881 cm
0 0 m
51.2 0 l
S
Q
0.505 w 
q 1 0 0 1 36 217.9691 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 103.68 217.9691 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 134.4 217.9691 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 185.6 217.9691 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 236.8 217.9691 cm
0 0 m
51.2 0 l
S
Q
1 w 
q 1 0 0 1 36 478.5817 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 103.68 478.5817 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 134.4 478.5817 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 185.6 478.5817 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 236.8 478.5817 cm
0 0 m
51.2 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0.145 Tw 8 0 0 8 36 490.1817 Tm
[(Table )121 (5:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.75 0 Td
[(Dose Adjustments for Non-Hematologic Toxicities in Pediatric)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Patients)Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 167.4464 467.2432 Tm
(Dose \(maximum dose per day\))Tj
/T1_0 1 Tf
-0.01 Tc -18.256 -1.867 Td
(1.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If a non-hema)-10 (tologic)-10 ( )]TJ
-1.25 -1 Td
[(toxicity grade 2 occurs,)27 ( )]TJ
0 -1 Td
[(consider interrupting)-10 ( )]TJ
0 -1 Td
[(SPR)18 (YCEL if no recover)-18 (y)-9.9 ( )]TJ
0 -1 Td
[(despite symptoma)-9.9 (tic)-10 ( )]TJ
0 -1 Td
[(thera)-10 (py; once recovered)-10 ( )]TJ
0 -1 Td
[(to grade \0341,)37 ( resume)-10 ( )]TJ
0 -1 Td
[(a)-10 (t the original starting)-10 ( )]TJ
0 -1 Td
[(dose.)37 ( Resume SPR)18 (YCEL)-9.9 ( )]TJ
0 -1 Td
[(a)-10 (t a reduced dose for)-9.9 ( )]TJ
0 -1 Td
(recurrent events.)Tj
/T1_1 1 Tf
0.01 Tw 13.667 10 Td
[(Original)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 157.9003 452.3048 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 134.4 444.3048 Tm
(Starting Dose)Tj
7.111 1 Td
[(One-Level Dose)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Reduction)Tj
0.024 Tw 7.111 1 Td
[(T)74 (wo-Level Dose)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Reduction)Tj
-18.489 -2.307 Td
[(T)74 (ablets)]TJ
/T1_0 1 Tf
0.024 Tw 4.267 0 Td
(40 mg)Tj
7.111 0 Td
(20 mg)Tj
0.01 Tw 7.111 0 Td
(**)Tj
0.024 Tw -14.222 -1.614 Td
(60 mg)Tj
7.111 0 Td
(40 mg)Tj
7.111 0 Td
(20 mg)Tj
-14.222 -1.673 Td
(70 mg)Tj
7.111 0 Td
(60 mg)Tj
7.111 0 Td
(50 mg)Tj
-14.222 -1.673 Td
(100 mg)Tj
7.111 0 Td
(80 mg)Tj
7.111 0 Td
(70 mg)Tj
-27.889 -3.346 Td
(2.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If a non-hema)-10 (tologic)-10 ( )]TJ
-1.25 -1 Td
[(toxicity grade 3 occurs,)27 ( )]TJ
0 -1 Td
[(stop SPR)18 (YCEL until)-10 ( )]TJ
0 -1 Td
[(recover)-18 (y to grade \0341 and)-10 ( )]TJ
0 -1 Td
[(then resume a)-10 (t a reduced)-10 ( )]TJ
0.01 Tw 0 -1 Td
(dose.)Tj
0.024 Tw 0 -1.614 Td
(3.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If direct bilirubin is)-10 ( )]TJ
-1.25 -1 Td
[(>5 ULN or )37 (AST/AL)94 (T)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 88.0695 298.481 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 36 290.481 Tm
[(>15 ULN,)37 ( interrupt)-9.9 ( )]TJ
0 -1 Td
[(SPR)18 (YCEL until recover)-18 (y)-10 ( )]TJ
0 -1 Td
[(to grade \0341 and then)-10 ( )]TJ
0 -1 Td
[(resume SPR)18.1 (YCEL a)-10 (t)-9.9 ( )]TJ
0 -1 Td
[(the original starting)-10 ( )]TJ
0 -1 Td
[(dose.)37 ( Resume SPR)18 (YCEL)-9.9 ( )]TJ
0 -1 Td
[(a)-10 (t a reduced dose for)-9.9 ( )]TJ
0 -1 Td
[(recurrent hepa)-10 (totoxicity)55 (.)]TJ
-0.005 Tc 0 Tw 8 0 0 8 36 221.569 Tm
(**)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.75 0 Td
[(lo)-10 (wer tablet dose not a)-10 (vailable)]TJ
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -0.75 -3.175 Td
(2.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Duration of T)73.9 (reatment)]TJ
/T1_0 1 Tf
0.179 Tw -3.375 -1.389 Td
[(In c)20 (linical studies,)37 ( trea)-9.9 (tment with SPR)18 (YCEL in adults and in pedia)-9.9 (tric pa)-10 (tients with)-10 ( )]TJ
0.015 Tw 0 -1.006 Td
[(chronic phase )0.5 (CML )0.5 (was )0.5 (continued until disease )0.5 (progression )0.5 (or )0.5 (until )0.5 (no )0.5 (longer )0.5 (tolera)-10 (ted)-10 ( )]TJ
0.124 Tw 0 -1.006 Td
[(by the pa)-10 (tient.)37 ( )36.6 (The effect of stopping trea)-10 (tment on long-term disease outcome after)-10 ( )]TJ
0.107 Tw 0 -1.006 Td
[(the achievement of a c)20 (ytogenetic response \(inc)20 (luding complete c)20 (ytogenetic response)-10 ( )]TJ
0 Tw 0 -1.006 Td
([CCyR]\) or major molecular response \(MMR and MR4.5\) has not been esta\blished.)Tj
0.168 Tw 0 -1.434 Td
[(In c)20 (linical studies,)37 ( trea)-10 (tment with SPR)18 (YCEL in pedia)-9.9 (tric pa)-9.9 (tients with Ph)]TJ
0 Tc 0 Tw 27.314 0.125 Td
(+)Tj
-0.01 Tc 0.131 Tw 0.59 -0.125 Td
[( ALL )-36.8 (was)-10 ( )]TJ
0.05 Tw -27.904 -1.006 Td
[(administered for a maximum dura)-9.9 (tion of 2 years )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
18.261 0 Td
(s)Tj
-0.01 Tc 0.05 Tw 0.397 0 Td
(ee Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.013 Tw 2.525 0 Td
[(a)-10 (ge )-36.8 (and Admini)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.05 Tw 6.086 0 Td
[(tra)-9.9 (tion \(2.2\))-9.9 ( )]TJ
0 Tw -27.269 -1.006 Td
(and Clinical Studie)Tj
0 Tc (s)Tj
-0.01 Tc 7.058 0 Td
( \(14.4\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.231 Tw -7.058 -1.434 Td
[(SPR)18 (YCEL is a hazardous product.)37 ( F)20 (ollo)-10 (w a)-10 (pplicable special handling and disposal)-10 ( )]TJ
0.01 Tw 0 -1.006 Td
(procedures.)Tj
0 Tc 0 Tw 6 0 0 6 70.2073 108.5689 Tm
(1)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 36 87.6391 Tm
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
/T1_0 1 Tf
0.082 Tw -3.375 -1.659 Td
[(SPR)18 (YCEL \(dasa)-10 (tinib\) )36.7 (T)74 (ablets are a)-10 (vailable as 20-mg,)37 ( 50-mg,)37 ( 70-mg,)37 ( 80-mg,)37 ( 100-mg,)27 ( )]TJ
0 Tw 0 -1.006 Td
[(and 140-mg white to off-white,)37 ( biconvex,)37.1 ( \037lm-coa)-9.9 (ted tablets.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -2.131 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(CONTRAINDIC)18 (A)55 (TIONS)]TJ
/T1_0 1 Tf
-3.375 -1.659 Td
(None.)Tj
/T1_1 1 Tf
36 86.406 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(W)18 (ARNINGS AND PREC)18 (AUTIONS)]TJ
0.01 Tw -3.375 -1.968 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Myelosuppression)Tj
/T1_0 1 Tf
0.362 Tw -3.375 -1.428 Td
[(T)74 (rea)-9.9 (tment with SPR)18 (YCEL is associa)-10 (ted with severe \(NCI CTCAE Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
28.416 0 Td
[(3 or 4\))-10 ( )]TJ
0 Tw -28.416 -1.045 Td
[(thromboc)20 (ytopenia,)37 ( )0.6 (neutropenia,)37 ( )0.6 (and )0.6 (anemia,)37 ( )0.5 (which )0.6 (occur )0.5 (earlier )0.6 (and )0.6 (more )0.6 (frequently )0.6 (in)-10 ( )]TJ
-0.005 Tw 0 -1.045 Td
[(pa)-10 (tients with advanced phase CML or Ph)]TJ
0 Tc 0 Tw 14.679 0.125 Td
(+)Tj
-0.01 Tc -0.005 Tw 0.59 -0.125 Td
[( )37.4 (ALL than in pa)-10 (tients with chronic phase CML)-10 ( )]TJ
/T1_2 1 Tf
0 Tc 0 Tw -15.269 -1.045 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 3.517 0 Td
(e Reaction)Tj
0 Tc (s)Tj
-0.01 Tc 4.184 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.214 Tw -8.347 -1.338 Td
[(In pa)-10 (tients with chronic phase CML,)37 ( perform complete blood counts \(CBCs\) ever)-17.9 (y)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.281 Tw -31.5 -1.045 Td
(2)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
0.7 0 Td
(weeks for 12)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
5.497 0 Td
[(weeks,)37 ( then ever)-18 (y 3)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
8.315 0 Td
[(months thereafter)74 (,)37 ( or as c)20 (linically indica)-9.9 (ted.)27 ( )]TJ
0.099 Tw -14.513 -1.045 Td
[(In pa)-10 (tients with advanced phase CML or Ph)]TJ
0 Tc 0 Tw 16.283 0.125 Td
(+)Tj
-0.01 Tc 0.099 Tw 0.59 -0.125 Td
[( )36.7 (ALL,)37 ( perform CBCs weekly for the \037rst)-10 ( )]TJ
0 Tw -16.873 -1.045 Td
(2)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(months and then monthly thereafter)74 (,)37 ( or as c)20 (linically indica)-10 (ted.)]TJ
0.359 Tw 0 -1.338 Td
[(In pedia)-10 (tric pa)-9.9 (tients with Ph)]TJ
0 Tc 0 Tw 11.457 0.125 Td
(+)Tj
-0.01 Tc 0.359 Tw 0.59 -0.125 Td
[( )37 (ALL trea)-10 (ted with SPR)18 (YCEL in combina)-9.9 (tion with)-10 ( )]TJ
0.074 Tw -12.047 -1.045 Td
[(chemothera)-9.9 (py)55 (,)37 ( perform CBCs prior to the start of each block of chemothera)-10 (py and as)-10 ( )]TJ
0.168 Tw 0 -1.045 Td
[(c)20 (linically indica)-10 (ted.)37 ( During the consolida)-9.9 (tion blocks of chemothera)-10 (py)55 (,)37 ( perform CBCs)-9.9 ( )]TJ
0 Tw 0 -1.045 Td
[(ever)-18 (y 2 days until recover)-18 (y)55 (.)]TJ
0.439 Tw 0 -1.473 Td
[(Myelosuppression is generally reversible and usually mana)-9.9 (ged by withholding)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -31.5 -1.045 Td
[(SPR)18 (YCEL temporarily and/or dose reduction )]TJ
/T1_2 1 Tf
0 Tc ([)Tj
16.189 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
(ee Do)Tj
0 Tc (s)Tj
-0.01 Tc -0.037 Tw 2.475 0 Td
[(a)-10 (ge )-37 (and Admini)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 5.987 0 Td
[(tra)-9.9 (tion \(2.5\)])]TJ
/T1_0 1 Tf
0 Tc (.)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -25.047 -1.743 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Bleeding-Related Events)Tj
/T1_0 1 Tf
0.062 Tw -3.375 -1.428 Td
[(SPR)18 (YCEL can )0.5 (cause )0.5 (serious )0.5 (and fa)-10 (tal )0.5 (bleeding.)37 ( )0.5 (In )0.5 (all )0.5 (CML )0.5 (or )0.5 (Ph)]TJ
0 Tc 0 Tw 23.459 0.125 Td
(+)Tj
-0.01 Tc 0.062 Tw 0.59 -0.125 Td
[( )37.4 (ALL )0.5 (c)20 (linical )0.5 (studies,)27 ( )]TJ
0.197 Tw -24.049 -1.045 Td
[(Grade \0363 central ner)-18 (vous system \(CNS\) hemorrha)-10 (ges,)37 ( inc)20 (luding fa)-10 (talities,)37 ( occurred)-10 ( )]TJ
0.276 Tw 0 -1.045 Td
[(in <1% of pa)-9.9 (tients receiving SPR)18 (YCEL.)37 ( )37.4 (The )0.5 (incidence of Grade 3/4 )0.5 (hemorrha)-10 (ge)-10 ( )]TJ
0.08 Tw 0 -1.045 Td
[(occurred in 5.8% of adult pa)-10 (tients and generally required trea)-9.9 (tment interruptions and)-10 ( )]TJ
0.037 Tw 0 -1.045 Td
[(transfusions.)37 ( )37.4 (The incidence of Grade 5 hemorrha)-10 (ge occurred in 0.4% of adult pa)-10 (tients.)27 ( )]TJ
-0.042 Tw 0 -1.045 Td
[(The most frequent site of hemorrha)-10 (ge was gastrointestinal )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
21.214 0 Td
(s)Tj
-0.01 Tc -0.079 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.042 Tw 3.475 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.042 Tw 4.142 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
-0.037 Tc 0.037 Tw (. )Tj
0 Tc 0 Tw 2.272 0 Td
( )Tj
-0.01 Tc 0.007 Tw -31.5 -1.045 Td
[(Most bleeding events in c)19.9 (linical studies were associa)-10 (ted with severe thromboc)20 (ytopenia.)27 ( )]TJ
0.089 Tw 0 -1.045 Td
[(In )0.5 (addition to causing thromboc)20 (ytopenia in )0.5 (human subjects,)37 ( )0.5 (dasa)-10 (tinib caused )0.5 (pla)-10 (telet)-10 ( )]TJ
0.01 Tw 0 -1.045 Td
[(d)-10 (ysfunction )]TJ
/T1_2 1 Tf
0 Tw 4.387 0 Td
(in vitro)Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.089 Tw -4.387 -1.338 Td
[(Concomitant medica)-10 (tions tha)-10 (t inhibit pla)-10 (telet function or anticoa)-9.9 (gulants may increase)-10 ( )]TJ
0 Tw 0 -1.045 Td
[(the risk of hemorrha)-10 (ge.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.608 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Fluid Retention)Tj
/T1_0 1 Tf
0.19 Tw -3.375 -1.428 Td
[(SPR)18 (YCEL may cause \035uid retention )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
14.065 0 Td
(s)Tj
-0.01 Tc 0.153 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.19 Tw 3.707 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.19 Tw 4.374 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
[(.)37 ( )36.7 (After 5 years of)-10 ( )]TJ
0.037 Tw -22.544 -1.045 Td
[(follo)-10 (w-up in the adult randomized newly dia)-9.9 (gnosed chronic phase CML stud)-9.9 (y \(n=258\),)27 ( )]TJ
0.092 Tw 0 -1.045 Td
[(Grade 3 or 4 \035uid retention was reported in 5% of pa)-10 (tients,)37 ( inc)20 (luding 3% of pa)-10 (tients)-10 ( )]TJ
0.058 Tw 0 -1.045 Td
[(with Grade 3 or 4 pleural effusion.)37 ( In adult pa)-10 (tients with newly dia)-9.9 (gnosed or ima)-10 (tinib-)]TJ
0.036 Tw 0 -1.045 Td
[(resistant or -intolerant chronic phase CML,)37.1 ( Grade 3 or 4 \035uid retention occurred in 6%)-10 ( )]TJ
0.051 Tw 0 -1.045 Td
[(of pa)-10 (tients trea)-10 (ted with SPR)17.9 (YCEL a)-10 (t the recommended dose \(n=548\).)37.1 ( In adult pa)-10 (tients)-10 ( )]TJ
-0.002 Tw 0 -1.045 Td
(with advanced phase CML or Ph)Tj
0 Tc 0 Tw 11.601 0.125 Td
(+)Tj
-0.01 Tc -0.002 Tw 0.59 -0.125 Td
[( )36.6 (ALL trea)-9.9 (ted with SPR)18 (YCEL a)-10 (t the recommended dose)-10 ( )]TJ
0.029 Tw -12.191 -1.045 Td
[(\(n=304\),)37 ( Grade 3 or 4 \035uid retention was reported in 8% of pa)-10 (tients,)37 ( inc)20 (luding Grade 3)-10 ( )]TJ
0.009 Tw 0 -1.045 Td
[(or 4 pleural effusion reported in 7% of pa)-9.9 (tients.)37 ( In pedia)-10 (tric pa)-9.9 (tients with chronic phase)-10 ( )]TJ
0 Tw 0 -1.045 Td
[(CML,)37 ( cases of Grade 1 or 2 \035uid retention were reported in 10.3% of pa)-10 (tients.)]TJ
0.132 Tw 0 -1.338 Td
[(Evalua)-10 (te pa)-10 (tients who develop symptoms of pleural effusion or other \035uid retenti\on,)27 ( )]TJ
0.102 Tw 0 -1.045 Td
[(such as new or worsened d)-10 (yspnea on exertion or a)-10 (t rest,)37 ( pleuritic chest pain,)37.1 ( or dr)-18 (y)-10 ( )]TJ
-0.025 Tw 0 -1.045 Td
[(cough,)37 ( promptly with a chest x-ray or additional dia)-10 (gnostic ima)-10 (ging as a)-9.9 (ppropria)-9.9 (te.)37 ( Fluid)-10 ( )]TJ
0.007 Tw 0 -1.045 Td
[(retention events were typically mana)-10 (ged by supportive care measures tha)-10 (t may inc)20 (lude)-10 ( )]TJ
0.01 Tw 0 -1.045 Td
[(diuretics or short courses of steroids.)37 ( Severe pleural effusion may require thoracentesis)-10 ( )]TJ
0.002 Tw 0 -1.045 Td
[(and oxygen thera)-10 (py)55 (.)37 ( Consider dose reduction or trea)-10 (tment interruption )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
25.713 0 Td
(s)Tj
-0.01 Tc 0.002 Tw 0.397 0 Td
(ee Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.002 Tw 2.477 0 Td
[(a)-10 (ge and)-10 ( )]TJ
0.01 Tw -28.587 -1.045 Td
(Admini)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 2.893 0 Td
[(tra)-9.9 (tion \(2.5\)])]TJ
/T1_0 1 Tf
0 Tc (.)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -2.893 -1.608 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Cardio)-10 (v)16 (ascular T)74 (oxicity)]TJ
/T1_0 1 Tf
0.126 Tw -3.375 -1.428 Td
[(SPR)18 (YCEL can cause cardiac d)-10 (ysfunction )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
15.555 0 Td
(s)Tj
-0.01 Tc 0.089 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.126 Tw 3.643 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.126 Tw 4.31 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
[(.)37 ( )37.2 (After 5 years)-10 ( )]TJ
0.18 Tw -23.905 -1.045 Td
[(of follo)-10 (w-up in the randomized newly dia)-10 (gnosed chronic phase CML trial in adults)-10 ( )]TJ
0.175 Tw 0 -1.045 Td
[(\(n=258\),)37 ( the follo)-9.9 (wing cardiac adverse reactions occurred:)37 ( cardiac ischemic events)-10 ( )]TJ
0.132 Tw 0 -1.045 Td
[(\(3.9% dasa)-10 (tinib vs 1.6% ima)-10 (tinib\),)37 ( cardiac-rela)-10 (ted \035uid retention \(8.5% dasa)-10 (tinib vs)-10 ( )]TJ
0.052 Tw 0 -1.045 Td
[(3.9% )0.5 (ima)-10 (tinib\),)37 ( )0.5 (and )0.5 (conduction )0.5 (system )0.5 (abnormalities,)37 ( )0.5 (most )0.5 (commonly )0.5 (arrhythmia )0.5 (and)-10 ( )]TJ
0.061 Tw 0 -1.045 Td
[(palpita)-10 (tions \(7.0% dasa)-9.9 (tinib vs 5.0% ima)-10 (tinib\).)37 ( )36.6 (T)74 (wo cases \(0.8%\) of peripheral arterial)-10 ( )]TJ
0.235 Tw 0 -1.045 Td
[(occ)20 (lusive disease occurred with ima)-10 (tinib and 2 \(0.8%\) transient ischemic a)-9.9 (ttacks)-9.9 ( )]TJ
-0.001 Tw 0 -1.045 Td
[(occurred with dasa)-10 (tinib.)37 ( Monitor pa)-9.9 (tients for signs or symptoms consistent with cardiac)-10 ( )]TJ
0 Tw 0 -1.045 Td
[(d)-10 (ysfunction and trea)-10 (t a)-9.9 (ppropria)-9.9 (tely)55 (.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.743 Td
(5.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Pulmonar)-18 (y Arterial Hypertension)]TJ
/T1_0 1 Tf
0.046 Tw -3.375 -1.405 Td
[(SPR)18 (YCEL may increase the risk of developing pulmonar)-17.9 (y arterial hypertension \(P)37 (AH\) in)-10 ( )]TJ
0.103 Tw 0 -1.045 Td
[(adult and pedia)-9.9 (tric )0.5 (pa)-10 (tients )0.5 (which )0.5 (may )0.5 (occur )0.5 (an)-10 (y )0.5 (time )0.5 (after initia)-10 (tion,)37 ( inc)20 (luding after)-10 ( )]TJ
0.097 Tw 0 -1.045 Td
[(more than 1 year of trea)-10 (tment.)37 ( Manifesta)-9.9 (tions inc)20 (lude d)-10 (yspnea,)37 ( fa)-9.9 (tigue,)37 ( hypoxia,)37 ( and)-10 ( )]TJ
0.047 Tw 0 -1.045 Td
(\035uid retention )Tj
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
5.542 0 Td
(s)Tj
-0.01 Tc 0.01 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.047 Tw 3.564 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.047 Tw 4.231 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
[(.)37 ( P)37 (AH may be reversible on discontinua)-10 (tion)-10 ( )]TJ
0.063 Tw -13.733 -1.045 Td
[(of SPR)18 (YCEL.)37 ( Evalua)-10 (te pa)-10 (tients for signs and symptoms of underlying cardiopulmonar)-18 (y)-10 ( )]TJ
0.027 Tw 0 -1.045 Td
[(disease prior to initia)-9.9 (ting SPR)18 (YCEL and during trea)-10 (tment.)37 ( If P)37 (AH is con\037rmed,)37 ( SPR)18 (YCEL)-10 ( )]TJ
0 Tw 0 -1.045 Td
(should be permanently discontinued.)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.743 Td
(5.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(QT Prolongation)Tj
/T1_0 1 Tf
0.049 Tw -3.375 -1.405 Td
[(SPR)18 (YCEL may increase the risk of prolonga)-9.9 (tion of QTc in pa)-9.9 (tients inc)20 (luding those with)-10 ( )]TJ
0.028 Tw 0 -1.045 Td
[(hypokalemia )0.5 (or )0.5 (hypoma)-10 (gnesemia,)37 ( )0.5 (pa)-10 (tients )0.5 (with )0.5 (congenital )0.5 (long )0.5 (QT )0.5 (syndrome,)37 ( )0.5 (pa)-9.9 (tients)-9.9 ( )]TJ
-0.056 Tw 0 -1.045 Td
[(taking antiarrhythmic medicines or other medicinal products tha)-9.9 (t lead to QT prolonga)-10 (tion,)27 ( )]TJ
0.051 Tw 0 -1.045 Td
[(and cumula)-10 (tive high-dose anthrac)20.1 (yc)20 (line thera)-10 (py )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
18.04 0 Td
(s)Tj
-0.01 Tc 0.014 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.051 Tw 3.568 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.051 Tw 4.235 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
[(.)37 ( Correct)-10 ( )]TJ
0 Tw -26.24 -1.045 Td
[(hypokalemia or hypoma)-10 (gnesemia prior to and during SPR)18 (YCEL administra)-9.9 (tion.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.743 Td
(5.7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Severe Dermatologic Reactions)Tj
/T1_0 1 Tf
0.177 Tw -3.375 -1.405 Td
[(Cases of severe mucocutaneous derma)-10 (tologic reactions,)37 ( inc)19.9 (luding Stevens-Johnson)-9.9 ( )]TJ
0.01 Tw 0 -1.045 Td
(syndrome )Tj
/T1_2 1 Tf
0 Tc 0 Tw 3.841 0 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc 0.009 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.046 Tw 3.563 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.046 Tw 4.23 0 Td
( \(6.2\)])Tj
/T1_0 1 Tf
[( and er)-18 (ythema multiforme,)37 ( ha)-9.9 (ve been reported)-10 ( )]TJ
0.04 Tw -12.28 -1.045 Td
[(in )0.6 (pa)-10 (tients )0.5 (trea)-10 (ted )0.6 (with )0.6 (SPR)18 (YCEL.)37 ( )0.6 (Discontinue )0.6 (permanently )0.6 (in )0.5 (pa)-9.9 (tients )0.6 (who )0.5 (experience)-10 ( )]TJ
-0.017 Tw 0 -1.045 Td
[(a severe mucocutaneous reaction during trea)-10 (tment if no other etiolog)-10 (y can be identi\037ed.)]TJ
ET
endstreamendobj106 0 obj<</Length 26195>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 324 747.0331 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 493.5973 750.2881 Tm
[(SPR)37 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 530.2369 752.0881 Tm
(\256)Tj
-0.01 Tc 8 0 0 8 534.9768 750.2881 Tm
( \(dasatinib\))Tj
/T1_1 1 Tf
-0.005 Tc -62.372 0 Td
[(FULL PRESCRIBING INFORMA)55 (TION)]TJ
-0.01 Tc 0.01 Tw 0 -2.125 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(INDIC)18 (A)55 (TIONS AND USAGE)]TJ
/T1_2 1 Tf
0.01 Tw -3.375 -1.653 Td
[(SPR)18 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 62.3997 721.8663 Tm
(\256)Tj
-0.01 Tc 8 0 0 8 67.1396 720.0663 Tm
[( \(dasa)-10 (tinib\) is indica)-9.9 (ted for the trea)-9.9 (tment of adult pa)-10 (tients with)]TJ
0.01 Tw -3.892 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.507 Tw 1.625 0 Td
[(newly dia)-10 (gnosed Philadelphia chromosome-positive \(Ph)]TJ
0 Tc 0 Tw 22.1 0.125 Td
(+)Tj
-0.01 Tc 0.507 Tw 0.59 -0.125 Td
[(\) chronic myeloid)-10 ( )]TJ
0 Tw -22.69 -1 Td
(leukemia \(CML\) in chronic phase.)Tj
0.01 Tw -1.625 -1.225 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.026 Tw 1.625 0 Td
[(chronic,)37 ( )0.5 (accelera)-10 (ted,)37 ( )0.5 (or )0.5 (myeloid )0.5 (or )0.5 (lymphoid blast )0.5 (phase )0.5 (Ph)]TJ
0 Tc 0 Tw 21.644 0.125 Td
(+)Tj
-0.01 Tc 0.026 Tw 0.59 -0.125 Td
[( )0.5 (CML )0.5 (with )0.5 (resistance)-10 ( )]TJ
0 Tw -22.234 -1 Td
[(or intolerance to prior thera)-9.9 (py inc)20 (luding ima)-10 (tinib.)]TJ
0.01 Tw -1.625 -1.225 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.144 Tw 1.625 0 Td
[(Philadelphia )0.5 (chromosome-positive )0.5 (acute )0.5 (lymphoblastic )0.5 (leukemia )0.5 (\(Ph)]TJ
0 Tc 0 Tw 25.442 0.125 Td
(+)Tj
-0.01 Tc 0.107 Tw 0.59 -0.125 Td
[( )0.5 (ALL\) )-36.5 (with)-10 ( )]TJ
0 Tw -26.032 -1 Td
[(resistance or intolerance to prior thera)-10 (py)55 (.)]TJ
0.097 Tw -1.625 -1.428 Td
[(SPR)18 (YCEL \(dasa)-10 (tinib\) is indica)-9.9 (ted for the trea)-10 (tment of pedia)-10 (tric pa)-10 (tients 1 year of a)-10 (ge)-9.9 ( )]TJ
0 Tw 0 -1 Td
(and older with)Tj
0.01 Tw 1.125 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.625 0 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( CML in chronic phase.)Tj
0.01 Tw -3.139 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(newly dia)-10 (gnosed Ph)]TJ
0 Tc 7.214 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( )37 (ALL in combina)-10 (tion with chemothera)-10 (py)55 (.)]TJ
/T1_1 1 Tf
0.01 Tw -10.554 -2.035 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(DOSAGE AND ADMINISTRA)55 (TION)]TJ
0.01 Tw -3.375 -1.653 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Dosage of SPR)18 (YCEL in Adult P)24 (atients)]TJ
/T1_2 1 Tf
0.168 Tw -3.375 -1.563 Td
[(The )0.6 (recommended )0.6 (starting )0.6 (dosa)-10 (ge )0.6 (of )0.6 (SPR)18 (YCEL )0.6 (for )0.6 (chronic )0.5 (phase )0.5 (CML )0.5 (in )0.6 (adults )0.6 (is)-10 ( )]TJ
0.034 Tw 0 -1 Td
[(100 mg administered orally once daily)55.1 (.)37 ( )37.2 (The recommended starting dosa)-10 (ge of SPR)18 (YCEL)-10 ( )]TJ
0.012 Tw 0 -1 Td
[(for accelera)-10 (ted phase CML,)37 ( myeloid or lymphoid blast phase CML,)37 ( or Ph)]TJ
0 Tc 0 Tw 26.026 0.125 Td
(+)Tj
-0.01 Tc 0.012 Tw 0.59 -0.125 Td
[( )36.8 (ALL in adults)-9.9 ( )]TJ
-0.011 Tw -26.616 -1 Td
[(is 140 mg administered orally once daily)55 (.)37 ( )37.2 (T)74 (ablets should not be crushed,)37.1 ( cut,)37 ( or chewed;)-9.9 ( )]TJ
0.03 Tw 0 -1 Td
[(they should be s)-10 (wallo)-10 (wed whole.)37 ( SPR)18 (YCEL can be taken with or without a meal,)37 ( either)-10 ( )]TJ
0 Tw 0 -1 Td
(in the morning or in the evening.)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.585 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Dosage of SPR)18 (YCEL in P)24 (ediatric P)24 (atients with CML or Ph)]TJ
0 Tc 21.693 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( ALL)Tj
/T1_2 1 Tf
0.034 Tw -25.658 -1.563 Td
[(The recommended starting dosa)-9.9 (ge for pedia)-10 (trics is based on bod)-9.9 (y weight as sho)-10 (wn in)-10 ( )]TJ
-0.041 Tw 0 -1 Td
[(T)74 (able 1.)37 ( )37 (The recommended dose should be administered orally once daily with or wi\thout)-9.9 ( )]TJ
0.047 Tw 0 -1 Td
[(food.)37 ( Recalcula)-10 (te the dose ever)-18 (y 3 months based on changes in bod)-10 (y weight,)37 ( or more)-10 ( )]TJ
0 Tw 0 -1 Td
[(often if necessar)-17.9 (y)55 (.)]TJ
/T1_1 1 Tf
0.158 Tw 0 -1.428 Td
[(Do not crush,)37 ( cut or chew tablets.)37 ( Swallow tablets whole.)]TJ
/T1_2 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
23.657 0 Td
[( )36.9 (There are additional)-10 ( )]TJ
0.243 Tw -23.657 -1 Td
[(administra)-10 (tion considera)-9.9 (tions for pedia)-9.9 (tric pa)-10 (tients who ha)-10 (ve dif\037culty s)-10 (wallo)-10 (wing)-10 ( )]TJ
0 Tw 0 -1 Td
(tablets whole )Tj
/T1_3 1 Tf
0 Tc ([)Tj
5.272 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
(ee U)Tj
0 Tc (s)Tj
-0.01 Tc 2.004 0 Td
[(e in Speci\037c P)18 (opula)-10 (tion)]TJ
0 Tc (s)Tj
-0.01 Tc 8.785 0 Td
[( \(8.4\) and Clinical Pharmacolog)-10 (y \(12.3\)])]TJ
/T1_2 1 Tf
0 Tc (.)Tj
ET
0 0 0 0 k
/GS1 gs
36 457.503 252 -9.312 re
36 448.191 138.96 -12.912 re
174.96 448.191 113.04 -12.912 re
36 435.279 138.96 -10.752 re
174.96 435.279 113.04 -10.752 re
36 424.527 138.96 -10.752 re
174.96 424.527 113.04 -10.752 re
36 413.775 138.96 -10.752 re
174.96 413.775 113.04 -10.752 re
36 403.023 138.96 -10.752 re
174.96 403.023 113.04 -10.752 re
36 392.271 252 -30.712 re
f
1 w 
/GS2 gs
q 1 0 0 1 36 392.2714 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 174.96 392.2714 cm
0 0 m
113.04 0 l
S
Q
0.5 w 
q 1 0 0 1 36 361.5595 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 174.96 361.5595 cm
0 0 m
113.04 0 l
S
Q
1 w 
q 1 0 0 1 36 448.191 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 174.96 448.191 cm
0 0 m
113.04 0 l
S
Q
0.5 w 
q 1 0 0 1 36 435.2791 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 174.96 435.2791 cm
0 0 m
113.04 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_1 1 Tf
-0.02 Tc 0.024 Tw 8 0 0 8 36 451.791 Tm
[(T)-10 (a)-10 (b)-10 (l)-10 (e)-10 ( )-10 (1)-10 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.068 0 Td
( )Tj
EMC 
3.557 0 Td
(Dosage of SPRYCEL for Pediatric Patients)Tj
0 Tc 0 Tw 6 0 0 6 214.7256 454.5909 Tm
(a)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 36 438.879 Tm
[(Body W)18 (eight \(kg\))]TJ
0 Tc 0 Tw 5.4 0 0 6 84.1025 441.679 Tm
(b)Tj
7.2 0 0 8 86.8025 438.879 Tm
( )Tj
-0.02 Tc 0.024 Tw 17.075 0 Td
(Daily Dose \(mg\))Tj
/T1_2 1 Tf
-0.01 Tc -24.131 -1.479 Td
(10 to less than 20)Tj
-0.005 Tc 25.956 0 Td
(40 mg)Tj
-0.01 Tc -25.956 -1.344 Td
(20 to less than 30)Tj
-0.005 Tc 25.956 0 Td
(60 mg)Tj
-0.01 Tc -25.956 -1.344 Td
(30 to less than 45)Tj
-0.005 Tc 25.956 0 Td
(70 mg)Tj
-0.01 Tc -25.956 -1.344 Td
[(a)-10 (t least 45)]TJ
-0.005 Tc 25.718 0 Td
(100 mg)Tj
0.005 Tw 5.4 0 0 6 36 385.7595 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.053 Tw 7.2 0 0 8 39.6 382.9595 Tm
[(F)20 (or pedia)-10 (tric pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 10.87 0.125 Td
(+)Tj
-0.005 Tc 0.053 Tw 0.595 -0.125 Td
[( )37 (ALL,)37 ( begin SPR)18 (YCEL thera)-10 (py on or before day 15 of induction)-5 ( )]TJ
0 Tw -11.465 -1 Td
[(chemothera)-10 (py)55 (,)37 ( when dia)-10 (gnosis is confirmed and continue for 2 years.)]TJ
0.005 Tw 5.4 0 0 6 36 367.9595 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 39.6 365.1595 Tm
[(T)74 (ablet dosing is not recommended for pa)-10 (tients weighing less than 10 kg.)]TJ
-0.01 Tc 0.077 Tw 8 0 0 8 36 346.4687 Tm
[(Refer to Section 2.4 for recommenda)-10 (tions on dose escala)-10 (tion in adults with CML and)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( )37 (ALL,)37 ( and pedia)-10 (tric pa)-10 (tients with CML.)]TJ
/T1_1 1 Tf
0.01 Tw -1.514 -1.585 Td
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Dose Modi\037cation)Tj
-3.375 -1.63 Td
(Strong CYP3A4 Inducers)Tj
/T1_2 1 Tf
0.081 Tw 0 -1.293 Td
[(Avoid the use of concomitant strong CYP3A4 inducers and St.)37.1 ( John\222)55 (s wort.)37.1 ( If pa)-10 (tients)-10 ( )]TJ
0.053 Tw 0 -1 Td
[(must be coadministered a strong CYP3A4 inducer)74 (,)37 ( consider a SPR)17.9 (YCEL dose increase.)27 ( )]TJ
0.038 Tw 0 -1 Td
[(If the dose of SPR)18 (YCEL is increased,)37 ( monitor the pa)-10 (tient carefully for toxicity )]TJ
/T1_3 1 Tf
0 Tc 0 Tw ([)Tj
28.219 0 Td
(s)Tj
-0.01 Tc 0.038 Tw 0.397 0 Td
[(ee Drug)-9.9 ( )]TJ
0.01 Tw -28.616 -1 Td
(Interaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.193 0 Td
( \(7.1\)])Tj
/T1_2 1 Tf
0 Tc (.)Tj
/T1_1 1 Tf
-0.01 Tc -4.193 -1.495 Td
(Strong CYP3A4 Inhibitors)Tj
/T1_2 1 Tf
-0.025 Tw 0 -1.293 Td
[(Avoid the use of concomitant strong CYP3A4 inhibitors and gra)-9.9 (pefruit juice.)37 ( Recommend)-10 ( )]TJ
0.136 Tw 0 -1 Td
[(selecting an alterna)-9.9 (te concomitant medica)-10 (tion with no or minimal enzyme inhibition)-10 ( )]TJ
0.049 Tw 0 -1 Td
[(potential,)37 ( if possible.)37 ( If SPR)18 (YCEL must be administered with a strong CYP3A4 inhibitor)74 (,)27 ( )]TJ
0 Tw 0 -1 Td
(consider a dose decrease to:)Tj
0.01 Tw 1.125 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(40 mg daily for pa)-9.9 (tients taking SPR)18 (YCEL 140 mg daily)55 (.)]TJ
0.01 Tw -1.625 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(20 mg daily for pa)-9.9 (tients taking SPR)18 (YCEL 100 mg daily)55 (.)]TJ
0.01 Tw -1.625 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(20 mg daily for pa)-9.9 (tients taking SPR)18 (YCEL 70 mg daily)55 (.)]TJ
0.013 Tw -2.75 -1.428 Td
[(F)20 (or pa)-10 (tients taking SPR)18.1 (YCEL 60 mg or 40 mg daily)55 (,)37 ( consider interrupting SPR)18 (YCEL until)-10 ( )]TJ
0.035 Tw 0 -1 Td
[(the )0.5 (inhibitor is )0.5 (discontinued.)37 ( )37.5 (Allo)-9.9 (w )0.5 (a )0.5 (washout )0.5 (period )0.5 (of )0.5 (a)-10 (pproxima)-9.9 (tely )0.5 (1 )0.5 (week )0.5 (after )0.5 (the)-10 ( )]TJ
0 Tw 0 -1 Td
[(inhibitor is stopped before reinitia)-10 (ting SPR)18 (YCEL.)]TJ
0.152 Tw 0 -1.428 Td
[(These reduced doses of SPR)18 (YCEL are predicted to adjust the area under the cur)-18 (ve)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.08 Tw -31.5 -1 Td
[(\(AUC\) to the range obser)-17.9 (ved without CYP3A4 inhibitors; ho)-9.9 (wever)74 (,)37 ( c)20 (linical da)-10 (ta are not)-10 ( )]TJ
0.096 Tw 0 -1 Td
[(a)-10 (vailable with )0.5 (these )0.5 (dose )0.5 (adjustments )0.5 (in pa)-9.9 (tients receiving strong )0.5 (CYP3A4 )0.5 (inhibitors.)27 ( )]TJ
0.058 Tw 0 -1 Td
[(If SPR)18 (YCEL is not tolera)-10 (ted after dose reduction,)37 ( either discontinue the strong CYP3A4)-10 ( )]TJ
0.01 Tw 0 -1 Td
[(inhibitor or interrupt SPR)18 (YCEL until the inhibitor is discontinued.)37 ( )37.1 (Allo)-9.9 (w a washout period)-10 ( )]TJ
0.163 Tw 0 -1 Td
[(of a)-9.9 (pproxima)-10 (tely 1 week after the inhibitor is stopped before the SPR)18 (YCEL dose is)-10 ( )]TJ
0.01 Tw 0 -1 Td
(increased )Tj
/T1_3 1 Tf
0 Tc 0 Tw 3.731 0 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
(ee Drug Interaction)Tj
0 Tc (s)Tj
-0.01 Tc 7.259 0 Td
( \(7.1\)])Tj
/T1_2 1 Tf
0 Tc (.)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -11.636 -2.013 Td
(2.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.033 Tw 3.375 0 Td
(Dose Escalation in Adults with CML and Ph)Tj
0 Tc 0 Tw 16.822 0.125 Td
(+)Tj
-0.01 Tc 0.033 Tw 0.59 -0.125 Td
[( ALL,)37 ( and P)24 (ediatric P)24 (atients)-10 ( )]TJ
0 Tw -17.412 -1 Td
(with CML)Tj
/T1_2 1 Tf
0.108 Tw -3.375 -1.563 Td
[(F)20 (or adult pa)-10 (tients with CML and Ph)]TJ
0 Tc 0 Tw 13.253 0.125 Td
(+)Tj
-0.01 Tc 0.108 Tw 0.59 -0.125 Td
[( )37 (ALL,)37 ( consider dose escala)-9.9 (tion to 140 mg once)-9.9 ( )]TJ
0.012 Tw -13.843 -1 Td
(daily \(chronic phase CML\) or 180 mg once daily \(advanced phase CML an\d Ph)Tj
0 Tc 0 Tw 28.217 0.125 Td
(+)Tj
-0.01 Tc -0.025 Tw 0.59 -0.125 Td
[( ALL\) )-37 (in)-9.9 ( )]TJ
-0.039 Tw -28.807 -1 Td
[(pa)-10 (tients who do not achieve a hema)-10 (tologic or c)20 (ytogenetic response a)-10 (t the recommended)-10 ( )]TJ
0.085 Tw 0 -1 Td
[(starting dosa)-9.9 (ge.)37 ( F)20 (or pedia)-9.9 (tric pa)-10 (tients with CML,)37 ( consider dose escala)-10 (tion to 120 mg)-10 ( )]TJ
-0.053 Tw 0 -1 Td
[(once daily \(see )37.1 (T)74 (able 2 belo)-9.9 (w\).)37 ( Dose escala)-9.9 (tion is not recommended for pedia)-10 (tric pa)-10 (tients)-10 ( )]TJ
0 Tw 0 -1 Td
(with Ph)Tj
0 Tc 2.688 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( )37 (ALL,)37 ( where SPR)18 (YCEL is administered in combina)-10 (tion with chemothera)-10 (py)55 (.)]TJ
-0.007 Tw 32.722 86.406 Td
[(Escala)-10 (te the SPR)18 (YCEL dose as sho)-10 (wn in )36.7 (T)74 (able 2 in pedia)-9.9 (tric pa)-10 (tients with chronic phase)-10 ( )]TJ
0.064 Tw 0 -1.02 Td
[(CML who do not achieve a hema)-10 (tologic or c)20 (ytogenetic response a)-10 (t the recommended)-10 ( )]TJ
0 Tw 0 -1.02 Td
[(starting dosa)-10 (ge.)]TJ
ET
0 0 0 0 k
/GS1 gs
324 701.762 252 -9.312 re
324 692.45 69.48 -12.912 re
393.48 692.45 182.52 -12.912 re
324 679.539 69.48 -12.912 re
393.48 679.539 91.26 -12.912 re
484.74 679.539 91.26 -12.912 re
324 666.627 69.48 -10.752 re
393.48 666.627 91.26 -10.752 re
484.74 666.627 91.26 -10.752 re
324 655.875 69.48 -10.752 re
393.48 655.875 91.26 -10.752 re
484.74 655.875 91.26 -10.752 re
324 645.123 69.48 -10.752 re
393.48 645.123 91.26 -10.752 re
484.74 645.123 91.26 -10.752 re
324 634.371 69.48 -10.752 re
393.48 634.371 91.26 -10.752 re
484.74 634.371 91.26 -10.752 re
f
1 w 
/GS2 gs
q 1 0 0 1 324 623.6189 cm
0 0 m
69.48 0 l
S
Q
q 1 0 0 1 393.48 623.6189 cm
0 0 m
91.26 0 l
S
Q
q 1 0 0 1 484.74 623.6189 cm
0 0 m
91.26 0 l
S
Q
0.5 w 
q 1 0 0 1 324 666.6266 cm
0 0 m
69.48 0 l
S
Q
q 1 0 0 1 393.48 666.6266 cm
0 0 m
91.26 0 l
S
Q
q 1 0 0 1 484.74 666.6266 cm
0 0 m
91.26 0 l
S
Q
1 w 
q 1 0 0 1 324 692.4504 cm
0 0 m
69.48 0 l
S
Q
q 1 0 0 1 393.48 692.4504 cm
0 0 m
91.26 0 l
S
Q
q 1 0 0 1 484.74 692.4504 cm
0 0 m
91.26 0 l
S
Q
0.5 w 
q 1 0 0 1 324 679.5385 cm
0 0 m
69.48 0 l
S
Q
q 1 0 0 1 393.48 679.5385 cm
0 0 m
91.26 0 l
S
Q
q 1 0 0 1 484.74 679.5385 cm
0 0 m
91.26 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_1 1 Tf
-0.02 Tc 0.024 Tw 8 0 0 8 324 696.0504 Tm
[(T)-10 (a)-10 (b)-10 (l)-10 (e)-10 ( )-10 (2)-10 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.068 0 Td
( )Tj
EMC 
3.557 0 Td
(Dose Escalation for Pediatric CML)Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 324 683.1385 Tm
(Formulation)Tj
0.024 Tw 9.65 0 Td
(Dose \(maximum dose per day\))Tj
0 -1.614 Td
(Starting Dose)Tj
0.01 Tw 12.675 0 Td
(Escalation)Tj
-22.325 -1.479 Td
[(T)74 (ablets)]TJ
/T1_2 1 Tf
0.024 Tw 9.65 0 Td
(40 mg)Tj
12.675 0 Td
(50 mg)Tj
-12.675 -1.344 Td
(60 mg)Tj
12.675 0 Td
(70 mg)Tj
-12.675 -1.344 Td
(70 mg)Tj
12.675 0 Td
(90 mg)Tj
-12.675 -1.344 Td
(100 mg)Tj
12.675 0 Td
(120 mg)Tj
/T1_1 1 Tf
0.01 Tw 8 0 0 8 324 608.1169 Tm
(2.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Dose Adjustment for Adverse Reactions)Tj
0.01 Tw -3.375 -1.47 Td
(Myelosuppression)Tj
/T1_2 1 Tf
-0.025 Tw 0 -1.313 Td
[(In )0.6 (c)20 (linical )0.5 (studies,)37 ( )0.5 (myelosuppression )0.5 (was )0.5 (mana)-10 (ged )0.6 (by )0.6 (dose )0.6 (interruption,)37 ( )0.6 (dose )0.5 (reduction,)27 ( )]TJ
0.188 Tw 0 -1.02 Td
[(or discontinua)-10 (tion of stud)-10 (y thera)-9.9 (py)55 (.)37 ( Hema)-10 (topoietic gro)-9.9 (wth factor has been used in)-10 ( )]TJ
0.134 Tw 0 -1.02 Td
[(pa)-10 (tients )0.5 (with resistant )0.5 (myelosuppression.)37 ( )0.5 (Guidelines )0.5 (for )0.5 (dose )0.5 (modi\037ca)-10 (tions )0.5 (for )0.5 (adult)-10 ( )]TJ
0 Tw 0 -1.02 Td
[(and pedia)-10 (tric pa)-10 (tients are summarized in )37 (T)74 (ables 3 and 4,)37 ( respectively)55 (.)]TJ
ET
0 0 0 0 k
/GS1 gs
324 552.205 252 -17.312 re
324 534.893 67.68 -135.72 re
391.68 534.893 75.6 -135.72 re
467.28 534.893 108.72 -135.72 re
324 399.173 67.68 -118.85 re
391.68 399.173 75.6 -118.85 re
467.28 399.173 108.72 -118.85 re
324 280.323 252 -12.912 re
f
1.01 w 
/GS2 gs
q 1 0 0 1 324 280.3234 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.68 280.3234 cm
0 0 m
75.6 0 l
S
Q
q 1 0 0 1 467.28 280.3234 cm
0 0 m
108.72 0 l
S
Q
0.505 w 
q 1 0 0 1 324 267.4115 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.68 267.4115 cm
0 0 m
75.6 0 l
S
Q
q 1 0 0 1 467.28 267.4115 cm
0 0 m
108.72 0 l
S
Q
1 w 
q 1 0 0 1 324 534.8934 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.68 534.8934 cm
0 0 m
75.6 0 l
S
Q
q 1 0 0 1 467.28 534.8934 cm
0 0 m
108.72 0 l
S
Q
0.5 w 
q 1 0 0 1 324 399.1734 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.68 399.1734 cm
0 0 m
75.6 0 l
S
Q
q 1 0 0 1 467.28 399.1734 cm
0 0 m
108.72 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_1 1 Tf
0.224 Tw 8 0 0 8 324 546.4934 Tm
[(Table )200 (3:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.75 0 Td
[(Dose Adjustments for Neutropenia and Thrombocytopenia in)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Adults)Tj
/T1_2 1 Tf
-0.005 Tc 0.024 Tw 7.2 0 0 8 332.0322 470.4884 Tm
(Chronic Phase CML)Tj
-0.468 -1 Td
(\(starting dose 100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
6.926 0 Td
[(mg)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 388.8496 462.4884 Tm
( )Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 343.6096 454.4884 Tm
(once daily\))Tj
8.385 2 Td
(ANC* <0.5 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 447.2484 473.2884 Tm
(9)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 449.8134 470.4884 Tm
(/L)Tj
-3.192 -1 Td
(or)Tj
0.024 Tw -3.658 -1 Td
[(Pla)-10 (telets <50 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 450.7365 457.2884 Tm
(9)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 453.3015 454.4884 Tm
(/L)Tj
-0.01 Tc 0.024 Tw 1.941 8.554 Td
(1.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(Stop SPR)18 (YCEL until )37 (ANC \0361.0 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 567.632 525.7234 Tm
(9)Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 570.1699 522.9234 Tm
[(/L)-10 ( )]TJ
0.024 Tw -13.04 -1 Td
[(and pla)-10 (telets \03650 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 536.4777 517.7234 Tm
(9)Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 539.0156 514.9234 Tm
(/L.)Tj
0.024 Tw -9.963 -1 Td
(2.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(Resume trea)-10 (tment with SPR)18 (YCEL a)-10 (t)-10 ( )]TJ
0 -1 Td
[(the original starting dose if recover)-18 (y)-10 ( )]TJ
0 -1 Td
(occurs in \0347 days.)Tj
-1.25 -1 Td
(3.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If pla)-10 (telets <25 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 530.7609 485.7234 Tm
(9)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 533.2988 482.9234 Tm
[(/L or recurrence)-9.9 ( )]TJ
-7.919 -1 Td
[(of )37 (ANC <0.5 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 523.0575 477.7234 Tm
(9)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 525.5955 474.9234 Tm
[(/L for >7 days,)27 ( )]TJ
-6.849 -1 Td
[(repea)-10 (t Step 1 and resume SPR)18.1 (YCEL)-10 ( )]TJ
0 -1 Td
[(a)-10 (t a reduced dose of 80)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once)-10 ( )]TJ
0 -1 Td
[(daily for second episode.)37 ( F)20 (or)-9.9 ( )]TJ
0 -1 Td
[(third episode,)37 ( further reduce dose)-10 ( )]TJ
0 -1 Td
(to 50)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily \(for newly)-10 ( )]TJ
0 -1 Td
[(dia)-9.9 (gnosed pa)-10 (tients\) or discontinue)-10 ( )]TJ
0 -1 Td
[(SPR)18 (YCEL \(for pa)-10 (tients resistant or)-10 ( )]TJ
0 -1 Td
[(intolerant to prior thera)-10 (py inc)20 (luding)-10 ( )]TJ
0.01 Tw 0 -1 Td
[(ima)-9.9 (tinib\).)]TJ
-0.005 Tc 0.024 Tw -20.896 -6.465 Td
[(Accelera)-10 (ted Phase CML,)32 ( )]TJ
0.54 -1 Td
[(Blast Phase CML and)-5 ( )]TJ
0.005 Tw 2.341 -1 Td
(Ph)Tj
0 Tc 0 Tw 0.934 0.125 Td
(+)Tj
-0.005 Tc -0.013 Tw 0.595 -0.125 Td
( ALL)Tj
0.024 Tw -4.017 -1 Td
(\(starting dose 140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
6.926 0 Td
[(mg)-5 ( )]TJ
-4.849 -1 Td
(once daily\))Tj
8.385 3 Td
(ANC* <0.5 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 447.2484 346.0034 Tm
(9)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 449.8133 343.2034 Tm
(/L)Tj
-3.192 -1 Td
(or)Tj
0.024 Tw -3.658 -1 Td
[(Pla)-10 (telets <10 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 450.7364 330.0034 Tm
(9)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 453.3014 327.2034 Tm
(/L)Tj
-0.01 Tc 0.024 Tw 1.941 7.5 Td
(1.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(Check if c)20 (ytopenia is rela)-10 (ted to)-10 ( )]TJ
0 -1 Td
[(leukemia \(marro)-9.9 (w aspira)-10 (te or biopsy\).)]TJ
-1.25 -1 Td
(2.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If c)20 (ytopenia is unrela)-10 (ted to leukemia,)27 ( )]TJ
0 -1 Td
[(stop SPR)18 (YCEL until )37 (ANC \0361)60 (.0 )40 (\327 )80 (10)]TJ
0 Tc 0 Tw 5.4 0 0 6 565.6663 366.0034 Tm
(9)Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 568.2043 363.2034 Tm
(/L)Tj
0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-14.017 -1 Td
( )Tj
EMC 
1.25 0 Td
[(and pla)-10 (telets \03620 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 536.4776 358.0034 Tm
(9)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 539.0156 355.2034 Tm
[(/L and)-10 ( )]TJ
-8.713 -1 Td
[(resume a)-9.9 (t the original starting dose.)]TJ
-1.25 -1 Td
(3.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If recurrence of c)20 (ytopenia,)37 ( repea)-10 (t)-9.9 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 564.3333 339.2034 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 476.2799 331.2034 Tm
[(Step 1 and resume SPR)18 (YCEL a)-10 (t a)-9.9 ( )]TJ
0 -1 Td
(reduced dose of 100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily)-10 ( )]TJ
0 -1 Td
(\(second episode\) or 80)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily)-9.9 ( )]TJ
0 -1 Td
(\(third episode\).)Tj
-1.25 -1 Td
(4.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If c)20 (ytopenia is rela)-10 (ted to leukemia,)27 ( )]TJ
0 -1 Td
[(consider dose escala)-10 (tion to 1)20.1 (80)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg)-10 ( )]TJ
0 -1 Td
[(once daily)55.1 (.)]TJ
-0.005 Tc 0.005 Tw 8 0 0 8 323.9999 271.0115 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 326.9999 271.0115 Tm
[(ANC:)37 ( absolute neutrophil count)]TJ
ET
0 0 0 0 k
/GS1 gs
324 257.457 252 -17.312 re
324 240.145 67.68 -16.965 re
391.68 240.145 30.72 -16.965 re
422.4 240.145 153.6 -16.965 re
324 223.18 67.68 -52.912 re
391.68 223.18 30.72 -26.456 re
422.4 223.18 51.2 -26.456 re
473.6 223.18 51.2 -26.456 re
524.8 223.18 51.2 -26.456 re
391.68 196.724 30.72 -26.456 re
422.4 196.724 51.2 -12.912 re
473.6 196.724 51.2 -12.912 re
524.8 196.724 51.2 -12.912 re
422.4 183.812 51.2 -13.544 re
473.6 183.812 51.2 -13.544 re
524.8 183.812 51.2 -13.544 re
324 170.268 67.68 -68.912 re
391.68 170.268 30.72 -68.912 re
422.4 170.268 51.2 -12.912 re
473.6 170.268 51.2 -12.912 re
524.8 170.268 51.2 -12.912 re
422.4 157.356 51.2 -12.912 re
473.6 157.356 51.2 -12.912 re
524.8 157.356 51.2 -12.912 re
422.4 144.444 51.2 -12.912 re
473.6 144.444 51.2 -12.912 re
524.8 144.444 51.2 -12.912 re
422.4 131.532 51.2 -30.176 re
473.6 131.532 51.2 -30.176 re
524.8 131.532 51.2 -30.176 re
324 101.356 67.68 -44.192 re
391.68 101.356 81.92 -44.192 re
473.6 101.356 51.2 -44.192 re
524.8 101.356 51.2 -44.192 re
324 57.164 252 -20.912 re
f
1.01 w 
/GS2 gs
q 1 0 0 1 323.9999 57.1644 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.6799 57.1644 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 422.3999 57.1644 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 473.5999 57.1644 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 524.7999 57.1644 cm
0 0 m
51.2 0 l
S
Q
0.505 w 
q 1 0 0 1 323.9999 36.2525 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.6799 36.2525 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 422.3999 36.2525 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 473.5999 36.2525 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 524.7999 36.2525 cm
0 0 m
51.2 0 l
S
Q
1 w 
q 1 0 0 1 323.9999 240.1451 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.6799 240.1451 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 422.3999 240.1451 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 473.5999 240.1451 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 524.7999 240.1451 cm
0 0 m
51.2 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_1 1 Tf
-0.01 Tc 0.024 Tw 8 0 0 8 323.9999 251.7451 Tm
(Table 4:)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Dose Adjustments for Neutropenia and Thrombocytopenia in)-10 ( )]TJ
0 -1 Td
(Pediatric Patients with Ph)Tj
0 Tc 0 Tw 10.065 0.125 Td
(+)Tj
-0.01 Tc 0.024 Tw 0.59 -0.125 Td
( CML)Tj
-0.02 Tc 7.2 0 0 8 457.2463 228.8067 Tm
(Dose \(maximum dose per day\))Tj
/T1_2 1 Tf
-0.01 Tc -18.506 -1.777 Td
(1.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If c)20 (ytopenia persists)-10 ( )]TJ
-1.25 -1 Td
[(for more than 3 weeks,)27 ( )]TJ
0 -1 Td
[(check if c)20.1 (ytopenia is)-10 ( )]TJ
0 -1 Td
[(rela)-10 (ted to leukemia)-9.9 ( )]TJ
0 -1 Td
[(\(marro)-10 (w aspira)-9.9 (te or)-10 ( )]TJ
0.01 Tw 0 -1 Td
(biopsy\).)Tj
/T1_1 1 Tf
0.024 Tw 13.667 5 Td
[(Original Starting)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 469.9405 214.5882 Tm
( )Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 422.3999 206.5882 Tm
(Dose)Tj
0.024 Tw 7.111 1 Td
[(One-Level Dose)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Reduction)Tj
0.024 Tw 7.111 1 Td
[(T)74 (wo-Level Dose)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Reduction)Tj
-18.489 -2.307 Td
[(T)74 (ablets)]TJ
/T1_2 1 Tf
0.024 Tw 4.267 0 Td
(40 mg)Tj
7.111 0 Td
(20 mg)Tj
0.01 Tw 7.111 0 Td
(**)Tj
0.024 Tw -14.222 -1.614 Td
(60 mg)Tj
7.111 0 Td
(40 mg)Tj
7.111 0 Td
(20 mg)Tj
-27.889 -1.783 Td
(2.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If c)19.9 (ytopenia is)-10 ( )]TJ
-1.25 -1 Td
[(unrela)-10 (ted to leukemia,)27 ( )]TJ
0 -1 Td
[(stop SPR)18 (YCEL until)-10 ( )]TJ
0 -1 Td
(ANC* \0361.0 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 366.0184 139.7563 Tm
(9)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 368.5564 136.9563 Tm
[(/L and)-10 ( )]TJ
-6.188 -1 Td
[(pla)-9.9 (telets \03675 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 372.7211 131.7563 Tm
(9)Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 375.259 128.9563 Tm
[(/L)-10 ( )]TJ
0.024 Tw -7.119 -1 Td
[(and resume a)-10 (t the)-10 ( )]TJ
0 -1 Td
[(original starting dose or)-10 ( )]TJ
0 -1 Td
[(a)-10 (t a reduced dose.)]TJ
13.667 7 Td
(70 mg)Tj
7.111 0 Td
(60 mg)Tj
7.111 0 Td
(50 mg)Tj
-14.222 -1.614 Td
(100 mg)Tj
7.111 0 Td
(80 mg)Tj
7.111 0 Td
(70 mg)Tj
-27.889 -6.955 Td
(3.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If c)20 (ytopenia recurs,)27 ( )]TJ
-1.25 -1 Td
[(repea)-10 (t marro)-10 (w aspira)-9.9 (te/)]TJ
0 -1 Td
[(biopsy and resume)-9.9 ( )]TJ
0 -1 Td
[(SPR)18 (YCEL a)-10 (t a reduced)-10 ( )]TJ
0.01 Tw 0 -1 Td
(dose.)Tj
-0.005 Tc 0 Tw 8 0 0 8 323.9999 47.8525 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.375 0 Td
[(ANC:)37 ( absolute neutrophil count)]TJ
-0.375 -1 Td
(**)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.75 0 Td
[(lo)-10 (wer tablet dose not a)-10 (vailable)]TJ
ET
endstreamendobj107 0 obj<</BaseFont/NXSWOC+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 111 0 R/LastChar 174/Subtype/Type1/ToUnicode 112 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 741 0 648 0 0 0 0 0 0 593 0 0 0 667 0 722 649 0 0 0 0 0 667 0 0 0 0 0 0 0 574 611 0 611 0 0 0 0 258 0 0 0 0 593 0 0 0 0 537 352 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj111 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/C/E/L/P/R/S/Y/a/b/d/i/n/s/t/registered)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 113 0 R/FontName/NXSWOC+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj112 0 obj<</Filter/FlateDecode/Length 312>>stream
Hâ\ëÀj√0E˜˙äY6ã‡G#;cn
^ÙA›~Ä#çSA-ŸY¯Ô;“Ñ*∞Á›{ëfí¶}j≠Y y˜ìÍpÅ¡XÌqûÆ^!úÒb¨»r–F-∑]¸´±w"!s∑Œé≠&QUê|–·º¯éz:„F$o^£7ˆ_M∑Å§ª:˜É#⁄R®k–8P–KÔ^˚!â∂m´È‹,Îñ<äœ’!‰qüÒe‘§qvΩBﬂ€ä*•UCıL´hıøÛlœ∂Û†æ{/™<à”î
Òûy¯¿| ﬁ=F¶B,ôe‡Üπ!ñú#CéÃôÛ¿Ïï¡+9SÜÃ"ãLÖòıE–;Ê]`÷Qb>óúYÜÃíıe–YC%<¸ˆ¬–ö‹˚´ÆﬁSk„8cOC7ç≈˚ƒ›‰Ä\·ø ][ó>endstreamendobj113 0 obj<</Filter/FlateDecode/Length 1660/Subtype/Type1C>>stream
HâÑTT◊ûawﬂíQYÜ‚ÆŒå+—z\`wA4(PƒÄ
˛ê(faY;fw˘Gm⁄‘BƒHêTå?%!∂QàGõZâä?±§çGOM”(bc{*•1)©Âﬁ==}K5=ÈiOÁùÛﬁΩoÓ˝Ó˝Ó{Ô≤å6àaYvZˆ˙‹u9isñ…eï≤œU‰»ñ+‰yπ>gÃg¿@TM¨°UßÜÒòåÓáóÈ‘g'™€'8UÔgÇ0õY_ö≤•∆„⁄\‚ìlIÛÁ[Ëúdü„-í›jµK©N•Pñrkº>π‹+e∫ãœ≈„…ŒX)µ¨LwˆJŸ+{*õˇqÖÀ≠¯j∂»““Ú¬eˇ‰^íÀ+9$ü«·îÀû$•¯ﬂ˛i4ïXÍ¥ŸEìÛ»N…Âñ|%≤¥&67VZISt˚$á€)Â}„ùS\Ï*í«7À5%ˆmÔ"Ÿ„s–U°0©¥¬„Ú:]E>ó‚ˆ>w; ÂˇíÖ‚ë\îAÖw{e˘?H∆e‰Êî…)3Ùcô&îâff21åçâgòdf	ì∆§3Àô&èY√fÙàòlf”»\d#ÿEl>{ê˝GêtP°)’\“igiµø“ÂcÙŒıãñŒ—=öùZµal•øÅ¿´ÿÀc
Ï—¡A	/P¸-z?)ó!©N‘Û|@¬Ä∆˘É8ú[˘…*ˆ<ò5∞bL·„—∞	sp∂≠=høçS%©Ì;ÿçwlü¬t·±ﬂH¿OãÀ˘?@¯)»ÅŸF∞ÊÉ=	¶	J>≈'ﬂE;⁄çWÇ∂TîÓãZàR´!ä=6Õÿ3™õá§jå∫á6æàëòÑ%XtÖ!&Åå˝"ZHÃˆ5ôsL8}-Ñ¡ò|Å.”o˛vÕ”Øã‹ÓùEm9à°∞◊(ÏµHıÁÂÁÈÊó¿·ó£>Aı£Ñ[OM’˛™«Vª 
ˇ™ˆ£çpoµWB+≈(.⁄¿B-®–
I4ák†É`Œ fàxùÄ98Ú˚+uVÎÚ∫%"rÑªI1:AatçG°B'ÿHˇ;•ã,ÓY›òq® òÍ {MÉ›;>©∏ûÚì‡]˙˛Œw/ÅI˛#F~˛QÄ≈‰„Âiry∫àã	◊\ú⁄\xX0,p,Ü>√Pºƒ„”ç›ß¿nÇµ_ﬂáÔ¿<LËZ◊&˙pÈ˚ÆñåøÓmÔπ˛õäπÕX$·¥+8y“q&GˇÆî—m)∆%âuyÇa(1ı¯∞® XA-î	¥®¸î¿AuÖ”Ì5«p”a:Å˝˛e:.}ÎpÚg √·ù`Ü0∫’0ÿ¿ó˝(5€.úÔçS≠¬©==MÌ¡ò˝Äø‘|ÏÕã¶ûìﬂœ^ï¸j¬61~{ºÇ!∆È7üΩ˘ÍÅ”›Ç°∫©vwms]0DìmÌ;Nü6¬õzòÑìﬁä∆`úPÑS~ p•[Gcá`p≤™¬/“»/—»gı#¡DgØÓ“Ø>zŸw√Ù5h`5¨BÕ@tVñwmâÿmh&ÍDˇ~nÒ¬ƒƒ‚˛œÔÔ<æ0·€®>;˛Ö™.†∞ch∆∂FrÓÖú√Ÿ&¥§–Bä¢·,Œ∏ÅÙ\ÌÌ∏‘%Ï"ç∞ñüß$≈ƒﬂ˘ÏNÁ≠°{G$
ú?≤ΩR›WıÑ∞ΩÙıÙFÇY›GÛ†1ÚyäfzQ©M‚˝Ÿ†g¥1PK «‰A◊/˚ÆæÌò'`7’ßá˘Œ…yFYµYh ÜæO–§Á§≠√Ùÿ_Pã,„X»„¥◊ § ¬L
°ß`Í_íèÃ?$&Z–rŒxÚÙkùÁN÷ÁÌh…¿Ω'PgBFYoªo◊à#÷?oÃ_WWòªÓÌè^°Ôø˚áÙ¶_fÔ:¿∂±Ñ@Íqs-üc/âæQu˜gGõvw†—7‘o}•ﬁÙ‹ˆΩgDh˝€=÷⁄[p
]∏≈ÓÅ)` vD≥ÚXô86—ë	≥†™0f‚&:2ÈM≠F"i7õL;É‚¿Äi'[ÑúÑqh√…0		0e~ ñû'#∏Twó†≤t5ü9“g¸” .≥Äv2∞úˇòú8Ûr¡˙íó7à©Ñ´=0Vp K˜¡S;	hiı˜Ì”?⁄‹á[æjÒˇyo»h(ò'åæÊ7¬ûÄ≥cQ¸? âëâêendstreamendobj105 0 obj<</Length 21465>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8 0 0 8 36 750.2881 Tm
[(HIGHLIGHTS OF PRESCRIBING INFORMA)55 (TION)]TJ
0.19 Tw 0 -1.315 Td
[(These )0.5 (highlights do )0.5 (not inc)20 (lude all the )0.5 (information )0.5 (needed to use )0.5 (SPR)18 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 283.2001 742.5681 Tm
(\256)Tj
8 0 0 8 288 739.7681 Tm
( )Tj
T*
( )Tj
-0.01 Tc -31.5 -1 Td
[(safely and effectively)55 (.)37 ( See full prescribing information for SPR)18 (YCEL.)]TJ
0 -1.697 Td
[(SPR)18 (YCEL \(dasatinib\) tablets,)37 ( for oral use)]TJ
0 -1.315 Td
[(Initial U.S.)37.1 ( Appro)-10 (v)16 (al: 2006)]TJ
0.01 Tw 0 -1.751 Td
(------------------------------)Tj
0 Tw 10.903 0 Td
[(INDIC)18.1 (A)54.9 (TIONS AND USAGE)]TJ
0.052 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-----------------------------)Tj
0 Tw -10.903 -1.315 Td
[(SPR)18 (YCEL is a kinase inhibitor indicated for the treatment of)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.185 Tw 2.25 0 Td
[(newly dia)-9.9 (gnosed adults with Philadelphia chromosome-positive \(Ph)]TJ
0 Tc 0 Tw 25.352 0.125 Td
(+)Tj
-0.01 Tc 0.185 Tw 0.59 -0.125 Td
[(\) chronic)-9.9 ( )]TJ
0 Tw -25.942 -1.062 Td
[(myeloid leukemia \(CML\) in chronic phase.)37 ( \(1,)37 ( 14\))]TJ
0.01 Tw -2.25 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.106 Tw 2.25 0 Td
[(adults with chronic,)37 ( accelera)-10 (ted,)37.1 ( or myeloid or lymphoid blast phase Ph)]TJ
0 Tc 0 Tw 26.677 0.125 Td
(+)Tj
-0.01 Tc 0.106 Tw 0.59 -0.125 Td
[( CML)-10 ( )]TJ
0 Tw -27.267 -1.062 Td
[(with resistance or intolerance to prior thera)-9.9 (py inc)20 (luding ima)-9.9 (tinib.)37 ( \(1,)37 ( 14\))]TJ
0.01 Tw -2.25 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.288 Tw 2.25 0 Td
[(adults with Philadelphia chromosome-positive acute lymphoblastic leukemi\a)-9.9 ( )]TJ
0 Tc 0 Tw 29.25 0 Td
( )Tj
-0.01 Tc 0.01 Tw -29.25 -1.062 Td
(\(Ph)Tj
0 Tc 0 Tw 1.155 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( )37 (ALL\) with resistance or intolerance to prior thera)-9.9 (py)55 (.)37 ( \(1,)37 ( 14\))]TJ
0.01 Tw -3.995 -1.513 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 2.25 0 Td
[(pedia)-9.9 (tric pa)-9.9 (tients 1 year of a)-9.9 (ge and older with Ph)]TJ
0 Tc 17.699 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( CML in chronic phase.)37 ( \(1,)37 ( 14\))]TJ
0.01 Tw -20.539 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.172 Tw 2.25 0 Td
[(pedia)-9.9 (tric pa)-9.9 (tients 1 year of a)-9.9 (ge and older with newly dia)-10 (gnosed Ph)]TJ
0 Tc 0 Tw 25.878 0.125 Td
(+)Tj
-0.01 Tc 0.135 Tw 0.59 -0.125 Td
[( ALL )-36.8 (in)-10 ( )]TJ
0 Tw -26.468 -1.062 Td
[(combina)-10 (tion with chemothera)-10 (py)55 (.)37 ( \(1,)37 ( 14\))]TJ
/T1_0 1 Tf
0.01 Tw -2.25 -1.796 Td
(---------------------------)Tj
0 Tw [(DOSAGE AND ADMINISTRA)55 (TION)]TJ
-0.05 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 2.25 0 Td
[(Chronic phase CML in adults:)37 ( 100)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily)55 (.)37 ( \(2\))]TJ
0.01 Tw -2.25 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.123 Tw 2.25 0 Td
[(Accelera)-10 (ted phase CML,)37 ( myeloid or lymphoid blast phase CML,)37 ( or Ph)]TJ
0 Tc 0 Tw 25.976 0.125 Td
(+)Tj
-0.01 Tc 0.086 Tw 0.59 -0.125 Td
[( ALL )-36.8 (in)-10 ( )]TJ
0 Tw -26.566 -1.062 Td
[(adults:)37 ( 140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily)55 (.)37 ( \(2\))]TJ
0.01 Tw -2.25 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.008 Tw 2.25 0 Td
[(Chronic phase CML and )37.2 (ALL in pedia)-10 (trics:)37 ( starting dose based on bod)-10 (y weight.)37 ( \(2\))]TJ
0.01 Tw -2.25 -1.513 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 2.25 0 Td
[(Administer orally)55 (,)37 ( with or without a meal.)37 ( Do not crush,)37.1 ( cut,)37 ( or chew tablets.)37 ( \(2\))]TJ
/T1_0 1 Tf
0.01 Tw -2.25 -1.796 Td
(-------------------------)Tj
0 Tw 9.27 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
-0.141 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-------------------------)Tj
/T1_1 1 Tf
0 Tw -9.27 -1.332 Td
[(T)74 (ablets:)37 ( 20)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg,)37 ( 50)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg,)37.1 ( 70)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg,)37 ( 80)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg,)37 ( 100)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg,)37 ( and 140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg.)37.1 ( \(3\))]TJ
/T1_0 1 Tf
0 Tc 0 -1.63 Td
(-------------------------------)Tj
-0.01 Tc 0.01 Tw 11.67 0 Td
[(CONTRAINDIC)18 (A)55 (TIONS)]TJ
0 Tc -0.09 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-------------------------------)Tj
/T1_1 1 Tf
-0.01 Tc 0 Tw -11.67 -1.332 Td
[(None.)37.1 ( \(4\))]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.661 Td
(---------------------------)Tj
0 Tw 9.833 0 Td
[(W)18 (ARNINGS AND PREC)18 (AUTIONS)]TJ
0.062 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------)Tj
/T1_1 1 Tf
0.01 Tw -9.833 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.108 Tw 2.25 0 Td
(Myelosuppression and Bleeding Events:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
14.625 0 Td
[( Severe thromboc)20 (ytopenia,)37 ( neutropenia,)27 ( )]TJ
0.05 Tw -14.625 -1.062 Td
[(and anemia may occur)74 (.)37 ( Use caution if used concomitantly with medica)-10 (tions tha)-10 (t)-9.9 ( )]TJ
-0.05 Tw 0 -1.062 Td
[(inhibit pla)-9.9 (telet function or anticoa)-10 (gulants.)37 ( Monitor complete blood counts regularly)55 (.)27 ( )]TJ
0 Tw 0 -1.062 Td
[(T)74 (ransfuse and interrupt SPR)18 (YCEL when indica)-10 (ted.)37 ( \(2.5,)37 ( 5.1,)37 ( 5.2\))]TJ
0.01 Tw -2.25 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.152 Tw 2.25 0 Td
(Fluid Retention:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.78 0 Td
[( Fluid retention,)37 ( sometimes severe,)37 ( inc)20 (luding pleural effusions.)27 ( )]TJ
0 Tw -5.78 -1.062 Td
[(Mana)-9.9 (ge with supportive care measures and/or dose modi\037ca)-10 (tion.)37 ( \(2.5,)37 ( 5.3\))]TJ
0.01 Tw -2.25 -1.49 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.298 Tw 2.25 0 Td
[(Cardiovascular T)74 (oxicity:)]TJ
/T1_1 1 Tf
0.335 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.768 0 Td
[( Monitor pa)-9.9 (tients for signs or symptoms and trea)-10 (t)-10 ( )]TJ
0 Tw -8.768 -1.062 Td
[(a)-10 (ppropria)-10 (tely)55 (.)37 ( \(5.4\))]TJ
0.01 Tw -2.25 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.321 Tw 2.25 0 Td
[(Pulmonar)-18 (y )37.5 (Arterial )0.5 (Hypertension )0.5 (\(P)37 (AH\):)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
14.917 0 Td
[( )0.5 (SPR)18 (YCEL )0.5 (may )0.5 (increase )0.5 (the )0.5 (risk of)-9.9 ( )]TJ
0.114 Tw -14.917 -1.062 Td
[(developing P)37 (AH which may be reversible on discontinua)-9.9 (tion.)37 ( Consider baseline)-10 ( )]TJ
0.188 Tw 0 -1.062 Td
[(risk and evalua)-9.9 (te pa)-10 (tients for signs and symptoms of P)37 (AH during trea)-9.9 (tment.)27 ( )]TJ
0 Tc 0 Tw 29.25 0 Td
( )Tj
-0.01 Tc -29.25 -1.062 Td
[(Stop SPR)18 (YCEL if P)37 (AH is con\037rmed.)37 ( \(5.5\))]TJ
0.01 Tw 33.75 51.215 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.084 Tw 2.25 0 Td
[(QT )0.5 (Prolonga)-10 (tion:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
6.073 0 Td
[( )0.5 (Use )0.5 (SPR)18 (YCEL \(dasa)-10 (tinib\) with caution )0.5 (in )0.5 (pa)-9.9 (tients )0.5 (who ha)-9.9 (ve )0.5 (or)-10 ( )]TJ
0 Tw -6.073 -1.062 Td
[(may develop prolonga)-10 (tion of the QT inter)-18 (val.)36.9 ( \(5.6\))]TJ
0.01 Tw -2.25 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.326 Tw 2.25 0 Td
[(Severe Derma)-9.9 (tologic Reactions:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
12.163 0 Td
[( Individual cases of severe mucocutaneous)-10 ( )]TJ
0 Tw -12.163 -1.062 Td
[(derma)-10 (tologic reactions ha)-10 (ve been reported.)37 ( \(5.7\))]TJ
0.01 Tw -2.25 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.272 Tw 2.25 0 Td
[(T)74 (umor L)37 (ysis Syndrome:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.969 0 Td
[( )36.7 (T)74 (umor lysis syndrome has been reported.)37 ( Maintain)-10 ( )]TJ
0.143 Tw -8.969 -1.062 Td
[(adequa)-10 (te hydra)-10 (tion and correct uric acid levels prior to initia)-10 (ting thera)-10 (py with)-10 ( )]TJ
0 Tw 0 -1.062 Td
[(SPR)18 (YCEL.)37 ( \(5.8\))]TJ
0.01 Tw -2.25 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.178 Tw 2.25 0 Td
[(Embr)-17.9 (yo-F)24 (etal T)74 (oxicity:)]TJ
/T1_1 1 Tf
0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.142 0 Td
[( Can cause fetal harm.)37.1 ( )37.1 (Advise pa)-10 (tients of reproductive)-10 ( )]TJ
-0.016 Tw -8.142 -1.062 Td
[(potential )0.5 (of )0.5 (potential )0.5 (risk )0.5 (to fetus )0.5 (and )0.5 (to )0.5 (use )0.5 (effective )0.5 (contraception.)37 ( )0.5 (\(5.9,)37.1 ( 8.1,)37 ( )0.5 (8.3\))]TJ
0.01 Tw -2.25 -1.468 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.205 Tw 2.25 0 Td
[(Effects on Gro)-10 (wth and Development in P)18 (edia)-10 (tric P)18 (a)-10 (tients:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
21.961 0 Td
[( epiphyses delayed)-10 ( )]TJ
0.151 Tw -21.961 -1.062 Td
[(fusion,)37 ( osteopenia,)37 ( gro)-10 (wth retarda)-10 (tion,)37 ( and g)-10 (ynecomastia ha)-10 (ve been reported.)27 ( )]TJ
0 Tw 0 -1.062 Td
[(Monitor bone gro)-9.9 (wth and development in pedia)-10 (tric pa)-10 (tients.)37 ( \(5.10\))]TJ
0.01 Tw -2.25 -1.49 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
2.25 0 Td
[(Hepa)-10 (totoxicity:)]TJ
/T1_1 1 Tf
0.132 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.33 0 Td
[( )37 (Assess liver function before initia)-9.9 (tion of trea)-9.9 (tment and monthly)-10 ( )]TJ
0.112 Tw -5.33 -1.062 Td
[(thereafter or as c)20 (linically indica)-10 (ted.)37 ( Monitor liver function when combined with)-10 ( )]TJ
0 Tw 0 -1.062 Td
[(chemothera)-10 (py kno)-9.9 (wn to be associa)-10 (ted with liver d)-10 (ysfunction.)37.1 ( \(5.11\))]TJ
/T1_0 1 Tf
0.01 Tw -2.25 -1.765 Td
(--------------------------------)Tj
0 Tw 11.614 0 Td
(ADVERSE REACTIONS)Tj
0 Tc -0.147 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-------------------------------)Tj
/T1_1 1 Tf
-0.01 Tc 0.008 Tw -11.614 -1.332 Td
[(Most )0.5 (common adverse )0.5 (reactions )0.5 (\(\03615%\) )0.5 (in pa)-9.9 (tients )0.5 (receiving )0.5 (SPR)18 (YCEL )0.5 (as single-a)-9.9 (gent)-10 ( )]TJ
0.194 Tw 0 -1.062 Td
[(thera)-10 (py )0.6 (inc)20 (luded )0.6 (myelosuppression,)37 ( )0.6 (\035uid )0.6 (retention )0.6 (events,)37 ( )0.5 (diarrhea,)37 ( )0.5 (headache,)37 ( )0.6 (skin)-10 ( )]TJ
0 Tw 0 -1.062 Td
[(rash,)37.1 ( hemorrha)-10 (ge,)37 ( d)-9.9 (yspnea,)37 ( fa)-10 (tigue,)37 ( nausea,)37 ( and musculoskeletal pain.)37 ( \(6\))]TJ
0.279 Tw 0 -1.242 Td
[(Most common adverse reactions \(\03630%\) in pedia)-10 (tric pa)-10 (tients receiving SPR)18 (YCEL)-9.9 ( )]TJ
0.213 Tw 0 -1.062 Td
[(in combina)-9.9 (tion with chemothera)-10 (py inc)20 (luded )0.5 (mucositis,)37 ( febrile neutropenia,)37 ( pyrexia,)27 ( )]TJ
0.157 Tw 0 -1.062 Td
[(diarrhea,)37 ( nausea,)37 ( vomiting,)37 ( musculoskeletal pain,)37 ( abdominal pain,)37 ( cough,)37 ( headache,)27 ( )]TJ
0.073 Tw 0 -1.062 Td
[(rash,)37.1 ( fa)-10 (tigue,)37 ( constipa)-9.9 (tion,)37 ( arrhythmia,)37 ( hypertension,)37 ( edema,)37 ( infections \(bacterial,)37 ( viral)-10 ( )]TJ
0.317 Tw 0 -1.062 Td
[(and fungal\),)37 ( hypotension,)37 ( decreased a)-9.9 (ppetite,)37 ( hypersensitivity)55 (,)37 ( d)-10 (yspnea,)37 ( epistaxis,)27 ( )]TJ
0 Tw 0 -1.062 Td
[(peripheral neuropa)-9.9 (thy)55 (,)37 ( and altered sta)-10 (te of consciousness.)37 ( \(6\))]TJ
/T1_0 1 Tf
0.253 Tw 0 -1.495 Td
[(T)74 (o report SUSPECTED ADVERSE REACTIONS,)37 ( contact Bristol-Myers Squibb at)-10 ( )]TJ
0 Tw 0 -1 Td
[(1-800-721-5072 or FD)34 (A at 1-800-FD)34.1 (A-1088 or www)37 (.fda.go)-10 (v/medwatch.)]TJ
0.01 Tw 0 -1.976 Td
(--------------------------------)Tj
0 Tw 11.684 0 Td
[(DR)-10 (UG INTERACTIONS)]TJ
0.113 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-------------------------------)Tj
/T1_1 1 Tf
0.01 Tw -11.684 -1.445 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0 Tw 2.25 0 Td
(Strong CYP3A4 Inhibitors:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.256 0 Td
[( Dose reduction may be necessar)-17.9 (y)55 (.)37 ( \(2.3,)37 ( 7.1\))]TJ
0.01 Tw -11.506 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0 Tw 2.25 0 Td
(Strong CYP3A4 Inducers:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.035 0 Td
[( Dose increase may be necessar)-18 (y)55 (.)37.1 ( \(2.3,)37 ( 7.1\))]TJ
0.01 Tw -11.285 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
2.25 0 Td
(Antacids:)Tj
/T1_1 1 Tf
0 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.348 0 Td
[( )37 (Avoid simultaneous administra)-10 (tion.)37 ( \(7.1\))]TJ
0.01 Tw -5.598 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0 Tc 0 Tw 2.25 0 Td
(H)Tj
-0.01 Tc 0.01 Tw 6 0 0 6 346.2158 437.6381 Tm
(2 )Tj
0 Tw 8 0 0 8 350.4157 438.1381 Tm
[(Anta)-9.9 (gonists and Proton Pump Inhibitors:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
14.457 0 Td
[( )37 (Avoid coadministra)-10 (tion.)37 ( \(7.1\))]TJ
/T1_0 1 Tf
0.01 Tw -17.759 -1.742 Td
(---------------------------)Tj
0 Tw 9.813 0 Td
[(USE IN SPECIFIC POPULA)54.9 (TIONS)]TJ
0 Tc -0.098 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -9.813 -1.445 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
2.25 0 Td
[(Lacta)-10 (tion:)]TJ
/T1_1 1 Tf
0 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.569 0 Td
[( )37 (Advise women not to breastfeed.)37.1 ( \(8.2\))]TJ
/T1_0 1 Tf
-0.051 Tw -5.819 -2.134 Td
[(See 1)40 (7 for P)54 (A)55 (TIENT COUNSELING INFORMA)55 (TION and FD)34 (A-appro)-10 (ved patient labeling.)]TJ
0.01 Tw 25.318 -1.526 Td
(Revised:)Tj
0 1 0 0 k
/GS1 gs
0 Tc 0 Tw ( )Tj
0 0 0 1 k
/GS0 gs
-0.01 Tc 0.01 Tw 3.5 0 Td
(7/2024)Tj
0 Tw -64.818 -9.565 Td
[(FULL PRESCRIBING INFORMA)55 (TION: CONTENTS*)]TJ
-0.005 Tc 0 -1.346 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(INDIC)18 (A)55 (TIONS AND USAGE)]TJ
-3.125 -1.301 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(DOSAGE AND ADMINISTRA)55 (TION)]TJ
/T1_1 1 Tf
0.025 -1.247 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dosa)-10 (ge of SPR)17.9 (YCEL in )37 (Adult P)18 (a)-10 (tients)]TJ
-3.038 -1.225 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dosa)-10 (ge of SPR)17.9 (YCEL in P)18 (edia)-10 (tric P)18 (a)-10 (tients with CML or Ph)]TJ
0 Tc 20.489 0.125 Td
(+)Tj
-0.005 Tc -0.037 Tw 0.595 -0.125 Td
( ALL)Tj
0 Tw -24.121 -1.225 Td
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dose Modi\037ca)-10 (tion)]TJ
-3.038 -1.225 Td
(2.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dose Escala)-10 (tion in )37 (Adults with CML and Ph)]TJ
0 Tc 15.575 0.125 Td
(+)Tj
-0.005 Tc 0.595 -0.125 Td
[( )37 (ALL,)37 ( and P)18 (edia)-10 (tric)-5 ( )]TJ
-16.17 -1 Td
[(P)18 (a)-10 (tients with CML)]TJ
-0.037 Tw -3.038 -1.225 Td
(2.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dose Adjustment )-37 (for Adverse )-37 (Reactions)]TJ
-3.038 -1.225 Td
(2.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dura)-10 (tion )-37 (of T)74 (rea)-9.9 (tment)]TJ
/T1_0 1 Tf
0 Tw -6.187 -1.279 Td
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
2.415 Tw -3.125 -1.301 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
[(CONTRAINDIC)18 (A)55 (TIONS)]TJ
0 Tw 0 -1.301 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(W)18 (ARNINGS AND PREC)18 (AUTIONS)]TJ
/T1_1 1 Tf
1.618 Tw 0.025 -1.247 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
(Myelosuppression)Tj
0 Tw -3.038 -1.225 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Bleeding-Rela)-10 (ted Events)]TJ
-3.038 -1.225 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
(Fluid Retention)Tj
-0.037 Tw -3.038 -1.225 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Cardiovascular T)74 (oxicity)]TJ
-3.038 -1.225 Td
(5.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Pulmonar)-18 (y Arterial )-37 (Hypertension)]TJ
0 Tw -3.038 -1.225 Td
(5.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(QT Prolonga)-10 (tion)]TJ
-3.038 -1.225 Td
(5.7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Severe Derma)-10 (tologic Reactions)]TJ
-3.038 -1.225 Td
(5.8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(T)74 (umor L)37 (ysis Syndrome)]TJ
-0.037 Tw -3.038 -1.225 Td
(5.9)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Embr)-18 (yo-F)24 (etal T)73.9 (oxicity)]TJ
0 Tw -3.038 -1.225 Td
(5.10)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Effects on Gro)-10 (wth and Development in P)18.1 (edia)-10 (tric P)18 (a)-10 (tients)]TJ
1.143 Tw -3.038 -1.225 Td
(5.11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Hepa)-10 (totoxicity)]TJ
/T1_0 1 Tf
0 Tw -6.187 -1.279 Td
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(ADVERSE REACTIONS)Tj
/T1_1 1 Tf
-0.037 Tw 0.025 -1.247 Td
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Clinical T)74 (rials )-37 (Experience)]TJ
0 Tw -3.038 -1.225 Td
(6.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(P)18 (ostmarketing Experience)]TJ
/T1_0 1 Tf
29.813 32.15 Td
(7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(DR)-10 (UG INTERACTIONS)]TJ
/T1_1 1 Tf
0.025 -1.247 Td
(7.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Effect of Other Drugs on Dasa)-10 (tinib)]TJ
/T1_0 1 Tf
-6.187 -1.279 Td
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(USE IN SPECIFIC POPULA)55 (TIONS)]TJ
/T1_1 1 Tf
1.618 Tw 0.025 -1.247 Td
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Pregnanc)20 (y)]TJ
-3.038 -1.225 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Lacta)-10 (tion)]TJ
0 Tw -3.038 -1.225 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(F)24 (emales and Males of Reproductive P)18 (otential)]TJ
-3.038 -1.225 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(P)18 (edia)-10 (tric Use)]TJ
-3.038 -1.225 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Geria)-10 (tric Use)]TJ
/T1_0 1 Tf
1.94 Tw -6.187 -1.279 Td
(10)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
(OVERDOSAGE)Tj
0 -1.301 Td
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
(DESCRIPTION)Tj
0 Tw 0 -1.301 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(CLINIC)18 (AL PHARMACOLOGY)]TJ
/T1_1 1 Tf
-0.037 Tw 0.025 -1.247 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Mechanism )-37 (of Action)]TJ
1.143 Tw -3.038 -1.225 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Pharmacod)-9.9 (ynamics)]TJ
-3.038 -1.225 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
(Pharmacokinetics)Tj
/T1_0 1 Tf
0 Tw -6.187 -1.279 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(NONCLINIC)18 (AL TOXICOLOGY)]TJ
/T1_1 1 Tf
0.025 -1.247 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Carcinogenesis,)37 ( Muta)-9.9 (genesis,)36.9 ( Impairment of F)24 (ertility)]TJ
/T1_0 1 Tf
-6.187 -1.279 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(CLINIC)18 (AL STUDIES)]TJ
/T1_1 1 Tf
0.025 -1.247 Td
(14.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Newly Dia)-10 (gnosed Chronic Phase CML in )37 (Adults)]TJ
-3.038 -1.225 Td
(14.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Ima)-10 (tinib-Resistant or -Intolerant CML or Ph)]TJ
0 Tc 15.639 0.125 Td
(+)Tj
-0.005 Tc -0.037 Tw 0.595 -0.125 Td
[( ALL )-37 (in Adults)]TJ
0 Tw -19.271 -1.225 Td
(14.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(CML in P)18 (edia)-10 (tric P)17.9 (a)-9.9 (tients)]TJ
1.143 Tw -3.038 -1.225 Td
(14.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
(Ph)Tj
0 Tc 0 Tw 0.934 0.125 Td
(+)Tj
-0.005 Tc 0.595 -0.125 Td
[( )37 (ALL in P)18 (edia)-10 (tric P)17.9 (a)-9.9 (tients)]TJ
/T1_0 1 Tf
1.94 Tw -7.716 -1.279 Td
(15)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
(REFERENCES)Tj
0 Tw 0 -1.301 Td
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
-3.125 -1.301 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(P)54 (A)55 (TIENT COUNSELING INFORMA)55 (TION)]TJ
/T1_1 1 Tf
-3.125 -2.385 Td
[(*Sections or subsections omitted from the full prescribing informa)-9.9 (tion are not listed.)]TJ
ET
0 0 0 1 K
4 M 
q 1 0 0 1 36 36.5 cm
0 0 m
540 0 l
S
Q
q 1 0 0 1 36 325.835 cm
0 0 m
540 0 l
S
Q
endstreamendobj114 0 obj<</CreationDate(D:20240806060902-04'00')/Creator(Adobe InDesign 19.5 \(Macintosh\))/ModDate(D:20240806060904-04'00')/Producer(Adobe PDF Library 17.0)/Trapped/False>>endobjxref
0 115
0000000000 65535 f
0000000016 00000 n
0000000124 00000 n
0000012576 00000 n
0000000000 00000 f
0000458249 00000 n
0000459203 00000 n
0000460182 00000 n
0000461373 00000 n
0000462564 00000 n
0000012855 00000 n
0000014046 00000 n
0000015249 00000 n
0000016442 00000 n
0000012636 00000 n
0000012725 00000 n
0000017723 00000 n
0000018926 00000 n
0000020118 00000 n
0000021310 00000 n
0000022433 00000 n
0000023556 00000 n
0000425427 00000 n
0000165524 00000 n
0000280014 00000 n
0000072893 00000 n
0000259131 00000 n
0000259743 00000 n
0000260533 00000 n
0000255466 00000 n
0000396594 00000 n
0000366190 00000 n
0000374128 00000 n
0000340331 00000 n
0000373965 00000 n
0000365273 00000 n
0000365730 00000 n
0000366027 00000 n
0000363536 00000 n
0000312524 00000 n
0000340217 00000 n
0000280126 00000 n
0000234645 00000 n
0000212917 00000 n
0000078885 00000 n
0000190792 00000 n
0000079502 00000 n
0000079014 00000 n
0000051702 00000 n
0000165637 00000 n
0000024693 00000 n
0000073004 00000 n
0000052182 00000 n
0000052679 00000 n
0000052932 00000 n
0000053313 00000 n
0000073041 00000 n
0000134942 00000 n
0000134967 00000 n
0000108034 00000 n
0000108281 00000 n
0000080065 00000 n
0000080318 00000 n
0000080845 00000 n
0000108775 00000 n
0000135575 00000 n
0000136043 00000 n
0000136112 00000 n
0000136372 00000 n
0000136481 00000 n
0000190926 00000 n
0000190951 00000 n
0000191447 00000 n
0000191825 00000 n
0000191894 00000 n
0000192160 00000 n
0000192261 00000 n
0000256152 00000 n
0000256655 00000 n
0000257005 00000 n
0000257386 00000 n
0000273960 00000 n
0000274057 00000 n
0000274614 00000 n
0000267147 00000 n
0000267278 00000 n
0000268004 00000 n
0000261086 00000 n
0000261182 00000 n
0000261734 00000 n
0000262346 00000 n
0000268723 00000 n
0000275244 00000 n
0000363573 00000 n
0000373482 00000 n
0000372220 00000 n
0000371004 00000 n
0000371092 00000 n
0000371364 00000 n
0000366647 00000 n
0000367052 00000 n
0000367561 00000 n
0000371668 00000 n
0000372526 00000 n
0000373740 00000 n
0000595498 00000 n
0000566264 00000 n
0000592512 00000 n
0000541356 00000 n
0000510923 00000 n
0000463754 00000 n
0000593018 00000 n
0000593370 00000 n
0000593752 00000 n
0000617016 00000 n
trailer<</Size 115/Root 1 0 R/Info 114 0 R/ID[<4325957DA24D4B268247B9A333CDF3E1><D0E872CA95D240308ECF37AF231069E4>]>>startxref617199%%EOF1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R/DisplayDocTitle true>>>>endobj2 0 obj<</Length 14742/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c001 79.675d0f7, 2023/06/11-19:21:16        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2024-08-06T06:09:02-04:00</xmp:CreateDate>
         <xmp:MetadataDate>2024-08-06T09:18:26-04:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-08-06T09:18:26-04:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 19.5 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:0745d62f-6067-af46-b1bf-e67d5a72899a</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:e39f43de-0c1a-4941-9dd9-0badbdf8b922</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:3e3683c0-b9fa-49de-b78c-930e9c60c92b</stRef:instanceID>
            <stRef:documentID>xmp.did:4bcd62d9-3e53-493a-a33d-d24571dfb7a9</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 19.5 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2024-08-06T06:09:02-04:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">SPRYCEL U.S. Prescribing Information</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Bag>
               <rdf:li>Bristol Myers Squibb</rdf:li>
            </rdf:Bag>
         </dc:creator>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2913240868</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Geneva</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>TrueType</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2913240868</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Apple Computer</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Geneva</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>17.0</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2360395111</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>PostScript</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2360395111</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>29583</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeue-Medium</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>001.002</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2027153225</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2027153225</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4218679263</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4218679263</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.100</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4226815537</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4226815537</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3939600684</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3939600684</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>20675831</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>TrueType</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>20675831</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Apple Computer</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Helvetica</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>9.0</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1593802331</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Verdana</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1593802331</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Microsoft</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Verdana-Bold</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.02</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2888882455</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Symbol Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2888882455</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>SymbolStd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.045</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                           
<?xpacket end="w"?>endstreamendobj115 0 obj<</Author(Bristol Myers Squibb)/CreationDate(D:20240806060902-04'00')/Creator(Adobe InDesign 19.5 \(Macintosh\))/ModDate(D:20240806091826-04'00')/Producer(Adobe PDF Library 17.0)/Title(SPRYCEL U.S. Prescribing Information)/Trapped/False>>endobjxref
0 3
0000000000 65535 f
0000619654 00000 n
0000619783 00000 n
115 1
0000634602 00000 n
trailer<</Size 116/Root 1 0 R/Info 115 0 R/ID[<4325957DA24D4B268247B9A333CDF3E1><CFC96F61452B498ABA0EF88A5D23FFA9>]/Prev 617199>>startxref634858%%EOF